Word	Tag	Begin-End
Both	O	0-4
natural	O	5-12
and	O	13-16
designed	O	17-25
micro	O	26-31
RNAs	O	32-36
can	O	37-40
inhibit	O	41-48
the	O	49-52
expression	O	53-63
of	O	64-66
cognate	O	67-74
mRNAs	O	75-80
when	O	81-85
expressed	O	86-95
in	O	96-98
human	O	99-104
cells	O	105-110
.	O	110-111

Animal	O	112-118
cells	O	119-124
have	O	125-129
recently	O	130-138
been	O	139-143
shown	O	144-149
to	O	150-152
express	O	153-160
a	O	161-162
range	O	163-168
of	O	169-171
approximately	O	172-185
22	O	186-188
nucleotide	O	189-199
noncoding	O	200-209
RNAs	O	210-214
termed	O	215-221
micro	O	222-227
RNAs	O	228-232
(	O	233-234
miRNAs	O	234-240
)	O	240-241
.	O	241-242

Here	O	243-247
,	O	247-248
we	O	249-251
show	O	252-256
that	O	257-261
the	O	262-265
human	O	266-271
mir	B	272-275
-	I	275-276
30	I	276-278
miRNA	O	279-284
can	O	285-288
be	O	289-291
excised	O	292-299
from	O	300-304
irrelevant	O	305-315
,	O	315-316
endogenously	O	317-329
transcribed	O	330-341
mRNAs	O	342-347
encompassing	O	348-360
the	O	361-364
predicted	O	365-374
71	O	375-377
nucleotide	O	378-388
mir	B	389-392
-	I	392-393
30	I	393-395
precursor	O	396-405
.	O	405-406

Expression	O	407-417
of	O	418-420
the	O	421-424
mir	B	425-428
-	I	428-429
30	I	429-431
miRNA	O	432-437
specifically	O	438-450
blocked	O	451-458
the	O	459-462
translation	O	463-474
in	O	475-477
human	O	478-483
cells	O	484-489
of	O	490-492
an	O	493-495
mRNA	O	496-500
containing	O	501-511
artificial	O	512-522
mir	B	523-526
-	I	526-527
30	I	527-529
target	O	530-536
sites	O	537-542
.	O	542-543

Similarly	O	544-553
,	O	553-554
designed	O	555-563
miRNAs	O	564-570
were	O	571-575
also	O	576-580
excised	O	581-588
from	O	589-593
transcripts	O	594-605
encompassing	O	606-618
artificial	O	619-629
miRNA	O	630-635
precursors	O	636-646
and	O	647-650
could	O	651-656
inhibit	O	657-664
the	O	665-668
expression	O	669-679
of	O	680-682
mRNAs	O	683-688
containing	O	689-699
a	O	700-701
complementary	O	702-715
target	O	716-722
site	O	723-727
.	O	727-728

These	O	729-734
data	O	735-739
indicate	O	740-748
that	O	749-753
novel	O	754-759
miRNAs	O	760-766
can	O	767-770
be	O	771-773
readily	O	774-781
produced	O	782-790
in	O	791-793
vivo	O	794-798
and	O	799-802
can	O	803-806
be	O	807-809
designed	O	810-818
to	O	819-821
specifically	O	822-834
inactivate	O	835-845
the	O	846-849
expression	O	850-860
of	O	861-863
selected	O	864-872
target	O	873-879
genes	O	880-885
in	O	886-888
human	O	889-894
cells	O	895-900
.	O	900-901

Modulation	O	0-10
of	O	11-13
hepatitis	O	14-23
C	O	24-25
virus	O	26-31
RNA	O	32-35
abundance	O	36-45
by	O	46-48
a	O	49-50
liver	O	51-56
-	O	56-57
specific	O	57-65
MicroRNA	O	66-74
.	O	74-75

MicroRNAs	O	76-85
are	O	86-89
small	O	90-95
RNA	O	96-99
molecules	O	100-109
that	O	110-114
regulate	O	115-123
messenger	O	124-133
RNA	O	134-137
(	O	138-139
mRNA	O	139-143
)	O	143-144
expression	O	145-155
.	O	155-156

MicroRNA	B	157-165
122	I	166-169
(	O	170-171
miR	B	171-174
-	I	174-175
122	I	175-178
)	O	178-179
is	O	180-182
specifically	O	183-195
expressed	O	196-205
and	O	206-209
highly	O	210-216
abundant	O	217-225
in	O	226-228
the	O	229-232
human	O	233-238
liver	O	239-244
.	O	244-245

We	O	246-248
show	O	249-253
that	O	254-258
the	O	259-262
sequestration	O	263-276
of	O	277-279
miR	B	280-283
-	I	283-284
122	I	284-287
in	O	288-290
liver	O	291-296
cells	O	297-302
results	O	303-310
in	O	311-313
marked	O	314-320
loss	O	321-325
of	O	326-328
autonomously	O	329-341
replicating	O	342-353
hepatitis	O	354-363
C	O	364-365
viral	O	366-371
RNAs	O	372-376
.	O	376-377

A	O	378-379
genetic	O	380-387
interaction	O	388-399
between	O	400-407
miR	B	408-411
-	I	411-412
122	I	412-415
and	O	416-419
the	O	420-423
5	O	424-425
'	O	425-426
noncoding	O	427-436
region	O	437-443
of	O	444-446
the	O	447-450
viral	O	451-456
genome	O	457-463
was	O	464-467
revealed	O	468-476
by	O	477-479
mutational	O	480-490
analyses	O	491-499
of	O	500-502
the	O	503-506
predicted	O	507-516
microRNA	O	517-525
binding	O	526-533
site	O	534-538
and	O	539-542
ectopic	O	543-550
expression	O	551-561
of	O	562-564
miR	B	565-568
-	I	568-569
122	I	569-572
molecules	O	573-582
containing	O	583-593
compensatory	O	594-606
mutations	O	607-616
.	O	616-617

Studies	O	618-625
with	O	626-630
replication	O	631-642
-	O	642-643
defective	O	643-652
RNAs	O	653-657
suggested	O	658-667
that	O	668-672
miR	B	673-676
-	I	676-677
122	I	677-680
did	O	681-684
not	O	685-688
detectably	O	689-699
affect	O	700-706
mRNA	O	707-711
translation	O	712-723
or	O	724-726
RNA	O	727-730
stability	O	731-740
.	O	740-741

Therefore	O	742-751
,	O	751-752
miR	B	753-756
-	I	756-757
122	I	757-760
is	O	761-763
likely	O	764-770
to	O	771-773
facilitate	O	774-784
replication	O	785-796
of	O	797-799
the	O	800-803
viral	O	804-809
RNA	O	810-813
,	O	813-814
suggesting	O	815-825
that	O	826-830
miR	B	831-834
-	I	834-835
122	I	835-838
may	O	839-842
present	O	843-850
a	O	851-852
target	O	853-859
for	O	860-863
antiviral	O	864-873
intervention	O	874-886
.	O	886-887

MicroRNA	B	0-8
-	I	8-9
9	I	9-10
controls	O	11-19
the	O	20-23
expression	O	24-34
of	O	35-37
Granuphilin	O	38-49
/	O	49-50
Slp4	O	50-54
and	O	55-58
the	O	59-62
secretory	O	63-72
response	O	73-81
of	O	82-84
insulin	O	85-92
-	O	92-93
producing	O	93-102
cells	O	103-108
.	O	108-109

Insulin	O	110-117
release	O	118-125
from	O	126-130
pancreatic	O	131-141
beta	O	142-146
-	O	146-147
cells	O	147-152
plays	O	153-158
an	O	159-161
essential	O	162-171
role	O	172-176
in	O	177-179
blood	O	180-185
glucose	O	186-193
homeostasis	O	194-205
.	O	205-206

Several	O	207-214
proteins	O	215-223
controlling	O	224-235
insulin	O	236-243
exocytosis	O	244-254
have	O	255-259
been	O	260-264
identified	O	265-275
,	O	275-276
but	O	277-280
the	O	281-284
factors	O	285-292
determining	O	293-304
the	O	305-308
expression	O	309-319
of	O	320-322
the	O	323-326
components	O	327-337
of	O	338-340
the	O	341-344
secretory	O	345-354
machinery	O	355-364
of	O	365-367
beta	O	368-372
-	O	372-373
cells	O	373-378
remain	O	379-385
largely	O	386-393
unknown	O	394-401
.	O	401-402

MicroRNAs	O	403-412
are	O	413-416
newly	O	417-422
discovered	O	423-433
small	O	434-439
non	O	440-443
-	O	443-444
coding	O	444-450
RNAs	O	451-455
acting	O	456-462
as	O	463-465
repressors	O	466-476
of	O	477-479
gene	O	480-484
expression	O	485-495
.	O	495-496

We	O	497-499
found	O	500-505
that	O	506-510
overexpression	O	511-525
of	O	526-528
mir	B	529-532
-	I	532-533
9	I	533-534
in	O	535-537
insulin	O	538-545
-	O	545-546
secreting	O	546-555
cells	O	556-561
causes	O	562-568
a	O	569-570
reduction	O	571-580
in	O	581-583
exocytosis	O	584-594
elicited	O	595-603
by	O	604-606
glucose	O	607-614
or	O	615-617
potassium	O	618-627
.	O	627-628

We	O	629-631
show	O	632-636
that	O	637-641
mir	B	642-645
-	I	645-646
9	I	646-647
acts	O	648-652
by	O	653-655
diminishing	O	656-667
the	O	668-671
expression	O	672-682
of	O	683-685
the	O	686-689
transcription	O	690-703
factor	O	704-710
Onecut	O	711-717
-	O	717-718
2	O	718-719
and	O	720-723
,	O	723-724
in	O	725-727
turn	O	728-732
,	O	732-733
by	O	734-736
increasing	O	737-747
the	O	748-751
level	O	752-757
of	O	758-760
Granuphilin	O	761-772
/	O	772-773
Slp4	O	773-777
,	O	777-778
a	O	779-780
Rab	O	781-784
GTPase	O	785-791
effector	O	792-800
associated	O	801-811
with	O	812-816
beta	O	817-821
-	O	821-822
cell	O	822-826
secretory	O	827-836
granules	O	837-845
that	O	846-850
exerts	O	851-857
a	O	858-859
negative	O	860-868
control	O	869-876
on	O	877-879
insulin	O	880-887
release	O	888-895
.	O	895-896

Indeed	O	897-903
,	O	903-904
electrophoretic	O	905-920
mobility	O	921-929
shift	O	930-935
assays	O	936-942
,	O	942-943
chromatin	O	944-953
immunoprecipitation	O	954-973
,	O	973-974
and	O	975-978
transfection	O	979-991
experiments	O	992-1003
demonstrated	O	1004-1016
that	O	1017-1021
Onecut	O	1022-1028
-	O	1028-1029
2	O	1029-1030
is	O	1031-1033
able	O	1034-1038
to	O	1039-1041
bind	O	1042-1046
to	O	1047-1049
the	O	1050-1053
granuphilin	O	1054-1065
promoter	O	1066-1074
and	O	1075-1078
to	O	1079-1081
repress	O	1082-1089
its	O	1090-1093
transcriptional	O	1094-1109
activity	O	1110-1118
.	O	1118-1119

Moreover	O	1120-1128
,	O	1128-1129
we	O	1130-1132
show	O	1133-1137
that	O	1138-1142
silencing	O	1143-1152
of	O	1153-1155
Onecut	O	1156-1162
-	O	1162-1163
2	O	1163-1164
by	O	1165-1167
RNA	O	1168-1171
interference	O	1172-1184
increases	O	1185-1194
Granuphilin	O	1195-1206
expression	O	1207-1217
and	O	1218-1221
mimics	O	1222-1228
the	O	1229-1232
effect	O	1233-1239
of	O	1240-1242
mir	B	1243-1246
-	I	1246-1247
9	I	1247-1248
on	O	1249-1251
stimulus	O	1252-1260
-	O	1260-1261
induced	O	1261-1268
exocytosis	O	1269-1279
.	O	1279-1280

Our	O	1281-1284
data	O	1285-1289
provide	O	1290-1297
evidence	O	1298-1306
that	O	1307-1311
in	O	1312-1314
insulin	O	1315-1322
-	O	1322-1323
producing	O	1323-1332
cells	O	1333-1338
adequate	O	1339-1347
levels	O	1348-1354
of	O	1355-1357
mir	B	1358-1361
-	I	1361-1362
9	I	1362-1363
are	O	1364-1367
mandatory	O	1368-1377
for	O	1378-1381
maintaining	O	1382-1393
appropriate	O	1394-1405
Granuphilin	O	1406-1417
levels	O	1418-1424
and	O	1425-1428
optimal	O	1429-1436
secretory	O	1437-1446
capacity	O	1447-1455
.	O	1455-1456

Peroxisome	O	0-10
proliferator	O	11-23
-	O	23-24
activated	O	24-33
receptor	O	34-42
alpha	O	43-48
regulates	O	49-58
a	O	59-60
microRNA	O	61-69
-	O	69-70
mediated	O	70-78
signaling	O	79-88
cascade	O	89-96
responsible	O	97-108
for	O	109-112
hepatocellular	O	113-127
proliferation	O	128-141
.	O	141-142

Activation	O	143-153
of	O	154-156
peroxisome	O	157-167
proliferator	O	168-180
-	O	180-181
activated	O	181-190
receptor	O	191-199
alpha	O	200-205
(	O	206-207
PPARalpha	O	207-216
)	O	216-217
leads	O	218-223
to	O	224-226
hepatocellular	O	227-241
proliferation	O	242-255
and	O	256-259
liver	O	260-265
carcinomas	O	266-276
.	O	276-277

The	O	278-281
early	O	282-287
events	O	288-294
mediating	O	295-304
these	O	305-310
effects	O	311-318
are	O	319-322
unknown	O	323-330
.	O	330-331

A	O	332-333
novel	O	334-339
mechanism	O	340-349
by	O	350-352
which	O	353-358
PPARalpha	O	359-368
regulates	O	369-378
gene	O	379-383
expression	O	384-394
and	O	395-398
hepatocellular	O	399-413
proliferation	O	414-427
was	O	428-431
uncovered	O	432-441
.	O	441-442

MicroRNA	O	443-451
(	O	452-453
miRNA	O	453-458
)	O	458-459
expression	O	460-470
profiling	O	471-480
demonstrated	O	481-493
that	O	494-498
activated	O	499-508
PPARalpha	O	509-518
was	O	519-522
a	O	523-524
major	O	525-530
regulator	O	531-540
of	O	541-543
hepatic	O	544-551
miRNA	O	552-557
expression	O	558-568
.	O	568-569

Of	O	570-572
particular	O	573-583
interest	O	584-592
,	O	592-593
let	B	594-597
-	I	597-598
7C	I	598-600
,	O	600-601
an	O	602-604
miRNA	O	605-610
important	O	611-620
in	O	621-623
cell	O	624-628
growth	O	629-635
,	O	635-636
was	O	637-640
inhibited	O	641-650
following	O	651-660
4	O	661-662
-	O	662-663
h	O	663-664
treatment	O	665-674
and	O	675-678
2	O	679-680
-	O	680-681
week	O	681-685
and	O	686-689
11	O	690-692
-	O	692-693
month	O	693-698
sustained	O	699-708
treatment	O	709-718
with	O	719-723
the	O	724-727
potent	O	728-734
PPARalpha	O	735-744
agonist	O	745-752
Wy	O	753-755
-	O	755-756
14	O	756-758
,	O	758-759
643	O	759-762
in	O	763-765
wild	O	766-770
-	O	770-771
type	O	771-775
mice	O	776-780
.	O	780-781

let	B	782-785
-	I	785-786
7C	I	786-788
was	O	789-792
shown	O	793-798
to	O	799-801
target	O	802-808
c	O	809-810
-	O	810-811
myc	O	811-814
via	O	815-818
direct	O	819-825
interaction	O	826-837
with	O	838-842
the	O	843-846
3	O	847-848
'	O	848-849
untranslated	O	850-862
region	O	863-869
of	O	870-872
c	O	873-874
-	O	874-875
myc	O	875-878
.	O	878-879

The	O	880-883
PPARalpha	O	884-893
-	O	893-894
mediated	O	894-902
induction	O	903-912
of	O	913-915
c	O	916-917
-	O	917-918
myc	O	918-921
via	O	922-925
let	B	926-929
-	I	929-930
7C	I	930-932
subsequently	O	933-945
increased	O	946-955
expression	O	956-966
of	O	967-969
the	O	970-973
oncogenic	O	974-983
mir	B	984-987
-	I	987-988
17	I	988-990
-	I	990-991
92	I	991-993
cluster	O	994-1001
;	O	1001-1002
these	O	1003-1008
events	O	1009-1015
did	O	1016-1019
not	O	1020-1023
occur	O	1024-1029
in	O	1030-1032
Pparalpha	O	1033-1042
-	O	1042-1043
null	O	1043-1047
mice	O	1048-1052
.	O	1052-1053

Overexpression	O	1054-1068
of	O	1069-1071
let	B	1072-1075
-	I	1075-1076
7C	I	1076-1078
decreased	O	1079-1088
c	O	1089-1090
-	O	1090-1091
myc	O	1091-1094
and	O	1095-1098
mir	B	1099-1102
-	I	1102-1103
17	I	1103-1105
and	O	1106-1109
suppressed	O	1110-1120
the	O	1121-1124
growth	O	1125-1131
of	O	1132-1134
Hepa	O	1135-1139
-	O	1139-1140
1	O	1140-1141
cells	O	1142-1147
.	O	1147-1148

Furthermore	O	1149-1160
,	O	1160-1161
using	O	1162-1167
the	O	1168-1171
human	O	1172-1177
PPARalpha	O	1178-1187
-	O	1187-1188
expressing	O	1188-1198
mouse	O	1199-1204
model	O	1205-1210
,	O	1210-1211
which	O	1212-1217
is	O	1218-1220
responsive	O	1221-1231
to	O	1232-1234
Wy	O	1235-1237
-	O	1237-1238
14	O	1238-1240
,	O	1240-1241
643	O	1241-1244
effects	O	1245-1252
on	O	1253-1255
beta	O	1256-1260
-	O	1260-1261
oxidation	O	1261-1270
and	O	1271-1274
serum	O	1275-1280
triglycerides	O	1281-1294
but	O	1295-1298
resistant	O	1299-1308
to	O	1309-1311
hepatocellular	O	1312-1326
proliferation	O	1327-1340
and	O	1341-1344
tumorigenesis	O	1345-1358
,	O	1358-1359
we	O	1360-1362
demonstrated	O	1363-1375
a	O	1376-1377
critical	O	1378-1386
role	O	1387-1391
for	O	1392-1395
let	B	1396-1399
-	I	1399-1400
7C	I	1400-1402
in	O	1403-1405
liver	O	1406-1411
oncogenesis	O	1412-1423
.	O	1423-1424

Wy	O	1425-1427
-	O	1427-1428
14	O	1428-1430
,	O	1430-1431
643	O	1431-1434
treatment	O	1435-1444
did	O	1445-1448
not	O	1449-1452
inhibit	O	1453-1460
let	B	1461-1464
-	I	1464-1465
7C	I	1465-1467
or	O	1468-1470
induce	O	1471-1477
c	O	1478-1479
-	O	1479-1480
myc	O	1480-1483
and	O	1484-1487
mir	B	1488-1491
-	I	1491-1492
17	I	1492-1494
expression	O	1495-1505
.	O	1505-1506

These	O	1507-1512
observations	O	1513-1525
reveal	O	1526-1532
a	O	1533-1534
let	B	1535-1538
-	I	1538-1539
7C	I	1539-1541
signaling	O	1542-1551
cascade	O	1552-1559
critical	O	1560-1568
for	O	1569-1572
PPARalpha	O	1573-1582
agonist	O	1583-1590
-	O	1590-1591
induced	O	1591-1598
liver	O	1599-1604
proliferation	O	1605-1618
and	O	1619-1622
tumorigenesis	O	1623-1636
.	O	1636-1637

Regulation	O	0-10
of	O	11-13
the	O	14-17
germinal	O	18-26
center	O	27-33
response	O	34-42
by	O	43-45
microRNA	B	46-54
-	I	54-55
155	I	55-58
.	O	58-59

MicroRNAs	O	60-69
are	O	70-73
small	O	74-79
RNA	O	80-83
species	O	84-91
involved	O	92-100
in	O	101-103
biological	O	104-114
control	O	115-122
at	O	123-125
multiple	O	126-134
levels	O	135-141
.	O	141-142

Using	O	143-148
genetic	O	149-156
deletion	O	157-165
and	O	166-169
transgenic	O	170-180
approaches	O	181-191
,	O	191-192
we	O	193-195
show	O	196-200
that	O	201-205
the	O	206-209
evolutionarily	O	210-224
conserved	O	225-234
microRNA	B	235-243
-	I	243-244
155	I	244-247
(	O	248-249
miR	B	249-252
-	I	252-253
155	I	253-256
)	O	256-257
has	O	258-261
an	O	262-264
important	O	265-274
role	O	275-279
in	O	280-282
the	O	283-286
mammalian	O	287-296
immune	O	297-303
system	O	304-310
,	O	310-311
specifically	O	312-324
in	O	325-327
regulating	O	328-338
T	O	339-340
helper	O	341-347
cell	O	348-352
differentiation	O	353-368
and	O	369-372
the	O	373-376
germinal	O	377-385
center	O	386-392
reaction	O	393-401
to	O	402-404
produce	O	405-412
an	O	413-415
optimal	O	416-423
T	O	424-425
cell	O	426-430
-	O	430-431
dependent	O	431-440
antibody	O	441-449
response	O	450-458
.	O	458-459

miR	B	460-463
-	I	463-464
155	I	464-467
exerts	O	468-474
this	O	475-479
control	O	480-487
,	O	487-488
at	O	489-491
least	O	492-497
in	O	498-500
part	O	501-505
,	O	505-506
by	O	507-509
regulating	O	510-520
cytokine	O	521-529
production	O	530-540
.	O	540-541

These	O	542-547
results	O	548-555
also	O	556-560
suggest	O	561-568
that	O	569-573
individual	O	574-584
microRNAs	O	585-594
can	O	595-598
exert	O	599-604
critical	O	605-613
control	O	614-621
over	O	622-626
mammalian	O	627-636
differentiation	O	637-652
processes	O	653-662
in	O	663-665
vivo	O	666-670
.	O	670-671

MicroRNAs	O	0-9
and	O	10-13
haematology	O	14-25
:	O	25-26
small	O	27-32
molecules	O	33-42
,	O	42-43
big	O	44-47
function	O	48-56
.	O	56-57

MicroRNAs	O	58-67
are	O	68-71
a	O	72-73
recently	O	74-82
discovered	O	83-93
class	O	94-99
of	O	100-102
small	O	103-108
(	O	109-110
approximately	O	111-124
22nt	O	125-129
)	O	129-130
endogenously	O	131-143
expressed	O	144-153
translational	O	154-167
-	O	167-168
repressor	O	168-177
RNAs	O	178-182
that	O	183-187
play	O	188-192
key	O	193-196
roles	O	197-202
in	O	203-205
many	O	206-210
cellular	O	211-219
pathways	O	220-228
and	O	229-232
whose	O	233-238
aberrant	O	239-247
expression	O	248-258
appears	O	259-266
to	O	267-269
be	O	270-272
a	O	273-274
common	O	275-281
feature	O	282-289
of	O	290-292
malignancy	O	293-303
.	O	303-304

MicroRNAs	O	305-314
are	O	315-318
expressed	O	319-328
in	O	329-331
specific	O	332-340
haematological	O	341-355
cell	O	356-360
types	O	361-366
and	O	367-370
play	O	371-375
important	O	376-385
regulatory	O	386-396
roles	O	397-402
in	O	403-405
early	O	406-411
haematopoietic	O	412-426
differentiation	O	427-442
,	O	442-443
erythropoiesis	O	444-458
,	O	458-459
granulocytosis	O	460-474
,	O	474-475
megakaryocytosis	O	476-492
and	O	493-496
lymphoid	O	497-505
development	O	506-517
.	O	517-518

Additionally	O	519-531
,	O	531-532
there	O	533-538
is	O	539-541
an	O	542-544
emerging	O	545-553
body	O	554-558
of	O	559-561
research	O	562-570
to	O	571-573
suggest	O	574-581
that	O	582-586
microRNAs	O	587-596
play	O	597-601
an	O	602-604
important	O	605-614
role	O	615-619
in	O	620-622
the	O	623-626
pathology	O	627-636
of	O	637-639
haematological	O	640-654
malignancies	O	655-667
.	O	667-668

MicroRNAs	O	669-678
have	O	679-683
been	O	684-688
found	O	689-694
to	O	695-697
act	O	698-701
as	O	702-704
both	O	705-709
tumour	O	710-716
suppressor	O	717-727
molecules	O	728-737
[	O	738-739
e	O	739-740
.	O	740-741
g	O	741-742
.	O	742-743

MIRN15A	B	744-751
(	O	752-753
miR	B	753-756
-	I	756-757
15a	I	757-760
)	O	760-761
,	O	761-762
MIRN16	B	763-769
-	I	769-770
1	I	770-771
(	O	772-773
miR	B	773-776
-	I	776-777
16	I	777-779
-	I	779-780
1	I	780-781
)	O	781-782
]	O	782-783
in	O	784-786
leukaemias	O	787-797
and	O	798-801
have	O	802-806
oncogenic	O	807-816
properties	O	817-827
[	O	828-829
e	O	829-830
.	O	830-831
g	O	831-832
.	O	832-833

MIRN155	B	834-841
(	O	842-843
miR	B	843-846
-	I	846-847
155	I	847-850
)	O	850-851
and	O	852-855
MIRN17	B	856-862
-	I	862-863
92	I	863-865
(	O	866-867
miR	B	867-870
-	I	870-871
17	I	871-873
-	O	873-874
miR	B	874-877
-	I	877-878
92	I	878-880
)	O	880-881
cluster	O	882-889
]	O	889-890
in	O	891-893
lymphomas	O	894-903
.	O	903-904

This	O	905-909
review	O	910-916
discusses	O	917-926
the	O	927-930
rapidly	O	931-938
accumulating	O	939-951
research	O	952-960
that	O	961-965
points	O	966-972
to	O	973-975
the	O	976-979
major	O	980-985
role	O	986-990
microRNAs	O	991-1000
play	O	1001-1005
in	O	1006-1008
both	O	1009-1013
haematopoiesis	O	1014-1028
and	O	1029-1032
haematological	O	1033-1047
malignancy	O	1048-1058
.	O	1058-1059

miRNAs	O	0-6
in	O	7-9
cancer	O	10-16
:	O	16-17
approaches	O	18-28
,	O	28-29
aetiology	O	30-39
,	O	39-40
diagnostics	O	41-52
and	O	53-56
therapy	O	57-64
.	O	64-65

MicroRNAs	O	66-75
(	O	76-77
miRNAs	O	77-83
)	O	83-84
are	O	85-88
causing	O	89-96
tremendous	O	97-107
excitement	O	108-118
in	O	119-121
cancer	O	122-128
research	O	129-137
.	O	137-138

MiRNAs	O	139-145
are	O	146-149
a	O	150-151
large	O	152-157
class	O	158-163
of	O	164-166
short	O	167-172
non	O	173-176
-	O	176-177
coding	O	177-183
RNAs	O	184-188
that	O	189-193
are	O	194-197
found	O	198-203
in	O	204-206
many	O	207-211
plants	O	212-218
,	O	218-219
animals	O	220-227
and	O	228-231
DNA	O	232-235
viruses	O	236-243
and	O	244-247
often	O	248-253
act	O	254-257
to	O	258-260
inhibit	O	261-268
gene	O	269-273
expression	O	274-284
post	O	285-289
-	O	289-290
transcriptionally	O	290-307
.	O	307-308

Approximately	O	309-322
500	O	323-326
miRNA	O	327-332
genes	O	333-338
have	O	339-343
been	O	344-348
identified	O	349-359
in	O	360-362
the	O	363-366
human	O	367-372
genome	O	373-379
.	O	379-380

Their	O	381-386
function	O	387-395
is	O	396-398
largely	O	399-406
unknown	O	407-414
,	O	414-415
but	O	416-419
data	O	420-424
from	O	425-429
worms	O	430-435
,	O	435-436
flies	O	437-442
,	O	442-443
fish	O	444-448
and	O	449-452
mice	O	453-457
suggest	O	458-465
that	O	466-470
they	O	471-475
have	O	476-480
important	O	481-490
roles	O	491-496
in	O	497-499
animal	O	500-506
growth	O	507-513
,	O	513-514
development	O	515-526
,	O	526-527
homeostasis	O	528-539
and	O	540-543
disease	O	544-551
.	O	551-552

MiRNA	O	553-558
expression	O	559-569
profiles	O	570-578
demonstrate	O	579-590
that	O	591-595
many	O	596-600
miRNAs	O	601-607
are	O	608-611
deregulated	O	612-623
in	O	624-626
human	O	627-632
cancers	O	633-640
.	O	640-641

MiRNAs	O	642-648
have	O	649-653
been	O	654-658
shown	O	659-664
to	O	665-667
regulate	O	668-676
oncogenes	O	677-686
,	O	686-687
tumour	O	688-694
suppressors	O	695-706
and	O	707-710
a	O	711-712
number	O	713-719
of	O	720-722
cancer	O	723-729
-	O	729-730
related	O	730-737
genes	O	738-743
controlling	O	744-755
cell	O	756-760
cycle	O	761-766
,	O	766-767
apoptosis	O	768-777
,	O	777-778
cell	O	779-783
migration	O	784-793
and	O	794-797
angiogenesis	O	798-810
.	O	810-811

MiRNAs	O	812-818
encoded	O	819-826
by	O	827-829
the	O	830-833
mir	B	834-837
-	I	837-838
17	I	838-840
-	I	840-841
92	I	841-843
cluster	O	844-851
have	O	852-856
oncogenic	O	857-866
potential	O	867-876
and	O	877-880
others	O	881-887
may	O	888-891
act	O	892-895
as	O	896-898
tumour	O	899-905
suppressors	O	906-917
.	O	917-918

Some	O	919-923
miRNAs	O	924-930
and	O	931-934
their	O	935-940
target	O	941-947
sites	O	948-953
were	O	954-958
found	O	959-964
to	O	965-967
be	O	968-970
mutated	O	971-978
in	O	979-981
cancer	O	982-988
.	O	988-989

MiRNAs	O	990-996
may	O	997-1000
have	O	1001-1005
great	O	1006-1011
diagnostic	O	1012-1022
potential	O	1023-1032
for	O	1033-1036
human	O	1037-1042
cancer	O	1043-1049
and	O	1050-1053
even	O	1054-1058
miRNA	O	1059-1064
-	O	1064-1065
based	O	1065-1070
cancer	O	1071-1077
therapies	O	1078-1087
may	O	1088-1091
be	O	1092-1094
on	O	1095-1097
the	O	1098-1101
horizon	O	1102-1109
.	O	1109-1110

Antagonism	O	0-10
of	O	11-13
microRNA	B	14-22
-	I	22-23
122	I	23-26
in	O	27-29
mice	O	30-34
by	O	35-37
systemically	O	38-50
administered	O	51-63
LNA	O	64-67
-	O	67-68
antimiR	O	68-75
leads	O	76-81
to	O	82-84
up	O	85-87
-	O	87-88
regulation	O	88-98
of	O	99-101
a	O	102-103
large	O	104-109
set	O	110-113
of	O	114-116
predicted	O	117-126
target	O	127-133
mRNAs	O	134-139
in	O	140-142
the	O	143-146
liver	O	147-152
.	O	152-153

MicroRNA	B	154-162
-	I	162-163
122	I	163-166
(	O	167-168
miR	B	168-171
-	I	171-172
122	I	172-175
)	O	175-176
is	O	177-179
an	O	180-182
abundant	O	183-191
liver	O	192-197
-	O	197-198
specific	O	198-206
miRNA	O	207-212
,	O	212-213
implicated	O	214-224
in	O	225-227
fatty	O	228-233
acid	O	234-238
and	O	239-242
cholesterol	O	243-254
metabolism	O	255-265
as	O	266-268
well	O	269-273
as	O	274-276
hepatitis	O	277-286
C	O	287-288
viral	O	289-294
replication	O	295-306
.	O	306-307

Here	O	308-312
,	O	312-313
we	O	314-316
report	O	317-323
that	O	324-328
a	O	329-330
systemically	O	331-343
administered	O	344-356
16	O	357-359
-	O	359-360
nt	O	360-362
,	O	362-363
unconjugated	O	364-376
LNA	O	377-380
(	O	381-382
locked	O	382-388
nucleic	O	389-396
acid	O	397-401
)	O	401-402
-	O	402-403
antimiR	O	403-410
oligonucleotide	O	411-426
complementary	O	427-440
to	O	441-443
the	O	444-447
5	O	448-449
'	O	449-450
end	O	451-454
of	O	455-457
miR	B	458-461
-	I	461-462
122	I	462-465
leads	O	466-471
to	O	472-474
specific	O	475-483
,	O	483-484
dose	O	485-489
-	O	489-490
dependent	O	490-499
silencing	O	500-509
of	O	510-512
miR	B	513-516
-	I	516-517
122	I	517-520
and	O	521-524
shows	O	525-530
no	O	531-533
hepatotoxicity	O	534-548
in	O	549-551
mice	O	552-556
.	O	556-557

Antagonism	O	558-568
of	O	569-571
miR	B	572-575
-	I	575-576
122	I	576-579
is	O	580-582
due	O	583-586
to	O	587-589
formation	O	590-599
of	O	600-602
stable	O	603-609
heteroduplexes	O	610-624
between	O	625-632
the	O	633-636
LNA	O	637-640
-	O	640-641
antimiR	O	641-648
and	O	649-652
miR	B	653-656
-	I	656-657
122	I	657-660
as	O	661-663
detected	O	664-672
by	O	673-675
northern	O	676-684
analysis	O	685-693
.	O	693-694

Fluorescence	O	695-707
in	O	708-710
situ	O	711-715
hybridization	O	716-729
demonstrated	O	730-742
uptake	O	743-749
of	O	750-752
the	O	753-756
LNA	O	757-760
-	O	760-761
antimiR	O	761-768
in	O	769-771
mouse	O	772-777
liver	O	778-783
cells	O	784-789
,	O	789-790
which	O	791-796
was	O	797-800
accompanied	O	801-812
by	O	813-815
markedly	O	816-824
reduced	O	825-832
hybridization	O	833-846
signals	O	847-854
for	O	855-858
mature	O	859-865
miR	B	866-869
-	I	869-870
122	I	870-873
in	O	874-876
treated	O	877-884
mice	O	885-889
.	O	889-890

Functional	O	891-901
antagonism	O	902-912
of	O	913-915
miR	B	916-919
-	I	919-920
122	I	920-923
was	O	924-927
inferred	O	928-936
from	O	937-941
a	O	942-943
low	O	944-947
cholesterol	O	948-959
phenotype	O	960-969
and	O	970-973
de	O	974-976
-	O	976-977
repression	O	977-987
within	O	988-994
24	O	995-997
h	O	998-999
of	O	1000-1002
199	O	1003-1006
liver	O	1007-1012
mRNAs	O	1013-1018
showing	O	1019-1026
significant	O	1027-1038
enrichment	O	1039-1049
for	O	1050-1053
miR	B	1054-1057
-	I	1057-1058
122	I	1058-1061
seed	O	1062-1066
matches	O	1067-1074
in	O	1075-1077
their	O	1078-1083
3	O	1084-1085
'	O	1085-1086
UTRs	O	1087-1091
.	O	1091-1092

Expression	O	1093-1103
profiling	O	1104-1113
extended	O	1114-1122
to	O	1123-1125
3	O	1126-1127
weeks	O	1128-1133
after	O	1134-1139
the	O	1140-1143
last	O	1144-1148
LNA	O	1149-1152
-	O	1152-1153
antimiR	O	1153-1160
dose	O	1161-1165
revealed	O	1166-1174
that	O	1175-1179
most	O	1180-1184
of	O	1185-1187
the	O	1188-1191
changes	O	1192-1199
in	O	1200-1202
liver	O	1203-1208
gene	O	1209-1213
expression	O	1214-1224
were	O	1225-1229
normalized	O	1230-1240
to	O	1241-1243
saline	O	1244-1250
control	O	1251-1258
levels	O	1259-1265
coinciding	O	1266-1276
with	O	1277-1281
normalized	O	1282-1292
miR	B	1293-1296
-	I	1296-1297
122	I	1297-1300
and	O	1301-1304
plasma	O	1305-1311
cholesterol	O	1312-1323
levels	O	1324-1330
.	O	1330-1331

Combined	O	1332-1340
,	O	1340-1341
these	O	1342-1347
data	O	1348-1352
suggest	O	1353-1360
that	O	1361-1365
miRNA	O	1366-1371
antagonists	O	1372-1383
comprised	O	1384-1393
of	O	1394-1396
LNA	O	1397-1400
are	O	1401-1404
valuable	O	1405-1413
tools	O	1414-1419
for	O	1420-1423
identifying	O	1424-1435
miRNA	O	1436-1441
targets	O	1442-1449
in	O	1450-1452
vivo	O	1453-1457
and	O	1458-1461
for	O	1462-1465
studying	O	1466-1474
the	O	1475-1478
biological	O	1479-1489
role	O	1490-1494
of	O	1495-1497
miRNAs	O	1498-1504
and	O	1505-1508
miRNA	O	1509-1514
-	O	1514-1515
associated	O	1515-1525
gene	O	1526-1530
-	O	1530-1531
regulatory	O	1531-1541
networks	O	1542-1550
in	O	1551-1553
a	O	1554-1555
physiological	O	1556-1569
context	O	1570-1577
.	O	1577-1578

Endogenous	O	0-10
human	O	11-16
microRNAs	O	17-26
that	O	27-31
suppress	O	32-40
breast	O	41-47
cancer	O	48-54
metastasis	O	55-65
.	O	65-66

A	O	67-68
search	O	69-75
for	O	76-79
general	O	80-87
regulators	O	88-98
of	O	99-101
cancer	O	102-108
metastasis	O	109-119
has	O	120-123
yielded	O	124-131
a	O	132-133
set	O	134-137
of	O	138-140
microRNAs	O	141-150
for	O	151-154
which	O	155-160
expression	O	161-171
is	O	172-174
specifically	O	175-187
lost	O	188-192
as	O	193-195
human	O	196-201
breast	O	202-208
cancer	O	209-215
cells	O	216-221
develop	O	222-229
metastatic	O	230-240
potential	O	241-250
.	O	250-251

Here	O	252-256
we	O	257-259
show	O	260-264
that	O	265-269
restoring	O	270-279
the	O	280-283
expression	O	284-294
of	O	295-297
these	O	298-303
microRNAs	O	304-313
in	O	314-316
malignant	O	317-326
cells	O	327-332
suppresses	O	333-343
lung	O	344-348
and	O	349-352
bone	O	353-357
metastasis	O	358-368
by	O	369-371
human	O	372-377
cancer	O	378-384
cells	O	385-390
in	O	391-393
vivo	O	394-398
.	O	398-399

Of	O	400-402
these	O	403-408
microRNAs	O	409-418
,	O	418-419
miR	B	420-423
-	I	423-424
126	I	424-427
restoration	O	428-439
reduces	O	440-447
overall	O	448-455
tumour	O	456-462
growth	O	463-469
and	O	470-473
proliferation	O	474-487
,	O	487-488
whereas	O	489-496
miR	B	497-500
-	I	500-501
335	I	501-504
inhibits	O	505-513
metastatic	O	514-524
cell	O	525-529
invasion	O	530-538
.	O	538-539

miR	B	540-543
-	I	543-544
335	I	544-547
regulates	O	548-557
a	O	558-559
set	O	560-563
of	O	564-566
genes	O	567-572
whose	O	573-578
collective	O	579-589
expression	O	590-600
in	O	601-603
a	O	604-605
large	O	606-611
cohort	O	612-618
of	O	619-621
human	O	622-627
tumours	O	628-635
is	O	636-638
associated	O	639-649
with	O	650-654
risk	O	655-659
of	O	660-662
distal	O	663-669
metastasis	O	670-680
.	O	680-681

miR	B	682-685
-	I	685-686
335	I	686-689
suppresses	O	690-700
metastasis	O	701-711
and	O	712-715
migration	O	716-725
through	O	726-733
targeting	O	734-743
of	O	744-746
the	O	747-750
progenitor	O	751-761
cell	O	762-766
transcription	O	767-780
factor	O	781-787
SOX4	O	788-792
and	O	793-796
extracellular	O	797-810
matrix	O	811-817
component	O	818-827
tenascin	O	828-836
C	O	837-838
.	O	838-839
Expression	O	840-850
of	O	851-853
miR	B	854-857
-	I	857-858
126	I	858-861
and	O	862-865
miR	B	866-869
-	I	869-870
335	I	870-873
is	O	874-876
lost	O	877-881
in	O	882-884
the	O	885-888
majority	O	889-897
of	O	898-900
primary	O	901-908
breast	O	909-915
tumours	O	916-923
from	O	924-928
patients	O	929-937
who	O	938-941
relapse	O	942-949
,	O	949-950
and	O	951-954
the	O	955-958
loss	O	959-963
of	O	964-966
expression	O	967-977
of	O	978-980
either	O	981-987
microRNA	O	988-996
is	O	997-999
associated	O	1000-1010
with	O	1011-1015
poor	O	1016-1020
distal	O	1021-1027
metastasis	O	1028-1038
-	O	1038-1039
free	O	1039-1043
survival	O	1044-1052
.	O	1052-1053

miR	B	1054-1057
-	I	1057-1058
335	I	1058-1061
and	O	1062-1065
miR	B	1066-1069
-	I	1069-1070
126	I	1070-1073
are	O	1074-1077
thus	O	1078-1082
identified	O	1083-1093
as	O	1094-1096
metastasis	O	1097-1107
suppressor	O	1108-1118
microRNAs	O	1119-1128
in	O	1129-1131
human	O	1132-1137
breast	O	1138-1144
cancer	O	1145-1151
.	O	1151-1152

Origin	O	0-6
,	O	6-7
evolution	O	8-17
,	O	17-18
and	O	19-22
biological	O	23-33
role	O	34-38
of	O	39-41
miRNA	O	42-47
cluster	O	48-55
in	O	56-58
DLK	O	59-62
-	O	62-63
DIO3	O	63-67
genomic	O	68-75
region	O	76-82
in	O	83-85
placental	O	86-95
mammals	O	96-103
.	O	103-104

MicroRNAs	O	105-114
(	O	115-116
miRNAs	O	116-122
)	O	122-123
are	O	124-127
a	O	128-129
rapidly	O	130-137
growing	O	138-145
family	O	146-152
of	O	153-155
small	O	156-161
regulatory	O	162-172
RNAs	O	173-177
modulating	O	178-188
gene	O	189-193
expression	O	194-204
in	O	205-207
plants	O	208-214
and	O	215-218
animals	O	219-226
.	O	226-227

In	O	228-230
animals	O	231-238
,	O	238-239
most	O	240-244
of	O	245-247
the	O	248-251
miRNAs	O	252-258
discovered	O	259-269
in	O	270-272
early	O	273-278
studies	O	279-286
were	O	287-291
found	O	292-297
to	O	298-300
be	O	301-303
evolutionarily	O	304-318
conserved	O	319-328
across	O	329-335
the	O	336-339
whole	O	340-345
kingdom	O	346-353
.	O	353-354

More	O	355-359
recent	O	360-366
studies	O	367-374
,	O	374-375
however	O	376-383
,	O	383-384
have	O	385-389
identified	O	390-400
many	O	401-405
miRNAs	O	406-412
that	O	413-417
are	O	418-421
specific	O	422-430
to	O	431-433
a	O	434-435
particular	O	436-446
group	O	447-452
of	O	453-455
organisms	O	456-465
or	O	466-468
even	O	469-473
a	O	474-475
single	O	476-482
species	O	483-490
.	O	490-491

These	O	492-497
present	O	498-505
a	O	506-507
question	O	508-516
about	O	517-522
evolution	O	523-532
of	O	533-535
the	O	536-539
individual	O	540-550
miRNAs	O	551-557
and	O	558-561
their	O	562-567
role	O	568-572
in	O	573-575
establishing	O	576-588
and	O	589-592
maintaining	O	593-604
lineage	O	605-612
-	O	612-613
specific	O	613-621
functions	O	622-631
and	O	632-635
characteristics	O	636-651
.	O	651-652

In	O	653-655
this	O	656-660
study	O	661-666
,	O	666-667
we	O	668-670
describe	O	671-679
a	O	680-681
detailed	O	682-690
analysis	O	691-699
of	O	700-702
the	O	703-706
miRNA	O	707-712
cluster	O	713-720
(	O	721-722
hereafter	O	722-731
mir	B	732-735
-	I	735-736
379	I	736-739
/	O	739-740
mir	B	740-743
-	I	743-744
656	I	744-747
cluster	O	748-755
)	O	755-756
located	O	757-764
within	O	765-771
the	O	772-775
imprinted	O	776-785
DLK	O	786-789
-	O	789-790
DIO3	O	790-794
region	O	795-801
on	O	802-804
human	O	805-810
chromosome	O	811-821
14	O	822-824
.	O	824-825

We	O	826-828
show	O	829-833
that	O	834-838
orthologous	O	839-850
miRNA	O	851-856
clusters	O	857-865
are	O	866-869
present	O	870-877
in	O	878-880
all	O	881-884
sequenced	O	885-894
genomes	O	895-902
of	O	903-905
the	O	906-909
placental	O	910-919
(	O	920-921
eutherian	O	921-930
)	O	930-931
mammals	O	932-939
but	O	940-943
not	O	944-947
in	O	948-950
the	O	951-954
marsupial	O	955-964
(	O	965-966
metatherian	O	966-977
)	O	977-978
,	O	978-979
monotreme	O	980-989
(	O	990-991
prototherian	O	991-1003
)	O	1003-1004
,	O	1004-1005
or	O	1006-1008
any	O	1009-1012
other	O	1013-1018
vertebrate	O	1019-1029
genomes	O	1030-1037
.	O	1037-1038

We	O	1039-1041
provide	O	1042-1049
evidence	O	1050-1058
that	O	1059-1063
the	O	1064-1067
locus	O	1068-1073
encompassing	O	1074-1086
this	O	1087-1091
cluster	O	1092-1099
emerged	O	1100-1107
in	O	1108-1110
an	O	1111-1113
early	O	1114-1119
eutherian	O	1120-1129
ancestor	O	1130-1138
prior	O	1139-1144
to	O	1145-1147
the	O	1148-1151
radiation	O	1152-1161
of	O	1162-1164
modern	O	1165-1171
placental	O	1172-1181
mammals	O	1182-1189
by	O	1190-1192
tandem	O	1193-1199
duplication	O	1200-1211
of	O	1212-1214
the	O	1215-1218
ancient	O	1219-1226
precursor	O	1227-1236
sequence	O	1237-1245
.	O	1245-1246

The	O	1247-1250
original	O	1251-1259
amplified	O	1260-1269
cluster	O	1270-1277
may	O	1278-1281
have	O	1282-1286
contained	O	1287-1296
in	O	1297-1299
excess	O	1300-1306
of	O	1307-1309
250	O	1310-1313
miRNA	O	1314-1319
precursor	O	1320-1329
sequences	O	1330-1339
,	O	1339-1340
most	O	1341-1345
of	O	1346-1348
which	O	1349-1354
now	O	1355-1358
appear	O	1359-1365
to	O	1366-1368
be	O	1369-1371
inactive	O	1372-1380
.	O	1380-1381

Examination	O	1382-1393
of	O	1394-1396
the	O	1397-1400
eutherian	O	1401-1410
genomes	O	1411-1418
showed	O	1419-1425
that	O	1426-1430
the	O	1431-1434
cluster	O	1435-1442
has	O	1443-1446
been	O	1447-1451
maintained	O	1452-1462
in	O	1463-1465
evolution	O	1466-1475
for	O	1476-1479
approximately	O	1480-1493
100	O	1494-1497
Myr	O	1498-1501
.	O	1501-1502

Analysis	O	1503-1511
of	O	1512-1514
genes	O	1515-1520
that	O	1521-1525
contain	O	1526-1533
predicted	O	1534-1543
evolutionarily	O	1544-1558
conserved	O	1559-1568
targets	O	1569-1576
for	O	1577-1580
miRNAs	O	1581-1587
from	O	1588-1592
this	O	1593-1597
cluster	O	1598-1605
revealed	O	1606-1614
significant	O	1615-1626
overrepresentation	O	1627-1645
of	O	1646-1648
the	O	1649-1652
Gene	O	1653-1657
Ontology	O	1658-1666
terms	O	1667-1672
associated	O	1673-1683
with	O	1684-1688
biological	O	1689-1699
processes	O	1700-1709
such	O	1710-1714
as	O	1715-1717
neurogenesis	O	1718-1730
,	O	1730-1731
embryonic	O	1732-1741
development	O	1742-1753
,	O	1753-1754
transcriptional	O	1755-1770
regulation	O	1771-1781
,	O	1781-1782
and	O	1783-1786
RNA	O	1787-1790
metabolism	O	1791-1801
.	O	1801-1802

Consistent	O	1803-1813
with	O	1814-1818
these	O	1819-1824
findings	O	1825-1833
,	O	1833-1834
a	O	1835-1836
survey	O	1837-1843
of	O	1844-1846
the	O	1847-1850
miRNA	O	1851-1856
expression	O	1857-1867
data	O	1868-1872
within	O	1873-1879
the	O	1880-1883
cluster	O	1884-1891
demonstrates	O	1892-1904
a	O	1905-1906
strong	O	1907-1913
bias	O	1914-1918
toward	O	1919-1925
brain	O	1926-1931
and	O	1932-1935
placenta	O	1936-1944
samples	O	1945-1952
from	O	1953-1957
adult	O	1958-1963
organisms	O	1964-1973
and	O	1974-1977
some	O	1978-1982
embryonic	O	1983-1992
tissues	O	1993-2000
.	O	2000-2001

Our	O	2002-2005
results	O	2006-2013
suggest	O	2014-2021
that	O	2022-2026
emergence	O	2027-2036
of	O	2037-2039
the	O	2040-2043
mir	B	2044-2047
-	I	2047-2048
379	I	2048-2051
/	O	2051-2052
mir	B	2052-2055
-	I	2055-2056
656	I	2056-2059
miRNA	O	2060-2065
cluster	O	2066-2073
was	O	2074-2077
one	O	2078-2081
of	O	2082-2084
the	O	2085-2088
factors	O	2089-2096
that	O	2097-2101
facilitated	O	2102-2113
evolution	O	2114-2123
of	O	2124-2126
the	O	2127-2130
placental	O	2131-2140
mammals	O	2141-2148
.	O	2148-2149

Overrepresentation	O	2150-2168
of	O	2169-2171
genes	O	2172-2177
involved	O	2178-2186
in	O	2187-2189
regulation	O	2190-2200
of	O	2201-2203
neurogenesis	O	2204-2216
among	O	2217-2222
predicted	O	2223-2232
miRNAs	O	2233-2239
targets	O	2240-2247
indicates	O	2248-2257
an	O	2258-2260
important	O	2261-2270
role	O	2271-2275
of	O	2276-2278
the	O	2279-2282
mir	B	2283-2286
-	I	2286-2287
379	I	2287-2290
/	O	2290-2291
mir	B	2291-2294
-	I	2294-2295
656	I	2295-2298
cluster	O	2299-2306
in	O	2307-2309
this	O	2310-2314
biological	O	2315-2325
process	O	2326-2333
in	O	2334-2336
the	O	2337-2340
placental	O	2341-2350
mammals	O	2351-2358
.	O	2358-2359

Drosophila	O	0-10
let	B	11-14
-	I	14-15
7	I	15-16
microRNA	O	17-25
is	O	26-28
required	O	29-37
for	O	38-41
remodeling	O	42-52
of	O	53-55
the	O	56-59
neuromusculature	O	60-76
during	O	77-83
metamorphosis	O	84-97
.	O	97-98

The	O	99-102
Drosophila	O	103-113
let	B	114-117
-	I	117-118
7	I	118-119
-	I	119-120
Complex	I	120-127
(	O	128-129
let	B	129-132
-	I	132-133
7	I	133-134
-	I	134-135
C	I	135-136
)	O	136-137
is	O	138-140
a	O	141-142
polycistronic	O	143-156
locus	O	157-162
encoding	O	163-171
three	O	172-177
ancient	O	178-185
microRNAs	O	186-195
:	O	195-196
let	B	197-200
-	I	200-201
7	I	201-202
,	O	202-203
miR	B	204-207
-	I	207-208
100	I	208-211
,	O	211-212
and	O	213-216
fly	O	217-220
lin	B	221-224
-	I	224-225
4	I	225-226
(	O	227-228
miR	B	228-231
-	I	231-232
125	I	232-235
)	O	235-236
.	O	236-237

We	O	238-240
find	O	241-245
that	O	246-250
the	O	251-254
let	B	255-258
-	I	258-259
7	I	259-260
-	I	260-261
C	I	261-262
locus	O	263-268
is	O	269-271
principally	O	272-283
expressed	O	284-293
in	O	294-296
the	O	297-300
pupal	O	301-306
and	O	307-310
adult	O	311-316
neuromusculature	O	317-333
.	O	333-334

let	B	335-338
-	I	338-339
7	I	339-340
-	I	340-341
C	I	341-342
knockout	O	343-351
flies	O	352-357
appear	O	358-364
normal	O	365-371
externally	O	372-382
but	O	383-386
display	O	387-394
defects	O	395-402
in	O	403-405
adult	O	406-411
behaviors	O	412-421
(	O	422-423
e	O	423-424
.	O	424-425
g	O	425-426
.	O	426-427
,	O	427-428
flight	O	429-435
,	O	435-436
motility	O	437-445
,	O	445-446
and	O	447-450
fertility	O	451-460
)	O	460-461
as	O	462-464
well	O	465-469
as	O	470-472
clear	O	473-478
juvenile	O	479-487
features	O	488-496
in	O	497-499
their	O	500-505
neuromusculature	O	506-522
.	O	522-523

We	O	524-526
find	O	527-531
that	O	532-536
the	O	537-540
function	O	541-549
of	O	550-552
let	B	553-556
-	I	556-557
7	I	557-558
-	I	558-559
C	I	559-560
to	O	561-563
ensure	O	564-570
the	O	571-574
appropriate	O	575-586
remodeling	O	587-597
of	O	598-600
the	O	601-604
abdominal	O	605-614
neuromusculature	O	615-631
during	O	632-638
the	O	639-642
larval	O	643-649
-	O	649-650
to	O	650-652
-	O	652-653
adult	O	653-658
transition	O	659-669
is	O	670-672
carried	O	673-680
out	O	681-684
predominantly	O	685-698
by	O	699-701
let	B	702-705
-	I	705-706
7	I	706-707
alone	O	708-713
.	O	713-714

This	O	715-719
heterochronic	O	720-733
role	O	734-738
of	O	739-741
let	B	742-745
-	I	745-746
7	I	746-747
is	O	748-750
likely	O	751-757
just	O	758-762
one	O	763-766
of	O	767-769
the	O	770-773
ways	O	774-778
in	O	779-781
which	O	782-787
let	B	788-791
-	I	791-792
7	I	792-793
-	I	793-794
C	I	794-795
promotes	O	796-804
adult	O	805-810
behavior	O	811-819
.	O	819-820

Differentiation	O	0-15
of	O	16-18
two	O	19-22
types	O	23-28
of	O	29-31
mobilized	O	32-41
peripheral	O	42-52
blood	O	53-58
stem	O	59-63
cells	O	64-69
by	O	70-72
microRNA	O	73-81
and	O	82-85
cDNA	O	86-90
expression	O	91-101
analysis	O	102-110
.	O	110-111

BACKGROUND	O	112-122
:	O	122-123
Mobilized	O	124-133
-	O	133-134
peripheral	O	134-144
blood	O	145-150
hematopoietic	O	151-164
stem	O	165-169
cells	O	170-175
(	O	176-177
HSCs	O	177-181
)	O	181-182
have	O	183-187
been	O	188-192
used	O	193-197
for	O	198-201
transplantation	O	202-217
,	O	217-218
immunotherapy	O	219-232
,	O	232-233
and	O	234-237
cardiovascular	O	238-252
regenerative	O	253-265
medicine	O	266-274
.	O	274-275

Agents	O	276-282
used	O	283-287
for	O	288-291
HSC	O	292-295
mobilization	O	296-308
include	O	309-316
G	O	317-318
-	O	318-319
CSF	O	319-322
and	O	323-326
the	O	327-330
CXCR4	O	331-336
inhibitor	O	337-346
AMD3100	O	347-354
(	O	355-356
plerixafor	O	356-366
)	O	366-367
.	O	367-368

The	O	369-372
HSCs	O	373-377
cells	O	378-383
mobilized	O	384-393
by	O	394-396
each	O	397-401
agent	O	402-407
may	O	408-411
contain	O	412-419
different	O	420-429
subtypes	O	430-438
and	O	439-442
have	O	443-447
different	O	448-457
functions	O	458-467
.	O	467-468

To	O	469-471
characterize	O	472-484
mobilized	O	485-494
HSCs	O	495-499
used	O	500-504
for	O	505-508
clinical	O	509-517
applications	O	518-530
,	O	530-531
microRNA	O	532-540
(	O	541-542
miRNA	O	542-547
)	O	547-548
profiling	O	549-558
and	O	559-562
gene	O	563-567
expression	O	568-578
profiling	O	579-588
were	O	589-593
used	O	594-598
to	O	599-601
compare	O	602-609
AMD3100	O	610-617
-	O	617-618
mobilized	O	618-627
CD133	O	628-633
+	O	633-634
cells	O	635-640
from	O	641-645
4	O	646-647
subjects	O	648-656
,	O	656-657
AMD3100	O	658-665
plus	O	666-670
G	O	671-672
-	O	672-673
CSF	O	673-676
-	O	676-677
mobilized	O	677-686
CD133	O	687-692
+	O	692-693
cells	O	694-699
from	O	700-704
4	O	705-706
subjects	O	707-715
and	O	716-719
G	O	720-721
-	O	721-722
CSF	O	722-725
-	O	725-726
mobilized	O	726-735
CD34	O	736-740
+	O	740-741
cells	O	742-747
from	O	748-752
5	O	753-754
subjects	O	755-763
.	O	763-764

The	O	765-768
HSCs	O	769-773
were	O	774-778
compared	O	779-787
to	O	788-790
peripheral	O	791-801
blood	O	802-807
leukocytes	O	808-818
(	O	819-820
PBLs	O	820-824
)	O	824-825
from	O	826-830
7	O	831-832
subjects	O	833-841
.	O	841-842

RESULTS	O	843-850
:	O	850-851
Hierarchical	O	852-864
clustering	O	865-875
of	O	876-878
miRNAs	O	879-885
separated	O	886-895
HSCs	O	896-900
from	O	901-905
PBLs	O	906-910
.	O	910-911

miRNAs	O	912-918
up	O	919-921
-	O	921-922
regulated	O	922-931
in	O	932-934
all	O	935-938
HSCs	O	939-943
included	O	944-952
hematopoiesis	O	953-966
-	O	966-967
associated	O	967-977
miRNA	O	978-983
;	O	983-984
miR	B	985-988
-	I	988-989
126	I	989-992
,	O	992-993
miR	B	994-997
-	I	997-998
10a	I	998-1001
,	O	1001-1002
miR	B	1003-1006
-	I	1006-1007
221	I	1007-1010
and	O	1011-1014
miR	B	1015-1018
-	I	1018-1019
17	I	1019-1021
-	I	1021-1022
92	I	1022-1024
cluster	O	1025-1032
.	O	1032-1033

miRNAs	O	1034-1040
up	O	1041-1043
-	O	1043-1044
regulated	O	1044-1053
in	O	1054-1056
PBLs	O	1057-1061
included	O	1062-1070
miR	B	1071-1074
-	I	1074-1075
142	I	1075-1078
-	I	1078-1079
3p	I	1079-1081
,	O	1081-1082
-	B	1083-1084
218	I	1084-1087
,	O	1087-1088
-	B	1089-1090
21	I	1090-1092
,	O	1092-1093
and	O	1094-1097
-	B	1098-1099
379	I	1099-1102
.	O	1102-1103

Hierarchical	O	1104-1116
clustering	O	1117-1127
analysis	O	1128-1136
of	O	1137-1139
miRNA	O	1140-1145
expression	O	1146-1156
separated	O	1157-1166
the	O	1167-1170
AMD3100	O	1171-1178
-	O	1178-1179
mobilized	O	1179-1188
CD133	O	1189-1194
+	O	1194-1195
cells	O	1196-1201
from	O	1202-1206
G	O	1207-1208
-	O	1208-1209
CSF	O	1209-1212
-	O	1212-1213
mobilized	O	1213-1222
CD34	O	1223-1227
+	O	1227-1228
cells	O	1229-1234
.	O	1234-1235

Gene	O	1236-1240
expression	O	1241-1251
analysis	O	1252-1260
of	O	1261-1263
the	O	1264-1267
HSCs	O	1268-1272
naturally	O	1273-1282
segregated	O	1283-1293
samples	O	1294-1301
according	O	1302-1311
to	O	1312-1314
mobilization	O	1315-1327
and	O	1328-1331
isolation	O	1332-1341
protocol	O	1342-1350
and	O	1351-1354
cell	O	1355-1359
differentiation	O	1360-1375
status	O	1376-1382
.	O	1382-1383

CONCLUSION	O	1384-1394
:	O	1394-1395
HSCs	O	1396-1400
and	O	1401-1404
PBLs	O	1405-1409
have	O	1410-1414
unique	O	1415-1421
miRNA	O	1422-1427
and	O	1428-1431
gene	O	1432-1436
expression	O	1437-1447
profiles	O	1448-1456
.	O	1456-1457

miRNA	O	1458-1463
and	O	1464-1467
gene	O	1468-1472
expression	O	1473-1483
microarrays	O	1484-1495
maybe	O	1496-1501
useful	O	1502-1508
for	O	1509-1512
assessing	O	1513-1522
differences	O	1523-1534
in	O	1535-1537
HSCs	O	1538-1542
.	O	1542-1543

miR	B	0-3
-	I	3-4
34a	I	4-7
repression	O	8-18
of	O	19-21
SIRT1	O	22-27
regulates	O	28-37
apoptosis	O	38-47
.	O	47-48

MicroRNA	B	49-57
34a	I	58-61
(	O	62-63
miR	B	63-66
-	I	66-67
34a	I	67-70
)	O	70-71
is	O	72-74
a	O	75-76
tumor	O	77-82
suppressor	O	83-93
gene	O	94-98
,	O	98-99
but	O	100-103
how	O	104-107
it	O	108-110
regulates	O	111-120
cell	O	121-125
proliferation	O	126-139
is	O	140-142
not	O	143-146
completely	O	147-157
understood	O	158-168
.	O	168-169

We	O	170-172
now	O	173-176
show	O	177-181
that	O	182-186
the	O	187-190
microRNA	O	191-199
miR	B	200-203
-	I	203-204
34a	I	204-207
regulates	O	208-217
silent	O	218-224
information	O	225-236
regulator	O	237-246
1	O	247-248
(	O	249-250
SIRT1	O	250-255
)	O	255-256
expression	O	257-267
.	O	267-268

MiR	B	269-272
-	I	272-273
34a	I	273-276
inhibits	O	277-285
SIRT1	O	286-291
expression	O	292-302
through	O	303-310
a	O	311-312
miR	B	313-316
-	I	316-317
34a	I	317-320
-	O	320-321
binding	O	321-328
site	O	329-333
within	O	334-340
the	O	341-344
3	O	345-346
'	O	346-347
UTR	O	348-351
of	O	352-354
SIRT1	O	355-360
.	O	360-361

MiR	B	362-365
-	I	365-366
34	I	366-368
inhibition	O	369-379
of	O	380-382
SIRT1	O	383-388
leads	O	389-394
to	O	395-397
an	O	398-400
increase	O	401-409
in	O	410-412
acetylated	O	413-423
p53	O	424-427
and	O	428-431
expression	O	432-442
of	O	443-445
p21	O	446-449
and	O	450-453
PUMA	O	454-458
,	O	458-459
transcriptional	O	460-475
targets	O	476-483
of	O	484-486
p53	O	487-490
that	O	491-495
regulate	O	496-504
the	O	505-508
cell	O	509-513
cycle	O	514-519
and	O	520-523
apoptosis	O	524-533
,	O	533-534
respectively	O	535-547
.	O	547-548

Furthermore	O	549-560
,	O	560-561
miR	B	562-565
-	I	565-566
34	I	566-568
suppression	O	569-580
of	O	581-583
SIRT1	O	584-589
ultimately	O	590-600
leads	O	601-606
to	O	607-609
apoptosis	O	610-619
in	O	620-622
WT	O	623-625
human	O	626-631
colon	O	632-637
cancer	O	638-644
cells	O	645-650
but	O	651-654
not	O	655-658
in	O	659-661
human	O	662-667
colon	O	668-673
cancer	O	674-680
cells	O	681-686
lacking	O	687-694
p53	O	695-698
.	O	698-699

Finally	O	700-707
,	O	707-708
miR	B	709-712
-	I	712-713
34a	I	713-716
itself	O	717-723
is	O	724-726
a	O	727-728
transcriptional	O	729-744
target	O	745-751
of	O	752-754
p53	O	755-758
,	O	758-759
suggesting	O	760-770
a	O	771-772
positive	O	773-781
feedback	O	782-790
loop	O	791-795
between	O	796-803
p53	O	804-807
and	O	808-811
miR	B	812-815
-	I	815-816
34a	I	816-819
.	O	819-820

Thus	O	821-825
,	O	825-826
miR	B	827-830
-	I	830-831
34a	I	831-834
functions	O	835-844
as	O	845-847
a	O	848-849
tumor	O	850-855
suppressor	O	856-866
,	O	866-867
in	O	868-870
part	O	871-875
,	O	875-876
through	O	877-884
a	O	885-886
SIRT1	O	887-892
-	O	892-893
p53	O	893-896
pathway	O	897-904
.	O	904-905

Impaired	O	0-8
micro	O	9-14
-	O	14-15
RNA	O	15-18
pathways	O	19-27
diminish	O	28-36
osteoclast	O	37-47
differentiation	O	48-63
and	O	64-67
function	O	68-76
.	O	76-77

Micro	O	78-83
-	O	83-84
RNAs	O	84-88
(	O	89-90
miRNAs	O	90-96
)	O	96-97
are	O	98-101
important	O	102-111
in	O	112-114
regulating	O	115-125
cell	O	126-130
fate	O	131-135
determination	O	136-149
because	O	150-157
many	O	158-162
of	O	163-165
their	O	166-171
target	O	172-178
mRNA	O	179-183
transcripts	O	184-195
are	O	196-199
engaged	O	200-207
in	O	208-210
cell	O	211-215
proliferation	O	216-229
,	O	229-230
differentiation	O	231-246
,	O	246-247
and	O	248-251
apoptosis	O	252-261
.	O	261-262

DGCR8	O	263-268
,	O	268-269
Dicer	O	270-275
,	O	275-276
and	O	277-280
Ago2	O	281-285
are	O	286-289
essential	O	290-299
factors	O	300-307
for	O	308-311
miRNA	O	312-317
homeostasis	O	318-329
.	O	329-330

Here	O	331-335
we	O	336-338
show	O	339-343
that	O	344-348
these	O	349-354
three	O	355-360
factors	O	361-368
have	O	369-373
critical	O	374-382
roles	O	383-388
in	O	389-391
osteoclast	O	392-402
differentiation	O	403-418
and	O	419-422
function	O	423-431
.	O	431-432

Gene	O	433-437
silencing	O	438-447
of	O	448-450
DGCR8	O	451-456
,	O	456-457
Dicer	O	458-463
,	O	463-464
or	O	465-467
Ago2	O	468-472
by	O	473-475
small	O	476-481
interfering	O	482-493
RNA	O	494-497
revealed	O	498-506
global	O	507-513
inhibition	O	514-524
of	O	525-527
osteoclast	O	528-538
transcription	O	539-552
factor	O	553-559
expression	O	560-570
and	O	571-574
function	O	575-583
,	O	583-584
decreased	O	585-594
osteoclastogenesis	O	595-613
,	O	613-614
and	O	615-618
decreased	O	619-628
bone	O	629-633
resorption	O	634-644
in	O	645-647
vitro	O	648-653
.	O	653-654

In	O	655-657
vivo	O	658-662
,	O	662-663
CD11b	O	664-669
(	O	669-670
+	O	670-671
)	O	671-672
-	O	672-673
cre	O	673-676
/	O	676-677
Dicer	O	677-682
-	O	682-683
null	O	683-687
mice	O	688-692
had	O	693-696
mild	O	697-701
osteopetrosis	O	702-715
caused	O	716-722
by	O	723-725
decreased	O	726-735
osteoclast	O	736-746
number	O	747-753
and	O	754-757
bone	O	758-762
resorption	O	763-773
.	O	773-774

These	O	775-780
results	O	781-788
suggest	O	789-796
that	O	797-801
miRNAs	O	802-808
play	O	809-813
important	O	814-823
roles	O	824-829
in	O	830-832
differentiation	O	833-848
and	O	849-852
function	O	853-861
of	O	862-864
osteoclasts	O	865-876
in	O	877-879
vitro	O	880-885
and	O	886-889
in	O	890-892
vivo	O	893-897
.	O	897-898

We	O	899-901
found	O	902-907
a	O	908-909
novel	O	910-915
mechanism	O	916-925
mediating	O	926-935
these	O	936-941
results	O	942-949
in	O	950-952
which	O	953-958
PU	O	959-961
.	O	961-962
1	O	962-963
,	O	963-964
miRNA	B	965-970
-	I	970-971
223	I	971-974
,	O	974-975
NFI	O	976-979
-	O	979-980
A	O	980-981
,	O	981-982
and	O	983-986
the	O	987-990
macrophage	O	991-1001
colony	O	1002-1008
-	O	1008-1009
stimulating	O	1009-1020
factor	O	1021-1027
receptor	O	1028-1036
(	O	1037-1038
M	O	1038-1039
-	O	1039-1040
CSFR	O	1040-1044
)	O	1044-1045
are	O	1046-1049
closely	O	1050-1057
linked	O	1058-1064
through	O	1065-1072
a	O	1073-1074
positive	O	1075-1083
feedback	O	1084-1092
loop	O	1093-1097
.	O	1097-1098

PU	O	1099-1101
.	O	1101-1102
1	O	1102-1103
stimulates	O	1104-1114
miRNA	B	1115-1120
-	I	1120-1121
223	I	1121-1124
expression	O	1125-1135
,	O	1135-1136
and	O	1137-1140
this	O	1141-1145
up	O	1146-1148
-	O	1148-1149
regulation	O	1149-1159
is	O	1160-1162
implicated	O	1163-1173
in	O	1174-1176
stimulating	O	1177-1188
differentiation	O	1189-1204
and	O	1205-1208
function	O	1209-1217
of	O	1218-1220
osteoclasts	O	1221-1232
through	O	1233-1240
negative	O	1241-1249
regulation	O	1250-1260
of	O	1261-1263
NFI	O	1264-1267
-	O	1267-1268
A	O	1268-1269
levels	O	1270-1276
.	O	1276-1277

Down	O	1278-1282
-	O	1282-1283
regulation	O	1283-1293
of	O	1294-1296
NFI	O	1297-1300
-	O	1300-1301
A	O	1301-1302
levels	O	1303-1309
is	O	1310-1312
important	O	1313-1322
for	O	1323-1326
expression	O	1327-1337
of	O	1338-1340
the	O	1341-1344
M	O	1345-1346
-	O	1346-1347
CSFR	O	1347-1351
,	O	1351-1352
which	O	1353-1358
is	O	1359-1361
critical	O	1362-1370
for	O	1371-1374
osteoclast	O	1375-1385
differentiation	O	1386-1401
and	O	1402-1405
function	O	1406-1414
.	O	1414-1415

NFI	O	1416-1419
-	O	1419-1420
A	O	1420-1421
overexpression	O	1422-1436
decreased	O	1437-1446
osteoclast	O	1447-1457
formation	O	1458-1467
and	O	1468-1471
function	O	1472-1480
with	O	1481-1485
down	O	1486-1490
-	O	1490-1491
regulation	O	1491-1501
of	O	1502-1504
M	O	1505-1506
-	O	1506-1507
CSFR	O	1507-1511
levels	O	1512-1518
.	O	1518-1519

Forced	O	1520-1526
expression	O	1527-1537
of	O	1538-1540
the	O	1541-1544
M	O	1545-1546
-	O	1546-1547
CSFR	O	1547-1551
in	O	1552-1554
M	O	1555-1556
-	O	1556-1557
CSF	O	1557-1560
-	O	1560-1561
dependent	O	1561-1570
bone	O	1571-1575
marrow	O	1576-1582
macrophages	O	1583-1594
from	O	1595-1599
Dicer	O	1600-1605
-	O	1605-1606
deficient	O	1606-1615
mice	O	1616-1620
rescued	O	1621-1628
osteoclast	O	1629-1639
differentiation	O	1640-1655
with	O	1656-1660
up	O	1661-1663
-	O	1663-1664
regulation	O	1664-1674
of	O	1675-1677
PU	O	1678-1680
.	O	1680-1681
1	O	1681-1682
levels	O	1683-1689
.	O	1689-1690

Our	O	1691-1694
studies	O	1695-1702
provide	O	1703-1710
new	O	1711-1714
molecular	O	1715-1724
mechanisms	O	1725-1735
controlling	O	1736-1747
osteoclast	O	1748-1758
differentiation	O	1759-1774
and	O	1775-1778
function	O	1779-1787
by	O	1788-1790
the	O	1791-1794
miRNA	O	1795-1800
system	O	1801-1807
and	O	1808-1811
specifically	O	1812-1824
by	O	1825-1827
miRNA	B	1828-1833
-	I	1833-1834
223	I	1834-1837
,	O	1837-1838
which	O	1839-1844
regulates	O	1845-1854
NFI	O	1855-1858
-	O	1858-1859
A	O	1859-1860
and	O	1861-1864
the	O	1865-1868
M	O	1869-1870
-	O	1870-1871
CSFR	O	1871-1875
levels	O	1876-1882
.	O	1882-1883

In	O	0-2
vitro	O	3-8
evidence	O	9-17
suggests	O	18-26
that	O	27-31
miR	B	32-35
-	I	35-36
133a	I	36-40
-	O	40-41
mediated	O	41-49
regulation	O	50-60
of	O	61-63
uncoupling	O	64-74
protein	O	75-82
2	O	83-84
(	O	85-86
UCP2	O	86-90
)	O	90-91
is	O	92-94
an	O	95-97
indispensable	O	98-111
step	O	112-116
in	O	117-119
myogenic	O	120-128
differentiation	O	129-144
.	O	144-145

UCP2	O	146-150
and	O	151-154
UCP3	O	155-159
,	O	159-160
two	O	161-164
novel	O	165-170
uncoupling	O	171-181
proteins	O	182-190
,	O	190-191
are	O	192-195
important	O	196-205
regulators	O	206-216
of	O	217-219
energy	O	220-226
expenditure	O	227-238
and	O	239-242
thermogenesis	O	243-256
in	O	257-259
various	O	260-267
organisms	O	268-277
.	O	277-278

The	O	279-282
striking	O	283-291
disparity	O	292-301
between	O	302-309
UCP2	O	310-314
mRNA	O	315-319
and	O	320-323
protein	O	324-331
levels	O	332-338
in	O	339-341
muscle	O	342-348
tissues	O	349-356
prompted	O	357-365
initial	O	366-373
speculation	O	374-385
that	O	386-390
microRNAs	O	391-400
are	O	401-404
implicated	O	405-415
in	O	416-418
the	O	419-422
regulatory	O	423-433
pathway	O	434-441
of	O	442-444
UCP2	O	445-449
.	O	449-450

We	O	451-453
found	O	454-459
,	O	459-460
for	O	461-464
the	O	465-468
first	O	469-474
time	O	475-479
,	O	479-480
that	O	481-485
the	O	486-489
repression	O	490-500
of	O	501-503
UCP2	O	504-508
expression	O	509-519
in	O	520-522
cardiac	O	523-530
and	O	531-534
skeletal	O	535-543
muscle	O	544-550
resulted	O	551-559
from	O	560-564
its	O	565-568
targeting	O	569-578
by	O	579-581
a	O	582-583
muscle	O	584-590
-	O	590-591
specific	O	591-599
microRNA	O	600-608
,	O	608-609
miR	B	610-613
-	I	613-614
133a	I	614-618
.	O	618-619

Moreover	O	620-628
,	O	628-629
our	O	630-633
findings	O	634-642
illustrate	O	643-653
a	O	654-655
novel	O	656-661
function	O	662-670
of	O	671-673
UCP2	O	674-678
as	O	679-681
a	O	682-683
brake	O	684-689
for	O	690-693
muscle	O	694-700
development	O	701-712
.	O	712-713

We	O	714-716
also	O	717-721
show	O	722-726
that	O	727-731
MyoD	O	732-736
can	O	737-740
remove	O	741-747
the	O	748-751
braking	O	752-759
role	O	760-764
of	O	765-767
UCP2	O	768-772
via	O	773-776
direct	O	777-783
up	O	784-786
-	O	786-787
regulation	O	787-797
of	O	798-800
miR	B	801-804
-	I	804-805
133a	I	805-809
during	O	810-816
myogenic	O	817-825
differentiation	O	826-841
.	O	841-842

Taken	O	843-848
together	O	849-857
,	O	857-858
our	O	859-862
current	O	863-870
work	O	871-875
delineates	O	876-886
a	O	887-888
novel	O	889-894
regulatory	O	895-905
network	O	906-913
employing	O	914-923
MyoD	O	924-928
,	O	928-929
microRNA	O	930-938
,	O	938-939
and	O	940-943
uncoupling	O	944-954
proteins	O	955-963
to	O	964-966
fine	O	967-971
-	O	971-972
tune	O	972-976
the	O	977-980
balance	O	981-988
between	O	989-996
muscle	O	997-1003
differentiation	O	1004-1019
and	O	1020-1023
proliferation	O	1024-1037
during	O	1038-1044
myogenesis	O	1045-1055
.	O	1055-1056

Involvement	O	0-11
of	O	12-14
MicroRNAs	O	15-24
in	O	25-27
hydrogen	O	28-36
peroxide	O	37-45
-	O	45-46
mediated	O	46-54
gene	O	55-59
regulation	O	60-70
and	O	71-74
cellular	O	75-83
injury	O	84-90
response	O	91-99
in	O	100-102
vascular	O	103-111
smooth	O	112-118
muscle	O	119-125
cells	O	126-131
.	O	131-132

MicroRNAs	O	133-142
(	O	143-144
miRNAs	O	144-150
)	O	150-151
comprise	O	152-160
a	O	161-162
novel	O	163-168
class	O	169-174
of	O	175-177
endogenous	O	178-188
,	O	188-189
small	O	190-195
,	O	195-196
noncoding	O	197-206
RNAs	O	207-211
that	O	212-216
negatively	O	217-227
regulate	O	228-236
approximately	O	237-250
30	O	251-253
%	O	253-254
of	O	255-257
genes	O	258-263
in	O	264-266
a	O	267-268
cell	O	269-273
via	O	274-277
degradation	O	278-289
or	O	290-292
translational	O	293-306
inhibition	O	307-317
of	O	318-320
their	O	321-326
target	O	327-333
mRNAs	O	334-339
.	O	339-340

However	O	341-348
,	O	348-349
the	O	350-353
effects	O	354-361
of	O	362-364
reactive	O	365-373
oxygen	O	374-380
species	O	381-388
(	O	389-390
ROS	O	390-393
)	O	393-394
on	O	395-397
miRNA	O	398-403
expression	O	404-414
and	O	415-418
the	O	419-422
roles	O	423-428
of	O	429-431
miRNAs	O	432-438
in	O	439-441
ROS	O	442-445
-	O	445-446
mediated	O	446-454
gene	O	455-459
regulation	O	460-470
and	O	471-474
biological	O	475-485
functions	O	486-495
of	O	496-498
vascular	O	499-507
cells	O	508-513
are	O	514-517
unclear	O	518-525
.	O	525-526

Using	O	527-532
microarray	O	533-543
analysis	O	544-552
,	O	552-553
we	O	554-556
demonstrated	O	557-569
that	O	570-574
miRNAs	O	575-581
are	O	582-585
aberrantly	O	586-596
expressed	O	597-606
in	O	607-609
vascular	O	610-618
smooth	O	619-625
muscle	O	626-632
cells	O	633-638
(	O	639-640
VSMCs	O	640-645
)	O	645-646
after	O	647-652
treatment	O	653-662
with	O	663-667
hydrogen	O	668-676
peroxide	O	677-685
(	O	686-687
H	O	687-688
(	O	688-689
2	O	689-690
)	O	690-691
O	O	691-692
(	O	692-693
2	O	693-694
)	O	694-695
)	O	695-696
.	O	696-697

H	O	698-699
(	O	699-700
2	O	700-701
)	O	701-702
O	O	702-703
(	O	703-704
2	O	704-705
)	O	705-706
-	O	706-707
mediated	O	707-715
up	O	716-718
-	O	718-719
regulation	O	719-729
of	O	730-732
microRNA	B	733-741
-	I	741-742
21	I	742-744
(	O	745-746
miR	B	746-749
-	I	749-750
21	I	750-752
)	O	752-753
was	O	754-757
further	O	758-765
confirmed	O	766-775
by	O	776-778
quantitative	O	779-791
real	O	792-796
-	O	796-797
time	O	797-801
PCR	O	802-805
.	O	805-806

To	O	807-809
determine	O	810-819
the	O	820-823
potential	O	824-833
roles	O	834-839
of	O	840-842
miRNAs	O	843-849
in	O	850-852
H	O	853-854
(	O	854-855
2	O	855-856
)	O	856-857
O	O	857-858
(	O	858-859
2	O	859-860
)	O	860-861
-	O	861-862
mediated	O	862-870
gene	O	871-875
regulation	O	876-886
and	O	887-890
cellular	O	891-899
effects	O	900-907
,	O	907-908
miR	B	909-912
-	I	912-913
21	I	913-915
expression	O	916-926
was	O	927-930
down	O	931-935
-	O	935-936
regulated	O	936-945
by	O	946-948
miR	B	949-952
-	I	952-953
21	I	953-955
inhibitor	O	956-965
and	O	966-969
up	O	970-972
-	O	972-973
regulated	O	973-982
by	O	983-985
pre	B	986-989
-	I	989-990
miR	I	990-993
-	I	993-994
21	I	994-996
.	O	996-997

H	O	998-999
(	O	999-1000
2	O	1000-1001
)	O	1001-1002
O	O	1002-1003
(	O	1003-1004
2	O	1004-1005
)	O	1005-1006
-	O	1006-1007
induced	O	1007-1014
VSMC	O	1015-1019
apoptosis	O	1020-1029
and	O	1030-1033
death	O	1034-1039
were	O	1040-1044
increased	O	1045-1054
by	O	1055-1057
miR	B	1058-1061
-	I	1061-1062
21	I	1062-1064
inhibitor	O	1065-1074
and	O	1075-1078
decreased	O	1079-1088
by	O	1089-1091
pre	B	1092-1095
-	I	1095-1096
miR	I	1096-1099
-	I	1099-1100
21	I	1100-1102
.	O	1102-1103

Programmed	O	1104-1114
cell	O	1115-1119
death	O	1120-1125
4	O	1126-1127
(	O	1127-1128
PDCD4	O	1128-1133
)	O	1133-1134
was	O	1135-1138
a	O	1139-1140
direct	O	1141-1147
target	O	1148-1154
of	O	1155-1157
miR	B	1158-1161
-	I	1161-1162
21	I	1162-1164
that	O	1165-1169
was	O	1170-1173
involved	O	1174-1182
in	O	1183-1185
miR	B	1186-1189
-	I	1189-1190
21	I	1190-1192
-	O	1192-1193
mediated	O	1193-1201
effects	O	1202-1209
on	O	1210-1212
VSMCs	O	1213-1218
.	O	1218-1219

Pre	B	1220-1223
-	I	1223-1224
miR	I	1224-1227
-	I	1227-1228
21	I	1228-1230
-	O	1230-1231
mediated	O	1231-1239
protective	O	1240-1250
effect	O	1251-1257
on	O	1258-1260
VSMC	O	1261-1265
apoptosis	O	1266-1275
and	O	1276-1279
death	O	1280-1285
was	O	1286-1289
blocked	O	1290-1297
via	O	1298-1301
adenovirus	O	1302-1312
-	O	1312-1313
mediated	O	1313-1321
overexpression	O	1322-1336
of	O	1337-1339
PDCD4	O	1340-1345
without	O	1346-1353
the	O	1354-1357
miR	B	1358-1361
-	I	1361-1362
21	I	1362-1364
binding	O	1365-1372
site	O	1373-1377
.	O	1377-1378

Moreover	O	1379-1387
,	O	1387-1388
activator	O	1389-1398
protein	O	1399-1406
1	O	1407-1408
was	O	1409-1412
a	O	1413-1414
downstream	O	1415-1425
signaling	O	1426-1435
molecule	O	1436-1444
of	O	1445-1447
PDCD4	O	1448-1453
in	O	1454-1456
miR	B	1457-1460
-	I	1460-1461
21	I	1461-1463
-	O	1463-1464
modulated	O	1464-1473
VSMCs	O	1474-1479
.	O	1479-1480

The	O	1481-1484
results	O	1485-1492
suggest	O	1493-1500
that	O	1501-1505
miRNAs	O	1506-1512
in	O	1513-1515
VSMCs	O	1516-1521
are	O	1522-1525
sensitive	O	1526-1535
to	O	1536-1538
H	O	1539-1540
(	O	1540-1541
2	O	1541-1542
)	O	1542-1543
O	O	1543-1544
(	O	1544-1545
2	O	1545-1546
)	O	1546-1547
stimulation	O	1548-1559
.	O	1559-1560

miRN	O	1561-1565
-	O	1565-1566
21	O	1566-1568
participates	O	1569-1581
in	O	1582-1584
H	O	1585-1586
(	O	1586-1587
2	O	1587-1588
)	O	1588-1589
O	O	1589-1590
(	O	1590-1591
2	O	1591-1592
)	O	1592-1593
-	O	1593-1594
mediated	O	1594-1602
gene	O	1603-1607
regulation	O	1608-1618
and	O	1619-1622
cellular	O	1623-1631
injury	O	1632-1638
response	O	1639-1647
through	O	1648-1655
PDCD4	O	1656-1661
and	O	1662-1665
the	O	1666-1669
activator	O	1670-1679
protein	O	1680-1687
1	O	1688-1689
pathway	O	1690-1697
.	O	1697-1698

miRNAs	O	1699-1705
might	O	1706-1711
play	O	1712-1716
a	O	1717-1718
role	O	1719-1723
in	O	1724-1726
vascular	O	1727-1735
diseases	O	1736-1744
related	O	1745-1752
to	O	1753-1755
ROS	O	1756-1759
.	O	1759-1760

[	O	0-1
MicroRNA	O	1-9
and	O	10-13
central	O	14-21
nervous	O	22-29
system	O	30-36
]	O	36-37
.	O	37-38

MicroRNAs	O	39-48
(	O	49-50
miRNAs	O	50-56
)	O	56-57
are	O	58-61
21	O	62-64
-	O	64-65
24	O	65-67
nucleotide	O	68-78
(	O	79-80
nt	O	80-82
)	O	82-83
duplex	O	84-90
RNAs	O	91-95
that	O	96-100
participate	O	101-112
in	O	113-115
the	O	116-119
translational	O	120-133
regulation	O	134-144
of	O	145-147
messenger	O	148-157
RNAs	O	158-162
(	O	163-164
mRNA	O	164-168
)	O	168-169
.	O	169-170

These	O	171-176
miRNAs	O	177-183
are	O	184-187
created	O	188-195
from	O	196-200
precursor	O	201-210
transcripts	O	211-222
by	O	223-225
subsequent	O	226-236
processing	O	237-247
steps	O	248-253
that	O	254-258
are	O	259-262
mediated	O	263-271
by	O	272-274
Drosha	O	275-281
and	O	282-285
Dicer	O	286-291
-	O	291-292
members	O	292-299
of	O	300-302
the	O	303-306
RNAseIII	O	307-315
family	O	316-322
.	O	322-323

One	O	324-327
of	O	328-330
the	O	331-334
two	O	335-338
strands	O	339-346
is	O	347-349
incorporated	O	350-362
into	O	363-367
the	O	368-371
active	O	372-378
sites	O	379-384
of	O	385-387
a	O	388-389
protein	O	390-397
that	O	398-402
belongs	O	403-410
to	O	411-413
the	O	414-417
argonaute	O	418-427
family	O	428-434
of	O	435-437
proteins	O	438-446
,	O	446-447
where	O	448-453
it	O	454-456
serves	O	457-463
as	O	464-466
a	O	467-468
guide	O	469-474
for	O	475-478
complementary	O	479-492
sequences	O	493-502
in	O	503-505
the	O	506-509
3	O	510-511
'	O	511-512
-	O	512-513
UTR	O	513-516
site	O	517-521
of	O	522-524
the	O	525-528
target	O	529-535
mRNAs	O	536-541
.	O	541-542

miRNAs	O	543-549
are	O	550-553
expressed	O	554-563
at	O	564-566
high	O	567-571
levels	O	572-578
within	O	579-585
the	O	586-589
as	O	590-592
well	O	593-597
as	O	598-600
mature	O	601-607
developing	O	608-618
brain	O	619-624
.	O	624-625

These	O	626-631
miRNAs	O	632-638
orchestrate	O	639-650
the	O	651-654
maintenance	O	655-666
of	O	667-669
adult	O	670-675
neural	O	676-682
cell	O	683-687
traits	O	688-694
,	O	694-695
promote	O	696-703
cellular	O	704-712
homeostasis	O	713-724
and	O	725-728
dampen	O	729-735
endogenous	O	736-746
and	O	747-750
exogenous	O	751-760
stress	O	761-767
responses	O	768-777
,	O	777-778
and	O	779-782
modulate	O	783-791
multiple	O	792-800
parameters	O	801-811
that	O	812-816
are	O	817-820
associated	O	821-831
with	O	832-836
synaptic	O	837-845
plasticity	O	846-856
.	O	856-857

In	O	858-860
this	O	861-865
regard	O	866-872
,	O	872-873
the	O	874-877
expression	O	878-888
of	O	889-891
a	O	892-893
brain	O	894-899
-	O	899-900
specific	O	900-908
miRNA	O	909-914
(	O	915-916
miR	B	916-919
-	I	919-920
124a	I	920-924
)	O	924-925
in	O	926-928
nonneuronal	O	929-940
cells	O	941-946
enables	O	947-954
the	O	955-958
conversion	O	959-969
of	O	970-972
the	O	973-976
overall	O	977-984
gene	O	985-989
-	O	989-990
expression	O	990-1000
pattern	O	1001-1008
to	O	1009-1011
a	O	1012-1013
neuronal	O	1014-1022
one	O	1023-1026
.	O	1026-1027

Another	O	1028-1035
brain	O	1036-1041
-	O	1041-1042
specific	O	1042-1050
miRNA	O	1051-1056
,	O	1056-1057
namely	O	1058-1064
,	O	1064-1065
miR	B	1066-1069
-	I	1069-1070
134	I	1070-1073
,	O	1073-1074
modulates	O	1075-1084
the	O	1085-1088
development	O	1089-1100
of	O	1101-1103
dendritic	O	1104-1113
spines	O	1114-1120
-	O	1120-1121
neuronal	O	1121-1129
protrusions	O	1130-1141
that	O	1142-1146
connect	O	1147-1154
with	O	1155-1159
other	O	1160-1165
neurons	O	1166-1173
-	O	1173-1174
and	O	1174-1177
therefore	O	1178-1187
probably	O	1188-1196
controls	O	1197-1205
neuronal	O	1206-1214
transmission	O	1215-1227
and	O	1228-1231
plasticity	O	1232-1242
.	O	1242-1243

Recent	O	1244-1250
evidence	O	1251-1259
suggests	O	1260-1268
that	O	1269-1273
miRNAs	O	1274-1280
may	O	1281-1284
be	O	1285-1287
a	O	1288-1289
contributing	O	1290-1302
factor	O	1303-1309
cases	O	1310-1315
of	O	1316-1318
neurodegeneration	O	1319-1336
,	O	1336-1337
such	O	1338-1342
as	O	1343-1345
those	O	1346-1351
in	O	1352-1354
Alzheimer	O	1355-1364
diseases	O	1365-1373
and	O	1374-1377
polyglutamine	O	1378-1391
diseases	O	1392-1400
.	O	1400-1401

Research	O	1402-1410
on	O	1411-1413
miRNAs	O	1414-1420
in	O	1421-1423
the	O	1424-1427
context	O	1428-1435
of	O	1436-1438
neurodegeneration	O	1439-1456
has	O	1457-1460
been	O	1461-1465
rapidly	O	1466-1473
advancing	O	1474-1483
,	O	1483-1484
and	O	1485-1488
the	O	1489-1492
goal	O	1493-1497
of	O	1498-1500
this	O	1501-1505
review	O	1506-1512
is	O	1513-1515
to	O	1516-1518
provide	O	1519-1526
perspective	O	1527-1538
for	O	1539-1542
new	O	1543-1546
data	O	1547-1551
that	O	1552-1556
may	O	1557-1560
aid	O	1561-1564
specialists	O	1565-1576
in	O	1577-1579
this	O	1580-1584
field	O	1585-1590
.	O	1590-1591

Identification	O	0-14
of	O	15-17
novel	O	18-23
microRNA	O	24-32
targets	O	33-40
based	O	41-46
on	O	47-49
microRNA	O	50-58
signatures	O	59-69
in	O	70-72
bladder	O	73-80
cancer	O	81-87
.	O	87-88

MicroRNAs	O	89-98
(	O	99-100
miRNAs	O	100-106
)	O	106-107
are	O	108-111
small	O	112-117
noncoding	O	118-127
RNAs	O	128-132
that	O	133-137
negatively	O	138-148
regulate	O	149-157
protein	O	158-165
-	O	165-166
coding	O	166-172
genes	O	173-178
.	O	178-179

To	O	180-182
identify	O	183-191
miRNAs	O	192-198
that	O	199-203
have	O	204-208
a	O	209-210
tumor	O	211-216
suppressive	O	217-228
function	O	229-237
in	O	238-240
bladder	O	241-248
cancer	O	249-255
(	O	256-257
BC	O	257-259
)	O	259-260
,	O	260-261
156	O	262-265
miRNAs	O	266-272
were	O	273-277
screened	O	278-286
in	O	287-289
14	O	290-292
BCs	O	293-296
,	O	296-297
5	O	298-299
normal	O	300-306
bladder	O	307-314
epithelium	O	315-325
(	O	326-327
NBE	O	327-330
)	O	330-331
samples	O	332-339
and	O	340-343
3	O	344-345
BC	O	346-348
cell	O	349-353
lines	O	354-359
.	O	359-360

We	O	361-363
identified	O	364-374
a	O	375-376
subset	O	377-383
of	O	384-386
7	O	387-388
miRNAs	O	389-395
(	O	396-397
miR	B	397-400
-	I	400-401
145	I	401-404
,	O	404-405
miR	B	406-409
-	I	409-410
30a	I	410-413
-	I	413-414
3p	I	414-416
,	O	416-417
miR	B	418-421
-	I	421-422
133a	I	422-426
,	O	426-427
miR	B	428-431
-	I	431-432
133b	I	432-436
,	O	436-437
miR	B	438-441
-	I	441-442
195	I	442-445
,	O	445-446
miR	B	447-450
-	I	450-451
125b	I	451-455
and	O	456-459
miR	B	460-463
-	I	463-464
199a	I	464-468
*	I	468-469
)	O	469-470
that	O	471-475
were	O	476-480
significantly	O	481-494
downregulated	O	495-508
in	O	509-511
BCs	O	512-515
.	O	515-516

To	O	517-519
confirm	O	520-527
these	O	528-533
results	O	534-541
,	O	541-542
104	O	543-546
BCs	O	547-550
and	O	551-554
31	O	555-557
NBEs	O	558-562
were	O	563-567
subjected	O	568-577
to	O	578-580
real	O	581-585
-	O	585-586
time	O	586-590
RT	O	591-593
-	O	593-594
PCR	O	594-597
-	O	597-598
based	O	598-603
experiments	O	604-615
,	O	615-616
and	O	617-620
the	O	621-624
expression	O	625-635
levels	O	636-642
of	O	643-645
each	O	646-650
miRNA	O	651-656
were	O	657-661
significantly	O	662-675
downregulated	O	676-689
in	O	690-692
BCs	O	693-696
(	O	697-698
p	O	698-699
<	O	700-701
0	O	702-703
.	O	703-704
0001	O	704-708
in	O	709-711
all	O	712-715
)	O	715-716
.	O	716-717

Receiver	O	718-726
-	O	726-727
operating	O	727-736
characteristic	O	737-751
curve	O	752-757
analysis	O	758-766
revealed	O	767-775
that	O	776-780
the	O	781-784
expression	O	785-795
levels	O	796-802
of	O	803-805
these	O	806-811
miRNAs	O	812-818
had	O	819-822
good	O	823-827
sensitivity	O	828-839
(	O	840-841
>	O	841-842
70	O	842-844
%	O	844-845
)	O	845-846
and	O	847-850
specificity	O	851-862
(	O	863-864
>	O	864-865
75	O	865-867
%	O	867-868
)	O	868-869
to	O	870-872
distinguish	O	873-884
BC	O	885-887
from	O	888-892
NBE	O	893-896
.	O	896-897

Our	O	898-901
target	O	902-908
search	O	909-915
algorithm	O	916-925
and	O	926-929
gene	O	930-934
-	O	934-935
expression	O	935-945
profiling	O	946-955
in	O	956-958
BCs	O	959-962
(	O	963-964
Kawakami	O	964-972
et	O	973-975
al	O	976-978
.	O	978-979
,	O	979-980
Oncol	O	981-986
Rep	O	987-990
2006	O	991-995
;	O	995-996
16	O	996-998
:	O	998-999
521	O	999-1002
-	O	1002-1003
31	O	1003-1005
)	O	1005-1006
revealed	O	1007-1015
that	O	1016-1020
Keratin7	O	1021-1029
(	O	1030-1031
KRT7	O	1031-1035
)	O	1035-1036
mRNA	O	1037-1041
was	O	1042-1045
a	O	1046-1047
common	O	1048-1054
target	O	1055-1061
of	O	1062-1064
the	O	1065-1068
downregulated	O	1069-1082
miRNAs	O	1083-1089
,	O	1089-1090
and	O	1091-1094
the	O	1095-1098
mRNA	O	1099-1103
expression	O	1104-1114
levels	O	1115-1121
of	O	1122-1124
KRT7	O	1125-1129
were	O	1130-1134
significantly	O	1135-1148
higher	O	1149-1155
in	O	1156-1158
BCs	O	1159-1162
than	O	1163-1167
in	O	1168-1170
NBEs	O	1171-1175
(	O	1176-1177
p	O	1177-1178
=	O	1179-1180
0	O	1181-1182
.	O	1182-1183
0004	O	1183-1187
)	O	1187-1188
.	O	1188-1189

Spearman	O	1190-1198
rank	O	1199-1203
correlation	O	1204-1215
analysis	O	1216-1224
revealed	O	1225-1233
significant	O	1234-1245
inverse	O	1246-1253
correlations	O	1254-1266
between	O	1267-1274
KRT7	O	1275-1279
mRNA	O	1280-1284
expression	O	1285-1295
and	O	1296-1299
each	O	1300-1304
downregulated	O	1305-1318
miRNA	O	1319-1324
(	O	1325-1326
p	O	1326-1327
<	O	1328-1329
0	O	1330-1331
.	O	1331-1332
0001	O	1332-1336
in	O	1337-1339
all	O	1340-1343
)	O	1343-1344
.	O	1344-1345

Gain	O	1346-1350
-	O	1350-1351
of	O	1351-1353
-	O	1353-1354
function	O	1354-1362
analysis	O	1363-1371
revealed	O	1372-1380
that	O	1381-1385
KRT7	O	1386-1390
mRNA	O	1391-1395
was	O	1396-1399
significantly	O	1400-1413
reduced	O	1414-1421
by	O	1422-1424
transfection	O	1425-1437
of	O	1438-1440
3	O	1441-1442
miRNAs	O	1443-1449
(	O	1450-1451
miR	B	1451-1454
-	I	1454-1455
30	I	1455-1457
-	I	1457-1458
3p	I	1458-1460
,	O	1460-1461
miR	B	1462-1465
-	I	1465-1466
133a	I	1466-1470
and	O	1471-1474
miR	B	1475-1478
-	I	1478-1479
199a	I	1479-1483
*	I	1483-1484
)	O	1484-1485
in	O	1486-1488
the	O	1489-1492
BC	O	1493-1495
cell	O	1496-1500
line	O	1501-1505
(	O	1506-1507
KK47	O	1507-1511
)	O	1511-1512
.	O	1512-1513

In	O	1514-1516
addition	O	1517-1525
,	O	1525-1526
significant	O	1527-1538
decreases	O	1539-1548
in	O	1549-1551
cell	O	1552-1556
growth	O	1557-1563
were	O	1564-1568
observed	O	1569-1577
after	O	1578-1583
transfection	O	1584-1596
of	O	1597-1599
3	O	1600-1601
miRNAs	O	1602-1608
and	O	1609-1612
si	O	1613-1615
-	O	1615-1616
KRT7	O	1616-1620
in	O	1621-1623
KK47	O	1624-1628
,	O	1628-1629
suggesting	O	1630-1640
that	O	1641-1645
miR	B	1646-1649
-	I	1649-1650
30	I	1650-1652
-	I	1652-1653
3p	I	1653-1655
,	O	1655-1656
miR	B	1657-1660
-	I	1660-1661
133a	I	1661-1665
and	O	1666-1669
miR	B	1670-1673
-	I	1673-1674
199a	I	1674-1678
*	I	1678-1679
may	O	1680-1683
have	O	1684-1688
a	O	1689-1690
tumor	O	1691-1696
suppressive	O	1697-1708
function	O	1709-1717
through	O	1718-1725
the	O	1726-1729
mechanism	O	1730-1739
underlying	O	1740-1750
transcriptional	O	1751-1766
repression	O	1767-1777
of	O	1778-1780
KRT7	O	1781-1785
.	O	1785-1786

A	O	0-1
pleiotropically	O	2-17
acting	O	18-24
microRNA	O	25-33
,	O	33-34
miR	B	35-38
-	I	38-39
31	I	39-41
,	O	41-42
inhibits	O	43-51
breast	O	52-58
cancer	O	59-65
metastasis	O	66-76
.	O	76-77

MicroRNAs	O	78-87
are	O	88-91
well	O	92-96
suited	O	97-103
to	O	104-106
regulate	O	107-115
tumor	O	116-121
metastasis	O	122-132
because	O	133-140
of	O	141-143
their	O	144-149
capacity	O	150-158
to	O	159-161
coordinately	O	162-174
repress	O	175-182
numerous	O	183-191
target	O	192-198
genes	O	199-204
,	O	204-205
thereby	O	206-213
potentially	O	214-225
enabling	O	226-234
their	O	235-240
intervention	O	241-253
at	O	254-256
multiple	O	257-265
steps	O	266-271
of	O	272-274
the	O	275-278
invasion	O	279-287
-	O	287-288
metastasis	O	288-298
cascade	O	299-306
.	O	306-307

We	O	308-310
identify	O	311-319
a	O	320-321
microRNA	O	322-330
exemplifying	O	331-343
these	O	344-349
attributes	O	350-360
,	O	360-361
miR	B	362-365
-	I	365-366
31	I	366-368
,	O	368-369
whose	O	370-375
expression	O	376-386
correlates	O	387-397
inversely	O	398-407
with	O	408-412
metastasis	O	413-423
in	O	424-426
human	O	427-432
breast	O	433-439
cancer	O	440-446
patients	O	447-455
.	O	455-456

Overexpression	O	457-471
of	O	472-474
miR	B	475-478
-	I	478-479
31	I	479-481
in	O	482-484
otherwise	O	485-494
-	O	494-495
aggressive	O	495-505
breast	O	506-512
tumor	O	513-518
cells	O	519-524
suppresses	O	525-535
metastasis	O	536-546
.	O	546-547

We	O	548-550
deploy	O	551-557
a	O	558-559
stable	O	560-566
microRNA	O	567-575
sponge	O	576-582
strategy	O	583-591
to	O	592-594
inhibit	O	595-602
miR	B	603-606
-	I	606-607
31	I	607-609
in	O	610-612
vivo	O	613-617
;	O	617-618
this	O	619-623
allows	O	624-630
otherwise	O	631-640
-	O	640-641
nonaggressive	O	641-654
breast	O	655-661
cancer	O	662-668
cells	O	669-674
to	O	675-677
metastasize	O	678-689
.	O	689-690

These	O	691-696
phenotypes	O	697-707
do	O	708-710
not	O	711-714
involve	O	715-722
confounding	O	723-734
influences	O	735-745
on	O	746-748
primary	O	749-756
tumor	O	757-762
development	O	763-774
and	O	775-778
are	O	779-782
specifically	O	783-795
attributable	O	796-808
to	O	809-811
miR	B	812-815
-	I	815-816
31	I	816-818
-	O	818-819
mediated	O	819-827
inhibition	O	828-838
of	O	839-841
several	O	842-849
steps	O	850-855
of	O	856-858
metastasis	O	859-869
,	O	869-870
including	O	871-880
local	O	881-886
invasion	O	887-895
,	O	895-896
extravasation	O	897-910
or	O	911-913
initial	O	914-921
survival	O	922-930
at	O	931-933
a	O	934-935
distant	O	936-943
site	O	944-948
,	O	948-949
and	O	950-953
metastatic	O	954-964
colonization	O	965-977
.	O	977-978

Such	O	979-983
pleiotropy	O	984-994
is	O	995-997
achieved	O	998-1006
via	O	1007-1010
coordinate	O	1011-1021
repression	O	1022-1032
of	O	1033-1035
a	O	1036-1037
cohort	O	1038-1044
of	O	1045-1047
metastasis	O	1048-1058
-	O	1058-1059
promoting	O	1059-1068
genes	O	1069-1074
,	O	1074-1075
including	O	1076-1085
RhoA	O	1086-1090
.	O	1090-1091

Indeed	O	1092-1098
,	O	1098-1099
RhoA	O	1100-1104
re	O	1105-1107
-	O	1107-1108
expression	O	1108-1118
partially	O	1119-1128
reverses	O	1129-1137
miR	B	1138-1141
-	I	1141-1142
31	I	1142-1144
-	O	1144-1145
imposed	O	1145-1152
metastasis	O	1153-1163
suppression	O	1164-1175
.	O	1175-1176

These	O	1177-1182
findings	O	1183-1191
indicate	O	1192-1200
that	O	1201-1205
miR	B	1206-1209
-	I	1209-1210
31	I	1210-1212
uses	O	1213-1217
multiple	O	1218-1226
mechanisms	O	1227-1237
to	O	1238-1240
oppose	O	1241-1247
metastasis	O	1248-1258
.	O	1258-1259

MicroRNA	O	0-8
92b	O	9-12
controls	O	13-21
the	O	22-25
G1	O	26-28
/	O	28-29
S	O	29-30
checkpoint	O	31-41
gene	O	42-46
p57	O	47-50
in	O	51-53
human	O	54-59
embryonic	O	60-69
stem	O	70-74
cells	O	75-80
.	O	80-81

Human	O	82-87
embryonic	O	88-97
stem	O	98-102
(	O	103-104
ES	O	104-106
)	O	106-107
cells	O	108-113
exhibit	O	114-121
a	O	122-123
shorter	O	124-131
G	O	132-133
(	O	133-134
1	O	134-135
)	O	135-136
cell	O	137-141
cycle	O	142-147
phase	O	148-153
than	O	154-158
most	O	159-163
somatic	O	164-171
cells	O	172-177
.	O	177-178

Here	O	179-183
,	O	183-184
we	O	185-187
examine	O	188-195
the	O	196-199
role	O	200-204
of	O	205-207
an	O	208-210
abundant	O	211-219
,	O	219-220
human	O	221-226
ES	O	227-229
cell	O	230-234
-	O	234-235
enriched	O	235-243
microRNA	O	244-252
,	O	252-253
miR	B	254-257
-	I	257-258
92b	I	258-261
,	O	261-262
in	O	263-265
cell	O	266-270
cycle	O	271-276
distribution	O	277-289
.	O	289-290

Inhibition	O	291-301
of	O	302-304
miR	B	305-308
-	I	308-309
92b	I	309-312
in	O	313-315
human	O	316-321
ES	O	322-324
cells	O	325-330
results	O	331-338
in	O	339-341
a	O	342-343
greater	O	344-351
number	O	352-358
of	O	359-361
cells	O	362-367
in	O	368-370
the	O	371-374
G	O	375-376
(	O	376-377
1	O	377-378
)	O	378-379
phase	O	380-385
and	O	386-389
a	O	390-391
lower	O	392-397
number	O	398-404
in	O	405-407
the	O	408-411
S	O	412-413
phase	O	414-419
.	O	419-420

Conversely	O	421-431
,	O	431-432
overexpression	O	433-447
of	O	448-450
miR	B	451-454
-	I	454-455
92b	I	455-458
in	O	459-461
differentiated	O	462-476
cells	O	477-482
results	O	483-490
in	O	491-493
a	O	494-495
decreased	O	496-505
number	O	506-512
of	O	513-515
cells	O	516-521
in	O	522-524
G1	O	525-527
phase	O	528-533
and	O	534-537
an	O	538-540
increased	O	541-550
number	O	551-557
in	O	558-560
S	O	561-562
-	O	562-563
phase	O	563-568
.	O	568-569

p57	O	570-573
,	O	573-574
a	O	575-576
gene	O	577-581
whose	O	582-587
product	O	588-595
inhibits	O	596-604
G	O	605-606
(	O	606-607
1	O	607-608
)	O	608-609
to	O	610-612
S	O	613-614
-	O	614-615
phase	O	615-620
progression	O	621-632
,	O	632-633
is	O	634-636
one	O	637-640
of	O	641-643
the	O	644-647
predicted	O	648-657
targets	O	658-665
of	O	666-668
miR	B	669-672
-	I	672-673
92b	I	673-676
.	O	676-677

Inhibition	O	678-688
of	O	689-691
miR	B	692-695
-	I	695-696
92b	I	696-699
in	O	700-702
human	O	703-708
ES	O	709-711
cells	O	712-717
increases	O	718-727
p57	O	728-731
protein	O	732-739
levels	O	740-746
,	O	746-747
and	O	748-751
miR	B	752-755
-	I	755-756
92b	I	756-759
overexpression	O	760-774
in	O	775-777
differentiated	O	778-792
cells	O	793-798
decreases	O	799-808
p57	O	809-812
protein	O	813-820
levels	O	821-827
.	O	827-828

Furthermore	O	829-840
,	O	840-841
miR	B	842-845
-	I	845-846
92b	I	846-849
inhibits	O	850-858
a	O	859-860
luciferase	O	861-871
reporter	O	872-880
construct	O	881-890
that	O	891-895
includes	O	896-904
part	O	905-909
of	O	910-912
the	O	913-916
3	O	917-918
'	O	918-919
untranslated	O	920-932
region	O	933-939
of	O	940-942
the	O	943-946
p57	O	947-950
gene	O	951-955
containing	O	956-966
the	O	967-970
predicted	O	971-980
target	O	981-987
of	O	988-990
the	O	991-994
miR	B	995-998
-	I	998-999
92b	I	999-1002
seed	O	1003-1007
sequence	O	1008-1016
.	O	1016-1017

Thus	O	1018-1022
,	O	1022-1023
we	O	1024-1026
show	O	1027-1031
that	O	1032-1036
the	O	1037-1040
miRNA	O	1041-1046
miR	B	1047-1050
-	I	1050-1051
92b	I	1051-1054
directly	O	1055-1063
downregulates	O	1064-1077
protein	O	1078-1085
levels	O	1086-1092
of	O	1093-1095
the	O	1096-1099
G	O	1100-1101
(	O	1101-1102
1	O	1102-1103
)	O	1103-1104
/	O	1104-1105
S	O	1105-1106
checkpoint	O	1107-1117
gene	O	1118-1122
p57	O	1123-1126
.	O	1126-1127

STEM	O	1128-1132
CELLS	O	1133-1138
2009	O	1139-1143
;	O	1143-1144
27	O	1144-1146
:	O	1146-1147
1524	O	1147-1151
-	O	1151-1152
1528	O	1152-1156
.	O	1156-1157

Differential	O	0-12
expression	O	13-23
of	O	24-26
microRNA	B	27-35
181b	I	36-40
and	O	41-44
microRNA	B	45-53
21	I	54-56
in	O	57-59
hyperplastic	O	60-72
polyps	O	73-79
and	O	80-83
sessile	O	84-91
serrated	O	92-100
adenomas	O	101-109
of	O	110-112
the	O	113-116
colon	O	117-122
.	O	122-123

This	O	124-128
study	O	129-134
was	O	135-138
designed	O	139-147
to	O	148-150
analyse	O	151-158
the	O	159-162
potential	O	163-172
diagnostic	O	173-183
value	O	184-189
of	O	190-192
miR	B	193-196
-	I	196-197
181b	I	197-201
and	O	202-205
miR	B	206-209
-	I	209-210
21	I	210-212
for	O	213-216
discriminating	O	217-231
hyperplastic	O	232-244
polyps	O	245-251
(	O	252-253
HP	O	253-255
)	O	255-256
from	O	257-261
sessile	O	262-269
serrated	O	270-278
adenomas	O	279-287
(	O	288-289
SSA	O	289-292
)	O	292-293
without	O	294-301
cytologic	O	302-311
dysplasia	O	312-321
.	O	321-322

Using	O	323-328
real	O	329-333
-	O	333-334
time	O	334-338
polymerase	O	339-349
chain	O	350-355
reaction	O	356-364
expression	O	365-375
levels	O	376-382
of	O	383-385
miR	B	386-389
-	I	389-390
181b	I	390-394
and	O	395-398
miR	B	399-402
-	I	402-403
21	I	403-405
in	O	406-408
18	O	409-411
HPs	O	412-415
,	O	415-416
19	O	417-419
SSAs	O	420-424
without	O	425-432
cytologic	O	433-442
dysplasia	O	443-452
and	O	453-456
20	O	457-459
normal	O	460-466
colonic	O	467-474
mucosal	O	475-482
specimens	O	483-492
were	O	493-497
examined	O	498-506
.	O	506-507

In	O	508-510
addition	O	511-519
,	O	519-520
20	O	521-523
colorectal	O	524-534
cancers	O	535-542
specimen	O	543-551
were	O	552-556
analysed	O	557-565
for	O	566-569
miR	B	570-573
-	I	573-574
181b	I	574-578
expression	O	579-589
.	O	589-590

Data	O	591-595
were	O	596-600
normalised	O	601-611
to	O	612-614
RNU48	O	615-620
as	O	621-623
an	O	624-626
internal	O	627-635
control	O	636-643
.	O	643-644

A	O	645-646
differential	O	647-659
expression	O	660-670
of	O	671-673
miR	B	674-677
-	I	677-678
181b	I	678-682
and	O	683-686
miR	B	687-690
-	I	690-691
21	I	691-693
was	O	694-697
found	O	698-703
in	O	704-706
HPs	O	707-710
,	O	710-711
SSAs	O	712-716
,	O	716-717
and	O	718-721
normal	O	722-728
colonic	O	729-736
mucosa	O	737-743
with	O	744-748
highest	O	749-756
expression	O	757-767
levels	O	768-774
in	O	775-777
SSAs	O	778-782
.	O	782-783

Levels	O	784-790
of	O	791-793
miR	B	794-797
-	I	797-798
181b	I	798-802
but	O	803-806
not	O	807-810
miR	B	811-814
-	I	814-815
21	I	815-817
differed	O	818-826
in	O	827-829
HPs	O	830-833
and	O	834-837
normal	O	838-844
mucosa	O	845-851
.	O	851-852

SSAs	O	853-857
exhibited	O	858-867
both	O	868-872
significantly	O	873-886
higher	O	887-893
miR	B	894-897
-	I	897-898
181b	I	898-902
levels	O	903-909
(	O	910-911
up	O	911-913
to	O	914-916
2	O	917-918
.	O	918-919
01	O	919-921
-	O	921-922
fold	O	922-926
;	O	926-927
P	O	928-929
<	O	930-931
0	O	932-933
.	O	933-934
001	O	934-937
)	O	937-938
and	O	939-942
miR	B	943-946
-	I	946-947
21	I	947-949
levels	O	950-956
(	O	957-958
up	O	958-960
to	O	961-963
1	O	964-965
.	O	965-966
82	O	966-968
-	O	968-969
fold	O	969-973
;	O	973-974
P	O	975-976
=	O	977-978
0	O	979-980
.	O	980-981
011	O	981-984
)	O	984-985
than	O	986-990
HPs	O	991-994
.	O	994-995

In	O	996-998
contrast	O	999-1007
to	O	1008-1010
HPs	O	1011-1014
,	O	1014-1015
SSAs	O	1016-1020
are	O	1021-1024
characterised	O	1025-1038
by	O	1039-1041
high	O	1042-1046
levels	O	1047-1053
of	O	1054-1056
miR	B	1057-1060
-	I	1060-1061
181b	I	1061-1065
and	O	1066-1069
miR	B	1070-1073
-	I	1073-1074
21	I	1074-1076
expression	O	1077-1087
.	O	1087-1088

However	O	1089-1096
,	O	1096-1097
due	O	1098-1101
to	O	1102-1104
the	O	1105-1108
overlap	O	1109-1116
of	O	1117-1119
values	O	1120-1126
,	O	1126-1127
miR	B	1128-1131
-	I	1131-1132
181b	I	1132-1136
and	O	1137-1140
miR	B	1141-1144
-	I	1144-1145
21	I	1145-1147
evaluation	O	1148-1158
did	O	1159-1162
not	O	1163-1166
allow	O	1167-1172
discrimination	O	1173-1187
of	O	1188-1190
the	O	1191-1194
two	O	1195-1198
lesions	O	1199-1206
in	O	1207-1209
every	O	1210-1215
case	O	1216-1220
.	O	1220-1221

Cellular	O	0-8
microRNA	O	9-17
and	O	18-21
P	O	22-23
bodies	O	24-30
modulate	O	31-39
host	O	40-44
-	O	44-45
HIV	O	45-48
-	O	48-49
1	O	49-50
interactions	O	51-63
.	O	63-64

MicroRNAs	O	65-74
(	O	75-76
miRNAs	O	76-82
)	O	82-83
,	O	83-84
approximately	O	85-98
22	O	99-101
nt	O	102-104
noncoding	O	105-114
RNAs	O	115-119
,	O	119-120
assemble	O	121-129
into	O	130-134
RNA	O	135-138
-	O	138-139
induced	O	139-146
silencing	O	147-156
complexes	O	157-166
(	O	167-168
RISCs	O	168-173
)	O	173-174
and	O	175-178
localize	O	179-187
to	O	188-190
cytoplasmic	O	191-202
substructures	O	203-216
called	O	217-223
P	O	224-225
bodies	O	226-232
.	O	232-233

Dictated	O	234-242
by	O	243-245
base	O	246-250
-	O	250-251
pair	O	251-255
complementarity	O	256-271
between	O	272-279
miRNA	O	280-285
and	O	286-289
a	O	290-291
target	O	292-298
mRNA	O	299-303
,	O	303-304
miRNAs	O	305-311
specifically	O	312-324
repress	O	325-332
posttranscriptional	O	333-352
expression	O	353-363
of	O	364-366
several	O	367-374
mRNAs	O	375-380
.	O	380-381

Here	O	382-386
we	O	387-389
report	O	390-396
that	O	397-401
HIV	O	402-405
-	O	405-406
1	O	406-407
mRNA	O	408-412
interacts	O	413-422
with	O	423-427
RISC	O	428-432
proteins	O	433-441
and	O	442-445
that	O	446-450
disrupting	O	451-461
P	O	462-463
body	O	464-468
structures	O	469-479
enhances	O	480-488
viral	O	489-494
production	O	495-505
and	O	506-509
infectivity	O	510-521
.	O	521-522

In	O	523-525
HIV	O	526-529
-	O	529-530
1	O	530-531
-	O	531-532
infected	O	532-540
human	O	541-546
T	O	547-548
lymphocytes	O	549-560
,	O	560-561
we	O	562-564
identified	O	565-575
a	O	576-577
highly	O	578-584
abundant	O	585-593
miRNA	O	594-599
,	O	599-600
miR	B	601-604
-	I	604-605
29a	I	605-608
,	O	608-609
which	O	610-615
specifically	O	616-628
targets	O	629-636
the	O	637-640
HIV	O	641-644
-	O	644-645
1	O	645-646
3	O	647-648
'	O	648-649
UTR	O	649-652
region	O	653-659
.	O	659-660

Inhibiting	O	661-671
miR	B	672-675
-	I	675-676
29a	I	676-679
enhanced	O	680-688
HIV	O	689-692
-	O	692-693
1	O	693-694
viral	O	695-700
production	O	701-711
and	O	712-715
infectivity	O	716-727
,	O	727-728
whereas	O	729-736
expressing	O	737-747
a	O	748-749
miR	B	750-753
-	I	753-754
29	I	754-756
mimic	O	757-762
suppressed	O	763-773
viral	O	774-779
replication	O	780-791
.	O	791-792

We	O	793-795
also	O	796-800
found	O	801-806
that	O	807-811
specific	O	812-820
miR	B	821-824
-	I	824-825
29a	I	825-828
-	O	828-829
HIV	O	829-832
-	O	832-833
1	O	833-834
mRNA	O	835-839
interactions	O	840-852
enhance	O	853-860
viral	O	861-866
mRNA	O	867-871
association	O	872-883
with	O	884-888
RISC	O	889-893
and	O	894-897
P	O	898-899
body	O	900-904
proteins	O	905-913
.	O	913-914

Thus	O	915-919
we	O	920-922
provide	O	923-930
an	O	931-933
example	O	934-941
of	O	942-944
a	O	945-946
single	O	947-953
host	O	954-958
miRNA	O	959-964
regulating	O	965-975
HIV	O	976-979
-	O	979-980
1	O	980-981
production	O	982-992
and	O	993-996
infectivity	O	997-1008
.	O	1008-1009

These	O	1010-1015
studies	O	1016-1023
highlight	O	1024-1033
the	O	1034-1037
significance	O	1038-1050
of	O	1051-1053
miRNAs	O	1054-1060
and	O	1061-1064
P	O	1065-1066
bodies	O	1067-1073
in	O	1074-1076
modulating	O	1077-1087
host	O	1088-1092
cell	O	1093-1097
interactions	O	1098-1110
with	O	1111-1115
HIV	O	1116-1119
-	O	1119-1120
1	O	1120-1121
and	O	1122-1125
possibly	O	1126-1134
other	O	1135-1140
viruses	O	1141-1148
.	O	1148-1149

Molecular	O	0-9
profiling	O	10-19
of	O	20-22
CD3	O	23-26
-	O	26-27
CD4	O	27-30
+	O	30-31
T	O	32-33
cells	O	34-39
from	O	40-44
patients	O	45-53
with	O	54-58
the	O	59-62
lymphocytic	O	63-74
variant	O	75-82
of	O	83-85
hypereosinophilic	O	86-103
syndrome	O	104-112
reveals	O	113-120
targeting	O	121-130
of	O	131-133
growth	O	134-140
control	O	141-148
pathways	O	149-157
.	O	157-158

The	O	159-162
clonal	O	163-169
CD3	O	170-173
(	O	173-174
-	O	174-175
)	O	175-176
CD4	O	176-179
(	O	179-180
+	O	180-181
)	O	181-182
T	O	183-184
-	O	184-185
cell	O	185-189
population	O	190-200
characterizing	O	201-215
lymphocytic	O	216-227
variant	O	228-235
hypereosinophilic	O	236-253
syndrome	O	254-262
(	O	263-264
L	O	264-265
-	O	265-266
HES	O	266-269
)	O	269-270
persists	O	271-279
for	O	280-283
years	O	284-289
,	O	289-290
with	O	291-295
a	O	296-297
subgroup	O	298-306
of	O	307-309
patients	O	310-318
ultimately	O	319-329
progressing	O	330-341
to	O	342-344
T	O	345-346
lymphoma	O	347-355
.	O	355-356

The	O	357-360
molecular	O	361-370
changes	O	371-378
associated	O	379-389
with	O	390-394
the	O	395-398
premalignant	O	399-411
clone	O	412-417
and	O	418-421
the	O	422-425
emergence	O	426-435
of	O	436-438
malignant	O	439-448
subclones	O	449-458
are	O	459-462
unknown	O	463-470
,	O	470-471
precluding	O	472-482
the	O	483-486
development	O	487-498
of	O	499-501
targeted	O	502-510
therapy	O	511-518
for	O	519-522
this	O	523-527
HES	O	528-531
variant	O	532-539
.	O	539-540

In	O	541-543
this	O	544-548
study	O	549-554
,	O	554-555
we	O	556-558
used	O	559-563
whole	O	564-569
genome	O	570-576
arrays	O	577-583
to	O	584-586
examine	O	587-594
gene	O	595-599
expression	O	600-610
in	O	611-613
the	O	614-617
CD3	O	618-621
(	O	621-622
-	O	622-623
)	O	623-624
CD4	O	624-627
(	O	627-628
+	O	628-629
)	O	629-630
T	O	631-632
cells	O	633-638
and	O	639-642
found	O	643-648
that	O	649-653
850	O	654-657
genes	O	658-663
were	O	664-668
differentially	O	669-683
regulated	O	684-693
during	O	694-700
chronic	O	701-708
disease	O	709-716
compared	O	717-725
with	O	726-730
CD3	O	731-734
(	O	734-735
+	O	735-736
)	O	736-737
CD4	O	737-740
(	O	740-741
+	O	741-742
)	O	742-743
T	O	744-745
cells	O	746-751
from	O	752-756
healthy	O	757-764
donors	O	765-771
.	O	771-772

Changes	O	773-780
in	O	781-783
the	O	784-787
expression	O	788-798
of	O	799-801
349	O	802-805
genes	O	806-811
were	O	812-816
altered	O	817-824
in	O	825-827
association	O	828-839
with	O	840-844
the	O	845-848
clinical	O	849-857
progression	O	858-869
from	O	870-874
chronic	O	875-882
L	O	883-884
-	O	884-885
HES	O	885-888
to	O	889-891
T	O	892-893
lymphoma	O	894-902
in	O	903-905
1	O	906-907
patient	O	908-915
,	O	915-916
with	O	917-921
87	O	922-924
of	O	925-927
349	O	928-931
genes	O	932-937
representing	O	938-950
further	O	951-958
changes	O	959-966
in	O	967-969
genes	O	970-975
whose	O	976-981
expression	O	982-992
was	O	993-996
altered	O	997-1004
in	O	1005-1007
all	O	1008-1011
chronic	O	1012-1019
disease	O	1020-1027
patients	O	1028-1036
(	O	1037-1038
87	O	1038-1040
of	O	1041-1043
850	O	1044-1047
)	O	1047-1048
.	O	1048-1049

Array	O	1050-1055
analysis	O	1056-1064
after	O	1065-1070
CD2	O	1071-1074
/	O	1074-1075
CD28	O	1075-1079
-	O	1079-1080
mediated	O	1080-1088
activation	O	1089-1099
revealed	O	1100-1108
that	O	1109-1113
the	O	1114-1117
major	O	1118-1123
gene	O	1124-1128
expression	O	1129-1139
changes	O	1140-1147
observed	O	1148-1156
in	O	1157-1159
the	O	1160-1163
CD3	O	1164-1167
(	O	1167-1168
-	O	1168-1169
)	O	1169-1170
CD4	O	1170-1173
(	O	1173-1174
+	O	1174-1175
)	O	1175-1176
T	O	1177-1178
cells	O	1179-1184
do	O	1185-1187
not	O	1188-1191
reflect	O	1192-1199
activation	O	1200-1210
induced	O	1211-1218
alterations	O	1219-1230
but	O	1231-1234
rather	O	1235-1241
pathways	O	1242-1250
involved	O	1251-1259
in	O	1260-1262
T	O	1263-1264
-	O	1264-1265
cell	O	1265-1269
homeostasis	O	1270-1281
,	O	1281-1282
including	O	1283-1292
transforming	O	1293-1305
growth	O	1306-1312
factor	O	1313-1319
-	O	1319-1320
beta	O	1320-1324
signaling	O	1325-1334
,	O	1334-1335
apoptosis	O	1336-1345
,	O	1345-1346
and	O	1347-1350
T	O	1351-1352
-	O	1352-1353
cell	O	1353-1357
maturation	O	1358-1368
,	O	1368-1369
signaling	O	1370-1379
,	O	1379-1380
and	O	1381-1384
migration	O	1385-1394
.	O	1394-1395

Examination	O	1396-1407
of	O	1408-1410
microRNA	O	1411-1419
expression	O	1420-1430
in	O	1431-1433
the	O	1434-1437
CD3	O	1438-1441
(	O	1441-1442
-	O	1442-1443
)	O	1443-1444
CD4	O	1444-1447
(	O	1447-1448
+	O	1448-1449
)	O	1449-1450
T	O	1451-1452
cells	O	1453-1458
from	O	1459-1463
patients	O	1464-1472
with	O	1473-1477
chronic	O	1478-1485
disease	O	1486-1493
identified	O	1494-1504
23	O	1505-1507
microRNAs	O	1508-1517
that	O	1518-1522
changed	O	1523-1530
significantly	O	1531-1544
,	O	1544-1545
among	O	1546-1551
which	O	1552-1557
miR	B	1558-1561
-	I	1561-1562
125a	I	1562-1566
further	O	1567-1574
decreased	O	1575-1584
in	O	1585-1587
association	O	1588-1599
with	O	1600-1604
one	O	1605-1608
patient	O	1609-1616
'	O	1616-1617
s	O	1617-1618
evolution	O	1619-1628
to	O	1629-1631
T	O	1632-1633
lymphoma	O	1634-1642
.	O	1642-1643

The	O	0-3
tumor	O	4-9
suppressor	O	10-20
microRNA	B	21-29
-	I	29-30
101	I	30-33
becomes	O	34-41
an	O	42-44
epigenetic	O	45-55
player	O	56-62
by	O	63-65
targeting	O	66-75
the	O	76-79
polycomb	O	80-88
group	O	89-94
protein	O	95-102
EZH2	O	103-107
in	O	108-110
cancer	O	111-117
.	O	117-118

miR	B	0-3
-	I	3-4
290	I	4-7
acts	O	8-12
as	O	13-15
a	O	16-17
physiological	O	18-31
effector	O	32-40
of	O	41-43
senescence	O	44-54
in	O	55-57
mouse	O	58-63
embryo	O	64-70
fibroblasts	O	71-82
.	O	82-83

The	O	84-87
culture	O	88-95
-	O	95-96
induced	O	96-103
senescence	O	104-114
of	O	115-117
mouse	O	118-123
embryo	O	124-130
fibroblasts	O	131-142
(	O	143-144
MEF	O	144-147
)	O	147-148
correlates	O	149-159
with	O	160-164
reduction	O	165-174
of	O	175-177
cell	O	178-182
proliferation	O	183-196
.	O	196-197

In	O	198-200
this	O	201-205
work	O	206-210
we	O	211-213
found	O	214-219
that	O	220-224
the	O	225-228
accumulation	O	229-241
of	O	242-244
cells	O	245-250
with	O	251-255
4C	O	256-258
DNA	O	259-262
content	O	263-270
and	O	271-274
the	O	275-278
transcriptional	O	279-294
change	O	295-301
of	O	302-304
several	O	305-312
microRNAs	O	313-322
(	O	323-324
miRNAs	O	324-330
or	O	331-333
miRs	O	334-338
)	O	338-339
are	O	340-343
relevant	O	344-352
events	O	353-359
in	O	360-362
culture	O	363-370
senescence	O	371-381
.	O	381-382

By	O	383-385
comparing	O	386-395
the	O	396-399
miRNA	O	400-405
expression	O	406-416
profiles	O	417-425
of	O	426-428
physiologically	O	429-444
senescent	O	445-454
MEF	O	455-458
and	O	459-462
that	O	463-467
of	O	468-470
senescent	O	471-480
MEF	O	481-484
induced	O	485-492
by	O	493-495
the	O	496-499
downregulation	O	500-514
of	O	515-517
leukemia	O	518-526
-	O	526-527
related	O	527-534
factor	O	535-541
,	O	541-542
we	O	543-545
identified	O	546-556
miR	B	557-560
-	I	560-561
290	I	561-564
as	O	565-567
a	O	568-569
common	O	570-576
upregulated	O	577-588
miRNA	O	589-594
.	O	594-595

When	O	596-600
miR	B	601-604
-	I	604-605
290	I	605-608
was	O	609-612
transfected	O	613-624
in	O	625-627
presenescent	O	628-640
MEF	O	641-644
,	O	644-645
SA	O	646-648
-	O	648-649
beta	O	649-653
-	O	653-654
gal	O	654-657
(	O	657-658
+	O	658-659
)	O	659-660
cells	O	661-666
and	O	667-670
p16	O	671-674
,	O	674-675
two	O	676-679
markers	O	680-687
of	O	688-690
culture	O	691-698
senescence	O	699-709
,	O	709-710
increased	O	711-720
compared	O	721-729
with	O	730-734
control	O	735-742
,	O	742-743
indicating	O	744-754
that	O	755-759
miR	B	760-763
-	I	763-764
290	I	764-767
is	O	768-770
causally	O	771-779
involved	O	780-788
in	O	789-791
senescence	O	792-802
.	O	802-803

Interestingly	O	804-817
,	O	817-818
nocodazole	O	819-829
(	O	830-831
NCZ	O	831-834
)	O	834-835
,	O	835-836
which	O	837-842
induces	O	843-850
G2	O	851-853
/	O	853-854
M	O	854-855
block	O	856-861
,	O	861-862
increased	O	863-872
the	O	873-876
percentage	O	877-887
of	O	888-890
senescent	O	891-900
cells	O	901-906
as	O	907-909
well	O	910-914
as	O	915-917
the	O	918-921
expression	O	922-932
of	O	933-935
miR	B	936-939
-	I	939-940
290	I	940-943
and	O	944-947
of	O	948-950
the	O	951-954
tumor	O	955-960
suppressor	O	961-971
p16	O	972-975
,	O	975-976
thus	O	977-981
mimicking	O	982-991
culture	O	992-999
senescence	O	1000-1010
.	O	1010-1011

As	O	1012-1014
miR	B	1015-1018
-	I	1018-1019
290	I	1019-1022
was	O	1023-1026
overexpressed	O	1027-1040
in	O	1041-1043
NCZ	O	1044-1047
-	O	1047-1048
treated	O	1048-1055
cells	O	1056-1061
and	O	1062-1065
it	O	1066-1068
was	O	1069-1072
able	O	1073-1077
to	O	1078-1080
induce	O	1081-1087
senescence	O	1088-1098
in	O	1099-1101
proliferating	O	1102-1115
MEF	O	1116-1119
,	O	1119-1120
we	O	1121-1123
investigated	O	1124-1136
whether	O	1137-1144
miR	B	1145-1148
-	I	1148-1149
290	I	1149-1152
and	O	1153-1156
NCZ	O	1157-1160
could	O	1161-1166
share	O	1167-1172
common	O	1173-1179
mechanisms	O	1180-1190
of	O	1191-1193
culture	O	1194-1201
senescence	O	1202-1212
.	O	1212-1213

Whereas	O	1214-1221
the	O	1222-1225
induction	O	1226-1235
of	O	1236-1238
SA	O	1239-1241
-	O	1241-1242
beta	O	1242-1246
-	O	1246-1247
gal	O	1247-1250
(	O	1250-1251
+	O	1251-1252
)	O	1252-1253
by	O	1254-1256
miR	B	1257-1260
-	I	1260-1261
290	I	1261-1264
was	O	1265-1268
not	O	1269-1272
strengthened	O	1273-1285
by	O	1286-1288
coupling	O	1289-1297
its	O	1298-1301
transfection	O	1302-1314
with	O	1315-1319
NCZ	O	1320-1323
treatment	O	1324-1333
,	O	1333-1334
the	O	1335-1338
transfection	O	1339-1351
of	O	1352-1354
the	O	1355-1358
antagomir	O	1359-1368
290	O	1369-1372
(	O	1373-1374
d	O	1374-1375
-	O	1375-1376
290	O	1376-1379
)	O	1379-1380
plus	O	1381-1385
NCZ	O	1386-1389
treatment	O	1390-1399
,	O	1399-1400
while	O	1401-1406
blocking	O	1407-1415
cells	O	1416-1421
at	O	1422-1424
G2	O	1425-1427
/	O	1427-1428
M	O	1428-1429
,	O	1429-1430
suppressed	O	1431-1441
SA	O	1442-1444
-	O	1444-1445
beta	O	1445-1449
-	O	1449-1450
gal	O	1450-1453
(	O	1453-1454
+	O	1454-1455
)	O	1455-1456
and	O	1457-1460
p16	O	1461-1464
induction	O	1465-1474
.	O	1474-1475

On	O	1476-1478
the	O	1479-1482
basis	O	1483-1488
of	O	1489-1491
these	O	1492-1497
findings	O	1498-1506
we	O	1507-1509
conclude	O	1510-1518
that	O	1519-1523
miR	B	1524-1527
-	I	1527-1528
290	I	1528-1531
might	O	1532-1537
act	O	1538-1541
as	O	1542-1544
a	O	1545-1546
physiological	O	1547-1560
effector	O	1561-1569
of	O	1570-1572
NCZ	O	1573-1576
induced	O	1577-1584
as	O	1585-1587
well	O	1588-1592
as	O	1593-1595
culture	O	1596-1603
senescence	O	1604-1614
via	O	1615-1618
p16	O	1619-1622
regulation	O	1623-1633
expanding	O	1634-1643
the	O	1644-1647
role	O	1648-1652
of	O	1653-1655
this	O	1656-1660
miRNA	O	1661-1666
from	O	1667-1671
embryonic	O	1672-1681
stem	O	1682-1686
to	O	1687-1689
differentiated	O	1690-1704
cells	O	1705-1710
.	O	1710-1711

Targeting	O	0-9
miR	B	10-13
-	I	13-14
205	I	14-17
in	O	18-20
breast	O	21-27
cancer	O	28-34
.	O	34-35

As	O	36-38
small	O	39-44
non	O	45-48
-	O	48-49
coding	O	49-55
regulatory	O	56-66
RNAs	O	67-71
,	O	71-72
microRNAs	O	73-82
are	O	83-86
capable	O	87-94
of	O	95-97
silencing	O	98-107
gene	O	108-112
expression	O	113-123
by	O	124-126
translational	O	127-140
repression	O	141-151
or	O	152-154
mRNA	O	155-159
degradation	O	160-171
.	O	171-172

Accumulating	O	173-185
evidence	O	186-194
indicates	O	195-204
that	O	205-209
deregulation	O	210-222
of	O	223-225
microRNAs	O	226-235
is	O	236-238
often	O	239-244
associated	O	245-255
with	O	256-260
human	O	261-266
malignancies	O	267-279
and	O	280-283
suggests	O	284-292
a	O	293-294
causal	O	295-301
role	O	302-306
of	O	307-309
microRNAs	O	310-319
in	O	320-322
neoplasia	O	323-332
,	O	332-333
presumably	O	334-344
because	O	345-352
microRNAs	O	353-362
can	O	363-366
function	O	367-375
as	O	376-378
oncogenes	O	379-388
or	O	389-391
tumor	O	392-397
suppressors	O	398-409
.	O	409-410

Among	O	411-416
them	O	417-421
,	O	421-422
miR	B	423-426
-	I	426-427
205	I	427-430
is	O	431-433
significantly	O	434-447
underexpressed	O	448-462
in	O	463-465
breast	O	466-472
tumors	O	473-479
compared	O	480-488
with	O	489-493
matched	O	494-501
normal	O	502-508
breast	O	509-515
tissue	O	516-522
although	O	523-531
miR	B	532-535
-	I	535-536
205	I	536-539
has	O	540-543
been	O	544-548
shown	O	549-554
to	O	555-557
be	O	558-560
upregulated	O	561-572
in	O	573-575
some	O	576-580
other	O	581-586
type	O	587-591
of	O	592-594
tumors	O	595-601
.	O	601-602

Furthermore	O	603-614
,	O	614-615
breast	O	616-622
cancer	O	623-629
cell	O	630-634
lines	O	635-640
,	O	640-641
including	O	642-651
MCF	O	652-655
-	O	655-656
7	O	656-657
and	O	658-661
MDA	O	662-665
-	O	665-666
MB	O	666-668
-	O	668-669
231	O	669-672
,	O	672-673
express	O	674-681
a	O	682-683
lower	O	684-689
level	O	690-695
of	O	696-698
miR	B	699-702
-	I	702-703
205	I	703-706
than	O	707-711
the	O	712-715
non	O	716-719
-	O	719-720
malignant	O	720-729
MCF	O	730-733
-	O	733-734
10A	O	734-737
cells	O	738-743
.	O	743-744

Ectopic	O	745-752
expression	O	753-763
of	O	764-766
miR	B	767-770
-	I	770-771
205	I	771-774
significantly	O	775-788
inhibits	O	789-797
cell	O	798-802
proliferation	O	803-816
and	O	817-820
anchorage	O	821-830
-	O	830-831
independent	O	831-842
growth	O	843-849
as	O	850-852
well	O	853-857
as	O	858-860
cell	O	861-865
invasion	O	866-874
.	O	874-875

These	O	876-881
findings	O	882-890
establish	O	891-900
the	O	901-904
tumor	O	905-910
suppressive	O	911-922
role	O	923-927
of	O	928-930
miR	B	931-934
-	I	934-935
205	I	935-938
,	O	938-939
which	O	940-945
is	O	946-948
probably	O	949-957
through	O	958-965
direct	O	966-972
targeting	O	973-982
of	O	983-985
oncogenes	O	986-995
such	O	996-1000
as	O	1001-1003
ErbB3	O	1004-1009
and	O	1010-1013
Zeb1	O	1014-1018
.	O	1018-1019

Therefore	O	1020-1029
,	O	1029-1030
miR	B	1031-1034
-	I	1034-1035
205	I	1035-1038
may	O	1039-1042
serve	O	1043-1048
as	O	1049-1051
a	O	1052-1053
unique	O	1054-1060
therapeutic	O	1061-1072
target	O	1073-1079
for	O	1080-1083
breast	O	1084-1090
cancer	O	1091-1097
.	O	1097-1098

Common	O	0-6
genetic	O	7-14
variants	O	15-23
in	O	24-26
pre	O	27-30
-	O	30-31
microRNAs	O	31-40
are	O	41-44
associated	O	45-55
with	O	56-60
risk	O	61-65
of	O	66-68
coal	O	69-73
workers	O	74-81
'	O	81-82
pneumoconiosis	O	83-97
.	O	97-98

microRNAs	O	99-108
(	O	109-110
miRNAs	O	110-116
)	O	116-117
are	O	118-121
an	O	122-124
abundant	O	125-133
class	O	134-139
of	O	140-142
small	O	143-148
noncoding	O	149-158
RNA	O	159-162
molecules	O	163-172
thought	O	173-180
to	O	181-183
be	O	184-186
involved	O	187-195
in	O	196-198
biological	O	199-209
functions	O	210-219
,	O	219-220
including	O	221-230
embryonic	O	231-240
development	O	241-252
,	O	252-253
chromosome	O	254-264
architecture	O	265-277
,	O	277-278
cell	O	279-283
proliferation	O	284-297
and	O	298-301
apoptosis	O	302-311
.	O	311-312

We	O	313-315
hypothesized	O	316-328
that	O	329-333
common	O	334-340
variants	O	341-349
in	O	350-352
the	O	353-356
miRNAs	O	357-363
are	O	364-367
associated	O	368-378
with	O	379-383
risk	O	384-388
of	O	389-391
coal	O	392-396
workers	O	397-404
'	O	404-405
pneumoconiosis	O	406-420
(	O	421-422
CWP	O	422-425
)	O	425-426
.	O	426-427

In	O	428-430
a	O	431-432
case	O	433-437
-	O	437-438
control	O	438-445
study	O	446-451
of	O	452-454
496	O	455-458
CWP	O	459-462
patients	O	463-471
and	O	472-475
513	O	476-479
control	O	480-487
subjects	O	488-496
frequency	O	497-506
matched	O	507-514
by	O	515-517
exposure	O	518-526
years	O	527-532
and	O	533-536
work	O	537-541
types	O	542-547
,	O	547-548
we	O	549-551
genotyped	O	552-561
four	O	562-566
single	O	567-573
-	O	573-574
nucleotide	O	574-584
polymorphisms	O	585-598
(	O	599-600
SNPs	O	600-604
)	O	604-605
(	O	606-607
rs2910164	O	607-616
,	O	616-617
rs2292832	O	618-627
,	O	627-628
rs11614913	O	629-639
and	O	640-643
rs3746444	O	644-653
)	O	653-654
in	O	655-657
pre	O	658-661
-	O	661-662
miRNAs	O	662-668
(	O	669-670
miR	B	670-673
-	I	673-674
146a	I	674-678
,	O	678-679
miR	B	680-683
-	I	683-684
149	I	684-687
,	O	687-688
miR	B	689-692
-	I	692-693
196a2	I	693-698
and	O	699-702
miR	B	703-706
-	I	706-707
499	I	707-710
)	O	710-711
and	O	712-715
assessed	O	716-724
the	O	725-728
associations	O	729-741
with	O	742-746
risk	O	747-751
of	O	752-754
CWP	O	755-758
.	O	758-759

A	O	760-761
significantly	O	762-775
increased	O	776-785
risk	O	786-790
of	O	791-793
CWP	O	794-797
was	O	798-801
found	O	802-807
for	O	808-811
the	O	812-815
miR	B	816-819
-	I	819-820
149	I	820-823
rs2292832	O	824-833
TT	O	834-836
genotype	O	837-845
(	O	846-847
odds	O	847-851
ratio	O	852-857
(	O	858-859
OR	O	859-861
)	O	861-862
,	O	862-863
1	O	864-865
.	O	865-866
31	O	866-868
;	O	868-869
95	O	870-872
%	O	872-873
confidence	O	874-884
interval	O	885-893
(	O	894-895
CI	O	895-897
)	O	897-898
,	O	898-899
1	O	900-901
.	O	901-902
01	O	902-904
-	O	904-905
1	O	905-906
.	O	906-907
69	O	907-909
)	O	909-910
,	O	910-911
compared	O	912-920
with	O	921-925
the	O	926-929
CT	O	930-932
/	O	932-933
CC	O	933-935
genotypes	O	936-945
,	O	945-946
and	O	947-950
this	O	951-955
increased	O	956-965
risk	O	966-970
was	O	971-974
evident	O	975-982
among	O	983-988
subgroups	O	989-998
of	O	999-1001
those	O	1002-1007
aged	O	1008-1012
>	O	1013-1014
or	O	1015-1017
=	O	1018-1019
68	O	1019-1021
years	O	1022-1027
(	O	1028-1029
OR	O	1029-1031
=	O	1031-1032
1	O	1032-1033
.	O	1033-1034
52	O	1034-1036
,	O	1036-1037
95	O	1038-1040
%	O	1040-1041
CI	O	1042-1044
=	O	1044-1045
1	O	1045-1046
.	O	1046-1047
03	O	1047-1049
-	O	1049-1050
2	O	1050-1051
.	O	1051-1052
25	O	1052-1054
)	O	1054-1055
,	O	1055-1056
dust	O	1057-1061
exposure	O	1062-1070
>	O	1071-1072
or	O	1073-1075
=	O	1076-1077
26	O	1077-1079
years	O	1080-1085
(	O	1086-1087
OR	O	1087-1089
=	O	1089-1090
1	O	1090-1091
.	O	1091-1092
42	O	1092-1094
,	O	1094-1095
95	O	1096-1098
%	O	1098-1099
CI	O	1100-1102
=	O	1102-1103
1	O	1103-1104
.	O	1104-1105
04	O	1105-1107
-	O	1107-1108
1	O	1108-1109
.	O	1109-1110
93	O	1110-1112
)	O	1112-1113
and	O	1114-1117
ever	O	1118-1122
smokers	O	1123-1130
(	O	1131-1132
OR	O	1132-1134
=	O	1134-1135
1	O	1135-1136
.	O	1136-1137
48	O	1137-1139
,	O	1139-1140
95	O	1141-1143
%	O	1143-1144
CI	O	1145-1147
=	O	1147-1148
1	O	1148-1149
.	O	1149-1150
00	O	1150-1152
-	O	1152-1153
2	O	1153-1154
.	O	1154-1155
20	O	1155-1157
)	O	1157-1158
.	O	1158-1159

Furthermore	O	1160-1171
,	O	1171-1172
a	O	1173-1174
significant	O	1175-1186
association	O	1187-1198
was	O	1199-1202
observed	O	1203-1211
between	O	1212-1219
the	O	1220-1223
genotypes	O	1224-1233
and	O	1234-1237
patients	O	1238-1246
with	O	1247-1251
stages	O	1252-1258
II	O	1259-1261
and	O	1262-1265
III	O	1266-1269
(	O	1270-1271
OR	O	1271-1273
=	O	1273-1274
1	O	1274-1275
.	O	1275-1276
50	O	1276-1278
,	O	1278-1279
95	O	1280-1282
%	O	1282-1283
CI	O	1284-1286
=	O	1286-1287
1	O	1287-1288
.	O	1288-1289
05	O	1289-1291
-	O	1291-1292
2	O	1292-1293
.	O	1293-1294
14	O	1294-1296
for	O	1297-1300
stage	O	1301-1306
II	O	1307-1309
,	O	1309-1310
and	O	1311-1314
OR	O	1315-1317
=	O	1317-1318
3	O	1318-1319
.	O	1319-1320
33	O	1320-1322
,	O	1322-1323
95	O	1324-1326
%	O	1326-1327
CI	O	1328-1330
=	O	1330-1331
1	O	1331-1332
.	O	1332-1333
67	O	1333-1335
-	O	1335-1336
6	O	1336-1337
.	O	1337-1338
65	O	1338-1340
for	O	1341-1344
stage	O	1345-1350
III	O	1351-1354
)	O	1354-1355
.	O	1355-1356

These	O	1357-1362
results	O	1363-1370
suggest	O	1371-1378
that	O	1379-1383
miR	B	1384-1387
-	I	1387-1388
149	I	1388-1391
rs2292832	O	1392-1401
polymorphism	O	1402-1414
is	O	1415-1417
involved	O	1418-1426
in	O	1427-1429
susceptibility	O	1430-1444
to	O	1445-1447
developing	O	1448-1458
CWP	O	1459-1462
.	O	1462-1463

Role	O	0-4
of	O	5-7
miR	B	8-11
-	I	11-12
29b	I	12-15
on	O	16-18
the	O	19-22
regulation	O	23-33
of	O	34-36
the	O	37-40
extracellular	O	41-54
matrix	O	55-61
in	O	62-64
human	O	65-70
trabecular	O	71-81
meshwork	O	82-90
cells	O	91-96
under	O	97-102
chronic	O	103-110
oxidative	O	111-120
stress	O	121-127
.	O	127-128

PURPOSE	O	129-136
:	O	136-137
To	O	138-140
investigate	O	141-152
the	O	153-156
role	O	157-161
of	O	162-164
miR	B	165-168
-	I	168-169
29b	I	169-172
on	O	173-175
the	O	176-179
changes	O	180-187
in	O	188-190
expression	O	191-201
of	O	202-204
genes	O	205-210
involved	O	211-219
in	O	220-222
the	O	223-226
synthesis	O	227-236
and	O	237-240
deposition	O	241-251
of	O	252-254
extracellular	O	255-268
matrix	O	269-275
(	O	276-277
ECM	O	277-280
)	O	280-281
induced	O	282-289
by	O	290-292
chronic	O	293-300
oxidative	O	301-310
stress	O	311-317
in	O	318-320
human	O	321-326
trabecular	O	327-337
meshwork	O	338-346
cells	O	347-352
(	O	353-354
HTM	O	354-357
)	O	357-358
.	O	358-359

METHODS	O	360-367
:	O	367-368
Changes	O	369-376
in	O	377-379
gene	O	380-384
expression	O	385-395
induced	O	396-403
by	O	404-406
miR	B	407-410
-	I	410-411
29b	I	411-414
in	O	415-417
HTM	O	418-421
cells	O	422-427
were	O	428-432
evaluated	O	433-442
by	O	443-445
gene	O	446-450
array	O	451-456
analysis	O	457-465
using	O	466-471
Affymetrix	O	472-482
U133A2	O	483-489
arrays	O	490-496
and	O	497-500
confirmed	O	501-510
by	O	511-513
quantitative	O	514-526
-	O	526-527
PCR	O	527-530
.	O	530-531

Pathway	O	532-539
analysis	O	540-548
was	O	549-552
conducted	O	553-562
using	O	563-568
Metacore	O	569-577
.	O	577-578

Targeting	O	579-588
of	O	589-591
miR	B	592-595
-	I	595-596
29b	I	596-599
to	O	600-602
the	O	603-606
3	O	607-608
'	O	608-609
-	O	609-610
untranslated	O	610-622
region	O	623-629
of	O	630-632
three	O	633-638
novel	O	639-644
putative	O	645-653
targets	O	654-661
was	O	662-665
evaluated	O	666-675
using	O	676-681
the	O	682-685
Psicheck	O	686-694
luciferase	O	695-705
system	O	706-712
.	O	712-713

Chronic	O	714-721
oxidative	O	722-731
stress	O	732-738
was	O	739-742
induced	O	743-750
by	O	751-753
incubation	O	754-764
at	O	765-767
40	O	768-770
%	O	770-771
oxygen	O	772-778
for	O	779-782
4	O	783-784
-	O	784-785
5	O	785-786
days	O	787-791
,	O	791-792
using	O	793-798
cultures	O	799-807
incubated	O	808-817
at	O	818-820
5	O	821-822
%	O	822-823
oxygen	O	824-830
as	O	831-833
controls	O	834-842
.	O	842-843

Changes	O	844-851
in	O	852-854
expression	O	855-865
in	O	866-868
microRNA	O	869-877
or	O	878-880
gene	O	881-885
expression	O	886-896
were	O	897-901
analyzed	O	902-910
by	O	911-913
Q	O	914-915
-	O	915-916
PCR	O	916-919
.	O	919-920

Cell	O	921-925
viability	O	926-935
was	O	936-939
measured	O	940-948
by	O	949-951
lactate	O	952-959
dehydrogenase	O	960-973
release	O	974-981
.	O	981-982

RESULTS	O	983-990
:	O	990-991
Transfection	O	992-1004
of	O	1005-1007
HTM	O	1008-1011
cells	O	1012-1017
with	O	1018-1022
miR	B	1023-1026
-	I	1026-1027
29b	I	1027-1030
mimic	O	1031-1036
resulted	O	1037-1045
in	O	1046-1048
downregulation	O	1049-1063
of	O	1064-1066
multiple	O	1067-1075
ECM	O	1076-1079
components	O	1080-1090
,	O	1090-1091
including	O	1092-1101
collagens	O	1102-1111
(	O	1112-1113
COL1A1	O	1113-1119
,	O	1119-1120
COL1A2	O	1121-1127
,	O	1127-1128
COL4A1	O	1129-1135
,	O	1135-1136
COL5A1	O	1137-1143
,	O	1143-1144
COL5A2	O	1145-1151
,	O	1151-1152
COL3A1	O	1153-1159
)	O	1159-1160
LAMC1	O	1161-1166
,	O	1166-1167
and	O	1168-1171
FBN	O	1172-1175
as	O	1176-1178
well	O	1179-1183
as	O	1184-1186
several	O	1187-1194
genes	O	1195-1200
involved	O	1201-1209
in	O	1210-1212
ECM	O	1213-1216
deposition	O	1217-1227
and	O	1228-1231
remodeling	O	1232-1242
,	O	1242-1243
such	O	1244-1248
as	O	1249-1251
SPARC	O	1252-1257
/	O	1257-1258
osteonectin	O	1258-1269
.	O	1269-1270

Three	O	1271-1276
additional	O	1277-1287
genes	O	1288-1293
,	O	1293-1294
BMP1	O	1295-1299
,	O	1299-1300
ADAM12	O	1301-1307
,	O	1307-1308
and	O	1309-1312
NKIRAS2	O	1313-1320
,	O	1320-1321
were	O	1322-1326
identified	O	1327-1337
as	O	1338-1340
direct	O	1341-1347
targets	O	1348-1355
of	O	1356-1358
miR	B	1359-1362
-	I	1362-1363
29b	I	1363-1366
.	O	1366-1367

Chronic	O	1368-1375
oxidative	O	1376-1385
stress	O	1386-1392
induced	O	1393-1400
a	O	1401-1402
significant	O	1403-1414
downregulation	O	1415-1429
of	O	1430-1432
miR	B	1433-1436
-	I	1436-1437
29b	I	1437-1440
in	O	1441-1443
two	O	1444-1447
HTM	O	1448-1451
cell	O	1452-1456
lines	O	1457-1462
that	O	1463-1467
was	O	1468-1471
associated	O	1472-1482
with	O	1483-1487
increased	O	1488-1497
expression	O	1498-1508
of	O	1509-1511
several	O	1512-1519
ECM	O	1520-1523
genes	O	1524-1529
known	O	1530-1535
to	O	1536-1538
be	O	1539-1541
regulated	O	1542-1551
by	O	1552-1554
miR	B	1555-1558
-	I	1558-1559
29b	I	1559-1562
.	O	1562-1563

The	O	1564-1567
increase	O	1568-1576
in	O	1577-1579
expression	O	1580-1590
of	O	1591-1593
these	O	1594-1599
genes	O	1600-1605
was	O	1606-1609
inhibited	O	1610-1619
by	O	1620-1622
transfection	O	1623-1635
with	O	1636-1640
miR	B	1641-1644
-	I	1644-1645
29b	I	1645-1648
mimic	O	1649-1654
.	O	1654-1655

MiR	B	1656-1659
-	I	1659-1660
29b	I	1660-1663
increased	O	1664-1673
cell	O	1674-1678
viability	O	1679-1688
under	O	1689-1694
both	O	1695-1699
chronic	O	1700-1707
oxidative	O	1708-1717
stress	O	1718-1724
and	O	1725-1728
physiologic	O	1729-1740
oxygen	O	1741-1747
concentrations	O	1748-1762
.	O	1762-1763

CONCLUSIONS	O	1764-1775
:	O	1775-1776
MiR	B	1777-1780
-	I	1780-1781
29b	I	1781-1784
negatively	O	1785-1795
regulates	O	1796-1805
the	O	1806-1809
expression	O	1810-1820
of	O	1821-1823
multiple	O	1824-1832
genes	O	1833-1838
involved	O	1839-1847
in	O	1848-1850
the	O	1851-1854
synthesis	O	1855-1864
and	O	1865-1868
deposition	O	1869-1879
of	O	1880-1882
ECM	O	1883-1886
in	O	1887-1889
trabecular	O	1890-1900
meshwork	O	1901-1909
(	O	1910-1911
TM	O	1911-1913
)	O	1913-1914
cells	O	1915-1920
.	O	1920-1921

Downregulation	O	1922-1936
of	O	1937-1939
miR	B	1940-1943
-	I	1943-1944
29b	I	1944-1947
might	O	1948-1953
contribute	O	1954-1964
to	O	1965-1967
increased	O	1968-1977
expression	O	1978-1988
of	O	1989-1991
several	O	1992-1999
ECM	O	2000-2003
genes	O	2004-2009
under	O	2010-2015
chronic	O	2016-2023
oxidative	O	2024-2033
stress	O	2034-2040
conditions	O	2041-2051
.	O	2051-2052

The	O	2053-2056
balance	O	2057-2064
between	O	2065-2072
the	O	2073-2076
activation	O	2077-2087
of	O	2088-2090
ECM	O	2091-2094
production	O	2095-2105
induced	O	2106-2113
by	O	2114-2116
oxidative	O	2117-2126
stress	O	2127-2133
and	O	2134-2137
the	O	2138-2141
protective	O	2142-2152
effects	O	2153-2160
of	O	2161-2163
miR	B	2164-2167
-	I	2167-2168
29b	I	2168-2171
could	O	2172-2177
be	O	2178-2180
a	O	2181-2182
relevant	O	2183-2191
factor	O	2192-2198
in	O	2199-2201
understanding	O	2202-2215
how	O	2216-2219
oxidative	O	2220-2229
damage	O	2230-2236
may	O	2237-2240
lead	O	2241-2245
to	O	2246-2248
increased	O	2249-2258
deposition	O	2259-2269
of	O	2270-2272
ECM	O	2273-2276
in	O	2277-2279
the	O	2280-2283
TM	O	2284-2286
and	O	2287-2290
contribute	O	2291-2301
to	O	2302-2304
the	O	2305-2308
elevation	O	2309-2318
of	O	2319-2321
intra	O	2322-2327
-	O	2327-2328
ocular	O	2328-2334
pressure	O	2335-2343
in	O	2344-2346
glaucoma	O	2347-2355
.	O	2355-2356

Upregulation	O	0-12
of	O	13-15
mir	B	16-19
-	I	19-20
221	I	20-23
and	O	24-27
mir	B	28-31
-	I	31-32
222	I	32-35
in	O	36-38
atypical	O	39-47
teratoid	O	48-56
/	O	56-57
rhabdoid	O	57-65
tumors	O	66-72
:	O	72-73
potential	O	74-83
therapeutic	O	84-95
targets	O	96-103
.	O	103-104

PURPOSE	O	105-112
:	O	112-113
The	O	114-117
aim	O	118-121
of	O	122-124
this	O	125-129
study	O	130-135
is	O	136-138
to	O	139-141
search	O	142-148
for	O	149-152
new	O	153-156
therapeutic	O	157-168
targets	O	169-176
for	O	177-180
atypical	O	181-189
teratoid	O	190-198
-	O	198-199
rhabdoid	O	199-207
tumors	O	208-214
(	O	215-216
ATRT	O	216-220
)	O	220-221
.	O	221-222

METHODS	O	223-230
:	O	230-231
To	O	232-234
achieve	O	235-242
this	O	243-247
,	O	247-248
we	O	249-251
compared	O	252-260
the	O	261-264
expression	O	265-275
of	O	276-278
365	O	279-282
microRNAs	O	283-292
among	O	293-298
ATRT	O	299-303
,	O	303-304
medulloblastomas	O	305-321
,	O	321-322
and	O	323-326
normal	O	327-333
brain	O	334-339
.	O	339-340

RESULTS	O	341-348
:	O	348-349
MiR	B	350-353
-	I	353-354
221	I	354-357
and	O	358-361
miR	B	362-365
-	I	365-366
222	I	366-369
were	O	370-374
within	O	375-381
the	O	382-385
top	O	386-389
differentially	O	390-404
expressed	O	405-414
microRNAs	O	415-424
.	O	424-425

The	O	426-429
deregulated	O	430-441
expression	O	442-452
of	O	453-455
miR221	B	456-462
/	O	462-463
222	B	463-466
was	O	467-470
demonstrated	O	471-483
to	O	484-486
inhibit	O	487-494
the	O	495-498
expression	O	499-509
of	O	510-512
the	O	513-516
tumor	O	517-522
suppressor	O	523-533
and	O	534-537
inhibitor	O	538-547
of	O	548-550
cell	O	551-555
cycle	O	556-561
p27	O	562-565
(	O	565-566
Kip1	O	566-570
)	O	570-571
.	O	571-572

Here	O	573-577
,	O	577-578
we	O	579-581
demonstrated	O	582-594
the	O	595-598
negative	O	599-607
regulation	O	608-618
of	O	619-621
p27	O	622-625
(	O	625-626
Kip1	O	626-630
)	O	630-631
by	O	632-634
miR	B	635-638
-	I	638-639
221	I	639-642
/	O	642-643
222	B	643-646
in	O	647-649
ATRT	O	650-654
using	O	655-660
microarray	O	661-671
,	O	671-672
real	O	673-677
-	O	677-678
time	O	678-682
reverse	O	683-690
transcriptase	O	691-704
polymerase	O	705-715
chain	O	716-721
reaction	O	722-730
,	O	730-731
and	O	732-735
immunohistochemistry	O	736-756
.	O	756-757

CONCLUSION	O	758-768
:	O	768-769
As	O	770-772
anti	O	773-777
-	O	777-778
miR	O	778-781
therapy	O	782-789
was	O	790-793
recently	O	794-802
proposed	O	803-811
as	O	812-814
an	O	815-817
alternative	O	818-829
treatment	O	830-839
for	O	840-843
cancer	O	844-850
,	O	850-851
these	O	852-857
findings	O	858-866
suggest	O	867-874
that	O	875-879
anti	O	880-884
-	O	884-885
miR	B	885-888
-	I	888-889
221	I	889-892
/	O	892-893
222	B	893-896
therapy	O	897-904
might	O	905-910
have	O	911-915
therapeutic	O	916-927
potential	O	928-937
in	O	938-940
ATRT	O	941-945
.	O	945-946

MicroRNA	O	0-8
miR	B	9-12
-	I	12-13
146a	I	13-17
is	O	18-20
induced	O	21-28
by	O	29-31
HTLV	O	32-36
-	O	36-37
1	O	37-38
tax	O	39-42
and	O	43-46
increases	O	47-56
the	O	57-60
growth	O	61-67
of	O	68-70
HTLV	O	71-75
-	O	75-76
1	O	76-77
-	O	77-78
infected	O	78-86
T	O	87-88
-	O	88-89
cells	O	89-94
.	O	94-95

Human	O	96-101
T	O	102-103
-	O	103-104
cell	O	104-108
leukemia	O	109-117
virus	O	118-123
type	O	124-128
1	O	129-130
(	O	131-132
HTLV	O	132-136
-	O	136-137
1	O	137-138
)	O	138-139
is	O	140-142
the	O	143-146
causative	O	147-156
agent	O	157-162
of	O	163-165
adult	O	166-171
T	O	172-173
-	O	173-174
cell	O	174-178
leukemia	O	179-187
(	O	188-189
ATL	O	189-192
)	O	192-193
,	O	193-194
which	O	195-200
is	O	201-203
an	O	204-206
aggressive	O	207-217
and	O	218-221
fatal	O	222-227
CD4	O	228-231
(	O	231-232
+	O	232-233
)	O	233-234
T	O	235-236
cell	O	237-241
malignancy	O	242-252
.	O	252-253

MicroRNA	O	254-262
(	O	263-264
miRNA	O	264-269
)	O	269-270
,	O	270-271
a	O	272-273
novel	O	274-279
class	O	280-285
of	O	286-288
RNA	O	289-292
that	O	293-297
regulates	O	298-307
gene	O	308-312
expression	O	313-323
,	O	323-324
is	O	325-327
involved	O	328-336
in	O	337-339
many	O	340-344
cellular	O	345-353
processes	O	354-363
such	O	364-368
as	O	369-371
growth	O	372-378
,	O	378-379
development	O	380-391
and	O	392-395
apoptosis	O	396-405
.	O	405-406

It	O	407-409
has	O	410-413
recently	O	414-422
been	O	423-427
linked	O	428-434
to	O	435-437
several	O	438-445
cancer	O	446-452
phenotypes	O	453-463
.	O	463-464

However	O	465-472
,	O	472-473
aberrant	O	474-482
miRNA	O	483-488
expression	O	489-499
and	O	500-503
its	O	504-507
pathologic	O	508-518
significance	O	519-531
in	O	532-534
ATL	O	535-538
are	O	539-542
not	O	543-546
well	O	547-551
documented	O	552-562
.	O	562-563

Here	O	564-568
,	O	568-569
we	O	570-572
investigated	O	573-585
the	O	586-589
role	O	590-594
of	O	595-597
miRNAs	O	598-604
in	O	605-607
HTLV	O	608-612
-	O	612-613
1	O	613-614
-	O	614-615
related	O	615-622
leukemogenesis	O	623-637
.	O	637-638

The	O	639-642
results	O	643-650
showed	O	651-657
that	O	658-662
miR	B	663-666
-	I	666-667
146a	I	667-671
was	O	672-675
upregulated	O	676-687
in	O	688-690
HTLV	O	691-695
-	O	695-696
1	O	696-697
-	O	697-698
infected	O	698-706
T	O	707-708
-	O	708-709
cell	O	709-713
lines	O	714-719
compared	O	720-728
to	O	729-731
uninfected	O	732-742
T	O	743-744
-	O	744-745
cell	O	745-749
lines	O	750-755
.	O	755-756

Tax	O	757-760
-	O	760-761
induced	O	761-768
miR	B	769-772
-	I	772-773
146a	I	773-777
expression	O	778-788
in	O	789-791
a	O	792-793
NF	O	794-796
-	O	796-797
kappaB	O	797-803
-	O	803-804
dependent	O	804-813
manner	O	814-820
and	O	821-824
inhibited	O	825-834
the	O	835-838
expression	O	839-849
of	O	850-852
gene	O	853-857
harboring	O	858-867
the	O	868-871
target	O	872-878
sequence	O	879-887
of	O	888-890
miR	B	891-894
-	I	894-895
146a	I	895-899
on	O	900-902
its	O	903-906
3	O	907-908
'	O	908-909
UTR	O	909-912
.	O	912-913

Inhibition	O	914-924
of	O	925-927
miR	B	928-931
-	I	931-932
146a	I	932-936
function	O	937-945
by	O	946-948
anti	O	949-953
-	O	953-954
miRNA	O	954-959
inhibitor	O	960-969
reduced	O	970-977
the	O	978-981
proliferation	O	982-995
of	O	996-998
HTLV	O	999-1003
-	O	1003-1004
1	O	1004-1005
-	O	1005-1006
infected	O	1006-1014
T	O	1015-1016
-	O	1016-1017
cell	O	1017-1021
lines	O	1022-1027
but	O	1028-1031
not	O	1032-1035
that	O	1036-1040
of	O	1041-1043
uninfected	O	1044-1054
T	O	1055-1056
-	O	1056-1057
cell	O	1057-1061
lines	O	1062-1067
.	O	1067-1068

Moreover	O	1069-1077
,	O	1077-1078
overexpression	O	1079-1093
of	O	1094-1096
miR	B	1097-1100
-	I	1100-1101
146a	I	1101-1105
enhanced	O	1106-1114
the	O	1115-1118
growth	O	1119-1125
of	O	1126-1128
an	O	1129-1131
HTLV	O	1132-1136
-	O	1136-1137
1	O	1137-1138
-	O	1138-1139
infected	O	1139-1147
T	O	1148-1149
-	O	1149-1150
cell	O	1150-1154
line	O	1155-1159
.	O	1159-1160

Our	O	1161-1164
findings	O	1165-1173
suggest	O	1174-1181
that	O	1182-1186
miR	B	1187-1190
-	I	1190-1191
146a	I	1191-1195
is	O	1196-1198
a	O	1199-1200
potentially	O	1201-1212
suitable	O	1213-1221
therapeutic	O	1222-1233
target	O	1234-1240
of	O	1241-1243
ATL	O	1244-1247
.	O	1247-1248

miR	B	0-3
-	I	3-4
449	I	4-7
regulates	O	8-17
CDK	O	18-21
-	O	21-22
Rb	O	22-24
-	O	24-25
E2F1	O	25-29
through	O	30-37
an	O	38-40
auto	O	41-45
-	O	45-46
regulatory	O	46-56
feedback	O	57-65
circuit	O	66-73
.	O	73-74

MiR	B	0-3
-	I	3-4
222	I	4-7
overexpression	O	8-22
confers	O	23-30
cell	O	31-35
migratory	O	36-45
advantages	O	46-56
in	O	57-59
hepatocellular	O	60-74
carcinoma	O	75-84
through	O	85-92
enhancing	O	93-102
AKT	O	103-106
signaling	O	107-116
.	O	116-117

PURPOSE	O	118-125
:	O	125-126
This	O	127-131
study	O	132-137
aims	O	138-142
to	O	143-145
profile	O	146-153
the	O	154-157
expressions	O	158-169
of	O	170-172
156	O	173-176
microRNAs	O	177-186
(	O	187-188
miRNA	O	188-193
)	O	193-194
in	O	195-197
hepatocellular	O	198-212
carcinoma	O	213-222
(	O	223-224
HCC	O	224-227
)	O	227-228
and	O	229-232
to	O	233-235
characterize	O	236-248
the	O	249-252
functions	O	253-262
of	O	263-265
miR	B	266-269
-	I	269-270
222	I	270-273
,	O	273-274
the	O	275-278
most	O	279-283
significantly	O	284-297
upregulated	O	298-309
candidate	O	310-319
identified	O	320-330
.	O	330-331

EXPERIMENTAL	O	332-344
DESIGN	O	345-351
:	O	351-352
miRNA	O	353-358
expression	O	359-369
profile	O	370-377
in	O	378-380
HCC	O	381-384
tumors	O	385-391
,	O	391-392
matching	O	393-401
adjacent	O	402-410
cirrhotic	O	411-420
livers	O	421-427
,	O	427-428
and	O	429-432
cell	O	433-437
lines	O	438-443
was	O	444-447
conducted	O	448-457
using	O	458-463
quantitative	O	464-476
PCR	O	477-480
.	O	480-481

Common	O	482-488
miR	B	489-492
-	I	492-493
222	I	493-496
upregulations	O	497-510
were	O	511-515
further	O	516-523
validated	O	524-533
in	O	534-536
a	O	537-538
larger	O	539-545
cohort	O	546-552
of	O	553-555
tumors	O	556-562
.	O	562-563

The	O	564-567
functional	O	568-578
effects	O	579-586
of	O	587-589
miR	B	590-593
-	I	593-594
222	I	594-597
inhibition	O	598-608
on	O	609-611
HCC	O	612-615
cell	O	616-620
lines	O	621-626
were	O	627-631
examined	O	632-640
.	O	640-641

The	O	642-645
downstream	O	646-656
modulated	O	657-666
pathways	O	667-675
and	O	676-679
target	O	680-686
of	O	687-689
miR	B	690-693
-	I	693-694
222	I	694-697
were	O	698-702
investigated	O	703-715
by	O	716-718
coupling	O	719-727
gene	O	728-732
expression	O	733-743
profiling	O	744-753
and	O	754-757
pathway	O	758-765
analysis	O	766-774
,	O	774-775
and	O	776-779
by	O	780-782
in	O	783-785
silico	O	786-792
prediction	O	793-803
,	O	803-804
respectively	O	805-817
.	O	817-818

Luciferase	O	819-829
reporter	O	830-838
assay	O	839-844
was	O	845-848
done	O	849-853
to	O	854-856
confirm	O	857-864
target	O	865-871
interaction	O	872-883
.	O	883-884

RESULTS	O	885-892
:	O	892-893
We	O	894-896
identified	O	897-907
a	O	908-909
40	O	910-912
-	O	912-913
miRNA	O	913-918
signature	O	919-928
that	O	929-933
could	O	934-939
discriminate	O	940-952
tumors	O	953-959
from	O	960-964
adjacent	O	965-973
cirrhotic	O	974-983
liver	O	984-989
tissue	O	990-996
,	O	996-997
and	O	998-1001
further	O	1002-1009
corroborated	O	1010-1022
common	O	1023-1029
miR	B	1030-1033
-	I	1033-1034
222	I	1034-1037
overexpression	O	1038-1052
in	O	1053-1055
tumors	O	1056-1062
relative	O	1063-1071
to	O	1072-1074
its	O	1075-1078
premalignant	O	1079-1091
counterpart	O	1092-1103
(	O	1104-1105
55	O	1105-1107
.	O	1107-1108
3	O	1108-1109
%	O	1109-1110
;	O	1110-1111
P	O	1112-1113
<	O	1114-1115
0	O	1116-1117
.	O	1117-1118
0001	O	1118-1122
)	O	1122-1123
.	O	1123-1124

Increased	O	1125-1134
miR	B	1135-1138
-	I	1138-1139
222	I	1139-1142
expression	O	1143-1153
correlated	O	1154-1164
significantly	O	1165-1178
with	O	1179-1183
advanced	O	1184-1192
stage	O	1193-1198
HCC	O	1199-1202
and	O	1203-1206
with	O	1207-1211
the	O	1212-1215
shorter	O	1216-1223
disease	O	1224-1231
-	O	1231-1232
free	O	1232-1236
survival	O	1237-1245
of	O	1246-1248
patients	O	1249-1257
(	O	1258-1259
P	O	1259-1260
<	O	1261-1262
or	O	1263-1265
=	O	1266-1267
0	O	1268-1269
.	O	1269-1270
01	O	1270-1272
)	O	1272-1273
.	O	1273-1274

Inhibition	O	1275-1285
of	O	1286-1288
miR	B	1289-1292
-	I	1292-1293
222	I	1293-1296
in	O	1297-1299
Hep3B	O	1300-1305
and	O	1306-1309
HKCI	O	1310-1314
-	O	1314-1315
9	O	1315-1316
significantly	O	1317-1330
retarded	O	1331-1339
cell	O	1340-1344
motility	O	1345-1353
(	O	1354-1355
P	O	1355-1356
<	O	1357-1358
0	O	1359-1360
.	O	1360-1361
05	O	1361-1363
)	O	1363-1364
.	O	1364-1365

Further	O	1366-1373
investigations	O	1374-1388
suggested	O	1389-1398
that	O	1399-1403
AKT	O	1404-1407
signaling	O	1408-1417
was	O	1418-1421
the	O	1422-1425
major	O	1426-1431
pathway	O	1432-1439
influenced	O	1440-1450
by	O	1451-1453
miR	B	1454-1457
-	I	1457-1458
222	I	1458-1461
.	O	1461-1462

A	O	1463-1464
consistent	O	1465-1475
reduction	O	1476-1485
of	O	1486-1488
AKT	O	1489-1492
phosphorylation	O	1493-1508
in	O	1509-1511
Hep3B	O	1512-1517
and	O	1518-1521
HKCI	O	1522-1526
-	O	1526-1527
9	O	1527-1528
was	O	1529-1532
shown	O	1533-1538
following	O	1539-1548
miR	B	1549-1552
-	I	1552-1553
222	I	1553-1556
suppression	O	1557-1568
.	O	1568-1569

The	O	1570-1573
protein	O	1574-1581
phosphatase	O	1582-1593
2A	O	1594-1596
subunit	O	1597-1604
B	O	1605-1606
(	O	1607-1608
PPP2R2A	O	1608-1615
)	O	1615-1616
was	O	1617-1620
predicted	O	1621-1630
as	O	1631-1633
a	O	1634-1635
putative	O	1636-1644
miR	B	1645-1648
-	I	1648-1649
222	I	1649-1652
target	O	1653-1659
in	O	1660-1662
silico	O	1663-1669
.	O	1669-1670

We	O	1671-1673
found	O	1674-1679
that	O	1680-1684
miR	B	1685-1688
-	I	1688-1689
222	I	1689-1692
inhibition	O	1693-1703
could	O	1704-1709
augment	O	1710-1717
the	O	1718-1721
tumor	O	1722-1727
protein	O	1728-1735
level	O	1736-1741
and	O	1742-1745
restore	O	1746-1753
luciferase	O	1754-1764
activity	O	1765-1773
in	O	1774-1776
reporter	O	1777-1785
construct	O	1786-1795
containing	O	1796-1806
the	O	1807-1810
PPP2R2A	O	1811-1818
3	O	1819-1820
'	O	1820-1821
untranslated	O	1822-1834
region	O	1835-1841
(	O	1842-1843
P	O	1843-1844
=	O	1845-1846
0	O	1847-1848
.	O	1848-1849
0066	O	1849-1853
)	O	1853-1854
.	O	1854-1855

CONCLUSIONS	O	1856-1867
:	O	1867-1868
Our	O	1869-1872
study	O	1873-1878
showed	O	1879-1885
that	O	1886-1890
miR	B	1891-1894
-	I	1894-1895
222	I	1895-1898
overexpression	O	1899-1913
is	O	1914-1916
common	O	1917-1923
in	O	1924-1926
HCC	O	1927-1930
and	O	1931-1934
could	O	1935-1940
confer	O	1941-1947
metastatic	O	1948-1958
potentials	O	1959-1969
in	O	1970-1972
HCC	O	1973-1976
cells	O	1977-1982
,	O	1982-1983
possibly	O	1984-1992
through	O	1993-2000
activating	O	2001-2011
AKT	O	2012-2015
signaling	O	2016-2025
.	O	2025-2026

miRNA	B	0-5
-	I	5-6
21	I	6-8
regulates	O	9-18
arsenic	O	19-26
-	O	26-27
induced	O	27-34
anti	O	35-39
-	O	39-40
leukemia	O	40-48
activity	O	49-57
in	O	58-60
myelogenous	O	61-72
cell	O	73-77
lines	O	78-83
.	O	83-84

MicroRNAs	O	85-94
(	O	95-96
miRNAs	O	96-102
)	O	102-103
are	O	104-107
endogenous	O	108-118
small	O	119-124
noncoding	O	125-134
RNA	O	135-138
molecules	O	139-148
involved	O	149-157
in	O	158-160
modulation	O	161-171
of	O	172-174
cellular	O	175-183
sensitivity	O	184-195
to	O	196-198
anti	O	199-203
-	O	203-204
cancer	O	204-210
drugs	O	211-216
.	O	216-217

miRNA	B	218-223
-	I	223-224
21	I	224-226
(	O	227-228
miR	B	228-231
-	I	231-232
21	I	232-234
)	O	234-235
,	O	235-236
one	O	237-240
of	O	241-243
the	O	244-247
most	O	248-252
prominent	O	253-262
miRNAs	O	263-269
in	O	270-272
the	O	273-276
genesis	O	277-284
and	O	285-288
progression	O	289-300
of	O	301-303
many	O	304-308
human	O	309-314
cancers	O	315-322
,	O	322-323
has	O	324-327
been	O	328-332
rarely	O	333-339
characterized	O	340-353
in	O	354-356
myelogenous	O	357-368
leukemia	O	369-377
.	O	377-378

Arsenic	O	379-386
trioxide	O	387-395
(	O	396-397
ATO	O	397-400
)	O	400-401
was	O	402-405
successfully	O	406-418
used	O	419-423
in	O	424-426
the	O	427-430
treatment	O	431-440
of	O	441-443
acute	O	444-449
promyelocytic	O	450-463
leukemia	O	464-472
(	O	473-474
APL	O	474-477
)	O	477-478
etc	O	479-482
.	O	482-483

However	O	484-491
,	O	491-492
cytotoxicity	O	493-505
or	O	506-508
insensitivity	O	509-522
is	O	523-525
a	O	526-527
major	O	528-533
concern	O	534-541
in	O	542-544
the	O	545-548
successful	O	549-559
treatment	O	560-569
of	O	570-572
leukemia	O	573-581
.	O	581-582

Here	O	583-587
,	O	587-588
we	O	589-591
used	O	592-596
a	O	597-598
specific	O	599-607
precursor	O	608-617
miRNA	B	618-623
-	I	623-624
21	I	624-626
(	O	627-628
pre	B	628-631
-	I	631-632
miR	I	632-635
-	I	635-636
21	I	636-638
)	O	638-639
or	O	640-642
anti	O	643-647
-	O	647-648
miRNA	B	648-653
-	I	653-654
21	I	654-656
oligonucleotide	O	657-672
(	O	673-674
AMO	O	674-677
-	O	677-678
miR	B	678-681
-	I	681-682
21	I	682-684
)	O	684-685
to	O	686-688
study	O	689-694
sensitivity	O	695-706
of	O	707-709
HL60	O	710-714
and	O	715-718
K562	O	719-723
cells	O	724-729
to	O	730-732
ATO	O	733-736
.	O	736-737

Cell	O	738-742
viability	O	743-752
and	O	753-756
cell	O	757-761
cycle	O	762-767
were	O	768-772
evaluated	O	773-782
by	O	783-785
MTT	O	786-789
assay	O	790-795
and	O	796-799
PI	O	800-802
assay	O	803-808
using	O	809-814
flow	O	815-819
cytometry	O	820-829
,	O	829-830
respectively	O	831-843
.	O	843-844

Levels	O	845-851
of	O	852-854
miR	B	855-858
-	I	858-859
21	I	859-861
and	O	862-865
its	O	866-869
target	O	870-876
PDCD4	O	877-882
were	O	883-887
quantified	O	888-898
by	O	899-901
real	O	902-906
-	O	906-907
time	O	907-911
PCR	O	912-915
and	O	916-919
/	O	919-920
or	O	920-922
western	O	923-930
blot	O	931-935
.	O	935-936

AMO	O	937-940
-	B	940-941
miR	I	941-944
-	I	944-945
21	I	945-947
or	O	948-950
ATO	O	951-954
alone	O	955-960
led	O	961-964
to	O	965-967
growth	O	968-974
inhibition	O	975-985
,	O	985-986
apoptosis	O	987-996
and	O	997-1000
G1	O	1001-1003
phase	O	1004-1009
arrest	O	1010-1016
of	O	1017-1019
cell	O	1020-1024
cycle	O	1025-1030
.	O	1030-1031

Apoptotic	O	1032-1041
cells	O	1042-1047
were	O	1048-1052
confirmed	O	1053-1062
morphologically	O	1063-1078
with	O	1079-1083
Hoechst	O	1084-1091
staining	O	1092-1100
.	O	1100-1101

Moreover	O	1102-1110
,	O	1110-1111
there	O	1112-1117
was	O	1118-1121
somewhat	O	1122-1130
synergistic	O	1131-1142
effect	O	1143-1149
of	O	1150-1152
AMO	O	1153-1156
-	O	1156-1157
miR	B	1157-1160
-	I	1160-1161
21	I	1161-1163
and	O	1164-1167
ATO	O	1168-1171
in	O	1172-1174
growth	O	1175-1181
inhibition	O	1182-1192
and	O	1193-1196
apoptosis	O	1197-1206
promotion	O	1207-1216
.	O	1216-1217

Meanwhile	O	1218-1227
,	O	1227-1228
enforced	O	1229-1237
pre	B	1238-1241
-	I	1241-1242
miR	I	1242-1245
-	I	1245-1246
21	I	1246-1248
expression	O	1249-1259
increased	O	1260-1269
resistance	O	1270-1280
to	O	1281-1283
ATO	O	1284-1287
,	O	1287-1288
nevertheless	O	1289-1301
not	O	1302-1305
affecting	O	1306-1315
cell	O	1316-1320
growth	O	1321-1327
alone	O	1328-1333
.	O	1333-1334

Dual	O	1335-1339
-	O	1339-1340
luciferase	O	1340-1350
reporter	O	1351-1359
vector	O	1360-1366
containing	O	1367-1377
two	O	1378-1381
tandem	O	1382-1388
PDCD4	O	1389-1394
3	O	1395-1396
'	O	1396-1397
UTR	O	1398-1401
validated	O	1402-1411
that	O	1412-1416
PDCD4	O	1417-1422
was	O	1423-1426
directly	O	1427-1435
up	O	1436-1438
-	O	1438-1439
regulated	O	1439-1448
by	O	1449-1451
miR	B	1452-1455
-	I	1455-1456
21	I	1456-1458
.	O	1458-1459

Therefore	O	1460-1469
,	O	1469-1470
miRNA	B	1471-1476
-	I	1476-1477
21	I	1477-1479
by	O	1480-1482
targeting	O	1483-1492
PDCD4	O	1493-1498
may	O	1499-1502
play	O	1503-1507
a	O	1508-1509
functional	O	1510-1520
role	O	1521-1525
in	O	1526-1528
modulating	O	1529-1539
ATO	O	1540-1543
-	O	1543-1544
induced	O	1544-1551
cell	O	1552-1556
death	O	1557-1562
,	O	1562-1563
and	O	1564-1567
strategy	O	1568-1576
using	O	1577-1582
AMO	O	1583-1586
-	O	1586-1587
miR	B	1587-1590
-	I	1590-1591
21	I	1591-1593
and	O	1594-1597
its	O	1598-1601
combination	O	1602-1613
with	O	1614-1618
ATO	O	1619-1622
may	O	1623-1626
be	O	1627-1629
useful	O	1630-1636
as	O	1637-1639
a	O	1640-1641
myelogenous	O	1642-1653
leukemia	O	1654-1662
therapy	O	1663-1670
.	O	1670-1671

Identifying	O	0-11
co	O	12-14
-	O	14-15
regulating	O	15-25
microRNA	O	26-34
groups	O	35-41
.	O	41-42

BACKGROUND	O	43-53
:	O	53-54
Current	O	55-62
miRNA	O	63-68
target	O	69-75
prediction	O	76-86
tools	O	87-92
have	O	93-97
the	O	98-101
common	O	102-108
problem	O	109-116
that	O	117-121
their	O	122-127
false	O	128-133
positive	O	134-142
rate	O	143-147
is	O	148-150
high	O	151-155
.	O	155-156

This	O	157-161
renders	O	162-169
identification	O	170-184
of	O	185-187
co	O	188-190
-	O	190-191
regulating	O	191-201
groups	O	202-208
of	O	209-211
miRNAs	O	212-218
and	O	219-222
target	O	223-229
genes	O	230-235
unreliable	O	236-246
.	O	246-247

In	O	248-250
this	O	251-255
study	O	256-261
,	O	261-262
we	O	263-265
describe	O	266-274
a	O	275-276
procedure	O	277-286
to	O	287-289
identify	O	290-298
highly	O	299-305
probable	O	306-314
co	O	315-317
-	O	317-318
regulating	O	318-328
miRNAs	O	329-335
and	O	336-339
the	O	340-343
corresponding	O	344-357
co	O	358-360
-	O	360-361
regulated	O	361-370
gene	O	371-375
groups	O	376-382
.	O	382-383

Our	O	384-387
procedure	O	388-397
involves	O	398-406
a	O	407-408
sequence	O	409-417
of	O	418-420
statistical	O	421-432
tests	O	433-438
:	O	438-439
(	O	440-441
1	O	441-442
)	O	442-443
identify	O	444-452
genes	O	453-458
that	O	459-463
are	O	464-467
highly	O	468-474
probable	O	475-483
miRNA	O	484-489
targets	O	490-497
;	O	497-498
(	O	499-500
2	O	500-501
)	O	501-502
determine	O	503-512
for	O	513-516
each	O	517-521
such	O	522-526
gene	O	527-531
,	O	531-532
the	O	533-536
minimum	O	537-544
number	O	545-551
of	O	552-554
miRNAs	O	555-561
that	O	562-566
co	O	567-569
-	O	569-570
regulate	O	570-578
it	O	579-581
with	O	582-586
high	O	587-591
probability	O	592-603
;	O	603-604
(	O	605-606
3	O	606-607
)	O	607-608
find	O	609-613
,	O	613-614
for	O	615-618
each	O	619-623
such	O	624-628
gene	O	629-633
,	O	633-634
the	O	635-638
combination	O	639-650
of	O	651-653
the	O	654-657
determined	O	658-668
minimum	O	669-676
size	O	677-681
of	O	682-684
miRNAs	O	685-691
that	O	692-696
co	O	697-699
-	O	699-700
regulate	O	700-708
it	O	709-711
with	O	712-716
the	O	717-720
lowest	O	721-727
p	O	728-729
-	O	729-730
value	O	730-735
;	O	735-736
and	O	737-740
(	O	741-742
4	O	742-743
)	O	743-744
discover	O	745-753
for	O	754-757
each	O	758-762
such	O	763-767
combination	O	768-779
of	O	780-782
miRNAs	O	783-789
,	O	789-790
the	O	791-794
group	O	795-800
of	O	801-803
genes	O	804-809
that	O	810-814
are	O	815-818
co	O	819-821
-	O	821-822
regulated	O	822-831
by	O	832-834
these	O	835-840
miRNAs	O	841-847
with	O	848-852
the	O	853-856
lowest	O	857-863
p	O	864-865
-	O	865-866
value	O	866-871
computed	O	872-880
based	O	881-886
on	O	887-889
GO	O	890-892
term	O	893-897
annotations	O	898-909
of	O	910-912
the	O	913-916
genes	O	917-922
.	O	922-923

RESULTS	O	924-931
:	O	931-932
Our	O	933-936
method	O	937-943
identifies	O	944-954
4	O	955-956
,	O	956-957
3	O	958-959
and	O	960-963
2	O	964-965
-	O	965-966
term	O	966-970
miRNA	O	971-976
groups	O	977-983
that	O	984-988
co	O	989-991
-	O	991-992
regulate	O	992-1000
gene	O	1001-1005
groups	O	1006-1012
of	O	1013-1015
size	O	1016-1020
at	O	1021-1023
least	O	1024-1029
3	O	1030-1031
in	O	1032-1034
human	O	1035-1040
.	O	1040-1041

Our	O	1042-1045
result	O	1046-1052
suggests	O	1053-1061
some	O	1062-1066
interesting	O	1067-1078
hypothesis	O	1079-1089
on	O	1090-1092
the	O	1093-1096
functional	O	1097-1107
role	O	1108-1112
of	O	1113-1115
several	O	1116-1123
miRNAs	O	1124-1130
through	O	1131-1138
a	O	1139-1140
"	O	1141-1142
guilt	O	1142-1147
by	O	1148-1150
association	O	1151-1162
"	O	1162-1163
reasoning	O	1164-1173
.	O	1173-1174

For	O	1175-1178
example	O	1179-1186
,	O	1186-1187
miR	B	1188-1191
-	I	1191-1192
130	I	1192-1195
,	O	1195-1196
miR	B	1197-1200
-	I	1200-1201
19	I	1201-1203
and	O	1204-1207
miR	B	1208-1211
-	I	1211-1212
101	I	1212-1215
are	O	1216-1219
known	O	1220-1225
neurodegenerative	O	1226-1243
diseases	O	1244-1252
associated	O	1253-1263
miRNAs	O	1264-1270
.	O	1270-1271

Our	O	1272-1275
3	O	1276-1277
-	O	1277-1278
term	O	1278-1282
miRNA	O	1283-1288
table	O	1289-1294
shows	O	1295-1300
that	O	1301-1305
miR	B	1306-1309
-	I	1309-1310
130	I	1310-1313
/	O	1313-1314
19	B	1314-1316
/	O	1316-1317
101	B	1317-1320
form	O	1321-1325
a	O	1326-1327
co	O	1328-1330
-	O	1330-1331
regulating	O	1331-1341
group	O	1342-1347
of	O	1348-1350
rank	O	1351-1355
22	O	1356-1358
(	O	1359-1360
p	O	1360-1361
-	O	1361-1362
value	O	1362-1367
=	O	1368-1369
1	O	1369-1370
.	O	1370-1371
16	O	1371-1373
x	O	1374-1375
10	O	1376-1378
(	O	1378-1379
-	O	1379-1380
2	O	1380-1381
)	O	1381-1382
)	O	1382-1383
.	O	1383-1384

Since	O	1385-1390
miR	B	1391-1394
-	I	1394-1395
144	I	1395-1398
is	O	1399-1401
co	O	1402-1404
-	O	1404-1405
regulating	O	1405-1415
with	O	1416-1420
miR	B	1421-1424
-	I	1424-1425
130	I	1425-1428
,	O	1428-1429
miR	B	1430-1433
-	I	1433-1434
19	I	1434-1436
and	O	1437-1440
miR	B	1441-1444
-	I	1444-1445
101	I	1445-1448
of	O	1449-1451
rank	O	1452-1456
4	O	1457-1458
(	O	1459-1460
p	O	1460-1461
-	O	1461-1462
value	O	1462-1467
=	O	1468-1469
1	O	1470-1471
.	O	1471-1472
16	O	1472-1474
x	O	1475-1476
10	O	1477-1479
(	O	1479-1480
-	O	1480-1481
2	O	1481-1482
)	O	1482-1483
)	O	1483-1484
in	O	1485-1487
our	O	1488-1491
4	O	1492-1493
-	O	1493-1494
term	O	1494-1498
miRNA	O	1499-1504
table	O	1505-1510
,	O	1510-1511
this	O	1512-1516
suggests	O	1517-1525
hsa	B	1526-1529
-	I	1529-1530
miR	I	1530-1533
-	I	1533-1534
144	I	1534-1537
may	O	1538-1541
be	O	1542-1544
neurodegenerative	O	1545-1562
diseases	O	1563-1571
related	O	1572-1579
miRNA	O	1580-1585
.	O	1585-1586

CONCLUSIONS	O	1587-1598
:	O	1598-1599
This	O	1600-1604
work	O	1605-1609
identifies	O	1610-1620
highly	O	1621-1627
probable	O	1628-1636
co	O	1637-1639
-	O	1639-1640
regulating	O	1640-1650
miRNAs	O	1651-1657
,	O	1657-1658
which	O	1659-1664
are	O	1665-1668
refined	O	1669-1676
from	O	1677-1681
the	O	1682-1685
prediction	O	1686-1696
by	O	1697-1699
computational	O	1700-1713
tools	O	1714-1719
using	O	1720-1725
(	O	1726-1727
1	O	1727-1728
)	O	1728-1729
signal	O	1730-1736
-	O	1736-1737
to	O	1737-1739
-	O	1739-1740
noise	O	1740-1745
ratio	O	1746-1751
to	O	1752-1754
get	O	1755-1758
high	O	1759-1763
accurate	O	1764-1772
regulating	O	1773-1783
miRNAs	O	1784-1790
for	O	1791-1794
every	O	1795-1800
gene	O	1801-1805
,	O	1805-1806
and	O	1807-1810
(	O	1811-1812
2	O	1812-1813
)	O	1813-1814
Gene	O	1815-1819
Ontology	O	1820-1828
to	O	1829-1831
obtain	O	1832-1838
functional	O	1839-1849
related	O	1850-1857
co	O	1858-1860
-	O	1860-1861
regulating	O	1861-1871
miRNA	O	1872-1877
groups	O	1878-1884
.	O	1884-1885

Our	O	1886-1889
result	O	1890-1896
has	O	1897-1900
partly	O	1901-1907
been	O	1908-1912
supported	O	1913-1922
by	O	1923-1925
biological	O	1926-1936
experiments	O	1937-1948
.	O	1948-1949

Based	O	1950-1955
on	O	1956-1958
prediction	O	1959-1969
by	O	1970-1972
TargetScanS	O	1973-1984
,	O	1984-1985
we	O	1986-1988
found	O	1989-1994
highly	O	1995-2001
probable	O	2002-2010
target	O	2011-2017
gene	O	2018-2022
groups	O	2023-2029
in	O	2030-2032
the	O	2033-2036
Supplementary	O	2037-2050
Information	O	2051-2062
.	O	2062-2063

This	O	2064-2068
result	O	2069-2075
might	O	2076-2081
help	O	2082-2086
biologists	O	2087-2097
to	O	2098-2100
find	O	2101-2105
small	O	2106-2111
set	O	2112-2115
of	O	2116-2118
miRNAs	O	2119-2125
for	O	2126-2129
genes	O	2130-2135
of	O	2136-2138
interest	O	2139-2147
rather	O	2148-2154
than	O	2155-2159
huge	O	2160-2164
amount	O	2165-2171
of	O	2172-2174
miRNA	O	2175-2180
set	O	2181-2184
.	O	2184-2185

SUPPLEMENTARY	O	2186-2199
INFORMATION	O	2200-2211
:	O	2211-2212
http	O	2213-2217
:	O	2217-2218
/	O	2218-2219
/	O	2219-2220
www	O	2220-2223
.	O	2223-2224
deakin	O	2224-2230
.	O	2230-2231
edu	O	2231-2234
.	O	2234-2235
au	O	2235-2237
/	O	2237-2238
~	O	2238-2239
phoebe	O	2239-2245
/	O	2245-2246
JBCBAnChen	O	2246-2256
/	O	2256-2257
JBCB	O	2257-2261
.	O	2261-2262
htm	O	2262-2265
.	O	2265-2266

A	O	0-1
polymorphism	O	2-14
of	O	15-17
microRNA196a	B	18-30
genome	O	31-37
region	O	38-44
was	O	45-48
associated	O	49-59
with	O	60-64
decreased	O	65-74
risk	O	75-79
of	O	80-82
glioma	O	83-89
in	O	90-92
Chinese	O	93-100
population	O	101-111
.	O	111-112

MicroRNAs	O	113-122
(	O	123-124
miRNAs	O	124-130
)	O	130-131
are	O	132-135
small	O	136-141
non	O	142-145
-	O	145-146
coding	O	146-152
RNAs	O	153-157
that	O	158-162
play	O	163-167
important	O	168-177
roles	O	178-183
in	O	184-186
regulation	O	187-197
of	O	198-200
eukaryotic	O	201-211
gene	O	212-216
expression	O	217-227
.	O	227-228

Aberrant	O	229-237
expression	O	238-248
and	O	249-252
structural	O	253-263
alternation	O	264-275
of	O	276-278
miRNAs	O	279-285
are	O	286-289
considered	O	290-300
to	O	301-303
participate	O	304-315
in	O	316-318
tumorigenesis	O	319-332
and	O	333-336
cancer	O	337-343
development	O	344-355
.	O	355-356

Recently	O	357-365
,	O	365-366
different	O	367-376
genotypes	O	377-386
of	O	387-389
miR	B	390-393
-	I	393-394
196a	I	394-398
polymorphisms	O	399-412
(	O	413-414
SNP	O	414-417
,	O	417-418
rs11614913	O	419-429
)	O	429-430
were	O	431-435
found	O	436-441
to	O	442-444
be	O	445-447
associated	O	448-458
with	O	459-463
the	O	464-467
survival	O	468-476
of	O	477-479
patients	O	480-488
with	O	489-493
lung	O	494-498
cancer	O	499-505
and	O	506-509
increased	O	510-519
risk	O	520-524
of	O	525-527
breast	O	528-534
cancer	O	535-541
.	O	541-542

To	O	543-545
further	O	546-553
investigate	O	554-565
whether	O	566-573
this	O	574-578
polymorphism	O	579-591
may	O	592-595
influence	O	596-605
glioma	O	606-612
risk	O	613-617
or	O	618-620
not	O	621-624
,	O	624-625
we	O	626-628
examined	O	629-637
the	O	638-641
SNP	O	642-645
allele	O	646-652
frequency	O	653-662
in	O	663-665
Chinese	O	666-673
population	O	674-684
.	O	684-685

Our	O	686-689
data	O	690-694
shows	O	695-700
the	O	701-704
genotype	O	705-713
CC	O	714-716
of	O	717-719
miR	B	720-723
-	I	723-724
196a	I	724-728
(	O	729-730
rs11614913	O	730-740
)	O	740-741
polymorphism	O	742-754
is	O	755-757
associated	O	758-768
with	O	769-773
decreased	O	774-783
risk	O	784-788
of	O	789-791
glioma	O	792-798
in	O	799-801
the	O	802-805
Chinese	O	806-813
population	O	814-824
(	O	825-826
OR	O	826-828
=	O	829-830
0	O	831-832
.	O	832-833
74	O	833-835
,	O	835-836
95	O	837-839
%	O	839-840
CI	O	841-843
:	O	843-844
0	O	844-845
.	O	845-846
56	O	846-848
-	O	848-849
0	O	849-850
.	O	850-851
98	O	851-853
)	O	853-854
.	O	854-855

Furthermore	O	856-867
,	O	867-868
a	O	869-870
significant	O	871-882
association	O	883-894
was	O	895-898
observed	O	899-907
between	O	908-915
this	O	916-920
genotype	O	921-929
and	O	930-933
glioma	O	934-940
risk	O	941-945
in	O	946-948
the	O	949-952
subgroups	O	953-962
of	O	963-965
adult	O	966-971
glioma	O	972-978
(	O	979-980
OR	O	980-982
=	O	983-984
0	O	985-986
.	O	986-987
73	O	987-989
,	O	989-990
95	O	991-993
%	O	993-994
CI	O	995-997
:	O	997-998
0	O	998-999
.	O	999-1000
55	O	1000-1002
-	O	1002-1003
0	O	1003-1004
.	O	1004-1005
98	O	1005-1007
)	O	1007-1008
,	O	1008-1009
male	O	1010-1014
glioma	O	1015-1021
(	O	1022-1023
OR	O	1023-1025
=	O	1026-1027
0	O	1028-1029
.	O	1029-1030
69	O	1030-1032
,	O	1032-1033
95	O	1034-1036
%	O	1036-1037
CI	O	1038-1040
:	O	1040-1041
0	O	1041-1042
.	O	1042-1043
48	O	1043-1045
-	O	1045-1046
0	O	1046-1047
.	O	1047-1048
99	O	1048-1050
)	O	1050-1051
and	O	1052-1055
patients	O	1056-1064
with	O	1065-1069
glioblastoma	O	1070-1082
(	O	1083-1084
OR	O	1084-1086
=	O	1087-1088
0	O	1089-1090
.	O	1090-1091
58	O	1091-1093
,	O	1093-1094
95	O	1095-1097
%	O	1097-1098
CI	O	1099-1101
:	O	1101-1102
0	O	1102-1103
.	O	1103-1104
37	O	1104-1106
-	O	1106-1107
0	O	1107-1108
.	O	1108-1109
91	O	1109-1111
)	O	1111-1112
.	O	1112-1113

This	O	1114-1118
was	O	1119-1122
the	O	1123-1126
first	O	1127-1132
study	O	1133-1138
investigating	O	1139-1152
the	O	1153-1156
association	O	1157-1168
between	O	1169-1176
the	O	1177-1180
miR	B	1181-1184
-	I	1184-1185
196a	I	1185-1189
rs11614913	O	1190-1200
and	O	1201-1204
glioma	O	1205-1211
risk	O	1212-1216
.	O	1216-1217

Compared	O	1218-1226
with	O	1227-1231
the	O	1232-1235
results	O	1236-1243
from	O	1244-1248
previous	O	1249-1257
studies	O	1258-1265
in	O	1266-1268
lung	O	1269-1273
cancer	O	1274-1280
and	O	1281-1284
breast	O	1285-1291
cancer	O	1292-1298
,	O	1298-1299
our	O	1300-1303
data	O	1304-1308
suggest	O	1309-1316
a	O	1317-1318
different	O	1319-1328
genotype	O	1329-1337
association	O	1338-1349
in	O	1350-1352
glioma	O	1353-1359
.	O	1359-1360

This	O	1361-1365
may	O	1366-1369
be	O	1370-1372
related	O	1373-1380
to	O	1381-1383
the	O	1384-1387
diversity	O	1388-1397
on	O	1398-1400
the	O	1401-1404
tissue	O	1405-1411
origin	O	1412-1418
,	O	1418-1419
tumor	O	1420-1425
type	O	1426-1430
,	O	1430-1431
tumorigenesis	O	1432-1445
,	O	1445-1446
and	O	1447-1450
developing	O	1451-1461
process	O	1462-1469
.	O	1469-1470

MicroRNA	B	0-8
-	I	8-9
34a	I	9-12
inhibits	O	13-21
cell	O	22-26
proliferation	O	27-40
by	O	41-43
repressing	O	44-54
mitogen	O	55-62
-	O	62-63
activated	O	63-72
protein	O	73-80
kinase	O	81-87
kinase	O	88-94
1	O	95-96
during	O	97-103
megakaryocytic	O	104-118
differentiation	O	119-134
of	O	135-137
K562	O	138-142
cells	O	143-148
.	O	148-149

Phorbol	O	150-157
12	O	158-160
-	O	160-161
myristate	O	161-170
13	O	171-173
-	O	173-174
acetate	O	174-181
(	O	182-183
PMA	O	183-186
)	O	186-187
induces	O	188-195
megakaryocytic	O	196-210
differentiation	O	211-226
of	O	227-229
the	O	230-233
human	O	234-239
chronic	O	240-247
myelocytic	O	248-258
leukemia	O	259-267
cell	O	268-272
line	O	273-277
K562	O	278-282
.	O	282-283

We	O	284-286
examined	O	287-295
the	O	296-299
potential	O	300-309
regulatory	O	310-320
role	O	321-325
of	O	326-328
microRNAs	O	329-338
(	O	339-340
miRNAs	O	340-346
)	O	346-347
in	O	348-350
this	O	351-355
process	O	356-363
.	O	363-364

Genome	O	365-371
-	O	371-372
wide	O	372-376
expression	O	377-387
profiling	O	388-397
identified	O	398-408
21	O	409-411
miRNAs	O	412-418
(	O	419-420
miRs	O	420-424
)	O	424-425
that	O	426-430
were	O	431-435
induced	O	436-443
by	O	444-446
the	O	447-450
treatment	O	451-460
of	O	461-463
K562	O	464-468
cells	O	469-474
with	O	475-479
PMA	O	480-483
.	O	483-484

Among	O	485-490
them	O	491-495
,	O	495-496
the	O	497-500
expression	O	501-511
of	O	512-514
miR	B	515-518
-	I	518-519
34a	I	519-522
,	O	522-523
miR	B	524-527
-	I	527-528
221	I	528-531
,	O	531-532
and	O	533-536
miR	B	537-540
-	I	540-541
222	I	541-544
was	O	545-548
induced	O	549-556
in	O	557-559
the	O	560-563
early	O	564-569
stages	O	570-576
and	O	577-580
maintained	O	581-591
throughout	O	592-602
the	O	603-606
late	O	607-611
stages	O	612-618
of	O	619-621
differentiation	O	622-637
.	O	637-638

Cell	O	639-643
signaling	O	644-653
analysis	O	654-662
showed	O	663-669
that	O	670-674
the	O	675-678
activation	O	679-689
of	O	690-692
extracellular	O	693-706
signal	O	707-713
-	O	713-714
regulated	O	714-723
protein	O	724-731
kinase	O	732-738
(	O	739-740
ERK	O	740-743
)	O	743-744
in	O	745-747
response	O	748-756
to	O	757-759
PMA	O	760-763
strongly	O	764-772
induced	O	773-780
miR	B	781-784
-	I	784-785
34a	I	785-788
expression	O	789-799
by	O	800-802
transactivation	O	803-818
via	O	819-822
the	O	823-826
activator	O	827-836
protein	O	837-844
-	O	844-845
1	O	845-846
binding	O	847-854
site	O	855-859
in	O	860-862
the	O	863-866
upstream	O	867-875
region	O	876-882
of	O	883-885
the	O	886-889
miR	B	890-893
-	I	893-894
34a	I	894-897
gene	O	898-902
.	O	902-903

Reporter	O	904-912
gene	O	913-917
assays	O	918-924
identified	O	925-935
mitogen	O	936-943
-	O	943-944
activated	O	944-953
protein	O	954-961
kinase	O	962-968
kinase	O	969-975
1	O	976-977
(	O	978-979
MEK1	O	979-983
)	O	983-984
as	O	985-987
a	O	988-989
direct	O	990-996
target	O	997-1003
of	O	1004-1006
miR	B	1007-1010
-	I	1010-1011
34a	I	1011-1014
and	O	1015-1018
c	O	1019-1020
-	O	1020-1021
fos	O	1021-1024
as	O	1025-1027
a	O	1028-1029
direct	O	1030-1036
target	O	1037-1043
of	O	1044-1046
miR	B	1047-1050
-	I	1050-1051
221	I	1051-1054
/	O	1054-1055
222	B	1055-1058
.	O	1058-1059

Although	O	1060-1068
overexpression	O	1069-1083
of	O	1084-1086
the	O	1087-1090
three	O	1091-1096
miRNAs	O	1097-1103
had	O	1104-1107
little	O	1108-1114
effect	O	1115-1121
on	O	1122-1124
cell	O	1125-1129
differentiation	O	1130-1145
,	O	1145-1146
overexpression	O	1147-1161
of	O	1162-1164
miR	B	1165-1168
-	I	1168-1169
34a	I	1169-1172
significantly	O	1173-1186
repressed	O	1187-1196
the	O	1197-1200
proliferation	O	1201-1214
of	O	1215-1217
K562	O	1218-1222
cells	O	1223-1228
with	O	1229-1233
a	O	1234-1235
concomitant	O	1236-1247
reduction	O	1248-1257
in	O	1258-1260
MEK1	O	1261-1265
protein	O	1266-1273
expression	O	1274-1284
.	O	1284-1285

Conversely	O	1286-1296
,	O	1296-1297
a	O	1298-1299
locked	O	1300-1306
nucleic	O	1307-1314
acid	O	1315-1319
probe	O	1320-1325
against	O	1326-1333
miR	B	1334-1337
-	I	1337-1338
34a	I	1338-1341
significantly	O	1342-1355
enhanced	O	1356-1364
the	O	1365-1368
proliferation	O	1369-1382
of	O	1383-1385
PMA	O	1386-1389
-	O	1389-1390
treated	O	1390-1397
K562	O	1398-1402
cells	O	1403-1408
.	O	1408-1409

Taken	O	1410-1415
together	O	1416-1424
,	O	1424-1425
the	O	1426-1429
results	O	1430-1437
show	O	1438-1442
that	O	1443-1447
PMA	O	1448-1451
activates	O	1452-1461
the	O	1462-1465
MEK	O	1466-1469
-	O	1469-1470
ERK	O	1470-1473
pathway	O	1474-1481
and	O	1482-1485
strongly	O	1486-1494
induces	O	1495-1502
miRNA	B	1503-1508
-	I	1508-1509
34a	I	1509-1512
expression	O	1513-1523
,	O	1523-1524
which	O	1525-1530
in	O	1531-1533
turn	O	1534-1538
inhibits	O	1539-1547
cell	O	1548-1552
proliferation	O	1553-1566
by	O	1567-1569
repressing	O	1570-1580
the	O	1581-1584
expression	O	1585-1595
of	O	1596-1598
MEK1	O	1599-1603
.	O	1603-1604

Thus	O	1605-1609
,	O	1609-1610
the	O	1611-1614
results	O	1615-1622
highlight	O	1623-1632
an	O	1633-1635
important	O	1636-1645
regulatory	O	1646-1656
role	O	1657-1661
for	O	1662-1665
miR	B	1666-1669
-	I	1669-1670
34a	I	1670-1673
in	O	1674-1676
the	O	1677-1680
process	O	1681-1688
of	O	1689-1691
megakaryocytic	O	1692-1706
differentiation	O	1707-1722
,	O	1722-1723
especially	O	1724-1734
in	O	1735-1737
the	O	1738-1741
arrest	O	1742-1748
of	O	1749-1751
cell	O	1752-1756
growth	O	1757-1763
,	O	1763-1764
which	O	1765-1770
is	O	1771-1773
a	O	1774-1775
prerequisite	O	1776-1788
for	O	1789-1792
cells	O	1793-1798
to	O	1799-1801
enter	O	1802-1807
differentiation	O	1808-1823
.	O	1823-1824

[	O	0-1
Study	O	1-6
on	O	7-9
the	O	10-13
sensitivity	O	14-25
of	O	26-28
leukemic	O	29-37
cells	O	38-43
to	O	44-46
arsenic	O	47-54
trioxide	O	55-63
enhanced	O	64-72
by	O	73-75
targeted	O	76-84
suppression	O	85-96
of	O	97-99
mIRNA	B	100-105
-	I	105-106
21	I	106-108
]	O	108-109
.	O	109-110

OBJECTIVE	O	111-120
:	O	120-121
To	O	122-124
study	O	125-130
the	O	131-134
effect	O	135-141
of	O	142-144
antisense	O	145-154
oligonucleotide	O	155-170
targeted	O	171-179
on	O	180-182
miRNA	B	183-188
-	I	188-189
21	I	189-191
(	O	192-193
AMO	O	193-196
-	O	196-197
miR	B	197-200
-	I	200-201
21	I	201-203
)	O	203-204
for	O	205-208
enhancing	O	209-218
the	O	219-222
arsenic	O	223-230
trioxide	O	231-239
(	O	240-241
As2O3	O	241-246
)	O	246-247
sensitivity	O	248-259
of	O	260-262
leukemic	O	263-271
K562	O	272-276
cells	O	277-282
and	O	283-286
its	O	287-290
possible	O	291-299
acting	O	300-306
mechanism	O	307-316
.	O	316-317

METHODS	O	318-325
:	O	325-326
Chemosynthetic	O	327-341
AMO	O	342-345
-	O	345-346
miR	B	346-349
-	I	349-350
21	I	350-352
was	O	353-356
transfected	O	357-368
to	O	369-371
K562	O	372-376
cells	O	377-382
using	O	383-388
Lipofectamine	O	389-402
TM	O	403-405
2000	O	406-410
.	O	410-411

The	O	412-415
inhibitory	O	416-426
effects	O	427-434
of	O	435-437
As2O3	O	438-443
and	O	444-447
AMO	O	448-451
-	O	451-452
miR	B	452-455
-	I	455-456
21	I	456-458
,	O	458-459
used	O	460-464
singly	O	465-471
or	O	472-474
in	O	475-477
combining	O	478-487
,	O	487-488
on	O	489-491
cell	O	492-496
proliferation	O	497-510
were	O	511-515
detected	O	516-524
by	O	525-527
MTT	O	528-531
,	O	531-532
their	O	533-538
inhibition	O	539-549
rate	O	550-554
and	O	555-558
IC50	O	559-563
were	O	564-568
calculated	O	569-579
.	O	579-580

Cell	O	581-585
cycle	O	586-591
and	O	592-595
apoptosis	O	596-605
were	O	606-610
assessed	O	611-619
with	O	620-624
PI	O	625-627
stain	O	628-633
;	O	633-634
expression	O	635-645
of	O	646-648
miRNA	B	649-654
-	I	654-655
21	I	655-657
in	O	658-660
cells	O	661-666
was	O	667-670
detected	O	671-679
quantitatively	O	680-694
by	O	695-697
real	O	698-702
-	O	702-703
time	O	703-707
PCR	O	708-711
,	O	711-712
and	O	713-716
the	O	717-720
potential	O	721-730
target	O	731-737
gene	O	738-742
PDCD	O	743-747
,	O	747-748
protein	O	749-756
expression	O	757-767
was	O	768-771
detected	O	772-780
by	O	781-783
immuno	O	784-790
-	O	790-791
fluorimetry	O	791-802
.	O	802-803

RESULTS	O	804-811
:	O	811-812
Used	O	813-817
in	O	818-820
combining	O	821-830
with	O	831-835
AMO	O	836-839
-	O	839-840
miR	B	840-843
-	I	843-844
21	I	844-846
,	O	846-847
the	O	848-851
IC50	O	852-856
of	O	857-859
As2O3	O	860-865
,	O	865-866
could	O	867-872
be	O	873-875
lowered	O	876-883
from	O	884-888
2	O	889-890
.	O	890-891
1	O	891-892
micromol	O	893-901
/	O	901-902
L	O	902-903
to	O	904-906
1	O	907-908
.	O	908-909
23	O	909-911
micromol	O	912-920
/	O	920-921
L	O	921-922
,	O	922-923
and	O	924-927
the	O	928-931
sensitivity	O	932-943
of	O	944-946
cells	O	947-952
to	O	953-955
As2O3	O	956-961
increased	O	962-971
to	O	972-974
1	O	975-976
.	O	976-977
78	O	977-979
-	O	979-980
fold	O	980-984
;	O	984-985
with	O	986-990
the	O	991-994
amount	O	995-1001
of	O	1002-1004
apoptotic	O	1005-1014
cells	O	1015-1020
increased	O	1021-1030
significantly	O	1031-1044
.	O	1044-1045

Transfection	O	1046-1058
with	O	1059-1063
AMO	O	1064-1067
-	O	1067-1068
miR	B	1068-1071
-	I	1071-1072
21	I	1072-1074
alone	O	1075-1080
could	O	1081-1086
downregulate	O	1087-1099
the	O	1100-1103
expression	O	1104-1114
of	O	1115-1117
miRNA	B	1118-1123
-	I	1123-1124
21	I	1124-1126
in	O	1127-1129
cells	O	1130-1135
(	O	1136-1137
P	O	1137-1138
<	O	1139-1140
0	O	1141-1142
.	O	1142-1143
01	O	1143-1145
)	O	1145-1146
,	O	1146-1147
and	O	1148-1151
up	O	1152-1154
-	O	1154-1155
regulate	O	1155-1163
PDCD	O	1164-1168
,	O	1168-1169
protein	O	1170-1177
expression	O	1178-1188
level	O	1189-1194
significantly	O	1195-1208
.	O	1208-1209

CONCLUSIONS	O	1210-1221
:	O	1221-1222
Combined	O	1223-1231
use	O	1232-1235
of	O	1236-1238
AMO	O	1239-1242
-	O	1242-1243
miR	B	1243-1246
-	I	1246-1247
21	I	1247-1249
and	O	1250-1253
As2O3	O	1254-1259
could	O	1260-1265
increase	O	1266-1274
the	O	1275-1278
sensitivity	O	1279-1290
of	O	1291-1293
K562	O	1294-1298
cells	O	1299-1304
to	O	1305-1307
As2O3	O	1308-1313
,	O	1313-1314
which	O	1315-1320
provides	O	1321-1329
a	O	1330-1331
novel	O	1332-1337
potential	O	1338-1347
approach	O	1348-1356
for	O	1357-1360
treatment	O	1361-1370
of	O	1371-1373
leukemia	O	1374-1382
.	O	1382-1383

AMO	O	1384-1387
-	O	1387-1388
miR	B	1388-1391
-	I	1391-1392
21	I	1392-1394
realizes	O	1395-1403
it	O	1404-1406
anti	O	1407-1411
-	O	1411-1412
tumor	O	1412-1417
action	O	1418-1424
by	O	1425-1427
way	O	1428-1431
of	O	1432-1434
targeted	O	1435-1443
inhibition	O	1444-1454
on	O	1455-1457
miRNA	B	1458-1463
-	I	1463-1464
21	I	1464-1466
,	O	1466-1467
and	O	1468-1471
further	O	1472-1479
up	O	1480-1482
-	O	1482-1483
regulates	O	1483-1492
the	O	1493-1496
expression	O	1497-1507
of	O	1508-1510
anti	O	1511-1515
-	O	1515-1516
tumor	O	1516-1521
gene	O	1522-1526
PDCD4	O	1527-1532
.	O	1532-1533

A	O	0-1
functional	O	2-12
polymorphism	O	13-25
in	O	26-28
the	O	29-32
pre	B	33-36
-	I	36-37
microRNA	I	37-45
-	I	45-46
196a2	I	46-51
and	O	52-55
the	O	56-59
risk	O	60-64
of	O	65-67
lung	O	68-72
cancer	O	73-79
in	O	80-82
a	O	83-84
Korean	O	85-91
population	O	92-102
.	O	102-103

Circulating	O	0-11
miRNAs	O	12-18
are	O	19-22
correlated	O	23-33
with	O	34-38
tumor	O	39-44
progression	O	45-56
in	O	57-59
prostate	O	60-68
cancer	O	69-75
.	O	75-76

Circulating	O	77-88
miRNAs	O	89-95
have	O	96-100
recently	O	101-109
been	O	110-114
indicated	O	115-124
as	O	125-127
practicable	O	128-139
and	O	140-143
promising	O	144-153
biomarkers	O	154-164
for	O	165-168
noninvasive	O	169-180
diagnosis	O	181-190
in	O	191-193
various	O	194-201
tumor	O	202-207
entities	O	208-216
.	O	216-217

However	O	218-225
,	O	225-226
cell	O	227-231
-	O	231-232
free	O	232-236
miRNAs	O	237-243
have	O	244-248
not	O	249-252
been	O	253-257
found	O	258-263
to	O	264-266
correlate	O	267-276
with	O	277-281
clinicopathological	O	282-301
variables	O	302-311
in	O	312-314
epithelial	O	315-325
carcinomas	O	326-336
.	O	336-337

To	O	338-340
learn	O	341-346
more	O	347-351
about	O	352-357
the	O	358-361
potential	O	362-371
clinical	O	372-380
relevance	O	381-390
of	O	391-393
circulating	O	394-405
miRNAs	O	406-412
in	O	413-415
prostate	O	416-424
cancer	O	425-431
,	O	431-432
we	O	433-435
screened	O	436-444
667	O	445-448
miRNAs	O	449-455
in	O	456-458
serum	O	459-464
samples	O	465-472
from	O	473-477
patients	O	478-486
with	O	487-491
metastatic	O	492-502
(	O	503-504
n	O	504-505
=	O	506-507
7	O	508-509
)	O	509-510
and	O	511-514
localized	O	515-524
prostate	O	525-533
cancer	O	534-540
(	O	541-542
n	O	542-543
=	O	544-545
14	O	546-548
)	O	548-549
.	O	549-550

Various	O	551-558
miRNAs	O	559-565
were	O	566-570
highly	O	571-577
abundant	O	578-586
in	O	587-589
the	O	590-593
sera	O	594-598
of	O	599-601
patients	O	602-610
with	O	611-615
metastatic	O	616-626
disease	O	627-634
,	O	634-635
and	O	636-639
five	O	640-644
upregulated	O	645-656
miRNAs	O	657-663
(	O	664-665
miRNA	B	665-670
-	I	670-671
375	I	671-674
,	O	674-675
miRNA	B	676-681
-	I	681-682
9	I	682-683
*	I	683-684
,	O	684-685
miRNA	B	686-691
-	I	691-692
141	I	692-695
,	O	695-696
miRNA	B	697-702
-	I	702-703
200b	I	703-707
and	O	708-711
miRNA	B	712-717
-	I	717-718
516a	I	718-722
-	I	722-723
3p	I	723-725
)	O	725-726
were	O	727-731
selected	O	732-740
for	O	741-744
further	O	745-752
validation	O	753-763
.	O	763-764

In	O	765-767
the	O	768-771
first	O	772-777
validation	O	778-788
study	O	789-794
(	O	795-796
n	O	796-797
=	O	798-799
45	O	800-802
)	O	802-803
,	O	803-804
selected	O	805-813
miRNAs	O	814-820
were	O	821-825
analyzed	O	826-834
in	O	835-837
a	O	838-839
prospectively	O	840-853
collected	O	854-863
serum	O	864-869
set	O	870-873
taken	O	874-879
from	O	880-884
different	O	885-894
prostate	O	895-903
cancer	O	904-910
risk	O	911-915
groups	O	916-922
.	O	922-923

Most	O	924-928
of	O	929-931
the	O	932-935
selected	O	936-944
miRNAs	O	945-951
were	O	952-956
significantly	O	957-970
correlated	O	971-981
with	O	982-986
adverse	O	987-994
risk	O	995-999
factors	O	1000-1007
when	O	1008-1012
different	O	1013-1022
clinicopathological	O	1023-1042
variables	O	1043-1052
were	O	1053-1057
analyzed	O	1058-1066
.	O	1066-1067

Circulating	O	1068-1079
miRNA	B	1080-1085
-	I	1085-1086
375	I	1086-1089
and	O	1090-1093
miRNA	B	1094-1099
-	I	1099-1100
141	I	1100-1103
turned	O	1104-1110
out	O	1111-1114
to	O	1115-1117
be	O	1118-1120
the	O	1121-1124
most	O	1125-1129
pronounced	O	1130-1140
markers	O	1141-1148
for	O	1149-1152
high	O	1153-1157
-	O	1157-1158
risk	O	1158-1162
tumors	O	1163-1169
.	O	1169-1170

Their	O	1171-1176
levels	O	1177-1183
also	O	1184-1188
correlated	O	1189-1199
with	O	1200-1204
high	O	1205-1209
Gleason	O	1210-1217
score	O	1218-1223
or	O	1224-1226
lymph	O	1227-1232
-	O	1232-1233
node	O	1233-1237
positive	O	1238-1246
status	O	1247-1253
in	O	1254-1256
a	O	1257-1258
second	O	1259-1265
independent	O	1266-1277
validation	O	1278-1288
study	O	1289-1294
(	O	1295-1296
n	O	1296-1297
=	O	1298-1299
71	O	1300-1302
)	O	1302-1303
.	O	1303-1304

In	O	1305-1307
addition	O	1308-1316
,	O	1316-1317
the	O	1318-1321
expression	O	1322-1332
levels	O	1333-1339
of	O	1340-1342
miRNA	B	1343-1348
-	I	1348-1349
375	I	1349-1352
and	O	1353-1356
miRNA	B	1357-1362
-	I	1362-1363
141	I	1363-1366
were	O	1367-1371
monitored	O	1372-1381
in	O	1382-1384
72	O	1385-1387
prostate	O	1388-1396
tissue	O	1397-1403
samples	O	1404-1411
(	O	1412-1413
36	O	1413-1415
tumor	O	1416-1421
vs	O	1422-1424
.	O	1424-1425
36	O	1426-1428
benign	O	1429-1435
)	O	1435-1436
.	O	1436-1437

Both	O	1438-1442
miRNAs	O	1443-1449
were	O	1450-1454
highly	O	1455-1461
expressed	O	1462-1471
in	O	1472-1474
all	O	1475-1478
samples	O	1479-1486
and	O	1487-1490
significantly	O	1491-1504
upregulated	O	1505-1516
in	O	1517-1519
the	O	1520-1523
tumors	O	1524-1530
compared	O	1531-1539
to	O	1540-1542
normal	O	1543-1549
tissues	O	1550-1557
.	O	1557-1558

Overall	O	1559-1566
,	O	1566-1567
our	O	1568-1571
observations	O	1572-1584
suggest	O	1585-1592
that	O	1593-1597
miRNA	B	1598-1603
-	I	1603-1604
375	I	1604-1607
and	O	1608-1611
miRNA	B	1612-1617
-	I	1617-1618
141	I	1618-1621
expression	O	1622-1632
is	O	1633-1635
enhanced	O	1636-1644
in	O	1645-1647
prostate	O	1648-1656
cancer	O	1657-1663
specimens	O	1664-1673
and	O	1674-1677
their	O	1678-1683
release	O	1684-1691
into	O	1692-1696
the	O	1697-1700
blood	O	1701-1706
is	O	1707-1709
further	O	1710-1717
associated	O	1718-1728
with	O	1729-1733
advanced	O	1734-1742
cancer	O	1743-1749
disease	O	1750-1757
.	O	1757-1758

Characterizing	O	0-14
light	O	15-20
-	O	20-21
regulated	O	21-30
retinal	O	31-38
microRNAs	O	39-48
reveals	O	49-56
rapid	O	57-62
turnover	O	63-71
as	O	72-74
a	O	75-76
common	O	77-83
property	O	84-92
of	O	93-95
neuronal	O	96-104
microRNAs	O	105-114
.	O	114-115

Adaptation	O	116-126
to	O	127-129
different	O	130-139
levels	O	140-146
of	O	147-149
illumination	O	150-162
is	O	163-165
central	O	166-173
to	O	174-176
the	O	177-180
function	O	181-189
of	O	190-192
the	O	193-196
retina	O	197-203
.	O	203-204

Here	O	205-209
,	O	209-210
we	O	211-213
demonstrate	O	214-225
that	O	226-230
levels	O	231-237
of	O	238-240
the	O	241-244
miR	B	245-248
-	I	248-249
183	I	249-252
/	O	252-253
96	B	253-255
/	O	255-256
182	B	256-259
cluster	O	260-267
,	O	267-268
miR	B	269-272
-	I	272-273
204	I	273-276
,	O	276-277
and	O	278-281
miR	B	282-285
-	I	285-286
211	I	286-289
are	O	290-293
regulated	O	294-303
by	O	304-306
different	O	307-316
light	O	317-322
levels	O	323-329
in	O	330-332
the	O	333-336
mouse	O	337-342
retina	O	343-349
.	O	349-350

Concentrations	O	351-365
of	O	366-368
these	O	369-374
microRNAs	O	375-384
were	O	385-389
downregulated	O	390-403
during	O	404-410
dark	O	411-415
adaptation	O	416-426
and	O	427-430
upregulated	O	431-442
in	O	443-445
light	O	446-451
-	O	451-452
adapted	O	452-459
retinas	O	460-467
,	O	467-468
with	O	469-473
rapid	O	474-479
decay	O	480-485
and	O	486-489
increased	O	490-499
transcription	O	500-513
being	O	514-519
responsible	O	520-531
for	O	532-535
the	O	536-539
respective	O	540-550
changes	O	551-558
.	O	558-559

We	O	560-562
identified	O	563-573
the	O	574-577
voltage	O	578-585
-	O	585-586
dependent	O	586-595
glutamate	O	596-605
transporter	O	606-617
Slc1a1	O	618-624
as	O	625-627
one	O	628-631
of	O	632-634
the	O	635-638
miR	B	639-642
-	I	642-643
183	I	643-646
/	O	646-647
96	B	647-649
/	O	649-650
182	B	650-653
targets	O	654-661
in	O	662-664
photoreceptor	O	665-678
cells	O	679-684
.	O	684-685

We	O	686-688
found	O	689-694
that	O	695-699
microRNAs	O	700-709
in	O	710-712
retinal	O	713-720
neurons	O	721-728
decay	O	729-734
much	O	735-739
faster	O	740-746
than	O	747-751
microRNAs	O	752-761
in	O	762-764
nonneuronal	O	765-776
cells	O	777-782
.	O	782-783

The	O	784-787
high	O	788-792
turnover	O	793-801
is	O	802-804
also	O	805-809
characteristic	O	810-824
of	O	825-827
microRNAs	O	828-837
in	O	838-840
hippocampal	O	841-852
and	O	853-856
cortical	O	857-865
neurons	O	866-873
,	O	873-874
and	O	875-878
neurons	O	879-886
differentiated	O	887-901
from	O	902-906
ES	O	907-909
cells	O	910-915
in	O	916-918
vitro	O	919-924
.	O	924-925

Blocking	O	926-934
activity	O	935-943
reduced	O	944-951
turnover	O	952-960
of	O	961-963
microRNAs	O	964-973
in	O	974-976
neuronal	O	977-985
cells	O	986-991
while	O	992-997
stimulation	O	998-1009
with	O	1010-1014
glutamate	O	1015-1024
accelerated	O	1025-1036
it	O	1037-1039
.	O	1039-1040

Our	O	1041-1044
results	O	1045-1052
demonstrate	O	1053-1064
that	O	1065-1069
microRNA	O	1070-1078
metabolism	O	1079-1089
in	O	1090-1092
neurons	O	1093-1100
is	O	1101-1103
higher	O	1104-1110
than	O	1111-1115
in	O	1116-1118
most	O	1119-1123
other	O	1124-1129
cells	O	1130-1135
types	O	1136-1141
and	O	1142-1145
linked	O	1146-1152
to	O	1153-1155
neuronal	O	1156-1164
activity	O	1165-1173
.	O	1173-1174

Alternative	O	0-11
splicing	O	12-20
regulates	O	21-30
mouse	O	31-36
embryonic	O	37-46
stem	O	47-51
cell	O	52-56
pluripotency	O	57-69
and	O	70-73
differentiation	O	74-89
.	O	89-90

Two	O	91-94
major	O	95-100
goals	O	101-106
of	O	107-109
regenerative	O	110-122
medicine	O	123-131
are	O	132-135
to	O	136-138
reproducibly	O	139-151
transform	O	152-161
adult	O	162-167
somatic	O	168-175
cells	O	176-181
into	O	182-186
a	O	187-188
pluripotent	O	189-200
state	O	201-206
and	O	207-210
to	O	211-213
control	O	214-221
their	O	222-227
differentiation	O	228-243
into	O	244-248
specific	O	249-257
cell	O	258-262
fates	O	263-268
.	O	268-269

Progress	O	270-278
toward	O	279-285
these	O	286-291
goals	O	292-297
would	O	298-303
be	O	304-306
greatly	O	307-314
helped	O	315-321
by	O	322-324
obtaining	O	325-334
a	O	335-336
complete	O	337-345
picture	O	346-353
of	O	354-356
the	O	357-360
RNA	O	361-364
isoforms	O	365-373
produced	O	374-382
by	O	383-385
these	O	386-391
cells	O	392-397
due	O	398-401
to	O	402-404
alternative	O	405-416
splicing	O	417-425
(	O	426-427
AS	O	427-429
)	O	429-430
and	O	431-434
alternative	O	435-446
promoter	O	447-455
selection	O	456-465
(	O	466-467
APS	O	467-470
)	O	470-471
.	O	471-472

To	O	473-475
investigate	O	476-487
the	O	488-491
roles	O	492-497
of	O	498-500
AS	O	501-503
and	O	504-507
APS	O	508-511
,	O	511-512
reciprocal	O	513-523
exon	O	524-528
-	O	528-529
exon	O	529-533
junctions	O	534-543
were	O	544-548
interrogated	O	549-561
on	O	562-564
a	O	565-566
genome	O	567-573
-	O	573-574
wide	O	574-578
scale	O	579-584
in	O	585-587
differentiating	O	588-603
mouse	O	604-609
embryonic	O	610-619
stem	O	620-624
(	O	625-626
ES	O	626-628
)	O	628-629
cells	O	630-635
with	O	636-640
a	O	641-642
prototype	O	643-652
Affymetrix	O	653-663
microarray	O	664-674
.	O	674-675

Using	O	676-681
a	O	682-683
recently	O	684-692
released	O	693-701
open	O	702-706
-	O	706-707
source	O	707-713
software	O	714-722
package	O	723-730
named	O	731-736
AltAnalyze	O	737-747
,	O	747-748
we	O	749-751
identified	O	752-762
144	O	763-766
genes	O	767-772
for	O	773-776
170	O	777-780
putative	O	781-789
isoform	O	790-797
variants	O	798-806
,	O	806-807
the	O	808-811
majority	O	812-820
(	O	821-822
67	O	822-824
%	O	824-825
)	O	825-826
of	O	827-829
which	O	830-835
were	O	836-840
predicted	O	841-850
to	O	851-853
alter	O	854-859
protein	O	860-867
sequence	O	868-876
and	O	877-880
domain	O	881-887
composition	O	888-899
.	O	899-900

Verified	O	901-909
alternative	O	910-921
exons	O	922-927
were	O	928-932
largely	O	933-940
associated	O	941-951
with	O	952-956
pathways	O	957-965
of	O	966-968
Wnt	O	969-972
signaling	O	973-982
and	O	983-986
cell	O	987-991
-	O	991-992
cycle	O	992-997
control	O	998-1005
,	O	1005-1006
and	O	1007-1010
most	O	1011-1015
were	O	1016-1020
conserved	O	1021-1030
between	O	1031-1038
mouse	O	1039-1044
and	O	1045-1048
human	O	1049-1054
.	O	1054-1055

To	O	1056-1058
examine	O	1059-1066
the	O	1067-1070
functional	O	1071-1081
impact	O	1082-1088
of	O	1089-1091
AS	O	1092-1094
,	O	1094-1095
we	O	1096-1098
characterized	O	1099-1112
isoforms	O	1113-1121
for	O	1122-1125
two	O	1126-1129
genes	O	1130-1135
.	O	1135-1136

As	O	1137-1139
predicted	O	1140-1149
by	O	1150-1152
AltAnalyze	O	1153-1163
,	O	1163-1164
we	O	1165-1167
found	O	1168-1173
that	O	1174-1178
alternative	O	1179-1190
isoforms	O	1191-1199
of	O	1200-1202
the	O	1203-1206
gene	O	1207-1211
Serca2	O	1212-1218
were	O	1219-1223
targeted	O	1224-1232
by	O	1233-1235
distinct	O	1236-1244
microRNAs	O	1245-1254
(	O	1255-1256
miRNA	B	1256-1261
-	I	1261-1262
200b	I	1262-1266
,	O	1266-1267
miRNA	B	1268-1273
-	I	1273-1274
214	I	1274-1277
)	O	1277-1278
,	O	1278-1279
suggesting	O	1280-1290
a	O	1291-1292
critical	O	1293-1301
role	O	1302-1306
for	O	1307-1310
AS	O	1311-1313
in	O	1314-1316
cardiac	O	1317-1324
development	O	1325-1336
.	O	1336-1337

Analysis	O	1338-1346
of	O	1347-1349
the	O	1350-1353
Wnt	O	1354-1357
transcription	O	1358-1371
factor	O	1372-1378
Tcf3	O	1379-1383
,	O	1383-1384
using	O	1385-1390
selective	O	1391-1400
knockdown	O	1401-1410
of	O	1411-1413
an	O	1414-1416
ES	O	1417-1419
cell	O	1420-1424
-	O	1424-1425
enriched	O	1425-1433
and	O	1434-1437
characterized	O	1438-1451
isoform	O	1452-1459
,	O	1459-1460
revealed	O	1461-1469
several	O	1470-1477
distinct	O	1478-1486
targets	O	1487-1494
for	O	1495-1498
transcriptional	O	1499-1514
repression	O	1515-1525
(	O	1526-1527
Stmn2	O	1527-1532
,	O	1532-1533
Ccnd2	O	1534-1539
,	O	1539-1540
Atf3	O	1541-1545
,	O	1545-1546
Klf4	O	1547-1551
,	O	1551-1552
Nodal	O	1553-1558
,	O	1558-1559
and	O	1560-1563
Jun	O	1564-1567
)	O	1567-1568
as	O	1569-1571
well	O	1572-1576
as	O	1577-1579
distinct	O	1580-1588
differentiation	O	1589-1604
outcomes	O	1605-1613
in	O	1614-1616
ES	O	1617-1619
cells	O	1620-1625
.	O	1625-1626

The	O	1627-1630
findings	O	1631-1639
herein	O	1640-1646
illustrate	O	1647-1657
a	O	1658-1659
critical	O	1660-1668
role	O	1669-1673
for	O	1674-1677
AS	O	1678-1680
in	O	1681-1683
the	O	1684-1687
specification	O	1688-1701
of	O	1702-1704
ES	O	1705-1707
cells	O	1708-1713
with	O	1714-1718
differentiation	O	1719-1734
,	O	1734-1735
and	O	1736-1739
highlight	O	1740-1749
the	O	1750-1753
utility	O	1754-1761
of	O	1762-1764
global	O	1765-1771
functional	O	1772-1782
analyses	O	1783-1791
of	O	1792-1794
AS	O	1795-1797
.	O	1797-1798

Secreted	O	0-8
monocytic	O	9-18
miR	B	19-22
-	I	22-23
150	I	23-26
enhances	O	27-35
targeted	O	36-44
endothelial	O	45-56
cell	O	57-61
migration	O	62-71
.	O	71-72

MicroRNAs	O	73-82
(	O	83-84
miRNAs	O	84-90
)	O	90-91
are	O	92-95
a	O	96-97
class	O	98-103
of	O	104-106
noncoding	O	107-116
RNAs	O	117-121
that	O	122-126
regulate	O	127-135
target	O	136-142
gene	O	143-147
expression	O	148-158
at	O	159-161
the	O	162-165
posttranscriptional	O	166-185
level	O	186-191
.	O	191-192

Here	O	193-197
,	O	197-198
we	O	199-201
report	O	202-208
that	O	209-213
secreted	O	214-222
miRNAs	O	223-229
can	O	230-233
serve	O	234-239
as	O	240-242
signaling	O	243-252
molecules	O	253-262
mediating	O	263-272
intercellular	O	273-286
communication	O	287-300
.	O	300-301

In	O	302-304
human	O	305-310
blood	O	311-316
cells	O	317-322
and	O	323-326
cultured	O	327-335
THP	O	336-339
-	O	339-340
1	O	340-341
cells	O	342-347
,	O	347-348
miR	B	349-352
-	I	352-353
150	I	353-356
was	O	357-360
selectively	O	361-372
packaged	O	373-381
into	O	382-386
microvesicles	O	387-400
(	O	401-402
MVs	O	402-405
)	O	405-406
and	O	407-410
actively	O	411-419
secreted	O	420-428
.	O	428-429

THP	O	430-433
-	O	433-434
1	O	434-435
-	O	435-436
derived	O	436-443
MVs	O	444-447
can	O	448-451
enter	O	452-457
and	O	458-461
deliver	O	462-469
miR	B	470-473
-	I	473-474
150	I	474-477
into	O	478-482
human	O	483-488
HMEC	O	489-493
-	O	493-494
1	O	494-495
cells	O	496-501
,	O	501-502
and	O	503-506
elevated	O	507-515
exogenous	O	516-525
miR	B	526-529
-	I	529-530
150	I	530-533
effectively	O	534-545
reduced	O	546-553
c	O	554-555
-	O	555-556
Myb	O	556-559
expression	O	560-570
and	O	571-574
enhanced	O	575-583
cell	O	584-588
migration	O	589-598
in	O	599-601
HMEC	O	602-606
-	O	606-607
1	O	607-608
cells	O	609-614
.	O	614-615

In	O	616-618
vivo	O	619-623
studies	O	624-631
confirmed	O	632-641
that	O	642-646
intravenous	O	647-658
injection	O	659-668
of	O	669-671
THP	O	672-675
-	O	675-676
1	O	676-677
MVs	O	678-681
significantly	O	682-695
increased	O	696-705
the	O	706-709
level	O	710-715
of	O	716-718
miR	B	719-722
-	I	722-723
150	I	723-726
in	O	727-729
mouse	O	730-735
blood	O	736-741
vessels	O	742-749
.	O	749-750

MVs	O	751-754
isolated	O	755-763
from	O	764-768
the	O	769-772
plasma	O	773-779
of	O	780-782
patients	O	783-791
with	O	792-796
atherosclerosis	O	797-812
contained	O	813-822
higher	O	823-829
levels	O	830-836
of	O	837-839
miR	B	840-843
-	I	843-844
150	I	844-847
,	O	847-848
and	O	849-852
they	O	853-857
more	O	858-862
effectively	O	863-874
promoted	O	875-883
HMEC	O	884-888
-	O	888-889
1	O	889-890
cell	O	891-895
migration	O	896-905
than	O	906-910
MVs	O	911-914
from	O	915-919
healthy	O	920-927
donors	O	928-934
.	O	934-935

These	O	936-941
results	O	942-949
demonstrate	O	950-961
that	O	962-966
cells	O	967-972
can	O	973-976
secrete	O	977-984
miRNAs	O	985-991
and	O	992-995
deliver	O	996-1003
them	O	1004-1008
into	O	1009-1013
recipient	O	1014-1023
cells	O	1024-1029
where	O	1030-1035
the	O	1036-1039
exogenous	O	1040-1049
miRNAs	O	1050-1056
can	O	1057-1060
regulate	O	1061-1069
target	O	1070-1076
gene	O	1077-1081
expression	O	1082-1092
and	O	1093-1096
recipient	O	1097-1106
cell	O	1107-1111
function	O	1112-1120
.	O	1120-1121

Nanoparticles	O	0-13
modified	O	14-22
with	O	23-27
tumor	O	28-33
-	O	33-34
targeting	O	34-43
scFv	O	44-48
deliver	O	49-56
siRNA	O	57-62
and	O	63-66
miRNA	O	67-72
for	O	73-76
cancer	O	77-83
therapy	O	84-91
.	O	91-92

Targeted	O	93-101
delivery	O	102-110
of	O	111-113
RNA	O	114-117
-	O	117-118
based	O	118-123
therapeutics	O	124-136
for	O	137-140
cancer	O	141-147
therapy	O	148-155
remains	O	156-163
a	O	164-165
challenge	O	166-175
.	O	175-176

We	O	177-179
have	O	180-184
developed	O	185-194
a	O	195-196
LPH	O	197-200
(	O	201-202
liposome	O	202-210
-	O	210-211
polycation	O	211-221
-	O	221-222
hyaluronic	O	222-232
acid	O	233-237
)	O	237-238
nanoparticle	O	239-251
formulation	O	252-263
modified	O	264-272
with	O	273-277
tumor	O	278-283
-	O	283-284
targeting	O	284-293
single	O	294-300
-	O	300-301
chain	O	301-306
antibody	O	307-315
fragment	O	316-324
(	O	325-326
scFv	O	326-330
)	O	330-331
for	O	332-335
systemic	O	336-344
delivery	O	345-353
of	O	354-356
small	O	357-362
interfering	O	363-374
RNA	O	375-378
(	O	379-380
siRNA	O	380-385
)	O	385-386
and	O	387-390
microRNA	O	391-399
(	O	400-401
miRNA	O	401-406
)	O	406-407
into	O	408-412
experimental	O	413-425
lung	O	426-430
metastasis	O	431-441
of	O	442-444
murine	O	445-451
B16F10	O	452-458
melanoma	O	459-467
.	O	467-468

The	O	469-472
siRNAs	O	473-479
delivered	O	480-489
by	O	490-492
the	O	493-496
scFv	O	497-501
targeted	O	502-510
nanoparticles	O	511-524
efficiently	O	525-536
downregulated	O	537-550
the	O	551-554
target	O	555-561
genes	O	562-567
(	O	568-569
c	O	569-570
-	O	570-571
Myc	O	571-574
/	O	574-575
MDM2	O	575-579
/	O	579-580
VEGF	O	580-584
)	O	584-585
in	O	586-588
the	O	589-592
lung	O	593-597
metastasis	O	598-608
.	O	608-609

Two	O	610-613
daily	O	614-619
intravenous	O	620-631
injections	O	632-642
of	O	643-645
the	O	646-649
combined	O	650-658
siRNAs	O	659-665
in	O	666-668
the	O	669-672
GC4	O	673-676
-	O	676-677
targeted	O	677-685
nanoparticles	O	686-699
significantly	O	700-713
reduced	O	714-721
the	O	722-725
tumor	O	726-731
load	O	732-736
in	O	737-739
the	O	740-743
lung	O	744-748
.	O	748-749

miRNA	B	750-755
-	I	755-756
34a	I	756-759
(	O	760-761
miR	B	761-764
-	I	764-765
34a	I	765-768
)	O	768-769
induced	O	770-777
apoptosis	O	778-787
,	O	787-788
inhibited	O	789-798
survivin	O	799-807
expression	O	808-818
,	O	818-819
and	O	820-823
downregulated	O	824-837
MAPK	O	838-842
pathway	O	843-850
in	O	851-853
B16F10	O	854-860
cells	O	861-866
.	O	866-867

miR	B	868-871
-	I	871-872
34a	I	872-875
delivered	O	876-885
by	O	886-888
the	O	889-892
GC4	O	893-896
-	O	896-897
targeted	O	897-905
nanoparticles	O	906-919
significantly	O	920-933
downregulated	O	934-947
the	O	948-951
survivin	O	952-960
expression	O	961-971
in	O	972-974
the	O	975-978
metastatic	O	979-989
tumor	O	990-995
and	O	996-999
reduced	O	1000-1007
tumor	O	1008-1013
load	O	1014-1018
in	O	1019-1021
the	O	1022-1025
lung	O	1026-1030
.	O	1030-1031

When	O	1032-1036
miR	B	1037-1040
-	I	1040-1041
34a	I	1041-1044
and	O	1045-1048
siRNAs	O	1049-1055
were	O	1056-1060
co	O	1061-1063
-	O	1063-1064
formulated	O	1064-1074
in	O	1075-1077
GC4	O	1078-1081
-	O	1081-1082
targeted	O	1082-1090
nanoparticles	O	1091-1104
,	O	1104-1105
an	O	1106-1108
enhanced	O	1109-1117
anticancer	O	1118-1128
effect	O	1129-1135
was	O	1136-1139
observed	O	1140-1148
.	O	1148-1149

miR	B	0-3
-	I	3-4
200c	I	4-8
regulates	O	9-18
induction	O	19-28
of	O	29-31
apoptosis	O	32-41
through	O	42-49
CD95	O	50-54
by	O	55-57
targeting	O	58-67
FAP	O	68-71
-	O	71-72
1	O	72-73
.	O	73-74

Tumor	O	75-80
progression	O	81-92
shares	O	93-99
many	O	100-104
characteristics	O	105-120
with	O	121-125
the	O	126-129
process	O	130-137
of	O	138-140
epithelial	O	141-151
-	O	151-152
to	O	152-154
-	O	154-155
mesenchymal	O	155-166
transition	O	167-177
(	O	178-179
EMT	O	179-182
)	O	182-183
.	O	183-184

Cells	O	185-190
that	O	191-195
have	O	196-200
undergone	O	201-210
an	O	211-213
EMT	O	214-217
are	O	218-221
known	O	222-227
to	O	228-230
have	O	231-235
an	O	236-238
increased	O	239-248
resistance	O	249-259
to	O	260-262
apoptosis	O	263-272
.	O	272-273

CD95	O	274-278
/	O	278-279
Fas	O	279-282
is	O	283-285
an	O	286-288
apoptosis	O	289-298
-	O	298-299
inducing	O	299-307
receptor	O	308-316
expressed	O	317-326
on	O	327-329
many	O	330-334
tissues	O	335-342
and	O	343-346
tumor	O	347-352
cells	O	353-358
.	O	358-359

During	O	360-366
tumor	O	367-372
progression	O	373-384
CD95	O	385-389
is	O	390-392
frequently	O	393-403
downregulated	O	404-417
,	O	417-418
and	O	419-422
tumor	O	423-428
cells	O	429-434
lose	O	435-439
apoptosis	O	440-449
sensitivity	O	450-461
.	O	461-462

miR	B	463-466
-	I	466-467
200	I	467-470
microRNAs	O	471-480
repress	O	481-488
both	O	489-493
the	O	494-497
EMT	O	498-501
-	O	501-502
inducing	O	502-510
ZEB1	O	511-515
and	O	516-519
ZEB2	O	520-524
transcription	O	525-538
factors	O	539-546
.	O	546-547

We	O	548-550
now	O	551-554
demonstrate	O	555-566
that	O	567-571
miR	B	572-575
-	I	575-576
200c	I	576-580
sensitizes	O	581-591
cells	O	592-597
to	O	598-600
apoptosis	O	601-610
mediated	O	611-619
by	O	620-622
CD95	O	623-627
.	O	627-628

We	O	629-631
have	O	632-636
identified	O	637-647
the	O	648-651
apoptosis	O	652-661
inhibitor	O	662-671
FAP	O	672-675
-	O	675-676
1	O	676-677
as	O	678-680
a	O	681-682
target	O	683-689
for	O	690-693
miR	B	694-697
-	I	697-698
200c	I	698-702
.	O	702-703

FAP	O	704-707
-	O	707-708
1	O	708-709
was	O	710-713
demonstrated	O	714-726
to	O	727-729
be	O	730-732
responsible	O	733-744
for	O	745-748
the	O	749-752
reduced	O	753-760
sensitivity	O	761-772
to	O	773-775
CD95	O	776-780
-	O	780-781
mediated	O	781-789
apoptosis	O	790-799
in	O	800-802
cells	O	803-808
with	O	809-813
inhibited	O	814-823
miR	B	824-827
-	I	827-828
200	I	828-831
.	O	831-832

The	O	833-836
identification	O	837-851
of	O	852-854
FAP	O	855-858
-	O	858-859
1	O	859-860
as	O	861-863
an	O	864-866
miR	B	867-870
-	I	870-871
200c	I	871-875
target	O	876-882
provides	O	883-891
a	O	892-893
molecular	O	894-903
mechanism	O	904-913
to	O	914-916
explain	O	917-924
both	O	925-929
the	O	930-933
downregulation	O	934-948
of	O	949-951
CD95	O	952-956
expression	O	957-967
and	O	968-971
the	O	972-975
reduction	O	976-985
in	O	986-988
sensitivity	O	989-1000
of	O	1001-1003
cells	O	1004-1009
to	O	1010-1012
CD95	O	1013-1017
-	O	1017-1018
mediated	O	1018-1026
apoptosis	O	1027-1036
that	O	1037-1041
is	O	1042-1044
observed	O	1045-1053
in	O	1054-1056
the	O	1057-1060
context	O	1061-1068
of	O	1069-1071
reduced	O	1072-1079
miR	B	1080-1083
-	I	1083-1084
200	I	1084-1087
expression	O	1088-1098
during	O	1099-1105
tumor	O	1106-1111
progression	O	1112-1123
.	O	1123-1124

Unique	O	0-6
microRNA	O	7-15
profile	O	16-23
in	O	24-26
Dupuytren	O	27-36
'	O	36-37
s	O	37-38
contracture	O	39-50
supports	O	51-59
deregulation	O	60-72
of	O	73-75
beta	O	76-80
-	O	80-81
catenin	O	81-88
pathway	O	89-96
.	O	96-97

Dupuytren	O	98-107
'	O	107-108
s	O	108-109
contracture	O	110-121
,	O	121-122
a	O	123-124
proliferative	O	125-138
disease	O	139-146
of	O	147-149
unknown	O	150-157
origin	O	158-164
,	O	164-165
is	O	166-168
characterized	O	169-182
by	O	183-185
an	O	186-188
abnormal	O	189-197
fibroblast	O	198-208
proliferation	O	209-222
process	O	223-230
.	O	230-231

Evidence	O	232-240
from	O	241-245
numerous	O	246-254
microRNA	O	255-263
(	O	264-265
miRNA	O	265-270
)	O	270-271
studies	O	272-279
shows	O	280-285
that	O	286-290
miRNAs	O	291-297
have	O	298-302
a	O	303-304
vital	O	305-310
function	O	311-319
in	O	320-322
many	O	323-327
biological	O	328-338
processes	O	339-348
,	O	348-349
for	O	350-353
instance	O	354-362
,	O	362-363
in	O	364-366
cellular	O	367-375
signaling	O	376-385
networks	O	386-394
,	O	394-395
cell	O	396-400
growth	O	401-407
,	O	407-408
tissue	O	409-415
differentiation	O	416-431
,	O	431-432
and	O	433-436
cell	O	437-441
proliferation	O	442-455
.	O	455-456

Our	O	457-460
aim	O	461-464
was	O	465-468
to	O	469-471
characterize	O	472-484
,	O	484-485
to	O	486-488
our	O	489-492
knowledge	O	493-502
for	O	503-506
the	O	507-510
first	O	511-516
time	O	517-521
,	O	521-522
the	O	523-526
miRNA	O	527-532
-	O	532-533
expression	O	533-543
profile	O	544-551
of	O	552-554
Dupuytren	O	555-564
'	O	564-565
s	O	565-566
contracture	O	567-578
.	O	578-579

The	O	580-583
miRNAs	O	584-590
identified	O	591-601
may	O	602-605
have	O	606-610
a	O	611-612
function	O	613-621
in	O	622-624
the	O	625-628
pathogenesis	O	629-641
of	O	642-644
Dupuytren	O	645-654
'	O	654-655
s	O	655-656
contracture	O	657-668
by	O	669-671
targeting	O	672-681
and	O	682-685
regulating	O	686-696
important	O	697-706
pathways	O	707-715
.	O	715-716

We	O	717-719
compared	O	720-728
the	O	729-732
miRNA	O	733-738
-	O	738-739
expression	O	739-749
profile	O	750-757
of	O	758-760
29	O	761-763
Dupuytren	O	764-773
'	O	773-774
s	O	774-775
contracture	O	776-787
patients	O	788-796
with	O	797-801
that	O	802-806
of	O	807-809
control	O	810-817
samples	O	818-825
(	O	826-827
fibroblast	O	827-837
cells	O	838-843
and	O	844-847
palmar	O	848-854
fascia	O	855-861
)	O	861-862
.	O	862-863

Some	O	864-868
of	O	869-871
the	O	872-875
miRNAs	O	876-882
identified	O	883-893
in	O	894-896
our	O	897-900
Dupuytren	O	901-910
'	O	910-911
s	O	911-912
contracture	O	913-924
samples	O	925-932
,	O	932-933
including	O	934-943
miR	B	944-947
-	I	947-948
29c	I	948-951
,	O	951-952
miR	B	953-956
-	I	956-957
130b	I	957-961
,	O	961-962
miR	B	963-966
-	I	966-967
101	I	967-970
,	O	970-971
miR	B	972-975
-	I	975-976
30b	I	976-979
,	O	979-980
and	O	981-984
miR	B	985-988
-	I	988-989
140	I	989-992
-	I	992-993
3p	I	993-995
,	O	995-996
were	O	997-1001
found	O	1002-1007
to	O	1008-1010
regulate	O	1011-1019
important	O	1020-1029
genes	O	1030-1035
related	O	1036-1043
to	O	1044-1046
the	O	1047-1050
beta	O	1051-1055
-	O	1055-1056
catenin	O	1056-1063
pathway	O	1064-1071
:	O	1071-1072
WNT5A	O	1073-1078
,	O	1078-1079
ZIC1	O	1080-1084
,	O	1084-1085
and	O	1086-1089
TGFB1	O	1090-1095
.	O	1095-1096

Expression	O	1097-1107
profiles	O	1108-1116
of	O	1117-1119
these	O	1120-1125
genes	O	1126-1131
reanalyzed	O	1132-1142
from	O	1143-1147
published	O	1148-1157
gene	O	1158-1162
-	O	1162-1163
expression	O	1163-1173
data	O	1174-1178
from	O	1179-1183
similar	O	1184-1191
patient	O	1192-1199
material	O	1200-1208
correlated	O	1209-1219
with	O	1220-1224
our	O	1225-1228
miRNA	O	1229-1234
results	O	1235-1242
.	O	1242-1243

Analysis	O	1244-1252
was	O	1253-1256
also	O	1257-1261
performed	O	1262-1271
for	O	1272-1275
groups	O	1276-1282
of	O	1283-1285
patients	O	1286-1294
with	O	1295-1299
recurrent	O	1300-1309
/	O	1309-1310
non	O	1310-1313
-	O	1313-1314
recurrent	O	1314-1323
and	O	1324-1327
patients	O	1328-1336
with	O	1337-1341
hereditary	O	1342-1352
/	O	1352-1353
non	O	1353-1356
-	O	1356-1357
hereditary	O	1357-1367
Dupuytren	O	1368-1377
'	O	1377-1378
s	O	1378-1379
contracture	O	1380-1391
,	O	1391-1392
but	O	1393-1396
no	O	1397-1399
significant	O	1400-1411
differences	O	1412-1423
appeared	O	1424-1432
in	O	1433-1435
miRNA	O	1436-1441
-	O	1441-1442
expression	O	1442-1452
profiles	O	1453-1461
of	O	1462-1464
these	O	1465-1470
groups	O	1471-1477
.	O	1477-1478

Identification	O	1479-1493
of	O	1494-1496
unique	O	1497-1503
miRNA	O	1504-1509
expression	O	1510-1520
in	O	1521-1523
Dupuytren	O	1524-1533
'	O	1533-1534
s	O	1534-1535
contracture	O	1536-1547
may	O	1548-1551
lead	O	1552-1556
to	O	1557-1559
the	O	1560-1563
development	O	1564-1575
of	O	1576-1578
novel	O	1579-1584
molecular	O	1585-1594
therapy	O	1595-1602
for	O	1603-1606
its	O	1607-1610
treatment	O	1611-1620
.	O	1620-1621

A	O	0-1
functional	O	2-12
varient	O	13-20
in	O	21-23
microRNA	B	24-32
-	I	32-33
146a	I	33-37
is	O	38-40
associated	O	41-51
with	O	52-56
risk	O	57-61
of	O	62-64
esophageal	O	65-75
squamous	O	76-84
cell	O	85-89
carcinoma	O	90-99
in	O	100-102
Chinese	O	103-110
Han	O	111-114
.	O	114-115

MicroRNAs	O	116-125
are	O	126-129
a	O	130-131
new	O	132-135
class	O	136-141
of	O	142-144
non	O	145-148
-	O	148-149
proteincoding	O	149-162
,	O	162-163
small	O	164-169
RNAs	O	170-174
that	O	175-179
function	O	180-188
as	O	189-191
tumor	O	192-197
suppressors	O	198-209
or	O	210-212
oncogenes	O	213-222
.	O	222-223

They	O	224-228
participate	O	229-240
in	O	241-243
diverse	O	244-251
biological	O	252-262
pathways	O	263-271
and	O	272-275
function	O	276-284
as	O	285-287
gene	O	288-292
regulators	O	293-303
.	O	303-304

A	O	305-306
G	O	307-308
>	O	308-309
C	O	309-310
polymorphism	O	311-323
(	O	324-325
rs2910164	O	325-334
)	O	334-335
,	O	335-336
which	O	337-342
is	O	343-345
located	O	346-353
in	O	354-356
the	O	357-360
sequence	O	361-369
of	O	370-372
miR	B	373-376
-	I	376-377
146a	I	377-381
precursor	O	382-391
,	O	391-392
results	O	393-400
in	O	401-403
a	O	404-405
change	O	406-412
from	O	413-417
G	O	418-419
:	O	419-420
U	O	420-421
to	O	422-424
C	O	425-426
:	O	426-427
U	O	427-428
in	O	429-431
its	O	432-435
stem	O	436-440
region	O	441-447
.	O	447-448

However	O	449-456
,	O	456-457
it	O	458-460
remains	O	461-468
largely	O	469-476
unknown	O	477-484
whether	O	485-492
this	O	493-497
single	O	498-504
nucleotide	O	505-515
polymorphism	O	516-528
(	O	529-530
SNP	O	530-533
)	O	533-534
may	O	535-538
alter	O	539-544
esophageal	O	545-555
squamous	O	556-564
cell	O	565-569
carcinoma	O	570-579
(	O	580-581
ESCC	O	581-585
)	O	585-586
susceptibility	O	587-601
.	O	601-602

In	O	603-605
the	O	606-609
current	O	610-617
study	O	618-623
,	O	623-624
we	O	625-627
evaluated	O	628-637
association	O	638-649
between	O	650-657
rs2910164	O	658-667
and	O	668-671
ESCC	O	672-676
susceptibility	O	677-691
in	O	692-694
a	O	695-696
case	O	697-701
-	O	701-702
control	O	702-709
study	O	710-715
of	O	716-718
444	O	719-722
sporadic	O	723-731
ESCC	O	732-736
patients	O	737-745
and	O	746-749
468	O	750-753
matched	O	754-761
cancer	O	762-768
-	O	768-769
free	O	769-773
controls	O	774-782
in	O	783-785
a	O	786-787
Chinese	O	788-795
Han	O	796-799
population	O	800-810
.	O	810-811

Compared	O	812-820
with	O	821-825
rs2910164	O	826-835
variant	O	836-843
genotype	O	844-852
CC	O	853-855
,	O	855-856
genotype	O	857-865
GG	O	866-868
was	O	869-872
associated	O	873-883
with	O	884-888
increased	O	889-898
risk	O	899-903
of	O	904-906
ESCC	O	907-911
(	O	912-913
Odds	O	913-917
Ratio	O	918-923
,	O	923-924
2	O	925-926
.	O	926-927
39	O	927-929
,	O	929-930
95	O	931-933
%	O	933-934
Confidence	O	935-945
Interval	O	946-954
,	O	954-955
1	O	956-957
.	O	957-958
36	O	958-960
-	O	960-961
4	O	961-962
.	O	962-963
20	O	963-965
)	O	965-966
.	O	966-967

In	O	968-970
the	O	971-974
smokers	O	975-982
,	O	982-983
the	O	984-987
risk	O	988-992
of	O	993-995
rs2910164	O	996-1005
GG	O	1006-1008
genotype	O	1009-1017
was	O	1018-1021
more	O	1022-1026
notable	O	1027-1034
(	O	1035-1036
Odds	O	1036-1040
Ratio	O	1041-1046
,	O	1046-1047
3	O	1048-1049
.	O	1049-1050
17	O	1050-1052
,	O	1052-1053
95	O	1054-1056
%	O	1056-1057
Confidence	O	1058-1068
Interval	O	1069-1077
,	O	1077-1078
1	O	1079-1080
.	O	1080-1081
71	O	1081-1083
-	O	1083-1084
4	O	1084-1085
.	O	1085-1086
46	O	1086-1088
)	O	1088-1089
.	O	1089-1090

In	O	1091-1093
the	O	1094-1097
stratification	O	1098-1112
analyses	O	1113-1121
,	O	1121-1122
we	O	1123-1125
also	O	1126-1130
found	O	1131-1136
there	O	1137-1142
was	O	1143-1146
a	O	1147-1148
strong	O	1149-1155
correlation	O	1156-1167
between	O	1168-1175
rs2910164	O	1176-1185
C	O	1186-1187
/	O	1187-1188
G	O	1188-1189
variant	O	1190-1197
and	O	1198-1201
the	O	1202-1205
clinical	O	1206-1214
TNM	O	1215-1218
stage	O	1219-1224
(	O	1225-1226
P	O	1226-1227
<	O	1228-1229
0	O	1230-1231
.	O	1231-1232
01	O	1232-1234
)	O	1234-1235
.	O	1235-1236

These	O	1237-1242
findings	O	1243-1251
suggest	O	1252-1259
that	O	1260-1264
this	O	1265-1269
functional	O	1270-1280
SNP	O	1281-1284
in	O	1285-1287
pre	B	1288-1291
-	I	1291-1292
miR	I	1292-1295
-	I	1295-1296
146a	I	1296-1300
could	O	1301-1306
contribute	O	1307-1317
to	O	1318-1320
ESCC	O	1321-1325
susceptibility	O	1326-1340
and	O	1341-1344
clinical	O	1345-1353
outcome	O	1354-1361
.	O	1361-1362

Ratio	O	0-5
of	O	6-8
miR	B	9-12
-	I	12-13
196s	I	13-17
to	O	18-20
HOXC8	O	21-26
messenger	O	27-36
RNA	O	37-40
correlates	O	41-51
with	O	52-56
breast	O	57-63
cancer	O	64-70
cell	O	71-75
migration	O	76-85
and	O	86-89
metastasis	O	90-100
.	O	100-101

Expression	O	102-112
profiling	O	113-122
has	O	123-126
identified	O	127-137
metastasis	O	138-148
-	O	148-149
associated	O	149-159
microRNAs	O	160-169
(	O	170-171
miRNA	O	171-176
)	O	176-177
but	O	178-181
technical	O	182-191
limitations	O	192-203
hinder	O	204-210
the	O	211-214
discovery	O	215-224
of	O	225-227
metastasis	O	228-238
-	O	238-239
suppressing	O	239-250
miRNAs	O	251-257
.	O	257-258

In	O	259-261
this	O	262-266
study	O	267-272
,	O	272-273
we	O	274-276
sought	O	277-283
metastasis	O	284-294
-	O	294-295
suppressing	O	295-306
miRNAs	O	307-313
by	O	314-316
functional	O	317-327
screening	O	328-337
.	O	337-338

Individual	O	339-349
miRNAs	O	350-356
were	O	357-361
lentivirally	O	362-374
introduced	O	375-385
into	O	386-390
metastatic	O	391-401
MDA	O	402-405
-	O	405-406
MB	O	406-408
-	O	408-409
231	O	409-412
breast	O	413-419
cancer	O	420-426
cells	O	427-432
and	O	433-436
analyzed	O	437-445
for	O	446-449
effects	O	450-457
on	O	458-460
cell	O	461-465
migration	O	466-475
,	O	475-476
a	O	477-478
critical	O	479-487
step	O	488-492
in	O	493-495
cancer	O	496-502
metastasis	O	503-513
.	O	513-514

Among	O	515-520
486	O	521-524
miRNAs	O	525-531
screened	O	532-540
,	O	540-541
14	O	542-544
were	O	545-549
identified	O	550-560
that	O	561-565
included	O	566-574
all	O	575-578
of	O	579-581
the	O	582-585
members	O	586-593
of	O	594-596
the	O	597-600
miRNA	B	601-606
-	I	606-607
196	I	607-610
family	O	611-617
(	O	618-619
miR	B	619-622
-	I	622-623
196a1	I	623-628
,	O	628-629
miR	B	630-633
-	I	633-634
196a2	I	634-639
,	O	639-640
and	O	641-644
miR	B	645-648
-	I	648-649
196b	I	649-653
)	O	653-654
.	O	654-655

Enforced	O	656-664
expression	O	665-675
of	O	676-678
miR	B	679-682
-	I	682-683
196a1	I	683-688
/	O	688-689
2	B	689-690
or	O	691-693
miR	B	694-697
-	I	697-698
196b	I	698-702
abrogated	O	703-712
in	O	713-715
vitro	O	716-721
invasion	O	722-730
and	O	731-734
in	O	735-737
vivo	O	738-742
spontaneous	O	743-754
metastasis	O	755-765
of	O	766-768
breast	O	769-775
cancer	O	776-782
cells	O	783-788
,	O	788-789
indicating	O	790-800
that	O	801-805
members	O	806-813
of	O	814-816
the	O	817-820
miR	B	821-824
-	I	824-825
196	I	825-828
family	O	829-835
are	O	836-839
potent	O	840-846
metastasis	O	847-857
suppressors	O	858-869
.	O	869-870

We	O	871-873
found	O	874-879
that	O	880-884
miR	B	885-888
-	I	888-889
196	I	889-892
inhibited	O	893-902
the	O	903-906
expression	O	907-917
of	O	918-920
transcription	O	921-934
factor	O	935-941
HOXC8	O	942-947
.	O	947-948

Functional	O	949-959
linkage	O	960-967
was	O	968-971
implied	O	972-979
by	O	980-982
small	O	983-988
interfering	O	989-1000
RNA	O	1001-1004
-	O	1004-1005
mediated	O	1005-1013
knockdown	O	1014-1023
of	O	1024-1026
HOXC8	O	1027-1032
,	O	1032-1033
which	O	1034-1039
suppressed	O	1040-1050
cell	O	1051-1055
migration	O	1056-1065
and	O	1066-1069
metastasis	O	1070-1080
,	O	1080-1081
and	O	1082-1085
by	O	1086-1088
ectopic	O	1089-1096
expression	O	1097-1107
of	O	1108-1110
HOXC8	O	1111-1116
,	O	1116-1117
which	O	1118-1123
prevented	O	1124-1133
the	O	1134-1137
effects	O	1138-1145
of	O	1146-1148
miR	B	1149-1152
-	I	1152-1153
196	I	1153-1156
on	O	1157-1159
cell	O	1160-1164
migration	O	1165-1174
and	O	1175-1178
metastasis	O	1179-1189
.	O	1189-1190

Unlike	O	1191-1197
other	O	1198-1203
metastasis	O	1204-1214
-	O	1214-1215
associated	O	1215-1225
miRNAs	O	1226-1232
that	O	1233-1237
have	O	1238-1242
been	O	1243-1247
described	O	1248-1257
,	O	1257-1258
the	O	1259-1262
expressions	O	1263-1274
of	O	1275-1277
miR	B	1278-1281
-	I	1281-1282
196	I	1282-1285
were	O	1286-1290
not	O	1291-1294
correlated	O	1295-1305
with	O	1306-1310
breast	O	1311-1317
cancer	O	1318-1324
cell	O	1325-1329
migration	O	1330-1339
or	O	1340-1342
the	O	1343-1346
metastatic	O	1347-1357
status	O	1358-1364
of	O	1365-1367
clinical	O	1368-1376
breast	O	1377-1383
tumor	O	1384-1389
specimens	O	1390-1399
.	O	1399-1400

Instead	O	1401-1408
,	O	1408-1409
we	O	1410-1412
detected	O	1413-1421
an	O	1422-1424
excellent	O	1425-1434
correlation	O	1435-1446
between	O	1447-1454
the	O	1455-1458
ratio	O	1459-1464
of	O	1465-1467
miR	B	1468-1471
-	I	1471-1472
196	I	1472-1475
to	O	1476-1478
HOXC8	O	1479-1484
messages	O	1485-1493
and	O	1494-1497
the	O	1498-1501
migratory	O	1502-1511
behavior	O	1512-1520
of	O	1521-1523
breast	O	1524-1530
cancer	O	1531-1537
cell	O	1538-1542
lines	O	1543-1548
as	O	1549-1551
well	O	1552-1556
as	O	1557-1559
the	O	1560-1563
metastatic	O	1564-1574
status	O	1575-1581
of	O	1582-1584
clinical	O	1585-1593
samples	O	1594-1601
.	O	1601-1602

Our	O	1603-1606
findings	O	1607-1615
identify	O	1616-1624
miRNA	B	1625-1630
-	I	1630-1631
196s	I	1631-1635
as	O	1636-1638
potent	O	1639-1645
metastasis	O	1646-1656
suppressors	O	1657-1668
and	O	1669-1672
reveal	O	1673-1679
that	O	1680-1684
the	O	1685-1688
ratio	O	1689-1694
of	O	1695-1697
miR	B	1698-1701
-	I	1701-1702
196s	I	1702-1706
to	O	1707-1709
HOXC8	O	1710-1715
mRNA	O	1716-1720
might	O	1721-1726
be	O	1727-1729
an	O	1730-1732
indicator	O	1733-1742
of	O	1743-1745
the	O	1746-1749
metastatic	O	1750-1760
capability	O	1761-1771
of	O	1772-1774
breast	O	1775-1781
tumors	O	1782-1788
.	O	1788-1789

Cooperative	O	0-11
and	O	12-15
individualistic	O	16-31
functions	O	32-41
of	O	42-44
the	O	45-48
microRNAs	O	49-58
in	O	59-61
the	O	62-65
miR	B	66-69
-	I	69-70
23a	I	70-73
~	O	73-74
27a	B	74-77
~	O	77-78
24	B	78-80
-	I	80-81
2	I	81-82
cluster	O	83-90
and	O	91-94
its	O	95-98
implication	O	99-110
in	O	111-113
human	O	114-119
diseases	O	120-128
.	O	128-129

The	O	130-133
small	O	134-139
RNA	O	140-143
molecules	O	144-153
of	O	154-156
about	O	157-162
19	O	163-165
-	O	165-166
22	O	166-168
nucleotides	O	169-180
in	O	181-183
length	O	184-190
,	O	190-191
aptly	O	192-197
called	O	198-204
microRNAs	O	205-214
,	O	214-215
perform	O	216-223
the	O	224-227
task	O	228-232
of	O	233-235
gene	O	236-240
regulation	O	241-251
in	O	252-254
the	O	255-258
cell	O	259-263
.	O	263-264

Interestingly	O	265-278
,	O	278-279
till	O	280-284
the	O	285-288
early	O	289-294
nineties	O	295-303
very	O	304-308
little	O	309-315
was	O	316-319
known	O	320-325
about	O	326-331
them	O	332-336
but	O	337-340
eventually	O	341-351
,	O	351-352
the	O	353-356
microRNAs	O	357-366
have	O	367-371
become	O	372-378
forefront	O	379-388
in	O	389-391
the	O	392-395
area	O	396-400
of	O	401-403
research	O	404-412
.	O	412-413

The	O	414-417
huge	O	418-422
number	O	423-429
of	O	430-432
microRNAs	O	433-442
plus	O	443-447
each	O	448-452
one	O	453-456
of	O	457-459
them	O	460-464
targeting	O	465-474
a	O	475-476
vast	O	477-481
number	O	482-488
of	O	489-491
related	O	492-499
as	O	500-502
well	O	503-507
as	O	508-510
unrelated	O	511-520
genes	O	521-526
makes	O	527-532
them	O	533-537
very	O	538-542
interesting	O	543-554
molecules	O	555-564
to	O	565-567
study	O	568-573
.	O	573-574

To	O	575-577
add	O	578-581
to	O	582-584
the	O	585-588
mystery	O	589-596
of	O	597-599
miRNAs	O	600-606
is	O	607-609
the	O	610-613
fact	O	614-618
that	O	619-623
the	O	624-627
same	O	628-632
miRNA	O	633-638
can	O	639-642
have	O	643-647
antagonizing	O	648-660
role	O	661-665
in	O	666-668
two	O	669-672
different	O	673-682
cell	O	683-687
types	O	688-693
i	O	694-695
.	O	695-696
e	O	696-697
.	O	697-698

in	O	699-701
one	O	702-705
cell	O	706-710
type	O	711-715
;	O	715-716
the	O	717-720
miRNA	O	721-726
promotes	O	727-735
proliferation	O	736-749
whereas	O	750-757
in	O	758-760
another	O	761-768
cell	O	769-773
type	O	774-778
the	O	779-782
same	O	783-787
miRNA	O	788-793
inhibits	O	794-802
proliferation	O	803-816
.	O	816-817

Another	O	818-825
remarkable	O	826-836
aspect	O	837-843
of	O	844-846
the	O	847-850
microRNAs	O	851-860
is	O	861-863
that	O	864-868
many	O	869-873
of	O	874-876
them	O	877-881
exist	O	882-887
in	O	888-890
clusters	O	891-899
.	O	899-900

In	O	901-903
humans	O	904-910
alone	O	911-916
,	O	916-917
out	O	918-921
of	O	922-924
721	O	925-928
microRNAs	O	929-938
known	O	939-944
,	O	944-945
247	O	946-949
of	O	950-952
them	O	953-957
occur	O	958-963
in	O	964-966
64	O	967-969
clusters	O	970-978
at	O	979-981
an	O	982-984
inter	O	985-990
-	O	990-991
miRNA	O	991-996
distance	O	997-1005
of	O	1006-1008
less	O	1009-1013
than	O	1014-1018
5000	O	1019-1023
bp	O	1024-1026
.	O	1026-1027

The	O	1028-1031
reason	O	1032-1038
for	O	1039-1042
this	O	1043-1047
clustering	O	1048-1058
of	O	1059-1061
miRNAs	O	1062-1068
is	O	1069-1071
not	O	1072-1075
fully	O	1076-1081
understood	O	1082-1092
but	O	1093-1096
since	O	1097-1102
the	O	1103-1106
miRNA	O	1107-1112
clusters	O	1113-1121
are	O	1122-1125
evolutionary	O	1126-1138
conserved	O	1139-1148
,	O	1148-1149
their	O	1150-1155
significance	O	1156-1168
cannot	O	1169-1175
be	O	1176-1178
ruled	O	1179-1184
out	O	1185-1188
.	O	1188-1189

The	O	1190-1193
objective	O	1194-1203
of	O	1204-1206
this	O	1207-1211
review	O	1212-1218
is	O	1219-1221
to	O	1222-1224
summarize	O	1225-1234
the	O	1235-1238
recent	O	1239-1245
progress	O	1246-1254
on	O	1255-1257
the	O	1258-1261
functional	O	1262-1272
characterization	O	1273-1289
of	O	1290-1292
miR	B	1293-1296
-	I	1296-1297
23a	I	1297-1300
~	O	1300-1301
27a	B	1301-1304
~	O	1304-1305
24	B	1305-1307
-	I	1307-1308
2	I	1308-1309
cluster	O	1310-1317
in	O	1318-1320
humans	O	1321-1327
in	O	1328-1330
relation	O	1331-1339
to	O	1340-1342
various	O	1343-1350
health	O	1351-1357
and	O	1358-1361
diseased	O	1362-1370
conditions	O	1371-1381
and	O	1382-1385
to	O	1386-1388
highlight	O	1389-1398
the	O	1399-1402
cooperative	O	1403-1414
effects	O	1415-1422
of	O	1423-1425
the	O	1426-1429
miRNAs	O	1430-1436
of	O	1437-1439
this	O	1440-1444
cluster	O	1445-1452
.	O	1452-1453

Differential	O	0-12
miRNA	O	13-18
expression	O	19-29
and	O	30-33
their	O	34-39
target	O	40-46
genes	O	47-52
between	O	53-60
NGX6	O	61-65
-	O	65-66
positive	O	66-74
and	O	75-78
negative	O	79-87
colon	O	88-93
cancer	O	94-100
cells	O	101-106
.	O	106-107

Nasopharyngeal	O	108-122
carcinoma	O	123-132
-	O	132-133
associated	O	133-143
gene	O	144-148
6	O	149-150
(	O	151-152
NGX6	O	152-156
)	O	156-157
was	O	158-161
shown	O	162-167
to	O	168-170
be	O	171-173
a	O	174-175
novel	O	176-181
putative	O	182-190
tumor	O	191-196
suppressor	O	197-207
gene	O	208-212
in	O	213-215
colon	O	216-221
cancer	O	222-228
.	O	228-229

The	O	230-233
purpose	O	234-241
of	O	242-244
this	O	245-249
study	O	250-255
is	O	256-258
to	O	259-261
investigate	O	262-273
its	O	274-277
role	O	278-282
in	O	283-285
regulation	O	286-296
of	O	297-299
miRNA	O	300-305
expression	O	306-316
for	O	317-320
in	O	321-323
the	O	324-327
hopes	O	328-333
of	O	334-336
translating	O	337-348
this	O	349-353
data	O	354-358
into	O	359-363
a	O	364-365
novel	O	366-371
strategy	O	372-380
in	O	381-383
control	O	384-391
of	O	392-394
colon	O	395-400
cancer	O	401-407
.	O	407-408

In	O	409-411
this	O	412-416
study	O	417-422
colon	O	423-428
cancer	O	429-435
HT	O	436-438
-	O	438-439
29	O	439-441
cells	O	442-447
were	O	448-452
stably	O	453-459
transfected	O	460-471
with	O	472-476
NGX6	O	477-481
or	O	482-484
vector	O	485-491
-	O	491-492
only	O	492-496
plasmid	O	497-504
and	O	505-508
then	O	509-513
subjected	O	514-523
to	O	524-526
miRNA	O	527-532
array	O	533-538
analysis	O	539-547
,	O	547-548
and	O	549-552
Q	O	553-554
-	O	554-555
RT	O	555-557
-	O	557-558
PCR	O	558-561
was	O	562-565
then	O	566-570
used	O	571-575
to	O	576-578
verify	O	579-585
miRNA	O	586-591
array	O	592-597
data	O	598-602
.	O	602-603

Then	O	604-608
bioinformatic	O	609-622
analyses	O	623-631
using	O	632-637
Sanger	O	638-644
,	O	644-645
Target	O	646-652
Scan	O	653-657
,	O	657-658
and	O	659-662
MicroRNA	O	663-671
software	O	672-680
were	O	681-685
performed	O	686-695
to	O	696-698
obtain	O	699-705
data	O	706-710
on	O	711-713
the	O	714-717
target	O	718-724
genes	O	725-730
of	O	731-733
each	O	734-738
miRNA	O	739-744
and	O	745-748
define	O	749-755
their	O	756-761
function	O	762-770
.	O	770-771

Our	O	772-775
results	O	776-783
showed	O	784-790
that	O	791-795
14	O	796-798
miRNAs	O	799-805
were	O	806-810
found	O	811-816
to	O	817-819
be	O	820-822
differentially	O	823-837
expressed	O	838-847
in	O	848-850
NGX6	O	851-855
-	O	855-856
transfected	O	856-867
cells	O	868-873
compared	O	874-882
to	O	883-885
the	O	886-889
control	O	890-897
cells	O	898-903
.	O	903-904

In	O	905-907
particular	O	908-918
,	O	918-919
miR	B	920-923
-	I	923-924
126	I	924-927
,	O	927-928
miR	B	929-932
-	I	932-933
142	I	933-936
-	I	936-937
3p	I	937-939
,	O	939-940
miR	B	941-944
-	I	944-945
155	I	945-948
,	O	948-949
miR	B	950-953
-	I	953-954
552	I	954-957
,	O	957-958
and	O	959-962
miR	B	963-966
-	I	966-967
630	I	967-970
were	O	971-975
all	O	976-979
upregulated	O	980-991
,	O	991-992
whereas	O	993-1000
miR	B	1001-1004
-	I	1004-1005
146a	I	1005-1009
,	O	1009-1010
miR	B	1011-1014
-	I	1014-1015
152	I	1015-1018
,	O	1018-1019
miR	B	1020-1023
-	I	1023-1024
205	I	1024-1027
,	O	1027-1028
miR	B	1029-1032
-	I	1032-1033
365	I	1033-1036
,	O	1036-1037
miR	B	1038-1041
-	I	1041-1042
449	I	1042-1045
,	O	1045-1046
miR	B	1047-1050
-	I	1050-1051
518c	I	1051-1055
,	O	1055-1056
miR	B	1057-1060
-	I	1060-1061
584	I	1061-1064
,	O	1064-1065
miR	B	1066-1069
-	I	1069-1070
615	I	1070-1073
,	O	1073-1074
and	O	1075-1078
miR	B	1079-1082
-	I	1082-1083
622	I	1083-1086
were	O	1087-1091
downregulated	O	1092-1105
after	O	1106-1111
NGX6	O	1112-1116
transfection	O	1117-1129
.	O	1129-1130

Q	O	1131-1132
-	O	1132-1133
RT	O	1133-1135
-	O	1135-1136
PCR	O	1136-1139
confirmed	O	1140-1149
all	O	1150-1153
of	O	1154-1156
these	O	1157-1162
miRNAs	O	1163-1169
,	O	1169-1170
and	O	1171-1174
invalidated	O	1175-1186
miR	B	1187-1190
-	I	1190-1191
552	I	1191-1194
and	O	1195-1198
miR	B	1199-1202
-	I	1202-1203
630	I	1203-1206
.	O	1206-1207

Furthermore	O	1208-1219
,	O	1219-1220
bioinformatic	O	1221-1234
analyses	O	1235-1243
of	O	1244-1246
these	O	1247-1252
12	O	1253-1255
miRNAs	O	1256-1262
,	O	1262-1263
among	O	1264-1269
these	O	1270-1275
miRNAs	O	1276-1282
,	O	1282-1283
target	O	1284-1290
genes	O	1291-1296
of	O	1297-1299
miR	B	1300-1303
-	I	1303-1304
615	I	1304-1307
are	O	1308-1311
unclear	O	1312-1319
,	O	1319-1320
another	O	1321-1328
11	O	1329-1331
miRNAs	O	1332-1338
produced	O	1339-1347
a	O	1348-1349
total	O	1350-1355
of	O	1356-1358
254	O	1359-1362
potential	O	1363-1372
target	O	1373-1379
genes	O	1380-1385
and	O	1386-1389
further	O	1390-1397
study	O	1398-1403
showed	O	1404-1410
that	O	1411-1415
these	O	1416-1421
genes	O	1422-1427
together	O	1428-1436
formed	O	1437-1443
a	O	1444-1445
regulatory	O	1446-1456
network	O	1457-1464
that	O	1465-1469
contributes	O	1470-1481
to	O	1482-1484
apoptosis	O	1485-1494
,	O	1494-1495
mobility	O	1496-1504
/	O	1504-1505
migration	O	1505-1514
,	O	1514-1515
hydrolysis	O	1516-1526
activity	O	1527-1535
,	O	1535-1536
and	O	1537-1540
molecular	O	1541-1550
signaling	O	1551-1560
through	O	1561-1568
targeting	O	1569-1578
JNK	O	1579-1582
and	O	1583-1586
Notch	O	1587-1592
pathways	O	1593-1601
.	O	1601-1602

Taken	O	1603-1608
together	O	1609-1617
,	O	1617-1618
these	O	1619-1624
results	O	1625-1632
have	O	1633-1637
suggested	O	1638-1647
that	O	1648-1652
NGX6	O	1653-1657
plays	O	1658-1663
an	O	1664-1666
important	O	1667-1676
role	O	1677-1681
in	O	1682-1684
regulation	O	1685-1695
of	O	1696-1698
apoptosis	O	1699-1708
,	O	1708-1709
mobility	O	1710-1718
/	O	1718-1719
migration	O	1719-1728
,	O	1728-1729
and	O	1730-1733
hydrolase	O	1734-1743
as	O	1744-1746
well	O	1747-1751
as	O	1752-1754
activity	O	1755-1763
of	O	1764-1766
JNK	O	1767-1770
and	O	1771-1774
Notch	O	1775-1780
pathways	O	1781-1789
through	O	1790-1797
NGX6	O	1798-1802
-	O	1802-1803
mediated	O	1803-1811
miRNA	O	1812-1817
expression	O	1818-1828
.	O	1828-1829

Further	O	1830-1837
investigation	O	1838-1851
will	O	1852-1856
reveal	O	1857-1863
the	O	1864-1867
function	O	1868-1876
of	O	1877-1879
these	O	1880-1885
differentially	O	1886-1900
expressed	O	1901-1910
miRNAs	O	1911-1917
and	O	1918-1921
verify	O	1922-1928
expression	O	1929-1939
of	O	1940-1942
the	O	1943-1946
miRNA	O	1947-1952
-	O	1952-1953
targeted	O	1953-1961
genes	O	1962-1967
for	O	1968-1971
development	O	1972-1983
of	O	1984-1986
novel	O	1987-1992
strategies	O	1993-2003
for	O	2004-2007
better	O	2008-2014
control	O	2015-2022
of	O	2023-2025
colon	O	2026-2031
cancer	O	2032-2038
.	O	2038-2039

Context	O	0-7
-	O	7-8
dependent	O	8-17
functions	O	18-27
of	O	28-30
specific	O	31-39
microRNAs	O	40-49
in	O	50-52
neuronal	O	53-61
development	O	62-73
.	O	73-74

MicroRNAs	O	75-84
(	O	85-86
miRNAs	O	86-92
)	O	92-93
are	O	94-97
small	O	98-103
noncoding	O	104-113
RNAs	O	114-118
that	O	119-123
regulate	O	124-132
multiple	O	133-141
developmental	O	142-155
processes	O	156-165
at	O	166-168
the	O	169-172
post	O	173-177
-	O	177-178
transcriptional	O	178-193
level	O	194-199
.	O	199-200

Recent	O	201-207
rapid	O	208-213
progresses	O	214-224
have	O	225-229
demonstrated	O	230-242
critical	O	243-251
roles	O	252-257
for	O	258-261
a	O	262-263
number	O	264-270
of	O	271-273
miRNAs	O	274-280
in	O	281-283
neuronal	O	284-292
development	O	293-304
and	O	305-308
function	O	309-317
.	O	317-318

In	O	319-321
particular	O	322-332
,	O	332-333
miR	B	334-337
-	I	337-338
9	I	338-339
and	O	340-343
miR	B	344-347
-	I	347-348
124	I	348-351
are	O	352-355
specifically	O	356-368
expressed	O	369-378
in	O	379-381
the	O	382-385
mammalian	O	386-395
nervous	O	396-403
system	O	404-410
,	O	410-411
and	O	412-415
their	O	416-421
respective	O	422-432
nucleotide	O	433-443
sequences	O	444-453
are	O	454-457
100	O	458-461
%	O	461-462
identical	O	463-472
among	O	473-478
many	O	479-483
species	O	484-491
.	O	491-492

Yet	O	493-496
,	O	496-497
their	O	498-503
expression	O	504-514
patterns	O	515-523
and	O	524-527
mRNA	O	528-532
targets	O	533-540
are	O	541-544
less	O	545-549
conserved	O	550-559
throughout	O	560-570
evolution	O	571-580
.	O	580-581

As	O	582-584
a	O	585-586
consequence	O	587-598
,	O	598-599
these	O	600-605
miRNAs	O	606-612
exhibit	O	613-620
diverse	O	621-628
context	O	629-636
-	O	636-637
dependent	O	637-646
functions	O	647-656
in	O	657-659
different	O	660-669
aspects	O	670-677
of	O	678-680
neuronal	O	681-689
development	O	690-701
,	O	701-702
ranging	O	703-710
from	O	711-715
early	O	716-721
neurogenesis	O	722-734
and	O	735-738
neuronal	O	739-747
differentiation	O	748-763
to	O	764-766
dendritic	O	767-776
morphogenesis	O	777-790
and	O	791-794
synaptic	O	795-803
plasticity	O	804-814
.	O	814-815

Some	O	816-820
other	O	821-826
neuronal	O	827-835
miRNAs	O	836-842
also	O	843-847
exhibit	O	848-855
context	O	856-863
-	O	863-864
dependent	O	864-873
functions	O	874-883
in	O	884-886
development	O	887-898
.	O	898-899

Thus	O	900-904
,	O	904-905
post	O	906-910
-	O	910-911
transcriptional	O	911-926
regulation	O	927-937
of	O	938-940
spatial	O	941-948
and	O	949-952
temporal	O	953-961
expression	O	962-972
levels	O	973-979
of	O	980-982
protein	O	983-990
-	O	990-991
coding	O	991-997
genes	O	998-1003
by	O	1004-1006
miRNAs	O	1007-1013
contributes	O	1014-1025
uniquely	O	1026-1034
to	O	1035-1037
the	O	1038-1041
proper	O	1042-1048
development	O	1049-1060
and	O	1061-1064
evolution	O	1065-1074
of	O	1075-1077
the	O	1078-1081
complex	O	1082-1089
nervous	O	1090-1097
system	O	1098-1104
.	O	1104-1105

Androgen	O	0-8
regulation	O	9-19
of	O	20-22
micro	O	23-28
-	O	28-29
RNAs	O	29-33
in	O	34-36
prostate	O	37-45
cancer	O	46-52
.	O	52-53

BACKGROUND	O	54-64
:	O	64-65
Androgens	O	66-75
play	O	76-80
a	O	81-82
critical	O	83-91
role	O	92-96
in	O	97-99
the	O	100-103
growth	O	104-110
of	O	111-113
both	O	114-118
androgen	O	119-127
dependent	O	128-137
and	O	138-141
castration	O	142-152
-	O	152-153
resistant	O	153-162
prostate	O	163-171
cancer	O	172-178
(	O	179-180
CRPC	O	180-184
)	O	184-185
.	O	185-186

Only	O	187-191
a	O	192-193
few	O	194-197
micro	O	198-203
-	O	203-204
RNAs	O	204-208
(	O	209-210
miRNAs	O	210-216
)	O	216-217
have	O	218-222
been	O	223-227
suggested	O	228-237
to	O	238-240
be	O	241-243
androgen	O	244-252
regulated	O	253-262
.	O	262-263

We	O	264-266
aim	O	267-270
to	O	271-273
identify	O	274-282
androgen	O	283-291
regulated	O	292-301
miRNAs	O	302-308
.	O	308-309

METHODS	O	310-317
:	O	317-318
We	O	319-321
utilized	O	322-330
LNCaP	O	331-336
derived	O	337-344
model	O	345-350
,	O	350-351
we	O	352-354
have	O	355-359
established	O	360-371
,	O	371-372
and	O	373-376
which	O	377-382
overexpresses	O	383-396
the	O	397-400
androgen	O	401-409
receptor	O	410-418
(	O	419-420
AR	O	420-422
)	O	422-423
,	O	423-424
the	O	425-428
VCaP	O	429-433
cell	O	434-438
line	O	439-443
,	O	443-444
and	O	445-448
13	O	449-451
intact	O	452-458
-	O	458-459
castrated	O	459-468
prostate	O	469-477
cancer	O	478-484
(	O	485-486
PC	O	486-488
)	O	488-489
xenograft	O	490-499
pairs	O	500-505
,	O	505-506
as	O	507-509
well	O	510-514
as	O	515-517
clinical	O	518-526
specimens	O	527-536
of	O	537-539
untreated	O	540-549
(	O	550-551
PC	O	551-553
)	O	553-554
and	O	555-558
CRPC	O	559-563
.	O	563-564

The	O	565-568
expression	O	569-579
of	O	580-582
miRNAs	O	583-589
was	O	590-593
analyzed	O	594-602
by	O	603-605
microarrays	O	606-617
and	O	618-621
quantitative	O	622-634
RT	O	635-637
-	O	637-638
PCR	O	638-641
(	O	642-643
Q	O	643-644
-	O	644-645
RT	O	645-647
-	O	647-648
PCR	O	648-651
)	O	651-652
.	O	652-653

Transfection	O	654-666
of	O	667-669
pre	B	670-673
-	I	673-674
miR	I	674-677
-	I	677-678
141	I	678-681
and	O	682-685
anti	O	686-690
-	O	690-691
miR	B	691-694
-	I	694-695
141	I	695-698
was	O	699-702
also	O	703-707
used	O	708-712
.	O	712-713

RESULTS	O	714-721
:	O	721-722
Seventeen	O	723-732
miRNAs	O	733-739
were	O	740-744
>	O	745-746
1	O	747-748
.	O	748-749
5	O	749-750
-	O	750-751
fold	O	751-755
up	O	756-758
-	O	758-759
or	O	760-762
downregulated	O	763-776
upon	O	777-781
dihydrotestosterone	O	782-801
(	O	802-803
DHT	O	803-806
)	O	806-807
treatment	O	808-817
in	O	818-820
the	O	821-824
cell	O	825-829
lines	O	830-835
,	O	835-836
and	O	837-840
42	O	841-843
after	O	844-849
castration	O	850-860
in	O	861-863
the	O	864-867
AR	O	868-870
-	O	870-871
positive	O	871-879
xenografts	O	880-890
.	O	890-891

Only	O	892-896
four	O	897-901
miRNAs	O	902-908
(	O	909-910
miR	B	910-913
-	I	913-914
10a	I	914-917
,	O	917-918
miR	B	919-922
-	I	922-923
141	I	923-926
,	O	926-927
miR	B	928-931
-	I	931-932
150	I	932-935
*	I	935-936
,	O	936-937
and	O	938-941
miR	B	942-945
-	I	945-946
1225	I	946-950
-	I	950-951
5p	I	951-953
)	O	953-954
showed	O	955-961
similar	O	962-969
androgen	O	970-978
regulation	O	979-989
in	O	990-992
both	O	993-997
cell	O	998-1002
lines	O	1003-1008
and	O	1009-1012
xenografts	O	1013-1023
.	O	1023-1024

Of	O	1025-1027
those	O	1028-1033
,	O	1033-1034
miR	B	1035-1038
-	I	1038-1039
141	I	1039-1042
was	O	1043-1046
found	O	1047-1052
to	O	1053-1055
be	O	1056-1058
expressed	O	1059-1068
more	O	1069-1073
in	O	1074-1076
PC	O	1077-1079
and	O	1080-1083
CRPC	O	1084-1088
compared	O	1089-1097
to	O	1098-1100
benign	O	1101-1107
prostate	O	1108-1116
hyperplasia	O	1117-1128
.	O	1128-1129

Additionally	O	1130-1142
,	O	1142-1143
the	O	1144-1147
overexpression	O	1148-1162
of	O	1163-1165
miR	B	1166-1169
-	I	1169-1170
141	I	1170-1173
enhanced	O	1174-1182
growth	O	1183-1189
of	O	1190-1192
parental	O	1193-1201
LNCaP	O	1202-1207
cells	O	1208-1213
while	O	1214-1219
inhibition	O	1220-1230
of	O	1231-1233
miR	B	1234-1237
-	I	1237-1238
141	I	1238-1241
by	O	1242-1244
anti	O	1245-1249
-	B	1249-1250
miR	I	1250-1253
-	I	1253-1254
141	I	1254-1257
suppressed	O	1258-1268
the	O	1269-1272
growth	O	1273-1279
of	O	1280-1282
the	O	1283-1286
LNCaP	O	1287-1292
subline	O	1293-1300
overexpressing	O	1301-1315
AR	O	1316-1318
.	O	1318-1319

CONCLUSIONS	O	1320-1331
:	O	1331-1332
Only	O	1333-1337
a	O	1338-1339
few	O	1340-1343
miRNAs	O	1344-1350
were	O	1351-1355
found	O	1356-1361
to	O	1362-1364
be	O	1365-1367
androgen	O	1368-1376
-	O	1376-1377
regulated	O	1377-1386
in	O	1387-1389
both	O	1390-1394
cell	O	1395-1399
lines	O	1400-1405
and	O	1406-1409
xenografts	O	1410-1420
models	O	1421-1427
.	O	1427-1428

Of	O	1429-1431
those	O	1432-1437
,	O	1437-1438
the	O	1439-1442
expression	O	1443-1453
of	O	1454-1456
miR	B	1457-1460
-	I	1460-1461
141	I	1461-1464
was	O	1465-1468
upregulated	O	1469-1480
in	O	1481-1483
cancer	O	1484-1490
.	O	1490-1491

The	O	1492-1495
ectopic	O	1496-1503
overexpression	O	1504-1518
of	O	1519-1521
miR	B	1522-1525
-	I	1525-1526
141	I	1526-1529
increased	O	1530-1539
growth	O	1540-1546
of	O	1547-1549
LNCaP	O	1550-1555
cell	O	1556-1560
suggesting	O	1561-1571
it	O	1572-1574
may	O	1575-1578
contribute	O	1579-1589
to	O	1590-1592
the	O	1593-1596
progression	O	1597-1608
of	O	1609-1611
PC	O	1612-1614
.	O	1614-1615

NF	O	0-2
-	O	2-3
kappaB	O	3-9
down	O	10-14
-	O	14-15
regulates	O	15-24
expression	O	25-35
of	O	36-38
the	O	39-42
B	O	43-44
-	O	44-45
lymphoma	O	45-53
marker	O	54-60
CD10	O	61-65
through	O	66-73
a	O	74-75
miR	B	76-79
-	I	79-80
155	I	80-83
/	O	83-84
PU	O	84-86
.	O	86-87
1	O	87-88
pathway	O	89-96
.	O	96-97

Cell	O	98-102
-	O	102-103
surface	O	103-110
protein	O	111-118
CD10	O	119-123
is	O	124-126
a	O	127-128
prognostic	O	129-139
marker	O	140-146
for	O	147-150
diffuse	O	151-158
large	O	159-164
B	O	165-166
-	O	166-167
cell	O	167-171
lymphoma	O	172-180
(	O	181-182
DLBCL	O	182-187
)	O	187-188
,	O	188-189
where	O	190-195
high	O	196-200
expression	O	201-211
of	O	212-214
CD10	O	215-219
is	O	220-222
found	O	223-228
in	O	229-231
the	O	232-235
germinal	O	236-244
center	O	245-251
B	O	252-253
-	O	253-254
cell	O	254-258
(	O	259-260
GCB	O	260-263
)	O	263-264
subtype	O	265-272
and	O	273-276
CD10	O	277-281
expression	O	282-292
is	O	293-295
low	O	296-299
or	O	300-302
absent	O	303-309
in	O	310-312
the	O	313-316
activated	O	317-326
B	O	327-328
-	O	328-329
cell	O	329-333
(	O	334-335
ABC	O	335-338
)	O	338-339
subtype	O	340-347
.	O	347-348

As	O	349-351
compared	O	352-360
with	O	361-365
the	O	366-369
GCB	O	370-373
subtype	O	374-381
,	O	381-382
patients	O	383-391
with	O	392-396
ABC	O	397-400
DLBCL	O	401-406
have	O	407-411
a	O	412-413
poorer	O	414-420
prognosis	O	421-430
after	O	431-436
standard	O	437-445
treatment	O	446-455
,	O	455-456
and	O	457-460
ABC	O	461-464
tumor	O	465-470
cells	O	471-476
have	O	477-481
higher	O	482-488
NF	O	489-491
-	O	491-492
kappaB	O	492-498
activity	O	499-507
.	O	507-508

Herein	O	509-515
,	O	515-516
we	O	517-519
show	O	520-524
that	O	525-529
increased	O	530-539
expression	O	540-550
of	O	551-553
the	O	554-557
NF	O	558-560
-	O	560-561
kappaB	O	561-567
target	O	568-574
micro	O	575-580
-	O	580-581
RNA	O	581-584
miR	B	585-588
-	I	588-589
155	I	589-592
is	O	593-595
correlated	O	596-606
with	O	607-611
reduced	O	612-619
expression	O	620-630
of	O	631-633
transcription	O	634-647
factor	O	648-654
PU	O	655-657
.	O	657-658
1	O	658-659
and	O	660-663
CD10	O	664-668
in	O	669-671
several	O	672-679
B	O	680-681
-	O	681-682
lymphoma	O	682-690
cell	O	691-695
lines	O	696-701
.	O	701-702

Moreover	O	703-711
,	O	711-712
electromobility	O	713-728
shift	O	729-734
assays	O	735-741
and	O	742-745
luciferase	O	746-756
reporter	O	757-765
assays	O	766-772
indicate	O	773-781
that	O	782-786
PU	O	787-789
.	O	789-790
1	O	790-791
can	O	792-795
directly	O	796-804
activate	O	805-813
expression	O	814-824
from	O	825-829
the	O	830-833
CD10	O	834-838
promoter	O	839-847
.	O	847-848

Expression	O	849-859
of	O	860-862
a	O	863-864
DLBCL	O	865-870
-	O	870-871
derived	O	871-878
mutant	O	879-885
of	O	886-888
the	O	889-892
adaptor	O	893-900
CARD11	O	901-907
(	O	908-909
a	O	909-910
constitutive	O	911-923
activator	O	924-933
of	O	934-936
NF	O	937-939
-	O	939-940
kappaB	O	940-946
)	O	946-947
in	O	948-950
the	O	951-954
GCB	O	955-958
-	O	958-959
like	O	959-963
human	O	964-969
BJAB	O	970-974
cell	O	975-979
line	O	980-984
or	O	985-987
v	O	988-989
-	O	989-990
Rel	O	990-993
in	O	994-996
the	O	997-1000
chicken	O	1001-1008
DT40	O	1009-1013
B	O	1014-1015
-	O	1015-1016
lymphoma	O	1016-1024
cell	O	1025-1029
line	O	1030-1034
causes	O	1035-1041
reduced	O	1042-1049
expression	O	1050-1060
of	O	1061-1063
PU	O	1064-1066
.	O	1066-1067
1	O	1067-1068
.	O	1068-1069

The	O	1070-1073
CARD11	O	1074-1080
mutant	O	1081-1087
also	O	1088-1092
causes	O	1093-1099
a	O	1100-1101
decrease	O	1102-1110
in	O	1111-1113
CD10	O	1114-1118
levels	O	1119-1125
in	O	1126-1128
BJAB	O	1129-1133
cells	O	1134-1139
.	O	1139-1140

Similarly	O	1141-1150
,	O	1150-1151
overexpression	O	1152-1166
of	O	1167-1169
miR	B	1170-1173
-	I	1173-1174
155	I	1174-1177
,	O	1177-1178
which	O	1179-1184
is	O	1185-1187
known	O	1188-1193
to	O	1194-1196
down	O	1197-1201
-	O	1201-1202
regulate	O	1202-1210
PU	O	1211-1213
.	O	1213-1214
1	O	1214-1215
,	O	1215-1216
leads	O	1217-1222
to	O	1223-1225
reduced	O	1226-1233
expression	O	1234-1244
of	O	1245-1247
CD10	O	1248-1252
in	O	1253-1255
BJAB	O	1256-1260
cells	O	1261-1266
.	O	1266-1267

Finally	O	1268-1275
,	O	1275-1276
we	O	1277-1279
show	O	1280-1284
that	O	1285-1289
CD10	O	1290-1294
expression	O	1295-1305
is	O	1306-1308
reduced	O	1309-1316
in	O	1317-1319
BJAB	O	1320-1324
cells	O	1325-1330
after	O	1331-1336
treatment	O	1337-1346
with	O	1347-1351
the	O	1352-1355
NF	O	1356-1358
-	O	1358-1359
kappaB	O	1359-1365
inducer	O	1366-1373
lipopolysaccharide	O	1374-1392
(	O	1393-1394
LPS	O	1394-1397
)	O	1397-1398
.	O	1398-1399

Additionally	O	1400-1412
,	O	1412-1413
miR	B	1414-1417
-	I	1417-1418
155	I	1418-1421
is	O	1422-1424
induced	O	1425-1432
by	O	1433-1435
LPS	O	1436-1439
treatment	O	1440-1449
or	O	1450-1452
expression	O	1453-1463
of	O	1464-1466
the	O	1467-1470
CARD11	O	1471-1477
mutant	O	1478-1484
in	O	1485-1487
BJAB	O	1488-1492
cells	O	1493-1498
.	O	1498-1499

These	O	1500-1505
results	O	1506-1513
point	O	1514-1519
to	O	1520-1522
an	O	1523-1525
NF	O	1526-1528
-	O	1528-1529
kappaB	O	1529-1535
-	O	1535-1536
dependent	O	1536-1545
mechanism	O	1546-1555
for	O	1556-1559
down	O	1560-1564
-	O	1564-1565
regulation	O	1565-1575
of	O	1576-1578
CD10	O	1579-1583
in	O	1584-1586
B	O	1587-1588
-	O	1588-1589
cell	O	1589-1593
lymphoma	O	1594-1602
:	O	1602-1603
namely	O	1604-1610
,	O	1610-1611
that	O	1612-1616
increased	O	1617-1626
NF	O	1627-1629
-	O	1629-1630
kappaB	O	1630-1636
activity	O	1637-1645
leads	O	1646-1651
to	O	1652-1654
increased	O	1655-1664
miR	B	1665-1668
-	I	1668-1669
155	I	1669-1672
,	O	1672-1673
which	O	1674-1679
results	O	1680-1687
in	O	1688-1690
decreased	O	1691-1700
PU	O	1701-1703
.	O	1703-1704
1	O	1704-1705
,	O	1705-1706
and	O	1707-1710
consequently	O	1711-1723
reduced	O	1724-1731
CD10	O	1732-1736
mRNA	O	1737-1741
and	O	1742-1745
protein	O	1746-1753
.	O	1753-1754

Identification	O	0-14
of	O	15-17
differentially	O	18-32
expressed	O	33-42
microRNA	O	43-51
in	O	52-54
parathyroid	O	55-66
tumors	O	67-73
.	O	73-74

BACKGROUND	O	75-85
:	O	85-86
The	O	87-90
molecular	O	91-100
factors	O	101-108
that	O	109-113
control	O	114-121
parathyroid	O	122-133
tumorigenesis	O	134-147
are	O	148-151
poorly	O	152-158
understood	O	159-169
.	O	169-170

In	O	171-173
the	O	174-177
absence	O	178-185
of	O	186-188
local	O	189-194
invasion	O	195-203
or	O	204-206
metastasis	O	207-217
,	O	217-218
distinguishing	O	219-233
benign	O	234-240
from	O	241-245
malignant	O	246-255
parathyroid	O	256-267
neoplasm	O	268-276
is	O	277-279
difficult	O	280-289
on	O	290-292
histologic	O	293-303
examination	O	304-315
.	O	315-316

We	O	317-319
studied	O	320-327
the	O	328-331
microRNA	O	332-340
(	O	341-342
miRNA	O	342-347
)	O	347-348
profile	O	349-356
in	O	357-359
normal	O	360-366
,	O	366-367
hyperplastic	O	368-380
,	O	380-381
and	O	382-385
benign	O	386-392
and	O	393-396
malignant	O	397-406
parathyroid	O	407-418
tumors	O	419-425
to	O	426-428
better	O	429-435
understand	O	436-446
the	O	447-450
molecular	O	451-460
factors	O	461-468
that	O	469-473
may	O	474-477
play	O	478-482
a	O	483-484
role	O	485-489
in	O	490-492
parathyroid	O	493-504
tumorigenesis	O	505-518
and	O	519-522
that	O	523-527
may	O	528-531
serve	O	532-537
as	O	538-540
diagnostic	O	541-551
markers	O	552-559
for	O	560-563
parathyroid	O	564-575
carcinoma	O	576-585
.	O	585-586

METHODS	O	587-594
:	O	594-595
miRNA	O	596-601
arrays	O	602-608
containing	O	609-619
825	O	620-623
human	O	624-629
microRNAs	O	630-639
with	O	640-644
four	O	645-649
duplicate	O	650-659
probes	O	660-666
per	O	667-670
miRNA	O	671-676
were	O	677-681
used	O	682-686
to	O	687-689
profile	O	690-697
parathyroid	O	698-709
tumor	O	710-715
(	O	716-717
12	O	717-719
adenomas	O	720-728
,	O	728-729
9	O	730-731
carcinomas	O	732-742
,	O	742-743
and	O	744-747
15	O	748-750
hyperplastic	O	751-763
)	O	763-764
samples	O	765-772
normalized	O	773-783
to	O	784-786
four	O	787-791
reference	O	792-801
normal	O	802-808
parathyroid	O	809-820
glands	O	821-827
.	O	827-828

Differentially	O	829-843
expressed	O	844-853
miRNA	O	854-859
were	O	860-864
validated	O	865-874
by	O	875-877
real	O	878-882
-	O	882-883
time	O	883-887
quantitative	O	888-900
TaqMan	O	901-907
polymerase	O	908-918
chain	O	919-924
reaction	O	925-933
(	O	934-935
PCR	O	935-938
)	O	938-939
.	O	939-940

RESULTS	O	941-948
:	O	948-949
One	O	950-953
hundred	O	954-961
fifty	O	962-967
-	O	967-968
six	O	968-971
miRNAs	O	972-978
in	O	979-981
parathyroid	O	982-993
hyperplasia	O	994-1005
,	O	1005-1006
277	O	1007-1010
microRNAs	O	1011-1020
in	O	1021-1023
parathyroid	O	1024-1035
adenoma	O	1036-1043
,	O	1043-1044
and	O	1045-1048
167	O	1049-1052
microRNAs	O	1053-1062
in	O	1063-1065
parathyroid	O	1066-1077
carcinomas	O	1078-1088
were	O	1089-1093
significantly	O	1094-1107
dysregulated	O	1108-1120
as	O	1121-1123
compared	O	1124-1132
with	O	1133-1137
normal	O	1138-1144
parathyroid	O	1145-1156
glands	O	1157-1163
[	O	1164-1165
false	O	1165-1170
discovery	O	1171-1180
rate	O	1181-1185
(	O	1186-1187
FDR	O	1187-1190
)	O	1190-1191
<	O	1192-1193
0	O	1194-1195
.	O	1195-1196
05	O	1196-1198
]	O	1198-1199
.	O	1199-1200

By	O	1201-1203
supervised	O	1204-1214
clustering	O	1215-1225
analysis	O	1226-1234
,	O	1234-1235
all	O	1236-1239
parathyroid	O	1240-1251
carcinomas	O	1252-1262
clustered	O	1263-1272
together	O	1273-1281
.	O	1281-1282

Three	O	1283-1288
miRNAs	O	1289-1295
(	O	1296-1297
miR	B	1297-1300
-	I	1300-1301
26b	I	1301-1304
,	O	1304-1305
miR	B	1306-1309
-	I	1309-1310
30b	I	1310-1313
,	O	1313-1314
and	O	1315-1318
miR	B	1319-1322
-	I	1322-1323
126	I	1323-1326
*	I	1326-1327
)	O	1327-1328
were	O	1329-1333
significantly	O	1334-1347
dysregulated	O	1348-1360
between	O	1361-1368
parathyroid	O	1369-1380
carcinoma	O	1381-1390
and	O	1391-1394
parathyroid	O	1395-1406
adenoma	O	1407-1414
.	O	1414-1415

Receiver	O	1416-1424
-	O	1424-1425
operating	O	1425-1434
characteristic	O	1435-1449
curve	O	1450-1455
analysis	O	1456-1464
showed	O	1465-1471
mir	B	1472-1475
-	I	1475-1476
126	I	1476-1479
*	I	1479-1480
was	O	1481-1484
the	O	1485-1488
best	O	1489-1493
diagnostic	O	1494-1504
marker	O	1505-1511
,	O	1511-1512
with	O	1513-1517
area	O	1518-1522
under	O	1523-1528
the	O	1529-1532
curve	O	1533-1538
of	O	1539-1541
0	O	1542-1543
.	O	1543-1544
776	O	1544-1547
.	O	1547-1548

CONCLUSIONS	O	1549-1560
:	O	1560-1561
Most	O	1562-1566
miRNAs	O	1567-1573
are	O	1574-1577
downregulated	O	1578-1591
in	O	1592-1594
parathyroid	O	1595-1606
carcinoma	O	1607-1616
,	O	1616-1617
while	O	1618-1623
in	O	1624-1626
parathyroid	O	1627-1638
hyperplasia	O	1639-1650
most	O	1651-1655
miRNAs	O	1656-1662
are	O	1663-1666
upregulated	O	1667-1678
.	O	1678-1679

miRNA	O	1680-1685
profiling	O	1686-1695
shows	O	1696-1701
distinct	O	1702-1710
differentially	O	1711-1725
expressed	O	1726-1735
miRNAs	O	1736-1742
by	O	1743-1745
tumor	O	1746-1751
type	O	1752-1756
which	O	1757-1762
may	O	1763-1766
serve	O	1767-1772
as	O	1773-1775
helpful	O	1776-1783
adjunct	O	1784-1791
to	O	1792-1794
distinguish	O	1795-1806
parathyroid	O	1807-1818
adenoma	O	1819-1826
from	O	1827-1831
carcinoma	O	1832-1841
.	O	1841-1842

Knockdown	O	0-9
of	O	10-12
microRNA	B	13-21
-	I	21-22
21	I	22-24
inhibits	O	25-33
proliferation	O	34-47
and	O	48-51
increases	O	52-61
cell	O	62-66
death	O	67-72
by	O	73-75
targeting	O	76-85
programmed	O	86-96
cell	O	97-101
death	O	102-107
4	O	108-109
(	O	110-111
PDCD4	O	111-116
)	O	116-117
in	O	118-120
pancreatic	O	121-131
ductal	O	132-138
adenocarcinoma	O	139-153
.	O	153-154

OBJECTIVE	O	155-164
:	O	164-165
This	O	166-170
study	O	171-176
aims	O	177-181
to	O	182-184
examine	O	185-192
the	O	193-196
expression	O	197-207
of	O	208-210
a	O	211-212
panel	O	213-218
of	O	219-221
five	O	222-226
microRNAs	O	227-236
(	O	237-238
miRNA	O	238-243
)	O	243-244
in	O	245-247
pancreatic	O	248-258
ductal	O	259-265
adenocarcinoma	O	266-280
(	O	281-282
PDAC	O	282-286
)	O	286-287
and	O	288-291
the	O	292-295
functional	O	296-306
effect	O	307-313
of	O	314-316
miR	B	317-320
-	I	320-321
21	I	321-323
inhibition	O	324-334
in	O	335-337
PDAC	O	338-342
cell	O	343-347
lines	O	348-353
.	O	353-354

BACKGROUND	O	355-365
:	O	365-366
miRNA	O	367-372
are	O	373-376
short	O	377-382
,	O	382-383
non	O	384-387
-	O	387-388
coding	O	388-394
RNA	O	395-398
molecules	O	399-408
,	O	408-409
which	O	410-415
play	O	416-420
important	O	421-430
roles	O	431-436
in	O	437-439
several	O	440-447
cellular	O	448-456
processes	O	457-466
by	O	467-469
silencing	O	470-479
expression	O	480-490
of	O	491-493
their	O	494-499
target	O	500-506
genes	O	507-512
through	O	513-520
translational	O	521-534
repression	O	535-545
or	O	546-548
mRNA	O	549-553
degradation	O	554-565
.	O	565-566

They	O	567-571
are	O	572-575
often	O	576-581
aberrantly	O	582-592
expressed	O	593-602
in	O	603-605
cancer	O	606-612
,	O	612-613
and	O	614-617
this	O	618-622
dysregulation	O	623-636
can	O	637-640
promote	O	641-648
carcinogenesis	O	649-663
by	O	664-666
altering	O	667-675
the	O	676-679
expression	O	680-690
of	O	691-693
tumour	O	694-700
suppressor	O	701-711
or	O	712-714
oncogenes	O	715-724
.	O	724-725

METHODS	O	726-733
:	O	733-734
miRNA	O	735-740
expression	O	741-751
levels	O	752-758
were	O	759-763
measured	O	764-772
in	O	773-775
24	O	776-778
PDAC	O	779-783
tumour	O	784-790
/	O	790-791
matched	O	791-798
adjacent	O	799-807
normal	O	808-814
tissue	O	815-821
samples	O	822-829
and	O	830-833
three	O	834-839
PDAC	O	840-844
cell	O	845-849
lines	O	850-855
using	O	856-861
reverse	O	862-869
transcription	O	870-883
polymerase	O	884-894
chain	O	895-900
reaction	O	901-909
.	O	909-910

Levels	O	911-917
of	O	918-920
cell	O	921-925
proliferation	O	926-939
and	O	940-943
death	O	944-949
and	O	950-953
expression	O	954-964
of	O	965-967
programmed	O	968-978
cell	O	979-983
death	O	984-989
4	O	990-991
(	O	992-993
PDCD4	O	993-998
;	O	998-999
tumour	O	1000-1006
suppressor	O	1007-1017
)	O	1017-1018
were	O	1019-1023
studied	O	1024-1031
in	O	1032-1034
PDAC	O	1035-1039
cells	O	1040-1045
(	O	1046-1047
MIA	O	1047-1050
-	O	1050-1051
Pa	O	1051-1053
-	O	1053-1054
Ca	O	1054-1056
-	O	1056-1057
2	O	1057-1058
)	O	1058-1059
in	O	1060-1062
the	O	1063-1066
absence	O	1067-1074
or	O	1075-1077
presence	O	1078-1086
of	O	1087-1089
a	O	1090-1091
miR	B	1092-1095
-	I	1095-1096
21	I	1096-1098
inhibitor	O	1099-1108
.	O	1108-1109

RESULTS	O	1110-1117
:	O	1117-1118
PDAC	O	1119-1123
primary	O	1124-1131
tissues	O	1132-1139
and	O	1140-1143
cell	O	1144-1148
lines	O	1149-1154
displayed	O	1155-1164
a	O	1165-1166
consistent	O	1167-1177
upregulation	O	1178-1190
of	O	1191-1193
miR	B	1194-1197
-	I	1197-1198
21	I	1198-1200
(	O	1201-1202
P	O	1202-1203
<	O	1204-1205
0	O	1206-1207
.	O	1207-1208
0001	O	1208-1212
)	O	1212-1213
and	O	1214-1217
downregulation	O	1218-1232
of	O	1233-1235
both	O	1236-1240
miR	B	1241-1244
-	I	1244-1245
148a	I	1245-1249
(	O	1250-1251
P	O	1251-1252
<	O	1253-1254
0	O	1255-1256
.	O	1256-1257
0001	O	1257-1261
)	O	1261-1262
and	O	1263-1266
miR	B	1267-1270
-	I	1270-1271
375	I	1271-1274
(	O	1275-1276
P	O	1276-1277
<	O	1278-1279
0	O	1280-1281
.	O	1281-1282
0001	O	1282-1286
)	O	1286-1287
relative	O	1288-1296
to	O	1297-1299
adjacent	O	1300-1308
normal	O	1309-1315
tissue	O	1316-1322
.	O	1322-1323

Furthermore	O	1324-1335
,	O	1335-1336
miR	B	1337-1340
-	I	1340-1341
21	I	1341-1343
levels	O	1344-1350
in	O	1351-1353
the	O	1354-1357
primary	O	1358-1365
tumours	O	1366-1373
correlated	O	1374-1384
with	O	1385-1389
disease	O	1390-1397
stage	O	1398-1403
(	O	1404-1405
P	O	1405-1406
<	O	1407-1408
0	O	1409-1410
.	O	1410-1411
0001	O	1411-1415
)	O	1415-1416
.	O	1416-1417

Inhibition	O	1418-1428
of	O	1429-1431
miR	B	1432-1435
-	I	1435-1436
21	I	1436-1438
in	O	1439-1441
MIA	O	1442-1445
-	O	1445-1446
Pa	O	1446-1448
-	O	1448-1449
Ca	O	1449-1451
-	O	1451-1452
2	O	1452-1453
PDAC	O	1454-1458
cells	O	1459-1464
led	O	1465-1468
to	O	1469-1471
reduced	O	1472-1479
cell	O	1480-1484
proliferation	O	1485-1498
(	O	1499-1500
P	O	1500-1501
<	O	1502-1503
0	O	1504-1505
.	O	1505-1506
01	O	1506-1508
)	O	1508-1509
and	O	1510-1513
increased	O	1514-1523
cell	O	1524-1528
death	O	1529-1534
(	O	1535-1536
P	O	1536-1537
<	O	1538-1539
0	O	1540-1541
.	O	1541-1542
01	O	1542-1544
)	O	1544-1545
,	O	1545-1546
with	O	1547-1551
simultaneous	O	1552-1564
increase	O	1565-1573
in	O	1574-1576
levels	O	1577-1583
of	O	1584-1586
the	O	1587-1590
tumour	O	1591-1597
suppressor	O	1598-1608
,	O	1608-1609
PDCD4	O	1610-1615
(	O	1616-1617
P	O	1617-1618
<	O	1619-1620
0	O	1621-1622
.	O	1622-1623
01	O	1623-1625
)	O	1625-1626
.	O	1626-1627

CONCLUSION	O	1628-1638
:	O	1638-1639
miRNA	O	1640-1645
expression	O	1646-1656
profiles	O	1657-1665
may	O	1666-1669
be	O	1670-1672
used	O	1673-1677
as	O	1678-1680
biomarkers	O	1681-1691
for	O	1692-1695
detecting	O	1696-1705
pancreatic	O	1706-1716
cancer	O	1717-1723
.	O	1723-1724

Moreover	O	1725-1733
,	O	1733-1734
miR	B	1735-1738
-	I	1738-1739
21	I	1739-1741
could	O	1742-1747
be	O	1748-1750
a	O	1751-1752
predictor	O	1753-1762
of	O	1763-1765
disease	O	1766-1773
progression	O	1774-1785
and	O	1786-1789
a	O	1790-1791
possible	O	1792-1800
therapeutic	O	1801-1812
target	O	1813-1819
in	O	1820-1822
part	O	1823-1827
by	O	1828-1830
upregulating	O	1831-1843
PDCD4	O	1844-1849
in	O	1850-1852
pancreatic	O	1853-1863
cancer	O	1864-1870
.	O	1870-1871

MicroRNAs	B	0-9
144	I	10-13
,	O	13-14
145	B	15-18
,	O	18-19
and	O	20-23
214	B	24-27
are	O	28-31
down	O	32-36
-	O	36-37
regulated	O	37-46
in	O	47-49
primary	O	50-57
neurons	O	58-65
responding	O	66-76
to	O	77-79
sciatic	O	80-87
nerve	O	88-93
transection	O	94-105
.	O	105-106

MicroRNAs	O	107-116
(	O	117-118
miRNAs	O	118-124
)	O	124-125
play	O	126-130
an	O	131-133
important	O	134-143
role	O	144-148
in	O	149-151
the	O	152-155
development	O	156-167
,	O	167-168
differentiation	O	169-184
,	O	184-185
proliferation	O	186-199
,	O	199-200
survival	O	201-209
,	O	209-210
and	O	211-214
oncogenesis	O	215-226
of	O	227-229
cells	O	230-235
and	O	236-239
organisms	O	240-249
including	O	250-259
nervous	O	260-267
system	O	268-274
.	O	274-275

However	O	276-283
,	O	283-284
the	O	285-288
role	O	289-293
of	O	294-296
miRNAs	O	297-303
in	O	304-306
primary	O	307-314
neurons	O	315-322
of	O	323-325
dorsal	O	326-332
root	O	333-337
ganglion	O	338-346
(	O	347-348
DRG	O	348-351
)	O	351-352
after	O	353-358
injury	O	359-365
was	O	366-369
not	O	370-373
clear	O	374-379
.	O	379-380

In	O	381-383
this	O	384-388
study	O	389-394
,	O	394-395
a	O	396-397
miRNA	O	398-403
microarray	O	404-414
analysis	O	415-423
was	O	424-427
performed	O	428-437
,	O	437-438
and	O	439-442
a	O	443-444
total	O	445-450
of	O	451-453
21	O	454-456
miRNAs	O	457-463
were	O	464-468
found	O	469-474
to	O	475-477
be	O	478-480
down	O	481-485
-	O	485-486
regulated	O	486-495
following	O	496-505
unilateral	O	506-516
sciatic	O	517-524
nerve	O	525-530
transection	O	531-542
.	O	542-543

The	O	544-547
miR	B	548-551
-	I	551-552
144	I	552-555
,	O	555-556
miR	B	557-560
-	I	560-561
145	I	561-564
,	O	564-565
and	O	566-569
miR	B	570-573
-	I	573-574
214	I	574-577
were	O	578-582
further	O	583-590
validated	O	591-600
using	O	601-606
quantitative	O	607-619
reverse	O	620-627
transcriptase	O	628-641
PCR	O	642-645
(	O	646-647
qRT	O	647-650
-	O	650-651
PCR	O	651-654
)	O	654-655
.	O	655-656

Moreover	O	657-665
,	O	665-666
in	O	667-669
situ	O	670-674
hybridization	O	675-688
(	O	689-690
ISH	O	690-693
)	O	693-694
experiments	O	695-706
using	O	707-712
locked	O	713-719
nucleic	O	720-727
acid	O	728-732
(	O	733-734
LNA	O	734-737
)	O	737-738
-	O	738-739
modified	O	739-747
DNA	O	748-751
oligonucleotide	O	752-767
probes	O	768-774
verified	O	775-783
that	O	784-788
miR	B	789-792
-	I	792-793
144	I	793-796
,	O	796-797
miR	B	798-801
-	I	801-802
145	I	802-805
,	O	805-806
and	O	807-810
miR	B	811-814
-	I	814-815
214	I	815-818
were	O	819-823
expressed	O	824-833
in	O	834-836
primary	O	837-844
neurons	O	845-852
of	O	853-855
DRG	O	856-859
and	O	860-863
down	O	864-868
-	O	868-869
regulated	O	869-878
following	O	879-888
sciatic	O	889-896
nerve	O	897-902
transection	O	903-914
.	O	914-915

Predictions	O	916-927
of	O	928-930
potential	O	931-940
miRNA	O	941-946
targets	O	947-954
involved	O	955-963
were	O	964-968
identified	O	969-979
by	O	980-982
performing	O	983-993
a	O	994-995
bioinformatics	O	996-1010
analysis	O	1011-1019
.	O	1019-1020

These	O	1021-1026
predictions	O	1027-1038
were	O	1039-1043
tested	O	1044-1050
using	O	1051-1056
miRNA	O	1057-1062
luciferase	O	1063-1073
reporter	O	1074-1082
vectors	O	1083-1090
,	O	1090-1091
with	O	1092-1096
Robo2	O	1097-1102
and	O	1103-1106
srGAP2	O	1107-1113
evaluated	O	1114-1123
as	O	1124-1126
the	O	1127-1130
potential	O	1131-1140
targets	O	1141-1148
of	O	1149-1151
miR	B	1152-1155
-	I	1155-1156
145	I	1156-1159
and	O	1160-1163
miR	B	1164-1167
-	I	1167-1168
214	I	1168-1171
,	O	1171-1172
respectively	O	1173-1185
.	O	1185-1186

The	O	1187-1190
role	O	1191-1195
of	O	1196-1198
miR	B	1199-1202
-	I	1202-1203
145	I	1203-1206
in	O	1207-1209
cultured	O	1210-1218
primary	O	1219-1226
neurons	O	1227-1234
was	O	1235-1238
also	O	1239-1243
investigated	O	1244-1256
,	O	1256-1257
and	O	1258-1261
the	O	1262-1265
result	O	1266-1272
found	O	1273-1278
that	O	1279-1283
miR	B	1284-1287
-	I	1287-1288
145	I	1288-1291
miR	B	1292-1295
-	I	1295-1296
145	I	1296-1299
inhibited	O	1300-1309
neurite	O	1310-1317
growth	O	1318-1324
and	O	1325-1328
down	O	1329-1333
-	O	1333-1334
regulated	O	1334-1343
Robo2	O	1344-1349
expression	O	1350-1360
.	O	1360-1361

Finding	O	1362-1369
from	O	1370-1374
this	O	1375-1379
study	O	1380-1385
suggested	O	1386-1395
that	O	1396-1400
miRNAs	O	1401-1407
of	O	1408-1410
DRG	O	1411-1414
can	O	1415-1418
mediated	O	1419-1427
the	O	1428-1431
course	O	1432-1438
of	O	1439-1441
regeneration	O	1442-1454
including	O	1455-1464
through	O	1465-1472
Slit	O	1473-1477
-	O	1477-1478
Robo	O	1478-1482
-	O	1482-1483
srGAP	O	1483-1488
signaling	O	1489-1498
pathway	O	1499-1506
after	O	1507-1512
injury	O	1513-1519
.	O	1519-1520

miRNAs	O	0-6
control	O	7-14
insulin	O	15-22
content	O	23-30
in	O	31-33
pancreatic	O	34-44
beta	O	45-49
-	O	49-50
cells	O	50-55
via	O	56-59
downregulation	O	60-74
of	O	75-77
transcriptional	O	78-93
repressors	O	94-104
.	O	104-105

MicroRNAs	O	106-115
(	O	116-117
miRNAs	O	117-123
)	O	123-124
were	O	125-129
shown	O	130-135
to	O	136-138
be	O	139-141
important	O	142-151
for	O	152-155
pancreas	O	156-164
development	O	165-176
,	O	176-177
yet	O	178-181
their	O	182-187
roles	O	188-193
in	O	194-196
differentiated	O	197-211
beta	O	212-216
-	O	216-217
cells	O	217-222
remain	O	223-229
unclear	O	230-237
.	O	237-238

Here	O	239-243
,	O	243-244
we	O	245-247
show	O	248-252
that	O	253-257
miRNA	O	258-263
inactivation	O	264-276
in	O	277-279
beta	O	280-284
-	O	284-285
cells	O	285-290
of	O	291-293
adult	O	294-299
mice	O	300-304
results	O	305-312
in	O	313-315
a	O	316-317
striking	O	318-326
diabetic	O	327-335
phenotype	O	336-345
.	O	345-346

While	O	347-352
islet	O	353-358
architecture	O	359-371
is	O	372-374
intact	O	375-381
and	O	382-385
differentiation	O	386-401
markers	O	402-409
are	O	410-413
maintained	O	414-424
,	O	424-425
Dicer1	O	426-432
-	O	432-433
deficient	O	433-442
beta	O	443-447
-	O	447-448
cells	O	448-453
show	O	454-458
a	O	459-460
dramatic	O	461-469
decrease	O	470-478
in	O	479-481
insulin	O	482-489
content	O	490-497
and	O	498-501
insulin	O	502-509
mRNA	O	510-514
.	O	514-515

As	O	516-518
a	O	519-520
consequence	O	521-532
of	O	533-535
the	O	536-539
change	O	540-546
in	O	547-549
insulin	O	550-557
content	O	558-565
,	O	565-566
the	O	567-570
animals	O	571-578
become	O	579-585
diabetic	O	586-594
.	O	594-595

We	O	596-598
provide	O	599-606
evidence	O	607-615
for	O	616-619
involvement	O	620-631
of	O	632-634
a	O	635-636
set	O	637-640
of	O	641-643
miRNAs	O	644-650
in	O	651-653
regulating	O	654-664
insulin	O	665-672
synthesis	O	673-682
.	O	682-683

The	O	684-687
specific	O	688-696
knockdown	O	697-706
of	O	707-709
miR	B	710-713
-	I	713-714
24	I	714-716
,	O	716-717
miR	B	718-721
-	I	721-722
26	I	722-724
,	O	724-725
miR	B	726-729
-	I	729-730
182	I	730-733
or	O	734-736
miR	B	737-740
-	I	740-741
148	I	741-744
in	O	745-747
cultured	O	748-756
beta	O	757-761
-	O	761-762
cells	O	762-767
or	O	768-770
in	O	771-773
isolated	O	774-782
primary	O	783-790
islets	O	791-797
downregulates	O	798-811
insulin	O	812-819
promoter	O	820-828
activity	O	829-837
and	O	838-841
insulin	O	842-849
mRNA	O	850-854
levels	O	855-861
.	O	861-862

Further	O	863-870
,	O	870-871
miRNA	O	872-877
-	O	877-878
dependent	O	878-887
regulation	O	888-898
of	O	899-901
insulin	O	902-909
expression	O	910-920
is	O	921-923
associated	O	924-934
with	O	935-939
upregulation	O	940-952
of	O	953-955
transcriptional	O	956-971
repressors	O	972-982
,	O	982-983
including	O	984-993
Bhlhe22	O	994-1001
and	O	1002-1005
Sox6	O	1006-1010
.	O	1010-1011

Thus	O	1012-1016
,	O	1016-1017
miRNAs	O	1018-1024
in	O	1025-1027
the	O	1028-1031
adult	O	1032-1037
pancreas	O	1038-1046
act	O	1047-1050
in	O	1051-1053
a	O	1054-1055
new	O	1056-1059
network	O	1060-1067
that	O	1068-1072
reinforces	O	1073-1083
insulin	O	1084-1091
expression	O	1092-1102
by	O	1103-1105
reducing	O	1106-1114
the	O	1115-1118
expression	O	1119-1129
of	O	1130-1132
insulin	O	1133-1140
transcriptional	O	1141-1156
repressors	O	1157-1167
.	O	1167-1168

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
exhibits	O	12-20
antiangiogenic	O	21-35
function	O	36-44
by	O	45-47
targeting	O	48-57
RhoB	O	58-62
expression	O	63-73
in	O	74-76
endothelial	O	77-88
cells	O	89-94
.	O	94-95

BACKGROUND	O	96-106
:	O	106-107
MicroRNAs	O	108-117
(	O	118-119
miRNAs	O	119-125
)	O	125-126
are	O	127-130
endogenously	O	131-143
expressed	O	144-153
small	O	154-159
non	O	160-163
-	O	163-164
coding	O	164-170
RNAs	O	171-175
that	O	176-180
regulate	O	181-189
gene	O	190-194
expression	O	195-205
at	O	206-208
post	O	209-213
-	O	213-214
transcriptional	O	214-229
level	O	230-235
.	O	235-236

The	O	237-240
recent	O	241-247
discovery	O	248-257
of	O	258-260
the	O	261-264
involvement	O	265-276
of	O	277-279
these	O	280-285
RNAs	O	286-290
in	O	291-293
the	O	294-297
control	O	298-305
of	O	306-308
angiogenesis	O	309-321
renders	O	322-329
them	O	330-334
very	O	335-339
attractive	O	340-350
in	O	351-353
the	O	354-357
development	O	358-369
of	O	370-372
new	O	373-376
approaches	O	377-387
for	O	388-391
restoring	O	392-401
the	O	402-405
angiogenic	O	406-416
balance	O	417-424
.	O	424-425

Whereas	O	426-433
miRNA	B	434-439
-	I	439-440
21	I	440-442
has	O	443-446
been	O	447-451
demonstrated	O	452-464
to	O	465-467
be	O	468-470
highly	O	471-477
expressed	O	478-487
in	O	488-490
endothelial	O	491-502
cells	O	503-508
,	O	508-509
the	O	510-513
potential	O	514-523
function	O	524-532
of	O	533-535
this	O	536-540
miRNA	O	541-546
in	O	547-549
angiogenesis	O	550-562
has	O	563-566
never	O	567-572
been	O	573-577
investigated	O	578-590
.	O	590-591

METHODOLOGY	O	592-603
/	O	603-604
PRINCIPAL	O	604-613
FINDINGS	O	614-622
:	O	622-623
We	O	624-626
first	O	627-632
observed	O	633-641
in	O	642-644
endothelial	O	645-656
cells	O	657-662
a	O	663-664
negative	O	665-673
regulation	O	674-684
of	O	685-687
miR	B	688-691
-	I	691-692
21	I	692-694
expression	O	695-705
by	O	706-708
serum	O	709-714
and	O	715-718
bFGF	O	719-723
,	O	723-724
two	O	725-728
pro	O	729-732
-	O	732-733
angiogenic	O	733-743
factors	O	744-751
.	O	751-752

Then	O	753-757
using	O	758-763
in	O	764-766
vitro	O	767-772
angiogenic	O	773-783
assays	O	784-790
,	O	790-791
we	O	792-794
observed	O	795-803
that	O	804-808
miR	B	809-812
-	I	812-813
21	I	813-815
acts	O	816-820
as	O	821-823
a	O	824-825
negative	O	826-834
modulator	O	835-844
of	O	845-847
angiogenesis	O	848-860
.	O	860-861

miR	B	862-865
-	I	865-866
21	I	866-868
overexpression	O	869-883
reduced	O	884-891
endothelial	O	892-903
cell	O	904-908
proliferation	O	909-922
,	O	922-923
migration	O	924-933
and	O	934-937
the	O	938-941
ability	O	942-949
of	O	950-952
these	O	953-958
cells	O	959-964
to	O	965-967
form	O	968-972
tubes	O	973-978
whereas	O	979-986
miR	B	987-990
-	I	990-991
21	I	991-993
inhibition	O	994-1004
using	O	1005-1010
a	O	1011-1012
LNA	O	1013-1016
-	O	1016-1017
anti	O	1017-1021
-	O	1021-1022
miR	O	1022-1025
led	O	1026-1029
to	O	1030-1032
opposite	O	1033-1041
effects	O	1042-1049
.	O	1049-1050

Expression	O	1051-1061
of	O	1062-1064
miR	B	1065-1068
-	I	1068-1069
21	I	1069-1071
in	O	1072-1074
endothelial	O	1075-1086
cells	O	1087-1092
also	O	1093-1097
led	O	1098-1101
to	O	1102-1104
a	O	1105-1106
reduction	O	1107-1116
in	O	1117-1119
the	O	1120-1123
organization	O	1124-1136
of	O	1137-1139
actin	O	1140-1145
into	O	1146-1150
stress	O	1151-1157
fibers	O	1158-1164
,	O	1164-1165
which	O	1166-1171
may	O	1172-1175
explain	O	1176-1183
the	O	1184-1187
decrease	O	1188-1196
in	O	1197-1199
cell	O	1200-1204
migration	O	1205-1214
.	O	1214-1215

Further	O	1216-1223
mechanistic	O	1224-1235
studies	O	1236-1243
showed	O	1244-1250
that	O	1251-1255
miR	B	1256-1259
-	I	1259-1260
21	I	1260-1262
targets	O	1263-1270
RhoB	O	1271-1275
,	O	1275-1276
as	O	1277-1279
revealed	O	1280-1288
by	O	1289-1291
a	O	1292-1293
decrease	O	1294-1302
in	O	1303-1305
RhoB	O	1306-1310
expression	O	1311-1321
and	O	1322-1325
activity	O	1326-1334
in	O	1335-1337
miR	B	1338-1341
-	I	1341-1342
21	I	1342-1344
overexpressing	O	1345-1359
cells	O	1360-1365
.	O	1365-1366

RhoB	O	1367-1371
silencing	O	1372-1381
impairs	O	1382-1389
endothelial	O	1390-1401
cell	O	1402-1406
migration	O	1407-1416
and	O	1417-1420
tubulogenesis	O	1421-1434
,	O	1434-1435
thus	O	1436-1440
providing	O	1441-1450
a	O	1451-1452
possible	O	1453-1461
mechanism	O	1462-1471
for	O	1472-1475
miR	B	1476-1479
-	I	1479-1480
21	I	1480-1482
to	O	1483-1485
inhibit	O	1486-1493
angiogenesis	O	1494-1506
.	O	1506-1507

Finally	O	1508-1515
,	O	1515-1516
the	O	1517-1520
therapeutic	O	1521-1532
potential	O	1533-1542
of	O	1543-1545
miR	B	1546-1549
-	I	1549-1550
21	I	1550-1552
as	O	1553-1555
an	O	1556-1558
angiogenesis	O	1559-1571
inhibitor	O	1572-1581
was	O	1582-1585
demonstrated	O	1586-1598
in	O	1599-1601
vivo	O	1602-1606
in	O	1607-1609
a	O	1610-1611
mouse	O	1612-1617
model	O	1618-1623
of	O	1624-1626
choroidal	O	1627-1636
neovascularization	O	1637-1655
.	O	1655-1656

CONCLUSIONS	O	1657-1668
/	O	1668-1669
SIGNIFICANCE	O	1669-1681
:	O	1681-1682
Our	O	1683-1686
results	O	1687-1694
identify	O	1695-1703
miR	B	1704-1707
-	I	1707-1708
21	I	1708-1710
as	O	1711-1713
a	O	1714-1715
new	O	1716-1719
angiogenesis	O	1720-1732
inhibitor	O	1733-1742
and	O	1743-1746
suggest	O	1747-1754
that	O	1755-1759
inhibition	O	1760-1770
of	O	1771-1773
cell	O	1774-1778
migration	O	1779-1788
and	O	1789-1792
tubulogenesis	O	1793-1806
is	O	1807-1809
mediated	O	1810-1818
through	O	1819-1826
repression	O	1827-1837
of	O	1838-1840
RhoB	O	1841-1845
.	O	1845-1846

Genomic	O	0-7
loss	O	8-12
of	O	13-15
miR	B	16-19
-	I	19-20
486	I	20-23
regulates	O	24-33
tumor	O	34-39
progression	O	40-51
and	O	52-55
the	O	56-59
OLFM4	O	60-65
antiapoptotic	O	66-79
factor	O	80-86
in	O	87-89
gastric	O	90-97
cancer	O	98-104
.	O	104-105

PURPOSE	O	106-113
:	O	113-114
MicroRNAs	O	115-124
(	O	125-126
miRNA	O	126-131
)	O	131-132
play	O	133-137
pivotal	O	138-145
oncogenic	O	146-155
and	O	156-159
tumor	O	160-165
-	O	165-166
suppressor	O	166-176
roles	O	177-182
in	O	183-185
several	O	186-193
human	O	194-199
cancers	O	200-207
.	O	207-208

We	O	209-211
sought	O	212-218
to	O	219-221
discover	O	222-230
novel	O	231-236
tumor	O	237-242
-	O	242-243
suppressor	O	243-253
miRNAs	O	254-260
in	O	261-263
gastric	O	264-271
cancer	O	272-278
(	O	279-280
GC	O	280-282
)	O	282-283
.	O	283-284

EXPERIMENTAL	O	285-297
DESIGN	O	298-304
:	O	304-305
Using	O	306-311
Agilent	O	312-319
miRNA	O	320-325
microarrays	O	326-337
,	O	337-338
we	O	339-341
compared	O	342-350
miRNA	O	351-356
expression	O	357-367
profiles	O	368-376
of	O	377-379
40	O	380-382
primary	O	383-390
gastric	O	391-398
tumors	O	399-405
and	O	406-409
40	O	410-412
gastric	O	413-420
normal	O	421-427
tissues	O	428-435
,	O	435-436
identifying	O	437-448
miRNAs	O	449-455
significantly	O	456-469
downregulated	O	470-483
in	O	484-486
gastric	O	487-494
tumors	O	495-501
.	O	501-502

RESULTS	O	503-510
:	O	510-511
Among	O	512-517
the	O	518-521
top	O	522-525
80	O	526-528
miRNAs	O	529-535
differentially	O	536-550
expressed	O	551-560
between	O	561-568
gastric	O	569-576
tumors	O	577-583
and	O	584-587
normals	O	588-595
(	O	596-597
false	O	597-602
discovery	O	603-612
rate	O	613-617
<	O	618-619
0	O	620-621
.	O	621-622
01	O	622-624
)	O	624-625
,	O	625-626
we	O	627-629
identified	O	630-640
hsa	B	641-644
-	I	644-645
miR	I	645-648
-	I	648-649
486	I	649-652
(	O	653-654
miR	B	654-657
-	I	657-658
486	I	658-661
)	O	661-662
as	O	663-665
a	O	666-667
significantly	O	668-681
downregulated	O	682-695
miRNA	O	696-701
in	O	702-704
primary	O	705-712
GCs	O	713-716
and	O	717-720
GC	O	721-723
cell	O	724-728
lines	O	729-734
.	O	734-735

Restoration	O	736-747
of	O	748-750
miR	B	751-754
-	I	754-755
486	I	755-758
expression	O	759-769
in	O	770-772
GC	O	773-775
cell	O	776-780
lines	O	781-786
(	O	787-788
YCC3	O	788-792
,	O	792-793
SCH	O	794-797
and	O	798-801
AGS	O	802-805
)	O	805-806
caused	O	807-813
suppression	O	814-825
of	O	826-828
several	O	829-836
pro	O	837-840
-	O	840-841
oncogenic	O	841-850
traits	O	851-857
,	O	857-858
whereas	O	859-866
conversely	O	867-877
inhibiting	O	878-888
miR	B	889-892
-	I	892-893
486	I	893-896
expression	O	897-907
in	O	908-910
YCC6	O	911-915
GC	O	916-918
cells	O	919-924
enhanced	O	925-933
cellular	O	934-942
proliferation	O	943-956
.	O	956-957

Array	O	958-963
-	O	963-964
CGH	O	964-967
analysis	O	968-976
of	O	977-979
106	O	980-983
primary	O	984-991
GCs	O	992-995
revealed	O	996-1004
genomic	O	1005-1012
loss	O	1013-1017
of	O	1018-1020
the	O	1021-1024
miR	B	1025-1028
-	I	1028-1029
486	I	1029-1032
locus	O	1033-1038
in	O	1039-1041
approximately	O	1042-1055
25	O	1056-1058
%	O	1058-1059
to	O	1060-1062
30	O	1063-1065
%	O	1065-1066
of	O	1067-1069
GCs	O	1070-1073
,	O	1073-1074
including	O	1075-1084
two	O	1085-1088
tumors	O	1089-1095
with	O	1096-1100
focal	O	1101-1106
genomic	O	1107-1114
losses	O	1115-1121
specifically	O	1122-1134
deleting	O	1135-1143
miR	B	1144-1147
-	I	1147-1148
486	I	1148-1151
,	O	1151-1152
consistent	O	1153-1163
with	O	1164-1168
miR	B	1169-1172
-	I	1172-1173
486	I	1173-1176
playing	O	1177-1184
a	O	1185-1186
tumor	O	1187-1192
-	O	1192-1193
suppressive	O	1193-1204
role	O	1205-1209
.	O	1209-1210

Bioinformatic	O	1211-1224
analysis	O	1225-1233
identified	O	1234-1244
the	O	1245-1248
secreted	O	1249-1257
antiapoptotic	O	1258-1271
glycoprotein	O	1272-1284
OLFM4	O	1285-1290
as	O	1291-1293
a	O	1294-1295
potential	O	1296-1305
miR	B	1306-1309
-	I	1309-1310
486	I	1310-1313
target	O	1314-1320
.	O	1320-1321

Restoring	O	1322-1331
miR	B	1332-1335
-	I	1335-1336
486	I	1336-1339
expression	O	1340-1350
in	O	1351-1353
GC	O	1354-1356
cells	O	1357-1362
decreased	O	1363-1372
endogenous	O	1373-1383
OLFM4	O	1384-1389
transcript	O	1390-1400
and	O	1401-1404
protein	O	1405-1412
levels	O	1413-1419
,	O	1419-1420
and	O	1421-1424
also	O	1425-1429
inhibited	O	1430-1439
expression	O	1440-1450
of	O	1451-1453
luciferase	O	1454-1464
reporters	O	1465-1474
containing	O	1475-1485
an	O	1486-1488
OLFM4	O	1489-1494
3	O	1495-1496
'	O	1496-1497
untranslated	O	1498-1510
region	O	1511-1517
with	O	1518-1522
predicted	O	1523-1532
miR	B	1533-1536
-	I	1536-1537
486	I	1537-1540
binding	O	1541-1548
sites	O	1549-1554
.	O	1554-1555

Supporting	O	1556-1566
the	O	1567-1570
biological	O	1571-1581
relevance	O	1582-1591
of	O	1592-1594
OLFM4	O	1595-1600
as	O	1601-1603
a	O	1604-1605
miR	B	1606-1609
-	I	1609-1610
486	I	1610-1613
target	O	1614-1620
,	O	1620-1621
proliferation	O	1622-1635
in	O	1636-1638
GC	O	1639-1641
cells	O	1642-1647
was	O	1648-1651
also	O	1652-1656
significantly	O	1657-1670
reduced	O	1671-1678
by	O	1679-1681
OLFM4	O	1682-1687
silencing	O	1688-1697
.	O	1697-1698

CONCLUSIONS	O	1699-1710
:	O	1710-1711
miR	B	1712-1715
-	I	1715-1716
486	I	1716-1719
may	O	1720-1723
function	O	1724-1732
as	O	1733-1735
a	O	1736-1737
novel	O	1738-1743
tumor	O	1744-1749
-	O	1749-1750
suppressor	O	1750-1760
miRNA	O	1761-1766
in	O	1767-1769
GC	O	1770-1772
.	O	1772-1773

Its	O	1774-1777
antioncogenic	O	1778-1791
activity	O	1792-1800
may	O	1801-1804
involve	O	1805-1812
the	O	1813-1816
direct	O	1817-1823
targeting	O	1824-1833
and	O	1834-1837
inhibition	O	1838-1848
of	O	1849-1851
OLFM4	O	1852-1857
.	O	1857-1858

mSEL	O	0-4
-	O	4-5
1L	O	5-7
(	O	8-9
Suppressor	O	9-19
/	O	19-20
enhancer	O	20-28
Lin12	O	29-34
-	O	34-35
like	O	35-39
)	O	39-40
protein	O	41-48
levels	O	49-55
influence	O	56-65
murine	O	66-72
neural	O	73-79
stem	O	80-84
cell	O	85-89
self	O	90-94
-	O	94-95
renewal	O	95-102
and	O	103-106
lineage	O	107-114
commitment	O	115-125
.	O	125-126

Murine	O	127-133
SEL	O	134-137
-	O	137-138
1L	O	138-140
(	O	141-142
mSEL	O	142-146
-	O	146-147
1L	O	147-149
)	O	149-150
is	O	151-153
a	O	154-155
key	O	156-159
component	O	160-169
of	O	170-172
the	O	173-176
endoplasmic	O	177-188
reticulum	O	189-198
-	O	198-199
associated	O	199-209
degradation	O	210-221
pathway	O	222-229
.	O	229-230

It	O	231-233
is	O	234-236
essential	O	237-246
during	O	247-253
development	O	254-265
as	O	266-268
revealed	O	269-277
by	O	278-280
the	O	281-284
multi	O	285-290
-	O	290-291
organ	O	291-296
dysfunction	O	297-308
and	O	309-312
in	O	313-315
uterus	O	316-322
lethality	O	323-332
occurring	O	333-342
in	O	343-345
homozygous	O	346-356
mSEL	O	357-361
-	O	361-362
1L	O	362-364
-	O	364-365
deficient	O	365-374
mice	O	375-379
.	O	379-380

Here	O	381-385
we	O	386-388
show	O	389-393
that	O	394-398
mSEL	O	399-403
-	O	403-404
1L	O	404-406
is	O	407-409
highly	O	410-416
expressed	O	417-426
in	O	427-429
pluripotent	O	430-441
embryonic	O	442-451
stem	O	452-456
cells	O	457-462
and	O	463-466
multipotent	O	467-478
neural	O	479-485
stem	O	486-490
cells	O	491-496
(	O	497-498
NSCs	O	498-502
)	O	502-503
but	O	504-507
silenced	O	508-516
in	O	517-519
all	O	520-523
mature	O	524-530
neural	O	531-537
derivatives	O	538-549
(	O	550-551
i	O	551-552
.	O	552-553
e	O	553-554
.	O	554-555

astrocytes	O	556-566
,	O	566-567
oligodendrocytes	O	568-584
,	O	584-585
and	O	586-589
neurons	O	590-597
)	O	597-598
by	O	599-601
mmu	B	602-605
-	I	605-606
miR	I	606-609
-	I	609-610
183	I	610-613
.	O	613-614

NSCs	O	615-619
derived	O	620-627
from	O	628-632
homozygous	O	633-643
mSEL	O	644-648
-	O	648-649
1L	O	649-651
-	O	651-652
deficient	O	652-661
embryos	O	662-669
(	O	670-671
mSEL	O	671-675
-	O	675-676
1L	O	676-678
(	O	678-679
-	O	679-680
/	O	680-681
-	O	681-682
)	O	682-683
NSCs	O	684-688
)	O	688-689
fail	O	690-694
to	O	695-697
proliferate	O	698-709
in	O	710-712
vitro	O	713-718
,	O	718-719
show	O	720-724
a	O	725-726
drastic	O	727-734
reduction	O	735-744
of	O	745-747
the	O	748-751
Notch	O	752-757
effector	O	758-766
HES	O	767-770
-	O	770-771
5	O	771-772
,	O	772-773
and	O	774-777
reveal	O	778-784
a	O	785-786
significant	O	787-798
down	O	799-803
-	O	803-804
modulation	O	804-814
of	O	815-817
the	O	818-821
early	O	822-827
neural	O	828-834
progenitor	O	835-845
markers	O	846-853
PAX	O	854-857
-	O	857-858
6	O	858-859
and	O	860-863
OLIG	O	864-868
-	O	868-869
2	O	869-870
,	O	870-871
when	O	872-876
compared	O	877-885
with	O	886-890
the	O	891-894
wild	O	895-899
type	O	900-904
(	O	905-906
mSEL	O	906-910
-	O	910-911
1L	O	911-913
(	O	913-914
+	O	914-915
/	O	915-916
+	O	916-917
)	O	917-918
NSCs	O	919-923
)	O	923-924
counterpart	O	925-936
.	O	936-937

Furthermore	O	938-949
,	O	949-950
these	O	951-956
cells	O	957-962
are	O	963-966
almost	O	967-973
completely	O	974-984
deprived	O	985-993
of	O	994-996
the	O	997-1000
neural	O	1001-1007
marker	O	1008-1014
Nestin	O	1015-1021
,	O	1021-1022
display	O	1023-1030
a	O	1031-1032
significant	O	1033-1044
decrease	O	1045-1053
of	O	1054-1056
SOX	O	1057-1060
-	O	1060-1061
2	O	1061-1062
expression	O	1063-1073
,	O	1073-1074
and	O	1075-1078
rapidly	O	1079-1086
undergo	O	1087-1094
premature	O	1095-1104
astrocytic	O	1105-1115
commitment	O	1116-1126
and	O	1127-1130
apoptosis	O	1131-1140
.	O	1140-1141

The	O	1142-1145
data	O	1146-1150
suggest	O	1151-1158
severe	O	1159-1165
self	O	1166-1170
-	O	1170-1171
renewal	O	1171-1178
defects	O	1179-1186
occurring	O	1187-1196
in	O	1197-1199
these	O	1200-1205
cells	O	1206-1211
probably	O	1212-1220
mediated	O	1221-1229
by	O	1230-1232
misregulation	O	1233-1246
of	O	1247-1249
the	O	1250-1253
Notch	O	1254-1259
signaling	O	1260-1269
.	O	1269-1270

The	O	1271-1274
results	O	1275-1282
reported	O	1283-1291
here	O	1292-1296
denote	O	1297-1303
mSEL	O	1304-1308
-	O	1308-1309
1L	O	1309-1311
as	O	1312-1314
a	O	1315-1316
primitive	O	1317-1326
marker	O	1327-1333
with	O	1334-1338
a	O	1339-1340
possible	O	1341-1349
involvement	O	1350-1361
in	O	1362-1364
the	O	1365-1368
regulation	O	1369-1379
of	O	1380-1382
neural	O	1383-1389
progenitor	O	1390-1400
stemness	O	1401-1409
maintenance	O	1410-1421
and	O	1422-1425
lineage	O	1426-1433
determination	O	1434-1447
.	O	1447-1448

Association	O	0-11
of	O	12-14
MiR	B	15-18
-	I	18-19
126	I	19-22
with	O	23-27
soluble	O	28-35
mesothelin	O	36-46
-	O	46-47
related	O	47-54
peptides	O	55-63
,	O	63-64
a	O	65-66
marker	O	67-73
for	O	74-77
malignant	O	78-87
mesothelioma	O	88-100
.	O	100-101

BACKGROUND	O	102-112
:	O	112-113
Improved	O	114-122
detection	O	123-132
methods	O	133-140
for	O	141-144
diagnosis	O	145-154
of	O	155-157
malignant	O	158-167
pleural	O	168-175
mesothelioma	O	176-188
(	O	189-190
MPM	O	190-193
)	O	193-194
are	O	195-198
essential	O	199-208
for	O	209-212
early	O	213-218
and	O	219-222
reliable	O	223-231
detection	O	232-241
as	O	242-244
well	O	245-249
as	O	250-252
treatment	O	253-262
.	O	262-263

Since	O	264-269
recent	O	270-276
data	O	277-281
point	O	282-287
to	O	288-290
abnormal	O	291-299
levels	O	300-306
of	O	307-309
microRNAs	O	310-319
(	O	320-321
miRNAs	O	321-327
)	O	327-328
in	O	329-331
tumors	O	332-338
,	O	338-339
we	O	340-342
hypothesized	O	343-355
that	O	356-360
a	O	361-362
profile	O	363-370
of	O	371-373
deregulated	O	374-385
miRNAs	O	386-392
may	O	393-396
be	O	397-399
a	O	400-401
marker	O	402-408
of	O	409-411
MPM	O	412-415
and	O	416-419
that	O	420-424
the	O	425-428
levels	O	429-435
of	O	436-438
specific	O	439-447
miRNAs	O	448-454
may	O	455-458
be	O	459-461
used	O	462-466
for	O	467-470
monitoring	O	471-481
its	O	482-485
progress	O	486-494
.	O	494-495

METHODS	O	496-503
AND	O	504-507
RESULTS	O	508-515
:	O	515-516
miRNAs	O	517-523
isolated	O	524-532
from	O	533-537
fresh	O	538-543
-	O	543-544
frozen	O	544-550
biopsies	O	551-559
of	O	560-562
MPM	O	563-566
patients	O	567-575
were	O	576-580
tested	O	581-587
for	O	588-591
the	O	592-595
expression	O	596-606
of	O	607-609
88	O	610-612
types	O	613-618
of	O	619-621
miRNA	O	622-627
involved	O	628-636
in	O	637-639
cancerogenesis	O	640-654
.	O	654-655

Most	O	656-660
of	O	661-663
the	O	664-667
tested	O	668-674
miRNAs	O	675-681
were	O	682-686
downregulated	O	687-700
in	O	701-703
the	O	704-707
malignant	O	708-717
tissues	O	718-725
compared	O	726-734
with	O	735-739
the	O	740-743
normal	O	744-750
tissues	O	751-758
.	O	758-759

Of	O	760-762
eight	O	763-768
significantly	O	769-782
downregulated	O	783-796
,	O	796-797
three	O	798-803
miRNAs	O	804-810
were	O	811-815
assayed	O	816-823
in	O	824-826
cancerous	O	827-836
tissue	O	837-843
and	O	844-847
adjacent	O	848-856
non	O	857-860
-	O	860-861
cancerous	O	861-870
tissue	O	871-877
sample	O	878-884
pairs	O	885-890
collected	O	891-900
from	O	901-905
27	O	906-908
formalin	O	909-917
-	O	917-918
fixed	O	918-923
,	O	923-924
paraffin	O	925-933
-	O	933-934
embedded	O	934-942
MPM	O	943-946
tissues	O	947-954
by	O	955-957
quantitative	O	958-970
RT	O	971-973
-	O	973-974
PCR	O	974-977
.	O	977-978

Among	O	979-984
the	O	985-988
miRNAs	O	989-995
tested	O	996-1002
,	O	1002-1003
only	O	1004-1008
miR	B	1009-1012
-	I	1012-1013
126	I	1013-1016
significantly	O	1017-1030
remained	O	1031-1039
downregulated	O	1040-1053
in	O	1054-1056
the	O	1057-1060
malignant	O	1061-1070
tissues	O	1071-1078
.	O	1078-1079

Furthermore	O	1080-1091
,	O	1091-1092
the	O	1093-1096
performance	O	1097-1108
of	O	1109-1111
the	O	1112-1115
selected	O	1116-1124
miR	B	1125-1128
-	I	1128-1129
126	I	1129-1132
as	O	1133-1135
biomarker	O	1136-1145
was	O	1146-1149
evaluated	O	1150-1159
in	O	1160-1162
serum	O	1163-1168
samples	O	1169-1176
of	O	1177-1179
asbestos	O	1180-1188
-	O	1188-1189
exposed	O	1189-1196
subjects	O	1197-1205
and	O	1206-1209
MPM	O	1210-1213
patients	O	1214-1222
and	O	1223-1226
compared	O	1227-1235
with	O	1236-1240
controls	O	1241-1249
.	O	1249-1250

MiR	B	1251-1254
-	I	1254-1255
126	I	1255-1258
was	O	1259-1262
not	O	1263-1266
affected	O	1267-1275
by	O	1276-1278
asbestos	O	1279-1287
exposure	O	1288-1296
,	O	1296-1297
whereas	O	1298-1305
it	O	1306-1308
was	O	1309-1312
found	O	1313-1318
strongly	O	1319-1327
associated	O	1328-1338
with	O	1339-1343
VEGF	O	1344-1348
serum	O	1349-1354
levels	O	1355-1361
.	O	1361-1362

Levels	O	1363-1369
of	O	1370-1372
miR	B	1373-1376
-	I	1376-1377
126	I	1377-1380
in	O	1381-1383
serum	O	1384-1389
,	O	1389-1390
and	O	1391-1394
its	O	1395-1398
levels	O	1399-1405
in	O	1406-1408
patients	O	1409-1417
'	O	1417-1418
serum	O	1419-1424
in	O	1425-1427
association	O	1428-1439
with	O	1440-1444
a	O	1445-1446
specific	O	1447-1455
marker	O	1456-1462
of	O	1463-1465
MPM	O	1466-1469
,	O	1469-1470
SMRPs	O	1471-1476
,	O	1476-1477
correlate	O	1478-1487
with	O	1488-1492
subjects	O	1493-1501
at	O	1502-1504
high	O	1505-1509
risk	O	1510-1514
to	O	1515-1517
develop	O	1518-1525
MPM	O	1526-1529
.	O	1529-1530

CONCLUSIONS	O	1531-1542
AND	O	1543-1546
SIGNIFICANCE	O	1547-1559
:	O	1559-1560
We	O	1561-1563
propose	O	1564-1571
miR	B	1572-1575
-	I	1575-1576
126	I	1576-1579
,	O	1579-1580
in	O	1581-1583
association	O	1584-1595
with	O	1596-1600
SMRPs	O	1601-1606
,	O	1606-1607
as	O	1608-1610
a	O	1611-1612
marker	O	1613-1619
for	O	1620-1623
early	O	1624-1629
detection	O	1630-1639
of	O	1640-1642
MPM	O	1643-1646
.	O	1646-1647

The	O	1648-1651
identification	O	1652-1666
of	O	1667-1669
tumor	O	1670-1675
biomarkers	O	1676-1686
used	O	1687-1691
alone	O	1692-1697
or	O	1698-1700
,	O	1700-1701
in	O	1702-1704
particular	O	1705-1715
,	O	1715-1716
in	O	1717-1719
combination	O	1720-1731
could	O	1732-1737
greatly	O	1738-1745
facilitate	O	1746-1756
the	O	1757-1760
surveillance	O	1761-1773
procedure	O	1774-1783
for	O	1784-1787
cohorts	O	1788-1795
of	O	1796-1798
subjects	O	1799-1807
exposed	O	1808-1815
to	O	1816-1818
asbestos	O	1819-1827
.	O	1827-1828

Circulating	O	0-11
micro	O	12-17
-	O	17-18
RNA	O	18-21
expression	O	22-32
profiles	O	33-41
in	O	42-44
early	O	45-50
stage	O	51-56
nonsmall	O	57-65
cell	O	66-70
lung	O	71-75
cancer	O	76-82
.	O	82-83

Circulating	O	84-95
micro	O	96-101
-	O	101-102
RNA	O	102-105
(	O	106-107
miR	O	107-110
)	O	110-111
profiles	O	112-120
have	O	121-125
been	O	126-130
proposed	O	131-139
as	O	140-142
promising	O	143-152
diagnostic	O	153-163
and	O	164-167
prognostic	O	168-178
biomarkers	O	179-189
for	O	190-193
cancer	O	194-200
,	O	200-201
including	O	202-211
lung	O	212-216
cancer	O	217-223
.	O	223-224

We	O	225-227
have	O	228-232
developed	O	233-242
methods	O	243-250
to	O	251-253
accurately	O	254-264
and	O	265-268
reproducibly	O	269-281
measure	O	282-289
micro	O	290-295
-	O	295-296
RNA	O	296-299
levels	O	300-306
in	O	307-309
serum	O	310-315
and	O	316-319
plasma	O	320-326
.	O	326-327

Here	O	328-332
,	O	332-333
we	O	334-336
study	O	337-342
paired	O	343-349
serum	O	350-355
and	O	356-359
plasma	O	360-366
samples	O	367-374
from	O	375-379
220	O	380-383
patients	O	384-392
with	O	393-397
early	O	398-403
stage	O	404-409
nonsmall	O	410-418
cell	O	419-423
lung	O	424-428
cancer	O	429-435
(	O	436-437
NSCLC	O	437-442
)	O	442-443
and	O	444-447
220	O	448-451
matched	O	452-459
controls	O	460-468
.	O	468-469

We	O	470-472
use	O	473-476
qRT	O	477-480
-	O	480-481
PCR	O	481-484
to	O	485-487
measure	O	488-495
the	O	496-499
circulating	O	500-511
levels	O	512-518
of	O	519-521
30	O	522-524
different	O	525-534
miRs	O	535-539
that	O	540-544
have	O	545-549
previously	O	550-560
been	O	561-565
reported	O	566-574
to	O	575-577
be	O	578-580
differently	O	581-592
expressed	O	593-602
in	O	603-605
lung	O	606-610
cancer	O	611-617
tissue	O	618-624
.	O	624-625

Duplicate	O	626-635
RNA	O	636-639
extractions	O	640-651
were	O	652-656
performed	O	657-666
for	O	667-670
10	O	671-673
%	O	673-674
of	O	675-677
all	O	678-681
samples	O	682-689
,	O	689-690
and	O	691-694
micro	O	695-700
-	O	700-701
RNA	O	701-704
measurements	O	705-717
were	O	718-722
highly	O	723-729
correlated	O	730-740
among	O	741-746
those	O	747-752
duplicates	O	753-763
.	O	763-764

This	O	765-769
demonstrates	O	770-782
high	O	783-787
reproducibility	O	788-803
of	O	804-806
our	O	807-810
assay	O	811-816
.	O	816-817

The	O	818-821
expressions	O	822-833
of	O	834-836
miR	B	837-840
-	I	840-841
146b	I	841-845
,	O	845-846
miR	B	847-850
-	I	850-851
221	I	851-854
,	O	854-855
let	B	856-859
-	I	859-860
7a	I	860-862
,	O	862-863
miR	B	864-867
-	I	867-868
155	I	868-871
,	O	871-872
miR	B	873-876
-	I	876-877
17	I	877-879
-	I	879-880
5p	I	880-882
,	O	882-883
miR	B	884-887
-	I	887-888
27a	I	888-891
and	O	892-895
miR	B	896-899
-	I	899-900
106a	I	900-904
were	O	905-909
significantly	O	910-923
reduced	O	924-931
in	O	932-934
the	O	935-938
serum	O	939-944
of	O	945-947
NSCLC	O	948-953
cases	O	954-959
,	O	959-960
while	O	961-966
miR	B	967-970
-	I	970-971
29c	I	971-974
was	O	975-978
significantly	O	979-992
increased	O	993-1002
.	O	1002-1003

No	O	1004-1006
significant	O	1007-1018
differences	O	1019-1030
were	O	1031-1035
observed	O	1036-1044
in	O	1045-1047
plasma	O	1048-1054
of	O	1055-1057
patients	O	1058-1066
compared	O	1067-1075
with	O	1076-1080
controls	O	1081-1089
.	O	1089-1090

Overall	O	1091-1098
,	O	1098-1099
expression	O	1100-1110
levels	O	1111-1117
in	O	1118-1120
serum	O	1121-1126
did	O	1127-1130
not	O	1131-1134
correlate	O	1135-1144
well	O	1145-1149
with	O	1150-1154
levels	O	1155-1161
in	O	1162-1164
plasma	O	1165-1171
.	O	1171-1172

In	O	1173-1175
secondary	O	1176-1185
analyses	O	1186-1194
,	O	1194-1195
reduced	O	1196-1203
plasma	O	1204-1210
expression	O	1211-1221
of	O	1222-1224
let	B	1225-1228
-	I	1228-1229
7b	I	1229-1231
was	O	1232-1235
modestly	O	1236-1244
associated	O	1245-1255
with	O	1256-1260
worse	O	1261-1266
cancer	O	1267-1273
-	O	1273-1274
specific	O	1274-1282
mortality	O	1283-1292
in	O	1293-1295
all	O	1296-1299
patients	O	1300-1308
,	O	1308-1309
and	O	1310-1313
reduced	O	1314-1321
serum	O	1322-1327
expression	O	1328-1338
of	O	1339-1341
miR	B	1342-1345
-	I	1345-1346
223	I	1346-1349
was	O	1350-1353
modestly	O	1354-1362
associated	O	1363-1373
with	O	1374-1378
cancer	O	1379-1385
-	O	1385-1386
specific	O	1386-1394
mortality	O	1395-1404
in	O	1405-1407
stage	O	1408-1413
IA	O	1414-1416
/	O	1416-1417
B	O	1417-1418
patients	O	1419-1427
.	O	1427-1428

MiR	O	1429-1432
profiles	O	1433-1441
also	O	1442-1446
showed	O	1447-1453
considerable	O	1454-1466
differences	O	1467-1478
comparing	O	1479-1488
African	O	1489-1496
American	O	1497-1505
and	O	1506-1509
European	O	1510-1518
Americans	O	1519-1528
.	O	1528-1529

In	O	1530-1532
summary	O	1533-1540
,	O	1540-1541
we	O	1542-1544
found	O	1545-1550
significant	O	1551-1562
differences	O	1563-1574
in	O	1575-1577
miR	O	1578-1581
expression	O	1582-1592
when	O	1593-1597
comparing	O	1598-1607
cases	O	1608-1613
and	O	1614-1617
controls	O	1618-1626
and	O	1627-1630
find	O	1631-1635
evidence	O	1636-1644
that	O	1645-1649
expression	O	1650-1660
of	O	1661-1663
let	B	1664-1667
-	I	1667-1668
7b	I	1668-1670
is	O	1671-1673
associated	O	1674-1684
with	O	1685-1689
prognosis	O	1690-1699
in	O	1700-1702
NSCLC	O	1703-1708
.	O	1708-1709

MicroRNA	B	0-8
-	I	8-9
98	I	9-11
negatively	O	12-22
regulates	O	23-32
IL	O	33-35
-	O	35-36
10	O	36-38
production	O	39-49
and	O	50-53
endotoxin	O	54-63
tolerance	O	64-73
in	O	74-76
macrophages	O	77-88
after	O	89-94
LPS	O	95-98
stimulation	O	99-110
.	O	110-111

Interleukin	O	112-123
10	O	124-126
(	O	127-128
IL	O	128-130
-	O	130-131
10	O	131-133
)	O	133-134
is	O	135-137
a	O	138-139
potent	O	140-146
anti	O	147-151
-	O	151-152
inflammatory	O	152-164
cytokine	O	165-173
that	O	174-178
is	O	179-181
crucial	O	182-189
for	O	190-193
dampening	O	194-203
the	O	204-207
inflammatory	O	208-220
response	O	221-229
after	O	230-235
pathogen	O	236-244
invasion	O	245-253
,	O	253-254
and	O	255-258
was	O	259-262
found	O	263-268
to	O	269-271
be	O	272-274
produced	O	275-283
by	O	284-286
macrophages	O	287-298
after	O	299-304
exposure	O	305-313
to	O	314-316
lipopolysaccharide	O	317-335
(	O	336-337
LPS	O	337-340
)	O	340-341
.	O	341-342

It	O	343-345
remains	O	346-353
unclear	O	354-361
whether	O	362-369
microRNA	O	370-378
-	O	378-379
mediated	O	379-387
regulatory	O	388-398
mechanism	O	399-408
is	O	409-411
involved	O	412-420
in	O	421-423
LPS	O	424-427
-	O	427-428
induced	O	428-435
IL	O	436-438
-	O	438-439
10	O	439-441
production	O	442-452
.	O	452-453

Here	O	454-458
we	O	459-461
reported	O	462-470
that	O	471-475
miR	B	476-479
-	I	479-480
98	I	480-482
expression	O	483-493
in	O	494-496
macrophages	O	497-508
significantly	O	509-522
decreased	O	523-532
following	O	533-542
LPS	O	543-546
stimulation	O	547-558
.	O	558-559

We	O	560-562
also	O	563-567
found	O	568-573
that	O	574-578
miR	B	579-582
-	I	582-583
98	I	583-585
targets	O	586-593
the	O	594-597
3	O	598-599
'	O	599-600
untranslated	O	600-612
region	O	613-619
of	O	620-622
IL	O	623-625
-	O	625-626
10	O	626-628
transcript	O	629-639
.	O	639-640

Overexpression	O	641-655
of	O	656-658
miR	B	659-662
-	I	662-663
98	I	663-665
inhibited	O	666-675
TLR4	O	676-680
-	O	680-681
triggered	O	681-690
IL	O	691-693
-	O	693-694
10	O	694-696
production	O	697-707
and	O	708-711
promoted	O	712-720
COX	O	721-724
-	O	724-725
2	O	725-726
expression	O	727-737
.	O	737-738

We	O	739-741
further	O	742-749
demonstrated	O	750-762
that	O	763-767
miR	B	768-771
-	I	771-772
98	I	772-774
significantly	O	775-788
mitigated	O	789-798
the	O	799-802
induction	O	803-812
of	O	813-815
endotoxin	O	816-825
tolerance	O	826-835
,	O	835-836
suggesting	O	837-847
that	O	848-852
miR	B	853-856
-	I	856-857
98	I	857-859
-	O	859-860
mediated	O	860-868
posttranscriptional	O	869-888
control	O	889-896
could	O	897-902
potentially	O	903-914
be	O	915-917
involved	O	918-926
in	O	927-929
fine	O	930-934
tuning	O	935-941
the	O	942-945
critical	O	946-954
level	O	955-960
of	O	961-963
IL	O	964-966
-	O	966-967
10	O	967-969
production	O	970-980
in	O	981-983
endotoxin	O	984-993
tolerance	O	994-1003
.	O	1003-1004

Differentially	O	0-14
expressed	O	15-24
micoRNAs	O	25-33
in	O	34-36
human	O	37-42
oocytes	O	43-50
.	O	50-51

PURPOSE	O	52-59
:	O	59-60
To	O	61-63
identify	O	64-72
differentially	O	73-87
expressed	O	88-97
microRNAs	O	98-107
(	O	108-109
miRNAs	O	109-115
)	O	115-116
and	O	117-120
expression	O	121-131
patterns	O	132-140
of	O	141-143
specific	O	144-152
miRNAs	O	153-159
during	O	160-166
meiosis	O	167-174
in	O	175-177
human	O	178-183
oocytes	O	184-191
.	O	191-192

MATERIALS	O	193-202
AND	O	203-206
METHODS	O	207-214
:	O	214-215
To	O	216-218
identify	O	219-227
differentially	O	228-242
expressed	O	243-252
miRNAs	O	253-259
,	O	259-260
GV	O	261-263
oocytes	O	264-271
and	O	272-275
MII	O	276-279
oocytes	O	280-287
matured	O	288-295
at	O	296-298
conventional	O	299-311
FSH	O	312-315
levels	O	316-322
(	O	323-324
5	O	324-325
.	O	325-326
5	O	326-327
ng	O	328-330
/	O	330-331
ml	O	331-333
)	O	333-334
were	O	335-339
analyzed	O	340-348
by	O	349-351
miRNA	O	352-357
microarray	O	358-368
.	O	368-369

Real	O	370-374
-	O	374-375
time	O	375-379
RT	O	380-382
-	O	382-383
PCR	O	383-386
was	O	387-390
used	O	391-395
to	O	396-398
confirm	O	399-406
the	O	407-410
changed	O	411-418
miRNAs	O	419-425
.	O	425-426

To	O	427-429
validate	O	430-438
the	O	439-442
dynamic	O	443-450
changes	O	451-458
of	O	459-461
miRNAs	O	462-468
from	O	469-473
GV	O	474-476
to	O	477-479
MII	O	480-483
stages	O	484-490
,	O	490-491
oocytes	O	492-499
were	O	500-504
divided	O	505-512
into	O	513-517
four	O	518-522
groups	O	523-529
(	O	530-531
#	O	531-532
1	O	532-533
-	O	533-534
4	O	534-535
)	O	535-536
,	O	536-537
corresponding	O	538-551
to	O	552-554
GV	O	555-557
oocytes	O	558-565
,	O	565-566
MI	O	567-569
oocytes	O	570-577
,	O	577-578
MII	O	579-582
oocytes	O	583-590
matured	O	591-598
in	O	599-601
conventional	O	602-614
FSH	O	615-618
level	O	619-624
and	O	625-628
MII	O	629-632
oocytes	O	633-640
matured	O	641-648
in	O	649-651
high	O	652-656
FSH	O	657-660
level	O	661-666
(	O	667-668
2	O	668-669
,	O	669-670
000	O	670-673
ng	O	674-676
/	O	676-677
ml	O	677-679
)	O	679-680
respectively	O	681-693
.	O	693-694

RESULTS	O	695-702
:	O	702-703
Compared	O	704-712
with	O	713-717
GV	O	718-720
oocytes	O	721-728
,	O	728-729
MII	O	730-733
oocytes	O	734-741
exhibited	O	742-751
up	O	752-754
-	O	754-755
regulation	O	755-765
of	O	766-768
4	O	769-770
miRNAs	O	771-777
(	O	778-779
hsa	B	779-782
-	I	782-783
miR	I	783-786
-	I	786-787
193a	I	787-791
-	I	791-792
5p	I	792-794
,	O	794-795
hsa	B	796-799
-	I	799-800
miR	I	800-803
-	I	803-804
297	I	804-807
,	O	807-808
hsa	B	809-812
-	I	812-813
miR	I	813-816
-	I	816-817
625	I	817-820
and	O	821-824
hsa	B	825-828
-	I	828-829
miR	I	829-832
-	I	832-833
602	I	833-836
)	O	836-837
,	O	837-838
and	O	839-842
down	O	843-847
-	O	847-848
regulation	O	848-858
of	O	859-861
11	O	862-864
miRNAs	O	865-871
(	O	872-873
hsa	B	873-876
-	I	876-877
miR	I	877-880
-	I	880-881
888	I	881-884
*	I	884-885
,	O	885-886
hsa	B	887-890
-	I	890-891
miR	I	891-894
-	I	894-895
212	I	895-898
,	O	898-899
hsa	B	900-903
-	I	903-904
miR	I	904-907
-	I	907-908
662	I	908-911
,	O	911-912
hsa	B	913-916
-	I	916-917
miR	I	917-920
-	I	920-921
299	I	921-924
-	I	924-925
5p	I	925-927
,	O	927-928
hsa	B	929-932
-	I	932-933
miR	I	933-936
-	I	936-937
339	I	937-940
-	I	940-941
5p	I	941-943
,	O	943-944
hsa	B	945-948
-	I	948-949
miR	I	949-952
-	I	952-953
20a	I	953-956
,	O	956-957
hsa	B	958-961
-	I	961-962
miR	I	962-965
-	I	965-966
486	I	966-969
-	I	969-970
5p	I	970-972
,	O	972-973
hsa	B	974-977
-	I	977-978
miR	I	978-981
-	I	981-982
141	I	982-985
*	I	985-986
,	O	986-987
hsa	B	988-991
-	I	991-992
miR	I	992-995
-	I	995-996
768	I	996-999
-	I	999-1000
5p	I	1000-1002
,	O	1002-1003
hsa	B	1004-1007
-	I	1007-1008
miR	I	1008-1011
-	I	1011-1012
376a	I	1012-1016
and	O	1017-1020
hsa	B	1021-1024
-	I	1024-1025
miR	I	1025-1028
-	I	1028-1029
15a	I	1029-1032
)	O	1032-1033
.	O	1033-1034

RT	O	1035-1037
-	O	1037-1038
PCR	O	1038-1041
analysis	O	1042-1050
of	O	1051-1053
hsa	B	1054-1057
-	I	1057-1058
miR	I	1058-1061
-	I	1061-1062
15a	I	1062-1065
and	O	1066-1069
hsa	B	1070-1073
-	I	1073-1074
miR	I	1074-1077
-	I	1077-1078
20a	I	1078-1081
expression	O	1082-1092
revealed	O	1093-1101
concordant	O	1102-1112
dynamic	O	1113-1120
changes	O	1121-1128
in	O	1129-1131
oocytes	O	1132-1139
from	O	1140-1144
group	O	1145-1150
1	O	1151-1152
to	O	1153-1155
group	O	1156-1161
4	O	1162-1163
.	O	1163-1164

CONCLUSION	O	1165-1175
(	O	1175-1176
S	O	1176-1177
)	O	1177-1178
:	O	1178-1179
Specific	O	1180-1188
miRNAs	O	1189-1195
in	O	1196-1198
human	O	1199-1204
oocytes	O	1205-1212
had	O	1213-1216
dynamic	O	1217-1224
changes	O	1225-1232
during	O	1233-1239
meiosis	O	1240-1247
.	O	1247-1248

High	O	1249-1253
-	O	1253-1254
concentration	O	1254-1267
FSH	O	1268-1271
in	O	1272-1274
IVM	O	1275-1278
medium	O	1279-1285
led	O	1286-1289
to	O	1290-1292
reverse	O	1293-1300
effect	O	1301-1307
on	O	1308-1310
the	O	1311-1314
expression	O	1315-1325
of	O	1326-1328
hsa	B	1329-1332
-	I	1332-1333
miR	I	1333-1336
-	I	1336-1337
15a	I	1337-1340
and	O	1341-1344
hsa	B	1345-1348
-	I	1348-1349
miR	I	1349-1352
-	I	1352-1353
20a	I	1353-1356
.	O	1356-1357

MicroRNA	O	0-8
control	O	9-16
of	O	17-19
ovarian	O	20-27
function	O	28-36
.	O	36-37

Post	O	38-42
-	O	42-43
transcriptional	O	43-58
gene	O	59-63
regulation	O	64-74
,	O	74-75
a	O	76-77
regulatory	O	78-88
mechanism	O	89-98
classically	O	99-110
involved	O	111-119
in	O	120-122
female	O	123-129
and	O	130-133
male	O	134-138
germ	O	139-143
cell	O	144-148
function	O	149-157
has	O	158-161
recently	O	162-170
been	O	171-175
implicated	O	176-186
in	O	187-189
control	O	190-197
of	O	198-200
somatic	O	201-208
cells	O	209-214
of	O	215-217
the	O	218-221
ovary	O	222-227
and	O	228-231
testis	O	232-238
.	O	238-239

Recent	O	240-246
advancements	O	247-259
in	O	260-262
this	O	263-267
field	O	268-273
may	O	274-277
be	O	278-280
attributed	O	281-291
primarily	O	292-301
to	O	302-304
the	O	305-308
discovery	O	309-318
and	O	319-322
study	O	323-328
of	O	329-331
microRNAs	O	332-341
(	O	342-343
miRNA	O	343-348
)	O	348-349
,	O	349-350
small	O	351-356
RNA	O	357-360
transcripts	O	361-372
that	O	373-377
can	O	378-381
influence	O	382-391
mRNA	O	392-396
expression	O	397-407
via	O	408-411
post	O	412-416
-	O	416-417
transcriptional	O	417-432
gene	O	433-437
regulatory	O	438-448
mechanisms	O	449-459
.	O	459-460

In	O	461-463
the	O	464-467
ovary	O	468-473
,	O	473-474
targeted	O	475-483
deletion	O	484-492
of	O	493-495
Dicer	O	496-501
1	O	502-503
,	O	503-504
a	O	505-506
key	O	507-510
enzyme	O	511-517
in	O	518-520
miRNA	O	521-526
biogenesis	O	527-537
,	O	537-538
provided	O	539-547
the	O	548-551
first	O	552-557
empirical	O	558-567
evidence	O	568-576
that	O	577-581
miRNA	O	582-587
/	O	587-588
siRNA	O	588-593
were	O	594-598
critically	O	599-609
involved	O	610-618
in	O	619-621
multiple	O	622-630
aspects	O	631-638
of	O	639-641
ovarian	O	642-649
function	O	650-658
(	O	659-660
folliculogenesis	O	660-676
,	O	676-677
oocyte	O	678-684
maturation	O	685-695
,	O	695-696
ovulation	O	697-706
,	O	706-707
and	O	708-711
luteal	O	712-718
function	O	719-727
)	O	727-728
.	O	728-729

Functional	O	730-740
studies	O	741-748
of	O	749-751
miRNA	O	752-757
in	O	758-760
the	O	761-764
ovary	O	765-770
have	O	771-775
mostly	O	776-782
focused	O	783-790
on	O	791-793
granulosa	O	794-803
cells	O	804-809
during	O	810-816
the	O	817-820
critical	O	821-829
period	O	830-836
of	O	837-839
the	O	840-843
ovarian	O	844-851
cycle	O	852-857
surrounding	O	858-869
the	O	870-873
ovulatory	O	874-883
surge	O	884-889
of	O	890-892
luteinizing	O	893-904
hormone	O	905-912
(	O	913-914
LH	O	914-916
)	O	916-917
.	O	917-918

Specific	O	919-927
miRNA	O	928-933
have	O	934-938
been	O	939-943
implicated	O	944-954
in	O	955-957
ovarian	O	958-965
responses	O	966-975
,	O	975-976
due	O	977-980
to	O	981-983
their	O	984-989
transcriptional	O	990-1005
induction	O	1006-1015
by	O	1016-1018
the	O	1019-1022
LH	O	1023-1025
surge	O	1026-1031
(	O	1032-1033
i	O	1033-1034
.	O	1034-1035
e	O	1035-1036
.	O	1036-1037
,	O	1037-1038
miR	B	1039-1042
-	I	1042-1043
21	I	1043-1045
,	O	1045-1046
-	B	1047-1048
132	I	1048-1051
and	O	1052-1055
-	B	1056-1057
212	I	1057-1060
)	O	1060-1061
or	O	1062-1064
through	O	1065-1072
bioinformatic	O	1073-1086
approaches	O	1087-1097
(	O	1098-1099
miR	B	1099-1102
-	I	1102-1103
224	I	1103-1106
,	O	1106-1107
-	B	1108-1109
17	I	1109-1111
-	I	1111-1112
5p	I	1112-1114
and	O	1115-1118
let	B	1119-1122
-	I	1122-1123
7b	I	1123-1125
)	O	1125-1126
.	O	1126-1127

Numerous	O	1128-1136
other	O	1137-1142
miRNA	O	1143-1148
are	O	1149-1152
highly	O	1153-1159
abundant	O	1160-1168
in	O	1169-1171
ovarian	O	1172-1179
somatic	O	1180-1187
tissues	O	1188-1195
,	O	1195-1196
suggesting	O	1197-1207
that	O	1208-1212
we	O	1213-1215
have	O	1216-1220
much	O	1221-1225
to	O	1226-1228
discover	O	1229-1237
with	O	1238-1242
respect	O	1243-1250
to	O	1251-1253
the	O	1254-1257
role	O	1258-1262
of	O	1263-1265
miRNA	O	1266-1271
and	O	1272-1275
regulation	O	1276-1286
of	O	1287-1289
ovarian	O	1290-1297
function	O	1298-1306
.	O	1306-1307

This	O	1308-1312
review	O	1313-1319
will	O	1320-1324
recap	O	1325-1330
the	O	1331-1334
key	O	1335-1338
observations	O	1339-1351
of	O	1352-1354
these	O	1355-1360
early	O	1361-1366
studies	O	1367-1374
and	O	1375-1378
provide	O	1379-1386
insight	O	1387-1394
into	O	1395-1399
future	O	1400-1406
experiments	O	1407-1418
that	O	1419-1423
might	O	1424-1429
further	O	1430-1437
our	O	1438-1441
understanding	O	1442-1455
of	O	1456-1458
ovarian	O	1459-1466
function	O	1467-1475
.	O	1475-1476

The	O	0-3
miR	B	4-7
-	I	7-8
143	I	8-11
/	O	11-12
145	B	12-15
cluster	O	16-23
is	O	24-26
a	O	27-28
novel	O	29-34
transcriptional	O	35-50
target	O	51-57
of	O	58-60
Jagged	O	61-67
-	O	67-68
1	O	68-69
/	O	69-70
Notch	O	70-75
signaling	O	76-85
in	O	86-88
vascular	O	89-97
smooth	O	98-104
muscle	O	105-111
cells	O	112-117
.	O	117-118

Activation	O	119-129
of	O	130-132
Notch	O	133-138
signaling	O	139-148
by	O	149-151
Jagged	O	152-158
-	O	158-159
1	O	159-160
(	O	161-162
Jag	O	162-165
-	O	165-166
1	O	166-167
)	O	167-168
in	O	169-171
vascular	O	172-180
smooth	O	181-187
muscle	O	188-194
cells	O	195-200
(	O	201-202
VSMC	O	202-206
)	O	206-207
promotes	O	208-216
a	O	217-218
differentiated	O	219-233
phenotype	O	234-243
characterized	O	244-257
by	O	258-260
increased	O	261-270
expression	O	271-281
of	O	282-284
contractile	O	285-296
proteins	O	297-305
.	O	305-306

Recent	O	307-313
studies	O	314-321
show	O	322-326
that	O	327-331
microRNAs	O	332-341
(	O	342-343
miR	O	343-346
)	O	346-347
-	O	347-348
143	O	348-351
/	O	351-352
145	O	352-355
regulates	O	356-365
VSMC	O	366-370
phenotype	O	371-380
.	O	380-381

The	O	382-385
serum	O	386-391
response	O	392-400
factor	O	401-407
(	O	408-409
SRF	O	409-412
)	O	412-413
/	O	413-414
myocardin	O	414-423
complex	O	424-431
binds	O	432-437
to	O	438-440
CArG	O	441-445
sequences	O	446-455
to	O	456-458
activate	O	459-467
miR	B	468-471
-	I	471-472
143	I	472-475
/	O	475-476
145	B	476-479
transcription	O	480-493
,	O	493-494
but	O	495-498
no	O	499-501
other	O	502-507
regulators	O	508-518
are	O	519-522
known	O	523-528
in	O	529-531
VSMC	O	532-536
.	O	536-537

Using	O	538-543
miR	O	544-547
arrays	O	548-554
,	O	554-555
we	O	556-558
found	O	559-564
miR	B	565-568
-	I	568-569
143	I	569-572
/	O	572-573
145	B	573-576
induced	O	577-584
following	O	585-594
expression	O	595-605
of	O	606-608
a	O	609-610
constitutively	O	611-625
active	O	626-632
Notch1	O	633-639
intracellular	O	640-653
domain	O	654-660
(	O	661-662
N1ICD	O	662-667
)	O	667-668
.	O	668-669

We	O	670-672
hypothesized	O	673-685
that	O	686-690
miR	B	691-694
-	I	694-695
143	I	695-698
/	O	698-699
145	B	699-702
is	O	703-705
required	O	706-714
for	O	715-718
Jag	O	719-722
-	O	722-723
1	O	723-724
/	O	724-725
Notch	O	725-730
-	O	730-731
induced	O	731-738
VSMC	O	739-743
differentiation	O	744-759
.	O	759-760

Activation	O	761-771
of	O	772-774
Notch	O	775-780
receptors	O	781-790
by	O	791-793
Jag	O	794-797
-	O	797-798
1	O	798-799
caused	O	800-806
CBF1	O	807-811
-	O	811-812
dependent	O	812-821
up	O	822-824
-	O	824-825
regulation	O	825-835
of	O	836-838
miR	B	839-842
-	I	842-843
143	I	843-846
/	O	846-847
145	B	847-850
,	O	850-851
increased	O	852-861
differentiation	O	862-877
,	O	877-878
and	O	879-882
decreased	O	883-892
proliferation	O	893-906
.	O	906-907

Conversely	O	908-918
,	O	918-919
inhibiting	O	920-930
basal	O	931-936
Notch	O	937-942
signaling	O	943-952
decreased	O	953-962
steady	O	963-969
state	O	970-975
levels	O	976-982
of	O	983-985
miR	B	986-989
-	I	989-990
143	I	990-993
/	O	993-994
145	B	994-997
.	O	997-998

Using	O	999-1004
SRF	O	1005-1008
knockdown	O	1009-1018
,	O	1018-1019
we	O	1020-1022
found	O	1023-1028
that	O	1029-1033
Jag	O	1034-1037
-	O	1037-1038
1	O	1038-1039
/	O	1039-1040
Notch	O	1040-1045
induction	O	1046-1055
of	O	1056-1058
miR	B	1059-1062
-	I	1062-1063
143	I	1063-1066
/	O	1066-1067
145	B	1067-1070
is	O	1071-1073
SRF	O	1074-1077
independent	O	1078-1089
,	O	1089-1090
although	O	1091-1099
full	O	1100-1104
acquisition	O	1105-1116
of	O	1117-1119
contractile	O	1120-1131
markers	O	1132-1139
requires	O	1140-1148
SRF	O	1149-1152
.	O	1152-1153

Using	O	1154-1159
miR	B	1160-1163
-	I	1163-1164
143	I	1164-1167
/	O	1167-1168
145	B	1168-1171
promoter	O	1172-1180
reporter	O	1181-1189
constructs	O	1190-1200
we	O	1201-1203
show	O	1204-1208
Jag	O	1209-1212
-	O	1212-1213
1	O	1213-1214
/	O	1214-1215
Notch	O	1215-1220
increases	O	1221-1230
promoter	O	1231-1239
activity	O	1240-1248
,	O	1248-1249
and	O	1250-1253
this	O	1254-1258
is	O	1259-1261
dependent	O	1262-1271
on	O	1272-1274
intact	O	1275-1281
CBF1	O	1282-1286
consensus	O	1287-1296
sites	O	1297-1302
within	O	1303-1309
the	O	1310-1313
promoter	O	1314-1322
.	O	1322-1323

Chromatin	O	1324-1333
immunoprecipitation	O	1334-1353
(	O	1354-1355
ChIP	O	1355-1359
)	O	1359-1360
assays	O	1361-1367
revealed	O	1368-1376
that	O	1377-1381
N1ICD	O	1382-1387
-	O	1387-1388
containing	O	1388-1398
complexes	O	1399-1408
bind	O	1409-1413
to	O	1414-1416
CBF1	O	1417-1421
sites	O	1422-1427
in	O	1428-1430
the	O	1431-1434
miR	B	1435-1438
-	I	1438-1439
143	I	1439-1442
/	O	1442-1443
145	B	1443-1446
promoter	O	1447-1455
.	O	1455-1456

We	O	1457-1459
also	O	1460-1464
identified	O	1465-1475
N1ICD	O	1476-1481
complex	O	1482-1489
binding	O	1490-1497
to	O	1498-1500
CBF1	O	1501-1505
sites	O	1506-1511
within	O	1512-1518
the	O	1519-1522
endogenous	O	1523-1533
human	O	1534-1539
miR	B	1540-1543
-	I	1543-1544
143	I	1544-1547
/	O	1547-1548
145	B	1548-1551
promoter	O	1552-1560
.	O	1560-1561

Using	O	1562-1567
miR	B	1568-1571
-	I	1571-1572
143	I	1572-1575
/	O	1575-1576
145	B	1576-1579
-	O	1579-1580
interfering	O	1580-1591
oligonucleotides	O	1592-1608
,	O	1608-1609
we	O	1610-1612
demonstrate	O	1613-1624
that	O	1625-1629
Jag	O	1630-1633
-	O	1633-1634
1	O	1634-1635
/	O	1635-1636
Notch	O	1636-1641
signaling	O	1642-1651
requires	O	1652-1660
induction	O	1661-1670
of	O	1671-1673
both	O	1674-1678
miR	B	1679-1682
-	I	1682-1683
143	I	1683-1686
and	O	1687-1690
miR	B	1691-1694
-	I	1694-1695
145	I	1695-1698
to	O	1699-1701
promote	O	1702-1709
the	O	1710-1713
VSMC	O	1714-1718
contractile	O	1719-1730
phenotype	O	1731-1740
.	O	1740-1741

Thus	O	1742-1746
,	O	1746-1747
miR	B	1748-1751
-	I	1751-1752
143	I	1752-1755
/	O	1755-1756
145	B	1756-1759
is	O	1760-1762
a	O	1763-1764
novel	O	1765-1770
transcriptional	O	1771-1786
target	O	1787-1793
of	O	1794-1796
Jag	O	1797-1800
-	O	1800-1801
1	O	1801-1802
/	O	1802-1803
Notch	O	1803-1808
signaling	O	1809-1818
in	O	1819-1821
VSMC	O	1822-1826
.	O	1826-1827

We	O	1828-1830
propose	O	1831-1838
miR	B	1839-1842
-	I	1842-1843
143	I	1843-1846
/	O	1846-1847
145	B	1847-1850
as	O	1851-1853
activated	O	1854-1863
independently	O	1864-1877
by	O	1878-1880
Jag	O	1881-1884
-	O	1884-1885
1	O	1885-1886
/	O	1886-1887
Notch	O	1887-1892
and	O	1893-1896
SRF	O	1897-1900
in	O	1901-1903
parallel	O	1904-1912
pathways	O	1913-1921
.	O	1921-1922

Multiple	O	1923-1931
pathways	O	1932-1940
converging	O	1941-1951
on	O	1952-1954
miR	B	1955-1958
-	I	1958-1959
143	I	1959-1962
/	O	1962-1963
145	B	1963-1966
provides	O	1967-1975
potential	O	1976-1985
for	O	1986-1989
fine	O	1990-1994
-	O	1994-1995
tuning	O	1995-2001
or	O	2002-2004
amplification	O	2005-2018
of	O	2019-2021
VSMC	O	2022-2026
differentiation	O	2027-2042
signals	O	2043-2050
.	O	2050-2051

microRNAs	O	0-9
modulate	O	10-18
iPS	O	19-22
cell	O	23-27
generation	O	28-38
.	O	38-39

Although	O	40-48
induced	O	49-56
pluripotent	O	57-68
stem	O	69-73
cells	O	74-79
(	O	80-81
iPSCs	O	81-86
)	O	86-87
hold	O	88-92
great	O	93-98
promise	O	99-106
for	O	107-110
customized	O	111-121
regenerative	O	122-134
medicine	O	135-143
,	O	143-144
the	O	145-148
molecular	O	149-158
basis	O	159-164
of	O	165-167
reprogramming	O	168-181
is	O	182-184
largely	O	185-192
unknown	O	193-200
.	O	200-201

Overcoming	O	202-212
barriers	O	213-221
that	O	222-226
maintain	O	227-235
cell	O	236-240
identities	O	241-251
is	O	252-254
a	O	255-256
critical	O	257-265
step	O	266-270
in	O	271-273
the	O	274-277
reprogramming	O	278-291
of	O	292-294
differentiated	O	295-309
cells	O	310-315
.	O	315-316

Since	O	317-322
microRNAs	O	323-332
(	O	333-334
miRNAs	O	334-340
)	O	340-341
modulate	O	342-350
target	O	351-357
genes	O	358-363
tissue	O	364-370
-	O	370-371
specifically	O	371-383
,	O	383-384
we	O	385-387
reasoned	O	388-396
that	O	397-401
distinct	O	402-410
mouse	O	411-416
embryonic	O	417-426
fibroblast	O	427-437
(	O	438-439
MEF	O	439-442
)	O	442-443
-	O	443-444
enriched	O	444-452
miRNAs	O	453-459
post	O	460-464
-	O	464-465
transcriptionally	O	465-482
modulate	O	483-491
proteins	O	492-500
that	O	501-505
function	O	506-514
as	O	515-517
reprogramming	O	518-531
barriers	O	532-540
.	O	540-541

Inhibiting	O	542-552
these	O	553-558
miRNAs	O	559-565
should	O	566-572
influence	O	573-582
cell	O	583-587
signaling	O	588-597
to	O	598-600
lower	O	601-606
those	O	607-612
barriers	O	613-621
.	O	621-622

Here	O	623-627
we	O	628-630
show	O	631-635
that	O	636-640
depleting	O	641-650
miR	B	651-654
-	I	654-655
21	I	655-657
and	O	658-661
miR	B	662-665
-	I	665-666
29a	I	666-669
enhances	O	670-678
reprogramming	O	679-692
efficiency	O	693-703
in	O	704-706
MEFs	O	707-711
.	O	711-712

We	O	713-715
also	O	716-720
show	O	721-725
that	O	726-730
the	O	731-734
p53	O	735-738
and	O	739-742
ERK1	O	743-747
/	O	747-748
2	O	748-749
pathways	O	750-758
are	O	759-762
regulated	O	763-772
by	O	773-775
miR	B	776-779
-	I	779-780
21	I	780-782
and	O	783-786
miR	B	787-790
-	I	790-791
29a	I	791-794
and	O	795-798
function	O	799-807
in	O	808-810
reprogramming	O	811-824
.	O	824-825

In	O	826-828
addition	O	829-837
,	O	837-838
we	O	839-841
provide	O	842-849
the	O	850-853
first	O	854-859
evidence	O	860-868
that	O	869-873
c	O	874-875
-	O	875-876
Myc	O	876-879
enhances	O	880-888
reprogramming	O	889-902
partly	O	903-909
by	O	910-912
repressing	O	913-923
MEF	O	924-927
-	O	927-928
enriched	O	928-936
miRNAs	O	937-943
,	O	943-944
such	O	945-949
as	O	950-952
miR	B	953-956
-	I	956-957
21	I	957-959
and	O	960-963
miR	B	964-967
-	I	967-968
29a	I	968-971
.	O	971-972

Our	O	973-976
results	O	977-984
demonstrate	O	985-996
the	O	997-1000
significance	O	1001-1013
of	O	1014-1016
miRNA	O	1017-1022
function	O	1023-1031
in	O	1032-1034
regulating	O	1035-1045
multiple	O	1046-1054
signaling	O	1055-1064
networks	O	1065-1073
involved	O	1074-1082
in	O	1083-1085
iPSC	O	1086-1090
generation	O	1091-1101
.	O	1101-1102

These	O	1103-1108
studies	O	1109-1116
should	O	1117-1123
facilitate	O	1124-1134
development	O	1135-1146
of	O	1147-1149
clinically	O	1150-1160
applicable	O	1161-1171
reprogramming	O	1172-1185
strategies	O	1186-1196
.	O	1196-1197

Diagnostic	O	0-10
microRNAs	O	11-20
in	O	21-23
myelodysplastic	O	24-39
syndrome	O	40-48
.	O	48-49

OBJECTIVE	O	50-59
:	O	59-60
The	O	61-64
myelodysplastic	O	65-80
syndromes	O	81-90
(	O	91-92
MDS	O	92-95
)	O	95-96
are	O	97-100
aging	O	101-106
-	O	106-107
associated	O	107-117
disorders	O	118-127
characterized	O	128-141
by	O	142-144
ineffective	O	145-156
maturation	O	157-167
of	O	168-170
hematopoietic	O	171-184
elements	O	185-193
,	O	193-194
which	O	195-200
are	O	201-204
often	O	205-210
diagnostically	O	211-225
challenging	O	226-237
.	O	237-238

This	O	239-243
study	O	244-249
identifies	O	250-260
microRNAs	O	261-270
(	O	271-272
miRNA	O	272-277
)	O	277-278
and	O	279-282
miRNA	O	283-288
targets	O	289-296
that	O	297-301
might	O	302-307
represent	O	308-317
diagnostic	O	318-328
markers	O	329-336
for	O	337-340
MDS	O	341-344
.	O	344-345

MATERIALS	O	346-355
AND	O	356-359
METHODS	O	360-367
:	O	367-368
This	O	369-373
study	O	374-379
utilized	O	380-388
a	O	389-390
total	O	391-396
of	O	397-399
42	O	400-402
MDS	O	403-406
samples	O	407-414
and	O	415-418
45	O	419-421
controls	O	422-430
.	O	430-431

A	O	432-433
discovery	O	434-443
set	O	444-447
of	O	448-450
20	O	451-453
frozen	O	454-460
bone	O	461-465
marrow	O	466-472
mononuclear	O	473-484
cell	O	485-489
samples	O	490-497
(	O	498-499
10	O	499-501
MDS	O	502-505
,	O	505-506
10	O	507-509
controls	O	510-518
)	O	518-519
was	O	520-523
profiled	O	524-532
on	O	533-535
a	O	536-537
custom	O	538-544
Agilent	O	545-552
miRNA	O	553-558
microarray	O	559-569
.	O	569-570

Classifier	O	571-581
miRNAs	O	582-588
were	O	589-593
validated	O	594-603
in	O	604-606
a	O	607-608
separate	O	609-617
set	O	618-621
of	O	622-624
49	O	625-627
paraffin	O	628-636
-	O	636-637
embedded	O	637-645
particle	O	646-654
preparations	O	655-667
by	O	668-670
real	O	671-675
-	O	675-676
time	O	676-680
polymerase	O	681-691
chain	O	692-697
reaction	O	698-706
(	O	707-708
24	O	708-710
MDS	O	711-714
,	O	714-715
25	O	716-718
controls	O	719-727
)	O	727-728
.	O	728-729

Target	O	730-736
prediction	O	737-747
analysis	O	748-756
was	O	757-760
compared	O	761-769
to	O	770-772
a	O	773-774
de	O	775-777
novo	O	778-782
transcriptional	O	783-798
profile	O	799-806
of	O	807-809
MDS	O	810-813
derived	O	814-821
from	O	822-826
the	O	827-830
Microarray	O	831-841
Innovations	O	842-853
in	O	854-856
Leukemia	O	857-865
study	O	866-871
.	O	871-872

c	O	873-874
-	O	874-875
Myb	O	875-878
and	O	879-882
Sufu	O	883-887
were	O	888-892
further	O	893-900
investigated	O	901-913
by	O	914-916
immunohistochemical	O	917-936
stains	O	937-943
on	O	944-946
a	O	947-948
set	O	949-952
of	O	953-955
26	O	956-958
paraffin	O	959-967
-	O	967-968
embedded	O	968-976
samples	O	977-984
.	O	984-985

RESULTS	O	986-993
:	O	993-994
We	O	995-997
identified	O	998-1008
13	O	1009-1011
miRNAs	O	1012-1018
of	O	1019-1021
interest	O	1022-1030
from	O	1031-1035
the	O	1036-1039
discovery	O	1040-1049
set	O	1050-1053
,	O	1053-1054
8	O	1055-1056
of	O	1057-1059
which	O	1060-1065
proved	O	1066-1072
statistically	O	1073-1086
significant	O	1087-1098
on	O	1099-1101
real	O	1102-1106
-	O	1106-1107
time	O	1107-1111
polymerase	O	1112-1122
chain	O	1123-1128
reaction	O	1129-1137
verification	O	1138-1150
.	O	1150-1151

These	O	1152-1157
eight	O	1158-1163
miRNAs	O	1164-1170
were	O	1171-1175
then	O	1176-1180
examined	O	1181-1189
in	O	1190-1192
an	O	1193-1195
independent	O	1196-1207
real	O	1208-1212
-	O	1212-1213
time	O	1213-1217
polymerase	O	1218-1228
chain	O	1229-1234
reaction	O	1235-1243
validation	O	1244-1254
set	O	1255-1258
.	O	1258-1259

Notably	O	1260-1267
,	O	1267-1268
hsa	B	1269-1272
-	I	1272-1273
miR	I	1273-1276
-	I	1276-1277
378	I	1277-1280
,	O	1280-1281
hsa	B	1282-1285
-	I	1285-1286
miR	I	1286-1289
-	I	1289-1290
632	I	1290-1293
,	O	1293-1294
and	O	1295-1298
hsa	B	1299-1302
-	I	1302-1303
miR	I	1303-1306
-	I	1306-1307
636	I	1307-1310
demonstrated	O	1311-1323
particularly	O	1324-1336
high	O	1337-1341
discrimination	O	1342-1356
between	O	1357-1364
MDS	O	1365-1368
and	O	1369-1372
normal	O	1373-1379
controls	O	1380-1388
.	O	1388-1389

Target	O	1390-1396
prediction	O	1397-1407
identified	O	1408-1418
potential	O	1419-1428
targets	O	1429-1436
of	O	1437-1439
miRNA	O	1440-1445
regulation	O	1446-1456
that	O	1457-1461
correspond	O	1462-1472
to	O	1473-1475
many	O	1476-1480
of	O	1481-1483
the	O	1484-1487
genes	O	1488-1493
that	O	1494-1498
characterize	O	1499-1511
MDS	O	1512-1515
.	O	1515-1516

Immunohistochemical	O	1517-1536
staining	O	1537-1545
performed	O	1546-1555
on	O	1556-1558
a	O	1559-1560
third	O	1561-1566
validation	O	1567-1577
set	O	1578-1581
confirmed	O	1582-1591
that	O	1592-1596
c	O	1597-1598
-	O	1598-1599
Myb	O	1599-1602
and	O	1603-1606
Sufu	O	1607-1611
are	O	1612-1615
differentially	O	1616-1630
expressed	O	1631-1640
in	O	1641-1643
MDS	O	1644-1647
.	O	1647-1648

CONCLUSIONS	O	1649-1660
:	O	1660-1661
Our	O	1662-1665
data	O	1666-1670
utilize	O	1671-1678
both	O	1679-1683
discovery	O	1684-1693
and	O	1694-1697
validation	O	1698-1708
sets	O	1709-1713
and	O	1714-1717
two	O	1718-1721
complementary	O	1722-1735
platforms	O	1736-1745
to	O	1746-1748
identify	O	1749-1757
miRNAs	O	1758-1764
associated	O	1765-1775
with	O	1776-1780
MDS	O	1781-1784
.	O	1784-1785

We	O	1786-1788
have	O	1789-1793
analyzed	O	1794-1802
predicted	O	1803-1812
targets	O	1813-1820
and	O	1821-1824
identified	O	1825-1835
c	O	1836-1837
-	O	1837-1838
Myb	O	1838-1841
and	O	1842-1845
Sufu	O	1846-1850
as	O	1851-1853
potential	O	1854-1863
diagnostic	O	1864-1874
markers	O	1875-1882
of	O	1883-1885
MDS	O	1886-1889
.	O	1889-1890

miR	B	0-3
-	I	3-4
520c	I	4-8
and	O	9-12
miR	B	13-16
-	I	16-17
373	I	17-20
upregulate	O	21-31
MMP9	O	32-36
expression	O	37-47
by	O	48-50
targeting	O	51-60
mTOR	O	61-65
and	O	66-69
SIRT1	O	70-75
,	O	75-76
and	O	77-80
activate	O	81-89
the	O	90-93
Ras	O	94-97
/	O	97-98
Raf	O	98-101
/	O	101-102
MEK	O	102-105
/	O	105-106
Erk	O	106-109
signaling	O	110-119
pathway	O	120-127
and	O	128-131
NF	O	132-134
-	O	134-135
kappaB	O	135-141
factor	O	142-148
in	O	149-151
human	O	152-157
fibrosarcoma	O	158-170
cells	O	171-176
.	O	176-177

MicroRNA	B	178-186
520c	I	187-191
and	O	192-195
373	B	196-199
(	O	200-201
miR	B	201-204
-	I	204-205
520c	I	205-209
and	O	210-213
miR	B	214-217
-	I	217-218
373	I	218-221
)	O	221-222
have	O	223-227
been	O	228-232
characterized	O	233-246
as	O	247-249
oncogenes	O	250-259
and	O	260-263
play	O	264-268
critical	O	269-277
roles	O	278-283
in	O	284-286
cancer	O	287-293
cell	O	294-298
metastasis	O	299-309
.	O	309-310

However	O	311-318
,	O	318-319
the	O	320-323
relationship	O	324-336
between	O	337-344
these	O	345-350
two	O	351-354
microRNAs	O	355-364
and	O	365-368
matrix	O	369-375
metalloproteinases	O	376-394
(	O	395-396
MMPs	O	396-400
)	O	400-401
,	O	401-402
which	O	403-408
are	O	409-412
important	O	413-422
in	O	423-425
cancer	O	426-432
cell	O	433-437
metastasis	O	438-448
,	O	448-449
remains	O	450-457
unknown	O	458-465
.	O	465-466

Here	O	467-471
,	O	471-472
we	O	473-475
report	O	476-482
new	O	483-486
evidence	O	487-495
in	O	496-498
which	O	499-504
miR	B	505-508
-	I	508-509
520c	I	509-513
and	O	514-517
miR	B	518-521
-	I	521-522
373	I	522-525
effects	O	526-533
in	O	534-536
human	O	537-542
fibrosarcoma	O	543-555
HT1080	O	556-562
cells	O	563-568
are	O	569-572
associated	O	573-583
with	O	584-588
MMP9	O	589-593
activity	O	594-602
,	O	602-603
and	O	604-607
this	O	608-612
upregulation	O	613-625
of	O	626-628
MMP9	O	629-633
is	O	634-636
not	O	637-640
only	O	641-645
at	O	646-648
the	O	649-652
activity	O	653-661
and	O	662-665
protein	O	666-673
levels	O	674-680
,	O	680-681
but	O	682-685
also	O	686-690
at	O	691-693
that	O	694-698
of	O	699-701
its	O	702-705
mRNA	O	706-710
.	O	710-711

Our	O	712-715
experimental	O	716-728
data	O	729-733
demonstrate	O	734-745
that	O	746-750
these	O	751-756
effects	O	757-764
occur	O	765-770
not	O	771-774
by	O	775-777
direct	O	778-784
binding	O	785-792
to	O	793-795
the	O	796-799
MMP9	O	800-804
promoter	O	805-813
,	O	813-814
but	O	815-818
by	O	819-821
miR	B	822-825
-	I	825-826
520c	I	826-830
and	O	831-834
miR	B	835-838
-	I	838-839
373	I	839-842
directly	O	843-851
targeting	O	852-861
the	O	862-865
3	O	866-867
'	O	867-868
-	O	868-869
untranslational	O	869-884
region	O	885-891
(	O	892-893
UTR	O	893-896
)	O	896-897
of	O	898-900
mRNAs	O	901-906
of	O	907-909
mTOR	O	910-914
and	O	915-918
SIRT1	O	919-924
(	O	925-926
negative	O	926-934
regulators	O	935-945
of	O	946-948
expression	O	949-959
of	O	960-962
MMP9	O	963-967
via	O	968-971
inactivating	O	972-984
the	O	985-988
Ras	O	989-992
/	O	992-993
Raf	O	993-996
/	O	996-997
MEK	O	997-1000
/	O	1000-1001
Erk	O	1001-1004
signaling	O	1005-1014
pathway	O	1015-1022
and	O	1023-1026
transcription	O	1027-1040
factor	O	1041-1047
NF	O	1048-1050
-	O	1050-1051
kappaB	O	1051-1057
activity	O	1058-1066
)	O	1066-1067
;	O	1067-1068
and	O	1069-1072
thus	O	1073-1077
suppressing	O	1078-1089
translation	O	1090-1101
levels	O	1102-1108
of	O	1109-1111
SIRT1	O	1112-1117
and	O	1118-1121
mTOR	O	1122-1126
.	O	1126-1127

Moreover	O	1128-1136
,	O	1136-1137
inhibition	O	1138-1148
of	O	1149-1151
key	O	1152-1155
kinases	O	1156-1163
of	O	1164-1166
the	O	1167-1170
Ras	O	1171-1174
/	O	1174-1175
Raf	O	1175-1178
/	O	1178-1179
MEK	O	1179-1182
/	O	1182-1183
Erk	O	1183-1186
signaling	O	1187-1196
pathway	O	1197-1204
and	O	1205-1208
Western	O	1209-1216
blots	O	1217-1222
for	O	1223-1226
selected	O	1227-1235
proteins	O	1236-1244
further	O	1245-1252
identified	O	1253-1263
miR	B	1264-1267
-	I	1267-1268
520c	I	1268-1272
and	O	1273-1276
miR	B	1277-1280
-	I	1280-1281
373	I	1281-1284
as	O	1285-1287
activating	O	1288-1298
this	O	1299-1303
signaling	O	1304-1313
pathway	O	1314-1321
and	O	1322-1325
NF	O	1326-1328
-	O	1328-1329
kappaB	O	1329-1335
.	O	1335-1336

In	O	1337-1339
conclusion	O	1340-1350
,	O	1350-1351
miR	B	1352-1355
-	I	1355-1356
520c	I	1356-1360
and	O	1361-1364
miR	B	1365-1368
-	I	1368-1369
373	I	1369-1372
increased	O	1373-1382
the	O	1383-1386
expression	O	1387-1397
of	O	1398-1400
MMP9	O	1401-1405
by	O	1406-1408
directly	O	1409-1417
targeting	O	1418-1427
the	O	1428-1431
3	O	1432-1433
'	O	1433-1434
-	O	1434-1435
UTRs	O	1435-1439
of	O	1440-1442
mRNAs	O	1443-1448
of	O	1449-1451
mTOR	O	1452-1456
and	O	1457-1460
SIRT1	O	1461-1466
and	O	1467-1470
suppressing	O	1471-1482
their	O	1483-1488
translation	O	1489-1500
;	O	1500-1501
resulting	O	1502-1511
in	O	1512-1514
activation	O	1515-1525
of	O	1526-1528
the	O	1529-1532
Ras	O	1533-1536
/	O	1536-1537
Raf	O	1537-1540
/	O	1540-1541
MEK	O	1541-1544
/	O	1544-1545
Erk	O	1545-1548
signaling	O	1549-1558
pathway	O	1559-1566
and	O	1567-1570
NF	O	1571-1573
-	O	1573-1574
kappaB	O	1574-1580
;	O	1580-1581
and	O	1582-1585
,	O	1585-1586
finally	O	1587-1594
,	O	1594-1595
increasing	O	1596-1606
the	O	1607-1610
mRNA	O	1611-1615
,	O	1615-1616
protein	O	1617-1624
,	O	1624-1625
and	O	1626-1629
activity	O	1630-1638
of	O	1639-1641
MMP9	O	1642-1646
and	O	1647-1650
enhancing	O	1651-1660
cell	O	1661-1665
migration	O	1666-1675
and	O	1676-1679
cell	O	1680-1684
growth	O	1685-1691
in	O	1692-1694
3D	O	1695-1697
type	O	1698-1702
I	O	1703-1704
collagen	O	1705-1713
gels	O	1714-1718
.	O	1718-1719

Haemolysis	O	0-10
during	O	11-17
sample	O	18-24
preparation	O	25-36
alters	O	37-43
microRNA	O	44-52
content	O	53-60
of	O	61-63
plasma	O	64-70
.	O	70-71

The	O	72-75
presence	O	76-84
of	O	85-87
cell	O	88-92
-	O	92-93
free	O	93-97
microRNAs	O	98-107
(	O	108-109
miRNAs	O	109-115
)	O	115-116
has	O	117-120
been	O	121-125
detected	O	126-134
in	O	135-137
a	O	138-139
range	O	140-145
of	O	146-148
body	O	149-153
fluids	O	154-160
.	O	160-161

The	O	162-165
miRNA	O	166-171
content	O	172-179
of	O	180-182
plasma	O	183-189
/	O	189-190
serum	O	190-195
in	O	196-198
particular	O	199-209
has	O	210-213
been	O	214-218
proposed	O	219-227
as	O	228-230
a	O	231-232
potential	O	233-242
source	O	243-249
of	O	250-252
novel	O	253-258
biomarkers	O	259-269
for	O	270-273
a	O	274-275
number	O	276-282
of	O	283-285
diseases	O	286-294
.	O	294-295

Nevertheless	O	296-308
,	O	308-309
the	O	310-313
quantification	O	314-328
of	O	329-331
miRNAs	O	332-338
from	O	339-343
plasma	O	344-350
or	O	351-353
serum	O	354-359
is	O	360-362
made	O	363-367
difficult	O	368-377
due	O	378-381
to	O	382-384
inefficient	O	385-396
isolation	O	397-406
and	O	407-410
lack	O	411-415
of	O	416-418
consensus	O	419-428
regarding	O	429-438
the	O	439-442
optimal	O	443-450
reference	O	451-460
miRNA	O	461-466
.	O	466-467

The	O	468-471
effect	O	472-478
of	O	479-481
haemolysis	O	482-492
on	O	493-495
the	O	496-499
quantification	O	500-514
and	O	515-518
normalisation	O	519-532
of	O	533-535
miRNAs	O	536-542
in	O	543-545
plasma	O	546-552
has	O	553-556
not	O	557-560
been	O	561-565
investigated	O	566-578
in	O	579-581
great	O	582-587
detail	O	588-594
.	O	594-595

We	O	596-598
found	O	599-604
that	O	605-609
levels	O	610-616
of	O	617-619
miR	B	620-623
-	I	623-624
16	I	624-626
,	O	626-627
a	O	628-629
commonly	O	630-638
used	O	639-643
reference	O	644-653
gene	O	654-658
,	O	658-659
showed	O	660-666
little	O	667-673
variation	O	674-683
when	O	684-688
measured	O	689-697
in	O	698-700
plasma	O	701-707
samples	O	708-715
from	O	716-720
healthy	O	721-728
volunteers	O	729-739
or	O	740-742
patients	O	743-751
with	O	752-756
malignant	O	757-766
mesothelioma	O	767-779
or	O	780-782
coronary	O	783-791
artery	O	792-798
disease	O	799-806
.	O	806-807

Including	O	808-817
samples	O	818-825
with	O	826-830
evidence	O	831-839
of	O	840-842
haemolysis	O	843-853
led	O	854-857
to	O	858-860
variation	O	861-870
in	O	871-873
miR	B	874-877
-	I	877-878
16	I	878-880
levels	O	881-887
and	O	888-891
consequently	O	892-904
decreased	O	905-914
its	O	915-918
ability	O	919-926
to	O	927-929
serve	O	930-935
as	O	936-938
a	O	939-940
reference	O	941-950
.	O	950-951

The	O	952-955
levels	O	956-962
of	O	963-965
miR	B	966-969
-	I	969-970
16	I	970-972
and	O	973-976
miR	B	977-980
-	I	980-981
451	I	981-984
,	O	984-985
both	O	986-990
present	O	991-998
in	O	999-1001
significant	O	1002-1013
levels	O	1014-1020
in	O	1021-1023
red	O	1024-1027
blood	O	1028-1033
cells	O	1034-1039
,	O	1039-1040
were	O	1041-1045
proportional	O	1046-1058
to	O	1059-1061
the	O	1062-1065
degree	O	1066-1072
of	O	1073-1075
haemolysis	O	1076-1086
.	O	1086-1087

Measurements	O	1088-1100
of	O	1101-1103
the	O	1104-1107
level	O	1108-1113
of	O	1114-1116
these	O	1117-1122
miRNAs	O	1123-1129
in	O	1130-1132
whole	O	1133-1138
blood	O	1139-1144
,	O	1144-1145
plasma	O	1146-1152
,	O	1152-1153
red	O	1154-1157
blood	O	1158-1163
cells	O	1164-1169
and	O	1170-1173
peripheral	O	1174-1184
blood	O	1185-1190
mononuclear	O	1191-1202
cells	O	1203-1208
revealed	O	1209-1217
that	O	1218-1222
the	O	1223-1226
miRNA	O	1227-1232
content	O	1233-1240
of	O	1241-1243
red	O	1244-1247
blood	O	1248-1253
cells	O	1254-1259
represents	O	1260-1270
the	O	1271-1274
major	O	1275-1280
source	O	1281-1287
of	O	1288-1290
variation	O	1291-1300
in	O	1301-1303
miR	B	1304-1307
-	I	1307-1308
16	I	1308-1310
and	O	1311-1314
miR	B	1315-1318
-	I	1318-1319
451	I	1319-1322
levels	O	1323-1329
measured	O	1330-1338
in	O	1339-1341
plasma	O	1342-1348
.	O	1348-1349

Adding	O	1350-1356
lysed	O	1357-1362
red	O	1363-1366
blood	O	1367-1372
cells	O	1373-1378
to	O	1379-1381
non	O	1382-1385
-	O	1385-1386
haemolysed	O	1386-1396
plasma	O	1397-1403
allowed	O	1404-1411
a	O	1412-1413
cut	O	1414-1417
-	O	1417-1418
off	O	1418-1421
level	O	1422-1427
of	O	1428-1430
free	O	1431-1435
haemoglobin	O	1436-1447
to	O	1448-1450
be	O	1451-1453
determined	O	1454-1464
,	O	1464-1465
below	O	1466-1471
which	O	1472-1477
miR	B	1478-1481
-	I	1481-1482
16	I	1482-1484
and	O	1485-1488
miR	B	1489-1492
-	I	1492-1493
451	I	1493-1496
levels	O	1497-1503
displayed	O	1504-1513
little	O	1514-1520
variation	O	1521-1530
between	O	1531-1538
individuals	O	1539-1550
.	O	1550-1551

In	O	1552-1554
conclusion	O	1555-1565
,	O	1565-1566
increases	O	1567-1576
in	O	1577-1579
plasma	O	1580-1586
miR	B	1587-1590
-	I	1590-1591
16	I	1591-1593
and	O	1594-1597
miR	B	1598-1601
-	I	1601-1602
451	I	1602-1605
are	O	1606-1609
caused	O	1610-1616
by	O	1617-1619
haemolysis	O	1620-1630
.	O	1630-1631

In	O	1632-1634
the	O	1635-1638
absence	O	1639-1646
of	O	1647-1649
haemolysis	O	1650-1660
the	O	1661-1664
levels	O	1665-1671
of	O	1672-1674
both	O	1675-1679
miR	B	1680-1683
-	I	1683-1684
16	I	1684-1686
and	O	1687-1690
miR	B	1691-1694
-	I	1694-1695
451	I	1695-1698
are	O	1699-1702
sufficiently	O	1703-1715
constant	O	1716-1724
to	O	1725-1727
serve	O	1728-1733
as	O	1734-1736
normalisers	O	1737-1748
.	O	1748-1749

Integrated	O	0-10
analysis	O	11-19
of	O	20-22
miRNA	O	23-28
and	O	29-32
mRNA	O	33-37
expression	O	38-48
in	O	49-51
childhood	O	52-61
medulloblastoma	O	62-77
compared	O	78-86
with	O	87-91
neural	O	92-98
stem	O	99-103
cells	O	104-109
.	O	109-110

Medulloblastoma	O	111-126
(	O	127-128
MB	O	128-130
)	O	130-131
is	O	132-134
the	O	135-138
most	O	139-143
common	O	144-150
malignant	O	151-160
brain	O	161-166
tumor	O	167-172
in	O	173-175
children	O	176-184
and	O	185-188
a	O	189-190
leading	O	191-198
cause	O	199-204
of	O	205-207
cancer	O	208-214
-	O	214-215
related	O	215-222
mortality	O	223-232
and	O	233-236
morbidity	O	237-246
.	O	246-247

Several	O	248-255
molecular	O	256-265
sub	O	266-269
-	O	269-270
types	O	270-275
of	O	276-278
MB	O	279-281
have	O	282-286
been	O	287-291
identified	O	292-302
,	O	302-303
suggesting	O	304-314
they	O	315-319
may	O	320-323
arise	O	324-329
from	O	330-334
distinct	O	335-343
cells	O	344-349
of	O	350-352
origin	O	353-359
.	O	359-360

Data	O	361-365
from	O	366-370
animal	O	371-377
models	O	378-384
indicate	O	385-393
that	O	394-398
some	O	399-403
MB	O	404-406
sub	O	407-410
-	O	410-411
types	O	411-416
arise	O	417-422
from	O	423-427
multipotent	O	428-439
cerebellar	O	440-450
neural	O	451-457
stem	O	458-462
cells	O	463-468
(	O	469-470
NSCs	O	470-474
)	O	474-475
.	O	475-476

Hence	O	477-482
,	O	482-483
microRNA	O	484-492
(	O	493-494
miRNA	O	494-499
)	O	499-500
expression	O	501-511
profiles	O	512-520
of	O	521-523
primary	O	524-531
MB	O	532-534
samples	O	535-542
were	O	543-547
compared	O	548-556
to	O	557-559
CD133	O	560-565
+	O	565-566
NSCs	O	567-571
,	O	571-572
aiming	O	573-579
to	O	580-582
identify	O	583-591
deregulated	O	592-603
miRNAs	O	604-610
involved	O	611-619
in	O	620-622
MB	O	623-625
pathogenesis	O	626-638
.	O	638-639

Expression	O	640-650
profiling	O	651-660
of	O	661-663
662	O	664-667
miRNAs	O	668-674
in	O	675-677
primary	O	678-685
MB	O	686-688
specimens	O	689-698
,	O	698-699
MB	O	700-702
cell	O	703-707
lines	O	708-713
,	O	713-714
and	O	715-718
human	O	719-724
CD133	O	725-730
+	O	730-731
NSCs	O	732-736
and	O	737-740
CD133	O	741-746
-	O	746-747
neural	O	748-754
progenitor	O	755-765
cells	O	766-771
was	O	772-775
performed	O	776-785
by	O	786-788
qRT	O	789-792
-	O	792-793
PCR	O	793-796
.	O	796-797

Clustering	O	798-808
analysis	O	809-817
identified	O	818-828
two	O	829-832
distinct	O	833-841
sub	O	842-845
-	O	845-846
types	O	846-851
of	O	852-854
MB	O	855-857
primary	O	858-865
specimens	O	866-875
,	O	875-876
reminiscent	O	877-888
of	O	889-891
sub	O	892-895
-	O	895-896
types	O	896-901
obtained	O	902-910
from	O	911-915
their	O	916-921
mRNA	O	922-926
profiles	O	927-935
.	O	935-936

21	O	937-939
significantly	O	940-953
up	O	954-956
-	O	956-957
regulated	O	957-966
and	O	967-970
12	O	971-973
significantly	O	974-987
down	O	988-992
-	O	992-993
regulated	O	993-1002
miRNAs	O	1003-1009
were	O	1010-1014
identified	O	1015-1025
in	O	1026-1028
MB	O	1029-1031
primary	O	1032-1039
specimens	O	1040-1049
relative	O	1050-1058
to	O	1059-1061
CD133	O	1062-1067
+	O	1067-1068
NSCs	O	1069-1073
(	O	1074-1075
p	O	1075-1076
<	O	1076-1077
0	O	1077-1078
.	O	1078-1079
01	O	1079-1081
)	O	1081-1082
.	O	1082-1083

The	O	1084-1087
majority	O	1088-1096
of	O	1097-1099
up	O	1100-1102
-	O	1102-1103
regulated	O	1103-1112
miRNAs	O	1113-1119
mapped	O	1120-1126
to	O	1127-1129
chromosomal	O	1130-1141
regions	O	1142-1149
14q32	O	1150-1155
and	O	1156-1159
17q	O	1160-1163
.	O	1163-1164

Integration	O	1165-1176
of	O	1177-1179
the	O	1180-1183
predicted	O	1184-1193
targets	O	1194-1201
of	O	1202-1204
deregulated	O	1205-1216
miRNAs	O	1217-1223
with	O	1224-1228
mRNA	O	1229-1233
expression	O	1234-1244
data	O	1245-1249
from	O	1250-1254
the	O	1255-1258
same	O	1259-1263
specimens	O	1264-1273
revealed	O	1274-1282
enrichment	O	1283-1293
of	O	1294-1296
pathways	O	1297-1305
regulating	O	1306-1316
neuronal	O	1317-1325
migration	O	1326-1335
,	O	1335-1336
nervous	O	1337-1344
system	O	1345-1351
development	O	1352-1363
and	O	1364-1367
cell	O	1368-1372
proliferation	O	1373-1386
.	O	1386-1387

Transient	O	1388-1397
over	O	1398-1402
-	O	1402-1403
expression	O	1403-1413
of	O	1414-1416
a	O	1417-1418
down	O	1419-1423
-	O	1423-1424
regulated	O	1424-1433
miRNA	O	1434-1439
,	O	1439-1440
miR	B	1441-1444
-	I	1444-1445
935	I	1445-1448
,	O	1448-1449
resulted	O	1450-1458
in	O	1459-1461
significant	O	1462-1473
down	O	1474-1478
-	O	1478-1479
regulation	O	1479-1489
of	O	1490-1492
three	O	1493-1498
of	O	1499-1501
the	O	1502-1505
seven	O	1506-1511
predicted	O	1512-1521
miR	B	1522-1525
-	I	1525-1526
935	I	1526-1529
target	O	1530-1536
genes	O	1537-1542
at	O	1543-1545
the	O	1546-1549
mRNA	O	1550-1554
level	O	1555-1560
in	O	1561-1563
a	O	1564-1565
MB	O	1566-1568
cell	O	1569-1573
line	O	1574-1578
,	O	1578-1579
confirming	O	1580-1590
the	O	1591-1594
validity	O	1595-1603
of	O	1604-1606
this	O	1607-1611
approach	O	1612-1620
.	O	1620-1621

This	O	1622-1626
study	O	1627-1632
represents	O	1633-1643
the	O	1644-1647
first	O	1648-1653
integrated	O	1654-1664
analysis	O	1665-1673
of	O	1674-1676
MB	O	1677-1679
miRNA	O	1680-1685
and	O	1686-1689
mRNA	O	1690-1694
expression	O	1695-1705
profiles	O	1706-1714
and	O	1715-1718
is	O	1719-1721
the	O	1722-1725
first	O	1726-1731
to	O	1732-1734
compare	O	1735-1742
MB	O	1743-1745
miRNA	O	1746-1751
expression	O	1752-1762
profiles	O	1763-1771
to	O	1772-1774
those	O	1775-1780
of	O	1781-1783
CD133	O	1784-1789
+	O	1789-1790
NSCs	O	1791-1795
.	O	1795-1796

We	O	1797-1799
identified	O	1800-1810
several	O	1811-1818
differentially	O	1819-1833
expressed	O	1834-1843
miRNAs	O	1844-1850
that	O	1851-1855
potentially	O	1856-1867
target	O	1868-1874
networks	O	1875-1883
of	O	1884-1886
genes	O	1887-1892
and	O	1893-1896
signaling	O	1897-1906
pathways	O	1907-1915
that	O	1916-1920
may	O	1921-1924
be	O	1925-1927
involved	O	1928-1936
in	O	1937-1939
the	O	1940-1943
transformation	O	1944-1958
of	O	1959-1961
normal	O	1962-1968
NSCs	O	1969-1973
to	O	1974-1976
brain	O	1977-1982
tumor	O	1983-1988
stem	O	1989-1993
cells	O	1994-1999
.	O	1999-2000

Based	O	2001-2006
on	O	2007-2009
this	O	2010-2014
integrative	O	2015-2026
approach	O	2027-2035
,	O	2035-2036
our	O	2037-2040
data	O	2041-2045
provide	O	2046-2053
an	O	2054-2056
important	O	2057-2066
platform	O	2067-2075
for	O	2076-2079
future	O	2080-2086
investigations	O	2087-2101
aimed	O	2102-2107
at	O	2108-2110
characterizing	O	2111-2125
the	O	2126-2129
role	O	2130-2134
of	O	2135-2137
specific	O	2138-2146
miRNAs	O	2147-2153
in	O	2154-2156
MB	O	2157-2159
pathogenesis	O	2160-2172
.	O	2172-2173

Potentially	O	0-11
predictive	O	12-22
microRNAs	O	23-32
of	O	33-35
gastric	O	36-43
cancer	O	44-50
with	O	51-55
metastasis	O	56-66
to	O	67-69
lymph	O	70-75
node	O	76-80
.	O	80-81

AIM	O	82-85
:	O	85-86
To	O	87-89
detect	O	90-96
the	O	97-100
expression	O	101-111
of	O	112-114
60	O	115-117
microRNAs	O	118-127
(	O	128-129
miRNAs	O	129-135
)	O	135-136
in	O	137-139
gastric	O	140-147
cancer	O	148-154
tissues	O	155-162
and	O	163-166
find	O	167-171
new	O	172-175
predictive	O	176-186
biomarkers	O	187-197
of	O	198-200
gastric	O	201-208
cancer	O	209-215
with	O	216-220
metastasis	O	221-231
.	O	231-232

METHODS	O	233-240
:	O	240-241
The	O	242-245
expressions	O	246-257
of	O	258-260
60	O	261-263
candidate	O	264-273
miRNAs	O	274-280
in	O	281-283
30	O	284-286
gastric	O	287-294
cancer	O	295-301
tissues	O	302-309
and	O	310-313
paired	O	314-320
normal	O	321-327
tissues	O	328-335
were	O	336-340
detected	O	341-349
by	O	350-352
stem	O	353-357
-	O	357-358
loop	O	358-362
real	O	363-367
-	O	367-368
time	O	368-372
reverse	O	373-380
transcription	O	381-394
-	O	394-395
polymerase	O	395-405
chain	O	406-411
reaction	O	412-420
.	O	420-421

After	O	422-427
primary	O	428-435
screening	O	436-445
of	O	446-448
miRNAs	O	449-455
expression	O	456-466
,	O	466-467
5	O	468-469
selected	O	470-478
miRNAs	O	479-485
were	O	486-490
further	O	491-498
testified	O	499-508
in	O	509-511
another	O	512-519
22	O	520-522
paired	O	523-529
gastric	O	530-537
tissues	O	538-545
.	O	545-546

Based	O	547-552
on	O	553-555
the	O	556-559
expression	O	560-570
level	O	571-576
of	O	577-579
miRNAs	O	580-586
and	O	587-590
the	O	591-594
status	O	595-601
of	O	602-604
metastasis	O	605-615
to	O	616-618
lymph	O	619-624
node	O	625-629
(	O	630-631
LN	O	631-633
)	O	633-634
,	O	634-635
receiver	O	636-644
-	O	644-645
operating	O	645-654
-	O	654-655
characteristic	O	655-669
(	O	670-671
ROC	O	671-674
)	O	674-675
curve	O	676-681
were	O	682-686
used	O	687-691
to	O	692-694
evaluate	O	695-703
their	O	704-709
ability	O	710-717
in	O	718-720
predicting	O	721-731
the	O	732-735
status	O	736-742
of	O	743-745
metastasis	O	746-756
to	O	757-759
LN	O	760-762
.	O	762-763

RESULTS	O	764-771
:	O	771-772
Thirty	O	773-779
-	O	779-780
eight	O	780-785
miRNAs	O	786-792
expressions	O	793-804
in	O	805-807
gastric	O	808-815
cancer	O	816-822
tissues	O	823-830
were	O	831-835
significantly	O	836-849
different	O	850-859
from	O	860-864
those	O	865-870
in	O	871-873
paired	O	874-880
normal	O	881-887
tissues	O	888-895
(	O	896-897
P	O	897-898
<	O	899-900
0	O	901-902
.	O	902-903
01	O	903-905
)	O	905-906
.	O	906-907

Among	O	908-913
them	O	914-918
,	O	918-919
31	O	920-922
miRNAs	O	923-929
were	O	930-934
found	O	935-940
to	O	941-943
be	O	944-946
up	O	947-949
-	O	949-950
expressed	O	950-959
in	O	960-962
cancer	O	963-969
tissues	O	970-977
and	O	978-981
1	O	982-983
miRNAs	O	984-990
were	O	991-995
down	O	996-1000
-	O	1000-1001
expressed	O	1001-1010
>	O	1011-1012
/	O	1012-1013
=	O	1013-1014
1	O	1015-1016
.	O	1016-1017
5	O	1017-1018
fold	O	1019-1023
vs	O	1024-1026
paired	O	1027-1033
normal	O	1034-1040
gastric	O	1041-1048
tissue	O	1049-1055
.	O	1055-1056

Five	O	1057-1061
microRNAs	O	1062-1071
(	O	1072-1073
miR	B	1073-1076
-	I	1076-1077
125a	I	1077-1081
-	I	1081-1082
3p	I	1082-1084
,	O	1084-1085
miR	B	1086-1089
-	I	1089-1090
133b	I	1090-1094
,	O	1094-1095
miR	B	1096-1099
-	I	1099-1100
143	I	1100-1103
,	O	1103-1104
miR	B	1105-1108
-	I	1108-1109
195	I	1109-1112
and	O	1113-1116
miR	B	1117-1120
-	I	1120-1121
212	I	1121-1124
)	O	1124-1125
were	O	1126-1130
differently	O	1131-1142
expressed	O	1143-1152
between	O	1153-1160
different	O	1161-1170
metastatic	O	1171-1181
groups	O	1182-1188
in	O	1189-1191
30	O	1192-1194
gastric	O	1195-1202
cancer	O	1203-1209
biopsies	O	1210-1218
(	O	1219-1220
P	O	1220-1221
<	O	1222-1223
0	O	1224-1225
.	O	1225-1226
05	O	1226-1228
)	O	1228-1229
.	O	1229-1230

Partial	O	1231-1238
correlation	O	1239-1250
analysis	O	1251-1259
showed	O	1260-1266
that	O	1267-1271
hsa	B	1272-1275
-	I	1275-1276
mir	I	1276-1279
-	I	1279-1280
212	I	1280-1283
and	O	1284-1287
hsa	B	1288-1291
-	I	1291-1292
mir	I	1292-1295
-	I	1295-1296
195	I	1296-1299
were	O	1300-1304
correlated	O	1305-1315
with	O	1316-1320
the	O	1321-1324
status	O	1325-1331
of	O	1332-1334
metastasis	O	1335-1345
to	O	1346-1348
LN	O	1349-1351
in	O	1352-1354
spite	O	1355-1360
of	O	1361-1363
age	O	1364-1367
,	O	1367-1368
gender	O	1369-1375
,	O	1375-1376
tumor	O	1377-1382
location	O	1383-1391
,	O	1391-1392
tumor	O	1393-1398
size	O	1399-1403
,	O	1403-1404
depth	O	1405-1410
of	O	1411-1413
invasion	O	1414-1422
and	O	1423-1426
cell	O	1427-1431
differentiation	O	1432-1447
.	O	1447-1448

ROC	O	1449-1452
analysis	O	1453-1461
indicated	O	1462-1471
that	O	1472-1476
miR	B	1477-1480
-	I	1480-1481
212	I	1481-1484
and	O	1485-1488
miR	B	1489-1492
-	I	1492-1493
195	I	1493-1496
have	O	1497-1501
better	O	1502-1508
sensitivities	O	1509-1522
(	O	1523-1524
84	O	1524-1526
.	O	1526-1527
6	O	1527-1528
%	O	1528-1529
and	O	1530-1533
69	O	1534-1536
.	O	1536-1537
2	O	1537-1538
%	O	1538-1539
,	O	1539-1540
respectively	O	1541-1553
)	O	1553-1554
and	O	1555-1558
specificities	O	1559-1572
(	O	1573-1574
both	O	1574-1578
100	O	1579-1582
%	O	1582-1583
)	O	1583-1584
in	O	1585-1587
distinguishing	O	1588-1602
biopsies	O	1603-1611
with	O	1612-1616
metastasis	O	1617-1627
to	O	1628-1630
LN	O	1631-1633
from	O	1634-1638
biopsies	O	1639-1647
without	O	1648-1655
metastasis	O	1656-1666
to	O	1667-1669
LN	O	1670-1672
.	O	1672-1673

CONCLUSION	O	1674-1684
:	O	1684-1685
miR	B	1686-1689
-	I	1689-1690
212	I	1690-1693
and	O	1694-1697
miR	B	1698-1701
-	I	1701-1702
195	I	1702-1705
could	O	1706-1711
be	O	1712-1714
independent	O	1715-1726
biomarkers	O	1727-1737
in	O	1738-1740
predicting	O	1741-1751
the	O	1752-1755
gastric	O	1756-1763
cancer	O	1764-1770
with	O	1771-1775
metastasis	O	1776-1786
to	O	1787-1789
LN	O	1790-1792
.	O	1792-1793

Serum	O	0-5
microRNA	B	6-14
-	I	14-15
21	I	15-17
as	O	18-20
marker	O	21-27
for	O	28-31
necroinflammation	O	32-49
in	O	50-52
hepatitis	O	53-62
C	O	63-64
patients	O	65-73
with	O	74-78
and	O	79-82
without	O	83-90
hepatocellular	O	91-105
carcinoma	O	106-115
.	O	115-116

BACKGROUND	O	117-127
:	O	127-128
MicroRNA	B	129-137
-	I	137-138
21	I	138-140
(	O	141-142
miR	B	142-145
-	I	145-146
21	I	146-148
)	O	148-149
is	O	150-152
up	O	153-155
-	O	155-156
regulated	O	156-165
in	O	166-168
tumor	O	169-174
tissue	O	175-181
of	O	182-184
patients	O	185-193
with	O	194-198
malignant	O	199-208
diseases	O	209-217
,	O	217-218
including	O	219-228
hepatocellular	O	229-243
carcinoma	O	244-253
(	O	254-255
HCC	O	255-258
)	O	258-259
.	O	259-260

Elevated	O	261-269
concentrations	O	270-284
of	O	285-287
miR	B	288-291
-	I	291-292
21	I	292-294
have	O	295-299
also	O	300-304
been	O	305-309
found	O	310-315
in	O	316-318
sera	O	319-323
or	O	324-326
plasma	O	327-333
from	O	334-338
patients	O	339-347
with	O	348-352
malignancies	O	353-365
,	O	365-366
rendering	O	367-376
it	O	377-379
an	O	380-382
interesting	O	383-394
candidate	O	395-404
as	O	405-407
serum	O	408-413
/	O	413-414
plasma	O	414-420
marker	O	421-427
for	O	428-431
malignancies	O	432-444
.	O	444-445

Here	O	446-450
we	O	451-453
correlated	O	454-464
serum	O	465-470
miR	B	471-474
-	I	474-475
21	I	475-477
levels	O	478-484
with	O	485-489
clinical	O	490-498
parameters	O	499-509
in	O	510-512
patients	O	513-521
with	O	522-526
different	O	527-536
stages	O	537-543
of	O	544-546
chronic	O	547-554
hepatitis	O	555-564
C	O	565-566
virus	O	567-572
infection	O	573-582
(	O	583-584
CHC	O	584-587
)	O	587-588
and	O	589-592
CHC	O	593-596
-	O	596-597
associated	O	597-607
HCC	O	608-611
.	O	611-612

METHODOLOGY	O	613-624
/	O	624-625
PRINCIPAL	O	625-634
FINDINGS	O	635-643
:	O	643-644
62	O	645-647
CHC	O	648-651
patients	O	652-660
,	O	660-661
29	O	662-664
patients	O	665-673
with	O	674-678
CHC	O	679-682
and	O	683-686
HCC	O	687-690
and	O	691-694
19	O	695-697
healthy	O	698-705
controls	O	706-714
were	O	715-719
prospectively	O	720-733
enrolled	O	734-742
.	O	742-743

RNA	O	744-747
was	O	748-751
extracted	O	752-761
from	O	762-766
the	O	767-770
sera	O	771-775
and	O	776-779
miR	B	780-783
-	I	783-784
21	I	784-786
as	O	787-789
well	O	790-794
as	O	795-797
miR	B	798-801
-	I	801-802
16	I	802-804
levels	O	805-811
were	O	812-816
analyzed	O	817-825
by	O	826-828
quantitative	O	829-841
real	O	842-846
-	O	846-847
time	O	847-851
PCR	O	852-855
;	O	855-856
miR	B	857-860
-	I	860-861
21	I	861-863
levels	O	864-870
(	O	871-872
normalized	O	872-882
by	O	883-885
miR	B	886-889
-	I	889-890
16	I	890-892
)	O	892-893
were	O	894-898
correlated	O	899-909
with	O	910-914
standard	O	915-923
liver	O	924-929
parameters	O	930-940
,	O	940-941
histological	O	942-954
grading	O	955-962
and	O	963-966
staging	O	967-974
of	O	975-977
CHC	O	978-981
.	O	981-982

The	O	983-986
data	O	987-991
show	O	992-996
that	O	997-1001
serum	O	1002-1007
levels	O	1008-1014
of	O	1015-1017
miR	B	1018-1021
-	I	1021-1022
21	I	1022-1024
were	O	1025-1029
elevated	O	1030-1038
in	O	1039-1041
patients	O	1042-1050
with	O	1051-1055
CHC	O	1056-1059
compared	O	1060-1068
to	O	1069-1071
healthy	O	1072-1079
controls	O	1080-1088
(	O	1089-1090
P	O	1090-1091
<	O	1091-1092
0	O	1092-1093
.	O	1093-1094
001	O	1094-1097
)	O	1097-1098
;	O	1098-1099
there	O	1100-1105
was	O	1106-1109
no	O	1110-1112
difference	O	1113-1123
between	O	1124-1131
serum	O	1132-1137
miR	B	1138-1141
-	I	1141-1142
21	I	1142-1144
in	O	1145-1147
patients	O	1148-1156
with	O	1157-1161
CHC	O	1162-1165
and	O	1166-1169
CHC	O	1170-1173
-	O	1173-1174
associated	O	1174-1184
HCC	O	1185-1188
.	O	1188-1189

Serum	O	1190-1195
miR	B	1196-1199
-	I	1199-1200
21	I	1200-1202
levels	O	1203-1209
correlated	O	1210-1220
with	O	1221-1225
histological	O	1226-1238
activity	O	1239-1247
index	O	1248-1253
(	O	1254-1255
HAI	O	1255-1258
)	O	1258-1259
in	O	1260-1262
the	O	1263-1266
liver	O	1267-1272
(	O	1273-1274
r	O	1274-1275
=	O	1276-1277
-	O	1278-1279
0	O	1279-1280
.	O	1280-1281
494	O	1281-1284
,	O	1284-1285
P	O	1286-1287
=	O	1288-1289
0	O	1290-1291
.	O	1291-1292
00002	O	1292-1297
)	O	1297-1298
,	O	1298-1299
alanine	O	1300-1307
aminotransferase	O	1308-1324
(	O	1325-1326
ALT	O	1326-1329
)	O	1329-1330
(	O	1331-1332
r	O	1332-1333
=	O	1334-1335
-	O	1336-1337
0	O	1337-1338
.	O	1338-1339
309	O	1339-1342
,	O	1342-1343
P	O	1344-1345
=	O	1346-1347
0	O	1348-1349
.	O	1349-1350
007	O	1350-1353
)	O	1353-1354
,	O	1354-1355
aspartate	O	1356-1365
aminotransferase	O	1366-1382
(	O	1383-1384
r	O	1384-1385
=	O	1386-1387
-	O	1388-1389
0	O	1389-1390
.	O	1390-1391
495	O	1391-1394
,	O	1394-1395
P	O	1396-1397
=	O	1398-1399
0	O	1400-1401
.	O	1401-1402
000007	O	1402-1408
)	O	1408-1409
,	O	1409-1410
bilirubin	O	1411-1420
(	O	1421-1422
r	O	1422-1423
=	O	1424-1425
-	O	1426-1427
0	O	1427-1428
.	O	1428-1429
362	O	1429-1432
,	O	1432-1433
P	O	1434-1435
=	O	1436-1437
0	O	1438-1439
.	O	1439-1440
002	O	1440-1443
)	O	1443-1444
,	O	1444-1445
international	O	1446-1459
normalized	O	1460-1470
ratio	O	1471-1476
(	O	1477-1478
r	O	1478-1479
=	O	1480-1481
-	O	1482-1483
0	O	1483-1484
.	O	1484-1485
338	O	1485-1488
,	O	1488-1489
P	O	1490-1491
=	O	1492-1493
0	O	1494-1495
.	O	1495-1496
034	O	1496-1499
)	O	1499-1500
and	O	1501-1504
gamma	O	1505-1510
-	O	1510-1511
glutamyltransferase	O	1511-1530
(	O	1531-1532
r	O	1532-1533
=	O	1534-1535
-	O	1536-1537
0	O	1537-1538
.	O	1538-1539
244	O	1539-1542
,	O	1542-1543
P	O	1544-1545
=	O	1546-1547
0	O	1548-1549
.	O	1549-1550
034	O	1550-1553
)	O	1553-1554
.	O	1554-1555

Multivariate	O	1556-1568
analysis	O	1569-1577
revealed	O	1578-1586
that	O	1587-1591
ALT	O	1592-1595
and	O	1596-1599
miR	B	1600-1603
-	I	1603-1604
21	I	1604-1606
serum	O	1607-1612
levels	O	1613-1619
were	O	1620-1624
independently	O	1625-1638
associated	O	1639-1649
with	O	1650-1654
HAI	O	1655-1658
.	O	1658-1659

At	O	1660-1662
a	O	1663-1664
cut	O	1665-1668
-	O	1668-1669
off	O	1669-1672
dC	O	1673-1675
(	O	1675-1676
T	O	1676-1677
)	O	1677-1678
of	O	1679-1681
1	O	1682-1683
.	O	1683-1684
96	O	1684-1686
,	O	1686-1687
miR	B	1688-1691
-	I	1691-1692
21	I	1692-1694
discriminated	O	1695-1708
between	O	1709-1716
minimal	O	1717-1724
and	O	1725-1728
mild	O	1729-1733
-	O	1733-1734
severe	O	1734-1740
necroinflammation	O	1741-1758
(	O	1759-1760
AUC	O	1760-1763
=	O	1764-1765
0	O	1766-1767
.	O	1767-1768
758	O	1768-1771
)	O	1771-1772
with	O	1773-1777
a	O	1778-1779
sensitivity	O	1780-1791
of	O	1792-1794
53	O	1795-1797
.	O	1797-1798
3	O	1798-1799
%	O	1799-1800
and	O	1801-1804
a	O	1805-1806
specificity	O	1807-1818
of	O	1819-1821
95	O	1822-1824
.	O	1824-1825
2	O	1825-1826
%	O	1826-1827
.	O	1827-1828

CONCLUSIONS	O	1829-1840
/	O	1840-1841
SIGNIFICANCE	O	1841-1853
:	O	1853-1854
The	O	1855-1858
serum	O	1859-1864
miR	B	1865-1868
-	I	1868-1869
21	I	1869-1871
level	O	1872-1877
is	O	1878-1880
a	O	1881-1882
marker	O	1883-1889
for	O	1890-1893
necroinflammatory	O	1894-1911
activity	O	1912-1920
,	O	1920-1921
but	O	1922-1925
does	O	1926-1930
not	O	1931-1934
differ	O	1935-1941
between	O	1942-1949
patients	O	1950-1958
with	O	1959-1963
HCV	O	1964-1967
and	O	1968-1971
HCV	O	1972-1975
-	O	1975-1976
induced	O	1976-1983
HCC	O	1984-1987
.	O	1987-1988

Nodal	O	0-5
marginal	O	6-14
zone	O	15-19
lymphoma	O	20-28
:	O	28-29
gene	O	30-34
expression	O	35-45
and	O	46-49
miRNA	O	50-55
profiling	O	56-65
identify	O	66-74
diagnostic	O	75-85
markers	O	86-93
and	O	94-97
potential	O	98-107
therapeutic	O	108-119
targets	O	120-127
.	O	127-128

Nodal	O	129-134
marginal	O	135-143
zone	O	144-148
lymphoma	O	149-157
(	O	158-159
NMZL	O	159-163
)	O	163-164
is	O	165-167
a	O	168-169
small	O	170-175
B	O	176-177
-	O	177-178
cell	O	178-182
neoplasm	O	183-191
whose	O	192-197
molecular	O	198-207
pathogenesis	O	208-220
is	O	221-223
still	O	224-229
essentially	O	230-241
unknown	O	242-249
and	O	250-253
whose	O	254-259
differentiation	O	260-275
from	O	276-280
other	O	281-286
small	O	287-292
B	O	293-294
-	O	294-295
cell	O	295-299
lymphomas	O	300-309
is	O	310-312
hampered	O	313-321
by	O	322-324
the	O	325-328
lack	O	329-333
of	O	334-336
specific	O	337-345
markers	O	346-353
.	O	353-354

We	O	355-357
have	O	358-362
analyzed	O	363-371
gene	O	372-376
expression	O	377-387
,	O	387-388
miRNA	O	389-394
profile	O	395-402
,	O	402-403
and	O	404-407
copy	O	408-412
number	O	413-419
data	O	420-424
from	O	425-429
15	O	430-432
NMZL	O	433-437
cases	O	438-443
.	O	443-444

For	O	445-448
comparison	O	449-459
,	O	459-460
16	O	461-463
follicular	O	464-474
lymphomas	O	475-484
(	O	485-486
FLs	O	486-489
)	O	489-490
,	O	490-491
9	O	492-493
extranodal	O	494-504
marginal	O	505-513
zone	O	514-518
lymphomas	O	519-528
,	O	528-529
and	O	530-533
8	O	534-535
reactive	O	536-544
lymph	O	545-550
nodes	O	551-556
and	O	557-560
B	O	561-562
-	O	562-563
cell	O	563-567
subtypes	O	568-576
were	O	577-581
included	O	582-590
.	O	590-591

The	O	592-595
results	O	596-603
were	O	604-608
validated	O	609-618
by	O	619-621
quantitative	O	622-634
RT	O	635-637
-	O	637-638
PCR	O	638-641
in	O	642-644
an	O	645-647
independent	O	648-659
series	O	660-666
,	O	666-667
including	O	668-677
61	O	678-680
paraffin	O	681-689
-	O	689-690
embedded	O	690-698
NMZLs	O	699-704
.	O	704-705

NMZL	O	706-710
signature	O	711-720
showed	O	721-727
an	O	728-730
enriched	O	731-739
expression	O	740-750
of	O	751-753
gene	O	754-758
sets	O	759-763
identifying	O	764-775
interleukins	O	776-788
,	O	788-789
integrins	O	790-799
,	O	799-800
CD40	O	801-805
,	O	805-806
PI3K	O	807-811
,	O	811-812
NF	O	813-815
-	O	815-816
kappaB	O	816-822
,	O	822-823
and	O	824-827
TGF	O	828-831
-	O	831-832
beta	O	832-836
,	O	836-837
and	O	838-841
included	O	842-850
genes	O	851-856
expressed	O	857-866
by	O	867-869
normal	O	870-876
marginal	O	877-885
zone	O	886-890
cells	O	891-896
and	O	897-900
memory	O	901-907
B	O	908-909
cells	O	910-915
.	O	915-916

The	O	917-920
most	O	921-925
highly	O	926-932
overexpressed	O	933-946
genes	O	947-952
were	O	953-957
SYK	O	958-961
,	O	961-962
TACI	O	963-967
,	O	967-968
CD74	O	969-973
,	O	973-974
CD82	O	975-979
,	O	979-980
and	O	981-984
CDC42EP5	O	985-993
.	O	993-994

Genes	O	995-1000
linked	O	1001-1007
to	O	1008-1010
G	O	1011-1012
(	O	1012-1013
2	O	1013-1014
)	O	1014-1015
/	O	1015-1016
M	O	1016-1017
and	O	1018-1021
germinal	O	1022-1030
center	O	1031-1037
were	O	1038-1042
down	O	1043-1047
-	O	1047-1048
regulated	O	1048-1057
.	O	1057-1058

Comparison	O	1059-1069
of	O	1070-1072
the	O	1073-1076
gene	O	1077-1081
expression	O	1082-1092
profiles	O	1093-1101
of	O	1102-1104
NMZL	O	1105-1109
and	O	1110-1113
FL	O	1114-1116
showed	O	1117-1123
enriched	O	1124-1132
expression	O	1133-1143
of	O	1144-1146
CHIT1	O	1147-1152
,	O	1152-1153
TGFB1	O	1154-1159
,	O	1159-1160
and	O	1161-1164
TACI	O	1165-1169
in	O	1170-1172
NMZL	O	1173-1177
,	O	1177-1178
and	O	1179-1182
BCL6	O	1183-1187
,	O	1187-1188
LMO2	O	1189-1193
,	O	1193-1194
and	O	1195-1198
CD10	O	1199-1203
in	O	1204-1206
FL	O	1207-1209
.	O	1209-1210

NMZL	O	1211-1215
displayed	O	1216-1225
increased	O	1226-1235
expression	O	1236-1246
of	O	1247-1249
miR	B	1250-1253
-	I	1253-1254
221	I	1254-1257
,	O	1257-1258
miR	B	1259-1262
-	I	1262-1263
223	I	1263-1266
,	O	1266-1267
and	O	1268-1271
let	B	1272-1275
-	I	1275-1276
7f	I	1276-1278
,	O	1278-1279
whereas	O	1280-1287
FL	O	1288-1290
strongly	O	1291-1299
expressed	O	1300-1309
miR	B	1310-1313
-	I	1313-1314
494	I	1314-1317
.	O	1317-1318

Our	O	1319-1322
study	O	1323-1328
identifies	O	1329-1339
new	O	1340-1343
candidate	O	1344-1353
diagnostic	O	1354-1364
molecules	O	1365-1374
for	O	1375-1378
NMZL	O	1379-1383
and	O	1384-1387
reveals	O	1388-1395
survival	O	1396-1404
pathways	O	1405-1413
activated	O	1414-1423
in	O	1424-1426
NMZL	O	1427-1431
.	O	1431-1432

MicroRNA	B	0-8
-	I	8-9
195	I	9-12
promotes	O	13-21
apoptosis	O	22-31
in	O	32-34
mouse	O	35-40
podocytes	O	41-50
via	O	51-54
enhanced	O	55-63
caspase	O	64-71
activity	O	72-80
driven	O	81-87
by	O	88-90
BCL2	O	91-95
insufficiency	O	96-109
.	O	109-110

BACKGROUND	O	111-121
:	O	121-122
The	O	123-126
apoptosis	O	127-136
of	O	137-139
podocytes	O	140-149
is	O	150-152
a	O	153-154
characteristic	O	155-169
event	O	170-175
in	O	176-178
diabetic	O	179-187
nephropathy	O	188-199
.	O	199-200

The	O	201-204
aim	O	205-208
of	O	209-211
this	O	212-216
study	O	217-222
was	O	223-226
to	O	227-229
investigate	O	230-241
whether	O	242-249
microRNAs	O	250-259
(	O	260-261
miRNAs	O	261-267
)	O	267-268
affect	O	269-275
podocyte	O	276-284
apoptosis	O	285-294
in	O	295-297
diabetic	O	298-306
circumstances	O	307-320
.	O	320-321

METHODS	O	322-329
:	O	329-330
Diabetic	O	331-339
nephropathy	O	340-351
was	O	352-355
induced	O	356-363
in	O	364-366
DBA	O	367-370
/	O	370-371
2	O	371-372
mice	O	373-377
by	O	378-380
intraperitoneal	O	381-396
injections	O	397-407
of	O	408-410
streptozotocin	O	411-425
,	O	425-426
and	O	427-430
the	O	431-434
levels	O	435-441
of	O	442-444
proteinuria	O	445-456
were	O	457-461
measured	O	462-470
with	O	471-475
ELISA	O	476-481
.	O	481-482

Apoptosis	O	483-492
-	O	492-493
related	O	493-500
miRNAs	O	501-507
were	O	508-512
screened	O	513-521
in	O	522-524
isolated	O	525-533
glomeruli	O	534-543
.	O	543-544

A	O	545-546
conditionally	O	547-560
immortalized	O	561-573
mouse	O	574-579
podocyte	O	580-588
cell	O	589-593
line	O	594-598
was	O	599-602
cultured	O	603-611
in	O	612-614
25	O	615-617
mMD	O	618-621
-	O	621-622
glucose	O	622-629
and	O	630-633
either	O	634-640
transfected	O	641-652
with	O	653-657
miRNA	B	658-663
-	I	663-664
195	I	664-667
(	O	668-669
miR	B	669-672
-	I	672-673
195	I	673-676
)	O	676-677
mimics	O	678-684
or	O	685-687
inhibitors	O	688-698
.	O	698-699

The	O	700-703
levels	O	704-710
of	O	711-713
BCL2	O	714-718
and	O	719-722
caspase	O	723-730
expression	O	731-741
were	O	742-746
determined	O	747-757
using	O	758-763
real	O	764-768
-	O	768-769
time	O	769-773
RT	O	774-776
-	O	776-777
PCR	O	777-780
and	O	781-784
Western	O	785-792
blot	O	793-797
analysis	O	798-806
,	O	806-807
respectively	O	808-820
.	O	820-821

We	O	822-824
also	O	825-829
measured	O	830-838
WT	O	839-841
-	O	841-842
1	O	842-843
and	O	844-847
synaptopodin	O	848-860
in	O	861-863
podocytes	O	864-873
.	O	873-874

Apoptosis	O	875-884
of	O	885-887
podocytes	O	888-897
was	O	898-901
assessed	O	902-910
with	O	911-915
Hoechst	O	916-923
33258	O	924-929
nuclear	O	930-937
staining	O	938-946
,	O	946-947
terminal	O	948-956
deoxynucleotidyl	O	957-973
transferase	O	974-985
dUTP	O	986-990
nick	O	991-995
end	O	996-999
labeling	O	1000-1008
(	O	1009-1010
TUNEL	O	1010-1015
)	O	1015-1016
,	O	1016-1017
and	O	1018-1021
flow	O	1022-1026
cytometry	O	1027-1036
.	O	1036-1037

RESULTS	O	1038-1045
:	O	1045-1046
The	O	1047-1050
expression	O	1051-1061
of	O	1062-1064
miR	B	1065-1068
-	I	1068-1069
195	I	1069-1072
was	O	1073-1076
elevated	O	1077-1085
in	O	1086-1088
both	O	1089-1093
diabetic	O	1094-1102
mice	O	1103-1107
with	O	1108-1112
proteinuria	O	1113-1124
and	O	1125-1128
podocytes	O	1129-1138
that	O	1139-1143
were	O	1144-1148
cultured	O	1149-1157
in	O	1158-1160
high	O	1161-1165
glucose	O	1166-1173
.	O	1173-1174

Transfection	O	1175-1187
with	O	1188-1192
miR	B	1193-1196
-	I	1196-1197
195	I	1197-1200
reduced	O	1201-1208
the	O	1209-1212
protein	O	1213-1220
levels	O	1221-1227
of	O	1228-1230
BCL2	O	1231-1235
and	O	1236-1239
contributed	O	1240-1251
to	O	1252-1254
podocyte	O	1255-1263
apoptosis	O	1264-1273
via	O	1274-1277
an	O	1278-1280
increase	O	1281-1289
in	O	1290-1292
caspase	O	1293-1300
-	O	1300-1301
3	O	1301-1302
.	O	1302-1303

miR	B	1304-1307
-	I	1307-1308
195	I	1308-1311
-	O	1311-1312
treated	O	1312-1319
podocytes	O	1320-1329
underwent	O	1330-1339
actin	O	1340-1345
rearrangement	O	1346-1359
and	O	1360-1363
failed	O	1364-1370
to	O	1371-1373
synthesize	O	1374-1384
sufficient	O	1385-1395
levels	O	1396-1402
of	O	1403-1405
WT	O	1406-1408
-	O	1408-1409
1	O	1409-1410
and	O	1411-1414
synaptopodin	O	1415-1427
proteins	O	1428-1436
,	O	1436-1437
which	O	1438-1443
suggests	O	1444-1452
that	O	1453-1457
the	O	1458-1461
cells	O	1462-1467
had	O	1468-1471
suffered	O	1472-1480
injuries	O	1481-1489
similar	O	1490-1497
to	O	1498-1500
those	O	1501-1506
observed	O	1507-1515
in	O	1516-1518
diabetic	O	1519-1527
nephropathy	O	1528-1539
in	O	1540-1542
both	O	1543-1547
humans	O	1548-1554
and	O	1555-1558
animal	O	1559-1565
models	O	1566-1572
.	O	1572-1573

CONCLUSIONS	O	1574-1585
:	O	1585-1586
Taken	O	1587-1592
together	O	1593-1601
,	O	1601-1602
our	O	1603-1606
findings	O	1607-1615
demonstrate	O	1616-1627
that	O	1628-1632
miR	B	1633-1636
-	I	1636-1637
195	I	1637-1640
promotes	O	1641-1649
apoptosis	O	1650-1659
of	O	1660-1662
podocytes	O	1663-1672
under	O	1673-1678
high	O	1679-1683
-	O	1683-1684
glucose	O	1684-1691
conditions	O	1692-1702
via	O	1703-1706
enhanced	O	1707-1715
caspase	O	1716-1723
cascades	O	1724-1732
for	O	1733-1736
BCL2	O	1737-1741
insufficiency	O	1742-1755
.	O	1755-1756

This	O	1757-1761
work	O	1762-1766
thus	O	1767-1771
presents	O	1772-1780
a	O	1781-1782
meaningful	O	1783-1793
approach	O	1794-1802
for	O	1803-1806
deciphering	O	1807-1818
mechanisms	O	1819-1829
,	O	1829-1830
by	O	1831-1833
which	O	1834-1839
miRNAs	O	1840-1846
participate	O	1847-1858
in	O	1859-1861
diabetic	O	1862-1870
renal	O	1871-1876
injury	O	1877-1883
.	O	1883-1884

microRNA	B	0-8
-	I	8-9
30c	I	9-12
negatively	O	13-23
regulates	O	24-33
endometrial	O	34-45
cancer	O	46-52
cells	O	53-58
by	O	59-61
targeting	O	62-71
metastasis	O	72-82
-	O	82-83
associated	O	83-93
gene	O	94-98
-	O	98-99
1	O	99-100
.	O	100-101

It	O	102-104
is	O	105-107
well	O	108-112
known	O	113-118
that	O	119-123
microRNAs	O	124-133
(	O	134-135
miRNAs	O	135-141
)	O	141-142
play	O	143-147
important	O	148-157
roles	O	158-163
in	O	164-166
cancer	O	167-173
development	O	174-185
by	O	186-188
targeting	O	189-198
oncogenes	O	199-208
or	O	209-211
tumor	O	212-217
-	O	217-218
suppressor	O	218-228
genes	O	229-234
.	O	234-235

However	O	236-243
,	O	243-244
little	O	245-251
is	O	252-254
known	O	255-260
regarding	O	261-270
the	O	271-274
mechanisms	O	275-285
of	O	286-288
miR	B	289-292
-	I	292-293
30c	I	293-296
action	O	297-303
in	O	304-306
endometrial	O	307-318
cancer	O	319-325
.	O	325-326

In	O	327-329
this	O	330-334
study	O	335-340
,	O	340-341
we	O	342-344
aimed	O	345-350
to	O	351-353
determine	O	354-363
whether	O	364-371
miR	B	372-375
-	I	375-376
30c	I	376-379
targets	O	380-387
metastasis	O	388-398
-	O	398-399
associated	O	399-409
gene	O	410-414
-	O	414-415
1	O	415-416
(	O	417-418
MTA1	O	418-422
)	O	422-423
and	O	424-427
acts	O	428-432
as	O	433-435
a	O	436-437
tumor	O	438-443
suppressor	O	444-454
in	O	455-457
endometrial	O	458-469
cancer	O	470-476
cell	O	477-481
lines	O	482-487
Ishikawa	O	488-496
(	O	497-498
estrogen	O	498-506
receptor	O	507-515
-	O	515-516
positive	O	516-524
,	O	524-525
ER	O	526-528
+	O	528-529
)	O	529-530
and	O	531-534
HEC	O	535-538
-	O	538-539
1	O	539-540
-	O	540-541
B	O	541-542
(	O	543-544
ER	O	544-546
-	O	546-547
)	O	547-548
by	O	549-551
down	O	552-556
-	O	556-557
regulating	O	557-567
MTA1	O	568-572
.	O	572-573

As	O	574-576
a	O	577-578
result	O	579-585
,	O	585-586
in	O	587-589
both	O	590-594
Ishikawa	O	595-603
and	O	604-607
HEC	O	608-611
-	O	611-612
1	O	612-613
-	O	613-614
B	O	614-615
cells	O	616-621
,	O	621-622
real	O	623-627
-	O	627-628
time	O	628-632
PCR	O	633-636
demonstrated	O	637-649
that	O	650-654
overexpression	O	655-669
of	O	670-672
miR	B	673-676
-	I	676-677
30c	I	677-680
led	O	681-684
to	O	685-687
the	O	688-691
down	O	692-696
-	O	696-697
regulation	O	697-707
of	O	708-710
MTA1	O	711-715
mRNA	O	716-720
(	O	721-722
P	O	722-723
<	O	723-724
0	O	724-725
.	O	725-726
05	O	726-728
)	O	728-729
,	O	729-730
while	O	731-736
Western	O	737-744
blotting	O	745-753
confirmed	O	754-763
the	O	764-767
reduced	O	768-775
expression	O	776-786
levels	O	787-793
of	O	794-796
MTA1	O	797-801
protein	O	802-809
(	O	810-811
P	O	811-812
<	O	812-813
0	O	813-814
.	O	814-815
01	O	815-817
)	O	817-818
.	O	818-819

A	O	820-821
dual	O	822-826
-	O	826-827
luciferase	O	827-837
reporter	O	838-846
assay	O	847-852
demonstrated	O	853-865
that	O	866-870
miR	B	871-874
-	I	874-875
30c	I	875-878
was	O	879-882
directly	O	883-891
bound	O	892-897
to	O	898-900
the	O	901-904
3	O	905-906
'	O	906-907
-	O	907-908
untranslated	O	908-920
regions	O	921-928
of	O	929-931
MTA1	O	932-936
.	O	936-937

Then	O	938-942
we	O	943-945
studied	O	946-953
the	O	954-957
biological	O	958-968
mechanisms	O	969-979
of	O	980-982
endometrial	O	983-994
cancer	O	995-1001
cells	O	1002-1007
transfected	O	1008-1019
with	O	1020-1024
the	O	1025-1028
Pre	B	1029-1032
-	I	1032-1033
miR	I	1033-1036
-	I	1036-1037
30c	I	1037-1040
plasmid	O	1041-1048
.	O	1048-1049

MTT	O	1050-1053
assay	O	1054-1059
and	O	1060-1063
growth	O	1064-1070
curves	O	1071-1077
revealed	O	1078-1086
that	O	1087-1091
miR	B	1092-1095
-	I	1095-1096
30c	I	1096-1099
inhibits	O	1100-1108
both	O	1109-1113
Ishikawa	O	1114-1122
and	O	1123-1126
HEC	O	1127-1130
-	O	1130-1131
1	O	1131-1132
-	O	1132-1133
B	O	1133-1134
cell	O	1135-1139
proliferation	O	1140-1153
.	O	1153-1154

However	O	1155-1162
,	O	1162-1163
we	O	1164-1166
did	O	1167-1170
not	O	1171-1174
see	O	1175-1178
obvious	O	1179-1186
differences	O	1187-1198
in	O	1199-1201
rates	O	1202-1207
of	O	1208-1210
apoptosis	O	1211-1220
between	O	1221-1228
miR	B	1229-1232
-	I	1232-1233
30c	I	1233-1236
-	O	1236-1237
overexpressing	O	1237-1251
and	O	1252-1255
the	O	1256-1259
negative	O	1260-1268
control	O	1269-1276
cells	O	1277-1282
.	O	1282-1283

Then	O	1284-1288
using	O	1289-1294
wound	O	1295-1300
-	O	1300-1301
healing	O	1301-1308
and	O	1309-1312
Matrigel	O	1313-1321
invasion	O	1322-1330
assays	O	1331-1337
,	O	1337-1338
we	O	1339-1341
found	O	1342-1347
that	O	1348-1352
the	O	1353-1356
migratory	O	1357-1366
and	O	1367-1370
invasive	O	1371-1379
abilities	O	1380-1389
of	O	1390-1392
cells	O	1393-1398
transfected	O	1399-1410
with	O	1411-1415
the	O	1416-1419
Pre	B	1420-1423
-	I	1423-1424
miR	I	1424-1427
-	I	1427-1428
30c	I	1428-1431
plasmid	O	1432-1439
were	O	1440-1444
significantly	O	1445-1458
suppressed	O	1459-1469
compared	O	1470-1478
with	O	1479-1483
the	O	1484-1487
control	O	1488-1495
cells	O	1496-1501
(	O	1502-1503
P	O	1503-1504
<	O	1504-1505
0	O	1505-1506
.	O	1506-1507
01	O	1507-1509
)	O	1509-1510
.	O	1510-1511

Overall	O	1512-1519
,	O	1519-1520
our	O	1521-1524
study	O	1525-1530
,	O	1530-1531
for	O	1532-1535
the	O	1536-1539
first	O	1540-1545
time	O	1546-1550
,	O	1550-1551
showed	O	1552-1558
that	O	1559-1563
MTA1	O	1564-1568
is	O	1569-1571
negatively	O	1572-1582
regulated	O	1583-1592
by	O	1593-1595
miR	B	1596-1599
-	I	1599-1600
30c	I	1600-1603
and	O	1604-1607
that	O	1608-1612
overexpression	O	1613-1627
of	O	1628-1630
miR	B	1631-1634
-	I	1634-1635
30c	I	1635-1638
inhibits	O	1639-1647
the	O	1648-1651
proliferative	O	1652-1665
,	O	1665-1666
migratory	O	1667-1676
and	O	1677-1680
invasive	O	1681-1689
abilities	O	1690-1699
of	O	1700-1702
endometrial	O	1703-1714
cancer	O	1715-1721
cells	O	1722-1727
.	O	1727-1728

These	O	1729-1734
results	O	1735-1742
suggest	O	1743-1750
that	O	1751-1755
miR	B	1756-1759
-	I	1759-1760
30c	I	1760-1763
acts	O	1764-1768
as	O	1769-1771
a	O	1772-1773
tumor	O	1774-1779
suppressor	O	1780-1790
and	O	1791-1794
negatively	O	1795-1805
regulates	O	1806-1815
endometrial	O	1816-1827
cancer	O	1828-1834
cells	O	1835-1840
by	O	1841-1843
targeting	O	1844-1853
MTA1	O	1854-1858
.	O	1858-1859

Microribonucleic	O	0-16
acids	O	17-22
and	O	23-26
gastric	O	27-34
cancer	O	35-41
.	O	41-42

Gastric	O	43-50
carcinogenesis	O	51-65
is	O	66-68
a	O	69-70
multistep	O	71-80
process	O	81-88
involving	O	89-98
genetic	O	99-106
and	O	107-110
epigenetic	O	111-121
alteration	O	122-132
of	O	133-135
protein	O	136-143
-	O	143-144
coding	O	144-150
proto	O	151-156
-	O	156-157
oncogenes	O	157-166
and	O	167-170
tumor	O	171-176
-	O	176-177
suppressor	O	177-187
genes	O	188-193
.	O	193-194

Microribonucleic	O	195-211
acids	O	212-217
(	O	218-219
miR	O	219-222
)	O	222-223
are	O	224-227
a	O	228-229
recently	O	230-238
-	O	238-239
described	O	239-248
class	O	249-254
of	O	255-257
genes	O	258-263
encoding	O	264-272
small	O	273-278
non	O	279-282
-	O	282-283
coding	O	283-289
RNA	O	290-293
molecules	O	294-303
,	O	303-304
which	O	305-310
primarily	O	311-320
act	O	321-324
by	O	325-327
downregulating	O	328-342
the	O	343-346
translation	O	347-358
of	O	359-361
target	O	362-368
mRNA	O	369-373
.	O	373-374

It	O	375-377
has	O	378-381
become	O	382-388
apparent	O	389-397
that	O	398-402
miR	O	403-406
are	O	407-410
also	O	411-415
key	O	416-419
factors	O	420-427
in	O	428-430
cancer	O	431-437
,	O	437-438
playing	O	439-446
both	O	447-451
oncogenic	O	452-461
and	O	462-465
tumor	O	466-471
-	O	471-472
suppressing	O	472-483
roles	O	484-489
in	O	490-492
gastric	O	493-500
cancer	O	501-507
.	O	507-508

Recent	O	509-515
studies	O	516-523
have	O	524-528
shown	O	529-534
that	O	535-539
a	O	540-541
substantial	O	542-553
number	O	554-560
of	O	561-563
miR	O	564-567
show	O	568-572
differential	O	573-585
expression	O	586-596
in	O	597-599
gastric	O	600-607
cancer	O	608-614
tissues	O	615-622
,	O	622-623
and	O	624-627
they	O	628-632
are	O	633-636
turning	O	637-644
out	O	645-648
to	O	649-651
be	O	652-654
just	O	655-659
like	O	660-664
any	O	665-668
other	O	669-674
regulatory	O	675-685
gene	O	686-690
.	O	690-691

In	O	692-694
this	O	695-699
connection	O	700-710
,	O	710-711
miR	O	712-715
dysregulation	O	716-729
are	O	730-733
reported	O	734-742
to	O	743-745
be	O	746-748
associated	O	749-759
with	O	760-764
incidence	O	765-774
,	O	774-775
early	O	776-781
diagnosis	O	782-791
and	O	792-795
prognosis	O	796-805
of	O	806-808
gastric	O	809-816
cancer	O	817-823
.	O	823-824

Therefore	O	825-834
,	O	834-835
investigation	O	836-849
of	O	850-852
the	O	853-856
biological	O	857-867
aspects	O	868-875
of	O	876-878
miR	O	879-882
dysregulation	O	883-896
might	O	897-902
help	O	903-907
us	O	908-910
better	O	911-917
understand	O	918-928
the	O	929-932
pathogenesis	O	933-945
of	O	946-948
gastric	O	949-956
cancer	O	957-963
and	O	964-967
promote	O	968-975
the	O	976-979
development	O	980-991
of	O	992-994
miR	O	995-998
-	O	998-999
directed	O	999-1007
therapeutics	O	1008-1020
against	O	1021-1028
this	O	1029-1033
deadly	O	1034-1040
disease	O	1041-1048
.	O	1048-1049

The	O	1050-1053
aim	O	1054-1057
of	O	1058-1060
the	O	1061-1064
present	O	1065-1072
review	O	1073-1079
was	O	1080-1083
to	O	1084-1086
describe	O	1087-1095
the	O	1096-1099
mechanisms	O	1100-1110
of	O	1111-1113
several	O	1114-1121
known	O	1122-1127
miR	O	1128-1131
,	O	1131-1132
summarize	O	1133-1142
recent	O	1143-1149
studies	O	1150-1157
on	O	1158-1160
oncogenic	O	1161-1170
miR	O	1171-1174
(	O	1175-1176
e	O	1176-1177
.	O	1177-1178
g	O	1178-1179
.	O	1179-1180

miR	B	1181-1184
-	I	1184-1185
21	I	1185-1187
,	O	1187-1188
miR	B	1189-1192
-	I	1192-1193
106a	I	1193-1197
and	O	1198-1201
miR	B	1202-1205
-	I	1205-1206
17	I	1206-1208
)	O	1208-1209
,	O	1209-1210
tumor	O	1211-1216
suppressor	O	1217-1227
miR	O	1228-1231
(	O	1232-1233
e	O	1233-1234
.	O	1234-1235
g	O	1235-1236
.	O	1236-1237

miR	B	1238-1241
-	I	1241-1242
101	I	1242-1245
,	O	1245-1246
miR	B	1247-1250
-	I	1250-1251
181	I	1251-1254
,	O	1254-1255
miR	B	1256-1259
-	I	1259-1260
449	I	1260-1263
,	O	1263-1264
miR	B	1265-1268
-	I	1268-1269
486	I	1269-1272
,	O	1272-1273
let	B	1274-1277
-	I	1277-1278
7a	I	1278-1280
)	O	1280-1281
and	O	1282-1285
controversial	O	1286-1299
roles	O	1300-1305
of	O	1306-1308
miR	O	1309-1312
(	O	1313-1314
e	O	1314-1315
.	O	1315-1316
g	O	1316-1317
.	O	1317-1318

miR	B	1319-1322
-	I	1322-1323
107	I	1323-1326
,	O	1326-1327
miR	B	1328-1331
-	I	1331-1332
126	I	1332-1335
)	O	1335-1336
for	O	1337-1340
gastric	O	1341-1348
cancer	O	1349-1355
.	O	1355-1356

In	O	1357-1359
addition	O	1360-1368
,	O	1368-1369
their	O	1370-1375
potential	O	1376-1385
clinical	O	1386-1394
applications	O	1395-1407
and	O	1408-1411
prospects	O	1412-1421
in	O	1422-1424
gastric	O	1425-1432
cancer	O	1433-1439
,	O	1439-1440
such	O	1441-1445
as	O	1446-1448
biomarkers	O	1449-1459
and	O	1460-1463
clinical	O	1464-1472
therapy	O	1473-1480
tools	O	1481-1486
,	O	1486-1487
are	O	1488-1491
also	O	1492-1496
briefly	O	1497-1504
discussed	O	1505-1514
.	O	1514-1515

Adenosine	O	0-9
A2A	O	10-13
receptor	O	14-22
upregulation	O	23-35
in	O	36-38
human	O	39-44
PMNs	O	45-49
is	O	50-52
controlled	O	53-63
by	O	64-66
miRNA	B	67-72
-	I	72-73
214	I	73-76
,	O	76-77
miRNA	B	78-83
-	I	83-84
15	I	84-86
,	O	86-87
and	O	88-91
miRNA	B	92-97
-	I	97-98
16	I	98-100
.	O	100-101

Immunosuppressive	O	102-119
signaling	O	120-129
via	O	130-133
the	O	134-137
adenosine	O	138-147
A2A	O	148-151
receptor	O	152-160
(	O	161-162
A2AR	O	162-166
)	O	166-167
is	O	168-170
an	O	171-173
important	O	174-183
pathway	O	184-191
to	O	192-194
control	O	195-202
inflammation	O	203-215
.	O	215-216

In	O	217-219
immune	O	220-226
cells	O	227-232
,	O	232-233
expression	O	234-244
levels	O	245-251
of	O	252-254
A2ARs	O	255-260
influence	O	261-270
responsiveness	O	271-285
to	O	286-288
inflammatory	O	289-301
stimuli	O	302-309
.	O	309-310

However	O	311-318
,	O	318-319
mechanisms	O	320-330
driving	O	331-338
expressional	O	339-351
changes	O	352-359
of	O	360-362
A2ARs	O	363-368
are	O	369-372
still	O	373-378
largely	O	379-386
elusive	O	387-394
.	O	394-395

In	O	396-398
the	O	399-402
current	O	403-410
study	O	411-416
,	O	416-417
we	O	418-420
have	O	421-425
investigated	O	426-438
the	O	439-442
impact	O	443-449
of	O	450-452
microRNAs	O	453-462
(	O	463-464
miRNAs	O	464-470
)	O	470-471
on	O	472-474
A2AR	O	475-479
expression	O	480-490
in	O	491-493
human	O	494-499
polymorphonuclear	O	500-517
leukocytes	O	518-528
(	O	529-530
PMNs	O	530-534
)	O	534-535
and	O	536-539
T	O	540-541
cells	O	542-547
.	O	547-548

Bioinformatic	O	549-562
analyses	O	563-571
and	O	572-575
reporter	O	576-584
gene	O	585-589
assays	O	590-596
revealed	O	597-605
that	O	606-610
A2AR	O	611-615
expression	O	616-626
is	O	627-629
controlled	O	630-640
by	O	641-643
miRNA	B	644-649
-	I	649-650
214	I	650-653
,	O	653-654
miRNA	B	655-660
-	I	660-661
15	I	661-663
,	O	663-664
and	O	665-668
miRNA	B	669-674
-	I	674-675
16	I	675-677
.	O	677-678

We	O	679-681
detected	O	682-690
all	O	691-694
three	O	695-700
miRNAs	O	701-707
in	O	708-710
both	O	711-715
human	O	716-721
PMNs	O	722-726
and	O	727-730
T	O	731-732
cells	O	733-738
.	O	738-739

However	O	740-747
,	O	747-748
in	O	749-751
PMNs	O	752-756
,	O	756-757
up	O	758-760
to	O	761-763
10	O	764-766
-	O	766-767
fold	O	767-771
higher	O	772-778
levels	O	779-785
of	O	786-788
miRNA	B	789-794
-	I	794-795
16	I	795-797
and	O	798-801
miRNA	B	802-807
-	I	807-808
214	I	808-811
were	O	812-816
detected	O	817-825
as	O	826-828
compared	O	829-837
with	O	838-842
T	O	843-844
cells	O	845-850
.	O	850-851

Upon	O	852-856
in	O	857-859
vitro	O	860-865
stimulation	O	866-877
,	O	877-878
no	O	879-881
significant	O	882-893
expressional	O	894-906
changes	O	907-914
occurred	O	915-923
.	O	923-924

Expression	O	925-935
levels	O	936-942
of	O	943-945
all	O	946-949
three	O	950-955
miRNAs	O	956-962
strongly	O	963-971
differed	O	972-980
between	O	981-988
individuals	O	989-1000
.	O	1000-1001

A2AR	O	1002-1006
expression	O	1007-1017
also	O	1018-1022
exhibited	O	1023-1032
significant	O	1033-1044
differences	O	1045-1056
between	O	1057-1064
PMNs	O	1065-1069
and	O	1070-1073
T	O	1074-1075
cells	O	1076-1081
:	O	1081-1082
In	O	1083-1085
PMNs	O	1086-1090
,	O	1090-1091
more	O	1092-1096
than	O	1097-1101
a	O	1102-1103
60	O	1104-1106
-	O	1106-1107
fold	O	1107-1111
increase	O	1112-1120
was	O	1121-1124
seen	O	1125-1129
upon	O	1130-1134
LPS	O	1135-1138
stimulation	O	1139-1150
,	O	1150-1151
whereas	O	1152-1159
in	O	1160-1162
T	O	1163-1164
cells	O	1165-1170
only	O	1171-1175
a	O	1176-1177
2	O	1178-1179
-	O	1179-1180
fold	O	1180-1184
increase	O	1185-1193
was	O	1194-1197
observed	O	1198-1206
upon	O	1207-1211
anti	O	1212-1216
-	O	1216-1217
CD3	O	1217-1220
/	O	1220-1221
CD28	O	1221-1225
activation	O	1226-1236
.	O	1236-1237

The	O	1238-1241
extent	O	1242-1248
of	O	1249-1251
A2AR	O	1252-1256
upregulation	O	1257-1269
in	O	1270-1272
PMNs	O	1273-1277
strongly	O	1278-1286
differed	O	1287-1295
between	O	1296-1303
individuals	O	1304-1315
(	O	1316-1317
from	O	1317-1321
less	O	1322-1326
than	O	1327-1331
10	O	1332-1334
-	O	1334-1335
fold	O	1335-1339
to	O	1340-1342
more	O	1343-1347
than	O	1348-1352
100	O	1353-1356
-	O	1356-1357
fold	O	1357-1361
)	O	1361-1362
.	O	1362-1363

In	O	1364-1366
PMNs	O	1367-1371
,	O	1371-1372
the	O	1373-1376
increase	O	1377-1385
in	O	1386-1388
A2AR	O	1389-1393
mRNA	O	1394-1398
expression	O	1399-1409
upon	O	1410-1414
stimulation	O	1415-1426
was	O	1427-1430
inversely	O	1431-1440
correlated	O	1441-1451
with	O	1452-1456
the	O	1457-1460
expression	O	1461-1471
levels	O	1472-1478
of	O	1479-1481
miRNA	B	1482-1487
-	I	1487-1488
214	I	1488-1491
,	O	1491-1492
miRNA	B	1493-1498
-	I	1498-1499
15	I	1499-1501
,	O	1501-1502
and	O	1503-1506
miRNA	B	1507-1512
-	I	1512-1513
16	I	1513-1515
(	O	1516-1517
R	O	1517-1518
=	O	1519-1520
-	O	1521-1522
0	O	1522-1523
.	O	1523-1524
87	O	1524-1526
,	O	1526-1527
P	O	1528-1529
<	O	1530-1531
0	O	1532-1533
.	O	1533-1534
0001	O	1534-1538
)	O	1538-1539
;	O	1539-1540
no	O	1541-1543
correlation	O	1544-1555
was	O	1556-1559
found	O	1560-1565
in	O	1566-1568
human	O	1569-1574
T	O	1575-1576
cells	O	1577-1582
.	O	1582-1583

These	O	1584-1589
results	O	1590-1597
indicate	O	1598-1606
that	O	1607-1611
individual	O	1612-1622
miRNA	O	1623-1628
profiles	O	1629-1637
gain	O	1638-1642
important	O	1643-1652
influence	O	1653-1662
on	O	1663-1665
A2AR	O	1666-1670
expression	O	1671-1681
regulation	O	1682-1692
in	O	1693-1695
PMNs	O	1696-1700
upon	O	1701-1705
stimulation	O	1706-1717
.	O	1717-1718

Determination	O	1719-1732
of	O	1733-1735
miRNA	O	1736-1741
expression	O	1742-1752
levels	O	1753-1759
may	O	1760-1763
help	O	1764-1768
to	O	1769-1771
identify	O	1772-1780
patients	O	1781-1789
with	O	1790-1794
an	O	1795-1797
increased	O	1798-1807
risk	O	1808-1812
for	O	1813-1816
severe	O	1817-1823
inflammation	O	1824-1836
.	O	1836-1837

Probing	O	0-7
the	O	8-11
polygenic	O	12-21
basis	O	22-27
of	O	28-30
cardiomyopathies	O	31-47
in	O	48-50
Drosophila	O	51-61
.	O	61-62

In	O	63-65
trying	O	66-72
to	O	73-75
understand	O	76-86
the	O	87-90
causes	O	91-97
for	O	98-101
congenital	O	102-112
heart	O	113-118
disease	O	119-126
and	O	127-130
cardiomyopathies	O	131-147
,	O	147-148
it	O	149-151
is	O	152-154
difficult	O	155-164
to	O	165-167
study	O	168-173
polygenic	O	174-183
interactions	O	184-196
that	O	197-201
contribute	O	202-212
to	O	213-215
the	O	216-219
severity	O	220-228
of	O	229-231
the	O	232-235
disease	O	236-243
,	O	243-244
which	O	245-250
is	O	251-253
in	O	254-256
part	O	257-261
due	O	262-265
to	O	266-268
genetic	O	269-276
complexity	O	277-287
and	O	288-291
generation	O	292-302
time	O	303-307
of	O	308-310
higher	O	311-317
organisms	O	318-327
that	O	328-332
hinder	O	333-339
efficient	O	340-349
screening	O	350-359
for	O	360-363
modifiers	O	364-373
of	O	374-376
primary	O	377-384
causes	O	385-391
of	O	392-394
heart	O	395-400
disease	O	401-408
.	O	408-409

The	O	410-413
adult	O	414-419
Drosophila	O	420-430
heart	O	431-436
has	O	437-440
recently	O	441-449
been	O	450-454
established	O	455-466
as	O	467-469
a	O	470-471
model	O	472-477
to	O	478-480
probe	O	481-486
genetic	O	487-494
interactions	O	495-507
that	O	508-512
lead	O	513-517
to	O	518-520
cardiac	O	521-528
dysfunction	O	529-540
in	O	541-543
this	O	544-548
genetically	O	549-560
simple	O	561-567
and	O	568-571
short	O	572-577
-	O	577-578
lived	O	578-583
organism	O	584-592
.	O	592-593

This	O	594-598
has	O	599-602
made	O	603-607
it	O	608-610
possible	O	611-619
to	O	620-622
systematically	O	623-637
and	O	638-641
efficiently	O	642-653
screen	O	654-660
for	O	661-664
polygenic	O	665-674
modulators	O	675-685
of	O	686-688
heart	O	689-694
dysfunction	O	695-706
inflicted	O	707-716
by	O	717-719
known	O	720-725
heart	O	726-731
disease	O	732-739
genes	O	740-745
.	O	745-746

As	O	747-749
heart	O	750-755
development	O	756-767
and	O	768-771
fundamental	O	772-783
aspects	O	784-791
of	O	792-794
cardiac	O	795-802
physiology	O	803-813
show	O	814-818
remarkable	O	819-829
evolutionary	O	830-842
conservation	O	843-855
,	O	855-856
it	O	857-859
has	O	860-863
become	O	864-870
possible	O	871-879
to	O	880-882
uncover	O	883-890
new	O	891-894
heart	O	895-900
disease	O	901-908
candidates	O	909-919
by	O	920-922
using	O	923-928
Drosophila	O	929-939
genetic	O	940-947
tools	O	948-953
in	O	954-956
combination	O	957-968
with	O	969-973
sensitive	O	974-983
heart	O	984-989
function	O	990-998
assays	O	999-1005
.	O	1005-1006

Here	O	1007-1011
,	O	1011-1012
we	O	1013-1015
review	O	1016-1022
the	O	1023-1026
discovery	O	1027-1036
of	O	1037-1039
several	O	1040-1047
new	O	1048-1051
genes	O	1052-1057
,	O	1057-1058
genetic	O	1059-1066
pathways	O	1067-1075
,	O	1075-1076
and	O	1077-1080
interactions	O	1081-1093
that	O	1094-1098
will	O	1099-1103
help	O	1104-1108
understand	O	1109-1119
human	O	1120-1125
heart	O	1126-1131
disease	O	1132-1139
.	O	1139-1140

For	O	1141-1144
example	O	1145-1152
,	O	1152-1153
interactions	O	1154-1166
between	O	1167-1174
cardiogenic	O	1175-1186
transcription	O	1187-1200
factors	O	1201-1208
,	O	1208-1209
discovered	O	1210-1220
in	O	1221-1223
Drosophila	O	1224-1234
,	O	1234-1235
are	O	1236-1239
also	O	1240-1244
critical	O	1245-1253
for	O	1254-1257
adult	O	1258-1263
heart	O	1264-1269
function	O	1270-1278
in	O	1279-1281
flies	O	1282-1287
and	O	1288-1291
mammals	O	1292-1299
.	O	1299-1300

These	O	1301-1306
include	O	1307-1314
interactions	O	1315-1327
between	O	1328-1335
tinman	O	1336-1342
/	O	1342-1343
Nkx2	O	1343-1347
-	O	1347-1348
5	O	1348-1349
and	O	1350-1353
neuromancer	O	1354-1365
/	O	1365-1366
Tbx20	O	1366-1371
,	O	1371-1372
which	O	1373-1378
led	O	1379-1382
to	O	1383-1385
the	O	1386-1389
discovery	O	1390-1399
of	O	1400-1402
possibly	O	1403-1411
disease	O	1412-1419
-	O	1419-1420
causing	O	1420-1427
familial	O	1428-1436
variants	O	1437-1445
in	O	1446-1448
human	O	1449-1454
TBX20	O	1455-1460
.	O	1460-1461

A	O	1462-1463
new	O	1464-1467
genetic	O	1468-1475
pathway	O	1476-1483
from	O	1484-1488
tinman	O	1489-1495
/	O	1495-1496
Nkx2	O	1496-1500
-	O	1500-1501
5	O	1501-1502
to	O	1503-1505
Cdc42	O	1506-1511
,	O	1511-1512
involving	O	1513-1522
the	O	1523-1526
microRNA	O	1527-1535
miR	B	1536-1539
-	I	1539-1540
1	I	1540-1541
,	O	1541-1542
was	O	1543-1546
recently	O	1547-1555
discovered	O	1556-1566
in	O	1567-1569
flies	O	1570-1575
and	O	1576-1579
subsequently	O	1580-1592
validated	O	1593-1602
to	O	1603-1605
function	O	1606-1614
similarly	O	1615-1624
in	O	1625-1627
mouse	O	1628-1633
heart	O	1634-1639
.	O	1639-1640

Thus	O	1641-1645
,	O	1645-1646
the	O	1647-1650
fly	O	1651-1654
heart	O	1655-1660
has	O	1661-1664
proven	O	1665-1671
to	O	1672-1674
be	O	1675-1677
a	O	1678-1679
useful	O	1680-1686
discovery	O	1687-1696
tool	O	1697-1701
for	O	1702-1705
screening	O	1706-1715
genetic	O	1716-1723
interactions	O	1724-1736
that	O	1737-1741
are	O	1742-1745
otherwise	O	1746-1755
difficult	O	1756-1765
to	O	1766-1768
conduct	O	1769-1776
.	O	1776-1777

Inhibition	O	0-10
of	O	11-13
microRNA	B	14-22
-	I	22-23
29b	I	23-26
reduces	O	27-34
murine	O	35-41
abdominal	O	42-51
aortic	O	52-58
aneurysm	O	59-67
development	O	68-79
.	O	79-80

MicroRNAs	O	81-90
(	O	91-92
miRs	O	92-96
)	O	96-97
regulate	O	98-106
gene	O	107-111
expression	O	112-122
at	O	123-125
the	O	126-129
posttranscriptional	O	130-149
level	O	150-155
and	O	156-159
play	O	160-164
crucial	O	165-172
roles	O	173-178
in	O	179-181
vascular	O	182-190
integrity	O	191-200
.	O	200-201

As	O	202-204
such	O	205-209
,	O	209-210
they	O	211-215
may	O	216-219
have	O	220-224
a	O	225-226
role	O	227-231
in	O	232-234
modifying	O	235-244
abdominal	O	245-254
aortic	O	255-261
aneurysm	O	262-270
(	O	271-272
AAA	O	272-275
)	O	275-276
expansion	O	277-286
,	O	286-287
the	O	288-291
pathophysiological	O	292-310
mechanisms	O	311-321
of	O	322-324
which	O	325-330
remain	O	331-337
incompletely	O	338-350
explored	O	351-359
.	O	359-360

Here	O	361-365
,	O	365-366
we	O	367-369
investigate	O	370-381
the	O	382-385
role	O	386-390
of	O	391-393
miRs	O	394-398
in	O	399-401
2	O	402-403
murine	O	404-410
models	O	411-417
of	O	418-420
experimental	O	421-433
AAA	O	434-437
:	O	437-438
the	O	439-442
porcine	O	443-450
pancreatic	O	451-461
elastase	O	462-470
(	O	471-472
PPE	O	472-475
)	O	475-476
infusion	O	477-485
model	O	486-491
in	O	492-494
C57BL	O	495-500
/	O	500-501
6	O	501-502
mice	O	503-507
and	O	508-511
the	O	512-515
AngII	O	516-521
infusion	O	522-530
model	O	531-536
in	O	537-539
Apoe	O	540-544
-	O	544-545
/	O	545-546
-	O	546-547
mice	O	548-552
.	O	552-553

AAA	O	554-557
development	O	558-569
was	O	570-573
accompanied	O	574-585
by	O	586-588
decreased	O	589-598
aortic	O	599-605
expression	O	606-616
of	O	617-619
miR	B	620-623
-	I	623-624
29b	I	624-627
,	O	627-628
along	O	629-634
with	O	635-639
increased	O	640-649
expression	O	650-660
of	O	661-663
known	O	664-669
miR	B	670-673
-	I	673-674
29b	I	674-677
targets	O	678-685
,	O	685-686
Col1a1	O	687-693
,	O	693-694
Col3a1	O	695-701
,	O	701-702
Col5a1	O	703-709
,	O	709-710
and	O	711-714
Eln	O	715-718
,	O	718-719
in	O	720-722
both	O	723-727
models	O	728-734
.	O	734-735

In	O	736-738
vivo	O	739-743
administration	O	744-758
of	O	759-761
locked	O	762-768
nucleic	O	769-776
acid	O	777-781
anti	O	782-786
-	O	786-787
miR	B	787-790
-	I	790-791
29b	I	791-794
greatly	O	795-802
increased	O	803-812
collagen	O	813-821
expression	O	822-832
,	O	832-833
leading	O	834-841
to	O	842-844
an	O	845-847
early	O	848-853
fibrotic	O	854-862
response	O	863-871
in	O	872-874
the	O	875-878
abdominal	O	879-888
aortic	O	889-895
wall	O	896-900
and	O	901-904
resulting	O	905-914
in	O	915-917
a	O	918-919
significant	O	920-931
reduction	O	932-941
in	O	942-944
AAA	O	945-948
progression	O	949-960
over	O	961-965
time	O	966-970
in	O	971-973
both	O	974-978
models	O	979-985
.	O	985-986

In	O	987-989
contrast	O	990-998
,	O	998-999
overexpression	O	1000-1014
of	O	1015-1017
miR	B	1018-1021
-	I	1021-1022
29b	I	1022-1025
using	O	1026-1031
a	O	1032-1033
lentiviral	O	1034-1044
vector	O	1045-1051
led	O	1052-1055
to	O	1056-1058
augmented	O	1059-1068
AAA	O	1069-1072
expansion	O	1073-1082
and	O	1083-1086
significant	O	1087-1098
increase	O	1099-1107
of	O	1108-1110
aortic	O	1111-1117
rupture	O	1118-1125
rate	O	1126-1130
.	O	1130-1131

Cell	O	1132-1136
culture	O	1137-1144
studies	O	1145-1152
identified	O	1153-1163
aortic	O	1164-1170
fibroblasts	O	1171-1182
as	O	1183-1185
the	O	1186-1189
likely	O	1190-1196
vascular	O	1197-1205
cell	O	1206-1210
type	O	1211-1215
mediating	O	1216-1225
the	O	1226-1229
profibrotic	O	1230-1241
effects	O	1242-1249
of	O	1250-1252
miR	B	1253-1256
-	I	1256-1257
29b	I	1257-1260
modulation	O	1261-1271
.	O	1271-1272

A	O	1273-1274
similar	O	1275-1282
pattern	O	1283-1290
of	O	1291-1293
reduced	O	1294-1301
miR	B	1302-1305
-	I	1305-1306
29b	I	1306-1309
expression	O	1310-1320
and	O	1321-1324
increased	O	1325-1334
target	O	1335-1341
gene	O	1342-1346
expression	O	1347-1357
was	O	1358-1361
observed	O	1362-1370
in	O	1371-1373
human	O	1374-1379
AAA	O	1380-1383
tissue	O	1384-1390
samples	O	1391-1398
compared	O	1399-1407
with	O	1408-1412
that	O	1413-1417
in	O	1418-1420
organ	O	1421-1426
donor	O	1427-1432
controls	O	1433-1441
.	O	1441-1442

These	O	1443-1448
data	O	1449-1453
suggest	O	1454-1461
that	O	1462-1466
therapeutic	O	1467-1478
manipulation	O	1479-1491
of	O	1492-1494
miR	B	1495-1498
-	I	1498-1499
29b	I	1499-1502
and	O	1503-1506
its	O	1507-1510
target	O	1511-1517
genes	O	1518-1523
holds	O	1524-1529
promise	O	1530-1537
for	O	1538-1541
limiting	O	1542-1550
AAA	O	1551-1554
disease	O	1555-1562
progression	O	1563-1574
and	O	1575-1578
protecting	O	1579-1589
from	O	1590-1594
rupture	O	1595-1602
.	O	1602-1603

Sulindac	O	0-8
inhibits	O	9-17
tumor	O	18-23
cell	O	24-28
invasion	O	29-37
by	O	38-40
suppressing	O	41-52
NF	O	53-55
-	O	55-56
kappaB	O	56-62
-	O	62-63
mediated	O	63-71
transcription	O	72-85
of	O	86-88
microRNAs	O	89-98
.	O	98-99

Non	O	100-103
-	O	103-104
steroidal	O	104-113
anti	O	114-118
-	O	118-119
inflammatory	O	119-131
drugs	O	132-137
(	O	138-139
NSAIDs	O	139-145
)	O	145-146
have	O	147-151
been	O	152-156
widely	O	157-163
reported	O	164-172
to	O	173-175
display	O	176-183
strong	O	184-190
efficacy	O	191-199
for	O	200-203
cancer	O	204-210
chemoprevention	O	211-226
,	O	226-227
although	O	228-236
their	O	237-242
mechanism	O	243-252
of	O	253-255
action	O	256-262
is	O	263-265
poorly	O	266-272
understood	O	273-283
.	O	283-284

The	O	285-288
most	O	289-293
well	O	294-298
-	O	298-299
documented	O	299-309
effects	O	310-317
of	O	318-320
NSAIDs	O	321-327
include	O	328-335
inhibition	O	336-346
of	O	347-349
tumor	O	350-355
cell	O	356-360
proliferation	O	361-374
and	O	375-378
induction	O	379-388
of	O	389-391
apoptosis	O	392-401
,	O	401-402
but	O	403-406
their	O	407-412
effect	O	413-419
on	O	420-422
tumor	O	423-428
cell	O	429-433
invasion	O	434-442
has	O	443-446
not	O	447-450
been	O	451-455
well	O	456-460
studied	O	461-468
.	O	468-469

Here	O	470-474
,	O	474-475
we	O	476-478
show	O	479-483
that	O	484-488
the	O	489-492
NSAID	O	493-498
,	O	498-499
sulindac	O	500-508
sulfide	O	509-516
(	O	517-518
SS	O	518-520
)	O	520-521
can	O	522-525
potently	O	526-534
inhibit	O	535-542
the	O	543-546
invasion	O	547-555
of	O	556-558
human	O	559-564
MDA	O	565-568
-	O	568-569
MB	O	569-571
-	O	571-572
231	O	572-575
breast	O	576-582
and	O	583-586
HCT116	O	587-593
colon	O	594-599
tumor	O	600-605
cells	O	606-611
in	O	612-614
vitro	O	615-620
at	O	621-623
concentrations	O	624-638
less	O	639-643
than	O	644-648
those	O	649-654
required	O	655-663
to	O	664-666
inhibit	O	667-674
tumor	O	675-680
cell	O	681-685
growth	O	686-692
.	O	692-693

To	O	694-696
study	O	697-702
the	O	703-706
molecular	O	707-716
basis	O	717-722
for	O	723-726
this	O	727-731
activity	O	732-740
,	O	740-741
we	O	742-744
investigated	O	745-757
the	O	758-761
involvement	O	762-773
of	O	774-776
microRNA	O	777-785
(	O	786-787
miRNA	O	787-792
)	O	792-793
.	O	793-794

A	O	795-796
total	O	797-802
of	O	803-805
132	O	806-809
miRNAs	O	810-816
were	O	817-821
found	O	822-827
to	O	828-830
be	O	831-833
altered	O	834-841
in	O	842-844
response	O	845-853
to	O	854-856
SS	O	857-859
treatment	O	860-869
,	O	869-870
including	O	871-880
miR	B	881-884
-	I	884-885
10b	I	885-888
,	O	888-889
miR	B	890-893
-	I	893-894
17	I	894-896
,	O	896-897
miR	B	898-901
-	I	901-902
21	I	902-904
and	O	905-908
miR	B	909-912
-	I	912-913
9	I	913-914
,	O	914-915
which	O	916-921
have	O	922-926
been	O	927-931
previously	O	932-942
implicated	O	943-953
in	O	954-956
tumor	O	957-962
invasion	O	963-971
and	O	972-975
metastasis	O	976-986
.	O	986-987

We	O	988-990
confirmed	O	991-1000
that	O	1001-1005
these	O	1006-1011
miRNA	O	1012-1017
can	O	1018-1021
stimulate	O	1022-1031
tumor	O	1032-1037
cell	O	1038-1042
invasion	O	1043-1051
and	O	1052-1055
show	O	1056-1060
that	O	1061-1065
SS	O	1066-1068
can	O	1069-1072
attenuate	O	1073-1082
their	O	1083-1088
invasive	O	1089-1097
effects	O	1098-1105
by	O	1106-1108
downregulating	O	1109-1123
their	O	1124-1129
expression	O	1130-1140
.	O	1140-1141

Employing	O	1142-1151
luciferase	O	1152-1162
and	O	1163-1166
chromatin	O	1167-1176
immunoprecipitation	O	1177-1196
assays	O	1197-1203
,	O	1203-1204
NF	O	1205-1207
-	O	1207-1208
kappaB	O	1208-1214
was	O	1215-1218
found	O	1219-1224
to	O	1225-1227
bind	O	1228-1232
the	O	1233-1236
promoters	O	1237-1246
of	O	1247-1249
all	O	1250-1253
four	O	1254-1258
miRNAs	O	1259-1265
to	O	1266-1268
suppress	O	1269-1277
their	O	1278-1283
expression	O	1284-1294
at	O	1295-1297
the	O	1298-1301
transcriptional	O	1302-1317
level	O	1318-1323
.	O	1323-1324

We	O	1325-1327
show	O	1328-1332
that	O	1333-1337
SS	O	1338-1340
can	O	1341-1344
inhibit	O	1345-1352
the	O	1353-1356
translocation	O	1357-1370
of	O	1371-1373
NF	O	1374-1376
-	O	1376-1377
kappaB	O	1377-1383
to	O	1384-1386
the	O	1387-1390
nucleus	O	1391-1398
by	O	1399-1401
decreasing	O	1402-1412
the	O	1413-1416
phosphorylation	O	1417-1432
of	O	1433-1435
IKKbeta	O	1436-1443
and	O	1444-1447
IkappaB	O	1448-1455
.	O	1455-1456

Analysis	O	1457-1465
of	O	1466-1468
the	O	1469-1472
promoter	O	1473-1481
sequences	O	1482-1491
of	O	1492-1494
the	O	1495-1498
miRNAs	O	1499-1505
suppressed	O	1506-1516
by	O	1517-1519
SS	O	1520-1522
revealed	O	1523-1531
that	O	1532-1536
81	O	1537-1539
of	O	1540-1542
115	O	1543-1546
sequences	O	1547-1556
contained	O	1557-1566
NF	O	1567-1569
-	O	1569-1570
kappaB	O	1570-1576
-	O	1576-1577
binding	O	1577-1584
sites	O	1585-1590
.	O	1590-1591

These	O	1592-1597
results	O	1598-1605
show	O	1606-1610
that	O	1611-1615
SS	O	1616-1618
can	O	1619-1622
inhibit	O	1623-1630
tumor	O	1631-1636
cell	O	1637-1641
invasion	O	1642-1650
by	O	1651-1653
suppressing	O	1654-1665
NF	O	1666-1668
-	O	1668-1669
kappaB	O	1669-1675
-	O	1675-1676
mediated	O	1676-1684
transcription	O	1685-1698
of	O	1699-1701
miRNAs	O	1702-1708
.	O	1708-1709

Computational	O	0-13
identification	O	14-28
of	O	29-31
miRNAs	O	32-38
in	O	39-41
medicinal	O	42-51
plant	O	52-57
Senecio	O	58-65
vulgaris	O	66-74
(	O	75-76
Groundsel	O	76-85
)	O	85-86
.	O	86-87

RNAs	O	88-92
Interference	O	93-105
plays	O	106-111
a	O	112-113
very	O	114-118
important	O	119-128
role	O	129-133
in	O	134-136
gene	O	137-141
silencing	O	142-151
.	O	151-152

In	O	153-155
vitro	O	156-161
identification	O	162-176
of	O	177-179
miRNAs	O	180-186
is	O	187-189
a	O	190-191
slow	O	192-196
process	O	197-204
as	O	205-207
it	O	208-210
is	O	211-213
difficult	O	214-223
to	O	224-226
isolate	O	227-234
them	O	235-239
.	O	239-240

Nucleotide	O	241-251
sequences	O	252-261
of	O	262-264
miRNAs	O	265-271
are	O	272-275
highly	O	276-282
conserved	O	283-292
among	O	293-298
the	O	299-302
plants	O	303-309
and	O	310-313
,	O	313-314
this	O	315-319
form	O	320-324
the	O	325-328
key	O	329-332
feature	O	333-340
behind	O	341-347
the	O	348-351
identification	O	352-366
of	O	367-369
miRNAs	O	370-376
in	O	377-379
plant	O	380-385
species	O	386-393
by	O	394-396
homology	O	397-405
alignment	O	406-415
.	O	415-416

In	O	417-419
silico	O	420-426
identification	O	427-441
of	O	442-444
miRNAs	O	445-451
from	O	452-456
EST	O	457-460
database	O	461-469
is	O	470-472
emerging	O	473-481
as	O	482-484
a	O	485-486
novel	O	487-492
,	O	492-493
faster	O	494-500
and	O	501-504
reliable	O	505-513
approach	O	514-522
.	O	522-523

Here	O	524-528
EST	O	529-532
sequences	O	533-542
of	O	543-545
Senecio	O	546-553
vulgaris	O	554-562
(	O	563-564
Groundsel	O	564-573
)	O	573-574
were	O	575-579
searched	O	580-588
against	O	589-596
known	O	597-602
miRNA	O	603-608
sequences	O	609-618
by	O	619-621
using	O	622-627
BLASTN	O	628-634
tool	O	635-639
.	O	639-640

A	O	641-642
total	O	643-648
of	O	649-651
10	O	652-654
miRNAs	O	655-661
were	O	662-666
identified	O	667-677
from	O	678-682
1956	O	683-687
EST	O	688-691
sequences	O	692-701
and	O	702-705
115	O	706-709
GSS	O	710-713
sequences	O	714-723
.	O	723-724

The	O	725-728
most	O	729-733
stable	O	734-740
miRNA	O	741-746
identified	O	747-757
is	O	758-760
svu	B	761-764
-	I	764-765
mir	I	765-768
-	I	768-769
1	I	769-770
.	O	770-771

This	O	772-776
approach	O	777-785
will	O	786-790
accelerate	O	791-801
advance	O	802-809
research	O	810-818
in	O	819-821
regulation	O	822-832
of	O	833-835
gene	O	836-840
expression	O	841-851
in	O	852-854
Groundsel	O	855-864
by	O	865-867
interfering	O	868-879
RNAs	O	880-884
.	O	884-885

MicroRNA	B	0-8
-	I	8-9
223	I	9-12
regulates	O	13-22
FOXO1	O	23-28
expression	O	29-39
and	O	40-43
cell	O	44-48
proliferation	O	49-62
.	O	62-63

In	O	64-66
HCT116	O	67-73
colorectal	O	74-84
cancer	O	85-91
cells	O	92-97
,	O	97-98
HeLa	O	99-103
cervical	O	104-112
cancer	O	113-119
cells	O	120-125
and	O	126-129
HuH	O	130-133
-	O	133-134
7	O	134-135
hepatoma	O	136-144
cells	O	145-150
,	O	150-151
miR	B	152-155
-	I	155-156
223	I	156-159
is	O	160-162
expressed	O	163-172
at	O	173-175
a	O	176-177
low	O	178-181
level	O	182-187
.	O	187-188

Through	O	189-196
infection	O	197-206
with	O	207-211
lentivirus	O	212-222
containing	O	223-233
miR	B	234-237
-	I	237-238
223	I	238-241
precursor	O	242-251
,	O	251-252
miR	B	253-256
-	I	256-257
223	I	257-260
[	O	261-262
corrected	O	262-271
]	O	271-272
was	O	273-276
overexpressed	O	277-290
in	O	291-293
all	O	294-297
these	O	298-303
cells	O	304-309
.	O	309-310

Interestingly	O	311-324
,	O	324-325
the	O	326-329
expression	O	330-340
levels	O	341-347
of	O	348-350
FOXO1	O	351-356
mRNA	O	357-361
and	O	362-365
protein	O	366-373
,	O	373-374
and	O	375-378
phosphorylation	O	379-394
levels	O	395-401
became	O	402-408
significantly	O	409-422
lower	O	423-428
than	O	429-433
those	O	434-439
of	O	440-442
their	O	443-448
control	O	449-456
.	O	456-457

FOXO1	O	458-463
was	O	464-467
down	O	468-472
-	O	472-473
regulated	O	473-482
mainly	O	483-489
in	O	490-492
the	O	493-496
cytoplasm	O	497-506
,	O	506-507
while	O	508-513
the	O	514-517
nuclear	O	518-525
FOXO1	O	526-531
level	O	532-537
became	O	538-544
relatively	O	545-555
high	O	556-560
compared	O	561-569
to	O	570-572
the	O	573-576
cytoplasm	O	577-586
.	O	586-587

As	O	588-590
the	O	591-594
unphosphorylated	O	595-611
active	O	612-618
form	O	619-623
of	O	624-626
FOXO1	O	627-632
increased	O	633-642
in	O	643-645
the	O	646-649
cells	O	650-655
,	O	655-656
cyclin	O	657-663
D1	O	664-666
/	O	666-667
p21	O	667-670
/	O	670-671
p27	O	671-674
were	O	675-679
up	O	680-682
-	O	682-683
regulated	O	683-692
at	O	693-695
either	O	696-702
mRNA	O	703-707
or	O	708-710
protein	O	711-718
level	O	719-724
.	O	724-725

Proliferation	O	726-739
of	O	740-742
the	O	743-746
cells	O	747-752
was	O	753-756
also	O	757-761
greatly	O	762-769
inhibited	O	770-779
when	O	780-784
miR	B	785-788
-	I	788-789
223	I	789-792
was	O	793-796
over	O	797-801
-	O	801-802
expressed	O	802-811
.	O	811-812

Therein	O	813-820
,	O	820-821
our	O	822-825
data	O	826-830
suggest	O	831-838
that	O	839-843
miR	B	844-847
-	I	847-848
223	I	848-851
regulates	O	852-861
FOXO1	O	862-867
expression	O	868-878
and	O	879-882
cell	O	883-887
proliferation	O	888-901
.	O	901-902

Global	O	0-6
microRNA	O	7-15
expression	O	16-26
profiling	O	27-36
of	O	37-39
high	O	40-44
-	O	44-45
risk	O	45-49
ER	O	50-52
+	O	52-53
breast	O	54-60
cancers	O	61-68
from	O	69-73
patients	O	74-82
receiving	O	83-92
adjuvant	O	93-101
tamoxifen	O	102-111
mono	O	112-116
-	O	116-117
therapy	O	117-124
:	O	124-125
a	O	126-127
DBCG	O	128-132
study	O	133-138
.	O	138-139

PURPOSE	O	140-147
:	O	147-148
Despite	O	149-156
the	O	157-160
benefits	O	161-169
of	O	170-172
estrogen	O	173-181
receptor	O	182-190
(	O	191-192
ER	O	192-194
)	O	194-195
-	O	195-196
targeted	O	196-204
endocrine	O	205-214
therapies	O	215-224
in	O	225-227
breast	O	228-234
cancer	O	235-241
,	O	241-242
many	O	243-247
tumors	O	248-254
develop	O	255-262
resistance	O	263-273
.	O	273-274

MicroRNAs	O	275-284
(	O	285-286
miRNAs	O	286-292
)	O	292-293
have	O	294-298
been	O	299-303
suggested	O	304-313
as	O	314-316
promising	O	317-326
biomarkers	O	327-337
and	O	338-341
we	O	342-344
here	O	345-349
evaluated	O	350-359
whether	O	360-367
a	O	368-369
miRNA	O	370-375
profile	O	376-383
could	O	384-389
be	O	390-392
identified	O	393-403
,	O	403-404
sub	O	405-408
-	O	408-409
grouping	O	409-417
ER	O	418-420
+	O	420-421
breast	O	422-428
cancer	O	429-435
patients	O	436-444
treated	O	445-452
with	O	453-457
adjuvant	O	458-466
Tamoxifen	O	467-476
with	O	477-481
regards	O	482-489
to	O	490-492
probability	O	493-504
of	O	505-507
recurrence	O	508-518
.	O	518-519

EXPERIMENTAL	O	520-532
DESIGN	O	533-539
:	O	539-540
Global	O	541-547
miRNA	O	548-553
analysis	O	554-562
was	O	563-566
performed	O	567-576
on	O	577-579
152	O	580-583
ER	O	584-586
+	O	586-587
primary	O	588-595
tumors	O	596-602
from	O	603-607
high	O	608-612
-	O	612-613
risk	O	613-617
breast	O	618-624
cancer	O	625-631
patients	O	632-640
with	O	641-645
an	O	646-648
initial	O	649-656
discovery	O	657-666
set	O	667-670
of	O	671-673
52	O	674-676
patients	O	677-685
,	O	685-686
followed	O	687-695
by	O	696-698
two	O	699-702
independent	O	703-714
test	O	715-719
sets	O	720-724
(	O	725-726
N	O	726-727
=	O	728-729
60	O	730-732
and	O	733-736
N	O	737-738
=	O	739-740
40	O	741-743
)	O	743-744
.	O	744-745

All	O	746-749
patients	O	750-758
had	O	759-762
received	O	763-771
adjuvant	O	772-780
Tamoxifen	O	781-790
as	O	791-793
mono	O	794-798
-	O	798-799
therapy	O	799-806
(	O	807-808
median	O	808-814
clinical	O	815-823
follow	O	824-830
-	O	830-831
up	O	831-833
:	O	833-834
4	O	835-836
.	O	836-837
6	O	837-838
years	O	839-844
)	O	844-845
and	O	846-849
half	O	850-854
had	O	855-858
developed	O	859-868
distant	O	869-876
recurrence	O	877-887
(	O	888-889
median	O	889-895
time	O	896-900
-	O	900-901
to	O	901-903
-	O	903-904
recurrence	O	904-914
:	O	914-915
3	O	916-917
.	O	917-918
5	O	918-919
years	O	920-925
)	O	925-926
.	O	926-927

MiRNA	O	928-933
expression	O	934-944
was	O	945-948
examined	O	949-957
by	O	958-960
unsupervised	O	961-973
hierarchical	O	974-986
clustering	O	987-997
and	O	998-1001
supervised	O	1002-1012
analysis	O	1013-1021
,	O	1021-1022
including	O	1023-1032
clinical	O	1033-1041
parameters	O	1042-1052
as	O	1053-1055
co	O	1056-1058
-	O	1058-1059
variables	O	1059-1068
.	O	1068-1069

RESULTS	O	1070-1077
:	O	1077-1078
The	O	1079-1082
discovery	O	1083-1092
set	O	1093-1096
identified	O	1097-1107
10	O	1108-1110
highly	O	1111-1117
significant	O	1118-1129
miRNAs	O	1130-1136
that	O	1137-1141
discriminated	O	1142-1155
between	O	1156-1163
the	O	1164-1167
patient	O	1168-1175
samples	O	1176-1183
according	O	1184-1193
to	O	1194-1196
outcome	O	1197-1204
.	O	1204-1205

However	O	1206-1213
,	O	1213-1214
the	O	1215-1218
subsequent	O	1219-1229
two	O	1230-1233
independent	O	1234-1245
test	O	1246-1250
sets	O	1251-1255
did	O	1256-1259
not	O	1260-1263
confirm	O	1264-1271
the	O	1272-1275
predictive	O	1276-1286
potential	O	1287-1296
of	O	1297-1299
these	O	1300-1305
miRNAs	O	1306-1312
.	O	1312-1313

A	O	1314-1315
significant	O	1316-1327
correlation	O	1328-1339
was	O	1340-1343
identified	O	1344-1354
between	O	1355-1362
miR	B	1363-1366
-	I	1366-1367
7	I	1367-1368
and	O	1369-1372
the	O	1373-1376
tumor	O	1377-1382
grade	O	1383-1388
.	O	1388-1389

Investigation	O	1390-1403
of	O	1404-1406
the	O	1407-1410
microRNAs	O	1411-1420
with	O	1421-1425
the	O	1426-1429
most	O	1430-1434
variable	O	1435-1443
expression	O	1444-1454
between	O	1455-1462
patients	O	1463-1471
in	O	1472-1474
different	O	1475-1484
runs	O	1485-1489
yielded	O	1490-1497
a	O	1498-1499
list	O	1500-1504
of	O	1505-1507
31	O	1508-1510
microRNAs	O	1511-1520
,	O	1520-1521
eight	O	1522-1527
of	O	1528-1530
which	O	1531-1536
are	O	1537-1540
associated	O	1541-1551
with	O	1552-1556
stem	O	1557-1561
cell	O	1562-1566
characteristics	O	1567-1582
.	O	1582-1583

CONCLUSIONS	O	1584-1595
:	O	1595-1596
Based	O	1597-1602
on	O	1603-1605
the	O	1606-1609
large	O	1610-1615
sample	O	1616-1622
size	O	1623-1627
,	O	1627-1628
our	O	1629-1632
data	O	1633-1637
strongly	O	1638-1646
suggests	O	1647-1655
that	O	1656-1660
there	O	1661-1666
is	O	1667-1669
no	O	1670-1672
single	O	1673-1679
miRNA	O	1680-1685
profile	O	1686-1693
predictive	O	1694-1704
of	O	1705-1707
outcome	O	1708-1715
following	O	1716-1725
adjuvant	O	1726-1734
Tamoxifen	O	1735-1744
treatment	O	1745-1754
in	O	1755-1757
a	O	1758-1759
broad	O	1760-1765
cohort	O	1766-1772
of	O	1773-1775
ER	O	1776-1778
+	O	1778-1779
breast	O	1780-1786
cancer	O	1787-1793
patients	O	1794-1802
.	O	1802-1803

We	O	1804-1806
identified	O	1807-1817
a	O	1818-1819
sub	O	1820-1823
-	O	1823-1824
group	O	1824-1829
of	O	1830-1832
Tamoxifen	O	1833-1842
-	O	1842-1843
treated	O	1843-1850
breast	O	1851-1857
cancer	O	1858-1864
patients	O	1865-1873
with	O	1874-1878
miRNA	O	1879-1884
-	O	1884-1885
expressing	O	1885-1895
tumors	O	1896-1902
associated	O	1903-1913
with	O	1914-1918
cancer	O	1919-1925
stem	O	1926-1930
cell	O	1931-1935
characteristics	O	1936-1951
.	O	1951-1952

MicroRNA	B	0-8
-	I	8-9
10a	I	9-12
targets	O	13-20
CHL1	O	21-25
and	O	26-29
promotes	O	30-38
cell	O	39-43
growth	O	44-50
,	O	50-51
migration	O	52-61
and	O	62-65
invasion	O	66-74
in	O	75-77
human	O	78-83
cervical	O	84-92
cancer	O	93-99
cells	O	100-105
.	O	105-106

MicroRNAs	O	107-116
(	O	117-118
miRNAs	O	118-124
)	O	124-125
play	O	126-130
an	O	131-133
important	O	134-143
role	O	144-148
in	O	149-151
cancer	O	152-158
initiation	O	159-169
,	O	169-170
progression	O	171-182
and	O	183-186
metastasis	O	187-197
by	O	198-200
regulating	O	201-211
their	O	212-217
target	O	218-224
genes	O	225-230
.	O	230-231

Here	O	232-236
,	O	236-237
we	O	238-240
found	O	241-246
microRNA	B	247-255
-	I	255-256
10a	I	256-259
(	O	260-261
miR	B	261-264
-	I	264-265
10a	I	265-268
)	O	268-269
is	O	270-272
upregulated	O	273-284
in	O	285-287
human	O	288-293
cervical	O	294-302
cancer	O	303-309
and	O	310-313
promotes	O	314-322
the	O	323-326
colony	O	327-333
formation	O	334-343
activity	O	344-352
,	O	352-353
migration	O	354-363
and	O	364-367
invasion	O	368-376
of	O	377-379
HeLa	O	380-384
and	O	385-388
C33A	O	389-393
cells	O	394-399
.	O	399-400

Subsequently	O	401-413
,	O	413-414
CHL1	O	415-419
is	O	420-422
confirmed	O	423-432
as	O	433-435
a	O	436-437
target	O	438-444
of	O	445-447
miR	B	448-451
-	I	451-452
10a	I	452-455
and	O	456-459
is	O	460-462
negatively	O	463-473
regulated	O	474-483
by	O	484-486
miR	B	487-490
-	I	490-491
10a	I	491-494
at	O	495-497
mRNA	O	498-502
and	O	503-506
protein	O	507-514
levels	O	515-521
.	O	521-522

Furthermore	O	523-534
,	O	534-535
knockdown	O	536-545
of	O	546-548
CHL1	O	549-553
expression	O	554-564
results	O	565-572
in	O	573-575
increased	O	576-585
colony	O	586-592
formation	O	593-602
activity	O	603-611
,	O	611-612
migration	O	613-622
and	O	623-626
invasion	O	627-635
.	O	635-636

Finally	O	637-644
,	O	644-645
overexpression	O	646-660
of	O	661-663
CHL1	O	664-668
lacked	O	669-675
the	O	676-679
3	O	680-681
'	O	681-682
UTR	O	682-685
abolished	O	686-695
the	O	696-699
effects	O	700-707
of	O	708-710
miR	B	711-714
-	I	714-715
10a	I	715-718
.	O	718-719

Our	O	720-723
results	O	724-731
may	O	732-735
provide	O	736-743
a	O	744-745
strategy	O	746-754
for	O	755-758
blocking	O	759-767
tumor	O	768-773
metastasis	O	774-784
.	O	784-785

The	O	0-3
let	B	4-7
-	I	7-8
7	I	8-9
microRNA	O	10-18
enhances	O	19-27
heme	O	28-32
oxygenase	O	33-42
-	O	42-43
1	O	43-44
by	O	45-47
suppressing	O	48-59
Bach1	O	60-65
and	O	66-69
attenuates	O	70-80
oxidant	O	81-88
injury	O	89-95
in	O	96-98
human	O	99-104
hepatocytes	O	105-116
.	O	116-117

The	O	118-121
let	B	122-125
-	I	125-126
7	I	126-127
microRNA	O	128-136
(	O	137-138
miRNA	O	138-143
)	O	143-144
plays	O	145-150
important	O	151-160
roles	O	161-166
in	O	167-169
human	O	170-175
liver	O	176-181
development	O	182-193
and	O	194-197
diseases	O	198-206
such	O	207-211
as	O	212-214
hepatocellular	O	215-229
carcinoma	O	230-239
,	O	239-240
liver	O	241-246
fibrosis	O	247-255
and	O	256-259
hepatitis	O	260-269
wherein	O	270-277
oxidative	O	278-287
stress	O	288-294
accelerates	O	295-306
the	O	307-310
progression	O	311-322
of	O	323-325
these	O	326-331
diseases	O	332-340
.	O	340-341

To	O	342-344
date	O	345-349
,	O	349-350
the	O	351-354
role	O	355-359
of	O	360-362
the	O	363-366
let	B	367-370
-	I	370-371
7	I	371-372
miRNA	O	373-378
family	O	379-385
in	O	386-388
modulation	O	389-399
of	O	400-402
heme	O	403-407
oxygenase	O	408-417
1	O	418-419
(	O	420-421
HMOX1	O	421-426
)	O	426-427
,	O	427-428
a	O	429-430
key	O	431-434
cytoprotective	O	435-449
enzyme	O	450-456
,	O	456-457
remains	O	458-465
unknown	O	466-473
.	O	473-474

Our	O	475-478
aims	O	479-483
were	O	484-488
to	O	489-491
determine	O	492-501
whether	O	502-509
let	B	510-513
-	I	513-514
7	I	514-515
miRNA	O	516-521
directly	O	522-530
regulates	O	531-540
Bach1	O	541-546
,	O	546-547
a	O	548-549
transcriptional	O	550-565
repressor	O	566-575
of	O	576-578
the	O	579-582
HMOX1	O	583-588
gene	O	589-593
,	O	593-594
and	O	595-598
whether	O	599-606
indirect	O	607-615
up	O	616-618
-	O	618-619
regulation	O	619-629
of	O	630-632
HMOX1	O	633-638
by	O	639-641
let	B	642-645
-	I	645-646
7	I	646-647
miRNA	O	648-653
attenuates	O	654-664
oxidant	O	665-672
injury	O	673-679
in	O	680-682
human	O	683-688
hepatocytes	O	689-700
.	O	700-701

The	O	702-705
effects	O	706-713
of	O	714-716
let	B	717-720
-	I	720-721
7	I	721-722
miRNA	O	723-728
on	O	729-731
Bach1	O	732-737
and	O	738-741
HMOX1	O	742-747
gene	O	748-752
expression	O	753-763
in	O	764-766
Huh	O	767-770
-	O	770-771
7	O	771-772
and	O	773-776
HepG2	O	777-782
cells	O	783-788
were	O	789-793
determined	O	794-804
by	O	805-807
real	O	808-812
-	O	812-813
time	O	813-817
qRT	O	818-821
-	O	821-822
PCR	O	822-825
,	O	825-826
Western	O	827-834
blot	O	835-839
,	O	839-840
and	O	841-844
luciferase	O	845-855
reporter	O	856-864
assays	O	865-871
.	O	871-872

Dual	O	873-877
luciferase	O	878-888
reporter	O	889-897
assays	O	898-904
revealed	O	905-913
that	O	914-918
let	B	919-922
-	I	922-923
7b	I	923-925
,	O	925-926
let	B	927-930
-	I	930-931
7c	I	931-933
,	O	933-934
or	O	935-937
miR	B	938-941
-	I	941-942
98	I	942-944
significantly	O	945-958
decreased	O	959-968
Bach1	O	969-974
3	O	975-976
'	O	976-977
-	O	977-978
untranslated	O	978-990
region	O	991-997
(	O	998-999
3	O	999-1000
'	O	1000-1001
-	O	1001-1002
UTR	O	1002-1005
)	O	1005-1006
-	O	1006-1007
dependent	O	1007-1016
luciferase	O	1017-1027
activity	O	1028-1036
but	O	1037-1040
not	O	1041-1044
mutant	O	1045-1051
Bach1	O	1052-1057
3	O	1058-1059
'	O	1059-1060
-	O	1060-1061
UTR	O	1061-1064
-	O	1064-1065
dependent	O	1065-1074
luciferase	O	1075-1085
activity	O	1086-1094
,	O	1094-1095
whereas	O	1096-1103
mutant	O	1104-1110
let	B	1111-1114
-	I	1114-1115
7	I	1115-1116
miRNA	O	1117-1122
containing	O	1123-1133
base	O	1134-1138
complementarity	O	1139-1154
with	O	1155-1159
mutant	O	1160-1166
Bach1	O	1167-1172
3	O	1173-1174
'	O	1174-1175
-	O	1175-1176
UTR	O	1176-1179
restored	O	1180-1188
its	O	1189-1192
effect	O	1193-1199
on	O	1200-1202
mutant	O	1203-1209
reporter	O	1210-1218
activity	O	1219-1227
.	O	1227-1228

let	B	1229-1232
-	I	1232-1233
7b	I	1233-1235
,	O	1235-1236
let	B	1237-1240
-	I	1240-1241
7c	I	1241-1243
,	O	1243-1244
or	O	1245-1247
miR	B	1248-1251
-	I	1251-1252
98	I	1252-1254
down	O	1255-1259
-	O	1259-1260
regulated	O	1260-1269
Bach1	O	1270-1275
protein	O	1276-1283
levels	O	1284-1290
by	O	1291-1293
50	O	1294-1296
-	O	1296-1297
70	O	1297-1299
%	O	1299-1300
,	O	1300-1301
and	O	1302-1305
subsequently	O	1306-1318
up	O	1319-1321
-	O	1321-1322
regulated	O	1322-1331
HMOX1	O	1332-1337
gene	O	1338-1342
expression	O	1343-1353
by	O	1354-1356
3	O	1357-1358
-	O	1358-1359
4	O	1359-1360
fold	O	1361-1365
,	O	1365-1366
compared	O	1367-1375
with	O	1376-1380
non	O	1381-1384
-	O	1384-1385
specific	O	1385-1393
controls	O	1394-1402
.	O	1402-1403

Furthermore	O	1404-1415
,	O	1415-1416
Huh	O	1417-1420
-	O	1420-1421
7	O	1421-1422
cells	O	1423-1428
transfected	O	1429-1440
with	O	1441-1445
let	B	1446-1449
-	I	1449-1450
7b	I	1450-1452
,	O	1452-1453
let	B	1454-1457
-	I	1457-1458
7c	I	1458-1460
or	O	1461-1463
miR	B	1464-1467
-	I	1467-1468
98	I	1468-1470
mimic	O	1471-1476
showed	O	1477-1483
increased	O	1484-1493
resistance	O	1494-1504
against	O	1505-1512
oxidant	O	1513-1520
injury	O	1521-1527
induced	O	1528-1535
by	O	1536-1538
tert	O	1539-1543
-	O	1543-1544
butyl	O	1544-1549
-	O	1549-1550
hydroperoxide	O	1550-1563
(	O	1564-1565
tBuOOH	O	1565-1571
)	O	1571-1572
,	O	1572-1573
whereas	O	1574-1581
the	O	1582-1585
protection	O	1586-1596
was	O	1597-1600
abrogated	O	1601-1610
by	O	1611-1613
over	O	1614-1618
-	O	1618-1619
expression	O	1619-1629
of	O	1630-1632
Bach1	O	1633-1638
.	O	1638-1639

In	O	1640-1642
conclusion	O	1643-1653
,	O	1653-1654
let	B	1655-1658
-	I	1658-1659
7	I	1659-1660
miRNA	O	1661-1666
directly	O	1667-1675
acts	O	1676-1680
on	O	1681-1683
the	O	1684-1687
3	O	1688-1689
'	O	1689-1690
-	O	1690-1691
UTR	O	1691-1694
of	O	1695-1697
Bach1	O	1698-1703
and	O	1704-1707
negatively	O	1708-1718
regulates	O	1719-1728
expression	O	1729-1739
of	O	1740-1742
this	O	1743-1747
protein	O	1748-1755
,	O	1755-1756
and	O	1757-1760
thereby	O	1761-1768
up	O	1769-1771
-	O	1771-1772
regulates	O	1772-1781
HMOX1	O	1782-1787
gene	O	1788-1792
expression	O	1793-1803
.	O	1803-1804

Over	O	1805-1809
-	O	1809-1810
expression	O	1810-1820
of	O	1821-1823
the	O	1824-1827
let	B	1828-1831
-	I	1831-1832
7	I	1832-1833
miRNA	O	1834-1839
family	O	1840-1846
members	O	1847-1854
may	O	1855-1858
represent	O	1859-1868
a	O	1869-1870
novel	O	1871-1876
approach	O	1877-1885
to	O	1886-1888
protecting	O	1889-1899
human	O	1900-1905
hepatocytes	O	1906-1917
from	O	1918-1922
oxidant	O	1923-1930
injury	O	1931-1937
.	O	1937-1938

MicroRNA	B	0-8
-	I	8-9
9	I	9-10
as	O	11-13
potential	O	14-23
biomarker	O	24-33
for	O	34-37
breast	O	38-44
cancer	O	45-51
local	O	52-57
recurrence	O	58-68
and	O	69-72
tumor	O	73-78
estrogen	O	79-87
receptor	O	88-96
status	O	97-103
.	O	103-104

MicroRNAs	O	105-114
(	O	115-116
miRs	O	116-120
)	O	120-121
are	O	122-125
small	O	126-131
,	O	131-132
non	O	133-136
-	O	136-137
protein	O	137-144
coding	O	145-151
transcripts	O	152-163
involved	O	164-172
in	O	173-175
many	O	176-180
cellular	O	181-189
functions	O	190-199
.	O	199-200

Many	O	201-205
miRs	O	206-210
have	O	211-215
emerged	O	216-223
as	O	224-226
important	O	227-236
cancer	O	237-243
biomarkers	O	244-254
.	O	254-255

In	O	256-258
the	O	259-262
present	O	263-270
study	O	271-276
,	O	276-277
we	O	278-280
investigated	O	281-293
whether	O	294-301
miR	O	302-305
levels	O	306-312
in	O	313-315
breast	O	316-322
tumors	O	323-329
are	O	330-333
predictive	O	334-344
of	O	345-347
breast	O	348-354
cancer	O	355-361
local	O	362-367
recurrence	O	368-378
(	O	379-380
LR	O	380-382
)	O	382-383
.	O	383-384

Sixty	O	385-390
-	O	390-391
eight	O	391-396
women	O	397-402
who	O	403-406
were	O	407-411
diagnosed	O	412-421
with	O	422-426
breast	O	427-433
cancer	O	434-440
at	O	441-443
the	O	444-447
Lombardi	O	448-456
Comprehensive	O	457-470
Cancer	O	471-477
Center	O	478-484
were	O	485-489
included	O	490-498
in	O	499-501
this	O	502-506
study	O	507-512
.	O	512-513

Breast	O	514-520
cancer	O	521-527
patients	O	528-536
with	O	537-541
LR	O	542-544
and	O	545-548
those	O	549-554
without	O	555-562
LR	O	563-565
were	O	566-570
matched	O	571-578
on	O	579-581
year	O	582-586
of	O	587-589
surgery	O	590-597
,	O	597-598
age	O	599-602
at	O	603-605
diagnosis	O	606-615
,	O	615-616
and	O	617-620
type	O	621-625
of	O	626-628
surgery	O	629-636
.	O	636-637

Candidate	O	638-647
miRs	O	648-652
were	O	653-657
identified	O	658-668
by	O	669-671
screening	O	672-681
the	O	682-685
expression	O	686-696
levels	O	697-703
of	O	704-706
754	O	707-710
human	O	711-716
miRs	O	717-721
using	O	722-727
miR	O	728-731
arrays	O	732-738
in	O	739-741
16	O	742-744
breast	O	745-751
tumor	O	752-757
samples	O	758-765
from	O	766-770
8	O	771-772
cases	O	773-778
with	O	779-783
LR	O	784-786
and	O	787-790
8	O	791-792
cases	O	793-798
without	O	799-806
LR	O	807-809
.	O	809-810

Eight	O	811-816
candidate	O	817-826
miRs	O	827-831
that	O	832-836
showed	O	837-843
significant	O	844-855
differences	O	856-867
between	O	868-875
tumors	O	876-882
with	O	883-887
and	O	888-891
without	O	892-899
LR	O	900-902
were	O	903-907
further	O	908-915
verified	O	916-924
in	O	925-927
52	O	928-930
tumor	O	931-936
samples	O	937-944
using	O	945-950
real	O	951-955
-	O	955-956
time	O	956-960
PCR	O	961-964
.	O	964-965

Higher	O	966-972
expression	O	973-983
of	O	984-986
miR	B	987-990
-	I	990-991
9	I	991-992
was	O	993-996
significantly	O	997-1010
associated	O	1011-1021
with	O	1022-1026
breast	O	1027-1033
cancer	O	1034-1040
LR	O	1041-1043
in	O	1044-1046
all	O	1047-1050
cases	O	1051-1056
as	O	1057-1059
well	O	1060-1064
as	O	1065-1067
the	O	1068-1071
subset	O	1072-1078
of	O	1079-1081
estrogen	O	1082-1090
receptor	O	1091-1099
(	O	1100-1101
ER	O	1101-1103
)	O	1103-1104
positive	O	1105-1113
cases	O	1114-1119
(	O	1120-1121
p	O	1121-1122
=	O	1123-1124
0	O	1125-1126
.	O	1126-1127
02	O	1127-1129
)	O	1129-1130
.	O	1130-1131

The	O	1132-1135
AUCs	O	1136-1140
(	O	1141-1142
Area	O	1142-1146
Under	O	1147-1152
Curve	O	1153-1158
)	O	1158-1159
of	O	1160-1162
receiver	O	1163-1171
operating	O	1172-1181
characteristic	O	1182-1196
(	O	1197-1198
ROC	O	1198-1201
)	O	1201-1202
curves	O	1203-1209
of	O	1210-1212
miR	B	1213-1216
-	I	1216-1217
9	I	1217-1218
for	O	1219-1222
all	O	1223-1226
tumors	O	1227-1233
and	O	1234-1237
ER	O	1238-1240
positive	O	1241-1249
tumors	O	1250-1256
are	O	1257-1260
0	O	1261-1262
.	O	1262-1263
68	O	1263-1265
(	O	1266-1267
p	O	1267-1268
=	O	1269-1270
0	O	1271-1272
.	O	1272-1273
02	O	1273-1275
)	O	1275-1276
and	O	1277-1280
0	O	1281-1282
.	O	1282-1283
69	O	1283-1285
(	O	1286-1287
p	O	1287-1288
=	O	1289-1290
0	O	1291-1292
.	O	1292-1293
02	O	1293-1295
)	O	1295-1296
,	O	1296-1297
respectively	O	1298-1310
.	O	1310-1311

In	O	1312-1314
ER	O	1315-1317
positive	O	1318-1326
cases	O	1327-1332
,	O	1332-1333
Kaplan	O	1334-1340
-	O	1340-1341
Meier	O	1341-1346
analysis	O	1347-1355
showed	O	1356-1362
that	O	1363-1367
patients	O	1368-1376
with	O	1377-1381
lower	O	1382-1387
miR	B	1388-1391
-	I	1391-1392
9	I	1392-1393
levels	O	1394-1400
had	O	1401-1404
significantly	O	1405-1418
better	O	1419-1425
10	O	1426-1428
-	O	1428-1429
year	O	1429-1433
LR	O	1434-1436
-	O	1436-1437
free	O	1437-1441
survival	O	1442-1450
(	O	1451-1452
67	O	1452-1454
.	O	1454-1455
9	O	1455-1456
%	O	1456-1457
vs	O	1458-1460
30	O	1461-1463
.	O	1463-1464
8	O	1464-1465
%	O	1465-1466
,	O	1466-1467
p	O	1468-1469
=	O	1470-1471
0	O	1472-1473
.	O	1473-1474
02	O	1474-1476
)	O	1476-1477
.	O	1477-1478

Expression	O	1479-1489
levels	O	1490-1496
of	O	1497-1499
miR	B	1500-1503
-	I	1503-1504
9	I	1504-1505
and	O	1506-1509
another	O	1510-1517
miR	O	1518-1521
candidate	O	1522-1531
,	O	1531-1532
miR	B	1533-1536
-	I	1536-1537
375	I	1537-1540
,	O	1540-1541
were	O	1542-1546
also	O	1547-1551
strongly	O	1552-1560
associated	O	1561-1571
with	O	1572-1576
ER	O	1577-1579
status	O	1580-1586
(	O	1587-1588
p	O	1588-1589
<	O	1589-1590
0	O	1590-1591
.	O	1591-1592
001	O	1592-1595
for	O	1596-1599
both	O	1600-1604
)	O	1604-1605
.	O	1605-1606

The	O	1607-1610
potential	O	1611-1620
of	O	1621-1623
miR	B	1624-1627
-	I	1627-1628
9	I	1628-1629
as	O	1630-1632
a	O	1633-1634
biomarker	O	1635-1644
for	O	1645-1648
LR	O	1649-1651
warrants	O	1652-1660
further	O	1661-1668
investigation	O	1669-1682
with	O	1683-1687
larger	O	1688-1694
sample	O	1695-1701
size	O	1702-1706
.	O	1706-1707

MiR	B	0-3
-	I	3-4
96	I	4-6
downregulates	O	7-20
REV1	O	21-25
and	O	26-29
RAD51	O	30-35
to	O	36-38
promote	O	39-46
cellular	O	47-55
sensitivity	O	56-67
to	O	68-70
cisplatin	O	71-80
and	O	81-84
PARP	O	85-89
inhibition	O	90-100
.	O	100-101

Cell	O	102-106
survival	O	107-115
after	O	116-121
DNA	O	122-125
damage	O	126-132
relies	O	133-139
on	O	140-142
DNA	O	143-146
repair	O	147-153
,	O	153-154
the	O	155-158
abrogation	O	159-169
of	O	170-172
which	O	173-178
causes	O	179-185
genomic	O	186-193
instability	O	194-205
.	O	205-206

The	O	207-210
DNA	O	211-214
repair	O	215-221
protein	O	222-229
RAD51	O	230-235
and	O	236-239
the	O	240-243
trans	O	244-249
-	O	249-250
lesion	O	250-256
synthesis	O	257-266
DNA	O	267-270
polymerase	O	271-281
REV1	O	282-286
are	O	287-290
required	O	291-299
for	O	300-303
resistance	O	304-314
to	O	315-317
DNA	O	318-321
interstrand	O	322-333
cross	O	334-339
-	O	339-340
linking	O	340-347
agents	O	348-354
such	O	355-359
as	O	360-362
cisplatin	O	363-372
.	O	372-373

In	O	374-376
this	O	377-381
study	O	382-387
,	O	387-388
we	O	389-391
show	O	392-396
that	O	397-401
overexpression	O	402-416
of	O	417-419
miR	B	420-423
-	I	423-424
96	I	424-426
in	O	427-429
human	O	430-435
cancer	O	436-442
cells	O	443-448
reduces	O	449-456
the	O	457-460
levels	O	461-467
of	O	468-470
RAD51	O	471-476
and	O	477-480
REV1	O	481-485
and	O	486-489
impacts	O	490-497
the	O	498-501
cellular	O	502-510
response	O	511-519
to	O	520-522
agents	O	523-529
that	O	530-534
cause	O	535-540
DNA	O	541-544
damage	O	545-551
.	O	551-552

MiR	B	553-556
-	I	556-557
96	I	557-559
directly	O	560-568
targeted	O	569-577
the	O	578-581
coding	O	582-588
region	O	589-595
of	O	596-598
RAD51	O	599-604
and	O	605-608
the	O	609-612
3	O	613-614
'	O	614-615
-	O	615-616
untranslated	O	616-628
region	O	629-635
of	O	636-638
REV1	O	639-643
.	O	643-644

Overexpression	O	645-659
of	O	660-662
miR	B	663-666
-	I	666-667
96	I	667-669
decreased	O	670-679
the	O	680-683
efficiency	O	684-694
of	O	695-697
homologous	O	698-708
recombination	O	709-722
and	O	723-726
enhanced	O	727-735
sensitivity	O	736-747
to	O	748-750
the	O	751-754
PARP	O	755-759
inhibitor	O	760-769
AZD2281	O	770-777
in	O	778-780
vitro	O	781-786
and	O	787-790
to	O	791-793
cisplatin	O	794-803
both	O	804-808
in	O	809-811
vitro	O	812-817
and	O	818-821
in	O	822-824
vivo	O	825-829
.	O	829-830

Taken	O	831-836
together	O	837-845
,	O	845-846
our	O	847-850
findings	O	851-859
indicate	O	860-868
that	O	869-873
miR	B	874-877
-	I	877-878
96	I	878-880
regulates	O	881-890
DNA	O	891-894
repair	O	895-901
and	O	902-905
chemosensitivity	O	906-922
by	O	923-925
repressing	O	926-936
RAD51	O	937-942
and	O	943-946
REV1	O	947-951
.	O	951-952

As	O	953-955
a	O	956-957
therapeutic	O	958-969
candidate	O	970-979
,	O	979-980
miR	B	981-984
-	I	984-985
96	I	985-987
may	O	988-991
improve	O	992-999
chemotherapeutic	O	1000-1016
efficacy	O	1017-1025
by	O	1026-1028
increasing	O	1029-1039
the	O	1040-1043
sensitivity	O	1044-1055
of	O	1056-1058
cancer	O	1059-1065
cells	O	1066-1071
to	O	1072-1074
DNA	O	1075-1078
damage	O	1079-1085
.	O	1085-1086

microrna	O	0-8
expression	O	9-19
signature	O	20-29
of	O	30-32
gastric	O	33-40
cancer	O	41-47
cells	O	48-53
relative	O	54-62
to	O	63-65
normal	O	66-72
gastric	O	73-80
mucosa	O	81-87
.	O	87-88

micrornas	O	89-98
(	O	99-100
miRNAs	O	100-106
)	O	106-107
play	O	108-112
an	O	113-115
important	O	116-125
role	O	126-130
in	O	131-133
a	O	134-135
wide	O	136-140
range	O	141-146
of	O	147-149
physiological	O	150-163
and	O	164-167
developmental	O	168-181
processes	O	182-191
by	O	192-194
negatively	O	195-205
regulating	O	206-216
the	O	217-220
expression	O	221-231
of	O	232-234
target	O	235-241
genes	O	242-247
at	O	248-250
the	O	251-254
post	O	255-259
-	O	259-260
transcriptional	O	260-275
level	O	276-281
.	O	281-282

In	O	283-285
this	O	286-290
study	O	291-296
,	O	296-297
we	O	298-300
investigated	O	301-313
the	O	314-317
differential	O	318-330
miRNA	O	331-336
expression	O	337-347
signature	O	348-357
between	O	358-365
gastric	O	366-373
cancer	O	374-380
cells	O	381-386
and	O	387-390
normal	O	391-397
gastric	O	398-405
mucosa	O	406-412
to	O	413-415
determine	O	416-425
changes	O	426-433
in	O	434-436
miRNA	O	437-442
expression	O	443-453
during	O	454-460
gastric	O	461-468
cancer	O	469-475
development	O	476-487
.	O	487-488

We	O	489-491
analyzed	O	492-500
the	O	501-504
global	O	505-511
miRNA	O	512-517
expression	O	518-528
profiles	O	529-537
of	O	538-540
9	O	541-542
gastric	O	543-550
cancer	O	551-557
cell	O	558-562
lines	O	563-568
and	O	569-572
6	O	573-574
normal	O	575-581
gastric	O	582-589
mucosa	O	590-596
lines	O	597-602
using	O	603-608
miRNA	O	609-614
microarrays	O	615-626
.	O	626-627

In	O	628-630
addition	O	631-639
,	O	639-640
we	O	641-643
performed	O	644-653
quantitative	O	654-666
real	O	667-671
-	O	671-672
time	O	672-676
PCR	O	677-680
(	O	681-682
Q	O	682-683
-	O	683-684
PCR	O	684-687
)	O	687-688
to	O	689-691
validate	O	692-700
the	O	701-704
results	O	705-712
.	O	712-713

Correlations	O	714-726
between	O	727-734
the	O	735-738
miRNA	O	739-744
expression	O	745-755
profile	O	756-763
and	O	764-767
tumor	O	768-773
clinicopathological	O	774-793
parameters	O	794-804
were	O	805-809
analyzed	O	810-818
.	O	818-819

We	O	820-822
found	O	823-828
that	O	829-833
17	O	834-836
miRNAs	O	837-843
were	O	844-848
upregulated	O	849-860
in	O	861-863
gastric	O	864-871
cancer	O	872-878
cell	O	879-883
lines	O	884-889
and	O	890-893
146	O	894-897
miRNAs	O	898-904
were	O	905-909
downregulated	O	910-923
compared	O	924-932
to	O	933-935
normal	O	936-942
gastric	O	943-950
mucosa	O	951-957
.	O	957-958

Using	O	959-964
microarray	O	965-975
data	O	976-980
and	O	981-984
Q	O	985-986
-	O	986-987
PCR	O	987-990
validation	O	991-1001
,	O	1001-1002
15	O	1003-1005
miRNAs	O	1006-1012
were	O	1013-1017
finally	O	1018-1025
selected	O	1026-1034
.	O	1034-1035

These	O	1036-1041
candidate	O	1042-1051
miRNAs	O	1052-1058
were	O	1059-1063
associated	O	1064-1074
with	O	1075-1079
gastric	O	1080-1087
cancer	O	1088-1094
clinicopathology	O	1095-1111
to	O	1112-1114
various	O	1115-1122
degrees	O	1123-1130
.	O	1130-1131

High	O	1132-1136
expression	O	1137-1147
levels	O	1148-1154
of	O	1155-1157
hsa	B	1158-1161
-	I	1161-1162
miR	I	1162-1165
-	I	1165-1166
93	I	1166-1168
were	O	1169-1173
found	O	1174-1179
to	O	1180-1182
predict	O	1183-1190
poor	O	1191-1195
survival	O	1196-1204
(	O	1205-1206
median	O	1206-1212
,	O	1212-1213
16	O	1214-1216
vs	O	1217-1219
.	O	1219-1220
40	O	1221-1223
months	O	1224-1230
;	O	1230-1231
log	O	1232-1235
-	O	1235-1236
rank	O	1236-1240
test	O	1241-1245
p	O	1246-1247
<	O	1247-1248
0	O	1248-1249
.	O	1249-1250
05	O	1250-1252
)	O	1252-1253
.	O	1253-1254

These	O	1255-1260
findings	O	1261-1269
suggest	O	1270-1277
that	O	1278-1282
miRNAs	O	1283-1289
play	O	1290-1294
vital	O	1295-1300
roles	O	1301-1306
in	O	1307-1309
human	O	1310-1315
gastric	O	1316-1323
cancer	O	1324-1330
.	O	1330-1331

The	O	1332-1335
findings	O	1336-1344
may	O	1345-1348
also	O	1349-1353
provide	O	1354-1361
clues	O	1362-1367
toward	O	1368-1374
understanding	O	1375-1388
the	O	1389-1392
molecular	O	1393-1402
functions	O	1403-1412
of	O	1413-1415
miRNAs	O	1416-1422
in	O	1423-1425
various	O	1426-1433
biological	O	1434-1444
processes	O	1445-1454
.	O	1454-1455

Mutant	O	0-6
p53	O	7-10
gain	O	11-15
-	O	15-16
of	O	16-18
-	O	18-19
function	O	19-27
induces	O	28-35
epithelial	O	36-46
-	O	46-47
mesenchymal	O	47-58
transition	O	59-69
through	O	70-77
modulation	O	78-88
of	O	89-91
the	O	92-95
miR	B	96-99
-	I	99-100
130b	I	100-104
-	O	104-105
ZEB1	O	105-109
axis	O	110-114
.	O	114-115

The	O	116-119
tumor	O	120-125
suppressor	O	126-136
gene	O	137-141
p53	O	142-145
has	O	146-149
been	O	150-154
implicated	O	155-165
in	O	166-168
the	O	169-172
regulation	O	173-183
of	O	184-186
epithelial	O	187-197
-	O	197-198
mesenchymal	O	198-209
transition	O	210-220
(	O	221-222
EMT	O	222-225
)	O	225-226
and	O	227-230
tumor	O	231-236
metastasis	O	237-247
by	O	248-250
regulating	O	251-261
microRNA	O	262-270
(	O	271-272
miRNA	O	272-277
)	O	277-278
expression	O	279-289
.	O	289-290

Here	O	291-295
,	O	295-296
we	O	297-299
report	O	300-306
that	O	307-311
mutant	O	312-318
p53	O	319-322
exerts	O	323-329
oncogenic	O	330-339
functions	O	340-349
and	O	350-353
promotes	O	354-362
EMT	O	363-366
in	O	367-369
endometrial	O	370-381
cancer	O	382-388
(	O	389-390
EC	O	390-392
)	O	392-393
by	O	394-396
directly	O	397-405
binding	O	406-413
to	O	414-416
the	O	417-420
promoter	O	421-429
of	O	430-432
miR	B	433-436
-	I	436-437
130b	I	437-441
(	O	442-443
a	O	443-444
negative	O	445-453
regulator	O	454-463
of	O	464-466
ZEB1	O	467-471
)	O	471-472
and	O	473-476
inhibiting	O	477-487
its	O	488-491
transcription	O	492-505
.	O	505-506

We	O	507-509
transduced	O	510-520
p53	O	521-524
mutants	O	525-532
into	O	533-537
p53	O	538-541
-	O	541-542
null	O	542-546
EC	O	547-549
cells	O	550-555
,	O	555-556
profiled	O	557-565
the	O	566-569
miRNA	O	570-575
expression	O	576-586
by	O	587-589
miRNA	O	590-595
microarray	O	596-606
and	O	607-610
identified	O	611-621
miR	B	622-625
-	I	625-626
130b	I	626-630
as	O	631-633
a	O	634-635
potential	O	636-645
target	O	646-652
of	O	653-655
mutant	O	656-662
p53	O	663-666
.	O	666-667

Ectopic	O	668-675
expression	O	676-686
of	O	687-689
p53	O	690-693
mutants	O	694-701
repressed	O	702-711
the	O	712-715
expression	O	716-726
of	O	727-729
miR	B	730-733
-	I	733-734
130b	I	734-738
and	O	739-742
triggered	O	743-752
ZEB1	O	753-757
-	O	757-758
dependent	O	758-767
EMT	O	768-771
and	O	772-775
cancer	O	776-782
cell	O	783-787
invasion	O	788-796
.	O	796-797

Loss	O	798-802
of	O	803-805
an	O	806-808
endogenous	O	809-819
p53	O	820-823
mutation	O	824-832
increased	O	833-842
the	O	843-846
expression	O	847-857
of	O	858-860
miR	B	861-864
-	I	864-865
130b	I	865-869
,	O	869-870
which	O	871-876
resulted	O	877-885
in	O	886-888
reduced	O	889-896
ZEB1	O	897-901
expression	O	902-912
and	O	913-916
attenuation	O	917-928
of	O	929-931
the	O	932-935
EMT	O	936-939
phenotype	O	940-949
.	O	949-950

Furthermore	O	951-962
,	O	962-963
re	O	964-966
-	O	966-967
expression	O	967-977
of	O	978-980
miR	B	981-984
-	I	984-985
130b	I	985-989
suppressed	O	990-1000
mutant	O	1001-1007
p53	O	1008-1011
-	O	1011-1012
induced	O	1012-1019
EMT	O	1020-1023
and	O	1024-1027
ZEB1	O	1028-1032
expression	O	1033-1043
.	O	1043-1044

Importantly	O	1045-1056
,	O	1056-1057
the	O	1058-1061
expression	O	1062-1072
of	O	1073-1075
miR	B	1076-1079
-	I	1079-1080
130	I	1080-1083
was	O	1084-1087
significantly	O	1088-1101
reduced	O	1102-1109
in	O	1110-1112
EC	O	1113-1115
tissues	O	1116-1123
,	O	1123-1124
and	O	1125-1128
patients	O	1129-1137
with	O	1138-1142
higher	O	1143-1149
expression	O	1150-1160
levels	O	1161-1167
of	O	1168-1170
miR	B	1171-1174
-	I	1174-1175
130b	I	1175-1179
survived	O	1180-1188
longer	O	1189-1195
.	O	1195-1196

These	O	1197-1202
data	O	1203-1207
provide	O	1208-1215
a	O	1216-1217
novel	O	1218-1223
understanding	O	1224-1237
of	O	1238-1240
the	O	1241-1244
roles	O	1245-1250
of	O	1251-1253
p53	O	1254-1257
gain	O	1258-1262
-	O	1262-1263
of	O	1263-1265
-	O	1265-1266
function	O	1266-1274
mutations	O	1275-1284
in	O	1285-1287
accelerating	O	1288-1300
tumor	O	1301-1306
progression	O	1307-1318
and	O	1319-1322
metastasis	O	1323-1333
through	O	1334-1341
modulation	O	1342-1352
of	O	1353-1355
the	O	1356-1359
miR	B	1360-1363
-	I	1363-1364
130b	I	1364-1368
-	O	1368-1369
ZEB1	O	1369-1373
axis	O	1374-1378
.	O	1378-1379

miR	B	0-3
-	I	3-4
146a	I	4-8
controls	O	9-17
the	O	18-21
resolution	O	22-32
of	O	33-35
T	O	36-37
cell	O	38-42
responses	O	43-52
in	O	53-55
mice	O	56-60
.	O	60-61

T	O	62-63
cell	O	64-68
responses	O	69-78
in	O	79-81
mammals	O	82-89
must	O	90-94
be	O	95-97
tightly	O	98-105
regulated	O	106-115
to	O	116-118
both	O	119-123
provide	O	124-131
effective	O	132-141
immune	O	142-148
protection	O	149-159
and	O	160-163
avoid	O	164-169
inflammation	O	170-182
-	O	182-183
induced	O	183-190
pathology	O	191-200
.	O	200-201

NF	O	202-204
-	O	204-205
kappaB	O	205-211
activation	O	212-222
is	O	223-225
a	O	226-227
key	O	228-231
signaling	O	232-241
event	O	242-247
induced	O	248-255
by	O	256-258
T	O	259-260
cell	O	261-265
receptor	O	266-274
(	O	275-276
TCR	O	276-279
)	O	279-280
stimulation	O	281-292
.	O	292-293

Dysregulation	O	294-307
of	O	308-310
NF	O	311-313
-	O	313-314
kappaB	O	314-320
is	O	321-323
associated	O	324-334
with	O	335-339
T	O	340-341
cell	O	342-346
-	O	346-347
mediated	O	347-355
inflammatory	O	356-368
diseases	O	369-377
and	O	378-381
malignancies	O	382-394
,	O	394-395
highlighting	O	396-408
the	O	409-412
importance	O	413-423
of	O	424-426
negative	O	427-435
feedback	O	436-444
control	O	445-452
of	O	453-455
TCR	O	456-459
-	O	459-460
induced	O	460-467
NF	O	468-470
-	O	470-471
kappaB	O	471-477
activity	O	478-486
.	O	486-487

In	O	488-490
this	O	491-495
study	O	496-501
we	O	502-504
show	O	505-509
that	O	510-514
in	O	515-517
mice	O	518-522
,	O	522-523
T	O	524-525
cells	O	526-531
lacking	O	532-539
miR	B	540-543
-	I	543-544
146a	I	544-548
are	O	549-552
hyperactive	O	553-564
in	O	565-567
both	O	568-572
acute	O	573-578
antigenic	O	579-588
responses	O	589-598
and	O	599-602
chronic	O	603-610
inflammatory	O	611-623
autoimmune	O	624-634
responses	O	635-644
.	O	644-645

TCR	O	646-649
-	O	649-650
driven	O	650-656
NF	O	657-659
-	O	659-660
kappaB	O	660-666
activation	O	667-677
up	O	678-680
-	O	680-681
regulates	O	681-690
the	O	691-694
expression	O	695-705
of	O	706-708
miR	B	709-712
-	I	712-713
146a	I	713-717
,	O	717-718
which	O	719-724
in	O	725-727
turn	O	728-732
down	O	733-737
-	O	737-738
regulates	O	738-747
NF	O	748-750
-	O	750-751
kappaB	O	751-757
activity	O	758-766
,	O	766-767
at	O	768-770
least	O	771-776
partly	O	777-783
through	O	784-791
repressing	O	792-802
the	O	803-806
NF	O	807-809
-	O	809-810
kappaB	O	810-816
signaling	O	817-826
transducers	O	827-838
TRAF6	O	839-844
and	O	845-848
IRAK1	O	849-854
.	O	854-855

Thus	O	856-860
,	O	860-861
our	O	862-865
results	O	866-873
identify	O	874-882
miR	B	883-886
-	I	886-887
146a	I	887-891
as	O	892-894
an	O	895-897
important	O	898-907
new	O	908-911
member	O	912-918
of	O	919-921
the	O	922-925
negative	O	926-934
feedback	O	935-943
loop	O	944-948
that	O	949-953
controls	O	954-962
TCR	O	963-966
signaling	O	967-976
to	O	977-979
NF	O	980-982
-	O	982-983
kappaB	O	983-989
.	O	989-990

Our	O	991-994
findings	O	995-1003
also	O	1004-1008
add	O	1009-1012
microRNA	O	1013-1021
to	O	1022-1024
the	O	1025-1028
list	O	1029-1033
of	O	1034-1036
regulators	O	1037-1047
that	O	1048-1052
control	O	1053-1060
the	O	1061-1064
resolution	O	1065-1075
of	O	1076-1078
T	O	1079-1080
cell	O	1081-1085
responses	O	1086-1095
.	O	1095-1096

MicroRNA	O	0-8
expression	O	9-19
in	O	20-22
ovarian	O	23-30
carcinoma	O	31-40
and	O	41-44
its	O	45-48
correlation	O	49-60
with	O	61-65
clinicopathological	O	66-85
features	O	86-94
.	O	94-95

BACKGROUND	O	96-106
:	O	106-107
MicroRNA	O	108-116
(	O	117-118
miRNA	O	118-123
)	O	123-124
expression	O	125-135
is	O	136-138
known	O	139-144
to	O	145-147
be	O	148-150
deregulated	O	151-162
in	O	163-165
ovarian	O	166-173
carcinomas	O	174-184
.	O	184-185

However	O	186-193
,	O	193-194
limited	O	195-202
data	O	203-207
is	O	208-210
available	O	211-220
about	O	221-226
the	O	227-230
miRNA	O	231-236
expression	O	237-247
pattern	O	248-255
for	O	256-259
the	O	260-263
benign	O	264-270
or	O	271-273
borderline	O	274-284
ovarian	O	285-292
tumors	O	293-299
as	O	300-302
well	O	303-307
as	O	308-310
differential	O	311-323
miRNA	O	324-329
expression	O	330-340
pattern	O	341-348
associated	O	349-359
with	O	360-364
histological	O	365-377
types	O	378-383
,	O	383-384
grades	O	385-391
or	O	392-394
clinical	O	395-403
stages	O	404-410
in	O	411-413
ovarian	O	414-421
carcinomas	O	422-432
.	O	432-433

We	O	434-436
defined	O	437-444
patterns	O	445-453
of	O	454-456
microRNA	O	457-465
expression	O	466-476
in	O	477-479
tissues	O	480-487
from	O	488-492
normal	O	493-499
,	O	499-500
benign	O	501-507
,	O	507-508
borderline	O	509-519
,	O	519-520
and	O	521-524
malignant	O	525-534
ovarian	O	535-542
tumors	O	543-549
and	O	550-553
explored	O	554-562
the	O	563-566
relationship	O	567-579
between	O	580-587
frequently	O	588-598
deregulated	O	599-610
miRNAs	O	611-617
and	O	618-621
clinicopathologic	O	622-639
findings	O	640-648
,	O	648-649
response	O	650-658
to	O	659-661
therapy	O	662-669
,	O	669-670
survival	O	671-679
,	O	679-680
and	O	681-684
association	O	685-696
with	O	697-701
Her	O	702-705
-	O	705-706
2	O	706-707
/	O	707-708
neu	O	708-711
status	O	712-718
in	O	719-721
ovarian	O	722-729
carcinomas	O	730-740
.	O	740-741

METHODS	O	742-749
:	O	749-750
We	O	751-753
measured	O	754-762
the	O	763-766
expression	O	767-777
of	O	778-780
nine	O	781-785
miRNAs	O	786-792
(	O	793-794
miR	B	794-797
-	I	797-798
181d	I	798-802
,	O	802-803
miR	B	804-807
-	I	807-808
30a	I	808-811
-	I	811-812
3p	I	812-814
,	O	814-815
miR	B	816-819
-	I	819-820
30c	I	820-823
,	O	823-824
miR	B	825-828
-	I	828-829
30d	I	829-832
,	O	832-833
miR	B	834-837
-	I	837-838
30e	I	838-841
-	I	841-842
3p	I	842-844
,	O	844-845
miR	B	846-849
-	I	849-850
368	I	850-853
,	O	853-854
miR	B	855-858
-	I	858-859
370	I	859-862
,	O	862-863
miR	B	864-867
-	I	867-868
493	I	868-871
-	I	871-872
5p	I	872-874
,	O	874-875
miR	B	876-879
-	I	879-880
532	I	880-883
-	I	883-884
5p	I	884-886
)	O	886-887
in	O	888-890
171	O	891-894
formalin	O	895-903
-	O	903-904
fixed	O	904-909
,	O	909-910
paraffin	O	911-919
-	O	919-920
embedded	O	920-928
ovarian	O	929-936
tissue	O	937-943
blocks	O	944-950
as	O	951-953
well	O	954-958
as	O	959-961
six	O	962-965
normal	O	966-972
human	O	973-978
ovarian	O	979-986
surface	O	987-994
epithelial	O	995-1005
(	O	1006-1007
HOSE	O	1007-1011
)	O	1011-1012
cell	O	1013-1017
lines	O	1018-1023
using	O	1024-1029
Taqman	O	1030-1036
-	O	1036-1037
based	O	1037-1042
real	O	1043-1047
-	O	1047-1048
time	O	1048-1052
PCR	O	1053-1056
assays	O	1057-1063
.	O	1063-1064

Her	O	1065-1068
-	O	1068-1069
2	O	1069-1070
/	O	1070-1071
neu	O	1071-1074
overexpression	O	1075-1089
was	O	1090-1093
assessed	O	1094-1102
in	O	1103-1105
ovarian	O	1106-1113
carcinomas	O	1114-1124
(	O	1125-1126
n	O	1126-1127
=	O	1128-1129
109	O	1130-1133
cases	O	1134-1139
)	O	1139-1140
by	O	1141-1143
immunohistochemistry	O	1144-1164
analysis	O	1165-1173
.	O	1173-1174

RESULTS	O	1175-1182
:	O	1182-1183
Expression	O	1184-1194
of	O	1195-1197
four	O	1198-1202
miRNAs	O	1203-1209
(	O	1210-1211
miR	B	1211-1214
-	I	1214-1215
30c	I	1215-1218
,	O	1218-1219
miR	B	1220-1223
-	I	1223-1224
30d	I	1224-1227
,	O	1227-1228
miR	B	1229-1232
-	I	1232-1233
30e	I	1233-1236
-	I	1236-1237
3p	I	1237-1239
,	O	1239-1240
miR	B	1241-1244
-	I	1244-1245
370	I	1245-1248
)	O	1248-1249
was	O	1250-1253
significantly	O	1254-1267
different	O	1268-1277
between	O	1278-1285
carcinomas	O	1286-1296
and	O	1297-1300
benign	O	1301-1307
ovarian	O	1308-1315
tissues	O	1316-1323
as	O	1324-1326
well	O	1327-1331
as	O	1332-1334
between	O	1335-1342
carcinoma	O	1343-1352
and	O	1353-1356
borderline	O	1357-1367
tissues	O	1368-1375
.	O	1375-1376

An	O	1377-1379
additional	O	1380-1390
three	O	1391-1396
miRNAs	O	1397-1403
(	O	1404-1405
miR	B	1405-1408
-	I	1408-1409
181d	I	1409-1413
,	O	1413-1414
miR	B	1415-1418
-	I	1418-1419
30a	I	1419-1422
-	I	1422-1423
3p	I	1423-1425
,	O	1425-1426
miR	B	1427-1430
-	I	1430-1431
532	I	1431-1434
-	I	1434-1435
5p	I	1435-1437
)	O	1437-1438
were	O	1439-1443
significantly	O	1444-1457
different	O	1458-1467
between	O	1468-1475
borderline	O	1476-1486
and	O	1487-1490
carcinoma	O	1491-1500
tissues	O	1501-1508
.	O	1508-1509

Expression	O	1510-1520
of	O	1521-1523
miR	B	1524-1527
-	I	1527-1528
532	I	1528-1531
-	I	1531-1532
5p	I	1532-1534
was	O	1535-1538
significantly	O	1539-1552
lower	O	1553-1558
in	O	1559-1561
borderline	O	1562-1572
than	O	1573-1577
in	O	1578-1580
benign	O	1581-1587
tissues	O	1588-1595
.	O	1595-1596

Among	O	1597-1602
ovarian	O	1603-1610
carcinomas	O	1611-1621
,	O	1621-1622
expression	O	1623-1633
of	O	1634-1636
four	O	1637-1641
miRNAs	O	1642-1648
(	O	1649-1650
miR	B	1650-1653
-	I	1653-1654
30a	I	1654-1657
-	I	1657-1658
3p	I	1658-1660
,	O	1660-1661
miR	B	1662-1665
-	I	1665-1666
30c	I	1666-1669
,	O	1669-1670
miR	B	1671-1674
-	I	1674-1675
30d	I	1675-1678
,	O	1678-1679
miR	B	1680-1683
-	I	1683-1684
30e	I	1684-1687
-	I	1687-1688
3p	I	1688-1690
)	O	1690-1691
was	O	1692-1695
lowest	O	1696-1702
in	O	1703-1705
mucinous	O	1706-1714
and	O	1715-1718
highest	O	1719-1726
in	O	1727-1729
clear	O	1730-1735
cell	O	1736-1740
samples	O	1741-1748
.	O	1748-1749

Expression	O	1750-1760
of	O	1761-1763
miR	B	1764-1767
-	I	1767-1768
30a	I	1768-1771
-	I	1771-1772
3p	I	1772-1774
was	O	1775-1778
higher	O	1779-1785
in	O	1786-1788
well	O	1789-1793
-	O	1793-1794
differentiated	O	1794-1808
compared	O	1809-1817
to	O	1818-1820
poorly	O	1821-1827
differentiated	O	1828-1842
tumors	O	1843-1849
(	O	1850-1851
P	O	1851-1852
=	O	1853-1854
0	O	1855-1856
.	O	1856-1857
02	O	1857-1859
)	O	1859-1860
,	O	1860-1861
and	O	1862-1865
expression	O	1866-1876
of	O	1877-1879
miR	B	1880-1883
-	I	1883-1884
370	I	1884-1887
was	O	1888-1891
higher	O	1892-1898
in	O	1899-1901
stage	O	1902-1907
I	O	1908-1909
/	O	1909-1910
II	O	1910-1912
compared	O	1913-1921
to	O	1922-1924
stage	O	1925-1930
III	O	1931-1934
/	O	1934-1935
IV	O	1935-1937
samples	O	1938-1945
(	O	1946-1947
P	O	1947-1948
=	O	1949-1950
0	O	1951-1952
.	O	1952-1953
03	O	1953-1955
)	O	1955-1956
.	O	1956-1957

In	O	1958-1960
multivariate	O	1961-1973
analyses	O	1974-1982
,	O	1982-1983
higher	O	1984-1990
expression	O	1991-2001
of	O	2002-2004
miR	B	2005-2008
-	I	2008-2009
181d	I	2009-2013
,	O	2013-2014
miR	B	2015-2018
-	I	2018-2019
30c	I	2019-2022
,	O	2022-2023
miR	B	2024-2027
-	I	2027-2028
30d	I	2028-2031
,	O	2031-2032
and	O	2033-2036
miR	B	2037-2040
-	I	2040-2041
30e	I	2041-2044
-	I	2044-2045
3p	I	2045-2047
was	O	2048-2051
associated	O	2052-2062
with	O	2063-2067
significantly	O	2068-2081
better	O	2082-2088
disease	O	2089-2096
-	O	2096-2097
free	O	2097-2101
or	O	2102-2104
overall	O	2105-2112
survival	O	2113-2121
.	O	2121-2122

Finally	O	2123-2130
,	O	2130-2131
lower	O	2132-2137
expression	O	2138-2148
of	O	2149-2151
miR	B	2152-2155
-	I	2155-2156
30c	I	2156-2159
,	O	2159-2160
miR	B	2161-2164
-	I	2164-2165
30d	I	2165-2168
,	O	2168-2169
miR	B	2170-2173
-	I	2173-2174
30e	I	2174-2177
-	I	2177-2178
3p	I	2178-2180
and	O	2181-2184
miR	B	2185-2188
-	I	2188-2189
532	I	2189-2192
-	I	2192-2193
5p	I	2193-2195
was	O	2196-2199
significantly	O	2200-2213
associated	O	2214-2224
with	O	2225-2229
overexpression	O	2230-2244
of	O	2245-2247
Her	O	2248-2251
-	O	2251-2252
2	O	2252-2253
/	O	2253-2254
neu	O	2254-2257
.	O	2257-2258

CONCLUSIONS	O	2259-2270
:	O	2270-2271
Aberrant	O	2272-2280
expression	O	2281-2291
of	O	2292-2294
miRNAs	O	2295-2301
is	O	2302-2304
common	O	2305-2311
in	O	2312-2314
ovarian	O	2315-2322
tumor	O	2323-2328
suggesting	O	2329-2339
involvement	O	2340-2351
of	O	2352-2354
miRNA	O	2355-2360
in	O	2361-2363
ovarian	O	2364-2371
tumorigenesis	O	2372-2385
.	O	2385-2386

They	O	2387-2391
are	O	2392-2395
associated	O	2396-2406
with	O	2407-2411
histology	O	2412-2421
,	O	2421-2422
clinical	O	2423-2431
stage	O	2432-2437
,	O	2437-2438
survival	O	2439-2447
and	O	2448-2451
oncogene	O	2452-2460
expression	O	2461-2471
in	O	2472-2474
ovarian	O	2475-2482
carcinoma	O	2483-2492
.	O	2492-2493

Spatiotemporal	O	0-14
control	O	15-22
of	O	23-25
microRNA	O	26-34
function	O	35-43
using	O	44-49
light	O	50-55
-	O	55-56
activated	O	56-65
antagomirs	O	66-76
.	O	76-77

MicroRNAs	O	78-87
(	O	88-89
miRNAs	O	89-95
)	O	95-96
are	O	97-100
small	O	101-106
non	O	107-110
-	O	110-111
coding	O	111-117
RNAs	O	118-122
that	O	123-127
act	O	128-131
as	O	132-134
post	O	135-139
-	O	139-140
transcriptional	O	140-155
gene	O	156-160
regulators	O	161-171
and	O	172-175
have	O	176-180
been	O	181-185
shown	O	186-191
to	O	192-194
regulate	O	195-203
many	O	204-208
biological	O	209-219
processes	O	220-229
including	O	230-239
embryonal	O	240-249
development	O	250-261
,	O	261-262
cell	O	263-267
differentiation	O	268-283
,	O	283-284
apoptosis	O	285-294
,	O	294-295
and	O	296-299
proliferation	O	300-313
.	O	313-314

Variations	O	315-325
in	O	326-328
the	O	329-332
expression	O	333-343
of	O	344-346
certain	O	347-354
miRNAs	O	355-361
have	O	362-366
been	O	367-371
linked	O	372-378
to	O	379-381
a	O	382-383
wide	O	384-388
range	O	389-394
of	O	395-397
human	O	398-403
diseases	O	404-412
-	O	413-414
especially	O	415-425
cancer	O	426-432
-	O	433-434
and	O	435-438
the	O	439-442
diversity	O	443-452
of	O	453-455
miRNA	O	456-461
targets	O	462-469
suggests	O	470-478
that	O	479-483
they	O	484-488
are	O	489-492
involved	O	493-501
in	O	502-504
various	O	505-512
cellular	O	513-521
networks	O	522-530
.	O	530-531

Several	O	532-539
tools	O	540-545
have	O	546-550
been	O	551-555
developed	O	556-565
to	O	566-568
control	O	569-576
the	O	577-580
function	O	581-589
of	O	590-592
individual	O	593-603
miRNAs	O	604-610
and	O	611-614
have	O	615-619
been	O	620-624
applied	O	625-632
to	O	633-635
study	O	636-641
their	O	642-647
biogenesis	O	648-658
,	O	658-659
biological	O	660-670
role	O	671-675
,	O	675-676
and	O	677-680
therapeutic	O	681-692
potential	O	693-702
;	O	702-703
however	O	704-711
,	O	711-712
common	O	713-719
methods	O	720-727
lack	O	728-732
a	O	733-734
precise	O	735-742
level	O	743-748
of	O	749-751
control	O	752-759
that	O	760-764
allows	O	765-771
for	O	772-775
the	O	776-779
study	O	780-785
of	O	786-788
miRNA	O	789-794
function	O	795-803
with	O	804-808
high	O	809-813
spatial	O	814-821
and	O	822-825
temporal	O	826-834
resolution	O	835-845
.	O	845-846

Light	O	847-852
-	O	852-853
activated	O	853-862
miRNA	O	863-868
antagomirs	O	869-879
for	O	880-883
mature	O	884-890
miR	B	891-894
-	I	894-895
122	I	895-898
and	O	899-902
miR	B	903-906
-	I	906-907
21	I	907-909
were	O	910-914
developed	O	915-924
through	O	925-932
the	O	933-936
site	O	937-941
-	O	941-942
specific	O	942-950
installation	O	951-963
of	O	964-966
caging	O	967-973
groups	O	974-980
on	O	981-983
the	O	984-987
bases	O	988-993
of	O	994-996
selected	O	997-1005
nucleotides	O	1006-1017
.	O	1017-1018

Installation	O	1019-1031
of	O	1032-1034
caged	O	1035-1040
nucleotides	O	1041-1052
led	O	1053-1056
to	O	1057-1059
complete	O	1060-1068
inhibition	O	1069-1079
of	O	1080-1082
the	O	1083-1086
antagomir	O	1087-1096
-	O	1096-1097
miRNA	O	1097-1102
hybridization	O	1103-1116
and	O	1117-1120
thus	O	1121-1125
inactivation	O	1126-1138
of	O	1139-1141
antagomir	O	1142-1151
function	O	1152-1160
.	O	1160-1161

The	O	1162-1165
miRNA	O	1166-1171
-	O	1171-1172
inhibitory	O	1172-1182
activity	O	1183-1191
of	O	1192-1194
the	O	1195-1198
caged	O	1199-1204
antagomirs	O	1205-1215
was	O	1216-1219
fully	O	1220-1225
restored	O	1226-1234
upon	O	1235-1239
decaging	O	1240-1248
through	O	1249-1256
a	O	1257-1258
brief	O	1259-1264
UV	O	1265-1267
irradiation	O	1268-1279
.	O	1279-1280

The	O	1281-1284
synthesized	O	1285-1296
antagomirs	O	1297-1307
were	O	1308-1312
applied	O	1313-1320
to	O	1321-1323
the	O	1324-1327
photochemical	O	1328-1341
regulation	O	1342-1352
of	O	1353-1355
miRNA	O	1356-1361
function	O	1362-1370
in	O	1371-1373
mammalian	O	1374-1383
cells	O	1384-1389
.	O	1389-1390

Moreover	O	1391-1399
,	O	1399-1400
spatial	O	1401-1408
control	O	1409-1416
over	O	1417-1421
antagomir	O	1422-1431
activity	O	1432-1440
was	O	1441-1444
obtained	O	1445-1453
in	O	1454-1456
mammalian	O	1457-1466
cells	O	1467-1472
through	O	1473-1480
localized	O	1481-1490
UV	O	1491-1493
exposure	O	1494-1502
.	O	1502-1503

The	O	1504-1507
presented	O	1508-1517
approach	O	1518-1526
enables	O	1527-1534
the	O	1535-1538
precise	O	1539-1546
regulation	O	1547-1557
of	O	1558-1560
miRNA	O	1561-1566
function	O	1567-1575
and	O	1576-1579
miRNA	O	1580-1585
networks	O	1586-1594
with	O	1595-1599
unprecedented	O	1600-1613
spatial	O	1614-1621
and	O	1622-1625
temporal	O	1626-1634
resolution	O	1635-1645
using	O	1646-1651
UV	O	1652-1654
irradiation	O	1655-1666
and	O	1667-1670
can	O	1671-1674
be	O	1675-1677
extended	O	1678-1686
to	O	1687-1689
any	O	1690-1693
miRNA	O	1694-1699
of	O	1700-1702
interest	O	1703-1711
.	O	1711-1712

Clinical	O	0-8
significance	O	9-21
of	O	22-24
miR	B	25-28
-	I	28-29
144	I	29-32
-	O	32-33
ZFX	O	33-36
axis	O	37-41
in	O	42-44
disseminated	O	45-57
tumour	O	58-64
cells	O	65-70
in	O	71-73
bone	O	74-78
marrow	O	79-85
in	O	86-88
gastric	O	89-96
cancer	O	97-103
cases	O	104-109
.	O	109-110

BACKGROUND	O	111-121
:	O	121-122
We	O	123-125
previously	O	126-136
reported	O	137-145
that	O	146-150
bone	O	151-155
marrow	O	156-162
(	O	163-164
BM	O	164-166
)	O	166-167
was	O	168-171
a	O	172-173
homing	O	174-180
site	O	181-185
for	O	186-189
gastric	O	190-197
cancer	O	198-204
(	O	205-206
GC	O	206-208
)	O	208-209
cells	O	210-215
leading	O	216-223
to	O	224-226
haematogenous	O	227-240
metastases	O	241-251
.	O	251-252

There	O	253-258
has	O	259-262
been	O	263-267
little	O	268-274
study	O	275-280
that	O	281-285
microRNAs	O	286-295
regulated	O	296-305
pathways	O	306-314
in	O	315-317
malignant	O	318-327
cells	O	328-333
or	O	334-336
host	O	337-341
cells	O	342-347
in	O	348-350
BM	O	351-353
,	O	353-354
and	O	355-358
thereby	O	359-366
regulated	O	367-376
the	O	377-380
progression	O	381-392
of	O	393-395
GC	O	396-398
.	O	398-399

METHODS	O	400-407
:	O	407-408
Both	O	409-413
microRNA	O	414-422
microarray	O	423-433
and	O	434-437
gene	O	438-442
expression	O	443-453
microarray	O	454-464
analyses	O	465-473
of	O	474-476
total	O	477-482
RNA	O	483-486
from	O	487-491
BM	O	492-494
were	O	495-499
conducted	O	500-509
,	O	509-510
comparing	O	511-520
five	O	521-525
early	O	526-531
and	O	532-535
five	O	536-540
advanced	O	541-549
GC	O	550-552
patients	O	553-561
.	O	561-562

We	O	563-565
focused	O	566-573
on	O	574-576
miR	B	577-580
-	I	580-581
144	I	581-584
-	O	584-585
ZFX	O	585-588
axis	O	589-593
as	O	594-596
a	O	597-598
candidate	O	599-608
BM	O	609-611
regulator	O	612-621
of	O	622-624
GC	O	625-627
progression	O	628-639
and	O	640-643
validated	O	644-653
the	O	654-657
origin	O	658-664
of	O	665-667
the	O	668-671
microRNA	O	672-680
expression	O	681-691
in	O	692-694
diverse	O	695-702
cell	O	703-707
fractions	O	708-717
(	O	718-719
EpCAM	O	719-724
(	O	724-725
+	O	725-726
)	O	726-727
CD45	O	727-731
(	O	731-732
-	O	732-733
)	O	733-734
,	O	734-735
EpCAM	O	736-741
(	O	741-742
-	O	742-743
)	O	743-744
CD45	O	744-748
(	O	748-749
+	O	749-750
)	O	750-751
,	O	751-752
and	O	753-756
CD14	O	757-761
(	O	761-762
+	O	762-763
)	O	763-764
)	O	764-765
by	O	766-768
magnetic	O	769-777
-	O	777-778
activated	O	778-787
cell	O	788-792
sorting	O	793-800
(	O	801-802
MACS	O	802-806
)	O	806-807
.	O	807-808

RESULTS	O	809-816
:	O	816-817
Quantitative	O	818-830
reverse	O	831-838
-	O	838-839
transcriptase	O	839-852
(	O	853-854
RT	O	854-856
)	O	856-857
-	O	857-858
PCR	O	858-861
analysis	O	862-870
validated	O	871-880
diminished	O	881-891
miR	B	892-895
-	I	895-896
144	I	896-899
expression	O	900-910
in	O	911-913
stage	O	914-919
IV	O	920-922
GC	O	923-925
patients	O	926-934
with	O	935-939
respect	O	940-947
to	O	948-950
stage	O	951-956
I	O	957-958
GC	O	959-961
patients	O	962-970
(	O	971-972
t	O	972-973
-	O	973-974
test	O	974-978
,	O	978-979
P	O	980-981
=	O	981-982
0	O	982-983
.	O	983-984
02	O	984-986
)	O	986-987
,	O	987-988
with	O	989-993
an	O	994-996
inverse	O	997-1004
correlation	O	1005-1016
to	O	1017-1019
ZFX	O	1020-1023
(	O	1024-1025
ANOVA	O	1025-1030
,	O	1030-1031
P	O	1032-1033
<	O	1033-1034
0	O	1034-1035
.	O	1035-1036
01	O	1036-1038
)	O	1038-1039
.	O	1039-1040

Luciferase	O	1041-1051
reporter	O	1052-1060
assays	O	1061-1067
in	O	1068-1070
five	O	1071-1075
GC	O	1076-1078
cell	O	1079-1083
lines	O	1084-1089
indicated	O	1090-1099
their	O	1100-1105
direct	O	1106-1112
binding	O	1113-1120
and	O	1121-1124
validated	O	1125-1134
by	O	1135-1137
western	O	1138-1145
blotting	O	1146-1154
.	O	1154-1155

Pre	B	1156-1159
-	I	1159-1160
miR144	I	1160-1166
treatment	O	1167-1176
and	O	1177-1180
the	O	1181-1184
resultant	O	1185-1194
repression	O	1195-1205
of	O	1206-1208
ZFX	O	1209-1212
in	O	1213-1215
GC	O	1216-1218
cell	O	1219-1223
lines	O	1224-1229
moderately	O	1230-1240
upregulated	O	1241-1252
their	O	1253-1258
susceptibility	O	1259-1273
to	O	1274-1276
5	O	1277-1278
-	O	1278-1279
fluorouracil	O	1279-1291
chemotherapy	O	1292-1304
.	O	1304-1305

In	O	1306-1308
MACS	O	1309-1313
-	O	1313-1314
purified	O	1314-1322
BM	O	1323-1325
fractions	O	1326-1335
,	O	1335-1336
the	O	1337-1340
level	O	1341-1346
of	O	1347-1349
miR	B	1350-1353
-	I	1353-1354
144	I	1354-1357
expression	O	1358-1368
was	O	1369-1372
significantly	O	1373-1386
diminished	O	1387-1397
in	O	1398-1400
disseminated	O	1401-1413
tumour	O	1414-1420
cell	O	1421-1425
fraction	O	1426-1434
(	O	1435-1436
P	O	1436-1437
=	O	1437-1438
0	O	1438-1439
.	O	1439-1440
0005	O	1440-1444
)	O	1444-1445
.	O	1445-1446

Diminished	O	1447-1457
miR	B	1458-1461
-	I	1461-1462
144	I	1462-1465
expression	O	1466-1476
in	O	1477-1479
93	O	1480-1482
cases	O	1483-1488
of	O	1489-1491
primary	O	1492-1499
GC	O	1500-1502
indicated	O	1503-1512
poor	O	1513-1517
prognosis	O	1518-1527
.	O	1527-1528

CONCLUSION	O	1529-1539
:	O	1539-1540
We	O	1541-1543
speculate	O	1544-1553
that	O	1554-1558
disseminated	O	1559-1571
cancer	O	1572-1578
cells	O	1579-1584
could	O	1585-1590
survive	O	1591-1598
in	O	1599-1601
BM	O	1602-1604
when	O	1605-1609
low	O	1610-1613
expression	O	1614-1624
of	O	1625-1627
miR	B	1628-1631
-	I	1631-1632
144	I	1632-1635
permits	O	1636-1643
upregulation	O	1644-1656
of	O	1657-1659
ZFX	O	1660-1663
.	O	1663-1664

The	O	1665-1668
regulation	O	1669-1679
of	O	1680-1682
the	O	1683-1686
miR	B	1687-1690
-	I	1690-1691
144	I	1691-1694
-	O	1694-1695
ZFX	O	1695-1698
axis	O	1699-1703
in	O	1704-1706
cancer	O	1707-1713
cells	O	1714-1719
has	O	1720-1723
a	O	1724-1725
key	O	1726-1729
role	O	1730-1734
in	O	1735-1737
the	O	1738-1741
indicator	O	1742-1751
of	O	1752-1754
the	O	1755-1758
progression	O	1759-1770
of	O	1771-1773
GC	O	1774-1776
cases	O	1777-1782
.	O	1782-1783

MicroRNA	B	0-8
-	I	8-9
21	I	9-11
(	O	12-13
miR	B	13-16
-	I	16-17
21	I	17-19
)	O	19-20
expression	O	21-31
promotes	O	32-40
growth	O	41-47
,	O	47-48
metastasis	O	49-59
,	O	59-60
and	O	61-64
chemo	O	65-70
-	O	70-71
or	O	72-74
radioresistance	O	75-90
in	O	91-93
non	O	94-97
-	O	97-98
small	O	98-103
cell	O	104-108
lung	O	109-113
cancer	O	114-120
cells	O	121-126
by	O	127-129
targeting	O	130-139
PTEN	O	140-144
.	O	144-145

MicroRNAs	O	146-155
(	O	156-157
miRNAs	O	157-163
)	O	163-164
regulate	O	165-173
gene	O	174-178
expression	O	179-189
by	O	190-192
binding	O	193-200
to	O	201-203
target	O	204-210
sites	O	211-216
and	O	217-220
initiating	O	221-231
translational	O	232-245
repression	O	246-256
and	O	257-260
/	O	260-261
or	O	261-263
mRNA	O	264-268
degradation	O	269-280
.	O	280-281

In	O	282-284
our	O	285-288
previous	O	289-297
study	O	298-303
,	O	303-304
we	O	305-307
have	O	308-312
shown	O	313-318
that	O	319-323
expression	O	324-334
of	O	335-337
serum	O	338-343
microRNA	B	344-352
(	I	353-354
miR	I	354-357
)	I	357-358
-	I	358-359
21	I	359-361
is	O	362-364
correlated	O	365-375
with	O	376-380
TNM	O	381-384
stage	O	385-390
and	O	391-394
lymph	O	395-400
node	O	401-405
metastasis	O	406-416
and	O	417-420
might	O	421-426
be	O	427-429
an	O	430-432
independent	O	433-444
prognostic	O	445-455
factor	O	456-462
for	O	463-466
NSCLC	O	467-472
patients	O	473-481
.	O	481-482

However	O	483-490
,	O	490-491
the	O	492-495
roles	O	496-501
of	O	502-504
miR	B	505-508
-	I	508-509
21	I	509-511
overexpression	O	512-526
in	O	527-529
NSCLC	O	530-535
development	O	536-547
are	O	548-551
still	O	552-557
unclear	O	558-565
.	O	565-566

The	O	567-570
purpose	O	571-578
of	O	579-581
this	O	582-586
study	O	587-592
is	O	593-595
to	O	596-598
investigate	O	599-610
the	O	611-614
effect	O	615-621
of	O	622-624
miR	B	625-628
-	I	628-629
21	I	629-631
and	O	632-635
determine	O	636-645
whether	O	646-653
miR	B	654-657
-	I	657-658
21	I	658-660
can	O	661-664
be	O	665-667
a	O	668-669
therapeutic	O	670-681
target	O	682-688
for	O	689-692
human	O	693-698
NSCLC	O	699-704
.	O	704-705

Taqman	O	706-712
real	O	713-717
-	O	717-718
time	O	718-722
quantitative	O	723-735
RT	O	736-738
-	O	738-739
PCR	O	739-742
assay	O	743-748
was	O	749-752
performed	O	753-762
to	O	763-765
detect	O	766-772
miR	B	773-776
-	I	776-777
21	I	777-779
expression	O	780-790
in	O	791-793
NSCLC	O	794-799
cell	O	800-804
lines	O	805-810
and	O	811-814
tissues	O	815-822
.	O	822-823

Next	O	824-828
,	O	828-829
the	O	830-833
effects	O	834-841
of	O	842-844
miR	B	845-848
-	I	848-849
21	I	849-851
expression	O	852-862
on	O	863-865
NSCLC	O	866-871
cell	O	872-876
characteristics	O	877-892
including	O	893-902
growth	O	903-909
,	O	909-910
invasion	O	911-919
,	O	919-920
and	O	921-924
chemo	O	925-930
-	O	930-931
or	O	932-934
radioresistance	O	935-950
were	O	951-955
also	O	956-960
determined	O	961-971
.	O	971-972

Results	O	973-980
showed	O	981-987
that	O	988-992
miR	B	993-996
-	I	996-997
21	I	997-999
is	O	1000-1002
commonly	O	1003-1011
upregulated	O	1012-1023
in	O	1024-1026
NSCLC	O	1027-1032
cell	O	1033-1037
lines	O	1038-1043
and	O	1044-1047
tissues	O	1048-1055
with	O	1056-1060
important	O	1061-1070
functional	O	1071-1081
consequences	O	1082-1094
.	O	1094-1095

In	O	1096-1098
addition	O	1099-1107
,	O	1107-1108
we	O	1109-1111
found	O	1112-1117
that	O	1118-1122
anti	O	1123-1127
-	O	1127-1128
miR	B	1128-1131
-	I	1131-1132
21	I	1132-1134
could	O	1135-1140
significantly	O	1141-1154
inhibit	O	1155-1162
growth	O	1163-1169
,	O	1169-1170
migration	O	1171-1180
and	O	1181-1184
invasion	O	1185-1193
,	O	1193-1194
and	O	1195-1198
reverse	O	1199-1206
chemo	O	1207-1212
-	O	1212-1213
or	O	1214-1216
radioresistance	O	1217-1232
of	O	1233-1235
NSCLC	O	1236-1241
cells	O	1242-1247
,	O	1247-1248
while	O	1249-1254
miR	B	1255-1258
-	I	1258-1259
21	I	1259-1261
mimics	O	1262-1268
could	O	1269-1274
increase	O	1275-1283
growth	O	1284-1290
,	O	1290-1291
promote	O	1292-1299
migration	O	1300-1309
and	O	1310-1313
invasion	O	1314-1322
,	O	1322-1323
and	O	1324-1327
enhance	O	1328-1335
chemo	O	1336-1341
-	O	1341-1342
or	O	1343-1345
radioresistance	O	1346-1361
of	O	1362-1364
NSCLC	O	1365-1370
cells	O	1371-1376
.	O	1376-1377

Meanwhile	O	1378-1387
,	O	1387-1388
miR	B	1389-1392
-	I	1392-1393
21	I	1393-1395
mimics	O	1396-1402
could	O	1403-1408
inhibit	O	1409-1416
expression	O	1417-1427
of	O	1428-1430
PTEN	O	1431-1435
mRNA	O	1436-1440
and	O	1441-1444
protein	O	1445-1452
and	O	1453-1456
the	O	1457-1460
luciferase	O	1461-1471
activity	O	1472-1480
of	O	1481-1483
a	O	1484-1485
PTEN	O	1486-1490
3	O	1491-1492
'	O	1492-1493
-	O	1493-1494
untranslated	O	1494-1506
region	O	1507-1513
(	O	1514-1515
UTR	O	1515-1518
)	O	1518-1519
-	O	1519-1520
based	O	1520-1525
reporter	O	1526-1534
construct	O	1535-1544
in	O	1545-1547
A549	O	1548-1552
cells	O	1553-1558
,	O	1558-1559
while	O	1560-1565
anti	O	1566-1570
-	O	1570-1571
miR	B	1571-1574
-	I	1574-1575
21	I	1575-1577
could	O	1578-1583
increase	O	1584-1592
expression	O	1593-1603
of	O	1604-1606
PTEN	O	1607-1611
mRNA	O	1612-1616
and	O	1617-1620
protein	O	1621-1628
and	O	1629-1632
the	O	1633-1636
luciferase	O	1637-1647
activity	O	1648-1656
of	O	1657-1659
a	O	1660-1661
PTEN	O	1662-1666
3	O	1667-1668
'	O	1668-1669
-	O	1669-1670
UTR	O	1670-1673
-	O	1673-1674
based	O	1674-1679
reporter	O	1680-1688
construct	O	1689-1698
in	O	1699-1701
A549	O	1702-1706
cells	O	1707-1712
.	O	1712-1713

Furthermore	O	1714-1725
,	O	1725-1726
overexpression	O	1727-1741
of	O	1742-1744
PTEN	O	1745-1749
could	O	1750-1755
mimic	O	1756-1761
the	O	1762-1765
same	O	1766-1770
effects	O	1771-1778
of	O	1779-1781
anti	O	1782-1786
-	O	1786-1787
miR	B	1787-1790
-	I	1790-1791
21	I	1791-1793
in	O	1794-1796
NSCLC	O	1797-1802
cells	O	1803-1808
,	O	1808-1809
and	O	1810-1813
siRNA	O	1814-1819
-	O	1819-1820
mediated	O	1820-1828
downregulation	O	1829-1843
of	O	1844-1846
PTEN	O	1847-1851
could	O	1852-1857
rescue	O	1858-1864
the	O	1865-1868
effects	O	1869-1876
on	O	1877-1879
NSCLC	O	1880-1885
cells	O	1886-1891
induced	O	1892-1899
by	O	1900-1902
anti	O	1903-1907
-	O	1907-1908
miR	B	1908-1911
-	I	1911-1912
21	I	1912-1914
.	O	1914-1915

Taken	O	1916-1921
together	O	1922-1930
,	O	1930-1931
these	O	1932-1937
results	O	1938-1945
provide	O	1946-1953
evidence	O	1954-1962
to	O	1963-1965
show	O	1966-1970
the	O	1971-1974
promotion	O	1975-1984
role	O	1985-1989
of	O	1990-1992
miR	B	1993-1996
-	I	1996-1997
21	I	1997-1999
in	O	2000-2002
NSCLC	O	2003-2008
development	O	2009-2020
through	O	2021-2028
modulation	O	2029-2039
of	O	2040-2042
the	O	2043-2046
PTEN	O	2047-2051
signaling	O	2052-2061
pathway	O	2062-2069
.	O	2069-2070

miR	B	0-3
-	I	3-4
200c	I	4-8
inhibits	O	9-17
melanoma	O	18-26
progression	O	27-38
and	O	39-42
drug	O	43-47
resistance	O	48-58
through	O	59-66
down	O	67-71
-	O	71-72
regulation	O	72-82
of	O	83-85
BMI	O	86-89
-	O	89-90
1	O	90-91
.	O	91-92

MicroRNAs	O	93-102
(	O	103-104
miRNAs	O	104-110
)	O	110-111
are	O	112-115
short	O	116-121
noncoding	O	122-131
RNAs	O	132-136
that	O	137-141
play	O	142-146
crucial	O	147-154
roles	O	155-160
in	O	161-163
tumorigenesis	O	164-177
and	O	178-181
tumor	O	182-187
progression	O	188-199
.	O	199-200

Melanoma	O	201-209
is	O	210-212
the	O	213-216
most	O	217-221
aggressive	O	222-232
skin	O	233-237
cancer	O	238-244
that	O	245-249
is	O	250-252
resistant	O	253-262
or	O	263-265
rapidly	O	266-273
develops	O	274-282
resistance	O	283-293
to	O	294-296
a	O	297-298
variety	O	299-306
of	O	307-309
chemotherapeutic	O	310-326
agents	O	327-333
.	O	333-334

The	O	335-338
role	O	339-343
of	O	344-346
miRNAs	O	347-353
in	O	354-356
melanoma	O	357-365
progression	O	366-377
and	O	378-381
drug	O	382-386
resistance	O	387-397
has	O	398-401
not	O	402-405
been	O	406-410
well	O	411-415
studied	O	416-423
.	O	423-424

Herein	O	425-431
,	O	431-432
we	O	433-435
demonstrate	O	436-447
that	O	448-452
miR	B	453-456
-	I	456-457
200c	I	457-461
is	O	462-464
down	O	465-469
-	O	469-470
regulated	O	470-479
in	O	480-482
melanomas	O	483-492
(	O	493-494
primary	O	494-501
and	O	502-505
metastatic	O	506-516
)	O	516-517
compared	O	518-526
with	O	527-531
melanocytic	O	532-543
nevi	O	544-548
.	O	548-549

Overexpression	O	550-564
of	O	565-567
miR	B	568-571
-	I	571-572
200c	I	572-576
in	O	577-579
melanoma	O	580-588
cells	O	589-594
resulted	O	595-603
in	O	604-606
significantly	O	607-620
decreased	O	621-630
cell	O	631-635
proliferation	O	636-649
and	O	650-653
migratory	O	654-663
capacity	O	664-672
as	O	673-675
well	O	676-680
as	O	681-683
drug	O	684-688
resistance	O	689-699
.	O	699-700

miR	B	701-704
-	I	704-705
200c	I	705-709
overexpression	O	710-724
resulted	O	725-733
in	O	734-736
significant	O	737-748
down	O	749-753
-	O	753-754
regulation	O	754-764
of	O	765-767
BMI	O	768-771
-	O	771-772
1	O	772-773
,	O	773-774
ABCG2	O	775-780
,	O	780-781
ABCG5	O	782-787
,	O	787-788
and	O	789-792
MDR1	O	793-797
expression	O	798-808
and	O	809-812
in	O	813-815
a	O	816-817
concomitant	O	818-829
increase	O	830-838
in	O	839-841
E	O	842-843
-	O	843-844
cadherin	O	844-852
levels	O	853-859
.	O	859-860

Knockdown	O	861-870
of	O	871-873
BMI	O	874-877
-	O	877-878
1	O	878-879
showed	O	880-886
similar	O	887-894
effects	O	895-902
as	O	903-905
miR	B	906-909
-	I	909-910
200c	I	910-914
overexpression	O	915-929
in	O	930-932
melanoma	O	933-941
cells	O	942-947
.	O	947-948

In	O	949-951
addition	O	952-960
,	O	960-961
miR	B	962-965
-	I	965-966
200c	I	966-970
overexpression	O	971-985
significantly	O	986-999
inhibited	O	1000-1009
melanoma	O	1010-1018
xenograft	O	1019-1028
growth	O	1029-1035
and	O	1036-1039
metastasis	O	1040-1050
in	O	1051-1053
vivo	O	1054-1058
,	O	1058-1059
and	O	1060-1063
this	O	1064-1068
correlated	O	1069-1079
with	O	1080-1084
diminished	O	1085-1095
expression	O	1096-1106
of	O	1107-1109
BMI	O	1110-1113
-	O	1113-1114
1	O	1114-1115
and	O	1116-1119
reduced	O	1120-1127
levels	O	1128-1134
of	O	1135-1137
E	O	1138-1139
-	O	1139-1140
cadherin	O	1140-1148
in	O	1149-1151
these	O	1152-1157
tumors	O	1158-1164
.	O	1164-1165

The	O	1166-1169
effects	O	1170-1177
of	O	1178-1180
miR	B	1181-1184
-	I	1184-1185
200c	I	1185-1189
on	O	1190-1192
melanoma	O	1193-1201
cell	O	1202-1206
proliferation	O	1207-1220
and	O	1221-1224
migratory	O	1225-1234
capacity	O	1235-1243
and	O	1244-1247
on	O	1248-1250
self	O	1251-1255
-	O	1255-1256
renewal	O	1256-1263
were	O	1264-1268
rescued	O	1269-1276
by	O	1277-1279
overexpression	O	1280-1294
of	O	1295-1297
Bmi	O	1298-1301
-	O	1301-1302
1	O	1302-1303
,	O	1303-1304
and	O	1305-1308
the	O	1309-1312
reversal	O	1313-1321
of	O	1322-1324
these	O	1325-1330
phenotypes	O	1331-1341
correlated	O	1342-1352
with	O	1353-1357
a	O	1358-1359
reduction	O	1360-1369
in	O	1370-1372
E	O	1373-1374
-	O	1374-1375
cadherin	O	1375-1383
expression	O	1384-1394
and	O	1395-1398
increased	O	1399-1408
levels	O	1409-1415
of	O	1416-1418
ABCG2	O	1419-1424
,	O	1424-1425
ABCG5	O	1426-1431
,	O	1431-1432
and	O	1433-1436
MDR1	O	1437-1441
.	O	1441-1442

Taken	O	1443-1448
together	O	1449-1457
,	O	1457-1458
these	O	1459-1464
findings	O	1465-1473
demonstrate	O	1474-1485
a	O	1486-1487
key	O	1488-1491
role	O	1492-1496
for	O	1497-1500
miR	B	1501-1504
-	I	1504-1505
200c	I	1505-1509
in	O	1510-1512
melanoma	O	1513-1521
progression	O	1522-1533
and	O	1534-1537
drug	O	1538-1542
resistance	O	1543-1553
.	O	1553-1554

These	O	1555-1560
results	O	1561-1568
suggest	O	1569-1576
that	O	1577-1581
miR	B	1582-1585
-	I	1585-1586
200c	I	1586-1590
may	O	1591-1594
represent	O	1595-1604
a	O	1605-1606
critical	O	1607-1615
target	O	1616-1622
for	O	1623-1626
increasing	O	1627-1637
melanoma	O	1638-1646
sensitivity	O	1647-1658
to	O	1659-1661
clinical	O	1662-1670
therapies	O	1671-1680
.	O	1680-1681

miR	B	0-3
-	I	3-4
134	I	4-7
inhibits	O	8-16
epithelial	O	17-27
to	O	28-30
mesenchymal	O	31-42
transition	O	43-53
by	O	54-56
targeting	O	57-66
FOXM1	O	67-72
in	O	73-75
non	O	76-79
-	O	79-80
small	O	80-85
cell	O	86-90
lung	O	91-95
cancer	O	96-102
cells	O	103-108
.	O	108-109

Recent	O	110-116
studies	O	117-124
have	O	125-129
implied	O	130-137
that	O	138-142
miRNAs	O	143-149
act	O	150-153
as	O	154-156
crucial	O	157-164
modulators	O	165-175
for	O	176-179
epithelial	O	180-190
-	O	190-191
to	O	191-193
-	O	193-194
mesenchymal	O	194-205
transition	O	206-216
(	O	217-218
EMT	O	218-221
)	O	221-222
.	O	222-223

We	O	224-226
found	O	227-232
that	O	233-237
miR	B	238-241
-	I	241-242
134	I	242-245
expression	O	246-256
correlated	O	257-267
with	O	268-272
invasive	O	273-281
potential	O	282-291
and	O	292-295
EMT	O	296-299
phenotype	O	300-309
of	O	310-312
NSCLC	O	313-318
cells	O	319-324
.	O	324-325

Functional	O	326-336
assays	O	337-343
demonstrated	O	344-356
that	O	357-361
miR	B	362-365
-	I	365-366
134	I	366-369
inhibited	O	370-379
EMT	O	380-383
in	O	384-386
NSCLC	O	387-392
cells	O	393-398
.	O	398-399

In	O	400-402
addition	O	403-411
,	O	411-412
we	O	413-415
showed	O	416-422
that	O	423-427
Forkhead	O	428-436
Box	O	437-440
M1	O	441-443
(	O	444-445
FOXM1	O	445-450
)	O	450-451
is	O	452-454
a	O	455-456
direct	O	457-463
target	O	464-470
of	O	471-473
miR	B	474-477
-	I	477-478
134	I	478-481
.	O	481-482

Knockdown	O	483-492
of	O	493-495
FOXM1	O	496-501
reversed	O	502-510
EMT	O	511-514
resembling	O	515-525
that	O	526-530
of	O	531-533
miR	B	534-537
-	I	537-538
134	I	538-541
overexpression	O	542-556
.	O	556-557

We	O	558-560
further	O	561-568
found	O	569-574
that	O	575-579
FOXM1	O	580-585
was	O	586-589
involved	O	590-598
in	O	599-601
TGF	O	602-605
-	O	605-606
beta1	O	606-611
-	O	611-612
induced	O	612-619
EMT	O	620-623
in	O	624-626
A549	O	627-631
cells	O	632-637
.	O	637-638

These	O	639-644
findings	O	645-653
suggest	O	654-661
that	O	662-666
miR	B	667-670
-	I	670-671
134	I	671-674
acts	O	675-679
as	O	680-682
a	O	683-684
novel	O	685-690
EMT	O	691-694
suppressor	O	695-705
in	O	706-708
NSCLC	O	709-714
cells	O	715-720
.	O	720-721

Age	O	0-3
-	O	3-4
related	O	4-11
differences	O	12-23
in	O	24-26
the	O	27-30
expression	O	31-41
of	O	42-44
circulating	O	45-56
microRNAs	O	57-66
:	O	66-67
miR	B	68-71
-	I	71-72
21	I	72-74
as	O	75-77
a	O	78-79
new	O	80-83
circulating	O	84-95
marker	O	96-102
of	O	103-105
inflammaging	O	106-118
.	O	118-119

Circulating	O	120-131
microRNAs	O	132-141
(	O	142-143
miRs	O	143-147
)	O	147-148
have	O	149-153
been	O	154-158
investigated	O	159-171
as	O	172-174
diagnostic	O	175-185
/	O	185-186
prognostic	O	186-196
biomarkers	O	197-207
in	O	208-210
human	O	211-216
diseases	O	217-225
.	O	225-226

However	O	227-234
,	O	234-235
little	O	236-242
is	O	243-245
known	O	246-251
about	O	252-257
their	O	258-263
expression	O	264-274
throughout	O	275-285
the	O	286-289
aging	O	290-295
process	O	296-303
.	O	303-304

Eleven	O	305-311
healthy	O	312-319
individuals	O	320-331
aged	O	332-336
20	O	337-339
,	O	339-340
80	O	341-343
and	O	344-347
100	O	348-351
years	O	352-357
underwent	O	358-367
miR	O	368-371
plasma	O	372-378
profiling	O	379-388
.	O	388-389

The	O	390-393
validation	O	394-404
cohort	O	405-411
consisted	O	412-421
of	O	422-424
111	O	425-428
healthy	O	429-436
adults	O	437-443
(	O	444-445
CTR	O	445-448
)	O	448-449
aged	O	450-454
20	O	455-457
-	O	457-458
105	O	458-461
years	O	462-467
and	O	468-471
included	O	472-480
30	O	481-483
centenarians	O	484-496
.	O	496-497

In	O	498-500
addition	O	501-509
,	O	509-510
34	O	511-513
patients	O	514-522
with	O	523-527
cardiovascular	O	528-542
disease	O	543-550
(	O	551-552
CVD	O	552-555
)	O	555-556
and	O	557-560
15	O	561-563
healthy	O	564-571
centenarian	O	572-583
offspring	O	584-593
(	O	594-595
CO	O	595-597
)	O	597-598
were	O	599-603
enrolled	O	604-612
.	O	612-613

An	O	614-616
exploratory	O	617-628
factorial	O	629-638
analysis	O	639-647
grouped	O	648-655
the	O	656-659
miRs	O	660-664
into	O	665-669
three	O	670-675
main	O	676-680
factors	O	681-688
:	O	688-689
factor	O	690-696
1	O	697-698
primarily	O	699-708
higher	O	709-715
in	O	716-718
20	O	719-721
-	O	721-722
year	O	722-726
-	O	726-727
old	O	727-730
subjects	O	731-739
,	O	739-740
but	O	741-744
these	O	745-750
differences	O	751-762
did	O	763-766
not	O	767-770
reach	O	771-776
statistical	O	777-788
significance	O	789-801
,	O	801-802
factor	O	803-809
2	O	810-811
primarily	O	812-821
higher	O	822-828
in	O	829-831
octogenarians	O	832-845
and	O	846-849
factor	O	850-856
3	O	857-858
primarily	O	859-868
higher	O	869-875
in	O	876-878
centenarians	O	879-891
.	O	891-892

MiR	B	893-896
-	I	896-897
21	I	897-899
,	O	899-900
the	O	901-904
most	O	905-909
highly	O	910-916
expressed	O	917-926
miR	O	927-930
of	O	931-933
factors	O	934-941
2	O	942-943
and	O	944-947
3	O	948-949
,	O	949-950
was	O	951-954
further	O	955-962
validated	O	963-972
,	O	972-973
confirming	O	974-984
the	O	985-988
differences	O	989-1000
in	O	1001-1003
the	O	1004-1007
age	O	1008-1011
groups	O	1012-1018
.	O	1018-1019

MiR	B	1020-1023
-	I	1023-1024
21	I	1024-1026
expression	O	1027-1037
was	O	1038-1041
higher	O	1042-1048
in	O	1049-1051
the	O	1052-1055
CVD	O	1056-1059
patients	O	1060-1068
and	O	1069-1072
lower	O	1073-1078
in	O	1079-1081
the	O	1082-1085
CO	O	1086-1088
compared	O	1089-1097
to	O	1098-1100
the	O	1101-1104
age	O	1105-1108
-	O	1108-1109
matched	O	1109-1116
CTR	O	1117-1120
.	O	1120-1121

MiR	B	1122-1125
-	I	1125-1126
21	I	1126-1128
was	O	1129-1132
correlated	O	1133-1143
with	O	1144-1148
C	O	1149-1150
-	O	1150-1151
reactive	O	1151-1159
protein	O	1160-1167
and	O	1168-1171
fibrinogen	O	1172-1182
levels	O	1183-1189
.	O	1189-1190

TGF	O	1191-1194
-	O	1194-1195
beta	O	1195-1199
signaling	O	1200-1209
was	O	1210-1213
the	O	1214-1217
predicted	O	1218-1227
common	O	1228-1234
pathway	O	1235-1242
targeted	O	1243-1251
by	O	1252-1254
miRs	O	1255-1259
of	O	1260-1262
factors	O	1263-1270
2	O	1271-1272
and	O	1273-1276
3	O	1277-1278
.	O	1278-1279

TGF	O	1280-1283
-	O	1283-1284
betaR2	O	1284-1290
mRNA	O	1291-1295
,	O	1295-1296
a	O	1297-1298
validated	O	1299-1308
miR	B	1309-1312
-	I	1312-1313
21	I	1313-1315
target	O	1316-1322
,	O	1322-1323
showed	O	1324-1330
the	O	1331-1334
highest	O	1335-1342
expression	O	1343-1353
in	O	1354-1356
the	O	1357-1360
leukocytes	O	1361-1371
from	O	1372-1376
a	O	1377-1378
subset	O	1379-1385
of	O	1386-1388
the	O	1389-1392
octogenarians	O	1393-1406
.	O	1406-1407

Our	O	1408-1411
findings	O	1412-1420
suggest	O	1421-1428
that	O	1429-1433
miR	B	1434-1437
-	I	1437-1438
21	I	1438-1440
may	O	1441-1444
be	O	1445-1447
a	O	1448-1449
new	O	1450-1453
biomarker	O	1454-1463
of	O	1464-1466
inflammation	O	1467-1479
.	O	1479-1480

MIR	B	0-3
-	I	3-4
34c	I	4-7
regulates	O	8-17
mouse	O	18-23
embryonic	O	24-33
stem	O	34-38
cells	O	39-44
differentiation	O	45-60
into	O	61-65
male	O	66-70
germ	O	71-75
-	O	75-76
like	O	76-80
cells	O	81-86
through	O	87-94
RARg	O	95-99
.	O	99-100

Embryonic	O	101-110
stem	O	111-115
cells	O	116-121
(	O	122-123
ESCs	O	123-127
)	O	127-128
have	O	129-133
the	O	134-137
capacity	O	138-146
to	O	147-149
differentiate	O	150-163
into	O	164-168
nearly	O	169-175
all	O	176-179
sorts	O	180-185
of	O	186-188
cell	O	189-193
types	O	194-199
,	O	199-200
including	O	201-210
germ	O	211-215
cells	O	216-221
,	O	221-222
which	O	223-228
were	O	229-233
regarded	O	234-242
as	O	243-245
one	O	246-249
type	O	250-254
of	O	255-257
highly	O	258-264
specialized	O	265-276
cells	O	277-282
in	O	283-285
mammals	O	286-293
,	O	293-294
taking	O	295-301
the	O	302-305
responsibility	O	306-320
of	O	321-323
transferring	O	324-336
genetic	O	337-344
materials	O	345-354
to	O	355-357
the	O	358-361
next	O	362-366
generation	O	367-377
.	O	377-378

Studies	O	379-386
on	O	387-389
induction	O	390-399
differentiation	O	400-415
of	O	416-418
murine	O	419-425
embryonic	O	426-435
stem	O	436-440
cells	O	441-446
(	O	447-448
mESCs	O	448-453
)	O	453-454
into	O	455-459
male	O	460-464
germ	O	465-469
cells	O	470-475
,	O	475-476
but	O	477-480
with	O	481-485
a	O	486-487
low	O	488-491
efficiency	O	492-502
,	O	502-503
basic	O	504-509
reason	O	510-516
is	O	517-519
that	O	520-524
the	O	525-528
regulation	O	529-539
mechanism	O	540-549
of	O	550-552
germ	O	553-557
cell	O	558-562
development	O	563-574
in	O	575-577
mammals	O	578-585
is	O	586-588
still	O	589-594
unclear	O	595-602
.	O	602-603

miRNA	O	604-609
might	O	610-615
play	O	616-620
an	O	621-623
important	O	624-633
role	O	634-638
in	O	639-641
spermatogenesis	O	642-657
in	O	658-660
mammals	O	661-668
.	O	668-669

In	O	670-672
this	O	673-677
study	O	678-683
,	O	683-684
several	O	685-692
miRNAs	O	693-699
,	O	699-700
which	O	701-706
might	O	707-712
be	O	713-715
related	O	716-723
to	O	724-726
spermatogenesis	O	727-742
,	O	742-743
were	O	744-748
initially	O	749-758
selected	O	759-767
and	O	768-771
detected	O	772-780
in	O	781-783
the	O	784-787
mouse	O	788-793
tissues	O	794-801
by	O	802-804
semi	O	805-809
-	O	809-810
polymerase	O	810-820
chain	O	821-826
reaction	O	827-835
(	O	836-837
PCR	O	837-840
)	O	840-841
and	O	842-845
quantitative	O	846-858
real	O	859-863
time	O	864-868
(	O	869-870
qRT	O	870-873
)	O	873-874
-	O	874-875
PCR	O	875-878
to	O	879-881
find	O	882-886
a	O	887-888
testis	O	889-895
-	O	895-896
specific	O	896-904
miRNA	O	905-910
.	O	910-911

To	O	912-914
study	O	915-920
its	O	921-924
effect	O	925-931
on	O	932-934
mESCs	O	935-940
differentiation	O	941-956
into	O	957-961
male	O	962-966
germ	O	967-971
cells	O	972-977
,	O	977-978
miR	B	979-982
-	I	982-983
34c	I	983-986
mimics	O	987-993
were	O	994-998
synthesized	O	999-1010
and	O	1011-1014
pri	B	1015-1018
-	I	1018-1019
miR	I	1019-1022
-	I	1022-1023
34c	I	1023-1026
-	O	1026-1027
GFP	O	1027-1030
plasmid	O	1031-1038
was	O	1039-1042
constructed	O	1043-1054
,	O	1054-1055
transfected	O	1056-1067
into	O	1068-1072
mESCs	O	1073-1078
and	O	1079-1082
combined	O	1083-1091
with	O	1092-1096
retinoic	O	1097-1105
acid	O	1106-1110
induction	O	1111-1120
.	O	1120-1121

The	O	1122-1125
effects	O	1126-1133
of	O	1134-1136
miR	B	1137-1140
-	I	1140-1141
34c	I	1141-1144
were	O	1145-1149
analysed	O	1150-1158
by	O	1159-1161
morphology	O	1162-1172
,	O	1172-1173
alkaline	O	1174-1182
phosphatase	O	1183-1194
staining	O	1195-1203
,	O	1203-1204
qRT	O	1205-1208
-	O	1208-1209
PCR	O	1209-1212
_	O	1212-1213
and	O	1213-1216
immunofluorescent	O	1217-1234
staining	O	1235-1243
.	O	1243-1244

The	O	1245-1248
results	O	1249-1256
showed	O	1257-1263
that	O	1264-1268
miR	B	1269-1272
-	I	1272-1273
34c	I	1273-1276
promoted	O	1277-1285
mESCs	O	1286-1291
differentiation	O	1292-1307
into	O	1308-1312
male	O	1313-1317
germ	O	1318-1322
-	O	1322-1323
like	O	1323-1327
cells	O	1328-1333
,	O	1333-1334
to	O	1335-1337
some	O	1338-1342
extent	O	1343-1349
.	O	1349-1350

Then	O	1351-1355
miR	B	1356-1359
-	I	1359-1360
34c	I	1360-1363
targeted	O	1364-1372
genes	O	1373-1378
were	O	1379-1383
predicted	O	1384-1393
by	O	1394-1396
bioinformatics	O	1397-1411
;	O	1411-1412
Retinoic	O	1413-1421
acid	O	1422-1426
receptor	O	1427-1435
gamma	O	1436-1441
(	O	1442-1443
RARg	O	1443-1447
)	O	1447-1448
was	O	1449-1452
selected	O	1453-1461
,	O	1461-1462
and	O	1463-1466
two	O	1467-1470
dual	O	1471-1475
-	O	1475-1476
luciferase	O	1476-1486
reporter	O	1487-1495
vectors	O	1496-1503
contained	O	1504-1513
the	O	1514-1517
normal	O	1518-1524
and	O	1525-1528
mutated	O	1529-1536
3	O	1537-1538
'	O	1538-1539
untranslated	O	1539-1551
region	O	1552-1558
of	O	1559-1561
RARg	O	1562-1566
were	O	1567-1571
constructed	O	1572-1583
,	O	1583-1584
respectively	O	1585-1597
.	O	1597-1598

By	O	1599-1601
miRNA	O	1602-1607
mimics	O	1608-1614
and	O	1615-1618
vector	O	1619-1625
co	O	1626-1628
-	O	1628-1629
transfection	O	1629-1641
experiment	O	1642-1652
,	O	1652-1653
the	O	1654-1657
predicted	O	1658-1667
target	O	1668-1674
gene	O	1675-1679
-	O	1679-1680
RARg	O	1680-1684
was	O	1685-1688
confirmed	O	1689-1698
.	O	1698-1699

In	O	1700-1702
conclusion	O	1703-1713
,	O	1713-1714
we	O	1715-1717
found	O	1718-1723
a	O	1724-1725
mammalian	O	1726-1735
male	O	1736-1740
germ	O	1741-1745
cell	O	1746-1750
specific	O	1751-1759
miRNA	O	1760-1765
-	O	1765-1766
-	O	1766-1767
miR	B	1767-1770
-	I	1770-1771
34c	I	1771-1774
,	O	1774-1775
and	O	1776-1779
it	O	1780-1782
might	O	1783-1788
be	O	1789-1791
pivotal	O	1792-1799
in	O	1800-1802
mESCs	O	1803-1808
differentiation	O	1809-1824
into	O	1825-1829
male	O	1830-1834
germ	O	1835-1839
cells	O	1840-1845
through	O	1846-1853
its	O	1854-1857
target	O	1858-1864
-	O	1864-1865
-	O	1865-1866
RARg	O	1866-1870
.	O	1870-1871

The	O	0-3
microRNA	B	4-12
-	I	12-13
29	I	13-15
plays	O	16-21
a	O	22-23
central	O	24-31
role	O	32-36
in	O	37-39
osteosarcoma	O	40-52
pathogenesis	O	53-65
and	O	66-69
progression	O	70-81
.	O	81-82

Osteosarcoma	O	83-95
is	O	96-98
the	O	99-102
most	O	103-107
common	O	108-114
type	O	115-119
of	O	120-122
bone	O	123-127
cancer	O	128-134
,	O	134-135
with	O	136-140
a	O	141-142
peak	O	143-147
incidence	O	148-157
in	O	158-160
the	O	161-164
early	O	165-170
childhood	O	171-180
.	O	180-181

The	O	182-185
relationship	O	186-198
between	O	199-206
microRNAs	O	207-216
(	O	217-218
miRNAs	O	218-224
)	O	224-225
and	O	226-229
cancer	O	230-236
development	O	237-248
attracted	O	249-258
more	O	259-263
and	O	264-267
more	O	268-272
attention	O	273-282
over	O	283-287
the	O	288-291
last	O	292-296
few	O	297-300
years	O	301-306
.	O	306-307

Members	O	308-315
of	O	316-318
the	O	319-322
miRNA	B	323-328
-	I	328-329
29	I	329-331
family	O	332-338
,	O	338-339
including	O	340-349
miRNA	B	350-355
-	I	355-356
29a	I	356-359
,	O	359-360
miRNA	B	361-366
-	I	366-367
29b	I	367-370
,	O	370-371
and	O	372-375
miRNA	B	376-381
-	I	381-382
29c	I	382-385
were	O	386-390
shown	O	391-396
to	O	397-399
participate	O	400-411
in	O	412-414
the	O	415-418
development	O	419-430
of	O	431-433
rhabdomyosarcoma	O	434-450
and	O	451-454
hepatocarcinogenesis	O	455-475
.	O	475-476

Here	O	477-481
,	O	481-482
it	O	483-485
has	O	486-489
been	O	490-494
demonstrated	O	495-507
miRNA	B	508-513
-	I	513-514
29a	I	514-517
and	O	518-521
miRNA	B	522-527
-	I	527-528
29b	I	528-531
expression	O	532-542
levels	O	543-549
to	O	550-552
be	O	553-555
downregulated	O	556-569
in	O	570-572
most	O	573-577
of	O	578-580
the	O	581-584
osteosarcoma	O	585-597
tissues	O	598-605
(	O	606-607
23	O	607-609
from	O	610-614
30	O	615-617
)	O	617-618
.	O	618-619

Besides	O	620-627
,	O	627-628
miRNA	B	629-634
-	I	634-635
29a	I	635-638
displayed	O	639-648
ability	O	649-656
to	O	657-659
induce	O	660-666
apoptosis	O	667-676
in	O	677-679
both	O	680-684
U2OS	O	685-689
and	O	690-693
SAOS	O	694-698
-	O	698-699
2	O	699-700
osteoblastic	O	701-713
cells	O	714-719
.	O	719-720

While	O	721-726
miRNA	B	727-732
-	I	732-733
29	I	733-735
members	O	736-743
induced	O	744-751
apoptosis	O	752-761
through	O	762-769
p53	O	770-773
gene	O	774-778
activation	O	779-789
,	O	789-790
the	O	791-794
effect	O	795-801
of	O	802-804
miRNA	B	805-810
-	I	810-811
29a	I	811-814
on	O	815-817
osteoblastic	O	818-830
cells	O	831-836
was	O	837-840
independent	O	841-852
on	O	853-855
p53	O	856-859
expression	O	860-870
level	O	871-876
.	O	876-877

Moreover	O	878-886
,	O	886-887
Bcl	O	888-891
-	O	891-892
2	O	892-893
and	O	894-897
Mcl	O	898-901
-	O	901-902
1	O	902-903
were	O	904-908
earlier	O	909-916
demonstrated	O	917-929
to	O	930-932
be	O	933-935
the	O	936-939
direct	O	940-946
targets	O	947-954
of	O	955-957
miRNA	B	958-963
-	I	963-964
29	I	964-966
in	O	967-969
many	O	970-974
types	O	975-980
of	O	981-983
cancer	O	984-990
tissues	O	991-998
and	O	999-1002
cancers	O	1003-1010
.	O	1010-1011

In	O	1012-1014
both	O	1015-1019
U2OS	O	1020-1024
and	O	1025-1028
SAOS	O	1029-1033
-	O	1033-1034
2	O	1034-1035
osteoblastic	O	1036-1048
cell	O	1049-1053
types	O	1054-1059
,	O	1059-1060
overexpression	O	1061-1075
of	O	1076-1078
miRNA	B	1079-1084
-	I	1084-1085
29a	I	1085-1088
also	O	1089-1093
downregulated	O	1094-1107
Bcl	O	1108-1111
-	O	1111-1112
2	O	1112-1113
and	O	1114-1117
Mcl	O	1118-1121
-	O	1121-1122
1	O	1122-1123
,	O	1123-1124
while	O	1125-1130
silencing	O	1131-1140
of	O	1141-1143
miRNA	B	1144-1149
-	I	1149-1150
29a	I	1150-1153
increased	O	1154-1163
their	O	1164-1169
expression	O	1170-1180
.	O	1180-1181

In	O	1182-1184
addition	O	1185-1193
,	O	1193-1194
enhanced	O	1195-1203
expression	O	1204-1214
of	O	1215-1217
miRNA	B	1218-1223
-	I	1223-1224
29a	I	1224-1227
increased	O	1228-1237
the	O	1238-1241
expression	O	1242-1252
of	O	1253-1255
two	O	1256-1259
tumor	O	1260-1265
suppressor	O	1266-1276
genes	O	1277-1282
,	O	1282-1283
E2F1	O	1284-1288
and	O	1289-1292
E2F3	O	1293-1297
.	O	1297-1298

In	O	1299-1301
summary	O	1302-1309
,	O	1309-1310
data	O	1311-1315
obtained	O	1316-1324
highlight	O	1325-1334
the	O	1335-1338
role	O	1339-1343
of	O	1344-1346
miRNA	B	1347-1352
-	I	1352-1353
29a	I	1353-1356
in	O	1357-1359
the	O	1360-1363
regulation	O	1364-1374
of	O	1375-1377
osteoblastic	O	1378-1390
cell	O	1391-1395
apoptosis	O	1396-1405
by	O	1406-1408
silencing	O	1409-1418
Bcl	O	1419-1422
-	O	1422-1423
2	O	1423-1424
and	O	1425-1428
Mcl	O	1429-1432
-	O	1432-1433
1	O	1433-1434
and	O	1435-1438
inducing	O	1439-1447
E2F1	O	1448-1452
and	O	1453-1456
E2F3	O	1457-1461
expression	O	1462-1472
.	O	1472-1473

Serum	O	0-5
miR	B	6-9
-	I	9-10
21	I	10-12
levels	O	13-19
in	O	20-22
patients	O	23-31
with	O	32-36
dermatomyositis	O	37-52
.	O	52-53

Hypoxia	O	0-7
-	O	7-8
inducible	O	8-17
factor	O	18-24
1	O	25-26
-	O	26-27
alpha	O	27-32
induces	O	33-40
miR	B	41-44
-	I	44-45
210	I	45-48
in	O	49-51
normoxic	O	52-60
differentiating	O	61-76
myoblasts	O	77-86
.	O	86-87

MicroRNA	B	88-96
-	I	96-97
210	I	97-100
(	O	101-102
miR	B	102-105
-	I	105-106
210	I	106-109
)	O	109-110
induction	O	111-120
is	O	121-123
a	O	124-125
virtually	O	126-135
constant	O	136-144
feature	O	145-152
of	O	153-155
the	O	156-159
hypoxic	O	160-167
response	O	168-176
in	O	177-179
both	O	180-184
normal	O	185-191
and	O	192-195
transformed	O	196-207
cells	O	208-213
,	O	213-214
regulating	O	215-225
several	O	226-233
key	O	234-237
aspects	O	238-245
of	O	246-248
cardiovascular	O	249-263
diseases	O	264-272
and	O	273-276
cancer	O	277-283
.	O	283-284

We	O	285-287
found	O	288-293
that	O	294-298
miR	B	299-302
-	I	302-303
210	I	303-306
was	O	307-310
induced	O	311-318
in	O	319-321
normoxic	O	322-330
myoblasts	O	331-340
upon	O	341-345
myogenic	O	346-354
differentiation	O	355-370
both	O	371-375
in	O	376-378
vitro	O	379-384
and	O	385-388
in	O	389-391
vivo	O	392-396
.	O	396-397

miR	B	398-401
-	I	401-402
210	I	402-405
transcription	O	406-419
was	O	420-423
activated	O	424-433
in	O	434-436
an	O	437-439
hypoxia	O	440-447
-	O	447-448
inducible	O	448-457
factor	O	458-464
1	O	465-466
-	O	466-467
alpha	O	467-472
(	O	473-474
Hif1a	O	474-479
)	O	479-480
-	O	480-481
dependent	O	481-490
manner	O	491-497
,	O	497-498
and	O	499-502
chromatin	O	503-512
immunoprecipitation	O	513-532
experiments	O	533-544
show	O	545-549
that	O	550-554
Hif1a	O	555-560
bound	O	561-566
to	O	567-569
the	O	570-573
miR	B	574-577
-	I	577-578
210	I	578-581
promoter	O	582-590
only	O	591-595
in	O	596-598
differentiated	O	599-613
myotubes	O	614-622
.	O	622-623

Accordingly	O	624-635
,	O	635-636
luciferase	O	637-647
reporter	O	648-656
assays	O	657-663
demonstrated	O	664-676
the	O	677-680
functional	O	681-691
relevance	O	692-701
of	O	702-704
the	O	705-708
Hif1a	O	709-714
binding	O	715-722
site	O	723-727
for	O	728-731
miR	B	732-735
-	I	735-736
210	I	736-739
promoter	O	740-748
activation	O	749-759
in	O	760-762
differentiating	O	763-778
myoblasts	O	779-788
.	O	788-789

To	O	790-792
investigate	O	793-804
the	O	805-808
functional	O	809-819
relevance	O	820-829
of	O	830-832
increased	O	833-842
miR	B	843-846
-	I	846-847
210	I	847-850
levels	O	851-857
in	O	858-860
differentiated	O	861-875
myofibers	O	876-885
,	O	885-886
we	O	887-889
blocked	O	890-897
miR	B	898-901
-	I	901-902
210	I	902-905
with	O	906-910
complementary	O	911-924
locked	O	925-931
nucleic	O	932-939
acid	O	940-944
oligonucleotides	O	945-961
(	O	962-963
anti	O	963-967
-	O	967-968
miR	B	968-971
-	I	971-972
210	I	972-975
)	O	975-976
.	O	976-977

We	O	978-980
found	O	981-986
that	O	987-991
C2C12	O	992-997
myoblast	O	998-1006
cell	O	1007-1011
line	O	1012-1016
differentiation	O	1017-1032
was	O	1033-1036
largely	O	1037-1044
unaffected	O	1045-1055
by	O	1056-1058
anti	O	1059-1063
-	O	1063-1064
miR	B	1064-1067
-	I	1067-1068
210	I	1068-1071
.	O	1071-1072

Likewise	O	1073-1081
,	O	1081-1082
miR	B	1083-1086
-	I	1086-1087
210	I	1087-1090
inhibition	O	1091-1101
did	O	1102-1105
not	O	1106-1109
affect	O	1110-1116
skeletal	O	1117-1125
muscle	O	1126-1132
regeneration	O	1133-1145
following	O	1146-1155
cardiotoxin	O	1156-1167
damage	O	1168-1174
.	O	1174-1175

However	O	1176-1183
,	O	1183-1184
we	O	1185-1187
found	O	1188-1193
that	O	1194-1198
miR	B	1199-1202
-	I	1202-1203
210	I	1203-1206
blockade	O	1207-1215
greatly	O	1216-1223
increased	O	1224-1233
myotube	O	1234-1241
sensitivity	O	1242-1253
to	O	1254-1256
oxidative	O	1257-1266
stress	O	1267-1273
and	O	1274-1277
mitochondrial	O	1278-1291
dysfunction	O	1292-1303
.	O	1303-1304

In	O	1305-1307
conclusion	O	1308-1318
,	O	1318-1319
miR	B	1320-1323
-	I	1323-1324
210	I	1324-1327
is	O	1328-1330
induced	O	1331-1338
in	O	1339-1341
normoxic	O	1342-1350
myofibers	O	1351-1360
,	O	1360-1361
playing	O	1362-1369
a	O	1370-1371
cytoprotective	O	1372-1386
role	O	1387-1391
.	O	1391-1392

miR	B	0-3
-	I	3-4
451	I	4-7
regulates	O	8-17
dendritic	O	18-27
cell	O	28-32
cytokine	O	33-41
responses	O	42-51
to	O	52-54
influenza	O	55-64
infection	O	65-74
.	O	74-75

MicroRNAs	O	76-85
(	O	86-87
miRNAs	O	87-93
)	O	93-94
are	O	95-98
important	O	99-108
posttranscriptional	O	109-128
regulators	O	129-139
in	O	140-142
immune	O	143-149
cells	O	150-155
,	O	155-156
but	O	157-160
how	O	161-164
viral	O	165-170
infection	O	171-180
regulates	O	181-190
miRNA	O	191-196
expression	O	197-207
to	O	208-210
shape	O	211-216
dendritic	O	217-226
cell	O	227-231
(	O	232-233
DC	O	233-235
)	O	235-236
responses	O	237-246
has	O	247-250
not	O	251-254
been	O	255-259
well	O	260-264
characterized	O	265-278
.	O	278-279

We	O	280-282
identified	O	283-293
20	O	294-296
miRNAs	O	297-303
that	O	304-308
were	O	309-313
differentially	O	314-328
expressed	O	329-338
in	O	339-341
primary	O	342-349
murine	O	350-356
DCs	O	357-360
in	O	361-363
response	O	364-372
to	O	373-375
the	O	376-379
dsRNA	O	380-385
agonist	O	386-393
polyinosinic	O	394-406
-	O	406-407
polycytidylic	O	407-420
acid	O	421-425
,	O	425-426
a	O	427-428
subset	O	429-435
of	O	436-438
which	O	439-444
were	O	445-449
modestly	O	450-458
regulated	O	459-468
by	O	469-471
influenza	O	472-481
infection	O	482-491
.	O	491-492

miR	B	493-496
-	I	496-497
451	I	497-500
was	O	501-504
unique	O	505-511
because	O	512-519
it	O	520-522
was	O	523-526
induced	O	527-534
more	O	535-539
strongly	O	540-548
in	O	549-551
primary	O	552-559
splenic	O	560-567
and	O	568-571
lung	O	572-576
DCs	O	577-580
by	O	581-583
live	O	584-588
viral	O	589-594
infection	O	595-604
than	O	605-609
by	O	610-612
purified	O	613-621
agonists	O	622-630
of	O	631-633
pattern	O	634-641
recognition	O	642-653
receptors	O	654-663
.	O	663-664

We	O	665-667
determined	O	668-678
that	O	679-683
miR	B	684-687
-	I	687-688
451	I	688-691
regulates	O	692-701
a	O	702-703
subset	O	704-710
of	O	711-713
proinflammatory	O	714-729
cytokine	O	730-738
responses	O	739-748
.	O	748-749

Three	O	750-755
types	O	756-761
of	O	762-764
primary	O	765-772
DCs	O	773-776
treated	O	777-784
with	O	785-789
antisense	O	790-799
RNA	O	800-803
antagomirs	O	804-814
directed	O	815-823
against	O	824-831
miR	B	832-835
-	I	835-836
451	I	836-839
secreted	O	840-848
elevated	O	849-857
levels	O	858-864
of	O	865-867
IL	O	868-870
-	O	870-871
6	O	871-872
,	O	872-873
TNF	O	874-877
,	O	877-878
CCL5	O	879-883
/	O	883-884
RANTES	O	884-890
,	O	890-891
and	O	892-895
CCL3	O	896-900
/	O	900-901
MIP1alpha	O	901-910
,	O	910-911
and	O	912-915
these	O	916-921
results	O	922-929
were	O	930-934
confirmed	O	935-944
using	O	945-950
miR	B	951-954
-	I	954-955
451	I	955-958
(	O	958-959
null	O	959-963
)	O	963-964
cells	O	965-970
.	O	970-971

miR	B	972-975
-	I	975-976
451	I	976-979
negatively	O	980-990
regulates	O	991-1000
YWHAZ	O	1001-1006
/	O	1006-1007
14	O	1007-1009
-	O	1009-1010
3	O	1010-1011
-	O	1011-1012
3zeta	O	1012-1017
protein	O	1018-1025
levels	O	1026-1032
in	O	1033-1035
various	O	1036-1043
cell	O	1044-1048
types	O	1049-1054
,	O	1054-1055
and	O	1056-1059
we	O	1060-1062
measured	O	1063-1071
a	O	1072-1073
similar	O	1074-1081
inhibition	O	1082-1092
of	O	1093-1095
YWHAZ	O	1096-1101
levels	O	1102-1108
in	O	1109-1111
DCs	O	1112-1115
.	O	1115-1116

It	O	1117-1119
is	O	1120-1122
known	O	1123-1128
that	O	1129-1133
YWHAZ	O	1134-1139
can	O	1140-1143
control	O	1144-1151
the	O	1152-1155
activity	O	1156-1164
of	O	1165-1167
two	O	1168-1171
negative	O	1172-1180
regulators	O	1181-1191
of	O	1192-1194
cytokine	O	1195-1203
production	O	1204-1214
:	O	1214-1215
FOXO3	O	1216-1221
,	O	1221-1222
which	O	1223-1228
is	O	1229-1231
an	O	1232-1234
inhibitory	O	1235-1245
transcription	O	1246-1259
factor	O	1260-1266
,	O	1266-1267
and	O	1268-1271
ZFP36	O	1272-1277
/	O	1277-1278
Tristetraprolin	O	1278-1293
,	O	1293-1294
which	O	1295-1300
binds	O	1301-1306
to	O	1307-1309
AU	O	1310-1312
-	O	1312-1313
rich	O	1313-1317
elements	O	1318-1326
within	O	1327-1333
3	O	1334-1335
'	O	1335-1336
-	O	1336-1337
untranslated	O	1337-1349
regions	O	1350-1357
to	O	1358-1360
destabilize	O	1361-1372
cytokine	O	1373-1381
mRNAs	O	1382-1387
.	O	1387-1388

Inhibition	O	1389-1399
of	O	1400-1402
miR	B	1403-1406
-	I	1406-1407
451	I	1407-1410
expression	O	1411-1421
correlated	O	1422-1432
with	O	1433-1437
increased	O	1438-1447
YWHAZ	O	1448-1453
protein	O	1454-1461
expression	O	1462-1472
and	O	1473-1476
decreased	O	1477-1486
ZFP36	O	1487-1492
expression	O	1493-1503
,	O	1503-1504
providing	O	1505-1514
a	O	1515-1516
possible	O	1517-1525
mechanism	O	1526-1535
for	O	1536-1539
the	O	1540-1543
elevated	O	1544-1552
secretion	O	1553-1562
of	O	1563-1565
IL	O	1566-1568
-	O	1568-1569
6	O	1569-1570
,	O	1570-1571
TNF	O	1572-1575
,	O	1575-1576
CCL5	O	1577-1581
/	O	1581-1582
RANTES	O	1582-1588
,	O	1588-1589
and	O	1590-1593
CCL3	O	1594-1598
/	O	1598-1599
MIP1alpha	O	1599-1608
.	O	1608-1609

miR	B	1610-1613
-	I	1613-1614
451	I	1614-1617
levels	O	1618-1624
are	O	1625-1628
themselves	O	1629-1639
increased	O	1640-1649
by	O	1650-1652
IL	O	1653-1655
-	O	1655-1656
6	O	1656-1657
and	O	1658-1661
type	O	1662-1666
I	O	1667-1668
IFN	O	1669-1672
,	O	1672-1673
potentially	O	1674-1685
forming	O	1686-1693
a	O	1694-1695
regulatory	O	1696-1706
loop	O	1707-1711
.	O	1711-1712

These	O	1713-1718
data	O	1719-1723
suggest	O	1724-1731
that	O	1732-1736
viral	O	1737-1742
infection	O	1743-1752
specifically	O	1753-1765
induces	O	1766-1773
a	O	1774-1775
miRNA	O	1776-1781
that	O	1782-1786
directs	O	1787-1794
a	O	1795-1796
negative	O	1797-1805
regulatory	O	1806-1816
cascade	O	1817-1824
to	O	1825-1827
tune	O	1828-1832
DC	O	1833-1835
cytokine	O	1836-1844
production	O	1845-1855
.	O	1855-1856

MicroRNA	B	0-8
-	I	8-9
203	I	9-12
contributes	O	13-24
to	O	25-27
skin	O	28-32
re	O	33-35
-	O	35-36
epithelialization	O	36-53
.	O	53-54

Keratinocyte	O	55-67
proliferation	O	68-81
and	O	82-85
migration	O	86-95
are	O	96-99
crucial	O	100-107
steps	O	108-113
for	O	114-117
the	O	118-121
rapid	O	122-127
closure	O	128-135
of	O	136-138
the	O	139-142
epidermis	O	143-152
during	O	153-159
wound	O	160-165
healing	O	166-173
,	O	173-174
but	O	175-178
the	O	179-182
molecular	O	183-192
mechanisms	O	193-203
involved	O	204-212
in	O	213-215
this	O	216-220
cellular	O	221-229
response	O	230-238
remain	O	239-245
to	O	246-248
be	O	249-251
completely	O	252-262
elucidated	O	263-273
.	O	273-274

Here	O	275-279
,	O	279-280
by	O	281-283
in	O	284-286
situ	O	287-291
hybridization	O	292-305
we	O	306-308
characterize	O	309-321
the	O	322-325
expression	O	326-336
pattern	O	337-344
of	O	345-347
miR	B	348-351
-	I	351-352
203	I	352-355
after	O	356-361
the	O	362-365
induction	O	366-375
of	O	376-378
wound	O	379-384
in	O	385-387
mouse	O	388-393
epidermis	O	394-403
,	O	403-404
showing	O	405-412
that	O	413-417
its	O	418-421
expression	O	422-432
is	O	433-435
downregulated	O	436-449
in	O	450-452
the	O	453-456
highly	O	457-463
proliferating	O	464-477
keratinocytes	O	478-491
of	O	492-494
the	O	495-498
'	O	499-500
migrating	O	500-509
tongue	O	510-516
'	O	516-517
,	O	517-518
whereas	O	519-526
it	O	527-529
is	O	530-532
strongly	O	533-541
expressed	O	542-551
in	O	552-554
the	O	555-558
differentiating	O	559-574
cells	O	575-580
of	O	581-583
the	O	584-587
skin	O	588-592
outside	O	593-600
the	O	601-604
wound	O	605-610
.	O	610-611

Furthermore	O	612-623
,	O	623-624
subcutaneous	O	625-637
injections	O	638-648
of	O	649-651
antagomiR	O	652-661
-	O	661-662
203	O	662-665
in	O	666-668
new	O	669-672
born	O	673-677
mice	O	678-682
dorsal	O	683-689
skin	O	690-694
strengthened	O	695-707
,	O	707-708
in	O	709-711
vivo	O	712-716
,	O	716-717
the	O	718-721
inverse	O	722-729
correlation	O	730-741
between	O	742-749
miR	B	750-753
-	I	753-754
203	I	754-757
expression	O	758-768
and	O	769-772
two	O	773-776
new	O	777-780
target	O	781-787
mRNAs	O	788-793
:	O	793-794
RAN	O	795-798
and	O	799-802
RAPH1	O	803-808
.	O	808-809

Our	O	810-813
data	O	814-818
suggest	O	819-826
that	O	827-831
miR	B	832-835
-	I	835-836
203	I	836-839
,	O	839-840
by	O	841-843
controlling	O	844-855
the	O	856-859
expression	O	860-870
of	O	871-873
target	O	874-880
proteins	O	881-889
that	O	890-894
are	O	895-898
responsible	O	899-910
for	O	911-914
both	O	915-919
keratinocyte	O	920-932
proliferation	O	933-946
and	O	947-950
migration	O	951-960
,	O	960-961
exerts	O	962-968
a	O	969-970
specific	O	971-979
role	O	980-984
in	O	985-987
wound	O	988-993
re	O	994-996
-	O	996-997
epithelialization	O	997-1014
and	O	1015-1018
epidermal	O	1019-1028
homeostasis	O	1029-1040
re	O	1041-1043
-	O	1043-1044
establishment	O	1044-1057
of	O	1058-1060
injured	O	1061-1068
skin	O	1069-1073
.	O	1073-1074

miR	B	0-3
-	I	3-4
29b	I	4-7
sensitizes	O	8-18
multiple	O	19-27
myeloma	O	28-35
cells	O	36-41
to	O	42-44
bortezomib	O	45-55
-	O	55-56
induced	O	56-63
apoptosis	O	64-73
through	O	74-81
the	O	82-85
activation	O	86-96
of	O	97-99
a	O	100-101
feedback	O	102-110
loop	O	111-115
with	O	116-120
the	O	121-124
transcription	O	125-138
factor	O	139-145
Sp1	O	146-149
.	O	149-150

MicroRNAs	O	151-160
(	O	161-162
miRNAs	O	162-168
)	O	168-169
with	O	170-174
tumor	O	175-180
-	O	180-181
suppressor	O	181-191
potential	O	192-201
might	O	202-207
have	O	208-212
therapeutic	O	213-224
applications	O	225-237
in	O	238-240
multiple	O	241-249
myeloma	O	250-257
(	O	258-259
MM	O	259-261
)	O	261-262
through	O	263-270
the	O	271-274
modulation	O	275-285
of	O	286-288
still	O	289-294
undiscovered	O	295-307
molecular	O	308-317
pathways	O	318-326
.	O	326-327

Here	O	328-332
,	O	332-333
we	O	334-336
investigated	O	337-349
the	O	350-353
effects	O	354-361
of	O	362-364
enforced	O	365-373
expression	O	374-384
of	O	385-387
miR	B	388-391
-	I	391-392
29b	I	392-395
on	O	396-398
the	O	399-402
apoptotic	O	403-412
occurrence	O	413-423
in	O	424-426
MM	O	427-429
and	O	430-433
highlighted	O	434-445
its	O	446-449
role	O	450-454
in	O	455-457
the	O	458-461
context	O	462-469
of	O	470-472
a	O	473-474
new	O	475-478
transcriptional	O	479-494
loop	O	495-499
that	O	500-504
is	O	505-507
finely	O	508-514
tuned	O	515-520
by	O	521-523
the	O	524-527
proteasome	O	528-538
inhibitor	O	539-548
bortezomib	O	549-559
.	O	559-560

In	O	561-563
details	O	564-571
,	O	571-572
in	O	573-575
vitro	O	576-581
growth	O	582-588
inhibition	O	589-599
and	O	600-603
apoptosis	O	604-613
of	O	614-616
MM	O	617-619
cells	O	620-625
was	O	626-629
induced	O	630-637
by	O	638-640
either	O	641-647
transient	O	648-657
expression	O	658-668
of	O	669-671
synthetic	O	672-681
miR	B	682-685
-	I	685-686
29b	I	686-689
or	O	690-692
its	O	693-696
stable	O	697-703
lentivirus	O	704-714
-	O	714-715
enforced	O	715-723
expression	O	724-734
.	O	734-735

We	O	736-738
identified	O	739-749
Sp1	O	750-753
,	O	753-754
a	O	755-756
transcription	O	757-770
factor	O	771-777
endowed	O	778-785
with	O	786-790
oncogenic	O	791-800
activity	O	801-809
,	O	809-810
as	O	811-813
a	O	814-815
negative	O	816-824
regulator	O	825-834
of	O	835-837
miR	B	838-841
-	I	841-842
29b	I	842-845
expression	O	846-856
in	O	857-859
MM	O	860-862
cells	O	863-868
.	O	868-869

Since	O	870-875
Sp1	O	876-879
expression	O	880-890
and	O	891-894
functions	O	895-904
are	O	905-908
regulated	O	909-918
via	O	919-922
the	O	923-926
26S	O	927-930
proteasome	O	931-941
,	O	941-942
we	O	943-945
investigated	O	946-958
the	O	959-962
effects	O	963-970
of	O	971-973
bortezomib	O	974-984
on	O	985-987
miR	B	988-991
-	I	991-992
29b	I	992-995
-	O	995-996
Sp1	O	996-999
loop	O	1000-1004
,	O	1004-1005
showing	O	1006-1013
that	O	1014-1018
miR	B	1019-1022
-	I	1022-1023
29b	I	1023-1026
levels	O	1027-1033
were	O	1034-1038
indeed	O	1039-1045
upregulated	O	1046-1057
by	O	1058-1060
the	O	1061-1064
drug	O	1065-1069
.	O	1069-1070

At	O	1071-1073
the	O	1074-1077
same	O	1078-1082
time	O	1083-1087
,	O	1087-1088
the	O	1089-1092
bortezomib	O	1093-1103
/	O	1103-1104
miR	B	1104-1107
-	I	1107-1108
29b	I	1108-1111
combination	O	1112-1123
produced	O	1124-1132
significant	O	1133-1144
pro	O	1145-1148
-	O	1148-1149
apoptotic	O	1149-1158
effects	O	1159-1166
.	O	1166-1167

We	O	1168-1170
also	O	1171-1175
demonstrated	O	1176-1188
that	O	1189-1193
the	O	1194-1197
PI3K	O	1198-1202
/	O	1202-1203
AKT	O	1203-1206
pathway	O	1207-1214
plays	O	1215-1220
a	O	1221-1222
major	O	1223-1228
role	O	1229-1233
in	O	1234-1236
the	O	1237-1240
regulation	O	1241-1251
of	O	1252-1254
miR	B	1255-1258
-	I	1258-1259
29b	I	1259-1262
-	O	1262-1263
Sp1	O	1263-1266
loop	O	1267-1271
and	O	1272-1275
induction	O	1276-1285
of	O	1286-1288
apoptosis	O	1289-1298
in	O	1299-1301
MM	O	1302-1304
cells	O	1305-1310
.	O	1310-1311

Finally	O	1312-1319
,	O	1319-1320
MM	O	1321-1323
xenografts	O	1324-1334
constitutively	O	1335-1349
expressing	O	1350-1360
miR	B	1361-1364
-	I	1364-1365
29b	I	1365-1368
showed	O	1369-1375
significant	O	1376-1387
reduction	O	1388-1397
of	O	1398-1400
their	O	1401-1406
tumorigenic	O	1407-1418
potential	O	1419-1428
.	O	1428-1429

Our	O	1430-1433
findings	O	1434-1442
indicate	O	1443-1451
that	O	1452-1456
miR	B	1457-1460
-	I	1460-1461
29b	I	1461-1464
is	O	1465-1467
involved	O	1468-1476
in	O	1477-1479
a	O	1480-1481
regulatory	O	1482-1492
loop	O	1493-1497
amenable	O	1498-1506
of	O	1507-1509
pharmacologic	O	1510-1523
intervention	O	1524-1536
and	O	1537-1540
modulates	O	1541-1550
the	O	1551-1554
anti	O	1555-1559
-	O	1559-1560
MM	O	1560-1562
activity	O	1563-1571
of	O	1572-1574
bortezomib	O	1575-1585
in	O	1586-1588
MM	O	1589-1591
cells	O	1592-1597
.	O	1597-1598

miRNA	B	0-5
-	I	5-6
7	I	6-7
-	I	7-8
5p	I	8-10
inhibits	O	11-19
melanoma	O	20-28
cell	O	29-33
migration	O	34-43
and	O	44-47
invasion	O	48-56
.	O	56-57

Aberrant	O	58-66
expression	O	67-77
of	O	78-80
microRNAs	O	81-90
(	O	91-92
miRNAs	O	92-98
)	O	98-99
,	O	99-100
a	O	101-102
class	O	103-108
of	O	109-111
small	O	112-117
non	O	118-121
-	O	121-122
coding	O	122-128
regulatory	O	129-139
RNAs	O	140-144
,	O	144-145
has	O	146-149
been	O	150-154
implicated	O	155-165
in	O	166-168
the	O	169-172
development	O	173-184
and	O	185-188
progression	O	189-200
of	O	201-203
melanoma	O	204-212
.	O	212-213

However	O	214-221
,	O	221-222
the	O	223-226
precise	O	227-234
mechanistic	O	235-246
role	O	247-251
of	O	252-254
many	O	255-259
of	O	260-262
these	O	263-268
miRNAs	O	269-275
remains	O	276-283
unclear	O	284-291
.	O	291-292

We	O	293-295
have	O	296-300
investigated	O	301-313
the	O	314-317
functional	O	318-328
role	O	329-333
of	O	334-336
miR	B	337-340
-	I	340-341
7	I	341-342
-	I	342-343
5p	I	343-345
in	O	346-348
melanoma	O	349-357
,	O	357-358
and	O	359-362
demonstrate	O	363-374
that	O	375-379
miR	B	380-383
-	I	383-384
7	I	384-385
-	I	385-386
5p	I	386-388
expression	O	389-399
is	O	400-402
reduced	O	403-410
in	O	411-413
metastatic	O	414-424
melanoma	O	425-433
-	O	433-434
derived	O	434-441
cell	O	442-446
lines	O	447-452
compared	O	453-461
with	O	462-466
primary	O	467-474
melanoma	O	475-483
cells	O	484-489
,	O	489-490
and	O	491-494
that	O	495-499
when	O	500-504
ectopically	O	505-516
expressed	O	517-526
miR	B	527-530
-	I	530-531
7	I	531-532
-	I	532-533
5p	I	533-535
significantly	O	536-549
inhibits	O	550-558
melanoma	O	559-567
cell	O	568-572
migration	O	573-582
and	O	583-586
invasion	O	587-595
.	O	595-596

Additionally	O	597-609
,	O	609-610
we	O	611-613
report	O	614-620
that	O	621-625
insulin	O	626-633
receptor	O	634-642
substrate	O	643-652
-	O	652-653
2	O	653-654
(	O	655-656
IRS	O	656-659
-	O	659-660
2	O	660-661
)	O	661-662
is	O	663-665
a	O	666-667
target	O	668-674
of	O	675-677
miR	B	678-681
-	I	681-682
7	I	682-683
-	I	683-684
5p	I	684-686
in	O	687-689
melanoma	O	690-698
cells	O	699-704
,	O	704-705
and	O	706-709
using	O	710-715
RNA	O	716-719
interference	O	720-732
(	O	733-734
RNAi	O	734-738
)	O	738-739
we	O	740-742
provide	O	743-750
evidence	O	751-759
that	O	760-764
IRS	O	765-768
-	O	768-769
2	O	769-770
activates	O	771-780
protein	O	781-788
kinase	O	789-795
B	O	796-797
(	O	798-799
Akt	O	799-802
)	O	802-803
,	O	803-804
and	O	805-808
promotes	O	809-817
melanoma	O	818-826
cell	O	827-831
migration	O	832-841
.	O	841-842

Thus	O	843-847
,	O	847-848
miR	B	849-852
-	I	852-853
7	I	853-854
-	I	854-855
5p	I	855-857
may	O	858-861
represent	O	862-871
a	O	872-873
novel	O	874-879
tumor	O	880-885
suppressor	O	886-896
miRNA	O	897-902
in	O	903-905
melanoma	O	906-914
,	O	914-915
acting	O	916-922
at	O	923-925
least	O	926-931
in	O	932-934
part	O	935-939
via	O	940-943
its	O	944-947
inhibition	O	948-958
of	O	959-961
IRS	O	962-965
-	O	965-966
2	O	966-967
expression	O	968-978
and	O	979-982
oncogenic	O	983-992
Akt	O	993-996
signaling	O	997-1006
.	O	1006-1007

miRNA	O	0-5
target	O	6-12
enrichment	O	13-23
analysis	O	24-32
reveals	O	33-40
directly	O	41-49
active	O	50-56
miRNAs	O	57-63
in	O	64-66
health	O	67-73
and	O	74-77
disease	O	78-85
.	O	85-86

microRNAs	O	87-96
(	O	97-98
miRNAs	O	98-104
)	O	104-105
are	O	106-109
short	O	110-115
non	O	116-119
-	O	119-120
coding	O	120-126
regulatory	O	127-137
RNA	O	138-141
molecules	O	142-151
.	O	151-152

The	O	153-156
activity	O	157-165
of	O	166-168
a	O	169-170
miRNA	O	171-176
in	O	177-179
a	O	180-181
biological	O	182-192
process	O	193-200
can	O	201-204
often	O	205-210
be	O	211-213
reflected	O	214-223
in	O	224-226
the	O	227-230
expression	O	231-241
program	O	242-249
that	O	250-254
characterizes	O	255-268
the	O	269-272
outcome	O	273-280
of	O	281-283
the	O	284-287
activity	O	288-296
.	O	296-297

We	O	298-300
introduce	O	301-310
a	O	311-312
computational	O	313-326
approach	O	327-335
that	O	336-340
infers	O	341-347
such	O	348-352
activity	O	353-361
from	O	362-366
high	O	367-371
-	O	371-372
throughput	O	372-382
data	O	383-387
using	O	388-393
a	O	394-395
novel	O	396-401
statistical	O	402-413
methodology	O	414-425
,	O	425-426
called	O	427-433
minimum	O	434-441
-	O	441-442
mHG	O	442-445
(	O	446-447
mmHG	O	447-451
)	O	451-452
,	O	452-453
that	O	454-458
examines	O	459-467
mutual	O	468-474
enrichment	O	475-485
in	O	486-488
two	O	489-492
ranked	O	493-499
lists	O	500-505
.	O	505-506

Based	O	507-512
on	O	513-515
this	O	516-520
methodology	O	521-532
,	O	532-533
we	O	534-536
provide	O	537-544
a	O	545-546
user	O	547-551
-	O	551-552
friendly	O	552-560
web	O	561-564
application	O	565-576
that	O	577-581
supports	O	582-590
the	O	591-594
statistical	O	595-606
assessment	O	607-617
of	O	618-620
miRNA	O	621-626
target	O	627-633
enrichment	O	634-644
analysis	O	645-653
(	O	654-655
miTEA	O	655-660
)	O	660-661
in	O	662-664
the	O	665-668
top	O	669-672
of	O	673-675
a	O	676-677
ranked	O	678-684
list	O	685-689
of	O	690-692
genes	O	693-698
or	O	699-701
proteins	O	702-710
.	O	710-711

Using	O	712-717
miTEA	O	718-723
,	O	723-724
we	O	725-727
analyze	O	728-735
several	O	736-743
target	O	744-750
prediction	O	751-761
tools	O	762-767
by	O	768-770
examining	O	771-780
performance	O	781-792
on	O	793-795
public	O	796-802
miRNA	O	803-808
constitutive	O	809-821
expression	O	822-832
data	O	833-837
.	O	837-838

We	O	839-841
also	O	842-846
apply	O	847-852
miTEA	O	853-858
to	O	859-861
analyze	O	862-869
several	O	870-877
integrative	O	878-889
biology	O	890-897
data	O	898-902
sets	O	903-907
,	O	907-908
including	O	909-918
a	O	919-920
novel	O	921-926
matched	O	927-934
miRNA	O	935-940
/	O	940-941
mRNA	O	941-945
data	O	946-950
set	O	951-954
covering	O	955-963
nine	O	964-968
human	O	969-974
tissue	O	975-981
types	O	982-987
.	O	987-988

Our	O	989-992
novel	O	993-998
findings	O	999-1007
include	O	1008-1015
proposed	O	1016-1024
direct	O	1025-1031
activity	O	1032-1040
of	O	1041-1043
miR	B	1044-1047
-	I	1047-1048
519	I	1048-1051
in	O	1052-1054
placenta	O	1055-1063
,	O	1063-1064
a	O	1065-1066
direct	O	1067-1073
activity	O	1074-1082
of	O	1083-1085
the	O	1086-1089
oncogenic	O	1090-1099
miR	B	1100-1103
-	I	1103-1104
15	I	1104-1106
in	O	1107-1109
different	O	1110-1119
healthy	O	1120-1127
tissue	O	1128-1134
types	O	1135-1140
and	O	1141-1144
a	O	1145-1146
direct	O	1147-1153
activity	O	1154-1162
of	O	1163-1165
the	O	1166-1169
poorly	O	1170-1176
characterized	O	1177-1190
miR	B	1191-1194
-	I	1194-1195
768	I	1195-1198
in	O	1199-1201
both	O	1202-1206
healthy	O	1207-1214
tissue	O	1215-1221
types	O	1222-1227
and	O	1228-1231
cancer	O	1232-1238
cell	O	1239-1243
lines	O	1244-1249
.	O	1249-1250

The	O	1251-1254
miTEA	O	1255-1260
web	O	1261-1264
application	O	1265-1276
is	O	1277-1279
available	O	1280-1289
at	O	1290-1292
http	O	1293-1297
:	O	1297-1298
/	O	1298-1299
/	O	1299-1300
cbl	O	1300-1303
-	O	1303-1304
gorilla	O	1304-1311
.	O	1311-1312
cs	O	1312-1314
.	O	1314-1315
technion	O	1315-1323
.	O	1323-1324
ac	O	1324-1326
.	O	1326-1327
il	O	1327-1329
/	O	1329-1330
miTEA	O	1330-1335
/	O	1335-1336
.	O	1336-1337

Dynamic	O	0-7
evolution	O	8-17
of	O	18-20
mir	B	21-24
-	I	24-25
17	I	25-27
-	I	27-28
92	I	28-30
gene	O	31-35
cluster	O	36-43
and	O	44-47
related	O	48-55
miRNA	O	56-61
gene	O	62-66
families	O	67-75
in	O	76-78
vertebrates	O	79-90
.	O	90-91

mir	B	92-95
-	I	95-96
17	I	96-98
-	I	98-99
92	I	99-101
gene	O	102-106
cluster	O	107-114
is	O	115-117
widely	O	118-124
distributed	O	125-136
in	O	137-139
vertebrates	O	140-151
and	O	152-155
plays	O	156-161
an	O	162-164
important	O	165-174
role	O	175-179
in	O	180-182
regulating	O	183-193
multiple	O	194-202
biological	O	203-213
processes	O	214-223
.	O	223-224

Its	O	225-228
dysregulation	O	229-242
may	O	243-246
be	O	247-249
associated	O	250-260
with	O	261-265
risk	O	266-270
of	O	271-273
some	O	274-278
human	O	279-284
cancers	O	285-292
.	O	292-293

The	O	294-297
microRNA	O	298-306
(	O	307-308
miRNA	O	308-313
)	O	313-314
members	O	315-322
are	O	323-326
identified	O	327-337
in	O	338-340
the	O	341-344
three	O	345-350
gene	O	351-355
families	O	356-364
:	O	364-365
mir	B	366-369
-	I	369-370
17	I	370-372
,	O	372-373
mir	B	374-377
-	I	377-378
19	I	378-380
and	O	381-384
mir	B	385-388
-	I	388-389
25	I	389-391
.	O	391-392

Herein	O	393-399
we	O	400-402
attempted	O	403-412
to	O	413-415
understand	O	416-426
the	O	427-430
evolutionary	O	431-443
processes	O	444-453
and	O	454-457
patterns	O	458-466
in	O	467-469
vertebrates	O	470-481
.	O	481-482

The	O	483-486
three	O	487-492
miRNA	O	493-498
gene	O	499-503
families	O	504-512
showed	O	513-519
difference	O	520-530
in	O	531-533
distribution	O	534-546
,	O	546-547
number	O	548-554
of	O	555-557
miRNA	O	558-563
genes	O	564-569
and	O	570-573
clustered	O	574-583
miRNA	O	584-589
genes	O	590-595
in	O	596-598
the	O	599-602
five	O	603-607
animal	O	608-614
species	O	615-622
.	O	622-623

Compared	O	624-632
to	O	633-635
other	O	636-641
related	O	642-649
gene	O	650-654
clusters	O	655-663
,	O	663-664
mir	B	665-668
-	I	668-669
17	I	669-671
-	I	671-672
92	I	672-674
cluster	O	675-682
was	O	683-686
well	O	687-691
-	O	691-692
conserved	O	692-701
and	O	702-705
had	O	706-709
more	O	710-714
abundant	O	715-723
roles	O	724-729
in	O	730-732
multiple	O	733-741
biological	O	742-752
processes	O	753-762
.	O	762-763

These	O	764-769
clustered	O	770-779
miRNAs	O	780-786
showed	O	787-793
inconsistent	O	794-806
nucleotide	O	807-817
divergence	O	818-828
patterns	O	829-837
across	O	838-844
different	O	845-854
animal	O	855-861
species	O	862-869
,	O	869-870
even	O	871-875
between	O	876-883
homologous	O	884-894
miRNA	O	895-900
genes	O	901-906
.	O	906-907

Simultaneously	O	908-922
,	O	922-923
they	O	924-928
also	O	929-933
indicated	O	934-943
inconsistent	O	944-956
expression	O	957-967
patterns	O	968-976
although	O	977-985
they	O	986-990
were	O	991-995
co	O	996-998
-	O	998-999
transcribed	O	999-1010
as	O	1011-1013
a	O	1014-1015
polycistronic	O	1016-1029
transcript	O	1030-1040
.	O	1040-1041

Phylogenetic	O	1042-1054
tree	O	1055-1059
based	O	1060-1065
on	O	1066-1068
human	O	1069-1074
pre	O	1075-1078
-	O	1078-1079
miRNA	O	1079-1084
sequences	O	1085-1094
showed	O	1095-1101
that	O	1102-1106
mir	B	1107-1110
-	I	1110-1111
19	I	1111-1113
gene	O	1114-1118
family	O	1119-1125
was	O	1126-1129
an	O	1130-1132
older	O	1133-1138
miRNA	O	1139-1144
species	O	1145-1152
,	O	1152-1153
while	O	1154-1159
tree	O	1160-1164
based	O	1165-1170
on	O	1171-1173
miRNA	O	1174-1179
gene	O	1180-1184
cluster	O	1185-1192
indicated	O	1193-1202
evolutionary	O	1203-1215
positions	O	1216-1225
of	O	1226-1228
different	O	1229-1238
animal	O	1239-1245
species	O	1246-1253
.	O	1253-1254

The	O	1255-1258
study	O	1259-1264
shows	O	1265-1270
dynamic	O	1271-1278
evolution	O	1279-1288
of	O	1289-1291
the	O	1292-1295
mir	B	1296-1299
-	I	1299-1300
17	I	1300-1302
-	I	1302-1303
92	I	1303-1305
gene	O	1306-1310
cluster	O	1311-1318
and	O	1319-1322
related	O	1323-1330
miRNA	O	1331-1336
gene	O	1337-1341
families	O	1342-1350
across	O	1351-1357
vertebrates	O	1358-1369
,	O	1369-1370
which	O	1371-1376
may	O	1377-1380
be	O	1381-1383
derived	O	1384-1391
from	O	1392-1396
potential	O	1397-1406
functional	O	1407-1417
implication	O	1418-1429
.	O	1429-1430

miRNA	O	1431-1436
gene	O	1437-1441
cluster	O	1442-1449
should	O	1450-1456
be	O	1457-1459
a	O	1460-1461
better	O	1462-1468
phylogenetic	O	1469-1481
marker	O	1482-1488
than	O	1489-1493
a	O	1494-1495
single	O	1496-1502
miRNA	O	1503-1508
gene	O	1509-1513
to	O	1514-1516
reveal	O	1517-1523
functional	O	1524-1534
and	O	1535-1538
evolutionary	O	1539-1551
relationships	O	1552-1565
.	O	1565-1566

Downregulation	O	0-14
of	O	15-17
miR	B	18-21
-	I	21-22
17	I	22-24
&	O	24-25
#	O	25-26
126	O	26-29
;	O	29-30
92	O	30-32
Expression	O	33-43
Increase	O	44-52
Paclitaxel	O	53-63
Sensitivity	O	64-75
in	O	76-78
Human	O	79-84
Ovarian	O	85-92
Carcinoma	O	93-102
SKOV3	O	103-108
-	O	108-109
TR30	O	109-113
Cells	O	114-119
via	O	120-123
BIM	O	124-127
Instead	O	128-135
of	O	136-138
PTEN	O	139-143
.	O	143-144

To	O	145-147
better	O	148-154
understand	O	155-165
the	O	166-169
molecular	O	170-179
mechanisms	O	180-190
of	O	191-193
paclitaxel	O	194-204
resistance	O	205-215
in	O	216-218
ovarian	O	219-226
carcinoma	O	227-236
,	O	236-237
we	O	238-240
evaluated	O	241-250
the	O	251-254
expression	O	255-265
of	O	266-268
miRNAs	O	269-275
using	O	276-281
miRNA	O	282-287
microarray	O	288-298
between	O	299-306
human	O	307-312
ovarian	O	313-320
carcinoma	O	321-330
SKOV3	O	331-336
cells	O	337-342
and	O	343-346
paclitaxel	O	347-357
resistant	O	358-367
SKOV3	O	368-373
-	O	373-374
TR30	O	374-378
cells	O	379-384
.	O	384-385

Results	O	386-393
showed	O	394-400
that	O	401-405
69	O	406-408
miRNAs	O	409-415
were	O	416-420
upregulated	O	421-432
while	O	433-438
102	O	439-442
miRNAs	O	443-449
were	O	450-454
downregulated	O	455-468
in	O	469-471
SKOV3	O	472-477
-	O	477-478
TR30	O	478-482
cells	O	483-488
.	O	488-489

Using	O	490-495
real	O	496-500
-	O	500-501
time	O	501-505
PCR	O	506-509
,	O	509-510
we	O	511-513
further	O	514-521
clarified	O	522-531
that	O	532-536
miR	B	537-540
-	I	540-541
17	I	541-543
~	I	543-544
92	I	544-546
was	O	547-550
overexpressed	O	551-564
in	O	565-567
SKOV3	O	568-573
-	O	573-574
TR30	O	574-578
cells	O	579-584
compared	O	585-593
with	O	594-598
that	O	599-603
in	O	604-606
SKOV3	O	607-612
cells	O	613-618
.	O	618-619

We	O	620-622
then	O	623-627
established	O	628-639
stable	O	640-646
virally	O	647-654
transduced	O	655-665
SKOV3	O	666-671
-	O	671-672
TR30	O	672-676
-	O	676-677
m	O	677-678
-	O	678-679
PTIP	O	679-683
-	O	683-684
Sponge	O	684-690
all	O	691-694
SKOV3	O	695-700
-	O	700-701
TR30	O	701-705
cells	O	706-711
and	O	712-715
its	O	716-719
vector	O	720-726
-	O	726-727
only	O	727-731
control	O	732-739
SKOV3	O	740-745
-	O	745-746
TR30	O	746-750
-	O	750-751
m	O	751-752
-	O	752-753
PTIP	O	753-757
-	O	757-758
GFP	O	758-761
cells	O	762-767
.	O	767-768

Real	O	769-773
time	O	774-778
-	O	778-779
PCR	O	779-782
revealed	O	783-791
that	O	792-796
SKOV3	O	797-802
-	O	802-803
TR30	O	803-807
-	O	807-808
m	O	808-809
-	O	809-810
PTIP	O	810-814
-	O	814-815
Sponge	O	815-821
all	O	822-825
cells	O	826-831
expressed	O	832-841
approximately	O	842-855
6	O	856-857
.	O	857-858
18	O	858-860
-	O	860-861
fold	O	861-865
lower	O	866-871
levels	O	872-878
of	O	879-881
miR	B	882-885
-	I	885-886
17	I	886-888
~	I	888-889
92	I	889-891
compared	O	892-900
with	O	901-905
the	O	906-909
control	O	910-917
group	O	918-923
.	O	923-924

Decreased	O	925-934
expression	O	935-945
of	O	946-948
miR	B	949-952
-	I	952-953
17	I	953-955
~	I	955-956
92	I	956-958
resulted	O	959-967
in	O	968-970
cell	O	971-975
cycle	O	976-981
arrest	O	982-988
in	O	989-991
the	O	992-995
G2	O	996-998
/	O	998-999
M	O	999-1000
phase	O	1001-1006
and	O	1007-1010
growth	O	1011-1017
inhibition	O	1018-1028
.	O	1028-1029

After	O	1030-1035
the	O	1036-1039
transduction	O	1040-1052
,	O	1052-1053
the	O	1054-1057
BIM	O	1058-1061
protein	O	1062-1069
level	O	1070-1075
was	O	1076-1079
increased	O	1080-1089
in	O	1090-1092
SKOV3	O	1093-1098
-	O	1098-1099
TR30	O	1099-1103
cells	O	1104-1109
and	O	1110-1113
luciferase	O	1114-1124
reporter	O	1125-1133
assays	O	1134-1140
revealed	O	1141-1149
that	O	1150-1154
miR	B	1155-1158
-	I	1158-1159
17	I	1159-1161
~	I	1161-1162
92	I	1162-1164
binds	O	1165-1170
directly	O	1171-1179
to	O	1180-1182
the	O	1183-1186
3	O	1187-1188
'	O	1188-1189
-	O	1189-1190
UTR	O	1190-1193
of	O	1194-1196
BIM	O	1197-1200
.	O	1200-1201

Results	O	1202-1209
of	O	1210-1212
luciferase	O	1213-1223
reporter	O	1224-1232
assays	O	1233-1239
accompanied	O	1240-1251
with	O	1252-1256
Western	O	1257-1264
Blot	O	1265-1269
showed	O	1270-1276
that	O	1277-1281
although	O	1282-1290
miR	B	1291-1294
-	I	1294-1295
17	I	1295-1297
~	I	1297-1298
92	I	1298-1300
binds	O	1301-1306
directly	O	1307-1315
to	O	1316-1318
the	O	1319-1322
3	O	1323-1324
'	O	1324-1325
-	O	1325-1326
UTR	O	1326-1329
of	O	1330-1332
PTEN	O	1333-1337
,	O	1337-1338
the	O	1339-1342
PTEN	O	1343-1347
protein	O	1348-1355
expression	O	1356-1366
level	O	1367-1372
was	O	1373-1376
upregulated	O	1377-1388
slightly	O	1389-1397
while	O	1398-1403
the	O	1404-1407
result	O	1408-1414
is	O	1415-1417
of	O	1418-1420
no	O	1421-1423
statistical	O	1424-1435
significance	O	1436-1448
.	O	1448-1449

Our	O	1450-1453
results	O	1454-1461
showed	O	1462-1468
that	O	1469-1473
miR	B	1474-1477
-	I	1477-1478
17	I	1478-1480
~	I	1480-1481
92	I	1481-1483
could	O	1484-1489
be	O	1490-1492
a	O	1493-1494
causal	O	1495-1501
factor	O	1502-1508
of	O	1509-1511
the	O	1512-1515
downregulation	O	1516-1530
of	O	1531-1533
BIM	O	1534-1537
in	O	1538-1540
SKOV3	O	1541-1546
-	O	1546-1547
TR30	O	1547-1551
cells	O	1552-1557
and	O	1558-1561
thus	O	1562-1566
induce	O	1567-1573
the	O	1574-1577
paclitaxel	O	1578-1588
resistance	O	1589-1599
in	O	1600-1602
SKOV3	O	1603-1608
-	O	1608-1609
TR30	O	1609-1613
cells	O	1614-1619
.	O	1619-1620

The	O	0-3
miRNA	O	4-9
and	O	10-13
mRNA	O	14-18
changes	O	19-26
in	O	27-29
rat	O	30-33
hippocampi	O	34-44
after	O	45-50
chronic	O	51-58
constriction	O	59-71
injury	O	72-78
.	O	78-79

OBJECTIVE	O	80-89
:	O	89-90
We	O	91-93
elaborated	O	94-104
the	O	105-108
rat	O	109-112
hippocampi	O	113-123
in	O	124-126
order	O	127-132
to	O	133-135
assess	O	136-142
for	O	143-146
central	O	147-154
nervous	O	155-162
system	O	163-169
changes	O	170-177
following	O	178-187
a	O	188-189
peripheral	O	190-200
neuropathic	O	201-212
injury	O	213-219
.	O	219-220

DESIGN	O	221-227
,	O	227-228
SETTING	O	229-236
,	O	236-237
SUBJECTS	O	238-246
:	O	246-247
We	O	248-250
examined	O	251-259
the	O	260-263
gene	O	264-268
changes	O	269-276
in	O	277-279
the	O	280-283
hippocampi	O	284-294
of	O	295-297
chronic	O	298-305
constriction	O	306-318
injury	O	319-325
(	O	326-327
CCI	O	327-330
)	O	330-331
rats	O	332-336
with	O	337-341
TaqMan	O	342-348
(	O	348-349
R	O	349-350
)	O	350-351
low	O	352-355
-	O	355-356
density	O	356-363
array	O	364-369
analysis	O	370-378
(	O	379-380
TLDA	O	380-384
)	O	384-385
and	O	386-389
quantitative	O	390-402
real	O	403-407
-	O	407-408
time	O	408-412
polymerase	O	413-423
chain	O	424-429
reaction	O	430-438
(	O	439-440
qRT	O	440-443
-	O	443-444
PCR	O	444-447
)	O	447-448
of	O	449-451
miR	B	452-455
-	I	455-456
125b	I	456-460
,	O	460-461
-	B	462-463
132	I	463-466
,	O	466-467
and	O	468-471
messenger	O	472-481
RNAs	O	482-486
(	O	487-488
mRNAs	O	488-493
)	O	493-494
of	O	495-497
neuropeptide	O	498-510
Y	O	511-512
,	O	512-513
brain	O	514-519
-	O	519-520
derived	O	520-527
neural	O	528-534
factor	O	535-541
,	O	541-542
N	O	543-544
-	O	544-545
methyl	O	545-551
-	O	551-552
D	O	552-553
-	O	553-554
aspartate	O	554-563
glutamate	O	564-573
2A	O	574-576
receptor	O	577-585
,	O	585-586
gamma	O	587-592
-	O	592-593
aminobutyric	O	593-605
acid	O	606-610
A	O	611-612
a1	O	613-615
receptor	O	616-624
,	O	624-625
gamma	O	626-631
-	O	631-632
aminobutyric	O	632-644
acid	O	645-649
A	O	650-651
b1	O	652-654
receptor	O	655-663
,	O	663-664
gamma	O	665-670
-	O	670-671
aminobutyric	O	671-683
acid	O	684-688
B	O	689-690
b2	O	691-693
receptor	O	694-702
,	O	702-703
serotonin	O	704-713
1A	O	714-716
receptor	O	717-725
,	O	725-726
serotonin	O	727-736
2A	O	737-739
receptor	O	740-748
,	O	748-749
serotonin	O	750-759
2C	O	760-762
receptor	O	763-771
,	O	771-772
and	O	773-776
serotonin	O	777-786
3A	O	787-789
receptor	O	790-798
on	O	799-801
days	O	802-806
0	O	807-808
,	O	808-809
7	O	810-811
,	O	811-812
and	O	813-816
15	O	817-819
after	O	820-825
surgery	O	826-833
.	O	833-834

INTERVENTIONS	O	835-848
:	O	848-849
None	O	850-854
.	O	854-855

OUTCOME	O	856-863
MEASURES	O	864-872
:	O	872-873
Two	O	874-877
behavioral	O	878-888
tests	O	889-894
(	O	895-896
thermal	O	896-903
and	O	904-907
mechanical	O	908-918
stimulation	O	919-930
tests	O	931-936
)	O	936-937
were	O	938-942
performed	O	943-952
three	O	953-958
times	O	959-964
at	O	965-967
5	O	968-969
-	O	969-970
minute	O	970-976
intervals	O	977-986
to	O	987-989
assess	O	990-996
pain	O	997-1001
thresholds	O	1002-1012
.	O	1012-1013

MicroRNA	O	1014-1022
(	O	1023-1024
miRNA	O	1024-1029
)	O	1029-1030
changes	O	1031-1038
were	O	1039-1043
examined	O	1044-1052
by	O	1053-1055
TLDA	O	1056-1060
.	O	1060-1061

mRNA	O	1062-1066
changes	O	1067-1074
were	O	1075-1079
examined	O	1080-1088
by	O	1089-1091
qRT	O	1092-1095
-	O	1095-1096
PCR	O	1096-1099
.	O	1099-1100

Statistical	O	1101-1112
significance	O	1113-1125
was	O	1126-1129
determined	O	1130-1140
by	O	1141-1143
Tukey	O	1144-1149
-	O	1149-1150
Kramer	O	1150-1156
'	O	1156-1157
s	O	1157-1158
method	O	1159-1165
and	O	1166-1169
paired	O	1170-1176
t	O	1177-1178
-	O	1178-1179
test	O	1179-1183
.	O	1183-1184

RESULTS	O	1185-1192
:	O	1192-1193
All	O	1194-1197
rats	O	1198-1202
showed	O	1203-1209
mechanical	O	1210-1220
and	O	1221-1224
thermal	O	1225-1232
hypersensitivity	O	1233-1249
on	O	1250-1252
the	O	1253-1256
ipsilateral	O	1257-1268
side	O	1269-1273
.	O	1273-1274

Out	O	1275-1278
of	O	1279-1281
373	O	1282-1285
miRNAs	O	1286-1292
analyzed	O	1293-1301
,	O	1301-1302
237	O	1303-1306
were	O	1307-1311
expressed	O	1312-1321
,	O	1321-1322
and	O	1323-1326
51	O	1327-1329
changed	O	1330-1337
their	O	1338-1343
expressions	O	1344-1355
after	O	1356-1361
CCI	O	1362-1365
.	O	1365-1366

By	O	1367-1369
TLDA	O	1370-1374
,	O	1374-1375
cluster	O	1376-1383
analysis	O	1384-1392
found	O	1393-1398
obvious	O	1399-1406
miRNA	O	1407-1412
changes	O	1413-1420
on	O	1421-1423
day	O	1424-1427
7	O	1428-1429
that	O	1430-1434
tended	O	1435-1441
to	O	1442-1444
recover	O	1445-1452
by	O	1453-1455
day	O	1456-1459
15	O	1460-1462
.	O	1462-1463

For	O	1464-1467
miR	B	1468-1471
-	I	1471-1472
125b	I	1472-1476
,	O	1476-1477
the	O	1478-1481
relative	O	1482-1490
expression	O	1491-1501
decreased	O	1502-1511
to	O	1512-1514
0	O	1515-1516
.	O	1516-1517
70	O	1517-1519
+	O	1520-1521
/	O	1521-1522
-	O	1522-1523
0	O	1524-1525
.	O	1525-1526
30	O	1526-1528
at	O	1529-1531
day	O	1532-1535
7	O	1536-1537
and	O	1538-1541
recovered	O	1542-1551
to	O	1552-1554
1	O	1555-1556
.	O	1556-1557
65	O	1557-1559
+	O	1560-1561
/	O	1561-1562
-	O	1562-1563
0	O	1564-1565
.	O	1565-1566
19	O	1566-1568
at	O	1569-1571
day	O	1572-1575
15	O	1576-1578
.	O	1578-1579

The	O	1580-1583
miR	B	1584-1587
-	I	1587-1588
132	I	1588-1591
relative	O	1592-1600
expressions	O	1601-1612
were	O	1613-1617
0	O	1618-1619
.	O	1619-1620
69	O	1620-1622
+	O	1623-1624
/	O	1624-1625
-	O	1625-1626
0	O	1627-1628
.	O	1628-1629
30	O	1629-1631
and	O	1632-1635
0	O	1636-1637
.	O	1637-1638
70	O	1638-1640
+	O	1641-1642
/	O	1642-1643
-	O	1643-1644
0	O	1645-1646
.	O	1646-1647
15	O	1647-1649
,	O	1649-1650
respectively	O	1651-1663
.	O	1663-1664

The	O	1665-1668
mRNA	O	1669-1673
changes	O	1674-1681
followed	O	1682-1690
the	O	1691-1694
miRNA	O	1695-1700
changes	O	1701-1708
.	O	1708-1709

CONCLUSIONS	O	1710-1721
:	O	1721-1722
Our	O	1723-1726
results	O	1727-1734
showed	O	1735-1741
that	O	1742-1746
the	O	1747-1750
peripheral	O	1751-1761
nerve	O	1762-1767
injury	O	1768-1774
altered	O	1775-1782
rat	O	1783-1786
hippocampal	O	1787-1798
miRNA	O	1799-1804
.	O	1804-1805

Circulating	O	0-11
microRNAs	O	12-21
and	O	22-25
aerobic	O	26-33
fitness	O	34-41
-	O	41-42
-	O	42-43
the	O	43-46
HUNT	O	47-51
-	O	51-52
Study	O	52-57
.	O	57-58

Aerobic	O	59-66
fitness	O	67-74
,	O	74-75
measured	O	76-84
as	O	85-87
maximal	O	88-95
oxygen	O	96-102
uptake	O	103-109
(	O	110-111
VO2max	O	111-117
)	O	117-118
,	O	118-119
is	O	120-122
a	O	123-124
good	O	125-129
indicator	O	130-139
of	O	140-142
cardiovascular	O	143-157
health	O	158-164
,	O	164-165
and	O	166-169
a	O	170-171
strong	O	172-178
predictor	O	179-188
of	O	189-191
cardiovascular	O	192-206
mortality	O	207-216
.	O	216-217

Biomarkers	O	218-228
associated	O	229-239
with	O	240-244
low	O	245-248
VO2max	O	249-255
may	O	256-259
therefore	O	260-269
represent	O	270-279
potential	O	280-289
early	O	290-295
markers	O	296-303
of	O	304-306
future	O	307-313
cardiovascular	O	314-328
disease	O	329-336
(	O	337-338
CVD	O	338-341
)	O	341-342
.	O	342-343

The	O	344-347
aim	O	348-351
of	O	352-354
this	O	355-359
study	O	360-365
was	O	366-369
to	O	370-372
assess	O	373-379
whether	O	380-387
circulating	O	388-399
microRNAs	O	400-409
(	O	410-411
miRs	O	411-415
)	O	415-416
are	O	417-420
associated	O	421-431
with	O	432-436
VO2max	O	437-443
-	O	443-444
level	O	444-449
in	O	450-452
healthy	O	453-460
individuals	O	461-472
.	O	472-473

In	O	474-476
a	O	477-478
screening	O	479-488
study	O	489-494
,	O	494-495
720	O	496-499
miRs	O	500-504
were	O	505-509
measured	O	510-518
in	O	519-521
serum	O	522-527
samples	O	528-535
from	O	536-540
healthy	O	541-548
individuals	O	549-560
(	O	561-562
40	O	562-564
-	O	564-565
45	O	565-567
yrs	O	568-571
)	O	571-572
with	O	573-577
high	O	578-582
(	O	583-584
n	O	584-585
=	O	586-587
12	O	588-590
)	O	590-591
or	O	592-594
low	O	595-598
(	O	599-600
n	O	600-601
=	O	602-603
12	O	604-606
)	O	606-607
VO2max	O	608-614
matched	O	615-622
for	O	623-626
gender	O	627-633
,	O	633-634
age	O	635-638
and	O	639-642
physical	O	643-651
activity	O	652-660
.	O	660-661

Candiate	O	662-670
miRs	O	671-675
were	O	676-680
validated	O	681-690
in	O	691-693
a	O	694-695
second	O	696-702
cohort	O	703-709
of	O	710-712
subjects	O	713-721
with	O	722-726
high	O	727-731
(	O	732-733
n	O	733-734
=	O	735-736
38	O	737-739
)	O	739-740
or	O	741-743
low	O	744-747
(	O	748-749
n	O	749-750
=	O	751-752
38	O	753-755
)	O	755-756
VO2max	O	757-763
.	O	763-764

miR	B	765-768
-	I	768-769
210	I	769-772
and	O	773-776
miR	B	777-780
-	I	780-781
222	I	781-784
were	O	785-789
found	O	790-795
to	O	796-798
be	O	799-801
higher	O	802-808
in	O	809-811
the	O	812-815
low	O	816-819
VO2max	O	820-826
-	O	826-827
group	O	827-832
(	O	833-834
p	O	834-835
<	O	835-836
0	O	836-837
.	O	837-838
05	O	838-840
)	O	840-841
.	O	841-842

In	O	843-845
addition	O	846-854
,	O	854-855
miR	B	856-859
-	I	859-860
21	I	860-862
was	O	863-866
increased	O	867-876
in	O	877-879
male	O	880-884
participants	O	885-897
with	O	898-902
low	O	903-906
VO2max	O	907-913
(	O	914-915
p	O	915-916
<	O	916-917
0	O	917-918
.	O	918-919
05	O	919-921
)	O	921-922
.	O	922-923

There	O	924-929
were	O	930-934
no	O	935-937
correlations	O	938-950
between	O	951-958
traditional	O	959-970
risk	O	971-975
factors	O	976-983
for	O	984-987
CVD	O	988-991
(	O	992-993
blood	O	993-998
pressure	O	999-1007
,	O	1007-1008
cholesterol	O	1009-1020
,	O	1020-1021
smoking	O	1022-1029
habit	O	1030-1035
,	O	1035-1036
or	O	1037-1039
obesity	O	1040-1047
)	O	1047-1048
and	O	1049-1052
miR	B	1053-1056
-	I	1056-1057
21	I	1057-1059
,	O	1059-1060
miR	B	1061-1064
-	I	1064-1065
210	I	1065-1068
and	O	1069-1072
miR	B	1073-1076
-	I	1076-1077
222	I	1077-1080
.	O	1080-1081

DIANA	O	1082-1087
-	O	1087-1088
mirPath	O	1088-1095
identified	O	1096-1106
611	O	1107-1110
potential	O	1111-1120
gene	O	1121-1125
-	O	1125-1126
targets	O	1126-1133
of	O	1134-1136
miR	B	1137-1140
-	I	1140-1141
21	I	1141-1143
,	O	1143-1144
miR	B	1145-1148
-	I	1148-1149
210	I	1149-1152
and	O	1153-1156
miR	B	1157-1160
-	I	1160-1161
222	I	1161-1164
,	O	1164-1165
and	O	1166-1169
pathway	O	1170-1177
analysis	O	1178-1186
indicated	O	1187-1196
alterations	O	1197-1208
in	O	1209-1211
several	O	1212-1219
important	O	1220-1229
signaling	O	1230-1239
systems	O	1240-1247
in	O	1248-1250
subjects	O	1251-1259
with	O	1260-1264
low	O	1265-1268
VO2max	O	1269-1275
.	O	1275-1276

Potential	O	1277-1286
bias	O	1287-1291
involve	O	1292-1299
that	O	1300-1304
blood	O	1305-1310
was	O	1311-1314
collected	O	1315-1324
from	O	1325-1329
non	O	1330-1333
-	O	1333-1334
fasting	O	1334-1341
individuals	O	1342-1353
,	O	1353-1354
and	O	1355-1358
that	O	1359-1363
8	O	1364-1365
performed	O	1366-1375
exercise	O	1376-1384
within	O	1385-1391
24	O	1392-1394
h	O	1395-1396
before	O	1397-1403
sampling	O	1404-1412
.	O	1412-1413

In	O	1414-1416
conclusion	O	1417-1427
,	O	1427-1428
we	O	1429-1431
found	O	1432-1437
that	O	1438-1442
miR	B	1443-1446
-	I	1446-1447
210	I	1447-1450
,	O	1450-1451
miR	B	1452-1455
-	I	1455-1456
21	I	1456-1458
,	O	1458-1459
and	O	1460-1463
miR	B	1464-1467
-	I	1467-1468
222	I	1468-1471
were	O	1472-1476
increased	O	1477-1486
in	O	1487-1489
healthy	O	1490-1497
subjects	O	1498-1506
with	O	1507-1511
low	O	1512-1515
VO2max	O	1516-1522
.	O	1522-1523

The	O	1524-1527
lack	O	1528-1532
of	O	1533-1535
association	O	1536-1547
between	O	1548-1555
these	O	1556-1561
three	O	1562-1567
miRs	O	1568-1572
,	O	1572-1573
and	O	1574-1577
other	O	1578-1583
fitness	O	1584-1591
related	O	1592-1599
variables	O	1600-1609
as	O	1610-1612
well	O	1613-1617
as	O	1618-1620
traditional	O	1621-1632
CVD	O	1633-1636
risk	O	1637-1641
factors	O	1642-1649
,	O	1649-1650
suggests	O	1651-1659
that	O	1660-1664
these	O	1665-1670
miRs	O	1671-1675
may	O	1676-1679
have	O	1680-1684
a	O	1685-1686
potential	O	1687-1696
as	O	1697-1699
new	O	1700-1703
independent	O	1704-1715
biomarkers	O	1716-1726
of	O	1727-1729
fitness	O	1730-1737
level	O	1738-1743
and	O	1744-1747
future	O	1748-1754
CVD	O	1755-1758
.	O	1758-1759

The	O	0-3
miR	B	4-7
-	I	7-8
183	I	8-11
/	O	11-12
Taok1	O	12-17
target	O	18-24
pair	O	25-29
is	O	30-32
implicated	O	33-43
in	O	44-46
cochlear	O	47-55
responses	O	56-65
to	O	66-68
acoustic	O	69-77
trauma	O	78-84
.	O	84-85

Acoustic	O	86-94
trauma	O	95-101
,	O	101-102
one	O	103-106
of	O	107-109
the	O	110-113
leading	O	114-121
causes	O	122-128
of	O	129-131
sensorineural	O	132-145
hearing	O	146-153
loss	O	154-158
,	O	158-159
induces	O	160-167
sensory	O	168-175
hair	O	176-180
cell	O	181-185
damage	O	186-192
in	O	193-195
the	O	196-199
cochlea	O	200-207
.	O	207-208

Identifying	O	209-220
the	O	221-224
molecular	O	225-234
mechanisms	O	235-245
involved	O	246-254
in	O	255-257
regulating	O	258-268
sensory	O	269-276
hair	O	277-281
cell	O	282-286
death	O	287-292
is	O	293-295
critical	O	296-304
towards	O	305-312
developing	O	313-323
effective	O	324-333
treatments	O	334-344
for	O	345-348
preventing	O	349-359
hair	O	360-364
cell	O	365-369
damage	O	370-376
.	O	376-377

Recently	O	378-386
,	O	386-387
microRNAs	O	388-397
(	O	398-399
miRNAs	O	399-405
)	O	405-406
have	O	407-411
been	O	412-416
shown	O	417-422
to	O	423-425
participate	O	426-437
in	O	438-440
the	O	441-444
regulatory	O	445-455
mechanisms	O	456-466
of	O	467-469
inner	O	470-475
ear	O	476-479
development	O	480-491
and	O	492-495
homeostasis	O	496-507
.	O	507-508

However	O	509-516
,	O	516-517
their	O	518-523
involvement	O	524-535
in	O	536-538
cochlear	O	539-547
sensory	O	548-555
cell	O	556-560
degeneration	O	561-573
following	O	574-583
acoustic	O	584-592
trauma	O	593-599
is	O	600-602
unknown	O	603-610
.	O	610-611

Here	O	612-616
,	O	616-617
we	O	618-620
profiled	O	621-629
the	O	630-633
expression	O	634-644
pattern	O	645-652
of	O	653-655
miRNAs	O	656-662
in	O	663-665
the	O	666-669
cochlear	O	670-678
sensory	O	679-686
epithelium	O	687-697
,	O	697-698
defined	O	699-706
miRNA	O	707-712
responses	O	713-722
to	O	723-725
acoustic	O	726-734
overstimulation	O	735-750
,	O	750-751
and	O	752-755
explored	O	756-764
potential	O	765-774
mRNA	O	775-779
targets	O	780-787
of	O	788-790
miRNAs	O	791-797
that	O	798-802
may	O	803-806
be	O	807-809
responsible	O	810-821
for	O	822-825
the	O	826-829
stress	O	830-836
responses	O	837-846
of	O	847-849
the	O	850-853
cochlea	O	854-861
.	O	861-862

Expression	O	863-873
analysis	O	874-882
of	O	883-885
miRNAs	O	886-892
in	O	893-895
the	O	896-899
cochlear	O	900-908
sensory	O	909-916
epithelium	O	917-927
revealed	O	928-936
constitutive	O	937-949
expression	O	950-960
of	O	961-963
176	O	964-967
miRNAs	O	968-974
,	O	974-975
many	O	976-980
of	O	981-983
which	O	984-989
have	O	990-994
not	O	995-998
been	O	999-1003
previously	O	1004-1014
reported	O	1015-1023
in	O	1024-1026
cochlear	O	1027-1035
tissue	O	1036-1042
.	O	1042-1043

Exposure	O	1044-1052
to	O	1053-1055
intense	O	1056-1063
noise	O	1064-1069
caused	O	1070-1076
significant	O	1077-1088
threshold	O	1089-1098
shift	O	1099-1104
and	O	1105-1108
apoptotic	O	1109-1118
activity	O	1119-1127
in	O	1128-1130
the	O	1131-1134
cochleae	O	1135-1143
.	O	1143-1144

Gene	O	1145-1149
expression	O	1150-1160
analysis	O	1161-1169
of	O	1170-1172
noise	O	1173-1178
-	O	1178-1179
traumatized	O	1179-1190
cochleae	O	1191-1199
revealed	O	1200-1208
time	O	1209-1213
-	O	1213-1214
dependent	O	1214-1223
transcriptional	O	1224-1239
changes	O	1240-1247
in	O	1248-1250
the	O	1251-1254
expression	O	1255-1265
of	O	1266-1268
miRNAs	O	1269-1275
.	O	1275-1276

Target	O	1277-1283
prediction	O	1284-1294
analysis	O	1295-1303
revealed	O	1304-1312
potential	O	1313-1322
target	O	1323-1329
genes	O	1330-1335
of	O	1336-1338
the	O	1339-1342
significantly	O	1343-1356
downregulated	O	1357-1370
miRNAs	O	1371-1377
,	O	1377-1378
many	O	1379-1383
of	O	1384-1386
which	O	1387-1392
had	O	1393-1396
cell	O	1397-1401
death	O	1402-1407
-	O	1407-1408
and	O	1409-1412
apoptosis	O	1413-1422
-	O	1422-1423
related	O	1423-1430
functions	O	1431-1440
.	O	1440-1441

Verification	O	1442-1454
of	O	1455-1457
the	O	1458-1461
predicted	O	1462-1471
targets	O	1472-1479
revealed	O	1480-1488
a	O	1489-1490
significant	O	1491-1502
upregulation	O	1503-1515
of	O	1516-1518
Taok1	O	1519-1524
,	O	1524-1525
a	O	1526-1527
target	O	1528-1534
of	O	1535-1537
miRNA	B	1538-1543
-	I	1543-1544
183	I	1544-1547
.	O	1547-1548

Moreover	O	1549-1557
,	O	1557-1558
inhibition	O	1559-1569
of	O	1570-1572
miR	B	1573-1576
-	I	1576-1577
183	I	1577-1580
with	O	1581-1585
morpholino	O	1586-1596
antisense	O	1597-1606
oligos	O	1607-1613
in	O	1614-1616
cochlear	O	1617-1625
organotypic	O	1626-1637
cultures	O	1638-1646
revealed	O	1647-1655
a	O	1656-1657
negative	O	1658-1666
correlation	O	1667-1678
between	O	1679-1686
the	O	1687-1690
expression	O	1691-1701
levels	O	1702-1708
of	O	1709-1711
miR	B	1712-1715
-	I	1715-1716
183	I	1716-1719
and	O	1720-1723
Taok1	O	1724-1729
,	O	1729-1730
suggesting	O	1731-1741
the	O	1742-1745
presence	O	1746-1754
of	O	1755-1757
a	O	1758-1759
miR	B	1760-1763
-	I	1763-1764
183	I	1764-1767
/	O	1767-1768
Taok1	O	1768-1773
target	O	1774-1780
pair	O	1781-1785
.	O	1785-1786

Together	O	1787-1795
,	O	1795-1796
miRNA	O	1797-1802
profiling	O	1803-1812
as	O	1813-1815
well	O	1816-1820
as	O	1821-1823
the	O	1824-1827
target	O	1828-1834
analysis	O	1835-1843
and	O	1844-1847
validation	O	1848-1858
suggest	O	1859-1866
the	O	1867-1870
involvement	O	1871-1882
of	O	1883-1885
miRNAs	O	1886-1892
in	O	1893-1895
the	O	1896-1899
regulation	O	1900-1910
of	O	1911-1913
the	O	1914-1917
degenerative	O	1918-1930
process	O	1931-1938
of	O	1939-1941
the	O	1942-1945
cochlea	O	1946-1953
following	O	1954-1963
acoustic	O	1964-1972
overstimulation	O	1973-1988
.	O	1988-1989

The	O	1990-1993
miR	B	1994-1997
-	I	1997-1998
183	I	1998-2001
/	O	2001-2002
Taok1	O	2002-2007
target	O	2008-2014
pair	O	2015-2019
is	O	2020-2022
likely	O	2023-2029
to	O	2030-2032
play	O	2033-2037
a	O	2038-2039
role	O	2040-2044
in	O	2045-2047
this	O	2048-2052
regulatory	O	2053-2063
process	O	2064-2071
.	O	2071-2072

Choline	O	0-7
protects	O	8-16
against	O	17-24
cardiac	O	25-32
hypertrophy	O	33-44
induced	O	45-52
by	O	53-55
increased	O	56-65
after	O	66-71
-	O	71-72
load	O	72-76
.	O	76-77

BACKGROUND	O	78-88
:	O	88-89
Although	O	90-98
inadequate	O	99-109
intake	O	110-116
of	O	117-119
essential	O	120-129
nutrient	O	130-138
choline	O	139-146
has	O	147-150
been	O	151-155
known	O	156-161
to	O	162-164
significantly	O	165-178
increase	O	179-187
cardiovascular	O	188-202
risk	O	203-207
,	O	207-208
whether	O	209-216
additional	O	217-227
supplement	O	228-238
of	O	239-241
choline	O	242-249
offering	O	250-258
a	O	259-260
protection	O	261-271
against	O	272-279
cardiac	O	280-287
hypertrophy	O	288-299
remain	O	300-306
unstudied	O	307-316
.	O	316-317

METHODS	O	318-325
:	O	325-326
The	O	327-330
effects	O	331-338
of	O	339-341
choline	O	342-349
supplements	O	350-361
on	O	362-364
pathological	O	365-377
cardiac	O	378-385
hypertrophic	O	386-398
growth	O	399-405
induced	O	406-413
by	O	414-416
transverse	O	417-427
aorta	O	428-433
constriction	O	434-446
(	O	447-448
TAC	O	448-451
)	O	451-452
for	O	453-456
three	O	457-462
weeks	O	463-468
and	O	469-472
cardiomyocyte	O	473-486
hypertrophy	O	487-498
in	O	499-501
cultured	O	502-510
cells	O	511-516
induced	O	517-524
by	O	525-527
isoproterenol	O	528-541
(	O	542-543
ISO	O	543-546
)	O	546-547
10	O	548-550
muM	O	551-554
for	O	555-558
48	O	559-561
h	O	562-563
stimulation	O	564-575
were	O	576-580
investigated	O	581-593
.	O	593-594

Western	O	595-602
blot	O	603-607
analysis	O	608-616
and	O	617-620
real	O	621-625
-	O	625-626
time	O	626-630
PCR	O	631-634
were	O	635-639
used	O	640-644
to	O	645-647
determine	O	648-657
the	O	658-661
expression	O	662-672
of	O	673-675
ANP	O	676-679
,	O	679-680
BNP	O	681-684
,	O	684-685
beta	O	686-690
-	O	690-691
MHC	O	691-694
,	O	694-695
miR	B	696-699
-	I	699-700
133a	I	700-704
and	O	705-708
Calcineurin	O	709-720
.	O	720-721

RESULTS	O	722-729
:	O	729-730
Administration	O	731-745
of	O	746-748
14	O	749-751
mg	O	752-754
/	O	754-755
kg	O	755-757
choline	O	758-765
to	O	766-768
mice	O	769-773
undergone	O	774-783
TAC	O	784-787
effectively	O	788-799
attenuated	O	800-810
the	O	811-814
cardiac	O	815-822
hypertrophic	O	823-835
responses	O	836-845
,	O	845-846
as	O	847-849
indicated	O	850-859
by	O	860-862
the	O	863-866
reduced	O	867-874
heart	O	875-880
weight	O	881-887
,	O	887-888
left	O	889-893
ventricular	O	894-905
weight	O	906-912
,	O	912-913
ventricular	O	914-925
thickness	O	926-935
,	O	935-936
and	O	937-940
reduced	O	941-948
expression	O	949-959
of	O	960-962
biomarker	O	963-972
genes	O	973-978
of	O	979-981
cardiac	O	982-989
hypertrophy	O	990-1001
.	O	1001-1002

This	O	1003-1007
anti	O	1008-1012
-	O	1012-1013
hypertrophic	O	1013-1025
efficacy	O	1026-1034
was	O	1035-1038
reproduced	O	1039-1049
in	O	1050-1052
a	O	1053-1054
cellular	O	1055-1063
model	O	1064-1069
of	O	1070-1072
cardiomyocyte	O	1073-1086
hypertrophy	O	1087-1098
induced	O	1099-1106
by	O	1107-1109
isoproterenol	O	1110-1123
in	O	1124-1126
cultured	O	1127-1135
neonatal	O	1136-1144
cardiomyocytes	O	1145-1159
.	O	1159-1160

Our	O	1161-1164
results	O	1165-1172
further	O	1173-1180
showed	O	1181-1187
that	O	1188-1192
choline	O	1193-1200
rescued	O	1201-1208
the	O	1209-1212
aberrant	O	1213-1221
downregulation	O	1222-1236
of	O	1237-1239
the	O	1240-1243
muscle	O	1244-1250
-	O	1250-1251
specific	O	1251-1259
microRNA	O	1260-1268
miR	B	1269-1272
-	I	1272-1273
133a	I	1273-1277
expression	O	1278-1288
,	O	1288-1289
a	O	1290-1291
recently	O	1292-1300
identified	O	1301-1311
anti	O	1312-1316
-	O	1316-1317
hypertrophic	O	1317-1329
factor	O	1330-1336
,	O	1336-1337
and	O	1338-1341
restored	O	1342-1350
the	O	1351-1354
elevated	O	1355-1363
calcineurin	O	1364-1375
protein	O	1376-1383
level	O	1384-1389
,	O	1389-1390
the	O	1391-1394
key	O	1395-1398
signaling	O	1399-1408
molecule	O	1409-1417
for	O	1418-1421
the	O	1422-1425
development	O	1426-1437
of	O	1438-1440
cardiac	O	1441-1448
hypertrophy	O	1449-1460
.	O	1460-1461

These	O	1462-1467
effects	O	1468-1475
of	O	1476-1478
choline	O	1479-1486
were	O	1487-1491
abolished	O	1492-1501
by	O	1502-1504
the	O	1505-1508
M3	O	1509-1511
mAChR	O	1512-1517
-	O	1517-1518
specific	O	1518-1526
antagonist	O	1527-1537
4	O	1538-1539
-	O	1539-1540
DAMP	O	1540-1544
.	O	1544-1545

CONCLUSION	O	1546-1556
:	O	1556-1557
Our	O	1558-1561
study	O	1562-1567
unraveled	O	1568-1577
for	O	1578-1581
the	O	1582-1585
first	O	1586-1591
time	O	1592-1596
the	O	1597-1600
cardioprotection	O	1601-1617
of	O	1618-1620
choline	O	1621-1628
against	O	1629-1636
cardiac	O	1637-1644
hypertrophy	O	1645-1656
,	O	1656-1657
with	O	1658-1662
correction	O	1663-1673
of	O	1674-1676
expression	O	1677-1687
of	O	1688-1690
miR	B	1691-1694
-	I	1694-1695
133a	I	1695-1699
and	O	1700-1703
calcineurin	O	1704-1715
as	O	1716-1718
a	O	1719-1720
possible	O	1721-1729
mechanism	O	1730-1739
.	O	1739-1740

Our	O	1741-1744
findings	O	1745-1753
suggest	O	1754-1761
that	O	1762-1766
choline	O	1767-1774
supplement	O	1775-1785
may	O	1786-1789
be	O	1790-1792
considered	O	1793-1803
for	O	1804-1807
adjunct	O	1808-1815
anti	O	1816-1820
-	O	1820-1821
hypertrophy	O	1821-1832
therapy	O	1833-1840
.	O	1840-1841

MicroRNA	O	0-8
regulation	O	9-19
of	O	20-22
adipose	O	23-30
derived	O	31-38
stem	O	39-43
cells	O	44-49
in	O	50-52
aging	O	53-58
rats	O	59-63
.	O	63-64

BACKGROUND	O	65-75
:	O	75-76
Perturbations	O	77-90
in	O	91-93
abdominal	O	94-103
fat	O	104-107
secreted	O	108-116
adipokines	O	117-127
play	O	128-132
a	O	133-134
key	O	135-138
role	O	139-143
in	O	144-146
metabolic	O	147-156
syndrome	O	157-165
.	O	165-166

This	O	167-171
process	O	172-179
is	O	180-182
further	O	183-190
altered	O	191-198
during	O	199-205
the	O	206-209
aging	O	210-215
process	O	216-223
,	O	223-224
probably	O	225-233
due	O	234-237
to	O	238-240
alterations	O	241-252
in	O	253-255
the	O	256-259
preadipocytes	O	260-273
(	O	274-275
aka	O	275-278
.	O	278-279

stromal	O	280-287
vascular	O	288-296
fraction	O	297-305
cells	O	306-311
-	O	311-312
SVF	O	312-315
cells	O	316-321
or	O	322-324
adipose	O	325-332
derived	O	333-340
stem	O	341-345
cells	O	346-351
-	O	351-352
ASCs	O	352-356
)	O	356-357
composition	O	358-369
and	O	370-373
/	O	373-374
or	O	374-376
function	O	377-385
.	O	385-386

Since	O	387-392
microRNAs	O	393-402
regulate	O	403-411
genes	O	412-417
involved	O	418-426
both	O	427-431
in	O	432-434
development	O	435-446
and	O	447-450
aging	O	451-456
processes	O	457-466
,	O	466-467
we	O	468-470
hypothesized	O	471-483
that	O	484-488
the	O	489-492
impaired	O	493-501
adipose	O	502-509
function	O	510-518
with	O	519-523
aging	O	524-529
is	O	530-532
due	O	533-536
to	O	537-539
altered	O	540-547
microRNA	O	548-556
regulation	O	557-567
of	O	568-570
adipogenic	O	571-581
pathways	O	582-590
in	O	591-593
SVF	O	594-597
cells	O	598-603
.	O	603-604

METHODOLOGY	O	605-616
AND	O	617-620
PRINCIPAL	O	621-630
FINDINGS	O	631-639
:	O	639-640
Alterations	O	641-652
in	O	653-655
mRNA	O	656-660
and	O	661-664
proteins	O	665-673
associated	O	674-684
with	O	685-689
adipogenic	O	690-700
differentiation	O	701-716
(	O	717-718
ERK5	O	718-722
and	O	723-726
PPARg	O	727-732
)	O	732-733
but	O	734-737
not	O	738-741
osteogenic	O	742-752
(	O	753-754
RUNX2	O	754-759
)	O	759-760
pathways	O	761-769
were	O	770-774
observed	O	775-783
in	O	784-786
SVF	O	787-790
cells	O	791-796
isolated	O	797-805
from	O	806-810
visceral	O	811-819
adipose	O	820-827
tissue	O	828-834
with	O	835-839
aging	O	840-845
(	O	846-847
6	O	847-848
to	O	849-851
30	O	852-854
mo	O	855-857
)	O	857-858
in	O	859-861
female	O	862-868
Fischer	O	869-876
344	O	877-880
x	O	881-882
Brown	O	883-888
Norway	O	889-895
Hybrid	O	896-902
(	O	903-904
FBN	O	904-907
)	O	907-908
rats	O	909-913
.	O	913-914

The	O	915-918
impaired	O	919-927
differentiation	O	928-943
capacity	O	944-952
with	O	953-957
aging	O	958-963
correlated	O	964-974
with	O	975-979
altered	O	980-987
levels	O	988-994
of	O	995-997
miRNAs	O	998-1004
involved	O	1005-1013
in	O	1014-1016
adipocyte	O	1017-1026
differentiation	O	1027-1042
(	O	1043-1044
miRNA	B	1044-1049
-	I	1049-1050
143	I	1050-1053
)	O	1053-1054
and	O	1055-1058
osteogenic	O	1059-1069
pathways	O	1070-1078
(	O	1079-1080
miRNA	B	1080-1085
-	I	1085-1086
204	I	1086-1089
)	O	1089-1090
.	O	1090-1091

Gain	O	1092-1096
and	O	1097-1100
loss	O	1101-1105
of	O	1106-1108
function	O	1109-1117
studies	O	1118-1125
using	O	1126-1131
premir	O	1132-1138
or	O	1139-1141
antagomir	O	1142-1151
-	O	1151-1152
143	O	1152-1155
validated	O	1156-1165
the	O	1166-1169
age	O	1170-1173
associated	O	1174-1184
adipocyte	O	1185-1194
dysfunction	O	1195-1206
.	O	1206-1207

CONCLUSIONS	O	1208-1219
AND	O	1220-1223
SIGNIFICANCE	O	1224-1236
:	O	1236-1237
Our	O	1238-1241
studies	O	1242-1249
for	O	1250-1253
the	O	1254-1257
first	O	1258-1263
time	O	1264-1268
indicate	O	1269-1277
a	O	1278-1279
role	O	1280-1284
for	O	1285-1288
miRNA	O	1289-1294
mediated	O	1295-1303
regulation	O	1304-1314
of	O	1315-1317
SVF	O	1318-1321
cells	O	1322-1327
with	O	1328-1332
aging	O	1333-1338
.	O	1338-1339

This	O	1340-1344
discovery	O	1345-1354
is	O	1355-1357
important	O	1358-1367
in	O	1368-1370
the	O	1371-1374
light	O	1375-1380
of	O	1381-1383
the	O	1384-1387
findings	O	1388-1396
that	O	1397-1401
dysfunctional	O	1402-1415
adipose	O	1416-1423
derived	O	1424-1431
stem	O	1432-1436
cells	O	1437-1442
contribute	O	1443-1453
to	O	1454-1456
age	O	1457-1460
related	O	1461-1468
chronic	O	1469-1476
diseases	O	1477-1485
.	O	1485-1486

Functional	O	0-10
cooperation	O	11-22
of	O	23-25
miR	B	26-29
-	I	29-30
125a	I	30-34
,	O	34-35
miR	B	36-39
-	I	39-40
125b	I	40-44
,	O	44-45
and	O	46-49
miR	B	50-53
-	I	53-54
205	I	54-57
in	O	58-60
entinostat	O	61-71
-	O	71-72
induced	O	72-79
downregulation	O	80-94
of	O	95-97
erbB2	O	98-103
/	O	103-104
erbB3	O	104-109
and	O	110-113
apoptosis	O	114-123
in	O	124-126
breast	O	127-133
cancer	O	134-140
cells	O	141-146
.	O	146-147

We	O	148-150
reported	O	151-159
that	O	160-164
the	O	165-168
class	O	169-174
I	O	175-176
HDAC	O	177-181
inhibitor	O	182-191
entinostat	O	192-202
induced	O	203-210
apoptosis	O	211-220
in	O	221-223
erbB2	O	224-229
-	O	229-230
overexpressing	O	230-244
breast	O	245-251
cancer	O	252-258
cells	O	259-264
via	O	265-268
downregulation	O	269-283
of	O	284-286
erbB2	O	287-292
and	O	293-296
erbB3	O	297-302
.	O	302-303

Here	O	304-308
,	O	308-309
we	O	310-312
study	O	313-318
the	O	319-322
molecular	O	323-332
mechanism	O	333-342
by	O	343-345
which	O	346-351
entinostat	O	352-362
dual	O	363-367
-	O	367-368
targets	O	368-375
erbB2	O	376-381
/	O	381-382
erbB3	O	382-387
.	O	387-388

Treatment	O	389-398
with	O	399-403
entinostat	O	404-414
had	O	415-418
no	O	419-421
effect	O	422-428
on	O	429-431
erbB2	O	432-437
/	O	437-438
erbB3	O	438-443
mRNA	O	444-448
,	O	448-449
suggesting	O	450-460
a	O	461-462
transcription	O	463-476
-	O	476-477
independent	O	477-488
mechanism	O	489-498
.	O	498-499

Entinostat	O	500-510
decreased	O	511-520
endogenous	O	521-531
but	O	532-535
not	O	536-539
exogenous	O	540-549
erbB2	O	550-555
/	O	555-556
erbB3	O	556-561
,	O	561-562
indicating	O	563-573
it	O	574-576
did	O	577-580
not	O	581-584
alter	O	585-590
their	O	591-596
protein	O	597-604
stability	O	605-614
.	O	614-615

We	O	616-618
hypothesized	O	619-631
that	O	632-636
entinostat	O	637-647
might	O	648-653
inhibit	O	654-661
erbB2	O	662-667
/	O	667-668
erbB3	O	668-673
protein	O	674-681
translation	O	682-693
via	O	694-697
specific	O	698-706
miRNAs	O	707-713
.	O	713-714

Indeed	O	715-721
,	O	721-722
entinostat	O	723-733
significantly	O	734-747
upregulated	O	748-759
miR	B	760-763
-	I	763-764
125a	I	764-768
,	O	768-769
miR	B	770-773
-	I	773-774
125b	I	774-778
,	O	778-779
and	O	780-783
miR	B	784-787
-	I	787-788
205	I	788-791
,	O	791-792
that	O	793-797
have	O	798-802
been	O	803-807
reported	O	808-816
to	O	817-819
target	O	820-826
erbB2	O	827-832
and	O	833-836
/	O	836-837
or	O	837-839
erbB3	O	840-845
.	O	845-846

Specific	O	847-855
inhibitors	O	856-866
were	O	867-871
then	O	872-876
used	O	877-881
to	O	882-884
determine	O	885-894
whether	O	895-902
these	O	903-908
miRNAs	O	909-915
had	O	916-919
a	O	920-921
causal	O	922-928
role	O	929-933
in	O	934-936
entinostat	O	937-947
-	O	947-948
induced	O	948-955
downregulation	O	956-970
of	O	971-973
erbB2	O	974-979
/	O	979-980
erbB3	O	980-985
and	O	986-989
apoptosis	O	990-999
.	O	999-1000

Transfection	O	1001-1013
with	O	1014-1018
a	O	1019-1020
single	O	1021-1027
inhibitor	O	1028-1037
dramatically	O	1038-1050
abrogated	O	1051-1060
entinostat	O	1061-1071
induction	O	1072-1081
of	O	1082-1084
miR	B	1085-1088
-	I	1088-1089
125a	I	1089-1093
,	O	1093-1094
miR	B	1095-1098
-	I	1098-1099
125b	I	1099-1103
,	O	1103-1104
or	O	1105-1107
miR	B	1108-1111
-	I	1111-1112
205	I	1112-1115
;	O	1115-1116
however	O	1117-1124
,	O	1124-1125
none	O	1126-1130
of	O	1131-1133
the	O	1134-1137
inhibitors	O	1138-1148
blocked	O	1149-1156
entinostat	O	1157-1167
action	O	1168-1174
on	O	1175-1177
erbB2	O	1178-1183
/	O	1183-1184
erbB3	O	1184-1189
.	O	1189-1190

In	O	1191-1193
contrast	O	1194-1202
,	O	1202-1203
co	O	1204-1206
-	O	1206-1207
transfection	O	1207-1219
with	O	1220-1224
two	O	1225-1228
inhibitors	O	1229-1239
not	O	1240-1243
only	O	1244-1248
reduced	O	1249-1256
their	O	1257-1262
corresponding	O	1263-1276
miRNAs	O	1277-1283
,	O	1283-1284
but	O	1285-1288
also	O	1289-1293
significantly	O	1294-1307
abrogated	O	1308-1317
entinostat	O	1318-1328
-	O	1328-1329
mediated	O	1329-1337
reduction	O	1338-1347
of	O	1348-1350
erbB2	O	1351-1356
/	O	1356-1357
erbB3	O	1357-1362
.	O	1362-1363

Moreover	O	1364-1372
,	O	1372-1373
simultaneous	O	1374-1386
inhibition	O	1387-1397
of	O	1398-1400
two	O	1401-1404
,	O	1404-1405
but	O	1406-1409
not	O	1410-1413
one	O	1414-1417
miRNA	O	1418-1423
significantly	O	1424-1437
attenuated	O	1438-1448
entinostat	O	1449-1459
-	O	1459-1460
induced	O	1460-1467
apoptosis	O	1468-1477
.	O	1477-1478

Interestingly	O	1479-1492
,	O	1492-1493
although	O	1494-1502
the	O	1503-1506
other	O	1507-1512
HDAC	O	1513-1517
inhibitors	O	1518-1528
,	O	1528-1529
such	O	1530-1534
as	O	1535-1537
SAHA	O	1538-1542
and	O	1543-1546
panobinostat	O	1547-1559
,	O	1559-1560
exhibited	O	1561-1570
activity	O	1571-1579
as	O	1580-1582
potent	O	1583-1589
as	O	1590-1592
entinostat	O	1593-1603
to	O	1604-1606
induce	O	1607-1613
growth	O	1614-1620
inhibition	O	1621-1631
and	O	1632-1635
apoptosis	O	1636-1645
in	O	1646-1648
erbB2	O	1649-1654
-	O	1654-1655
overexpressing	O	1655-1669
breast	O	1670-1676
cancer	O	1677-1683
cells	O	1684-1689
,	O	1689-1690
they	O	1691-1695
had	O	1696-1699
no	O	1700-1702
significant	O	1703-1714
effects	O	1715-1722
on	O	1723-1725
the	O	1726-1729
three	O	1730-1735
miRNAs	O	1736-1742
.	O	1742-1743

Instead	O	1744-1751
,	O	1751-1752
both	O	1753-1757
SAHA	O	1758-1762
-	O	1762-1763
and	O	1764-1767
panobinostat	O	1768-1780
-	O	1780-1781
decreased	O	1781-1790
erbB2	O	1791-1796
/	O	1796-1797
erbB3	O	1797-1802
expression	O	1803-1813
correlated	O	1814-1824
with	O	1825-1829
the	O	1830-1833
reduction	O	1834-1843
of	O	1844-1846
their	O	1847-1852
mRNA	O	1853-1857
levels	O	1858-1864
.	O	1864-1865

Collectively	O	1866-1878
,	O	1878-1879
we	O	1880-1882
demonstrate	O	1883-1894
that	O	1895-1899
entinostat	O	1900-1910
specifically	O	1911-1923
induces	O	1924-1931
expression	O	1932-1942
of	O	1943-1945
miR	B	1946-1949
-	I	1949-1950
125a	I	1950-1954
,	O	1954-1955
miR	B	1956-1959
-	I	1959-1960
125b	I	1960-1964
,	O	1964-1965
and	O	1966-1969
miR	B	1970-1973
-	I	1973-1974
205	I	1974-1977
,	O	1977-1978
which	O	1979-1984
act	O	1985-1988
in	O	1989-1991
concert	O	1992-1999
to	O	2000-2002
downregulate	O	2003-2015
erbB2	O	2016-2021
/	O	2021-2022
erbB3	O	2022-2027
in	O	2028-2030
breast	O	2031-2037
cancer	O	2038-2044
cells	O	2045-2050
.	O	2050-2051

Our	O	2052-2055
data	O	2056-2060
suggest	O	2061-2068
that	O	2069-2073
epigenetic	O	2074-2084
regulation	O	2085-2095
via	O	2096-2099
miRNA	O	2100-2105
-	O	2105-2106
dependent	O	2106-2115
or	O	2116-2118
-	O	2119-2120
independent	O	2120-2131
mechanisms	O	2132-2142
may	O	2143-2146
represent	O	2147-2156
a	O	2157-2158
novel	O	2159-2164
approach	O	2165-2173
to	O	2174-2176
treat	O	2177-2182
breast	O	2183-2189
cancer	O	2190-2196
patients	O	2197-2205
with	O	2206-2210
erbB2	O	2211-2216
-	O	2216-2217
overexpressing	O	2217-2231
tumors	O	2232-2238
.	O	2238-2239

Induction	O	0-9
of	O	10-12
thoracic	O	13-21
aortic	O	22-28
remodeling	O	29-39
by	O	40-42
endothelial	O	43-54
-	O	54-55
specific	O	55-63
deletion	O	64-72
of	O	73-75
microRNA	B	76-84
-	I	84-85
21	I	85-87
in	O	88-90
mice	O	91-95
.	O	95-96

MicroRNAs	O	97-106
(	O	107-108
miRs	O	108-112
)	O	112-113
are	O	114-117
known	O	118-123
to	O	124-126
have	O	127-131
an	O	132-134
important	O	135-144
role	O	145-149
in	O	150-152
modulating	O	153-163
vascular	O	164-172
biology	O	173-180
.	O	180-181

MiR21	B	182-187
was	O	188-191
found	O	192-197
to	O	198-200
be	O	201-203
involved	O	204-212
in	O	213-215
the	O	216-219
pathogenesis	O	220-232
of	O	233-235
proliferative	O	236-249
vascular	O	250-258
disease	O	259-266
.	O	266-267

The	O	268-271
role	O	272-276
of	O	277-279
miR21	B	280-285
in	O	286-288
endothelial	O	289-300
cells	O	301-306
(	O	307-308
ECs	O	308-311
)	O	311-312
has	O	313-316
well	O	317-321
studied	O	322-329
in	O	330-332
vitro	O	333-338
,	O	338-339
but	O	340-343
the	O	344-347
study	O	348-353
in	O	354-356
vivo	O	357-361
remains	O	362-369
to	O	370-372
be	O	373-375
elucidated	O	376-386
.	O	386-387

In	O	388-390
this	O	391-395
study	O	396-401
,	O	401-402
miR21	B	403-408
endothelial	O	409-420
-	O	420-421
specific	O	421-429
knockout	O	430-438
mice	O	439-443
were	O	444-448
generated	O	449-458
by	O	459-461
Cre	O	462-465
/	O	465-466
LoxP	O	466-470
system	O	471-477
.	O	477-478

Compared	O	479-487
with	O	488-492
wild	O	493-497
-	O	497-498
type	O	498-502
mice	O	503-507
,	O	507-508
the	O	509-512
miR21	B	513-518
deletion	O	519-527
in	O	528-530
ECs	O	531-534
resulted	O	535-543
in	O	544-546
structural	O	547-557
and	O	558-561
functional	O	562-572
remodeling	O	573-583
of	O	584-586
aorta	O	587-592
significantly	O	593-606
,	O	606-607
such	O	608-612
as	O	613-615
diastolic	O	616-625
pressure	O	626-634
dropping	O	635-643
,	O	643-644
maximal	O	645-652
tension	O	653-660
depression	O	661-671
,	O	671-672
endothelium	O	673-684
-	O	684-685
dependent	O	685-694
relaxation	O	695-705
impairment	O	706-716
,	O	716-717
an	O	718-720
increase	O	721-729
of	O	730-732
opening	O	733-740
angles	O	741-747
and	O	748-751
wall	O	752-756
-	O	756-757
thickness	O	757-766
/	O	766-767
inner	O	767-772
diameter	O	773-781
ratio	O	782-787
,	O	787-788
and	O	789-792
compliance	O	793-803
decrease	O	804-812
,	O	812-813
in	O	814-816
the	O	817-820
miR21	B	821-826
endothelial	O	827-838
-	O	838-839
specific	O	839-847
knockout	O	848-856
mice	O	857-861
.	O	861-862

Furthermore	O	863-874
,	O	874-875
the	O	876-879
miR21	B	880-885
deletion	O	886-894
in	O	895-897
ECs	O	898-901
induced	O	902-909
down	O	910-914
-	O	914-915
regulation	O	915-925
of	O	926-928
collagen	O	929-937
I	O	938-939
,	O	939-940
collagen	O	941-949
III	O	950-953
and	O	954-957
elastin	O	958-965
mRNA	O	966-970
and	O	971-974
proteins	O	975-983
,	O	983-984
as	O	985-987
well	O	988-992
as	O	993-995
up	O	996-998
-	O	998-999
regulation	O	999-1009
of	O	1010-1012
Smad7	O	1013-1018
and	O	1019-1022
down	O	1023-1027
-	O	1027-1028
regulation	O	1028-1038
of	O	1039-1041
Smad2	O	1042-1047
/	O	1047-1048
5	O	1048-1049
in	O	1050-1052
the	O	1053-1056
aorta	O	1057-1062
of	O	1063-1065
miR21	B	1066-1071
endothelial	O	1072-1083
-	O	1083-1084
specific	O	1084-1092
knockout	O	1093-1101
mice	O	1102-1106
.	O	1106-1107

CTGF	O	1108-1112
and	O	1113-1116
downstream	O	1117-1127
MMP	O	1128-1131
/	O	1131-1132
TIMP	O	1132-1136
changes	O	1137-1144
were	O	1145-1149
also	O	1150-1154
identified	O	1155-1165
to	O	1166-1168
mediate	O	1169-1176
vascular	O	1177-1185
remodeling	O	1186-1196
.	O	1196-1197

The	O	1198-1201
results	O	1202-1209
showed	O	1210-1216
that	O	1217-1221
miR21	B	1222-1227
is	O	1228-1230
identified	O	1231-1241
as	O	1242-1244
a	O	1245-1246
critical	O	1247-1255
molecule	O	1256-1264
to	O	1265-1267
modulate	O	1268-1276
vascular	O	1277-1285
remodeling	O	1286-1296
,	O	1296-1297
which	O	1298-1303
will	O	1304-1308
help	O	1309-1313
to	O	1314-1316
understand	O	1317-1327
the	O	1328-1331
role	O	1332-1336
of	O	1337-1339
miR21	B	1340-1345
in	O	1346-1348
vascular	O	1349-1357
biology	O	1358-1365
and	O	1366-1369
the	O	1370-1373
pathogenesis	O	1374-1386
of	O	1387-1389
vascular	O	1390-1398
diseases	O	1399-1407
.	O	1407-1408

Maternal	O	0-8
asthma	O	9-15
and	O	16-19
microRNA	O	20-28
regulation	O	29-39
of	O	40-42
soluble	O	43-50
HLA	O	51-54
-	O	54-55
G	O	55-56
in	O	57-59
the	O	60-63
airway	O	64-70
.	O	70-71

BACKGROUND	O	72-82
:	O	82-83
We	O	84-86
previously	O	87-97
reported	O	98-106
an	O	107-109
interaction	O	110-121
between	O	122-129
maternal	O	130-138
asthma	O	139-145
and	O	146-149
the	O	150-153
child	O	154-159
'	O	159-160
s	O	160-161
HLA	O	162-165
-	O	165-166
G	O	166-167
genotype	O	168-176
on	O	177-179
the	O	180-183
child	O	184-189
'	O	189-190
s	O	190-191
subsequent	O	192-202
risk	O	203-207
for	O	208-211
asthma	O	212-218
.	O	218-219

The	O	220-223
implicated	O	224-234
single	O	235-241
nucleotide	O	242-252
polymorphism	O	253-265
at	O	266-268
+	O	269-270
3142	O	270-274
disrupted	O	275-284
a	O	285-286
target	O	287-293
site	O	294-298
for	O	299-302
the	O	303-306
microRNA	O	307-315
(	B	316-317
miR	I	317-320
)	I	320-321
-	I	321-322
152	I	322-325
family	O	326-332
.	O	332-333

We	O	334-336
hypothesized	O	337-349
that	O	350-354
the	O	355-358
interaction	O	359-370
effect	O	371-377
might	O	378-383
be	O	384-386
mediated	O	387-395
by	O	396-398
these	O	399-404
miRs	O	405-409
.	O	409-410

OBJECTIVE	O	411-420
:	O	420-421
The	O	422-425
objective	O	426-435
of	O	436-438
this	O	439-443
study	O	444-449
was	O	450-453
to	O	454-456
test	O	457-461
this	O	462-466
hypothesis	O	467-477
in	O	478-480
adults	O	481-487
with	O	488-492
asthma	O	493-499
who	O	500-503
are	O	504-507
a	O	508-509
subset	O	510-516
of	O	517-519
the	O	520-523
same	O	524-528
subjects	O	529-537
who	O	538-541
participated	O	542-554
in	O	555-557
our	O	558-561
earlier	O	562-569
family	O	570-576
-	O	576-577
based	O	577-582
studies	O	583-590
.	O	590-591

METHODS	O	592-599
:	O	599-600
We	O	601-603
measured	O	604-612
soluble	O	613-620
HLA	O	621-624
-	O	624-625
G	O	625-626
(	O	627-628
sHLA	O	628-632
-	O	632-633
G	O	633-634
)	O	634-635
concentrations	O	636-650
in	O	651-653
bronchoalveolar	O	654-669
lavage	O	670-676
fluid	O	677-682
(	O	683-684
n	O	684-685
=	O	686-687
36	O	688-690
)	O	690-691
and	O	692-695
plasma	O	696-702
(	O	703-704
n	O	704-705
=	O	706-707
57	O	708-710
)	O	710-711
from	O	712-716
adult	O	717-722
asthmatic	O	723-732
subjects	O	733-741
with	O	742-746
and	O	747-750
without	O	751-758
a	O	759-760
mother	O	761-767
with	O	768-772
asthma	O	773-779
,	O	779-780
and	O	781-784
HLA	O	785-788
-	O	788-789
G	O	789-790
and	O	791-794
miR	B	795-798
-	I	798-799
152	I	799-802
family	O	803-809
(	O	810-811
miR	B	811-814
-	I	814-815
148a	I	815-819
,	O	819-820
miR	B	821-824
-	I	824-825
148b	I	825-829
,	O	829-830
and	O	831-834
miR	B	835-838
-	I	838-839
152	I	839-842
)	O	842-843
transcript	O	844-854
levels	O	855-861
in	O	862-864
airway	O	865-871
epithelial	O	872-882
cells	O	883-888
from	O	889-893
the	O	894-897
same	O	898-902
subjects	O	903-911
.	O	911-912

RESULTS	O	913-920
:	O	920-921
miR	B	922-925
-	I	925-926
148b	I	926-930
levels	O	931-937
were	O	938-942
significantly	O	943-956
increased	O	957-966
in	O	967-969
airway	O	970-976
epithelial	O	977-987
cells	O	988-993
from	O	994-998
asthmatic	O	999-1008
subjects	O	1009-1017
with	O	1018-1022
an	O	1023-1025
asthmatic	O	1026-1035
mother	O	1036-1042
compared	O	1043-1051
with	O	1052-1056
those	O	1057-1062
seen	O	1063-1067
in	O	1068-1070
asthmatic	O	1071-1080
subjects	O	1081-1089
without	O	1090-1097
an	O	1098-1100
asthmatic	O	1101-1110
mother	O	1111-1117
,	O	1117-1118
and	O	1119-1122
+	O	1123-1124
3142	O	1124-1128
genotypes	O	1129-1138
were	O	1139-1143
associated	O	1144-1154
with	O	1155-1159
sHLA	O	1160-1164
-	O	1164-1165
G	O	1165-1166
concentrations	O	1167-1181
in	O	1182-1184
bronchoalveolar	O	1185-1200
lavage	O	1201-1207
fluid	O	1208-1213
among	O	1214-1219
asthmatic	O	1220-1229
subjects	O	1230-1238
with	O	1239-1243
an	O	1244-1246
asthmatic	O	1247-1256
mother	O	1257-1263
but	O	1264-1267
not	O	1268-1271
among	O	1272-1277
those	O	1278-1283
with	O	1284-1288
a	O	1289-1290
nonasthmatic	O	1291-1303
mother	O	1304-1310
.	O	1310-1311

Neither	O	1312-1319
effect	O	1320-1326
was	O	1327-1330
observed	O	1331-1339
in	O	1340-1342
the	O	1343-1346
plasma	O	1347-1353
(	O	1354-1355
sHLA	O	1355-1359
-	O	1359-1360
G	O	1360-1361
)	O	1361-1362
or	O	1363-1365
white	O	1366-1371
blood	O	1372-1377
cells	O	1378-1383
(	O	1384-1385
miRNA	O	1385-1390
)	O	1390-1391
.	O	1391-1392

CONCLUSION	O	1393-1403
:	O	1403-1404
These	O	1405-1410
combined	O	1411-1419
results	O	1420-1427
are	O	1428-1431
consistent	O	1432-1442
with	O	1443-1447
+	O	1448-1449
3142	O	1449-1453
allele	O	1454-1460
-	O	1460-1461
specific	O	1461-1469
targeting	O	1470-1479
of	O	1480-1482
HLA	O	1483-1486
-	O	1486-1487
G	O	1487-1488
by	O	1489-1491
the	O	1492-1495
miR	B	1496-1499
-	I	1499-1500
152	I	1500-1503
family	O	1504-1510
and	O	1511-1514
support	O	1515-1522
our	O	1523-1526
hypothesis	O	1527-1537
that	O	1538-1542
miRNA	O	1543-1548
regulation	O	1549-1559
of	O	1560-1562
sHLA	O	1563-1567
-	O	1567-1568
G	O	1568-1569
in	O	1570-1572
the	O	1573-1576
airway	O	1577-1583
is	O	1584-1586
influenced	O	1587-1597
by	O	1598-1600
both	O	1601-1605
the	O	1606-1609
asthma	O	1610-1616
status	O	1617-1623
of	O	1624-1626
the	O	1627-1630
subject	O	1631-1638
'	O	1638-1639
s	O	1639-1640
mother	O	1641-1647
and	O	1648-1651
the	O	1652-1655
subject	O	1656-1663
'	O	1663-1664
s	O	1664-1665
genotype	O	1666-1674
.	O	1674-1675

Moreover	O	1676-1684
,	O	1684-1685
we	O	1686-1688
demonstrate	O	1689-1700
that	O	1701-1705
the	O	1706-1709
effects	O	1710-1717
of	O	1718-1720
maternal	O	1721-1729
asthma	O	1730-1736
on	O	1737-1739
the	O	1740-1743
gene	O	1744-1748
regulatory	O	1749-1759
landscape	O	1760-1769
in	O	1770-1772
the	O	1773-1776
airways	O	1777-1784
of	O	1785-1787
the	O	1788-1791
mother	O	1792-1798
'	O	1798-1799
s	O	1799-1800
children	O	1801-1809
persist	O	1810-1817
into	O	1818-1822
adulthood	O	1823-1832
.	O	1832-1833

MicroRNA	B	0-8
-	I	8-9
214	I	9-12
suppresses	O	13-23
osteogenic	O	24-34
differentiation	O	35-50
of	O	51-53
C2C12	O	54-59
myoblast	O	60-68
cells	O	69-74
by	O	75-77
targeting	O	78-87
Osterix	O	88-95
.	O	95-96

Osterix	O	97-104
(	O	105-106
Osx	O	106-109
)	O	109-110
is	O	111-113
an	O	114-116
osteoblast	O	117-127
-	O	127-128
specific	O	128-136
transcription	O	137-150
factor	O	151-157
that	O	158-162
is	O	163-165
essential	O	166-175
for	O	176-179
osteoblast	O	180-190
differentiation	O	191-206
and	O	207-210
bone	O	211-215
formation	O	216-225
.	O	225-226

Osx	O	227-230
-	O	230-231
null	O	231-235
mice	O	236-240
,	O	240-241
which	O	242-247
exhibit	O	248-255
a	O	256-257
complete	O	258-266
absence	O	267-274
of	O	275-277
bone	O	278-282
formation	O	283-292
and	O	293-296
arrested	O	297-305
osteoblast	O	306-316
differentiation	O	317-332
,	O	332-333
die	O	334-337
immediately	O	338-349
after	O	350-355
birth	O	356-361
.	O	361-362

However	O	363-370
,	O	370-371
our	O	372-375
understanding	O	376-389
of	O	390-392
the	O	393-396
regulatory	O	397-407
mechanism	O	408-417
of	O	418-420
Osx	O	421-424
expression	O	425-435
remains	O	436-443
poor	O	444-448
.	O	448-449

MicroRNAs	O	450-459
(	O	460-461
miRNAs	O	461-467
)	O	467-468
are	O	469-472
a	O	473-474
class	O	475-480
of	O	481-483
small	O	484-489
non	O	490-493
-	O	493-494
coding	O	494-500
RNAs	O	501-505
that	O	506-510
play	O	511-515
pivotal	O	516-523
roles	O	524-529
in	O	530-532
diverse	O	533-540
biological	O	541-551
processes	O	552-561
,	O	561-562
including	O	563-572
the	O	573-576
development	O	577-588
,	O	588-589
differentiation	O	590-605
,	O	605-606
proliferation	O	607-620
,	O	620-621
survival	O	622-630
,	O	630-631
and	O	632-635
oncogenesis	O	636-647
of	O	648-650
cells	O	651-656
and	O	657-660
organisms	O	661-670
.	O	670-671

In	O	672-674
this	O	675-679
study	O	680-685
,	O	685-686
we	O	687-689
aimed	O	690-695
to	O	696-698
investigate	O	699-710
the	O	711-714
impact	O	715-721
of	O	722-724
miRNAs	O	725-731
on	O	732-734
Osx	O	735-738
expression	O	739-749
.	O	749-750

Bioinformatic	O	751-764
analyses	O	765-773
predicted	O	774-783
that	O	784-788
miR	B	789-792
-	I	792-793
214	I	793-796
would	O	797-802
be	O	803-805
a	O	806-807
potential	O	808-817
regulator	O	818-827
of	O	828-830
Osx	O	831-834
.	O	834-835

The	O	836-839
direct	O	840-846
binding	O	847-854
of	O	855-857
miR	B	858-861
-	I	861-862
214	I	862-865
to	O	866-868
the	O	869-872
Osx	O	873-876
3	O	877-878
'	O	878-879
untranslated	O	880-892
region	O	893-899
(	O	900-901
3	O	901-902
'	O	902-903
UTR	O	904-907
)	O	907-908
was	O	909-912
demonstrated	O	913-925
by	O	926-928
a	O	929-930
luciferase	O	931-941
reporter	O	942-950
assay	O	951-956
using	O	957-962
a	O	963-964
construct	O	965-974
containing	O	975-985
the	O	986-989
Osx	O	990-993
3	O	994-995
'	O	995-996
UTR	O	997-1000
.	O	1000-1001

Deletion	O	1002-1010
mutant	O	1011-1017
construction	O	1018-1030
revealed	O	1031-1039
that	O	1040-1044
the	O	1045-1048
Osx	O	1049-1052
3	O	1053-1054
'	O	1054-1055
UTR	O	1056-1059
contained	O	1060-1069
two	O	1070-1073
miR	B	1074-1077
-	I	1077-1078
214	I	1078-1081
binding	O	1082-1089
sites	O	1090-1095
.	O	1095-1096

MiR	B	1097-1100
-	I	1100-1101
214	I	1101-1104
expression	O	1105-1115
was	O	1116-1119
inversely	O	1120-1129
correlated	O	1130-1140
with	O	1141-1145
Osx	O	1146-1149
expression	O	1150-1160
in	O	1161-1163
Saos	O	1164-1168
-	O	1168-1169
2	O	1169-1170
and	O	1171-1174
U2OS	O	1175-1179
cells	O	1180-1185
.	O	1185-1186

The	O	1187-1190
forced	O	1191-1197
expression	O	1198-1208
of	O	1209-1211
miR	B	1212-1215
-	I	1215-1216
214	I	1216-1219
in	O	1220-1222
Saos	O	1223-1227
-	O	1227-1228
2	O	1228-1229
cells	O	1230-1235
led	O	1236-1239
to	O	1240-1242
a	O	1243-1244
reduction	O	1245-1254
in	O	1255-1257
the	O	1258-1261
level	O	1262-1267
of	O	1268-1270
Osx	O	1271-1274
protein	O	1275-1282
.	O	1282-1283

Moreover	O	1284-1292
,	O	1292-1293
the	O	1294-1297
role	O	1298-1302
of	O	1303-1305
miR	B	1306-1309
-	I	1309-1310
214	I	1310-1313
in	O	1314-1316
the	O	1317-1320
osteogenic	O	1321-1331
differentiation	O	1332-1347
of	O	1348-1350
C2C12	O	1351-1356
cells	O	1357-1362
was	O	1363-1366
investigated	O	1367-1379
.	O	1379-1380

We	O	1381-1383
found	O	1384-1389
that	O	1390-1394
the	O	1395-1398
osteogenic	O	1399-1409
differentiation	O	1410-1425
of	O	1426-1428
C2C12	O	1429-1434
cells	O	1435-1440
was	O	1441-1444
enhanced	O	1445-1453
by	O	1454-1456
the	O	1457-1460
downregulation	O	1461-1475
of	O	1476-1478
miR	B	1479-1482
-	I	1482-1483
214	I	1483-1486
expression	O	1487-1497
,	O	1497-1498
as	O	1499-1501
measured	O	1502-1510
by	O	1511-1513
increased	O	1514-1523
alkaline	O	1524-1532
phosphatase	O	1533-1544
activity	O	1545-1553
and	O	1554-1557
matrix	O	1558-1564
mineralization	O	1565-1579
.	O	1579-1580

Taken	O	1581-1586
together	O	1587-1595
,	O	1595-1596
these	O	1597-1602
results	O	1603-1610
indicate	O	1611-1619
that	O	1620-1624
miR	B	1625-1628
-	I	1628-1629
214	I	1629-1632
is	O	1633-1635
a	O	1636-1637
novel	O	1638-1643
regulator	O	1644-1653
of	O	1654-1656
Osx	O	1657-1660
,	O	1660-1661
and	O	1662-1665
that	O	1666-1670
it	O	1671-1673
plays	O	1674-1679
an	O	1680-1682
important	O	1683-1692
role	O	1693-1697
in	O	1698-1700
the	O	1701-1704
osteogenic	O	1705-1715
differentiation	O	1716-1731
of	O	1732-1734
C2C12	O	1735-1740
cells	O	1741-1746
as	O	1747-1749
a	O	1750-1751
suppressor	O	1752-1762
.	O	1762-1763

The	O	0-3
induction	O	4-13
of	O	14-16
miR	B	17-20
-	I	20-21
96	I	21-23
by	O	24-26
mitochondrial	O	27-40
dysfunction	O	41-52
causes	O	53-59
impaired	O	60-68
glycogen	O	69-77
synthesis	O	78-87
through	O	88-95
translational	O	96-109
repression	O	110-120
of	O	121-123
IRS	O	124-127
-	O	127-128
1	O	128-129
in	O	130-132
SK	O	133-135
-	O	135-136
Hep1	O	136-140
cells	O	141-146
.	O	146-147

MicroRNA	O	148-156
(	O	157-158
miRNA	O	158-163
)	O	163-164
is	O	165-167
a	O	168-169
class	O	170-175
of	O	176-178
endogenous	O	179-189
small	O	190-195
noncoding	O	196-205
RNA	O	206-209
that	O	210-214
negatively	O	215-225
regulates	O	226-235
gene	O	236-240
expression	O	241-251
at	O	252-254
the	O	255-258
post	O	259-263
-	O	263-264
transcriptional	O	264-279
level	O	280-285
and	O	286-289
plays	O	290-295
an	O	296-298
important	O	299-308
role	O	309-313
in	O	314-316
the	O	317-320
pathogenesis	O	321-333
of	O	334-336
various	O	337-344
diseases	O	345-353
.	O	353-354

However	O	355-362
,	O	362-363
the	O	364-367
identity	O	368-376
and	O	377-380
role	O	381-385
of	O	386-388
miRNAs	O	389-395
involved	O	396-404
in	O	405-407
the	O	408-411
development	O	412-423
of	O	424-426
insulin	O	427-434
resistance	O	435-445
resulting	O	446-455
from	O	456-460
mitochondrial	O	461-474
dysfunction	O	475-486
are	O	487-490
largely	O	491-498
unknown	O	499-506
.	O	506-507

In	O	508-510
this	O	511-515
study	O	516-521
,	O	521-522
mitochondrial	O	523-536
dysfunction	O	537-548
by	O	549-551
genetic	O	552-559
or	O	560-562
metabolic	O	563-572
inhibition	O	573-583
induced	O	584-591
an	O	592-594
impairment	O	595-605
of	O	606-608
insulin	O	609-616
signaling	O	617-626
in	O	627-629
SK	O	630-632
-	O	632-633
Hep1	O	633-637
cells	O	638-643
via	O	644-647
a	O	648-649
reduction	O	650-659
in	O	660-662
the	O	663-666
expression	O	667-677
of	O	678-680
IRS	O	681-684
-	O	684-685
1	O	685-686
protein	O	687-694
.	O	694-695

Significant	O	696-707
up	O	708-710
-	O	710-711
regulation	O	711-721
of	O	722-724
miR	B	725-728
-	I	728-729
96	I	729-731
,	O	731-732
which	O	733-738
was	O	739-742
presumed	O	743-751
to	O	752-754
target	O	755-761
IRS	O	762-765
-	O	765-766
1	O	766-767
3	O	768-769
'	O	769-770
UTR	O	770-773
,	O	773-774
was	O	775-778
found	O	779-784
in	O	785-787
SK	O	788-790
-	O	790-791
Hep1	O	791-795
cells	O	796-801
with	O	802-806
mitochondrial	O	807-820
dysfunction	O	821-832
.	O	832-833

Using	O	834-839
reporter	O	840-848
gene	O	849-853
assay	O	854-859
we	O	860-862
confirmed	O	863-872
that	O	873-877
miR	B	878-881
-	I	881-882
96	I	882-884
authentically	O	885-898
targeted	O	899-907
IRS	O	908-911
-	O	911-912
1	O	912-913
3	O	914-915
'	O	915-916
UTR	O	916-919
.	O	919-920

Furthermore	O	921-932
,	O	932-933
the	O	934-937
ectopic	O	938-945
expression	O	946-956
of	O	957-959
miR	B	960-963
-	I	963-964
96	I	964-966
caused	O	967-973
a	O	974-975
substantial	O	976-987
decrease	O	988-996
in	O	997-999
IRS	O	1000-1003
-	O	1003-1004
1	O	1004-1005
protein	O	1006-1013
expression	O	1014-1024
,	O	1024-1025
and	O	1026-1029
a	O	1030-1031
consequent	O	1032-1042
impairment	O	1043-1053
in	O	1054-1056
insulin	O	1057-1064
signaling	O	1065-1074
.	O	1074-1075

These	O	1076-1081
findings	O	1082-1090
suggest	O	1091-1098
that	O	1099-1103
the	O	1104-1107
up	O	1108-1110
-	O	1110-1111
regulation	O	1111-1121
of	O	1122-1124
miR	B	1125-1128
-	I	1128-1129
96	I	1129-1131
by	O	1132-1134
mitochondrial	O	1135-1148
dysfunction	O	1149-1160
contributes	O	1161-1172
to	O	1173-1175
the	O	1176-1179
development	O	1180-1191
of	O	1192-1194
insulin	O	1195-1202
resistance	O	1203-1213
by	O	1214-1216
targeting	O	1217-1226
IRS	O	1227-1230
-	O	1230-1231
1	O	1231-1232
in	O	1233-1235
SK	O	1236-1238
-	O	1238-1239
Hep1	O	1239-1243
cells	O	1244-1249
.	O	1249-1250

Differential	O	0-12
regulation	O	13-23
of	O	24-26
microRNA	B	27-35
-	I	35-36
146a	I	36-40
and	O	41-44
microRNA	B	45-53
-	I	53-54
146b	I	54-58
-	I	58-59
5p	I	59-61
in	O	62-64
human	O	65-70
retinal	O	71-78
pigment	O	79-86
epithelial	O	87-97
cells	O	98-103
by	O	104-106
interleukin	O	107-118
-	O	118-119
1beta	O	119-124
,	O	124-125
tumor	O	126-131
necrosis	O	132-140
factor	O	141-147
-	O	147-148
alpha	O	148-153
,	O	153-154
and	O	155-158
interferon	O	159-169
-	O	169-170
gamma	O	170-175
.	O	175-176

PURPOSE	O	177-184
:	O	184-185
The	O	186-189
inflammatory	O	190-202
response	O	203-211
of	O	212-214
the	O	215-218
retinal	O	219-226
pigment	O	227-234
epithelium	O	235-245
(	O	246-247
RPE	O	247-250
)	O	250-251
is	O	252-254
implicated	O	255-265
in	O	266-268
the	O	269-272
pathogenesis	O	273-285
of	O	286-288
age	O	289-292
-	O	292-293
related	O	293-300
macular	O	301-308
degeneration	O	309-321
.	O	321-322

The	O	323-326
microRNAs	O	327-336
miR	B	337-340
-	I	340-341
146a	I	341-345
and	O	346-349
miR	B	350-353
-	I	353-354
146b	I	354-358
-	I	358-359
5p	I	359-361
can	O	362-365
regulate	O	366-374
the	O	375-378
inflammatory	O	379-391
process	O	392-399
by	O	400-402
attenuating	O	403-414
cytokine	O	415-423
signaling	O	424-433
via	O	434-437
the	O	438-441
nuclear	O	442-449
factor	O	450-456
-	O	456-457
kappaB	O	457-463
pathway	O	464-471
.	O	471-472

The	O	473-476
aim	O	477-480
of	O	481-483
the	O	484-487
present	O	488-495
study	O	496-501
is	O	502-504
to	O	505-507
investigate	O	508-519
the	O	520-523
expression	O	524-534
of	O	535-537
miR	B	538-541
-	I	541-542
146a	I	542-546
and	O	547-550
miR	B	551-554
-	I	554-555
146b	I	555-559
-	I	559-560
5p	I	560-562
in	O	563-565
human	O	566-571
RPE	O	572-575
cells	O	576-581
and	O	582-585
their	O	586-591
response	O	592-600
to	O	601-603
proinflammatory	O	604-619
cytokines	O	620-629
.	O	629-630

METHODS	O	631-638
:	O	638-639
Confluent	O	640-649
cultures	O	650-658
of	O	659-661
RPE	O	662-665
cells	O	666-671
established	O	672-683
from	O	684-688
adult	O	689-694
human	O	695-700
donor	O	701-706
eyes	O	707-711
were	O	712-716
treated	O	717-724
with	O	725-729
the	O	730-733
proinflammatory	O	734-749
cytokines	O	750-759
interferon	O	760-770
(	O	771-772
IFN	O	772-775
)	O	775-776
-	O	776-777
gamma	O	777-782
,	O	782-783
tumor	O	784-789
necrosis	O	790-798
factor	O	799-805
(	O	806-807
TNF	O	807-810
)	O	810-811
-	O	811-812
alpha	O	812-817
,	O	817-818
and	O	819-822
interleukin	O	823-834
(	O	835-836
IL	O	836-838
)	O	838-839
-	O	839-840
1beta	O	840-845
.	O	845-846

The	O	847-850
expression	O	851-861
of	O	862-864
microRNAs	O	865-874
was	O	875-878
analyzed	O	879-887
by	O	888-890
real	O	891-895
-	O	895-896
time	O	896-900
PCR	O	901-904
using	O	905-910
total	O	911-916
RNA	O	917-920
fraction	O	921-929
.	O	929-930

The	O	931-934
retinal	O	935-942
pigment	O	943-950
epithelial	O	951-961
cell	O	962-966
line	O	967-971
ARPE	O	972-976
-	O	976-977
19	O	977-979
was	O	980-983
employed	O	984-992
to	O	993-995
analyze	O	996-1003
the	O	1004-1007
promoter	O	1008-1016
activity	O	1017-1025
of	O	1026-1028
the	O	1029-1032
genes	O	1033-1038
encoding	O	1039-1047
miR	B	1048-1051
-	I	1051-1052
146a	I	1052-1056
and	O	1057-1060
miR	B	1061-1064
-	I	1064-1065
146b	I	1065-1069
-	I	1069-1070
5p	I	1070-1072
.	O	1072-1073

STAT1	O	1074-1079
-	O	1079-1080
binding	O	1080-1087
activity	O	1088-1096
of	O	1097-1099
oligonucleotides	O	1100-1116
was	O	1117-1120
analyzed	O	1121-1129
by	O	1130-1132
electrophoretic	O	1133-1148
mobility	O	1149-1157
shift	O	1158-1163
assay	O	1164-1169
.	O	1169-1170

ARPE	O	1171-1175
-	O	1175-1176
19	O	1176-1178
cells	O	1179-1184
were	O	1185-1189
transiently	O	1190-1201
transfected	O	1202-1213
with	O	1214-1218
miR	B	1219-1222
-	I	1222-1223
146a	I	1223-1227
and	O	1228-1231
miR	B	1232-1235
-	I	1235-1236
146b	I	1236-1240
-	I	1240-1241
5p	I	1241-1243
mimics	O	1244-1250
for	O	1251-1254
the	O	1255-1258
analysis	O	1259-1267
of	O	1268-1270
IRAK1	O	1271-1276
expression	O	1277-1287
by	O	1288-1290
western	O	1291-1298
immunoblotting	O	1299-1313
.	O	1313-1314

RESULTS	O	1315-1322
:	O	1322-1323
Real	O	1324-1328
-	O	1328-1329
time	O	1329-1333
PCR	O	1334-1337
analysis	O	1338-1346
showed	O	1347-1353
that	O	1354-1358
miR	B	1359-1362
-	I	1362-1363
146a	I	1363-1367
and	O	1368-1371
146b	B	1372-1376
-	I	1376-1377
5p	I	1377-1379
are	O	1380-1383
expressed	O	1384-1393
in	O	1394-1396
RPE	O	1397-1400
cells	O	1401-1406
.	O	1406-1407

The	O	1408-1411
cells	O	1412-1417
responded	O	1418-1427
to	O	1428-1430
proinflammatory	O	1431-1446
cytokines	O	1447-1456
(	O	1457-1458
IFN	O	1458-1461
-	O	1461-1462
gamma	O	1462-1467
+	O	1468-1469
TNF	O	1470-1473
-	O	1473-1474
alpha	O	1474-1479
+	O	1480-1481
IL	O	1482-1484
-	O	1484-1485
1beta	O	1485-1490
)	O	1490-1491
by	O	1492-1494
highly	O	1495-1501
increasing	O	1502-1512
the	O	1513-1516
expression	O	1517-1527
of	O	1528-1530
both	O	1531-1535
miR	B	1536-1539
-	I	1539-1540
146a	I	1540-1544
and	O	1545-1548
miR	B	1549-1552
-	I	1552-1553
146b	I	1553-1557
-	I	1557-1558
5p	I	1558-1560
.	O	1560-1561

This	O	1562-1566
was	O	1567-1570
associated	O	1571-1581
with	O	1582-1586
an	O	1587-1589
increase	O	1590-1598
in	O	1599-1601
the	O	1602-1605
expression	O	1606-1616
of	O	1617-1619
transcripts	O	1620-1631
for	O	1632-1635
CCL2	O	1636-1640
,	O	1640-1641
CCL5	O	1642-1646
,	O	1646-1647
CXCL9	O	1648-1653
,	O	1653-1654
CXCL10	O	1655-1661
,	O	1661-1662
and	O	1663-1666
IL	O	1667-1669
-	O	1669-1670
6	O	1670-1671
,	O	1671-1672
and	O	1673-1676
a	O	1677-1678
decrease	O	1679-1687
in	O	1688-1690
that	O	1691-1695
for	O	1696-1699
HMOX1	O	1700-1705
.	O	1705-1706

The	O	1707-1710
miR	B	1711-1714
-	I	1714-1715
146a	I	1715-1719
induction	O	1720-1729
was	O	1730-1733
more	O	1734-1738
dependent	O	1739-1748
on	O	1749-1751
IL	O	1752-1754
-	O	1754-1755
1beta	O	1755-1760
,	O	1760-1761
since	O	1762-1767
its	O	1768-1771
omission	O	1772-1780
from	O	1781-1785
the	O	1786-1789
cytokine	O	1790-1798
mix	O	1799-1802
resulted	O	1803-1811
in	O	1812-1814
a	O	1815-1816
greatly	O	1817-1824
reduced	O	1825-1832
response	O	1833-1841
.	O	1841-1842

Similarly	O	1843-1852
,	O	1852-1853
the	O	1854-1857
induction	O	1858-1867
of	O	1868-1870
miR	B	1871-1874
-	I	1874-1875
146b	I	1875-1879
-	I	1879-1880
5p	I	1880-1882
was	O	1883-1886
more	O	1887-1891
dependent	O	1892-1901
on	O	1902-1904
IFN	O	1905-1908
-	O	1908-1909
gamma	O	1909-1914
,	O	1914-1915
since	O	1916-1921
its	O	1922-1925
omission	O	1926-1934
from	O	1935-1939
the	O	1940-1943
cytokine	O	1944-1952
mix	O	1953-1956
minimized	O	1957-1966
the	O	1967-1970
effect	O	1971-1977
.	O	1977-1978

In	O	1979-1981
addition	O	1982-1990
,	O	1990-1991
the	O	1992-1995
increase	O	1996-2004
in	O	2005-2007
MIR146B	B	2008-2015
promoter	O	2016-2024
activity	O	2025-2033
by	O	2034-2036
the	O	2037-2040
cytokine	O	2041-2049
mix	O	2050-2053
was	O	2054-2057
effectively	O	2058-2069
blocked	O	2070-2077
by	O	2078-2080
JAK	O	2081-2084
inhibitor	O	2085-2094
1	O	2095-2096
,	O	2096-2097
a	O	2098-2099
known	O	2100-2105
inhibitor	O	2106-2115
of	O	2116-2118
the	O	2119-2122
JAK	O	2123-2126
/	O	2126-2127
STAT	O	2127-2131
signaling	O	2132-2141
pathway	O	2142-2149
.	O	2149-2150

The	O	2151-2154
expression	O	2155-2165
of	O	2166-2168
IRAK1	O	2169-2174
protein	O	2175-2182
was	O	2183-2186
decreased	O	2187-2196
when	O	2197-2201
ARPE	O	2202-2206
-	O	2206-2207
19	O	2207-2209
cells	O	2210-2215
were	O	2216-2220
transiently	O	2221-2232
transfected	O	2233-2244
with	O	2245-2249
either	O	2250-2256
miR	B	2257-2260
-	I	2260-2261
146a	I	2261-2265
mimic	O	2266-2271
or	O	2272-2274
miR	B	2275-2278
-	I	2278-2279
146b	I	2279-2283
-	I	2283-2284
5p	I	2284-2286
mimic	O	2287-2292
.	O	2292-2293

CONCLUSIONS	O	2294-2305
:	O	2305-2306
Our	O	2307-2310
results	O	2311-2318
clearly	O	2319-2326
show	O	2327-2331
that	O	2332-2336
both	O	2337-2341
miR	B	2342-2345
-	I	2345-2346
146a	I	2346-2350
and	O	2351-2354
miR	B	2355-2358
-	I	2358-2359
146b	I	2359-2363
-	I	2363-2364
5p	I	2364-2366
are	O	2367-2370
expressed	O	2371-2380
in	O	2381-2383
human	O	2384-2389
RPE	O	2390-2393
cells	O	2394-2399
in	O	2400-2402
culture	O	2403-2410
and	O	2411-2414
their	O	2415-2420
expression	O	2421-2431
is	O	2432-2434
highly	O	2435-2441
induced	O	2442-2449
by	O	2450-2452
proinflammatory	O	2453-2468
cytokines	O	2469-2478
(	O	2479-2480
IFN	O	2480-2483
-	O	2483-2484
gamma	O	2484-2489
+	O	2490-2491
TNF	O	2492-2495
-	O	2495-2496
alpha	O	2496-2501
+	O	2502-2503
IL	O	2504-2506
-	O	2506-2507
1beta	O	2507-2512
)	O	2512-2513
.	O	2513-2514

The	O	2515-2518
induction	O	2519-2528
of	O	2529-2531
miR	B	2532-2535
-	I	2535-2536
146a	I	2536-2540
showed	O	2541-2547
a	O	2548-2549
dependency	O	2550-2560
on	O	2561-2563
IL	O	2564-2566
-	O	2566-2567
1beta	O	2567-2572
,	O	2572-2573
while	O	2574-2579
that	O	2580-2584
of	O	2585-2587
miR	B	2588-2591
-	I	2591-2592
146b	I	2592-2596
-	I	2596-2597
5p	I	2597-2599
on	O	2600-2602
IFN	O	2603-2606
-	O	2606-2607
gamma	O	2607-2612
.	O	2612-2613

Our	O	2614-2617
results	O	2618-2625
show	O	2626-2630
for	O	2631-2634
the	O	2635-2638
first	O	2639-2644
time	O	2645-2649
that	O	2650-2654
miR	B	2655-2658
-	I	2658-2659
146b	I	2659-2663
-	I	2663-2664
5p	I	2664-2666
expression	O	2667-2677
is	O	2678-2680
regulated	O	2681-2690
by	O	2691-2693
IFN	O	2694-2697
-	O	2697-2698
gamma	O	2698-2703
,	O	2703-2704
potentially	O	2705-2716
via	O	2717-2720
the	O	2721-2724
JAK	O	2725-2728
/	O	2728-2729
STAT	O	2729-2733
pathway	O	2734-2741
.	O	2741-2742

These	O	2743-2748
two	O	2749-2752
microRNAs	O	2753-2762
could	O	2763-2768
play	O	2769-2773
a	O	2774-2775
role	O	2776-2780
in	O	2781-2783
inflammatory	O	2784-2796
processes	O	2797-2806
underlying	O	2807-2817
age	O	2818-2821
-	O	2821-2822
related	O	2822-2829
macular	O	2830-2837
degeneration	O	2838-2850
or	O	2851-2853
other	O	2854-2859
retinal	O	2860-2867
degenerative	O	2868-2880
diseases	O	2881-2889
through	O	2890-2897
their	O	2898-2903
ability	O	2904-2911
to	O	2912-2914
negatively	O	2915-2925
regulate	O	2926-2934
the	O	2935-2938
nuclear	O	2939-2946
factor	O	2947-2953
-	O	2953-2954
kappaB	O	2954-2960
pathway	O	2961-2968
by	O	2969-2971
targeting	O	2972-2981
the	O	2982-2985
expression	O	2986-2996
of	O	2997-2999
IRAK1	O	3000-3005
.	O	3005-3006

MicroRNA	B	0-8
-	I	8-9
106b	I	9-13
-	I	13-14
25	I	14-16
cluster	O	17-24
targets	O	25-32
beta	O	33-37
-	O	37-38
TRCP2	O	38-43
,	O	43-44
increases	O	45-54
the	O	55-58
expression	O	59-69
of	O	70-72
Snail	O	73-78
and	O	79-82
enhances	O	83-91
cell	O	92-96
migration	O	97-106
and	O	107-110
invasion	O	111-119
in	O	120-122
H1299	O	123-128
(	O	129-130
non	O	130-133
small	O	134-139
cell	O	140-144
lung	O	145-149
cancer	O	150-156
)	O	156-157
cells	O	158-163
.	O	163-164

Lung	O	165-169
cancer	O	170-176
causes	O	177-183
high	O	184-188
mortality	O	189-198
without	O	199-206
a	O	207-208
declining	O	209-218
trend	O	219-224
and	O	225-228
non	O	229-232
small	O	233-238
cell	O	239-243
lung	O	244-248
cancer	O	249-255
represents	O	256-266
85	O	267-269
%	O	269-270
of	O	271-273
all	O	274-277
pulmonary	O	278-287
carcinomas	O	288-298
.	O	298-299

MicroRNAs	O	300-309
(	O	310-311
miRNAs	O	311-317
)	O	317-318
serve	O	319-324
as	O	325-327
fine	O	328-332
regulators	O	333-343
of	O	344-346
proliferation	O	347-360
,	O	360-361
migration	O	362-371
,	O	371-372
invasion	O	373-381
/	O	381-382
metastasis	O	382-392
and	O	393-396
angiogenesis	O	397-409
of	O	410-412
normal	O	413-419
and	O	420-423
cancer	O	424-430
cells	O	431-436
.	O	436-437

Using	O	438-443
TargetScan6	O	444-455
.	O	455-456
2	O	456-457
,	O	457-458
we	O	459-461
predicted	O	462-471
that	O	472-476
the	O	477-480
ubiquitin	O	481-490
ligase	O	491-497
,	O	497-498
beta	O	499-503
-	O	503-504
TRCP2	O	504-509
,	O	509-510
could	O	511-516
be	O	517-519
a	O	520-521
target	O	522-528
for	O	529-532
two	O	533-536
of	O	537-539
the	O	540-543
constituent	O	544-555
miRNAs	O	556-562
of	O	563-565
the	O	566-569
miR	B	570-573
-	I	573-574
106b	I	574-578
-	I	578-579
25	I	579-581
cluster	O	582-589
(	O	590-591
miR	B	591-594
-	I	594-595
106b	I	595-599
and	O	600-603
miR	B	604-607
-	I	607-608
93	I	608-610
)	O	610-611
.	O	611-612

We	O	613-615
generated	O	616-625
a	O	626-627
stable	O	628-634
clone	O	635-640
of	O	641-643
miR	B	644-647
-	I	647-648
106b	I	648-652
-	I	652-653
25	I	653-655
cluster	O	656-663
(	O	664-665
CL	O	665-667
)	O	667-668
or	O	669-671
the	O	672-675
empty	O	676-681
vector	O	682-688
(	O	689-690
EV	O	690-692
)	O	692-693
in	O	694-696
H1299	O	697-702
(	O	703-704
non	O	704-707
small	O	708-713
cell	O	714-718
lung	O	719-723
cancer	O	724-730
)	O	730-731
cells	O	732-737
.	O	737-738

The	O	739-742
expression	O	743-753
of	O	754-756
beta	O	757-761
-	O	761-762
TRCP2	O	762-767
mRNA	O	768-772
was	O	773-776
significantly	O	777-790
lower	O	791-796
in	O	797-799
CL	O	800-802
than	O	803-807
that	O	808-812
in	O	813-815
EV	O	816-818
cells	O	819-824
.	O	824-825

Transient	O	826-835
expression	O	836-846
of	O	847-849
miR	B	850-853
-	I	853-854
93	I	854-856
but	O	857-860
not	O	861-864
antimiR	O	865-872
-	O	872-873
93	O	873-875
decreased	O	876-885
the	O	886-889
expression	O	890-900
of	O	901-903
beta	O	904-908
-	O	908-909
TRCP2	O	909-914
mRNA	O	915-919
in	O	920-922
H1299	O	923-928
cells	O	929-934
.	O	934-935

beta	O	936-940
-	O	940-941
TRCP2	O	941-946
-	O	946-947
3	O	947-948
'	O	948-949
UTR	O	949-952
reporter	O	953-961
assay	O	962-967
revealed	O	968-976
that	O	977-981
its	O	982-985
activity	O	986-994
in	O	995-997
CL	O	998-1000
cells	O	1001-1006
was	O	1007-1010
only	O	1011-1015
60	O	1016-1018
%	O	1018-1019
of	O	1020-1022
that	O	1023-1027
in	O	1028-1030
EV	O	1031-1033
cells	O	1034-1039
.	O	1039-1040

Snail	O	1041-1046
protein	O	1047-1054
expression	O	1055-1065
was	O	1066-1069
higher	O	1070-1076
in	O	1077-1079
CL	O	1080-1082
than	O	1083-1087
that	O	1088-1092
in	O	1093-1095
EV	O	1096-1098
cells	O	1099-1104
and	O	1105-1108
H1299	O	1109-1114
cells	O	1115-1120
exhibited	O	1121-1130
an	O	1131-1133
increase	O	1134-1142
in	O	1143-1145
the	O	1146-1149
expression	O	1150-1160
of	O	1161-1163
Snail	O	1164-1169
upon	O	1170-1174
transient	O	1175-1184
transfection	O	1185-1197
with	O	1198-1202
miR	B	1203-1206
-	I	1206-1207
93	I	1207-1209
.	O	1209-1210

miR	B	1211-1214
-	I	1214-1215
106b	I	1215-1219
-	I	1219-1220
25	I	1220-1222
cluster	O	1223-1230
-	O	1230-1231
induced	O	1231-1238
migration	O	1239-1248
of	O	1249-1251
CL	O	1252-1254
measured	O	1255-1263
by	O	1264-1266
scratch	O	1267-1274
assay	O	1275-1280
was	O	1281-1284
more	O	1285-1289
than	O	1290-1294
that	O	1295-1299
in	O	1300-1302
EV	O	1303-1305
cells	O	1306-1311
and	O	1312-1315
no	O	1316-1318
significant	O	1319-1330
difference	O	1331-1341
in	O	1342-1344
migration	O	1345-1354
was	O	1355-1358
observed	O	1359-1367
between	O	1368-1375
antimiR	O	1376-1383
-	O	1383-1384
93	O	1384-1386
-	O	1386-1387
transfected	O	1387-1398
H1299	O	1399-1404
cells	O	1405-1410
and	O	1411-1414
the	O	1415-1418
corresponding	O	1419-1432
control	O	1433-1440
-	O	1440-1441
oligo	O	1441-1446
-	O	1446-1447
transfected	O	1447-1458
cells	O	1459-1464
.	O	1464-1465

miR	B	1466-1469
-	I	1469-1470
106b	I	1470-1474
-	I	1474-1475
25	I	1475-1477
cluster	O	1478-1485
-	O	1485-1486
induced	O	1486-1493
migration	O	1494-1503
of	O	1504-1506
CL	O	1507-1509
cells	O	1510-1515
was	O	1516-1519
again	O	1520-1525
confirmed	O	1526-1535
in	O	1536-1538
a	O	1539-1540
Boyden	O	1541-1547
chamber	O	1548-1555
assay	O	1556-1561
without	O	1562-1569
the	O	1570-1573
matrigel	O	1574-1582
.	O	1582-1583

CL	O	1584-1586
cells	O	1587-1592
were	O	1593-1597
more	O	1598-1602
invasive	O	1603-1611
than	O	1612-1616
EV	O	1617-1619
cells	O	1620-1625
when	O	1626-1630
assessed	O	1631-1639
using	O	1640-1645
Boyden	O	1646-1652
chambers	O	1653-1661
with	O	1662-1666
matrigel	O	1667-1675
but	O	1676-1679
there	O	1680-1685
were	O	1686-1690
no	O	1691-1693
significant	O	1694-1705
changes	O	1706-1713
in	O	1714-1716
the	O	1717-1720
cell	O	1721-1725
viabilities	O	1726-1737
between	O	1738-1745
EV	O	1746-1748
and	O	1749-1752
CL	O	1753-1755
cells	O	1756-1761
.	O	1761-1762

Colony	O	1763-1769
formation	O	1770-1779
assay	O	1780-1785
revealed	O	1786-1794
that	O	1795-1799
the	O	1800-1803
CL	O	1804-1806
cells	O	1807-1812
formed	O	1813-1819
more	O	1820-1824
number	O	1825-1831
of	O	1832-1834
colonies	O	1835-1843
than	O	1844-1848
EV	O	1849-1851
cells	O	1852-1857
but	O	1858-1861
they	O	1862-1866
were	O	1867-1871
smaller	O	1872-1879
in	O	1880-1882
size	O	1883-1887
than	O	1888-1892
those	O	1893-1898
formed	O	1899-1905
by	O	1906-1908
EV	O	1909-1911
cells	O	1912-1917
.	O	1917-1918

The	O	1919-1922
supernatant	O	1923-1934
from	O	1935-1939
CL	O	1940-1942
cells	O	1943-1948
was	O	1949-1952
more	O	1953-1957
effective	O	1958-1967
than	O	1968-1972
that	O	1973-1977
from	O	1978-1982
EV	O	1983-1985
cells	O	1986-1991
in	O	1992-1994
inducing	O	1995-2003
tube	O	2004-2008
formation	O	2009-2018
in	O	2019-2021
endothelial	O	2022-2033
cells	O	2034-2039
.	O	2039-2040

Taken	O	2041-2046
together	O	2047-2055
,	O	2055-2056
our	O	2057-2060
data	O	2061-2065
indicate	O	2066-2074
that	O	2075-2079
miR	B	2080-2083
-	I	2083-2084
106b	I	2084-2088
-	I	2088-2089
25	I	2089-2091
cluster	O	2092-2099
may	O	2100-2103
play	O	2104-2108
an	O	2109-2111
important	O	2112-2121
role	O	2122-2126
in	O	2127-2129
the	O	2130-2133
metastasis	O	2134-2144
of	O	2145-2147
human	O	2148-2153
non	O	2154-2157
-	O	2157-2158
small	O	2158-2163
cell	O	2164-2168
lung	O	2169-2173
cancer	O	2174-2180
cells	O	2181-2186
by	O	2187-2189
directly	O	2190-2198
suppressing	O	2199-2210
the	O	2211-2214
beta	O	2215-2219
-	O	2219-2220
TRCP2	O	2220-2225
gene	O	2226-2230
expression	O	2231-2241
with	O	2242-2246
a	O	2247-2248
consequent	O	2249-2259
increase	O	2260-2268
in	O	2269-2271
the	O	2272-2275
expression	O	2276-2286
of	O	2287-2289
Snail	O	2290-2295
.	O	2295-2296

Prostaglandin	O	0-13
E2	O	14-16
-	O	16-17
induced	O	17-24
changes	O	25-32
in	O	33-35
alveolar	O	36-44
macrophage	O	45-55
scavenger	O	56-65
receptor	O	66-74
profiles	O	75-83
differentially	O	84-98
alter	O	99-104
phagocytosis	O	105-117
of	O	118-120
Pseudomonas	O	121-132
aeruginosa	O	133-143
and	O	144-147
Staphylococcus	O	148-162
aureus	O	163-169
post	O	170-174
-	O	174-175
bone	O	175-179
marrow	O	180-186
transplant	O	187-197
.	O	197-198

The	O	199-202
effectiveness	O	203-216
of	O	217-219
hematopoietic	O	220-233
stem	O	234-238
cell	O	239-243
transplantation	O	244-259
as	O	260-262
a	O	263-264
therapy	O	265-272
for	O	273-276
malignant	O	277-286
and	O	287-290
nonmalignant	O	291-303
conditions	O	304-314
is	O	315-317
complicated	O	318-329
by	O	330-332
pulmonary	O	333-342
infections	O	343-353
.	O	353-354

Using	O	355-360
our	O	361-364
syngeneic	O	365-374
bone	O	375-379
marrow	O	380-386
transplant	O	387-397
(	O	398-399
BMT	O	399-402
)	O	402-403
mouse	O	404-409
model	O	410-415
,	O	415-416
BMT	O	417-420
mice	O	421-425
with	O	426-430
a	O	431-432
reconstituted	O	433-446
hematopoietic	O	447-460
system	O	461-467
displayed	O	468-477
increased	O	478-487
susceptibility	O	488-502
to	O	503-505
Pseudomonas	O	506-517
aeruginosa	O	518-528
and	O	529-532
Staphylococcus	O	533-547
aureus	O	548-554
.	O	554-555

BMT	O	556-559
alveolar	O	560-568
macrophages	O	569-580
(	O	581-582
AMs	O	582-585
)	O	585-586
exhibited	O	587-596
a	O	597-598
defect	O	599-605
in	O	606-608
P	O	609-610
.	O	610-611
aeruginosa	O	612-622
phagocytosis	O	623-635
,	O	635-636
whereas	O	637-644
S	O	645-646
.	O	646-647
aureus	O	648-654
uptake	O	655-661
was	O	662-665
surprisingly	O	666-678
enhanced	O	679-687
.	O	687-688

We	O	689-691
hypothesized	O	692-704
that	O	705-709
the	O	710-713
difference	O	714-724
in	O	725-727
phagocytosis	O	728-740
was	O	741-744
due	O	745-748
to	O	749-751
an	O	752-754
altered	O	755-762
scavenger	O	763-772
receptor	O	773-781
(	O	782-783
SR	O	783-785
)	O	785-786
profile	O	787-794
.	O	794-795

Interestingly	O	796-809
,	O	809-810
MARCO	O	811-816
expression	O	817-827
was	O	828-831
decreased	O	832-841
,	O	841-842
whereas	O	843-850
SR	O	851-853
-	O	853-854
AI	O	854-856
/	O	856-857
II	O	857-859
was	O	860-863
increased	O	864-873
.	O	873-874

To	O	875-877
understand	O	878-888
how	O	889-892
these	O	893-898
dysregulated	O	899-911
SR	O	912-914
profiles	O	915-923
might	O	924-929
affect	O	930-936
macrophage	O	937-947
function	O	948-956
,	O	956-957
CHO	O	958-961
cells	O	962-967
were	O	968-972
transfected	O	973-984
with	O	985-989
SR	O	990-992
-	O	992-993
AI	O	993-995
/	O	995-996
II	O	996-998
,	O	998-999
and	O	1000-1003
phagocytosis	O	1004-1016
assays	O	1017-1023
revealed	O	1024-1032
that	O	1033-1037
SR	O	1038-1040
-	O	1040-1041
AI	O	1041-1043
/	O	1043-1044
II	O	1044-1046
was	O	1047-1050
important	O	1051-1060
for	O	1061-1064
S	O	1065-1066
.	O	1066-1067
aureus	O	1068-1074
uptake	O	1075-1081
but	O	1082-1085
not	O	1086-1089
for	O	1090-1093
P	O	1094-1095
.	O	1095-1096
aeruginosa	O	1097-1107
.	O	1107-1108

Conversely	O	1109-1119
,	O	1119-1120
AMs	O	1121-1124
treated	O	1125-1132
in	O	1133-1135
vitro	O	1136-1141
with	O	1142-1146
soluble	O	1147-1154
MARCO	O	1155-1160
exhibited	O	1161-1170
similar	O	1171-1178
defects	O	1179-1186
in	O	1187-1189
P	O	1190-1191
.	O	1191-1192
aeruginosa	O	1193-1203
internalization	O	1204-1219
as	O	1220-1222
did	O	1223-1226
BMT	O	1227-1230
AMs	O	1231-1234
.	O	1234-1235

The	O	1236-1239
3	O	1240-1241
'	O	1241-1242
-	O	1242-1243
untranslated	O	1243-1255
region	O	1256-1262
of	O	1263-1265
SR	O	1266-1268
-	O	1268-1269
AI	O	1269-1271
contains	O	1272-1280
a	O	1281-1282
putative	O	1283-1291
target	O	1292-1298
region	O	1299-1305
for	O	1306-1309
microRNA	B	1310-1318
-	I	1318-1319
155	I	1319-1322
(	O	1323-1324
miR	B	1324-1327
-	I	1327-1328
155	I	1328-1331
)	O	1331-1332
,	O	1332-1333
and	O	1334-1337
miR	B	1338-1341
-	I	1341-1342
155	I	1342-1345
expression	O	1346-1356
is	O	1357-1359
decreased	O	1360-1369
post	O	1370-1374
-	O	1374-1375
BMT	O	1375-1378
.	O	1378-1379

Anti	O	1380-1384
-	O	1384-1385
miR	B	1385-1388
-	I	1388-1389
155	I	1389-1392
-	O	1392-1393
transfected	O	1393-1404
AMs	O	1405-1408
exhibited	O	1409-1418
an	O	1419-1421
increase	O	1422-1430
in	O	1431-1433
SR	O	1434-1436
-	O	1436-1437
AI	O	1437-1439
/	O	1439-1440
II	O	1440-1442
expression	O	1443-1453
and	O	1454-1457
S	O	1458-1459
.	O	1459-1460
aureus	O	1461-1467
phagocytosis	O	1468-1480
.	O	1480-1481

Elevated	O	1482-1490
PGE2	O	1491-1495
has	O	1496-1499
been	O	1500-1504
implicated	O	1505-1515
in	O	1516-1518
driving	O	1519-1526
an	O	1527-1529
impaired	O	1530-1538
innate	O	1539-1545
immune	O	1546-1552
response	O	1553-1561
post	O	1562-1566
-	O	1566-1567
BMT	O	1567-1570
.	O	1570-1571

In	O	1572-1574
vitro	O	1575-1580
treatment	O	1581-1590
of	O	1591-1593
AMs	O	1594-1597
with	O	1598-1602
PGE2	O	1603-1607
increased	O	1608-1617
SR	O	1618-1620
-	O	1620-1621
AI	O	1621-1623
/	O	1623-1624
II	O	1624-1626
and	O	1627-1630
decreased	O	1631-1640
MARCO	O	1641-1646
and	O	1647-1650
miR	B	1651-1654
-	I	1654-1655
155	I	1655-1658
.	O	1658-1659

Despite	O	1660-1667
a	O	1668-1669
difference	O	1670-1680
in	O	1681-1683
phagocytic	O	1684-1694
ability	O	1695-1702
,	O	1702-1703
BMT	O	1704-1707
AMs	O	1708-1711
harbor	O	1712-1718
a	O	1719-1720
killing	O	1721-1728
defect	O	1729-1735
to	O	1736-1738
both	O	1739-1743
P	O	1744-1745
.	O	1745-1746
aeruginosa	O	1747-1757
and	O	1758-1761
S	O	1762-1763
.	O	1763-1764
aureus	O	1765-1771
.	O	1771-1772

Thus	O	1773-1777
,	O	1777-1778
our	O	1779-1782
data	O	1783-1787
suggest	O	1788-1795
that	O	1796-1800
PGE2	O	1801-1805
-	O	1805-1806
driven	O	1806-1812
alterations	O	1813-1824
in	O	1825-1827
SR	O	1828-1830
and	O	1831-1834
miR	B	1835-1838
-	I	1838-1839
155	I	1839-1842
expression	O	1843-1853
account	O	1854-1861
for	O	1862-1865
the	O	1866-1869
differential	O	1870-1882
phagocytosis	O	1883-1895
of	O	1896-1898
P	O	1899-1900
.	O	1900-1901
aeruginosa	O	1902-1912
and	O	1913-1916
S	O	1917-1918
.	O	1918-1919
aureus	O	1920-1926
,	O	1926-1927
but	O	1928-1931
impaired	O	1932-1940
killing	O	1941-1948
ultimately	O	1949-1959
confers	O	1960-1967
increased	O	1968-1977
susceptibility	O	1978-1992
to	O	1993-1995
pulmonary	O	1996-2005
infection	O	2006-2015
.	O	2015-2016

Increased	O	0-9
levels	O	10-16
of	O	17-19
microRNA	B	20-28
-	I	28-29
424	I	29-32
are	O	33-36
associated	O	37-47
with	O	48-52
the	O	53-56
pathogenesis	O	57-69
of	O	70-72
fetal	O	73-78
growth	O	79-85
restriction	O	86-97
.	O	97-98

Studies	O	99-106
show	O	107-111
a	O	112-113
number	O	114-120
of	O	121-123
miRNAs	O	124-130
are	O	131-134
expressed	O	135-144
in	O	145-147
the	O	148-151
placenta	O	152-160
including	O	161-170
miRNA	B	171-176
-	I	176-177
424	I	177-180
,	O	180-181
a	O	182-183
hypoxia	O	184-191
-	O	191-192
regulated	O	192-201
miRNA	O	202-207
,	O	207-208
suggesting	O	209-219
miRNA	B	220-225
-	I	225-226
424	I	226-229
may	O	230-233
have	O	234-238
a	O	239-240
potential	O	241-250
regulatory	O	251-261
role	O	262-266
in	O	267-269
fetal	O	270-275
growth	O	276-282
restriction	O	283-294
(	O	295-296
FGR	O	296-299
)	O	299-300
.	O	300-301

The	O	302-305
levels	O	306-312
of	O	313-315
miRNA	B	316-321
-	I	321-322
424	I	322-325
and	O	326-329
its	O	330-333
target	O	334-340
gene	O	341-345
,	O	345-346
mitogen	O	347-354
-	O	354-355
activated	O	355-364
protein	O	365-372
kinase	O	373-379
1	O	380-381
(	O	382-383
MEK1	O	383-387
)	O	387-388
,	O	388-389
and	O	390-393
fibroblast	O	394-404
growth	O	405-411
factor	O	412-418
receptor	O	419-427
1	O	428-429
(	O	430-431
FGFR1	O	431-436
)	O	436-437
were	O	438-442
examined	O	443-451
.	O	451-452

The	O	453-456
levels	O	457-463
of	O	464-466
miRNA	B	467-472
-	I	472-473
424	I	473-476
were	O	477-481
significantly	O	482-495
increased	O	496-505
in	O	506-508
placentae	O	509-518
from	O	519-523
women	O	524-529
with	O	530-534
FGR	O	535-538
.	O	538-539

Both	O	540-544
mRNA	O	545-549
levels	O	550-556
and	O	557-560
protein	O	561-568
levels	O	569-575
of	O	576-578
MEK1	O	579-583
and	O	584-587
FGFR1	O	588-593
were	O	594-598
significantly	O	599-612
reduced	O	613-620
in	O	621-623
placentae	O	624-633
complicated	O	634-645
with	O	646-650
FGR	O	651-654
.	O	654-655

Furthermore	O	656-667
,	O	667-668
the	O	669-672
increased	O	673-682
levels	O	683-689
of	O	690-692
miRNA	B	693-698
-	I	698-699
424	I	699-702
were	O	703-707
negatively	O	708-718
correlated	O	719-729
with	O	730-734
the	O	735-738
mRNA	O	739-743
levels	O	744-750
of	O	751-753
MEK1	O	754-758
in	O	759-761
placentae	O	762-771
complicated	O	772-783
with	O	784-788
FGR	O	789-792
.	O	792-793

Our	O	794-797
study	O	798-803
suggests	O	804-812
upregulated	O	813-824
miRNA	B	825-830
-	I	830-831
424	I	831-834
may	O	835-838
be	O	839-841
associated	O	842-852
with	O	853-857
the	O	858-861
pathogenesis	O	862-874
of	O	875-877
FGR	O	878-881
.	O	881-882

Zeb1	O	0-4
regulates	O	5-14
E	O	15-16
-	O	16-17
cadherin	O	17-25
and	O	26-29
Epcam	O	30-35
(	O	36-37
epithelial	O	37-47
cell	O	48-52
adhesion	O	53-61
molecule	O	62-70
)	O	70-71
expression	O	72-82
to	O	83-85
control	O	86-93
cell	O	94-98
behavior	O	99-107
in	O	108-110
early	O	111-116
zebrafish	O	117-126
development	O	127-138
.	O	138-139

The	O	140-143
ZEB1	O	144-148
transcription	O	149-162
factor	O	163-169
is	O	170-172
best	O	173-177
known	O	178-183
as	O	184-186
an	O	187-189
inducer	O	190-197
of	O	198-200
epithelial	O	201-211
-	O	211-212
mesenchymal	O	212-223
transitions	O	224-235
(	O	236-237
EMT	O	237-240
)	O	240-241
in	O	242-244
cancer	O	245-251
metastasis	O	252-262
,	O	262-263
acting	O	264-270
through	O	271-278
transcriptional	O	279-294
repression	O	295-305
of	O	306-308
CDH1	O	309-313
(	O	314-315
encoding	O	315-323
E	O	324-325
-	O	325-326
cadherin	O	326-334
)	O	334-335
and	O	336-339
the	O	340-343
EMT	O	344-347
-	O	347-348
suppressing	O	348-359
microRNA	B	360-368
-	I	368-369
200s	I	369-373
(	O	374-375
miR	B	375-378
-	I	378-379
200s	I	379-383
)	O	383-384
.	O	384-385

Here	O	386-390
we	O	391-393
analyze	O	394-401
roles	O	402-407
of	O	408-410
the	O	411-414
ZEB1	O	415-419
zebrafish	O	420-429
orthologs	O	430-439
,	O	439-440
Zeb1a	O	441-446
and	O	447-450
Zeb1b	O	451-456
,	O	456-457
and	O	458-461
of	O	462-464
miR	B	465-468
-	I	468-469
200s	I	469-473
in	O	474-476
control	O	477-484
of	O	485-487
cell	O	488-492
adhesion	O	493-501
and	O	502-505
morphogenesis	O	506-519
during	O	520-526
gastrulation	O	527-539
and	O	540-543
segmentation	O	544-556
stages	O	557-563
.	O	563-564

Loss	O	565-569
and	O	570-573
gain	O	574-578
of	O	579-581
function	O	582-590
analyses	O	591-599
revealed	O	600-608
that	O	609-613
Zeb1	O	614-618
represses	O	619-628
cdh1	O	629-633
expression	O	634-644
to	O	645-647
fine	O	648-652
-	O	652-653
tune	O	653-657
adhesiveness	O	658-670
of	O	671-673
migrating	O	674-683
deep	O	684-688
blastodermal	O	689-701
cells	O	702-707
.	O	707-708

Furthermore	O	709-720
,	O	720-721
Zeb1	O	722-726
acts	O	727-731
as	O	732-734
a	O	735-736
repressor	O	737-746
of	O	747-749
epcam	O	750-755
in	O	756-758
the	O	759-762
deep	O	763-767
cells	O	768-773
of	O	774-776
the	O	777-780
blastoderm	O	781-791
and	O	792-795
may	O	796-799
contribute	O	800-810
to	O	811-813
control	O	814-821
of	O	822-824
epithelial	O	825-835
integrity	O	836-845
of	O	846-848
enveloping	O	849-859
layer	O	860-865
cells	O	866-871
,	O	871-872
the	O	873-876
outermost	O	877-886
cells	O	887-892
of	O	893-895
the	O	896-899
blastoderm	O	900-910
.	O	910-911

We	O	912-914
found	O	915-920
a	O	921-922
similar	O	923-930
ZEB1	O	931-935
-	O	935-936
dependent	O	936-945
repression	O	946-956
of	O	957-959
EPCAM	O	960-965
expression	O	966-976
in	O	977-979
human	O	980-985
pancreatic	O	986-996
and	O	997-1000
breast	O	1001-1007
cancer	O	1008-1014
cell	O	1015-1019
lines	O	1020-1025
,	O	1025-1026
mediated	O	1027-1035
through	O	1036-1043
direct	O	1044-1050
binding	O	1051-1058
of	O	1059-1061
ZEB1	O	1062-1066
to	O	1067-1069
the	O	1070-1073
EPCAM	O	1074-1079
promoter	O	1080-1088
.	O	1088-1089

Thus	O	1090-1094
,	O	1094-1095
Zeb1	O	1096-1100
proteins	O	1101-1109
employ	O	1110-1116
several	O	1117-1124
evolutionary	O	1125-1137
conserved	O	1138-1147
mechanisms	O	1148-1158
to	O	1159-1161
regulate	O	1162-1170
cell	O	1171-1175
-	O	1175-1176
cell	O	1176-1180
adhesion	O	1181-1189
during	O	1190-1196
development	O	1197-1208
and	O	1209-1212
cancer	O	1213-1219
.	O	1219-1220

Multiple	O	0-8
-	O	8-9
to	O	9-11
-	O	11-12
multiple	O	12-20
relationships	O	21-34
between	O	35-42
microRNAs	O	43-52
and	O	53-56
target	O	57-63
genes	O	64-69
in	O	70-72
gastric	O	73-80
cancer	O	81-87
.	O	87-88

MicroRNAs	O	89-98
(	O	99-100
miRNAs	O	100-106
)	O	106-107
act	O	108-111
as	O	112-114
transcriptional	O	115-130
regulators	O	131-141
and	O	142-145
play	O	146-150
pivotal	O	151-158
roles	O	159-164
in	O	165-167
carcinogenesis	O	168-182
.	O	182-183

According	O	184-193
to	O	194-196
miRNA	O	197-202
target	O	203-209
databases	O	210-219
,	O	219-220
one	O	221-224
miRNA	O	225-230
may	O	231-234
regulate	O	235-243
many	O	244-248
genes	O	249-254
as	O	255-257
its	O	258-261
targets	O	262-269
,	O	269-270
while	O	271-276
one	O	277-280
gene	O	281-285
may	O	286-289
be	O	290-292
targeted	O	293-301
by	O	302-304
many	O	305-309
miRNAs	O	310-316
.	O	316-317

These	O	318-323
findings	O	324-332
indicate	O	333-341
that	O	342-346
relationships	O	347-360
between	O	361-368
miRNAs	O	369-375
and	O	376-379
their	O	380-385
targets	O	386-393
may	O	394-397
not	O	398-401
be	O	402-404
one	O	405-408
-	O	408-409
to	O	409-411
-	O	411-412
one	O	412-415
.	O	415-416

However	O	417-424
,	O	424-425
many	O	426-430
reports	O	431-438
have	O	439-443
described	O	444-453
only	O	454-458
a	O	459-460
one	O	461-464
-	O	464-465
to	O	465-467
-	O	467-468
one	O	468-471
,	O	471-472
one	O	473-476
-	O	476-477
to	O	477-479
-	O	479-480
multiple	O	480-488
or	O	489-491
multiple	O	492-500
-	O	500-501
to	O	501-503
-	O	503-504
one	O	504-507
relationship	O	508-520
between	O	521-528
miRNA	O	529-534
and	O	535-538
its	O	539-542
target	O	543-549
gene	O	550-554
in	O	555-557
human	O	558-563
cancers	O	564-571
.	O	571-572

Thus	O	573-577
,	O	577-578
it	O	579-581
is	O	582-584
necessary	O	585-594
to	O	595-597
determine	O	598-607
whether	O	608-615
or	O	616-618
not	O	619-622
a	O	623-624
combination	O	625-636
of	O	637-639
some	O	640-644
miRNAs	O	645-651
would	O	652-657
regulate	O	658-666
multiple	O	667-675
targets	O	676-683
and	O	684-687
be	O	688-690
involved	O	691-699
in	O	700-702
carcinogenesis	O	703-717
.	O	717-718

To	O	719-721
find	O	722-726
some	O	727-731
groups	O	732-738
of	O	739-741
miRNAs	O	742-748
that	O	749-753
may	O	754-757
synergistically	O	758-773
regulate	O	774-782
their	O	783-788
targets	O	789-796
in	O	797-799
human	O	800-805
gastric	O	806-813
cancer	O	814-820
(	O	821-822
GC	O	822-824
)	O	824-825
,	O	825-826
we	O	827-829
re	O	830-832
-	O	832-833
analyzed	O	833-841
our	O	842-845
previous	O	846-854
miRNA	O	855-860
expression	O	861-871
array	O	872-877
data	O	878-882
and	O	883-886
found	O	887-892
that	O	893-897
50	O	898-900
miRNAs	O	901-907
were	O	908-912
up	O	913-915
-	O	915-916
regulated	O	916-925
on	O	926-928
treatment	O	929-938
with	O	939-943
5	O	944-945
-	O	945-946
aza	O	946-949
-	O	949-950
2	O	950-951
'	O	951-952
-	O	952-953
deoxycytidine	O	953-966
in	O	967-969
a	O	970-971
GC	O	972-974
cell	O	975-979
line	O	980-984
.	O	984-985

The	O	986-989
"	O	990-991
TargetScan	O	991-1001
"	O	1001-1002
miRNA	O	1003-1008
target	O	1009-1015
database	O	1016-1024
predicted	O	1025-1034
that	O	1035-1039
some	O	1040-1044
of	O	1045-1047
these	O	1048-1053
miRNAs	O	1054-1060
have	O	1061-1065
common	O	1066-1072
target	O	1073-1079
genes	O	1080-1085
.	O	1085-1086

We	O	1087-1089
also	O	1090-1094
referred	O	1095-1103
to	O	1104-1106
the	O	1107-1110
GEO	O	1111-1114
database	O	1115-1123
for	O	1124-1127
expression	O	1128-1138
of	O	1139-1141
these	O	1142-1147
common	O	1148-1154
target	O	1155-1161
genes	O	1162-1167
in	O	1168-1170
human	O	1171-1176
GCs	O	1177-1180
,	O	1180-1181
which	O	1182-1187
might	O	1188-1193
be	O	1194-1196
related	O	1197-1204
to	O	1205-1207
gastric	O	1208-1215
carcinogenesis	O	1216-1230
.	O	1230-1231

In	O	1232-1234
this	O	1235-1239
study	O	1240-1245
,	O	1245-1246
we	O	1247-1249
analyzed	O	1250-1258
two	O	1259-1262
miRNA	O	1263-1268
combinations	O	1269-1281
,	O	1281-1282
miR	B	1283-1286
-	I	1286-1287
224	I	1287-1290
and	O	1291-1294
-	B	1295-1296
452	I	1296-1299
,	O	1299-1300
and	O	1301-1304
miR	B	1305-1308
-	I	1308-1309
181c	I	1309-1313
and	O	1314-1317
-	B	1318-1319
340	I	1319-1322
.	O	1322-1323

Over	O	1324-1328
-	O	1328-1329
expression	O	1329-1339
of	O	1340-1342
both	O	1343-1347
miRNA	O	1348-1353
combinations	O	1354-1366
dramatically	O	1367-1379
down	O	1380-1384
-	O	1384-1385
regulated	O	1385-1394
their	O	1395-1400
target	O	1401-1407
genes	O	1408-1413
,	O	1413-1414
DPYSL2	O	1415-1421
and	O	1422-1425
KRAS	O	1426-1430
,	O	1430-1431
and	O	1432-1435
KRAS	O	1436-1440
and	O	1441-1444
MECP2	O	1445-1450
,	O	1450-1451
respectively	O	1452-1464
.	O	1464-1465

These	O	1466-1471
miRNA	O	1472-1477
combinations	O	1478-1490
synergistically	O	1491-1506
decreased	O	1507-1516
cell	O	1517-1521
proliferation	O	1522-1535
upon	O	1536-1540
transfection	O	1541-1553
.	O	1553-1554

Furthermore	O	1555-1566
,	O	1566-1567
we	O	1568-1570
revealed	O	1571-1579
that	O	1580-1584
these	O	1585-1590
miRNAs	O	1591-1597
were	O	1598-1602
down	O	1603-1607
-	O	1607-1608
regulated	O	1608-1617
through	O	1618-1625
promoter	O	1626-1634
hypermethylation	O	1635-1651
in	O	1652-1654
GC	O	1655-1657
cells	O	1658-1663
.	O	1663-1664

Thus	O	1665-1669
,	O	1669-1670
it	O	1671-1673
is	O	1674-1676
likely	O	1677-1683
that	O	1684-1688
the	O	1689-1692
relationships	O	1693-1706
between	O	1707-1714
miRNAs	O	1715-1721
and	O	1722-1725
their	O	1726-1731
targets	O	1732-1739
are	O	1740-1743
not	O	1744-1747
one	O	1748-1751
-	O	1751-1752
to	O	1752-1754
-	O	1754-1755
one	O	1755-1758
but	O	1759-1762
multiple	O	1763-1771
-	O	1771-1772
to	O	1772-1774
-	O	1774-1775
multiple	O	1775-1783
in	O	1784-1786
GCs	O	1787-1790
,	O	1790-1791
and	O	1792-1795
that	O	1796-1800
these	O	1801-1806
complex	O	1807-1814
relationships	O	1815-1828
may	O	1829-1832
be	O	1833-1835
related	O	1836-1843
to	O	1844-1846
gastric	O	1847-1854
carcinogenesis	O	1855-1869
.	O	1869-1870

Identification	O	0-14
of	O	15-17
miRNAs	O	18-24
associated	O	25-35
with	O	36-40
sexual	O	41-47
maturity	O	48-56
in	O	57-59
chicken	O	60-67
ovary	O	68-73
by	O	74-76
Illumina	O	77-85
small	O	86-91
RNA	O	92-95
deep	O	96-100
sequencing	O	101-111
.	O	111-112

BACKGROUND	O	113-123
:	O	123-124
MicroRNAs	O	125-134
have	O	135-139
been	O	140-144
suggested	O	145-154
to	O	155-157
play	O	158-162
important	O	163-172
roles	O	173-178
in	O	179-181
the	O	182-185
regulation	O	186-196
of	O	197-199
gene	O	200-204
expression	O	205-215
in	O	216-218
various	O	219-226
biological	O	227-237
processes	O	238-247
.	O	247-248

To	O	249-251
investigate	O	252-263
the	O	264-267
function	O	268-276
of	O	277-279
miRNAs	O	280-286
in	O	287-289
chicken	O	290-297
ovarian	O	298-305
development	O	306-317
and	O	318-321
folliculogenesis	O	322-338
,	O	338-339
two	O	340-343
small	O	344-349
RNA	O	350-353
libraries	O	354-363
constructed	O	364-375
from	O	376-380
sexually	O	381-389
mature	O	390-396
(	O	397-398
162	O	398-401
-	O	401-402
day	O	402-405
old	O	406-409
)	O	409-410
and	O	411-414
immature	O	415-423
(	O	424-425
42	O	425-427
-	O	427-428
day	O	428-431
old	O	432-435
)	O	435-436
ovary	O	437-442
tissues	O	443-450
of	O	451-453
Single	O	454-460
Comb	O	461-465
White	O	466-471
Leghorn	O	472-479
chicken	O	480-487
were	O	488-492
sequenced	O	493-502
using	O	503-508
Illumina	O	509-517
small	O	518-523
RNA	O	524-527
deep	O	528-532
sequencing	O	533-543
.	O	543-544

RESULTS	O	545-552
:	O	552-553
In	O	554-556
the	O	557-560
present	O	561-568
study	O	569-574
,	O	574-575
14	O	576-578
,	O	578-579
545	O	579-582
,	O	582-583
100	O	583-586
and	O	587-590
14	O	591-593
,	O	593-594
774	O	594-597
,	O	597-598
864	O	598-601
clean	O	602-607
reads	O	608-613
were	O	614-618
obtained	O	619-627
from	O	628-632
sexually	O	633-641
mature	O	642-648
(	O	649-650
162	O	650-653
-	O	653-654
d	O	654-655
)	O	655-656
and	O	657-660
sexually	O	661-669
immature	O	670-678
(	O	679-680
42	O	680-682
-	O	682-683
d	O	683-684
)	O	684-685
ovaries	O	686-693
,	O	693-694
respectively	O	695-707
.	O	707-708

In	O	709-711
total	O	712-717
,	O	717-718
202	O	719-722
known	O	723-728
miRNAs	O	729-735
were	O	736-740
identified	O	741-751
,	O	751-752
and	O	753-756
93	O	757-759
of	O	760-762
them	O	763-767
were	O	768-772
found	O	773-778
to	O	779-781
be	O	782-784
significantly	O	785-798
differentially	O	799-813
expressed	O	814-823
:	O	823-824
42	O	825-827
miRNAs	O	828-834
were	O	835-839
up	O	840-842
-	O	842-843
regulated	O	843-852
and	O	853-856
51	O	857-859
miRNAs	O	860-866
were	O	867-871
down	O	872-876
-	O	876-877
regulated	O	877-886
in	O	887-889
the	O	890-893
mature	O	894-900
ovary	O	901-906
compared	O	907-915
to	O	916-918
the	O	919-922
immature	O	923-931
ovary	O	932-937
.	O	937-938

Among	O	939-944
the	O	945-948
up	O	949-951
-	O	951-952
regulated	O	952-961
miRNAs	O	962-968
,	O	968-969
gga	B	970-973
-	I	973-974
miR	I	974-977
-	I	977-978
1a	I	978-980
has	O	981-984
the	O	985-988
largest	O	989-996
fold	O	997-1001
-	O	1001-1002
change	O	1002-1008
(	O	1009-1010
6	O	1010-1011
.	O	1011-1012
405	O	1012-1015
-	O	1015-1016
fold	O	1016-1020
)	O	1020-1021
,	O	1021-1022
while	O	1023-1028
gga	B	1029-1032
-	I	1032-1033
miR	I	1033-1036
-	I	1036-1037
375	I	1037-1040
has	O	1041-1044
the	O	1045-1048
largest	O	1049-1056
fold	O	1057-1061
-	O	1061-1062
change	O	1062-1068
(	O	1069-1070
11	O	1070-1072
.	O	1072-1073
345	O	1073-1076
-	O	1076-1077
fold	O	1077-1081
)	O	1081-1082
among	O	1083-1088
the	O	1089-1092
down	O	1093-1097
-	O	1097-1098
regulated	O	1098-1107
miRNAs	O	1108-1114
.	O	1114-1115

The	O	1116-1119
three	O	1120-1125
most	O	1126-1130
abundant	O	1131-1139
miRNAs	O	1140-1146
in	O	1147-1149
the	O	1150-1153
chicken	O	1154-1161
ovary	O	1162-1167
are	O	1168-1171
gga	B	1172-1175
-	I	1175-1176
miR	I	1176-1179
-	I	1179-1180
10a	I	1180-1183
,	O	1183-1184
gga	B	1185-1188
-	I	1188-1189
let	I	1189-1192
-	I	1192-1193
7	I	1193-1194
and	O	1195-1198
gga	B	1199-1202
-	I	1202-1203
miR	I	1203-1206
-	I	1206-1207
21	I	1207-1209
.	O	1209-1210

Five	O	1211-1215
differentially	O	1216-1230
expressed	O	1231-1240
miRNAs	O	1241-1247
(	O	1248-1249
gga	B	1249-1252
-	I	1252-1253
miR	I	1253-1256
-	I	1256-1257
1a	I	1257-1259
,	O	1259-1260
21	B	1261-1263
,	O	1263-1264
26a	B	1265-1268
,	O	1268-1269
137	B	1270-1273
and	O	1274-1277
375	B	1278-1281
)	O	1281-1282
were	O	1283-1287
validated	O	1288-1297
by	O	1298-1300
real	O	1301-1305
-	O	1305-1306
time	O	1306-1310
quantitative	O	1311-1323
RT	O	1324-1326
-	O	1326-1327
PCR	O	1327-1330
(	O	1331-1332
qRT	O	1332-1335
-	O	1335-1336
PCR	O	1336-1339
)	O	1339-1340
.	O	1340-1341

Furthermore	O	1342-1353
,	O	1353-1354
the	O	1355-1358
expression	O	1359-1369
patterns	O	1370-1378
of	O	1379-1381
the	O	1382-1385
five	O	1386-1390
miRNAs	O	1391-1397
were	O	1398-1402
analyzed	O	1403-1411
in	O	1412-1414
different	O	1415-1424
developmental	O	1425-1438
stages	O	1439-1445
of	O	1446-1448
chicken	O	1449-1456
ovary	O	1457-1462
and	O	1463-1466
follicles	O	1467-1476
of	O	1477-1479
various	O	1480-1487
sizes	O	1488-1493
.	O	1493-1494

CONCLUSION	O	1495-1505
:	O	1505-1506
The	O	1507-1510
present	O	1511-1518
study	O	1519-1524
provides	O	1525-1533
the	O	1534-1537
first	O	1538-1543
miRNA	O	1544-1549
profile	O	1550-1557
in	O	1558-1560
sexually	O	1561-1569
immature	O	1570-1578
and	O	1579-1582
mature	O	1583-1589
chicken	O	1590-1597
ovaries	O	1598-1605
.	O	1605-1606

Some	O	1607-1611
miRNAs	O	1612-1618
such	O	1619-1623
as	O	1624-1626
gga	B	1627-1630
-	I	1630-1631
miR	I	1631-1634
-	I	1634-1635
1a	I	1635-1637
and	O	1638-1641
gga	B	1642-1645
-	I	1645-1646
miR	I	1646-1649
-	I	1649-1650
21are	O	1650-1655
expressed	O	1656-1665
differentially	O	1666-1680
in	O	1681-1683
immature	O	1684-1692
and	O	1693-1696
mature	O	1697-1703
chicken	O	1704-1711
ovaries	O	1712-1719
as	O	1720-1722
well	O	1723-1727
as	O	1728-1730
among	O	1731-1736
different	O	1737-1746
sized	O	1747-1752
follicles	O	1753-1762
,	O	1762-1763
suggesting	O	1764-1774
an	O	1775-1777
important	O	1778-1787
role	O	1788-1792
in	O	1793-1795
the	O	1796-1799
follicular	O	1800-1810
growth	O	1811-1817
or	O	1818-1820
ovulation	O	1821-1830
mechanism	O	1831-1840
in	O	1841-1843
the	O	1844-1847
chicken	O	1848-1855
.	O	1855-1856

Over	O	0-4
-	O	4-5
expression	O	5-15
of	O	16-18
the	O	19-22
miRNA	O	23-28
cluster	O	29-36
at	O	37-39
chromosome	O	40-50
14q32	O	51-56
in	O	57-59
the	O	60-63
alcoholic	O	64-73
brain	O	74-79
correlates	O	80-90
with	O	91-95
suppression	O	96-107
of	O	108-110
predicted	O	111-120
target	O	121-127
mRNA	O	128-132
required	O	133-141
for	O	142-145
oligodendrocyte	O	146-161
proliferation	O	162-175
.	O	175-176

We	O	177-179
examined	O	180-188
miRNA	O	189-194
expression	O	195-205
from	O	206-210
RNA	O	211-214
isolated	O	215-223
from	O	224-228
the	O	229-232
frontal	O	233-240
cortex	O	241-247
(	O	248-249
Broadman	O	249-257
area	O	258-262
9	O	263-264
)	O	264-265
of	O	266-268
9	O	269-270
alcoholics	O	271-281
(	O	282-283
6	O	283-284
males	O	285-290
,	O	290-291
3	O	292-293
females	O	294-301
,	O	301-302
mean	O	303-307
age	O	308-311
48	O	312-314
years	O	315-320
)	O	320-321
and	O	322-325
9	O	326-327
matched	O	328-335
controls	O	336-344
using	O	345-350
both	O	351-355
the	O	356-359
Affymetrix	O	360-370
GeneChip	O	371-379
miRNA	O	380-385
2	O	386-387
.	O	387-388
0	O	388-389
and	O	390-393
Human	O	394-399
Exon	O	400-404
1	O	405-406
.	O	406-407
0	O	407-408
ST	O	409-411
Arrays	O	412-418
to	O	419-421
further	O	422-429
characterize	O	430-442
genetic	O	443-450
influences	O	451-461
in	O	462-464
alcoholism	O	465-475
and	O	476-479
the	O	480-483
effects	O	484-491
of	O	492-494
alcohol	O	495-502
consumption	O	503-514
on	O	515-517
predicted	O	518-527
target	O	528-534
mRNA	O	535-539
expression	O	540-550
.	O	550-551

A	O	552-553
total	O	554-559
of	O	560-562
12	O	563-565
human	O	566-571
miRNAs	O	572-578
were	O	579-583
significantly	O	584-597
up	O	598-600
-	O	600-601
regulated	O	601-610
in	O	611-613
alcohol	O	614-621
dependent	O	622-631
subjects	O	632-640
(	O	641-642
fold	O	642-646
change	O	647-653
>	O	653-654
/	O	654-655
=	O	655-656
1	O	656-657
.	O	657-658
5	O	658-659
,	O	659-660
false	O	661-666
discovery	O	667-676
rate	O	677-681
(	O	682-683
FDR	O	683-686
)	O	686-687
<	O	687-688
/	O	688-689
=	O	689-690
0	O	690-691
.	O	691-692
3	O	692-693
;	O	693-694
p	O	695-696
<	O	696-697
0	O	697-698
.	O	698-699
05	O	699-701
)	O	701-702
compared	O	703-711
with	O	712-716
controls	O	717-725
including	O	726-735
a	O	736-737
cluster	O	738-745
of	O	746-748
4	O	749-750
miRNAs	O	751-757
(	O	758-759
e	O	759-760
.	O	760-761
g	O	761-762
.	O	762-763
,	O	763-764
miR	B	765-768
-	I	768-769
377	I	769-772
,	O	772-773
miR	B	774-777
-	I	777-778
379	I	778-781
)	O	781-782
from	O	783-787
the	O	788-791
maternally	O	792-802
expressed	O	803-812
14q32	O	813-818
chromosome	O	819-829
region	O	830-836
.	O	836-837

The	O	838-841
status	O	842-848
of	O	849-851
the	O	852-855
up	O	856-858
-	O	858-859
regulated	O	859-868
miRNAs	O	869-875
was	O	876-879
supported	O	880-889
using	O	890-895
the	O	896-899
high	O	900-904
-	O	904-905
throughput	O	905-915
method	O	916-922
of	O	923-925
exon	O	926-930
microarrays	O	931-942
showing	O	943-950
decreased	O	951-960
predicted	O	961-970
mRNA	O	971-975
gene	O	976-980
target	O	981-987
expression	O	988-998
as	O	999-1001
anticipated	O	1002-1013
from	O	1014-1018
the	O	1019-1022
same	O	1023-1027
RNA	O	1028-1031
aliquot	O	1032-1039
.	O	1039-1040

Predicted	O	1041-1050
mRNA	O	1051-1055
targets	O	1056-1063
were	O	1064-1068
involved	O	1069-1077
in	O	1078-1080
cellular	O	1081-1089
adhesion	O	1090-1098
(	O	1099-1100
e	O	1100-1101
.	O	1101-1102
g	O	1102-1103
.	O	1103-1104
,	O	1104-1105
THBS2	O	1106-1111
)	O	1111-1112
,	O	1112-1113
tissue	O	1114-1120
differentiation	O	1121-1136
(	O	1137-1138
e	O	1138-1139
.	O	1139-1140
g	O	1140-1141
.	O	1141-1142
,	O	1142-1143
CHN2	O	1144-1148
)	O	1148-1149
,	O	1149-1150
neuronal	O	1151-1159
migration	O	1160-1169
(	O	1170-1171
e	O	1171-1172
.	O	1172-1173
g	O	1173-1174
.	O	1174-1175
,	O	1175-1176
NDE1	O	1177-1181
)	O	1181-1182
,	O	1182-1183
myelination	O	1184-1195
(	O	1196-1197
e	O	1197-1198
.	O	1198-1199
g	O	1199-1200
.	O	1200-1201
,	O	1201-1202
UGT8	O	1203-1207
,	O	1207-1208
CNP	O	1209-1212
)	O	1212-1213
and	O	1214-1217
oligodendrocyte	O	1218-1233
proliferation	O	1234-1247
(	O	1248-1249
e	O	1249-1250
.	O	1250-1251
g	O	1251-1252
.	O	1252-1253
,	O	1253-1254
ENPP2	O	1255-1260
,	O	1260-1261
SEMA4D1	O	1262-1269
)	O	1269-1270
.	O	1270-1271

Our	O	1272-1275
data	O	1276-1280
support	O	1281-1288
an	O	1289-1291
association	O	1292-1303
of	O	1304-1306
alcoholism	O	1307-1317
with	O	1318-1322
up	O	1323-1325
-	O	1325-1326
regulation	O	1326-1336
of	O	1337-1339
a	O	1340-1341
cluster	O	1342-1349
of	O	1350-1352
miRNAs	O	1353-1359
located	O	1360-1367
in	O	1368-1370
the	O	1371-1374
genomic	O	1375-1382
imprinted	O	1383-1392
domain	O	1393-1399
on	O	1400-1402
chromosome	O	1403-1413
14q32	O	1414-1419
with	O	1420-1424
their	O	1425-1430
predicted	O	1431-1440
gene	O	1441-1445
targets	O	1446-1453
involved	O	1454-1462
with	O	1463-1467
oligodendrocyte	O	1468-1483
growth	O	1484-1490
,	O	1490-1491
differentiation	O	1492-1507
and	O	1508-1511
signaling	O	1512-1521
.	O	1521-1522

Attenuation	O	0-11
of	O	12-14
dexamethasone	O	15-28
-	O	28-29
induced	O	29-36
cell	O	37-41
death	O	42-47
in	O	48-50
multiple	O	51-59
myeloma	O	60-67
is	O	68-70
mediated	O	71-79
by	O	80-82
miR	B	83-86
-	I	86-87
125b	I	87-91
expression	O	92-102
.	O	102-103

Dexamethasone	O	104-117
is	O	118-120
a	O	121-122
key	O	123-126
front	O	127-132
-	O	132-133
line	O	133-137
chemotherapeutic	O	138-154
for	O	155-158
B	O	159-160
-	O	160-161
cell	O	161-165
malignant	O	166-175
multiple	O	176-184
myeloma	O	185-192
(	O	193-194
MM	O	194-196
)	O	196-197
.	O	197-198

Dexamethasone	O	199-212
modulates	O	213-222
MM	O	223-225
cell	O	226-230
survival	O	231-239
signaling	O	240-249
but	O	250-253
fails	O	254-259
to	O	260-262
induce	O	263-269
marked	O	270-276
cytotoxicity	O	277-289
when	O	290-294
used	O	295-299
as	O	300-302
a	O	303-304
monotherapy	O	305-316
.	O	316-317

We	O	318-320
demonstrate	O	321-332
here	O	333-337
the	O	338-341
mechanism	O	342-351
behind	O	352-358
this	O	359-363
insufficient	O	364-376
responsiveness	O	377-391
of	O	392-394
MM	O	395-397
cells	O	398-403
toward	O	404-410
dexamethasone	O	411-424
,	O	424-425
revealing	O	426-435
in	O	436-438
MM	O	439-441
a	O	442-443
dramatic	O	444-452
anti	O	453-457
-	O	457-458
apoptotic	O	458-467
role	O	468-472
for	O	473-476
microRNA	B	477-485
(	I	486-487
miRNA	I	487-492
)	I	492-493
-	I	493-494
125b	I	494-498
in	O	499-501
the	O	502-505
insensitivity	O	506-519
toward	O	520-526
dexamethasone	O	527-540
-	O	540-541
induced	O	541-548
apoptosis	O	549-558
.	O	558-559

MM	O	560-562
cells	O	563-568
responding	O	569-579
to	O	580-582
dexamethasone	O	583-596
exhibited	O	597-606
enhanced	O	607-615
expression	O	616-626
of	O	627-629
oncogenic	O	630-639
miR	B	640-643
-	I	643-644
125b	I	644-648
.	O	648-649

Dexamethasone	O	650-663
also	O	664-668
induced	O	669-676
expression	O	677-687
of	O	688-690
miR	B	691-694
-	I	694-695
34a	I	695-698
,	O	698-699
which	O	700-705
acts	O	706-710
to	O	711-713
suppress	O	714-722
SIRT1	O	723-728
deacetylase	O	729-740
,	O	740-741
and	O	742-745
thus	O	746-750
allows	O	751-757
maintained	O	758-768
acetylation	O	769-780
and	O	781-784
inactivation	O	785-797
of	O	798-800
p53	O	801-804
.	O	804-805

p53	O	806-809
mRNA	O	810-814
is	O	815-817
also	O	818-822
suppressed	O	823-833
by	O	834-836
miR	B	837-840
-	I	840-841
125b	I	841-845
targeting	O	846-855
.	O	855-856

Reporter	O	857-865
assays	O	866-872
showed	O	873-879
that	O	880-884
both	O	885-889
these	O	890-895
dexamethasone	O	896-909
-	O	909-910
induced	O	910-917
miRNAs	O	918-924
act	O	925-928
downstream	O	929-939
of	O	940-942
their	O	943-948
target	O	949-955
genes	O	956-961
to	O	962-964
prevent	O	965-972
p53	O	973-976
tumor	O	977-982
suppressor	O	983-993
actions	O	994-1001
and	O	1002-1005
,	O	1005-1006
ultimately	O	1007-1017
,	O	1017-1018
resist	O	1019-1025
cytotoxic	O	1026-1035
responses	O	1036-1045
in	O	1046-1048
MM	O	1049-1051
.	O	1051-1052

Use	O	1053-1056
of	O	1057-1059
antisense	O	1060-1069
miR	B	1070-1073
-	I	1073-1074
125b	I	1074-1078
transcripts	O	1079-1090
enhanced	O	1091-1099
expression	O	1100-1110
of	O	1111-1113
pro	O	1114-1117
-	O	1117-1118
apoptotic	O	1118-1127
p53	O	1128-1131
,	O	1131-1132
repressed	O	1133-1142
expression	O	1143-1153
of	O	1154-1156
anti	O	1157-1161
-	O	1161-1162
apoptotic	O	1162-1171
SIRT1	O	1172-1177
and	O	1178-1181
,	O	1181-1182
importantly	O	1183-1194
,	O	1194-1195
significantly	O	1196-1209
enhanced	O	1210-1218
dexamethasone	O	1219-1232
-	O	1232-1233
induced	O	1233-1240
cell	O	1241-1245
death	O	1246-1251
responses	O	1252-1261
in	O	1262-1264
MM	O	1265-1267
.	O	1267-1268

Pharmacological	O	1269-1284
manipulations	O	1285-1298
showed	O	1299-1305
that	O	1306-1310
the	O	1311-1314
key	O	1315-1318
regulation	O	1319-1329
enabling	O	1330-1338
complete	O	1339-1347
dexamethasone	O	1348-1361
sensitivity	O	1362-1373
in	O	1374-1376
MM	O	1377-1379
cells	O	1380-1385
lies	O	1386-1390
with	O	1391-1395
miR	B	1396-1399
-	I	1399-1400
125b	I	1400-1404
.	O	1404-1405

In	O	1406-1408
summary	O	1409-1416
,	O	1416-1417
dexamethasone	O	1418-1431
-	O	1431-1432
induced	O	1432-1439
miR	B	1440-1443
-	I	1443-1444
125b	I	1444-1448
induces	O	1449-1456
cell	O	1457-1461
death	O	1462-1467
resistance	O	1468-1478
mechanisms	O	1479-1489
in	O	1490-1492
MM	O	1493-1495
cells	O	1496-1501
via	O	1502-1505
the	O	1506-1509
p53	O	1510-1513
/	O	1513-1514
miR	B	1514-1517
-	I	1517-1518
34a	I	1518-1521
/	O	1521-1522
SIRT1	O	1522-1527
signaling	O	1528-1537
network	O	1538-1545
and	O	1546-1549
provides	O	1550-1558
these	O	1559-1564
cells	O	1565-1570
with	O	1571-1575
an	O	1576-1578
enhanced	O	1579-1587
level	O	1588-1593
of	O	1594-1596
resistance	O	1597-1607
to	O	1608-1610
cytotoxic	O	1611-1620
chemotherapeutics	O	1621-1638
.	O	1638-1639

Clearly	O	1640-1647
,	O	1647-1648
such	O	1649-1653
anti	O	1654-1658
-	O	1658-1659
apoptotic	O	1659-1668
mechanisms	O	1669-1679
will	O	1680-1684
need	O	1685-1689
to	O	1690-1692
be	O	1693-1695
overcome	O	1696-1704
to	O	1705-1707
more	O	1708-1712
effectively	O	1713-1724
treat	O	1725-1730
nascent	O	1731-1738
,	O	1738-1739
refractory	O	1740-1750
and	O	1751-1754
relapsed	O	1755-1763
MM	O	1764-1766
patients	O	1767-1775
.	O	1775-1776

These	O	1777-1782
mechanisms	O	1783-1793
provide	O	1794-1801
insight	O	1802-1809
into	O	1810-1814
the	O	1815-1818
role	O	1819-1823
of	O	1824-1826
miRNA	O	1827-1832
regulation	O	1833-1843
of	O	1844-1846
apoptosis	O	1847-1856
and	O	1857-1860
their	O	1861-1866
promotion	O	1867-1876
of	O	1877-1879
MM	O	1880-1882
cell	O	1883-1887
proliferative	O	1888-1901
mechanisms	O	1902-1912
.	O	1912-1913

Regulation	O	0-10
of	O	11-13
TIMP3	O	14-19
in	O	20-22
diabetic	O	23-31
nephropathy	O	32-43
:	O	43-44
a	O	45-46
role	O	47-51
for	O	52-55
microRNAs	O	56-65
.	O	65-66

Diabetic	O	67-75
nephropathy	O	76-87
(	O	88-89
DN	O	89-91
)	O	91-92
is	O	93-95
the	O	96-99
major	O	100-105
cause	O	106-111
of	O	112-114
chronic	O	115-122
kidney	O	123-129
disease	O	130-137
in	O	138-140
developed	O	141-150
countries	O	151-160
and	O	161-164
contributes	O	165-176
significantly	O	177-190
to	O	191-193
increased	O	194-203
morbidity	O	204-213
and	O	214-217
mortality	O	218-227
among	O	228-233
diabetic	O	234-242
patients	O	243-251
.	O	251-252

Morphologically	O	253-268
,	O	268-269
DN	O	270-272
is	O	273-275
characterized	O	276-289
by	O	290-292
tubulo	O	293-299
-	O	299-300
interstitial	O	300-312
fibrosis	O	313-321
,	O	321-322
thickening	O	323-333
of	O	334-336
the	O	337-340
glomerular	O	341-351
basement	O	352-360
membrane	O	361-369
and	O	370-373
mesangial	O	374-383
expansion	O	384-393
mainly	O	394-400
due	O	401-404
to	O	405-407
accumulation	O	408-420
of	O	421-423
extracellular	O	424-437
matrix	O	438-444
(	O	445-446
ECM	O	446-449
)	O	449-450
.	O	450-451

ECM	O	452-455
turnover	O	456-464
is	O	465-467
regulated	O	468-477
by	O	478-480
metalloproteinases	O	481-499
and	O	500-503
tissue	O	504-510
inhibitors	O	511-521
of	O	522-524
metalloproteinases	O	525-543
(	O	544-545
TIMPs	O	545-550
)	O	550-551
activities	O	552-562
.	O	562-563

In	O	564-566
diabetic	O	567-575
conditions	O	576-586
,	O	586-587
TIMP3	O	588-593
expression	O	594-604
in	O	605-607
kidney	O	608-614
is	O	615-617
strongly	O	618-626
reduced	O	627-634
,	O	634-635
but	O	636-639
the	O	640-643
causes	O	644-650
of	O	651-653
this	O	654-658
reduction	O	659-668
are	O	669-672
still	O	673-678
unknown	O	679-686
.	O	686-687

The	O	688-691
aim	O	692-695
of	O	696-698
this	O	699-703
study	O	704-709
was	O	710-713
to	O	714-716
elucidate	O	717-726
at	O	727-729
least	O	730-735
one	O	736-739
of	O	740-742
these	O	743-748
mechanisms	O	749-759
which	O	760-765
relies	O	766-772
on	O	773-775
differential	O	776-788
expression	O	789-799
of	O	800-802
TIMP3	O	803-808
-	O	808-809
targeting	O	809-818
microRNAs	O	819-828
(	O	829-830
miRs	O	830-834
)	O	834-835
in	O	836-838
a	O	839-840
hyperglycemic	O	841-854
environment	O	855-866
either	O	867-873
in	O	874-876
vitro	O	877-882
(	O	883-884
MES13	O	884-889
cell	O	890-894
line	O	895-899
)	O	899-900
or	O	901-903
in	O	904-906
vivo	O	907-911
(	O	912-913
mouse	O	913-918
kidney	O	919-925
and	O	926-929
human	O	930-935
biopsies	O	936-944
)	O	944-945
.	O	945-946

Among	O	947-952
the	O	953-956
TIMP3	O	957-962
-	O	962-963
targeting	O	963-972
miRs	O	973-977
,	O	977-978
miR	B	979-982
-	I	982-983
21	I	983-985
and	O	986-989
miR	B	990-993
-	I	993-994
221	I	994-997
were	O	998-1002
significantly	O	1003-1016
upregulated	O	1017-1028
in	O	1029-1031
kidneys	O	1032-1039
from	O	1040-1044
diabetic	O	1045-1053
mice	O	1054-1058
compared	O	1059-1067
to	O	1068-1070
control	O	1071-1078
littermates	O	1079-1090
,	O	1090-1091
and	O	1092-1095
in	O	1096-1098
a	O	1099-1100
mesangial	O	1101-1110
cell	O	1111-1115
line	O	1116-1120
grown	O	1121-1126
in	O	1127-1129
high	O	1130-1134
glucose	O	1135-1142
conditions	O	1143-1153
.	O	1153-1154

In	O	1155-1157
human	O	1158-1163
samples	O	1164-1171
,	O	1171-1172
only	O	1173-1177
miR	B	1178-1181
-	I	1181-1182
21	I	1182-1184
expression	O	1185-1195
was	O	1196-1199
increased	O	1200-1209
in	O	1210-1212
kidney	O	1213-1219
biopsies	O	1220-1228
from	O	1229-1233
diabetic	O	1234-1242
patients	O	1243-1251
compared	O	1252-1260
to	O	1261-1263
healthy	O	1264-1271
controls	O	1272-1280
.	O	1280-1281

The	O	1282-1285
expression	O	1286-1296
of	O	1297-1299
miR	B	1300-1303
-	I	1303-1304
217	I	1304-1307
,	O	1307-1308
which	O	1309-1314
targets	O	1315-1322
TIMP3	O	1323-1328
indirectly	O	1329-1339
through	O	1340-1347
downregulation	O	1348-1362
of	O	1363-1365
SirT1	O	1366-1371
,	O	1371-1372
was	O	1373-1376
also	O	1377-1381
increased	O	1382-1391
in	O	1392-1394
diabetic	O	1395-1403
kidney	O	1404-1410
and	O	1411-1414
MES13	O	1415-1420
cell	O	1421-1425
line	O	1426-1430
.	O	1430-1431

In	O	1432-1434
agreement	O	1435-1444
with	O	1445-1449
these	O	1450-1455
result	O	1456-1462
,	O	1462-1463
SirT1	O	1464-1469
expression	O	1470-1480
was	O	1481-1484
reduced	O	1485-1492
in	O	1493-1495
mouse	O	1496-1501
and	O	1502-1505
human	O	1506-1511
diabetic	O	1512-1520
kidneys	O	1521-1528
as	O	1529-1531
well	O	1532-1536
as	O	1537-1539
in	O	1540-1542
MES13	O	1543-1548
mesangial	O	1549-1558
cell	O	1559-1563
line	O	1564-1568
.	O	1568-1569

TIMP3	O	1570-1575
deficiency	O	1576-1586
has	O	1587-1590
recently	O	1591-1599
emerged	O	1600-1607
as	O	1608-1610
a	O	1611-1612
hallmark	O	1613-1621
of	O	1622-1624
DN	O	1625-1627
in	O	1628-1630
mouse	O	1631-1636
and	O	1637-1640
human	O	1641-1646
.	O	1646-1647

In	O	1648-1650
this	O	1651-1655
study	O	1656-1661
,	O	1661-1662
we	O	1663-1665
demonstrated	O	1666-1678
that	O	1679-1683
this	O	1684-1688
reduction	O	1689-1698
is	O	1699-1701
due	O	1702-1705
,	O	1705-1706
at	O	1707-1709
least	O	1710-1715
in	O	1716-1718
part	O	1719-1723
,	O	1723-1724
to	O	1725-1727
increased	O	1728-1737
expression	O	1738-1748
of	O	1749-1751
certain	O	1752-1759
TIMP3	O	1760-1765
-	O	1765-1766
targeting	O	1766-1775
miRs	O	1776-1780
in	O	1781-1783
diabetic	O	1784-1792
kidneys	O	1793-1800
compared	O	1801-1809
to	O	1810-1812
healthy	O	1813-1820
controls	O	1821-1829
.	O	1829-1830

Unveiling	O	1831-1840
the	O	1841-1844
post	O	1845-1849
-	O	1849-1850
transcriptional	O	1850-1865
mechanisms	O	1866-1876
responsible	O	1877-1888
for	O	1889-1892
TIMP3	O	1893-1898
downregulation	O	1899-1913
in	O	1914-1916
hyperglycemic	O	1917-1930
conditions	O	1931-1941
may	O	1942-1945
orient	O	1946-1952
toward	O	1953-1959
the	O	1960-1963
use	O	1964-1967
of	O	1968-1970
this	O	1971-1975
protein	O	1976-1983
as	O	1984-1986
a	O	1987-1988
possible	O	1989-1997
therapeutic	O	1998-2009
target	O	2010-2016
in	O	2017-2019
DN	O	2020-2022
.	O	2022-2023

MiRNA	B	0-5
-	I	5-6
20	I	6-8
and	O	9-12
mirna	B	13-18
-	I	18-19
106a	I	19-23
regulate	O	24-32
spermatogonial	O	33-47
stem	O	48-52
cell	O	53-57
renewal	O	58-65
at	O	66-68
the	O	69-72
post	O	73-77
-	O	77-78
transcriptional	O	78-93
level	O	94-99
via	O	100-103
targeting	O	104-113
STAT3	O	114-119
and	O	120-123
Ccnd1	O	124-129
.	O	129-130

Studies	O	131-138
on	O	139-141
spermatogonial	O	142-156
stem	O	157-161
cells	O	162-167
(	O	168-169
SSCs	O	169-173
)	O	173-174
are	O	175-178
of	O	179-181
unusual	O	182-189
significance	O	190-202
because	O	203-210
they	O	211-215
are	O	216-219
the	O	220-223
unique	O	224-230
stem	O	231-235
cells	O	236-241
that	O	242-246
transmit	O	247-255
genetic	O	256-263
information	O	264-275
to	O	276-278
subsequent	O	279-289
generations	O	290-301
and	O	302-305
they	O	306-310
can	O	311-314
acquire	O	315-322
pluripotency	O	323-335
to	O	336-338
become	O	339-345
embryonic	O	346-355
stem	O	356-360
-	O	360-361
like	O	361-365
cells	O	366-371
that	O	372-376
have	O	377-381
therapeutic	O	382-393
applications	O	394-406
in	O	407-409
human	O	410-415
diseases	O	416-424
.	O	424-425

MicroRNAs	O	426-435
(	O	436-437
miRNAs	O	437-443
)	O	443-444
have	O	445-449
recently	O	450-458
emerged	O	459-466
as	O	467-469
critical	O	470-478
endogenous	O	479-489
regulators	O	490-500
in	O	501-503
mammalian	O	504-513
cells	O	514-519
.	O	519-520

However	O	521-528
,	O	528-529
the	O	530-533
function	O	534-542
and	O	543-546
mechanisms	O	547-557
of	O	558-560
individual	O	561-571
miRNAs	O	572-578
in	O	579-581
regulating	O	582-592
SSC	O	593-596
fate	O	597-601
remain	O	602-608
unknown	O	609-616
.	O	616-617

Here	O	618-622
,	O	622-623
we	O	624-626
report	O	627-633
for	O	634-637
the	O	638-641
first	O	642-647
time	O	648-652
that	O	653-657
miRNA	B	658-663
-	I	663-664
20	I	664-666
and	O	667-670
miRNA	B	671-676
-	I	676-677
106a	I	677-681
are	O	682-685
preferentially	O	686-700
expressed	O	701-710
in	O	711-713
mouse	O	714-719
SSCs	O	720-724
.	O	724-725

Functional	O	726-736
assays	O	737-743
in	O	744-746
vitro	O	747-752
and	O	753-756
in	O	757-759
vivo	O	760-764
using	O	765-770
miRNA	O	771-776
mimics	O	777-783
and	O	784-787
inhibitors	O	788-798
reveal	O	799-805
that	O	806-810
miRNA	B	811-816
-	I	816-817
20	I	817-819
and	O	820-823
miRNA	B	824-829
-	I	829-830
106a	I	830-834
are	O	835-838
essential	O	839-848
for	O	849-852
renewal	O	853-860
of	O	861-863
SSCs	O	864-868
.	O	868-869

We	O	870-872
further	O	873-880
demonstrate	O	881-892
that	O	893-897
these	O	898-903
two	O	904-907
miRNAs	O	908-914
promote	O	915-922
renewal	O	923-930
at	O	931-933
the	O	934-937
post	O	938-942
-	O	942-943
transcriptional	O	943-958
level	O	959-964
via	O	965-968
targeting	O	969-978
STAT3	O	979-984
and	O	985-988
Ccnd1	O	989-994
and	O	995-998
that	O	999-1003
knockdown	O	1004-1013
of	O	1014-1016
STAT3	O	1017-1022
,	O	1022-1023
Fos	O	1024-1027
,	O	1027-1028
and	O	1029-1032
Ccnd1	O	1033-1038
results	O	1039-1046
in	O	1047-1049
renewal	O	1050-1057
of	O	1058-1060
SSCs	O	1061-1065
.	O	1065-1066

This	O	1067-1071
study	O	1072-1077
thus	O	1078-1082
provides	O	1083-1091
novel	O	1092-1097
insights	O	1098-1106
into	O	1107-1111
molecular	O	1112-1121
mechanisms	O	1122-1132
regulating	O	1133-1143
renewal	O	1144-1151
and	O	1152-1155
differentiation	O	1156-1171
of	O	1172-1174
SSCs	O	1175-1179
and	O	1180-1183
may	O	1184-1187
have	O	1188-1192
important	O	1193-1202
implications	O	1203-1215
for	O	1216-1219
regulating	O	1220-1230
male	O	1231-1235
reproduction	O	1236-1248
.	O	1248-1249

Circulating	O	0-11
microRNAs	O	12-21
predict	O	22-29
biochemical	O	30-41
recurrence	O	42-52
in	O	53-55
prostate	O	56-64
cancer	O	65-71
patients	O	72-80
.	O	80-81

BACKGROUND	O	82-92
:	O	92-93
Circulating	O	94-105
microRNAs	O	106-115
(	O	116-117
miRNAs	O	117-123
)	O	123-124
are	O	125-128
emerging	O	129-137
as	O	138-140
promising	O	141-150
biomarkers	O	151-161
for	O	162-165
prostate	O	166-174
cancer	O	175-181
.	O	181-182

Here	O	183-187
,	O	187-188
we	O	189-191
investigated	O	192-204
the	O	205-208
potential	O	209-218
of	O	219-221
these	O	222-227
molecules	O	228-237
to	O	238-240
assist	O	241-247
in	O	248-250
prognosis	O	251-260
and	O	261-264
treatment	O	265-274
decision	O	275-283
-	O	283-284
making	O	284-290
.	O	290-291

METHODS	O	292-299
:	O	299-300
MicroRNAs	O	301-310
in	O	311-313
the	O	314-317
serum	O	318-323
of	O	324-326
patients	O	327-335
who	O	336-339
had	O	340-343
experienced	O	344-355
rapid	O	356-361
biochemical	O	362-373
recurrence	O	374-384
(	O	385-386
BCR	O	386-389
)	O	389-390
(	O	391-392
n	O	392-393
=	O	393-394
8	O	394-395
)	O	395-396
or	O	397-399
no	O	400-402
recurrence	O	403-413
(	O	414-415
n	O	415-416
=	O	416-417
8	O	417-418
)	O	418-419
following	O	420-429
radical	O	430-437
prostatectomy	O	438-451
(	O	452-453
RP	O	453-455
)	O	455-456
were	O	457-461
profiled	O	462-470
using	O	471-476
high	O	477-481
-	O	481-482
throughput	O	482-492
qRT	O	493-496
-	O	496-497
PCR	O	497-500
.	O	500-501

Recurrence	O	502-512
-	O	512-513
associated	O	513-523
miRNAs	O	524-530
were	O	531-535
subsequently	O	536-548
quantitated	O	549-560
by	O	561-563
qRT	O	564-567
-	O	567-568
PCR	O	568-571
in	O	572-574
a	O	575-576
validation	O	577-587
cohort	O	588-594
comprised	O	595-604
of	O	605-607
70	O	608-610
patients	O	611-619
with	O	620-624
Gleason	O	625-632
7	O	633-634
cancers	O	635-642
treated	O	643-650
by	O	651-653
RP	O	654-656
,	O	656-657
31	O	658-660
of	O	661-663
whom	O	664-668
had	O	669-672
undergone	O	673-682
disease	O	683-690
progression	O	691-702
following	O	703-712
surgery	O	713-720
.	O	720-721

The	O	722-725
expression	O	726-736
of	O	737-739
recurrence	O	740-750
-	O	750-751
associated	O	751-761
miRNAs	O	762-768
was	O	769-772
also	O	773-777
examined	O	778-786
in	O	787-789
tumour	O	790-796
tissue	O	797-803
cohorts	O	804-811
.	O	811-812

RESULTS	O	813-820
:	O	820-821
Three	O	822-827
miRNAs	O	828-834
-	O	835-836
miR	B	837-840
-	I	840-841
141	I	841-844
,	O	844-845
miR	B	846-849
-	I	849-850
146b	I	850-854
-	I	854-855
3p	I	855-857
and	O	858-861
miR	B	862-865
-	I	865-866
194	I	866-869
-	O	870-871
were	O	872-876
elevated	O	877-885
in	O	886-888
patients	O	889-897
who	O	898-901
subsequently	O	902-914
experienced	O	915-926
BCR	O	927-930
in	O	931-933
the	O	934-937
screening	O	938-947
study	O	948-953
.	O	953-954

MiR	B	955-958
-	I	958-959
146b	I	959-963
-	I	963-964
3p	I	964-966
and	O	967-970
miR	B	971-974
-	I	974-975
194	I	975-978
were	O	979-983
also	O	984-988
associated	O	989-999
with	O	1000-1004
disease	O	1005-1012
progression	O	1013-1024
in	O	1025-1027
the	O	1028-1031
validation	O	1032-1042
cohort	O	1043-1049
,	O	1049-1050
as	O	1051-1053
determined	O	1054-1064
by	O	1065-1067
log	O	1068-1071
-	O	1071-1072
rank	O	1072-1076
tests	O	1077-1082
and	O	1083-1086
Cox	O	1087-1090
proportional	O	1091-1103
hazards	O	1104-1111
regression	O	1112-1122
.	O	1122-1123

Multivariate	O	1124-1136
analysis	O	1137-1145
revealed	O	1146-1154
that	O	1155-1159
miR	B	1160-1163
-	I	1163-1164
146b	I	1164-1168
-	I	1168-1169
3p	I	1169-1171
possessed	O	1172-1181
prognostic	O	1182-1192
information	O	1193-1204
beyond	O	1205-1211
standard	O	1212-1220
clinicopathological	O	1221-1240
parameters	O	1241-1251
.	O	1251-1252

Analysis	O	1253-1261
of	O	1262-1264
tissue	O	1265-1271
cohorts	O	1272-1279
revealed	O	1280-1288
that	O	1289-1293
miR	B	1294-1297
-	I	1297-1298
194	I	1298-1301
was	O	1302-1305
robustly	O	1306-1314
expressed	O	1315-1324
in	O	1325-1327
the	O	1328-1331
prostate	O	1332-1340
,	O	1340-1341
elevated	O	1342-1350
in	O	1351-1353
metastases	O	1354-1364
,	O	1364-1365
and	O	1366-1369
its	O	1370-1373
expression	O	1374-1384
in	O	1385-1387
primary	O	1388-1395
tumours	O	1396-1403
was	O	1404-1407
associated	O	1408-1418
with	O	1419-1423
a	O	1424-1425
poor	O	1426-1430
prognosis	O	1431-1440
.	O	1440-1441

CONCLUSION	O	1442-1452
:	O	1452-1453
Our	O	1454-1457
study	O	1458-1463
suggests	O	1464-1472
that	O	1473-1477
circulating	O	1478-1489
miRNAs	O	1490-1496
,	O	1496-1497
measured	O	1498-1506
at	O	1507-1509
the	O	1510-1513
time	O	1514-1518
of	O	1519-1521
RP	O	1522-1524
,	O	1524-1525
could	O	1526-1531
be	O	1532-1534
combined	O	1535-1543
with	O	1544-1548
current	O	1549-1556
prognostic	O	1557-1567
tools	O	1568-1573
to	O	1574-1576
predict	O	1577-1584
future	O	1585-1591
disease	O	1592-1599
progression	O	1600-1611
in	O	1612-1614
men	O	1615-1618
with	O	1619-1623
intermediate	O	1624-1636
risk	O	1637-1641
prostate	O	1642-1650
cancers	O	1651-1658
.	O	1658-1659

Global	O	0-6
microRNA	O	7-15
expression	O	16-26
profiling	O	27-36
reveals	O	37-44
differential	O	45-57
expression	O	58-68
of	O	69-71
target	O	72-78
genes	O	79-84
in	O	85-87
6	O	88-89
-	O	89-90
hydroxydopamine	O	90-105
-	O	105-106
injured	O	106-113
MN9D	O	114-118
cells	O	119-124
.	O	124-125

Recent	O	126-132
evidence	O	133-141
indicates	O	142-151
that	O	152-156
microRNAs	O	157-166
(	O	167-168
miRNAs	O	168-174
)	O	174-175
play	O	176-180
a	O	181-182
key	O	183-186
role	O	187-191
in	O	192-194
neurodegenerative	O	195-212
diseases	O	213-221
.	O	221-222

However	O	223-230
,	O	230-231
little	O	232-238
is	O	239-241
known	O	242-247
about	O	248-253
how	O	254-257
these	O	258-263
small	O	264-269
RNAs	O	270-274
contribute	O	275-285
to	O	286-288
dopaminergic	O	289-301
neuronal	O	302-310
apoptosis	O	311-320
.	O	320-321

Here	O	322-326
,	O	326-327
we	O	328-330
profiled	O	331-339
the	O	340-343
expression	O	344-354
of	O	355-357
miRNAs	O	358-364
in	O	365-367
MN9D	O	368-372
cells	O	373-378
with	O	379-383
and	O	384-387
without	O	388-395
6	O	396-397
-	O	397-398
hydroxydopamine	O	398-413
(	O	414-415
6	O	415-416
-	O	416-417
OHDA	O	417-421
)	O	421-422
treatment	O	423-432
by	O	433-435
miRCURY	O	436-443
LNA	O	444-447
microRNA	O	448-456
arrays	O	457-463
.	O	463-464

We	O	465-467
identified	O	468-478
six	O	479-482
miRNAs	O	483-489
(	O	490-491
miR	B	491-494
-	I	494-495
668	I	495-498
-	I	498-499
3p	I	499-501
,	O	501-502
let	B	503-506
-	I	506-507
7d	I	507-509
-	I	509-510
3p	I	510-512
,	O	512-513
miR	B	514-517
-	I	517-518
3077	I	518-522
-	I	522-523
3p	I	523-525
,	O	525-526
miR	B	527-530
-	I	530-531
665	I	531-534
-	I	534-535
5p	I	535-537
,	O	537-538
miR	B	539-542
-	I	542-543
99b	I	543-546
-	I	546-547
3p	I	547-549
,	O	549-550
and	O	551-554
miR	B	555-558
-	I	558-559
323	I	559-562
-	I	562-563
3p	I	563-565
)	O	565-566
that	O	567-571
were	O	572-576
significantly	O	577-590
lower	O	591-596
and	O	597-600
five	O	601-605
miRNAs	O	606-612
(	O	613-614
miR	B	614-617
-	I	617-618
875	I	618-621
,	O	621-622
miR	B	623-626
-	I	626-627
207	I	627-630
,	O	630-631
miR	B	632-635
-	I	635-636
425	I	636-639
-	I	639-640
5p	I	640-642
,	O	642-643
miR	B	644-647
-	I	647-648
19b	I	648-651
-	I	651-652
3p	I	652-654
,	O	654-655
and	O	656-659
miR	B	660-663
-	I	663-664
338	I	664-667
-	I	667-668
3p	I	668-670
)	O	670-671
that	O	672-676
were	O	677-681
significantly	O	682-695
higher	O	696-702
after	O	703-708
6	O	709-710
-	O	710-711
OHDA	O	711-715
treatment	O	716-725
.	O	725-726

Among	O	727-732
them	O	733-737
,	O	737-738
five	O	739-743
have	O	744-748
been	O	749-753
demonstrated	O	754-766
to	O	767-769
be	O	770-772
implicated	O	773-783
in	O	784-786
neurodegenerative	O	787-804
diseases	O	805-813
.	O	813-814

Consistent	O	815-825
with	O	826-830
our	O	831-834
prediction	O	835-845
,	O	845-846
the	O	847-850
deregulated	O	851-862
miRNA	O	863-868
'	O	868-869
s	O	869-870
target	O	871-877
mRNAs	O	878-883
,	O	883-884
such	O	885-889
as	O	890-892
peroxiredoxin	O	893-906
III	O	907-910
(	O	911-912
Prx	O	912-915
III	O	916-919
)	O	919-920
and	O	921-924
Myc	O	925-928
,	O	928-929
also	O	930-934
showed	O	935-941
changes	O	942-949
in	O	950-952
their	O	953-958
expression	O	959-969
levels	O	970-976
.	O	976-977

Furthermore	O	978-989
,	O	989-990
using	O	991-996
a	O	997-998
dual	O	999-1003
-	O	1003-1004
luciferase	O	1004-1014
reporter	O	1015-1023
assay	O	1024-1029
,	O	1029-1030
we	O	1031-1033
confirmed	O	1034-1043
that	O	1044-1048
Prx	O	1049-1052
III	O	1053-1056
was	O	1057-1060
a	O	1061-1062
direct	O	1063-1069
target	O	1070-1076
gene	O	1077-1081
of	O	1082-1084
miR	B	1085-1088
-	I	1088-1089
875	I	1089-1092
.	O	1092-1093

Taken	O	1094-1099
together	O	1100-1108
,	O	1108-1109
these	O	1110-1115
findings	O	1116-1124
demonstrate	O	1125-1136
that	O	1137-1141
changes	O	1142-1149
in	O	1150-1152
miRNA	O	1153-1158
expression	O	1159-1169
occur	O	1170-1175
after	O	1176-1181
6	O	1182-1183
-	O	1183-1184
OHDA	O	1184-1188
treatment	O	1189-1198
and	O	1199-1202
suggest	O	1203-1210
that	O	1211-1215
miRNAs	O	1216-1222
and	O	1223-1226
their	O	1227-1232
predicted	O	1233-1242
targets	O	1243-1250
have	O	1251-1255
a	O	1256-1257
potential	O	1258-1267
role	O	1268-1272
in	O	1273-1275
apoptosis	O	1276-1285
of	O	1286-1288
MN9D	O	1289-1293
cells	O	1294-1299
.	O	1299-1300

Diallyl	O	0-7
disulfide	O	8-17
suppresses	O	18-28
proliferation	O	29-42
and	O	43-46
induces	O	47-54
apoptosis	O	55-64
in	O	65-67
human	O	68-73
gastric	O	74-81
cancer	O	82-88
through	O	89-96
Wnt	O	97-100
-	O	100-101
1	O	101-102
signaling	O	103-112
pathway	O	113-120
by	O	121-123
up	O	124-126
-	O	126-127
regulation	O	127-137
of	O	138-140
miR	B	141-144
-	I	144-145
200b	I	145-149
and	O	150-153
miR	B	154-157
-	I	157-158
22	I	158-160
.	O	160-161

The	O	162-165
purpose	O	166-173
of	O	174-176
this	O	177-181
study	O	182-187
was	O	188-191
to	O	192-194
identify	O	195-203
a	O	204-205
mechanism	O	206-215
related	O	216-223
to	O	224-226
miRNA	O	227-232
pathway	O	233-240
which	O	241-246
plays	O	247-252
a	O	253-254
role	O	255-259
in	O	260-262
the	O	263-266
anti	O	267-271
-	O	271-272
tumor	O	272-277
effects	O	278-285
of	O	286-288
Diallyl	O	289-296
disulfide	O	297-306
.	O	306-307

Alterations	O	308-319
in	O	320-322
miRNA	O	323-328
expression	O	329-339
were	O	340-344
observed	O	345-353
in	O	354-356
Diallyl	O	357-364
disulfide	O	365-374
-	O	374-375
treated	O	375-382
MGC	O	383-386
-	O	386-387
803	O	387-390
cells	O	391-396
,	O	396-397
including	O	398-407
up	O	408-410
-	O	410-411
regulation	O	411-421
of	O	422-424
miR	B	425-428
-	I	428-429
200b	I	429-433
and	O	434-437
miR	B	438-441
-	I	441-442
22	I	442-444
expression	O	445-455
.	O	455-456

Furthermore	O	457-468
,	O	468-469
Wnt	O	470-473
-	O	473-474
1	O	474-475
was	O	476-479
identified	O	480-490
as	O	491-493
a	O	494-495
target	O	496-502
of	O	503-505
both	O	506-510
miR	B	511-514
-	I	514-515
200b	I	515-519
and	O	520-523
miR	B	524-527
-	I	527-528
22	I	528-530
.	O	530-531

MiR	B	532-535
-	I	535-536
200b	I	536-540
and	O	541-544
miR	B	545-548
-	I	548-549
22	I	549-551
not	O	552-555
only	O	556-560
synergistically	O	561-576
inhibited	O	577-586
gastric	O	587-594
cancer	O	595-601
growth	O	602-608
,	O	608-609
but	O	610-613
also	O	614-618
enhanced	O	619-627
the	O	628-631
antitumor	O	632-641
effect	O	642-648
of	O	649-651
Diallyl	O	652-659
disulfide	O	660-669
both	O	670-674
in	O	675-677
vitro	O	678-683
and	O	684-687
in	O	688-690
vivo	O	691-695
.	O	695-696

It	O	697-699
indicated	O	700-709
that	O	710-714
miR	B	715-718
-	I	718-719
200b	I	719-723
and	O	724-727
miR	B	728-731
-	I	731-732
22	I	732-734
may	O	735-738
serve	O	739-744
as	O	745-747
potential	O	748-757
gene	O	758-762
therapy	O	763-770
and	O	771-774
enhance	O	775-782
Diallyl	O	783-790
disulfide	O	791-800
antitumor	O	801-810
effects	O	811-818
.	O	818-819

The	O	0-3
role	O	4-8
of	O	9-11
miR	B	12-15
-	I	15-16
145	I	16-19
in	O	20-22
microvasculature	O	23-39
.	O	39-40

Increasing	O	41-51
evidence	O	52-60
suggests	O	61-69
that	O	70-74
microRNAs	O	75-84
(	O	84-85
miRs	O	85-89
)	O	89-90
play	O	91-95
a	O	96-97
crucial	O	98-105
role	O	106-110
in	O	111-113
the	O	114-117
cardiovascular	O	118-132
system	O	133-139
,	O	139-140
and	O	141-144
recent	O	145-151
studies	O	152-159
have	O	160-164
revealed	O	165-173
a	O	174-175
significant	O	176-187
role	O	188-192
of	O	193-195
miRs	O	196-200
in	O	201-203
vascular	O	204-212
biology	O	213-220
and	O	221-224
disease	O	225-232
,	O	232-233
miR	B	234-237
-	I	237-238
145	I	238-241
is	O	242-244
one	O	245-248
of	O	249-251
the	O	252-255
most	O	256-260
-	O	260-261
studied	O	261-268
miRs	O	269-273
,	O	273-274
and	O	275-278
especially	O	279-289
in	O	290-292
the	O	293-296
vascular	O	297-305
smooth	O	306-312
muscle	O	313-319
cell	O	320-324
(	O	325-326
VSMCs	O	326-331
)	O	331-332
proliferation	O	333-346
,	O	346-347
differentiation	O	348-363
,	O	363-364
and	O	365-368
phenotypic	O	369-379
switching	O	380-389
.	O	389-390

In	O	391-393
cardiovascular	O	394-408
system	O	409-415
,	O	415-416
miR	B	417-420
-	I	420-421
145	I	421-424
is	O	425-427
not	O	428-431
only	O	432-436
important	O	437-446
for	O	447-450
heart	O	451-456
and	O	457-460
vascular	O	461-469
development	O	470-481
but	O	482-485
also	O	486-490
plays	O	491-496
an	O	497-499
essential	O	500-509
role	O	510-514
in	O	515-517
cardiac	O	518-525
pathological	O	526-538
factors	O	539-546
,	O	546-547
such	O	548-552
as	O	553-555
hypertrophy	O	556-567
,	O	567-568
and	O	569-572
ischemia	O	573-581
.	O	581-582

However	O	583-590
,	O	590-591
its	O	592-595
potential	O	596-605
role	O	606-610
in	O	611-613
microvasculature	O	614-630
has	O	631-634
not	O	635-638
been	O	639-643
systematically	O	644-658
evaluated	O	659-668
yet	O	669-672
.	O	672-673

We	O	674-676
are	O	677-680
just	O	681-685
beginning	O	686-695
to	O	696-698
understand	O	699-709
the	O	710-713
regulation	O	714-724
of	O	725-727
miR	O	728-731
in	O	732-734
vascular	O	735-743
biology	O	744-751
.	O	751-752

In	O	753-755
particular	O	756-766
,	O	766-767
the	O	768-771
miR	O	772-775
biogenesis	O	776-786
and	O	787-790
regulatory	O	791-801
pathways	O	802-810
in	O	811-813
the	O	814-817
vascular	O	818-826
system	O	827-833
have	O	834-838
not	O	839-842
yet	O	843-846
been	O	847-851
well	O	852-856
characterized	O	857-870
,	O	870-871
This	O	872-876
review	O	877-883
focuses	O	884-891
on	O	892-894
the	O	895-898
basic	O	899-904
biology	O	905-912
and	O	913-916
mechanism	O	917-926
of	O	927-929
action	O	930-936
of	O	937-939
miR	B	940-943
-	I	943-944
145	I	944-947
specifically	O	948-960
pertaining	O	961-971
to	O	972-974
microvascular	O	975-988
development	O	989-1000
,	O	1000-1001
pericyte	O	1002-1010
and	O	1011-1014
disease	O	1015-1022
,	O	1022-1023
In	O	1024-1026
addition	O	1027-1035
it	O	1036-1038
addresses	O	1039-1048
the	O	1049-1052
potential	O	1053-1062
for	O	1063-1066
miR	B	1067-1070
-	I	1070-1071
145	I	1071-1074
to	O	1075-1077
be	O	1078-1080
used	O	1081-1085
therapeutically	O	1086-1101
in	O	1102-1104
the	O	1105-1108
treatment	O	1109-1118
of	O	1119-1121
microvascular	O	1122-1135
disease	O	1136-1143
.	O	1143-1144

MicroRNA	O	0-8
regulate	O	9-17
immune	O	18-24
pathways	O	25-33
in	O	34-36
T	O	37-38
-	O	38-39
cells	O	39-44
in	O	45-47
multiple	O	48-56
sclerosis	O	57-66
(	O	67-68
MS	O	68-70
)	O	70-71
.	O	71-72

BACKGROUND	O	73-83
:	O	83-84
MicroRNA	O	85-93
are	O	94-97
small	O	98-103
noncoding	O	104-113
RNA	O	114-117
molecules	O	118-127
that	O	128-132
are	O	133-136
involved	O	137-145
in	O	146-148
the	O	149-152
control	O	153-160
of	O	161-163
gene	O	164-168
expression	O	169-179
.	O	179-180

To	O	181-183
investigate	O	184-195
the	O	196-199
role	O	200-204
of	O	205-207
microRNA	O	208-216
in	O	217-219
multiple	O	220-228
sclerosis	O	229-238
(	O	239-240
MS	O	240-242
)	O	242-243
,	O	243-244
we	O	245-247
performed	O	248-257
genome	O	258-264
-	O	264-265
wide	O	265-269
expression	O	270-280
analyses	O	281-289
of	O	290-292
mRNA	O	293-297
and	O	298-301
microRNA	O	302-310
in	O	311-313
T	O	314-315
-	O	315-316
cells	O	316-321
from	O	322-326
MS	O	327-329
patients	O	330-338
and	O	339-342
controls	O	343-351
.	O	351-352

METHODS	O	353-360
:	O	360-361
Heparin	O	362-369
-	O	369-370
anticoagulated	O	370-384
peripheral	O	385-395
blood	O	396-401
was	O	402-405
collected	O	406-415
from	O	416-420
MS	O	421-423
-	O	423-424
patients	O	424-432
and	O	433-436
healthy	O	437-444
controls	O	445-453
followed	O	454-462
by	O	463-465
isolation	O	466-475
of	O	476-478
T	O	479-480
-	O	480-481
cells	O	481-486
.	O	486-487

MicroRNA	O	488-496
and	O	497-500
RNA	O	501-504
from	O	505-509
T	O	510-511
-	O	511-512
cells	O	512-517
was	O	518-521
prepared	O	522-530
and	O	531-534
hybridized	O	535-545
to	O	546-548
Affymetrix	O	549-559
miR	O	560-563
2	O	564-565
.	O	565-566
0	O	566-567
array	O	568-573
and	O	574-577
Affymetrix	O	578-588
U133Plus	O	589-597
2	O	598-599
.	O	599-600
0	O	600-601
Human	O	602-607
Genome	O	608-614
array	O	615-620
(	O	621-622
Santa	O	622-627
Clara	O	628-633
,	O	633-634
CA	O	635-637
)	O	637-638
,	O	638-639
respectively	O	640-652
.	O	652-653

Verifications	O	654-667
were	O	668-672
performed	O	673-682
with	O	683-687
real	O	688-692
-	O	692-693
time	O	693-697
polymerase	O	698-708
chain	O	709-714
reaction	O	715-723
(	O	724-725
PCR	O	725-728
)	O	728-729
and	O	730-733
enzyme	O	734-740
-	O	740-741
linked	O	741-747
immunosorbent	O	748-761
assay	O	762-767
(	O	768-769
ELISA	O	769-774
)	O	774-775
.	O	775-776

RESULTS	O	777-784
:	O	784-785
We	O	786-788
identified	O	789-799
2	O	800-801
,	O	801-802
452	O	802-805
differentially	O	806-820
expressed	O	821-830
genes	O	831-836
and	O	837-840
21	O	841-843
differentially	O	844-858
expressed	O	859-868
microRNA	O	869-877
between	O	878-885
MS	O	886-888
patients	O	889-897
and	O	898-901
controls	O	902-910
.	O	910-911

By	O	912-914
Kolmogorov	O	915-925
-	O	925-926
Smirnov	O	926-933
test	O	934-938
,	O	938-939
20	O	940-942
of	O	943-945
21	O	946-948
differentially	O	949-963
expressed	O	964-973
microRNA	O	974-982
were	O	983-987
shown	O	988-993
to	O	994-996
affect	O	997-1003
the	O	1004-1007
expression	O	1008-1018
of	O	1019-1021
their	O	1022-1027
target	O	1028-1034
genes	O	1035-1040
,	O	1040-1041
many	O	1042-1046
of	O	1047-1049
which	O	1050-1055
were	O	1056-1060
involved	O	1061-1069
in	O	1070-1072
the	O	1073-1076
immune	O	1077-1083
system	O	1084-1090
.	O	1090-1091

Tumor	O	1092-1097
necrosis	O	1098-1106
factor	O	1107-1113
ligand	O	1114-1120
superfamily	O	1121-1132
member	O	1133-1139
14	O	1140-1142
(	O	1143-1144
TNFSF14	O	1144-1151
)	O	1151-1152
was	O	1153-1156
a	O	1157-1158
microRNA	O	1159-1167
target	O	1168-1174
gene	O	1175-1179
significantly	O	1180-1193
decreased	O	1194-1203
in	O	1204-1206
MS	O	1207-1209
.	O	1209-1210

The	O	1211-1214
differential	O	1215-1227
expression	O	1228-1238
of	O	1239-1241
mir	B	1242-1245
-	I	1245-1246
494	I	1246-1249
,	O	1249-1250
mir	B	1251-1254
-	I	1254-1255
197	I	1255-1258
and	O	1259-1262
the	O	1263-1266
predicted	O	1267-1276
microRNA	O	1277-1285
target	O	1286-1292
gene	O	1293-1297
TNFSF14	O	1298-1305
was	O	1306-1309
verified	O	1310-1318
by	O	1319-1321
real	O	1322-1326
-	O	1326-1327
time	O	1327-1331
PCR	O	1332-1335
and	O	1336-1339
ELISA	O	1340-1345
.	O	1345-1346

CONCLUSION	O	1347-1357
:	O	1357-1358
These	O	1359-1364
findings	O	1365-1373
indicate	O	1374-1382
that	O	1383-1387
microRNA	O	1388-1396
may	O	1397-1400
be	O	1401-1403
important	O	1404-1413
regulatory	O	1414-1424
molecules	O	1425-1434
in	O	1435-1437
T	O	1438-1439
-	O	1439-1440
cells	O	1440-1445
in	O	1446-1448
MS	O	1449-1451
.	O	1451-1452

miR	B	0-3
-	I	3-4
133a	I	4-8
represses	O	9-18
tumour	O	19-25
growth	O	26-32
and	O	33-36
metastasis	O	37-47
in	O	48-50
colorectal	O	51-61
cancer	O	62-68
by	O	69-71
targeting	O	72-81
LIM	O	82-85
and	O	86-89
SH3	O	90-93
protein	O	94-101
1	O	102-103
and	O	104-107
inhibiting	O	108-118
the	O	119-122
MAPK	O	123-127
pathway	O	128-135
.	O	135-136

In	O	137-139
recent	O	140-146
studies	O	147-154
of	O	155-157
microRNA	O	158-166
expression	O	167-177
,	O	177-178
miR	B	179-182
-	I	182-183
133a	I	183-187
deregulation	O	188-200
was	O	201-204
identified	O	205-215
in	O	216-218
colorectal	O	219-229
carcinoma	O	230-239
(	O	240-241
CRC	O	241-244
)	O	244-245
.	O	245-246

However	O	247-254
,	O	254-255
the	O	256-259
mechanisms	O	260-270
underlying	O	271-281
the	O	282-285
pathogenesis	O	286-298
and	O	299-302
progression	O	303-314
of	O	315-317
CRC	O	318-321
are	O	322-325
poorly	O	326-332
understood	O	333-343
.	O	343-344

We	O	345-347
found	O	348-353
that	O	354-358
miR	B	359-362
-	I	362-363
133a	I	363-367
expression	O	368-378
was	O	379-382
usually	O	383-390
down	O	391-395
-	O	395-396
regulated	O	396-405
in	O	406-408
CRC	O	409-412
cell	O	413-417
lines	O	418-423
and	O	424-427
tissue	O	428-434
specimens	O	435-444
.	O	444-445

Ectopic	O	446-453
miR	B	454-457
-	I	457-458
133a	I	458-462
expression	O	463-473
inhibited	O	474-483
cell	O	484-488
proliferation	O	489-502
and	O	503-506
cell	O	507-511
migration	O	512-521
.	O	521-522

Stable	O	523-529
overexpression	O	530-544
of	O	545-547
miR	B	548-551
-	I	551-552
133a	I	552-556
was	O	557-560
sufficient	O	561-571
to	O	572-574
suppress	O	575-583
tumour	O	584-590
growth	O	591-597
and	O	598-601
intrahepatic	O	602-614
and	O	615-618
pulmonary	O	619-628
metastasis	O	629-639
in	O	640-642
vivo	O	643-647
.	O	647-648

Additional	O	649-659
studies	O	660-667
showed	O	668-674
that	O	675-679
miR	B	680-683
-	I	683-684
133a	I	684-688
can	O	689-692
target	O	693-699
the	O	700-703
3	O	704-705
'	O	705-706
untranslated	O	707-719
region	O	720-726
(	O	727-728
3	O	728-729
'	O	729-730
UTR	O	730-733
)	O	733-734
of	O	735-737
LIM	O	738-741
and	O	742-745
SH3	O	746-749
protein	O	750-757
1	O	758-759
(	O	760-761
LASP1	O	761-766
)	O	766-767
mRNA	O	768-772
and	O	773-776
suppress	O	777-785
the	O	786-789
expression	O	790-800
of	O	801-803
LASP1	O	804-809
,	O	809-810
which	O	811-816
we	O	817-819
identified	O	820-830
in	O	831-833
previous	O	834-842
studies	O	843-850
as	O	851-853
a	O	854-855
CRC	O	856-859
-	O	859-860
associated	O	860-870
protein	O	871-878
.	O	878-879

In	O	880-882
contrast	O	883-891
to	O	892-894
the	O	895-898
phenotypes	O	899-909
induced	O	910-917
by	O	918-920
miR	B	921-924
-	I	924-925
133a	I	925-929
restoration	O	930-941
,	O	941-942
LASP1	O	943-948
-	O	948-949
induced	O	949-956
cell	O	957-961
proliferation	O	962-975
and	O	976-979
migration	O	980-989
rescued	O	990-997
miR	B	998-1001
-	I	1001-1002
133a	I	1002-1006
-	O	1006-1007
mediated	O	1007-1015
biological	O	1016-1026
behaviours	O	1027-1037
,	O	1037-1038
as	O	1039-1041
did	O	1042-1045
LASP1	O	1046-1051
overexpression	O	1052-1066
.	O	1066-1067

Investigations	O	1068-1082
of	O	1083-1085
possible	O	1086-1094
mechanisms	O	1095-1105
underlying	O	1106-1116
these	O	1117-1122
behaviours	O	1123-1133
revealed	O	1134-1142
that	O	1143-1147
miR	B	1148-1151
-	I	1151-1152
133a	I	1152-1156
modulates	O	1157-1166
the	O	1167-1170
expression	O	1171-1181
of	O	1182-1184
key	O	1185-1188
cellular	O	1189-1197
molecules	O	1198-1207
and	O	1208-1211
participates	O	1212-1224
in	O	1225-1227
the	O	1228-1231
MAPK	O	1232-1236
pathway	O	1237-1244
by	O	1245-1247
inhibiting	O	1248-1258
phosphorylation	O	1259-1274
of	O	1275-1277
ERK	O	1278-1281
and	O	1282-1285
MEK	O	1286-1289
.	O	1289-1290

miR	B	1291-1294
-	I	1294-1295
133a	I	1295-1299
may	O	1300-1303
play	O	1304-1308
a	O	1309-1310
key	O	1311-1314
role	O	1315-1319
in	O	1320-1322
CRC	O	1323-1326
genesis	O	1327-1334
and	O	1335-1338
metastasis	O	1339-1349
,	O	1349-1350
which	O	1351-1356
suggests	O	1357-1365
its	O	1366-1369
potential	O	1370-1379
role	O	1380-1384
in	O	1385-1387
the	O	1388-1391
molecular	O	1392-1401
therapy	O	1402-1409
of	O	1410-1412
cancer	O	1413-1419
.	O	1419-1420

Novel	O	0-5
anthranilamide	O	6-20
-	O	20-21
pyrazolo	O	21-29
[	O	29-30
1	O	30-31
,	O	31-32
5	O	32-33
-	O	33-34
a	O	34-35
]	O	35-36
pyrimidine	O	36-46
conjugates	O	47-57
modulate	O	58-66
the	O	67-70
expression	O	71-81
of	O	82-84
p53	O	85-88
-	O	88-89
MYCN	O	89-93
associated	O	94-104
micro	O	105-110
RNAs	O	111-115
in	O	116-118
neuroblastoma	O	119-132
cells	O	133-138
and	O	139-142
cause	O	143-148
cell	O	149-153
cycle	O	154-159
arrest	O	160-166
and	O	167-170
apoptosis	O	171-180
.	O	180-181

It	O	182-184
has	O	185-188
previously	O	189-199
been	O	200-204
shown	O	205-210
that	O	211-215
anthranilamide	O	216-230
-	O	230-231
pyrazolo	O	231-239
[	O	239-240
1	O	240-241
,	O	241-242
5	O	242-243
-	O	243-244
a	O	244-245
]	O	245-246
pyrimidine	O	246-256
conjugates	O	257-267
activate	O	268-276
p53	O	277-280
and	O	281-284
cause	O	285-290
apoptosis	O	291-300
in	O	301-303
cervical	O	304-312
cancer	O	313-319
cells	O	320-325
such	O	326-330
as	O	331-333
HeLa	O	334-338
and	O	339-342
SiHa	O	343-347
.	O	347-348

Here	O	349-353
we	O	354-356
establish	O	357-366
the	O	367-370
role	O	371-375
of	O	376-378
these	O	379-384
conjugates	O	385-395
in	O	396-398
activating	O	399-409
p53	O	410-413
pathway	O	414-421
by	O	422-424
phosphorylation	O	425-440
at	O	441-443
Ser15	O	444-449
,	O	449-450
20	O	451-453
and	O	454-457
46	O	458-460
residues	O	461-469
and	O	470-473
downregulate	O	474-486
key	O	487-490
oncogenic	O	491-500
proteins	O	501-509
such	O	510-514
as	O	515-517
MYCN	O	518-522
and	O	523-526
Mdm2	O	527-531
in	O	532-534
IMR	O	535-538
-	O	538-539
32	O	539-541
neuroblastoma	O	542-555
cells	O	556-561
.	O	561-562

Compounds	O	563-572
decreased	O	573-582
the	O	583-586
proliferation	O	587-600
rate	O	601-605
of	O	606-608
neuroblastoma	O	609-622
cells	O	623-628
such	O	629-633
as	O	634-636
IMR	O	637-640
-	O	640-641
32	O	641-643
,	O	643-644
Neuro	O	645-650
-	O	650-651
2a	O	651-653
,	O	653-654
SK	O	655-657
-	O	657-658
N	O	658-659
-	O	659-660
SH	O	660-662
.	O	662-663

Compound	O	664-672
treatment	O	673-682
resulted	O	683-691
in	O	692-694
G2	O	695-697
/	O	697-698
M	O	698-699
cell	O	700-704
cycle	O	705-710
arrest	O	711-717
.	O	717-718

The	O	719-722
expression	O	723-733
of	O	734-736
p53	O	737-740
dependent	O	741-750
genes	O	751-756
such	O	757-761
as	O	762-764
p21	O	765-768
,	O	768-769
Bax	O	770-773
,	O	773-774
caspases	O	775-783
was	O	784-787
increased	O	788-797
with	O	798-802
concomitant	O	803-814
decrease	O	815-823
of	O	824-826
the	O	827-830
survival	O	831-839
proteins	O	840-848
as	O	849-851
well	O	852-856
as	O	857-859
anti	O	860-864
-	O	864-865
apoptotic	O	865-874
proteins	O	875-883
such	O	884-888
as	O	889-891
Akt1	O	892-896
,	O	896-897
E2F1	O	898-902
and	O	903-906
Bcl2	O	907-911
.	O	911-912

In	O	913-915
addition	O	916-924
the	O	925-928
expression	O	929-939
of	O	940-942
important	O	943-952
microRNAs	O	953-962
such	O	963-967
as	O	968-970
miR	B	971-974
-	I	974-975
34a	I	975-978
,	O	978-979
c	B	980-981
,	O	981-982
miR	B	983-986
-	I	986-987
200b	I	987-991
,	O	991-992
miR	B	993-996
-	I	996-997
107	I	997-1000
,	O	1000-1001
miR	B	1002-1005
-	I	1005-1006
542	I	1006-1009
-	I	1009-1010
5p	I	1010-1012
and	O	1013-1016
miR	B	1017-1020
-	I	1020-1021
605	I	1021-1024
were	O	1025-1029
significantly	O	1030-1043
increased	O	1044-1053
that	O	1054-1058
eventually	O	1059-1069
lead	O	1070-1074
to	O	1075-1077
the	O	1078-1081
activation	O	1082-1092
of	O	1093-1095
apoptotic	O	1096-1105
pathway	O	1106-1113
.	O	1113-1114

Our	O	1115-1118
data	O	1119-1123
revealed	O	1124-1132
that	O	1133-1137
conjugates	O	1138-1148
of	O	1149-1151
this	O	1152-1156
nature	O	1157-1163
cause	O	1164-1169
cell	O	1170-1174
cycle	O	1175-1180
arrest	O	1181-1187
and	O	1188-1191
apoptosis	O	1192-1201
in	O	1202-1204
IMR	O	1205-1208
-	O	1208-1209
32	O	1209-1211
cells	O	1212-1217
[	O	1218-1219
MYCN	O	1219-1223
(	O	1224-1225
+	O	1225-1226
)	O	1226-1227
with	O	1228-1232
intact	O	1233-1239
wild	O	1240-1244
-	O	1244-1245
type	O	1245-1249
p53	O	1250-1253
]	O	1253-1254
by	O	1255-1257
activating	O	1258-1268
p53	O	1269-1272
signalling	O	1273-1283
and	O	1284-1287
provides	O	1288-1296
a	O	1297-1298
lead	O	1299-1303
for	O	1304-1307
the	O	1308-1311
development	O	1312-1323
of	O	1324-1326
anti	O	1327-1331
-	O	1331-1332
cancer	O	1332-1338
therapeutics	O	1339-1351
.	O	1351-1352

Extracellular	O	0-13
matrix	O	14-20
secretion	O	21-30
by	O	31-33
cardiac	O	34-41
fibroblasts	O	42-53
:	O	53-54
role	O	55-59
of	O	60-62
microRNA	B	63-71
-	I	71-72
29b	I	72-75
and	O	76-79
microRNA	B	80-88
-	I	88-89
30c	I	89-92
.	O	92-93

RATIONALE	O	94-103
:	O	103-104
MicroRNAs	O	105-114
(	O	115-116
miRNAs	O	116-122
)	O	122-123
,	O	123-124
in	O	125-127
particular	O	128-138
miR	B	139-142
-	I	142-143
29b	I	143-146
and	O	147-150
miR	B	151-154
-	I	154-155
30c	I	155-158
,	O	158-159
have	O	160-164
been	O	165-169
implicated	O	170-180
as	O	181-183
important	O	184-193
regulators	O	194-204
of	O	205-207
cardiac	O	208-215
fibrosis	O	216-224
.	O	224-225

OBJECTIVE	O	226-235
:	O	235-236
To	O	237-239
perform	O	240-247
a	O	248-249
proteomics	O	250-260
comparison	O	261-271
of	O	272-274
miRNA	O	275-280
effects	O	281-288
on	O	289-291
extracellular	O	292-305
matrix	O	306-312
secretion	O	313-322
by	O	323-325
cardiac	O	326-333
fibroblasts	O	334-345
.	O	345-346

METHODS	O	347-354
AND	O	355-358
RESULTS	O	359-366
:	O	366-367
Mouse	O	368-373
cardiac	O	374-381
fibroblasts	O	382-393
were	O	394-398
transfected	O	399-410
with	O	411-415
pre	O	416-419
-	O	419-420
/	O	420-421
anti	O	421-425
-	O	425-426
miR	O	426-429
of	O	430-432
miR	B	433-436
-	I	436-437
29b	I	437-440
and	O	441-444
miR	B	445-448
-	I	448-449
30c	I	449-452
,	O	452-453
and	O	454-457
their	O	458-463
conditioned	O	464-475
medium	O	476-482
was	O	483-486
analyzed	O	487-495
by	O	496-498
mass	O	499-503
spectrometry	O	504-516
.	O	516-517

miR	B	518-521
-	I	521-522
29b	I	522-525
targeted	O	526-534
a	O	535-536
cadre	O	537-542
of	O	543-545
proteins	O	546-554
involved	O	555-563
in	O	564-566
fibrosis	O	567-575
,	O	575-576
including	O	577-586
multiple	O	587-595
collagens	O	596-605
,	O	605-606
matrix	O	607-613
metalloproteinases	O	614-632
,	O	632-633
and	O	634-637
leukemia	O	638-646
inhibitory	O	647-657
factor	O	658-664
,	O	664-665
insulin	O	666-673
-	O	673-674
like	O	674-678
growth	O	679-685
factor	O	686-692
1	O	693-694
,	O	694-695
and	O	696-699
pentraxin	O	700-709
3	O	710-711
,	O	711-712
3	O	713-714
predicted	O	715-724
targets	O	725-732
of	O	733-735
miR	B	736-739
-	I	739-740
29b	I	740-743
.	O	743-744

miR	B	745-748
-	I	748-749
29b	I	749-752
also	O	753-757
attenuated	O	758-768
the	O	769-772
cardiac	O	773-780
fibroblast	O	781-791
response	O	792-800
to	O	801-803
transforming	O	804-816
growth	O	817-823
factor	O	824-830
-	O	830-831
beta	O	831-835
.	O	835-836

In	O	837-839
contrast	O	840-848
,	O	848-849
miR	B	850-853
-	I	853-854
30c	I	854-857
had	O	858-861
little	O	862-868
effect	O	869-875
on	O	876-878
extracellular	O	879-892
matrix	O	893-899
production	O	900-910
but	O	911-914
opposite	O	915-923
effects	O	924-931
regarding	O	932-941
leukemia	O	942-950
inhibitory	O	951-961
factor	O	962-968
and	O	969-972
insulin	O	973-980
-	O	980-981
like	O	981-985
growth	O	986-992
factor	O	993-999
1	O	1000-1001
.	O	1001-1002

Both	O	1003-1007
miRNAs	O	1008-1014
indirectly	O	1015-1025
affected	O	1026-1034
cardiac	O	1035-1042
myocytes	O	1043-1051
.	O	1051-1052

On	O	1053-1055
transfection	O	1056-1068
with	O	1069-1073
pre	B	1074-1077
-	I	1077-1078
miR	I	1078-1081
-	I	1081-1082
29b	I	1082-1085
,	O	1085-1086
the	O	1087-1090
conditioned	O	1091-1102
medium	O	1103-1109
of	O	1110-1112
cardiac	O	1113-1120
fibroblasts	O	1121-1132
lost	O	1133-1137
its	O	1138-1141
ability	O	1142-1149
to	O	1150-1152
support	O	1153-1160
adhesion	O	1161-1169
of	O	1170-1172
rat	O	1173-1176
ventricular	O	1177-1188
myocytes	O	1189-1197
and	O	1198-1201
led	O	1202-1205
to	O	1206-1208
a	O	1209-1210
significant	O	1211-1222
reduction	O	1223-1232
of	O	1233-1235
cardiac	O	1236-1243
myocyte	O	1244-1251
proteins	O	1252-1260
(	O	1261-1262
alpha	O	1262-1267
-	O	1267-1268
actinin	O	1268-1275
,	O	1275-1276
cardiac	O	1277-1284
myosin	O	1285-1291
-	O	1291-1292
binding	O	1292-1299
protein	O	1300-1307
C	O	1308-1309
,	O	1309-1310
and	O	1311-1314
cardiac	O	1315-1322
troponin	O	1323-1331
I	O	1332-1333
)	O	1333-1334
.	O	1334-1335

Similarly	O	1336-1345
,	O	1345-1346
cardiomyocytes	O	1347-1361
derived	O	1362-1369
from	O	1370-1374
mouse	O	1375-1380
embryonic	O	1381-1390
stem	O	1391-1395
cells	O	1396-1401
atrophied	O	1402-1411
under	O	1412-1417
pre	B	1418-1421
-	I	1421-1422
miR	I	1422-1425
-	I	1425-1426
29	I	1426-1428
conditioned	O	1429-1440
medium	O	1441-1447
,	O	1447-1448
whereas	O	1449-1456
pre	B	1457-1460
-	I	1460-1461
miR	I	1461-1464
-	I	1464-1465
30c	I	1465-1468
conditioned	O	1469-1480
medium	O	1481-1487
had	O	1488-1491
a	O	1492-1493
prohypertrophic	O	1494-1509
effect	O	1510-1516
.	O	1516-1517

Levels	O	1518-1524
of	O	1525-1527
miR	B	1528-1531
-	I	1531-1532
29a	I	1532-1535
,	O	1535-1536
miR	B	1537-1540
-	I	1540-1541
29c	I	1541-1544
,	O	1544-1545
and	O	1546-1549
miR	B	1550-1553
-	I	1553-1554
30c	I	1554-1557
,	O	1557-1558
but	O	1559-1562
not	O	1563-1566
miR	B	1567-1570
-	I	1570-1571
29b	I	1571-1574
,	O	1574-1575
were	O	1576-1580
significantly	O	1581-1594
reduced	O	1595-1602
in	O	1603-1605
a	O	1606-1607
mouse	O	1608-1613
model	O	1614-1619
of	O	1620-1622
pathological	O	1623-1635
but	O	1636-1639
not	O	1640-1643
physiological	O	1644-1657
hypertrophy	O	1658-1669
.	O	1669-1670

Treatment	O	1671-1680
with	O	1681-1685
antagomiRs	O	1686-1696
to	O	1697-1699
miR	B	1700-1703
-	I	1703-1704
29b	I	1704-1707
induced	O	1708-1715
excess	O	1716-1722
fibrosis	O	1723-1731
after	O	1732-1737
aortic	O	1738-1744
constriction	O	1745-1757
without	O	1758-1765
overt	O	1766-1771
deterioration	O	1772-1785
in	O	1786-1788
cardiac	O	1789-1796
function	O	1797-1805
.	O	1805-1806

CONCLUSIONS	O	1807-1818
:	O	1818-1819
Our	O	1820-1823
proteomic	O	1824-1833
analysis	O	1834-1842
revealed	O	1843-1851
novel	O	1852-1857
molecular	O	1858-1867
targets	O	1868-1875
of	O	1876-1878
miRNAs	O	1879-1885
that	O	1886-1890
are	O	1891-1894
linked	O	1895-1901
to	O	1902-1904
a	O	1905-1906
fibrogenic	O	1907-1917
cardiac	O	1918-1925
phenotype	O	1926-1935
.	O	1935-1936

Such	O	1937-1941
comprehensive	O	1942-1955
screening	O	1956-1965
methods	O	1966-1973
are	O	1974-1977
essential	O	1978-1987
to	O	1988-1990
define	O	1991-1997
the	O	1998-2001
concerted	O	2002-2011
actions	O	2012-2019
of	O	2020-2022
miRNAs	O	2023-2029
in	O	2030-2032
cardiovascular	O	2033-2047
disease	O	2048-2055
.	O	2055-2056

Acute	O	0-5
stress	O	6-12
alters	O	13-19
amygdala	O	20-28
microRNA	O	29-37
miR	B	38-41
-	I	41-42
135a	I	42-46
and	O	47-50
miR	B	51-54
-	I	54-55
124	I	55-58
expression	O	59-69
:	O	69-70
inferences	O	71-81
for	O	82-85
corticosteroid	O	86-100
dependent	O	101-110
stress	O	111-117
response	O	118-126
.	O	126-127

The	O	128-131
amygdala	O	132-140
is	O	141-143
a	O	144-145
brain	O	146-151
structure	O	152-161
considered	O	162-172
a	O	173-174
key	O	175-178
node	O	179-183
for	O	184-187
the	O	188-191
regulation	O	192-202
of	O	203-205
neuroendocrine	O	206-220
stress	O	221-227
response	O	228-236
.	O	236-237

Stress	O	238-244
-	O	244-245
induced	O	245-252
response	O	253-261
in	O	262-264
amygdala	O	265-273
is	O	274-276
accomplished	O	277-289
through	O	290-297
neurotransmitter	O	298-314
activation	O	315-325
and	O	326-329
an	O	330-332
alteration	O	333-343
of	O	344-346
gene	O	347-351
expression	O	352-362
.	O	362-363

MicroRNAs	O	364-373
(	O	374-375
miRNAs	O	375-381
)	O	381-382
are	O	383-386
important	O	387-396
regulators	O	397-407
of	O	408-410
gene	O	411-415
expression	O	416-426
in	O	427-429
the	O	430-433
nervous	O	434-441
system	O	442-448
and	O	449-452
are	O	453-456
very	O	457-461
well	O	462-466
suited	O	467-473
effectors	O	474-483
of	O	484-486
stress	O	487-493
response	O	494-502
for	O	503-506
their	O	507-512
ability	O	513-520
to	O	521-523
reversibly	O	524-534
silence	O	535-542
specific	O	543-551
mRNAs	O	552-557
.	O	557-558

In	O	559-561
order	O	562-567
to	O	568-570
study	O	571-576
how	O	577-580
acute	O	581-586
stress	O	587-593
affects	O	594-601
miRNAs	O	602-608
expression	O	609-619
in	O	620-622
amygdala	O	623-631
we	O	632-634
analyzed	O	635-643
the	O	644-647
miRNA	O	648-653
profile	O	654-661
after	O	662-667
two	O	668-671
hours	O	672-677
of	O	678-680
mouse	O	681-686
restraint	O	687-696
,	O	696-697
by	O	698-700
microarray	O	701-711
analysis	O	712-720
and	O	721-724
reverse	O	725-732
transcription	O	733-746
real	O	747-751
time	O	752-756
PCR	O	757-760
.	O	760-761

We	O	762-764
found	O	765-770
that	O	771-775
miR	B	776-779
-	I	779-780
135a	I	780-784
and	O	785-788
miR	B	789-792
-	I	792-793
124	I	793-796
were	O	797-801
negatively	O	802-812
regulated	O	813-822
.	O	822-823

Among	O	824-829
in	O	830-832
silico	O	833-839
predicted	O	840-849
targets	O	850-857
we	O	858-860
identified	O	861-871
the	O	872-875
mineralocorticoid	O	876-893
receptor	O	894-902
(	O	903-904
MR	O	904-906
)	O	906-907
as	O	908-910
a	O	911-912
target	O	913-919
of	O	920-922
both	O	923-927
miR	B	928-931
-	I	931-932
135a	I	932-936
and	O	937-940
miR	B	941-944
-	I	944-945
124	I	945-948
.	O	948-949

Luciferase	O	950-960
experiments	O	961-972
and	O	973-976
endogenous	O	977-987
protein	O	988-995
expression	O	996-1006
analysis	O	1007-1015
upon	O	1016-1020
miRNA	O	1021-1026
upregulation	O	1027-1039
and	O	1040-1043
inhibition	O	1044-1054
allowed	O	1055-1062
us	O	1063-1065
to	O	1066-1068
demonstrate	O	1069-1080
that	O	1081-1085
mir	B	1086-1089
-	I	1089-1090
135a	I	1090-1094
and	O	1095-1098
mir	B	1099-1102
-	I	1102-1103
124	I	1103-1106
are	O	1107-1110
able	O	1111-1115
to	O	1116-1118
negatively	O	1119-1129
affect	O	1130-1136
the	O	1137-1140
expression	O	1141-1151
of	O	1152-1154
the	O	1155-1158
MR	O	1159-1161
.	O	1161-1162

The	O	1163-1166
increased	O	1167-1176
levels	O	1177-1183
of	O	1184-1186
the	O	1187-1190
amygdala	O	1191-1199
MR	O	1200-1202
protein	O	1203-1210
after	O	1211-1216
two	O	1217-1220
hours	O	1221-1226
of	O	1227-1229
restraint	O	1230-1239
,	O	1239-1240
that	O	1241-1245
we	O	1246-1248
analyzed	O	1249-1257
by	O	1258-1260
western	O	1261-1268
blot	O	1269-1273
,	O	1273-1274
negatively	O	1275-1285
correlate	O	1286-1295
with	O	1296-1300
miR	B	1301-1304
-	I	1304-1305
135a	I	1305-1309
and	O	1310-1313
miR	B	1314-1317
-	I	1317-1318
124	I	1318-1321
expression	O	1322-1332
.	O	1332-1333

These	O	1334-1339
findings	O	1340-1348
point	O	1349-1354
to	O	1355-1357
a	O	1358-1359
role	O	1360-1364
of	O	1365-1367
miR	B	1368-1371
-	I	1371-1372
135a	I	1372-1376
and	O	1377-1380
miR	B	1381-1384
-	I	1384-1385
124	I	1385-1388
in	O	1389-1391
acute	O	1392-1397
stress	O	1398-1404
as	O	1405-1407
regulators	O	1408-1418
of	O	1419-1421
the	O	1422-1425
MR	O	1426-1428
,	O	1428-1429
an	O	1430-1432
important	O	1433-1442
effector	O	1443-1451
of	O	1452-1454
early	O	1455-1460
stress	O	1461-1467
response	O	1468-1476
.	O	1476-1477

miR	B	0-3
-	I	3-4
210	I	4-7
inhibits	O	8-16
trophoblast	O	17-28
invasion	O	29-37
and	O	38-41
is	O	42-44
a	O	45-46
serum	O	47-52
biomarker	O	53-62
for	O	63-66
preeclampsia	O	67-79
.	O	79-80

Preeclampsia	O	81-93
is	O	94-96
characterized	O	97-110
by	O	111-113
hypertension	O	114-126
and	O	127-130
proteinuria	O	131-142
in	O	143-145
pregnant	O	146-154
women	O	155-160
.	O	160-161

Its	O	162-165
exact	O	166-171
cause	O	172-177
is	O	178-180
unknown	O	181-188
.	O	188-189

Preeclampsia	O	190-202
increases	O	203-212
the	O	213-216
risk	O	217-221
of	O	222-224
maternal	O	225-233
and	O	234-237
fetal	O	238-243
morbidity	O	244-253
and	O	254-257
mortality	O	258-267
.	O	267-268

Although	O	269-277
delivery	O	278-286
,	O	286-287
often	O	288-293
premature	O	294-303
,	O	303-304
is	O	305-307
the	O	308-311
only	O	312-316
known	O	317-322
cure	O	323-327
,	O	327-328
early	O	329-334
targeted	O	335-343
interventions	O	344-357
may	O	358-361
improve	O	362-369
maternal	O	370-378
and	O	379-382
fetal	O	383-388
outcomes	O	389-397
.	O	397-398

Successful	O	399-409
intervention	O	410-422
requires	O	423-431
a	O	432-433
better	O	434-440
understanding	O	441-454
of	O	455-457
the	O	458-461
molecular	O	462-471
etiology	O	472-480
of	O	481-483
preeclampsia	O	484-496
and	O	497-500
the	O	501-504
development	O	505-516
of	O	517-519
accurate	O	520-528
methods	O	529-536
to	O	537-539
predict	O	540-547
women	O	548-553
at	O	554-556
risk	O	557-561
.	O	561-562

To	O	563-565
this	O	566-570
end	O	571-574
,	O	574-575
we	O	576-578
tested	O	579-585
the	O	586-589
role	O	590-594
of	O	595-597
miR	B	598-601
-	I	601-602
210	I	602-605
,	O	605-606
a	O	607-608
miRNA	O	609-614
up	O	615-617
-	O	617-618
regulated	O	618-627
in	O	628-630
preeclamptic	O	631-643
placentas	O	644-653
,	O	653-654
in	O	655-657
first	O	658-663
-	O	663-664
trimester	O	664-673
extravillous	O	674-686
trophoblasts	O	687-699
.	O	699-700

miR	B	701-704
-	I	704-705
210	I	705-708
overexpression	O	709-723
reduced	O	724-731
trophoblast	O	732-743
invasion	O	744-752
,	O	752-753
a	O	754-755
process	O	756-763
necessary	O	764-773
for	O	774-777
uteroplacental	O	778-792
perfusion	O	793-802
,	O	802-803
in	O	804-806
an	O	807-809
extracellular	O	810-823
signal	O	824-830
-	O	830-831
regulated	O	831-840
kinase	O	841-847
/	O	847-848
mitogen	O	848-855
-	O	855-856
activated	O	856-865
protein	O	866-873
kinase	O	874-880
-	O	880-881
dependent	O	881-890
manner	O	891-897
.	O	897-898

Conversely	O	899-909
,	O	909-910
miR	B	911-914
-	I	914-915
210	I	915-918
inhibition	O	919-929
promoted	O	930-938
invasion	O	939-947
.	O	947-948

Furthermore	O	949-960
,	O	960-961
given	O	962-967
that	O	968-972
the	O	973-976
placenta	O	977-985
secretes	O	986-994
miRNAs	O	995-1001
into	O	1002-1006
the	O	1007-1010
maternal	O	1011-1019
circulation	O	1020-1031
,	O	1031-1032
we	O	1033-1035
tested	O	1036-1042
if	O	1043-1045
serum	O	1046-1051
expression	O	1052-1062
of	O	1063-1065
miR	B	1066-1069
-	I	1069-1070
210	I	1070-1073
was	O	1074-1077
associated	O	1078-1088
with	O	1089-1093
the	O	1094-1097
disease	O	1098-1105
.	O	1105-1106

We	O	1107-1109
measured	O	1110-1118
miR	B	1119-1122
-	I	1122-1123
210	I	1123-1126
expression	O	1127-1137
in	O	1138-1140
two	O	1141-1144
clinical	O	1145-1153
studies	O	1154-1161
:	O	1161-1162
a	O	1163-1164
case	O	1165-1169
-	O	1169-1170
control	O	1170-1177
study	O	1178-1183
and	O	1184-1187
a	O	1188-1189
prospective	O	1190-1201
cohort	O	1202-1208
study	O	1209-1214
.	O	1214-1215

Serum	O	1216-1221
miR	B	1222-1225
-	I	1225-1226
210	I	1226-1229
expression	O	1230-1240
was	O	1241-1244
significantly	O	1245-1258
associated	O	1259-1269
with	O	1270-1274
a	O	1275-1276
diagnosis	O	1277-1286
of	O	1287-1289
preeclampsia	O	1290-1302
(	O	1303-1304
P	O	1304-1305
=	O	1306-1307
0	O	1308-1309
.	O	1309-1310
007	O	1310-1313
,	O	1313-1314
area	O	1315-1319
under	O	1320-1325
the	O	1326-1329
receiver	O	1330-1338
operator	O	1339-1347
curves	O	1348-1354
=	O	1355-1356
0	O	1357-1358
.	O	1358-1359
81	O	1359-1361
)	O	1361-1362
and	O	1363-1366
was	O	1367-1370
predictive	O	1371-1381
of	O	1382-1384
the	O	1385-1388
disease	O	1389-1396
,	O	1396-1397
even	O	1398-1402
months	O	1403-1409
before	O	1410-1416
clinical	O	1417-1425
diagnosis	O	1426-1435
(	O	1436-1437
P	O	1437-1438
<	O	1439-1440
0	O	1441-1442
.	O	1442-1443
0001	O	1443-1447
,	O	1447-1448
area	O	1449-1453
under	O	1454-1459
the	O	1460-1463
receiver	O	1464-1472
operator	O	1473-1481
curve	O	1482-1487
=	O	1488-1489
0	O	1490-1491
.	O	1491-1492
89	O	1492-1494
)	O	1494-1495
.	O	1495-1496

Hence	O	1497-1502
,	O	1502-1503
we	O	1504-1506
conclude	O	1507-1515
that	O	1516-1520
aberrant	O	1521-1529
expression	O	1530-1540
of	O	1541-1543
miR	B	1544-1547
-	I	1547-1548
210	I	1548-1551
may	O	1552-1555
contribute	O	1556-1566
to	O	1567-1569
trophoblast	O	1570-1581
function	O	1582-1590
and	O	1591-1594
that	O	1595-1599
miR	B	1600-1603
-	I	1603-1604
210	I	1604-1607
is	O	1608-1610
a	O	1611-1612
novel	O	1613-1618
predictive	O	1619-1629
serum	O	1630-1635
biomarker	O	1636-1645
for	O	1646-1649
preeclampsia	O	1650-1662
that	O	1663-1667
can	O	1668-1671
help	O	1672-1676
in	O	1677-1679
identifying	O	1680-1691
at	O	1692-1694
-	O	1694-1695
risk	O	1695-1699
women	O	1700-1705
for	O	1706-1709
monitoring	O	1710-1720
and	O	1721-1724
treatment	O	1725-1734
.	O	1734-1735

Maintenance	O	0-11
of	O	12-14
the	O	15-18
stemness	O	19-27
in	O	28-30
CD44	O	31-35
(	O	35-36
+	O	36-37
)	O	37-38
HCT	O	39-42
-	O	42-43
15	O	43-45
and	O	46-49
HCT	O	50-53
-	O	53-54
116	O	54-57
human	O	58-63
colon	O	64-69
cancer	O	70-76
cells	O	77-82
requires	O	83-91
miR	B	92-95
-	I	95-96
203	I	96-99
suppression	O	100-111
.	O	111-112

The	O	113-116
purpose	O	117-124
of	O	125-127
this	O	128-132
study	O	133-138
was	O	139-142
to	O	143-145
isolate	O	146-153
cancer	O	154-160
stem	O	161-165
cells	O	166-171
(	O	172-173
CSCs	O	173-177
,	O	177-178
also	O	179-183
called	O	184-190
tumor	O	191-196
-	O	196-197
initiating	O	197-207
cells	O	208-213
,	O	213-214
TICs	O	215-219
)	O	219-220
from	O	221-225
established	O	226-237
human	O	238-243
colorectal	O	244-254
carcinoma	O	255-264
(	O	265-266
CRC	O	266-269
)	O	269-270
cell	O	271-275
lines	O	276-281
,	O	281-282
characterize	O	283-295
them	O	296-300
extensively	O	301-312
and	O	313-316
dissect	O	317-324
the	O	325-328
mechanism	O	329-338
for	O	339-342
their	O	343-348
stemness	O	349-357
.	O	357-358

Freshly	O	359-366
isolated	O	367-375
CD44	O	376-380
(	O	380-381
+	O	381-382
)	O	382-383
and	O	384-387
CD44	O	388-392
(	O	392-393
-	O	393-394
)	O	394-395
cells	O	396-401
from	O	402-406
the	O	407-410
HCT	O	411-414
-	O	414-415
15	O	415-417
human	O	418-423
colon	O	424-429
cancer	O	430-436
cell	O	437-441
line	O	442-446
were	O	447-451
subjected	O	452-461
to	O	462-464
various	O	465-472
analyses	O	473-481
.	O	481-482

Interestingly	O	483-496
,	O	496-497
CD44	O	498-502
(	O	502-503
+	O	503-504
)	O	504-505
cells	O	506-511
exhibited	O	512-521
higher	O	522-528
soft	O	529-533
agar	O	534-538
colony	O	539-545
-	O	545-546
forming	O	546-553
ability	O	554-561
and	O	562-565
in	O	566-568
vivo	O	569-573
tumorigenicity	O	574-588
than	O	589-593
CD44	O	594-598
(	O	598-599
-	O	599-600
)	O	600-601
cells	O	602-607
.	O	607-608

In	O	609-611
addition	O	612-620
,	O	620-621
the	O	622-625
significant	O	626-637
upregulation	O	638-650
of	O	651-653
the	O	654-657
protein	O	658-665
Snail	O	666-671
and	O	672-675
the	O	676-679
downregulation	O	680-694
of	O	695-697
miR	B	698-701
-	I	701-702
203	I	702-705
,	O	705-706
a	O	707-708
stemness	O	709-717
inhibitor	O	718-727
,	O	727-728
in	O	729-731
CD44	O	732-736
(	O	736-737
+	O	737-738
)	O	738-739
cells	O	740-745
suggested	O	746-755
that	O	756-760
this	O	761-765
population	O	766-776
possessed	O	777-786
higher	O	787-793
invasion	O	794-802
/	O	802-803
metastasis	O	803-813
and	O	814-817
differentiation	O	818-833
potential	O	834-843
than	O	844-848
CD44	O	849-853
(	O	853-854
-	O	854-855
)	O	855-856
cells	O	857-862
.	O	862-863

By	O	864-866
manipulating	O	867-879
the	O	880-883
expression	O	884-894
of	O	895-897
CD44	O	898-902
in	O	903-905
HCT	O	906-909
-	O	909-910
15	O	910-912
and	O	913-916
HCT	O	917-920
-	O	920-921
116	O	921-924
cells	O	925-930
,	O	930-931
we	O	932-934
found	O	935-940
that	O	941-945
the	O	946-949
levels	O	950-956
of	O	957-959
several	O	960-967
EMT	O	968-971
activators	O	972-982
and	O	983-986
miR	B	987-990
-	I	990-991
203	I	991-994
were	O	995-999
positively	O	1000-1010
and	O	1011-1014
negatively	O	1015-1025
correlated	O	1026-1036
with	O	1037-1041
those	O	1042-1047
of	O	1048-1050
CD44	O	1051-1055
,	O	1055-1056
respectively	O	1057-1069
.	O	1069-1070

Further	O	1071-1078
analyses	O	1079-1087
revealed	O	1088-1096
that	O	1097-1101
miR	B	1102-1105
-	I	1105-1106
203	I	1106-1109
levels	O	1110-1116
were	O	1117-1121
repressed	O	1122-1131
by	O	1132-1134
Snail	O	1135-1140
,	O	1140-1141
which	O	1142-1147
was	O	1148-1151
shown	O	1152-1157
to	O	1158-1160
bind	O	1161-1165
to	O	1166-1168
specific	O	1169-1177
E	O	1178-1179
-	O	1179-1180
box	O	1180-1183
(	O	1183-1184
es	O	1184-1186
)	O	1186-1187
present	O	1188-1195
in	O	1196-1198
the	O	1199-1202
miR	B	1203-1206
-	I	1206-1207
203	I	1207-1210
promoter	O	1211-1219
.	O	1219-1220

In	O	1221-1223
agreement	O	1224-1233
,	O	1233-1234
silencing	O	1235-1244
miR	B	1245-1248
-	I	1248-1249
203	I	1249-1252
expression	O	1253-1263
in	O	1264-1266
wild	O	1267-1271
-	O	1271-1272
type	O	1272-1276
HCT	O	1277-1280
-	O	1280-1281
116	O	1281-1284
human	O	1285-1290
colon	O	1291-1296
cancer	O	1297-1303
cells	O	1304-1309
also	O	1310-1314
resulted	O	1315-1323
in	O	1324-1326
an	O	1327-1329
increase	O	1330-1338
of	O	1339-1341
their	O	1342-1347
stemness	O	1348-1356
.	O	1356-1357

Finally	O	1358-1365
,	O	1365-1366
we	O	1367-1369
discovered	O	1370-1380
that	O	1381-1385
c	O	1386-1387
-	O	1387-1388
Src	O	1388-1391
kinase	O	1392-1398
activity	O	1399-1407
was	O	1408-1411
required	O	1412-1420
for	O	1421-1424
the	O	1425-1428
downregulation	O	1429-1443
of	O	1444-1446
miR	B	1447-1450
-	I	1450-1451
203	I	1451-1454
in	O	1455-1457
HCT	O	1458-1461
-	O	1461-1462
15	O	1462-1464
cells	O	1465-1470
,	O	1470-1471
which	O	1472-1477
was	O	1478-1481
stimulated	O	1482-1492
by	O	1493-1495
the	O	1496-1499
interaction	O	1500-1511
between	O	1512-1519
hyaluronan	O	1520-1530
(	O	1531-1532
HA	O	1532-1534
)	O	1534-1535
and	O	1536-1539
CD44	O	1540-1544
.	O	1544-1545

Taken	O	1546-1551
together	O	1552-1560
,	O	1560-1561
CD44	O	1562-1566
is	O	1567-1569
a	O	1570-1571
critical	O	1572-1580
molecule	O	1581-1589
for	O	1590-1593
modulating	O	1594-1604
stemness	O	1605-1613
in	O	1614-1616
CSCs	O	1617-1621
.	O	1621-1622

More	O	1623-1627
importantly	O	1628-1639
,	O	1639-1640
we	O	1641-1643
show	O	1644-1648
for	O	1649-1652
the	O	1653-1656
first	O	1657-1662
time	O	1663-1667
that	O	1668-1672
the	O	1673-1676
downregulation	O	1677-1691
of	O	1692-1694
miR	B	1695-1698
-	I	1698-1699
203	I	1699-1702
by	O	1703-1705
HA	O	1706-1708
/	O	1708-1709
CD44	O	1709-1713
signaling	O	1714-1723
is	O	1724-1726
the	O	1727-1730
main	O	1731-1735
reason	O	1736-1742
for	O	1743-1746
stemness	O	1747-1755
-	O	1755-1756
maintenance	O	1756-1767
in	O	1768-1770
colon	O	1771-1776
cancer	O	1777-1783
cells	O	1784-1789
.	O	1789-1790

Involvement	O	0-11
of	O	12-14
miRNAs	O	15-21
in	O	22-24
the	O	25-28
differentiation	O	29-44
of	O	45-47
human	O	48-53
glioblastoma	O	54-66
multiforme	O	67-77
stem	O	78-82
-	O	82-83
like	O	83-87
cells	O	88-93
.	O	93-94

Glioblastoma	O	95-107
multiforme	O	108-118
(	O	119-120
GBM	O	120-123
)	O	123-124
-	O	124-125
initiating	O	125-135
cells	O	136-141
(	O	142-143
GICs	O	143-147
)	O	147-148
represent	O	149-158
a	O	159-160
tumor	O	161-166
subpopulation	O	167-180
with	O	181-185
neural	O	186-192
stem	O	193-197
cell	O	198-202
-	O	202-203
like	O	203-207
properties	O	208-218
that	O	219-223
is	O	224-226
responsible	O	227-238
for	O	239-242
the	O	243-246
development	O	247-258
,	O	258-259
progression	O	260-271
and	O	272-275
therapeutic	O	276-287
resistance	O	288-298
of	O	299-301
human	O	302-307
GBM	O	308-311
.	O	311-312

We	O	313-315
have	O	316-320
recently	O	321-329
shown	O	330-335
that	O	336-340
blockade	O	341-349
of	O	350-352
NFkappaB	O	353-361
pathway	O	362-369
promotes	O	370-378
terminal	O	379-387
differentiation	O	388-403
and	O	404-407
senescence	O	408-418
of	O	419-421
GICs	O	422-426
both	O	427-431
in	O	432-434
vitro	O	435-440
and	O	441-444
in	O	445-447
vivo	O	448-452
,	O	452-453
indicating	O	454-464
that	O	465-469
induction	O	470-479
of	O	480-482
differentiation	O	483-498
may	O	499-502
be	O	503-505
a	O	506-507
potential	O	508-517
therapeutic	O	518-529
strategy	O	530-538
for	O	539-542
GBM	O	543-546
.	O	546-547

MicroRNAs	O	548-557
have	O	558-562
been	O	563-567
implicated	O	568-578
in	O	579-581
the	O	582-585
pathogenesis	O	586-598
of	O	599-601
GBM	O	602-605
,	O	605-606
but	O	607-610
a	O	611-612
high	O	613-617
-	O	617-618
throughput	O	618-628
analysis	O	629-637
of	O	638-640
their	O	641-646
role	O	647-651
in	O	652-654
GIC	O	655-658
differentiation	O	659-674
has	O	675-678
not	O	679-682
been	O	683-687
reported	O	688-696
.	O	696-697

We	O	698-700
have	O	701-705
established	O	706-717
human	O	718-723
GIC	O	724-727
cell	O	728-732
lines	O	733-738
that	O	739-743
can	O	744-747
be	O	748-750
efficiently	O	751-762
differentiated	O	763-777
into	O	778-782
cells	O	783-788
expressing	O	789-799
astrocytic	O	800-810
and	O	811-814
neuronal	O	815-823
lineage	O	824-831
markers	O	832-839
.	O	839-840

Using	O	841-846
this	O	847-851
in	O	852-854
vitro	O	855-860
system	O	861-867
,	O	867-868
a	O	869-870
microarray	O	871-881
-	O	881-882
based	O	882-887
high	O	888-892
-	O	892-893
throughput	O	893-903
analysis	O	904-912
to	O	913-915
determine	O	916-925
global	O	926-932
expression	O	933-943
changes	O	944-951
of	O	952-954
microRNAs	O	955-964
during	O	965-971
differentiation	O	972-987
of	O	988-990
GICs	O	991-995
was	O	996-999
performed	O	1000-1009
.	O	1009-1010

A	O	1011-1012
number	O	1013-1019
of	O	1020-1022
changes	O	1023-1030
in	O	1031-1033
the	O	1034-1037
levels	O	1038-1044
of	O	1045-1047
microRNAs	O	1048-1057
were	O	1058-1062
detected	O	1063-1071
in	O	1072-1074
differentiating	O	1075-1090
GICs	O	1091-1095
,	O	1095-1096
including	O	1097-1106
over	O	1107-1111
-	O	1111-1112
expression	O	1112-1122
of	O	1123-1125
hsa	B	1126-1129
-	I	1129-1130
miR	I	1130-1133
-	I	1133-1134
21	I	1134-1136
,	O	1136-1137
hsa	B	1138-1141
-	I	1141-1142
miR	I	1142-1145
-	I	1145-1146
29a	I	1146-1149
,	O	1149-1150
hsa	B	1151-1154
-	I	1154-1155
miR	I	1155-1158
-	I	1158-1159
29b	I	1159-1162
,	O	1162-1163
hsa	B	1164-1167
-	I	1167-1168
miR	I	1168-1171
-	I	1171-1172
221	I	1172-1175
and	O	1176-1179
hsa	B	1180-1183
-	I	1183-1184
miR	I	1184-1187
-	I	1187-1188
222	I	1188-1191
,	O	1191-1192
and	O	1193-1196
down	O	1197-1201
-	O	1201-1202
regulation	O	1202-1212
of	O	1213-1215
hsa	B	1216-1219
-	I	1219-1220
miR	I	1220-1223
-	I	1223-1224
93	I	1224-1226
and	O	1227-1230
hsa	B	1231-1234
-	I	1234-1235
miR	I	1235-1238
-	I	1238-1239
106a	I	1239-1243
.	O	1243-1244

Functional	O	1245-1255
studies	O	1256-1263
showed	O	1264-1270
that	O	1271-1275
miR	B	1276-1279
-	I	1279-1280
21	I	1280-1282
over	O	1283-1287
-	O	1287-1288
expression	O	1288-1298
in	O	1299-1301
GICs	O	1302-1306
induced	O	1307-1314
comparable	O	1315-1325
cell	O	1326-1330
differentiation	O	1331-1346
features	O	1347-1355
and	O	1356-1359
targeted	O	1360-1368
SPRY1	O	1369-1374
mRNA	O	1375-1379
,	O	1379-1380
which	O	1381-1386
encodes	O	1387-1394
for	O	1395-1398
a	O	1399-1400
negative	O	1401-1409
regulator	O	1410-1419
of	O	1420-1422
neural	O	1423-1429
stem	O	1430-1434
-	O	1434-1435
cell	O	1435-1439
differentiation	O	1440-1455
.	O	1455-1456

In	O	1457-1459
addition	O	1460-1468
,	O	1468-1469
miR	B	1470-1473
-	I	1473-1474
221	I	1474-1477
and	O	1478-1481
miR	B	1482-1485
-	I	1485-1486
222	I	1486-1489
inhibition	O	1490-1500
in	O	1501-1503
differentiated	O	1504-1518
cells	O	1519-1524
restored	O	1525-1533
the	O	1534-1537
expression	O	1538-1548
of	O	1549-1551
stem	O	1552-1556
cell	O	1557-1561
markers	O	1562-1569
while	O	1570-1575
reducing	O	1576-1584
differentiation	O	1585-1600
markers	O	1601-1608
.	O	1608-1609

Finally	O	1610-1617
,	O	1617-1618
miR	B	1619-1622
-	I	1622-1623
29a	I	1623-1626
and	O	1627-1630
miR	B	1631-1634
-	I	1634-1635
29b	I	1635-1638
targeted	O	1639-1647
MCL1	O	1648-1652
mRNA	O	1653-1657
in	O	1658-1660
GICs	O	1661-1665
and	O	1666-1669
increased	O	1670-1679
apoptosis	O	1680-1689
.	O	1689-1690

Our	O	1691-1694
study	O	1695-1700
uncovers	O	1701-1709
the	O	1710-1713
microRNA	O	1714-1722
dynamic	O	1723-1730
expression	O	1731-1741
changes	O	1742-1749
occurring	O	1750-1759
during	O	1760-1766
differentiation	O	1767-1782
of	O	1783-1785
GICs	O	1786-1790
,	O	1790-1791
and	O	1792-1795
identifies	O	1796-1806
miR	B	1807-1810
-	I	1810-1811
21	I	1811-1813
and	O	1814-1817
miR	B	1818-1821
-	I	1821-1822
221	I	1822-1825
/	O	1825-1826
222	B	1826-1829
as	O	1830-1832
key	O	1833-1836
regulators	O	1837-1847
of	O	1848-1850
this	O	1851-1855
process	O	1856-1863
.	O	1863-1864

miR	B	0-3
-	I	3-4
139	I	4-7
-	I	7-8
5p	I	8-10
is	O	11-13
a	O	14-15
regulator	O	16-25
of	O	26-28
metastatic	O	29-39
pathways	O	40-48
in	O	49-51
breast	O	52-58
cancer	O	59-65
.	O	65-66

Metastasis	O	67-77
is	O	78-80
a	O	81-82
complex	O	83-90
,	O	90-91
multistep	O	92-101
process	O	102-109
involved	O	110-118
in	O	119-121
the	O	122-125
progression	O	126-137
of	O	138-140
cancer	O	141-147
from	O	148-152
a	O	153-154
localized	O	155-164
primary	O	165-172
tissue	O	173-179
to	O	180-182
distant	O	183-190
sites	O	191-196
,	O	196-197
often	O	198-203
characteristic	O	204-218
of	O	219-221
the	O	222-225
more	O	226-230
aggressive	O	231-241
forms	O	242-247
of	O	248-250
this	O	251-255
disease	O	256-263
.	O	263-264

Despite	O	265-272
being	O	273-278
studied	O	279-286
in	O	287-289
great	O	290-295
detail	O	296-302
in	O	303-305
recent	O	306-312
years	O	313-318
,	O	318-319
the	O	320-323
mechanisms	O	324-334
that	O	335-339
govern	O	340-346
this	O	347-351
process	O	352-359
remain	O	360-366
poorly	O	367-373
understood	O	374-384
.	O	384-385

In	O	386-388
this	O	389-393
study	O	394-399
,	O	399-400
we	O	401-403
identify	O	404-412
a	O	413-414
novel	O	415-420
role	O	421-425
for	O	426-429
miR	B	430-433
-	I	433-434
139	I	434-437
-	I	437-438
5p	I	438-440
in	O	441-443
the	O	444-447
inhibition	O	448-458
of	O	459-461
breast	O	462-468
cancer	O	469-475
progression	O	476-487
.	O	487-488

We	O	489-491
highlight	O	492-501
its	O	502-505
clinical	O	506-514
relevance	O	515-524
by	O	525-527
reviewing	O	528-537
miR	B	538-541
-	I	541-542
139	I	542-545
-	I	545-546
5p	I	546-548
expression	O	549-559
across	O	560-566
a	O	567-568
wide	O	569-573
variety	O	574-581
of	O	582-584
breast	O	585-591
cancer	O	592-598
subtypes	O	599-607
using	O	608-613
in	O	614-616
-	O	616-617
house	O	617-622
generated	O	623-632
and	O	633-636
online	O	637-643
data	O	644-648
sets	O	649-653
to	O	654-656
show	O	657-661
that	O	662-666
it	O	667-669
is	O	670-672
most	O	673-677
frequently	O	678-688
lost	O	689-693
in	O	694-696
invasive	O	697-705
tumors	O	706-712
.	O	712-713

A	O	714-715
biotin	O	716-722
pull	O	723-727
-	O	727-728
down	O	728-732
approach	O	733-741
was	O	742-745
then	O	746-750
used	O	751-755
to	O	756-758
identify	O	759-767
the	O	768-771
mRNA	O	772-776
targets	O	777-784
of	O	785-787
miR	B	788-791
-	I	791-792
139	I	792-795
-	I	795-796
5p	I	796-798
in	O	799-801
the	O	802-805
breast	O	806-812
cancer	O	813-819
cell	O	820-824
line	O	825-829
MCF7	O	830-834
.	O	834-835

Functional	O	836-846
enrichment	O	847-857
analysis	O	858-866
of	O	867-869
the	O	870-873
pulled	O	874-880
-	O	880-881
down	O	881-885
targets	O	886-893
showed	O	894-900
significant	O	901-912
enrichment	O	913-923
of	O	924-926
genes	O	927-932
in	O	933-935
pathways	O	936-944
previously	O	945-955
implicated	O	956-966
in	O	967-969
breast	O	970-976
cancer	O	977-983
metastasis	O	984-994
(	O	995-996
P	O	996-997
<	O	998-999
0	O	1000-1001
.	O	1001-1002
05	O	1002-1004
)	O	1004-1005
.	O	1005-1006

Further	O	1007-1014
bioinformatic	O	1015-1028
analysis	O	1029-1037
revealed	O	1038-1046
a	O	1047-1048
predicted	O	1049-1058
disruption	O	1059-1069
to	O	1070-1072
the	O	1073-1076
TGFbeta	O	1077-1084
,	O	1084-1085
Wnt	O	1086-1089
,	O	1089-1090
Rho	O	1091-1094
,	O	1094-1095
and	O	1096-1099
MAPK	O	1100-1104
/	O	1104-1105
PI3K	O	1105-1109
signaling	O	1110-1119
cascades	O	1120-1128
,	O	1128-1129
implying	O	1130-1138
a	O	1139-1140
potential	O	1141-1150
role	O	1151-1155
for	O	1156-1159
miR	B	1160-1163
-	I	1163-1164
139	I	1164-1167
-	I	1167-1168
5p	I	1168-1170
in	O	1171-1173
regulating	O	1174-1184
the	O	1185-1188
ability	O	1189-1196
of	O	1197-1199
cells	O	1200-1205
to	O	1206-1208
invade	O	1209-1215
and	O	1216-1219
migrate	O	1220-1227
.	O	1227-1228

To	O	1229-1231
corroborate	O	1232-1243
this	O	1244-1248
finding	O	1249-1256
,	O	1256-1257
using	O	1258-1263
the	O	1264-1267
MDA	O	1268-1271
-	O	1271-1272
MB	O	1272-1274
-	O	1274-1275
231	O	1275-1278
breast	O	1279-1285
cancer	O	1286-1292
cell	O	1293-1297
line	O	1298-1302
,	O	1302-1303
we	O	1304-1306
show	O	1307-1311
that	O	1312-1316
overexpression	O	1317-1331
of	O	1332-1334
miR	B	1335-1338
-	I	1338-1339
139	I	1339-1342
-	I	1342-1343
5p	I	1343-1345
results	O	1346-1353
in	O	1354-1356
suppression	O	1357-1368
of	O	1369-1371
these	O	1372-1377
cellular	O	1378-1386
phenotypes	O	1387-1397
.	O	1397-1398

Furthermore	O	1399-1410
,	O	1410-1411
we	O	1412-1414
validate	O	1415-1423
the	O	1424-1427
interaction	O	1428-1439
between	O	1440-1447
miR	B	1448-1451
-	I	1451-1452
139	I	1452-1455
-	I	1455-1456
5p	I	1456-1458
and	O	1459-1462
predicted	O	1463-1472
targets	O	1473-1480
involved	O	1481-1489
in	O	1490-1492
these	O	1493-1498
pathways	O	1499-1507
.	O	1507-1508

Collectively	O	1509-1521
,	O	1521-1522
these	O	1523-1528
results	O	1529-1536
suggest	O	1537-1544
a	O	1545-1546
significant	O	1547-1558
functional	O	1559-1569
role	O	1570-1574
for	O	1575-1578
miR	B	1579-1582
-	I	1582-1583
139	I	1583-1586
-	I	1586-1587
5p	I	1587-1589
in	O	1590-1592
breast	O	1593-1599
cancer	O	1600-1606
cell	O	1607-1611
motility	O	1612-1620
and	O	1621-1624
invasion	O	1625-1633
and	O	1634-1637
its	O	1638-1641
potential	O	1642-1651
to	O	1652-1654
be	O	1655-1657
used	O	1658-1662
as	O	1663-1665
a	O	1666-1667
prognostic	O	1668-1678
marker	O	1679-1685
for	O	1686-1689
the	O	1690-1693
aggressive	O	1694-1704
forms	O	1705-1710
of	O	1711-1713
breast	O	1714-1720
cancer	O	1721-1727
.	O	1727-1728

Dynamically	O	0-11
regulated	O	12-21
miRNA	O	22-27
-	O	27-28
mRNA	O	28-32
networks	O	33-41
revealed	O	42-50
by	O	51-53
exercise	O	54-62
.	O	62-63

BACKGROUND	O	64-74
:	O	74-75
MiRNAs	O	76-82
are	O	83-86
essential	O	87-96
mediators	O	97-106
of	O	107-109
many	O	110-114
biological	O	115-125
processes	O	126-135
.	O	135-136

The	O	137-140
aim	O	141-144
of	O	145-147
this	O	148-152
study	O	153-158
was	O	159-162
to	O	163-165
investigate	O	166-177
the	O	178-181
dynamics	O	182-190
of	O	191-193
miRNA	O	194-199
-	O	199-200
mRNA	O	200-204
regulatory	O	205-215
networks	O	216-224
during	O	225-231
exercise	O	232-240
and	O	241-244
the	O	245-248
subsequent	O	249-259
recovery	O	260-268
period	O	269-275
.	O	275-276

RESULTS	O	277-284
:	O	284-285
Here	O	286-290
we	O	291-293
monitored	O	294-303
the	O	304-307
transcriptome	O	308-321
changes	O	322-329
using	O	330-335
microarray	O	336-346
analysis	O	347-355
of	O	356-358
the	O	359-362
whole	O	363-368
blood	O	369-374
of	O	375-377
eight	O	378-383
highly	O	384-390
trained	O	391-398
athletes	O	399-407
before	O	408-414
and	O	415-418
after	O	419-424
30	O	425-427
min	O	428-431
of	O	432-434
moderate	O	435-443
exercise	O	444-452
followed	O	453-461
by	O	462-464
30	O	465-467
min	O	468-471
and	O	472-475
60	O	476-478
min	O	479-482
of	O	483-485
recovery	O	486-494
period	O	495-501
.	O	501-502

We	O	503-505
combined	O	506-514
expression	O	515-525
profiling	O	526-535
and	O	536-539
bioinformatics	O	540-554
and	O	555-558
analysed	O	559-567
metabolic	O	568-577
pathways	O	578-586
enriched	O	587-595
with	O	596-600
differentially	O	601-615
expressed	O	616-625
mRNAs	O	626-631
and	O	632-635
mRNAs	O	636-641
which	O	642-647
are	O	648-651
known	O	652-657
to	O	658-660
be	O	661-663
validated	O	664-673
targets	O	674-681
of	O	682-684
differentially	O	685-699
expressed	O	700-709
miRNAs	O	710-716
.	O	716-717

Finally	O	718-725
we	O	726-728
revealed	O	729-737
four	O	738-742
dynamically	O	743-754
regulated	O	755-764
networks	O	765-773
comprising	O	774-784
differentially	O	785-799
expressed	O	800-809
miRNAs	O	810-816
and	O	817-820
their	O	821-826
known	O	827-832
target	O	833-839
mRNAs	O	840-845
with	O	846-850
anti	O	851-855
-	O	855-856
correlated	O	856-866
expression	O	867-877
profiles	O	878-886
over	O	887-891
time	O	892-896
.	O	896-897

The	O	898-901
data	O	902-906
suggest	O	907-914
that	O	915-919
hsa	B	920-923
-	I	923-924
miR	I	924-927
-	I	927-928
21	I	928-930
-	I	930-931
5p	I	931-933
regulated	O	934-943
TGFBR3	O	944-950
,	O	950-951
PDGFD	O	952-957
and	O	958-961
PPM1L	O	962-967
mRNAs	O	968-973
.	O	973-974

Hsa	B	975-978
-	I	978-979
miR	I	979-982
-	I	982-983
24	I	983-985
-	I	985-986
2	I	986-987
-	I	987-988
5p	I	988-990
was	O	991-994
likely	O	995-1001
to	O	1002-1004
be	O	1005-1007
responsible	O	1008-1019
for	O	1020-1023
MYC	O	1024-1027
and	O	1028-1031
KCNJ2	O	1032-1037
genes	O	1038-1043
and	O	1044-1047
hsa	B	1048-1051
-	I	1051-1052
miR	I	1052-1055
-	I	1055-1056
27a	I	1056-1059
-	I	1059-1060
5p	I	1060-1062
for	O	1063-1066
ST3GAL6	O	1067-1074
.	O	1074-1075

The	O	1076-1079
targets	O	1080-1087
of	O	1088-1090
hsa	B	1091-1094
-	I	1094-1095
miR	I	1095-1098
-	I	1098-1099
181a	I	1099-1103
-	I	1103-1104
5p	I	1104-1106
included	O	1107-1115
ROPN1L	O	1116-1122
and	O	1123-1126
SLC37A3	O	1127-1134
.	O	1134-1135

All	O	1136-1139
these	O	1140-1145
mRNAs	O	1146-1151
are	O	1152-1155
involved	O	1156-1164
in	O	1165-1167
processes	O	1168-1177
highly	O	1178-1184
relevant	O	1185-1193
to	O	1194-1196
exercise	O	1197-1205
response	O	1206-1214
,	O	1214-1215
including	O	1216-1225
immune	O	1226-1232
function	O	1233-1241
,	O	1241-1242
apoptosis	O	1243-1252
,	O	1252-1253
membrane	O	1254-1262
traffic	O	1263-1270
of	O	1271-1273
proteins	O	1274-1282
and	O	1283-1286
transcription	O	1287-1300
regulation	O	1301-1311
.	O	1311-1312

CONCLUSIONS	O	1313-1324
:	O	1324-1325
We	O	1326-1328
have	O	1329-1333
identified	O	1334-1344
metabolic	O	1345-1354
pathways	O	1355-1363
involved	O	1364-1372
in	O	1373-1375
response	O	1376-1384
to	O	1385-1387
exercise	O	1388-1396
and	O	1397-1400
revealed	O	1401-1409
four	O	1410-1414
miRNA	O	1415-1420
-	O	1420-1421
mRNA	O	1421-1425
networks	O	1426-1434
dynamically	O	1435-1446
regulated	O	1447-1456
following	O	1457-1466
exercise	O	1467-1475
.	O	1475-1476

This	O	1477-1481
work	O	1482-1486
is	O	1487-1489
the	O	1490-1493
first	O	1494-1499
study	O	1500-1505
to	O	1506-1508
monitor	O	1509-1516
miRNAs	O	1517-1523
and	O	1524-1527
mRNAs	O	1528-1533
in	O	1534-1536
parallel	O	1537-1545
into	O	1546-1550
the	O	1551-1554
recovery	O	1555-1563
period	O	1564-1570
.	O	1570-1571

The	O	1572-1575
results	O	1576-1583
provide	O	1584-1591
a	O	1592-1593
novel	O	1594-1599
insight	O	1600-1607
into	O	1608-1612
the	O	1613-1616
regulatory	O	1617-1627
role	O	1628-1632
of	O	1633-1635
miRNAs	O	1636-1642
in	O	1643-1645
stress	O	1646-1652
adaptation	O	1653-1663
.	O	1663-1664

miR	B	0-3
-	I	3-4
203	I	4-7
inhibits	O	8-16
the	O	17-20
proliferation	O	21-34
and	O	35-38
self	O	39-43
-	O	43-44
renewal	O	44-51
of	O	52-54
esophageal	O	55-65
cancer	O	66-72
stem	O	73-77
-	O	77-78
like	O	78-82
cells	O	83-88
by	O	89-91
suppressing	O	92-103
stem	O	104-108
renewal	O	109-116
factor	O	117-123
Bmi	O	124-127
-	O	127-128
1	O	128-129
.	O	129-130

Cancer	O	131-137
stem	O	138-142
-	O	142-143
like	O	143-147
cells	O	148-153
exist	O	154-159
in	O	160-162
many	O	163-167
malignancies	O	168-180
and	O	181-184
several	O	185-192
stem	O	193-197
cell	O	198-202
-	O	202-203
related	O	203-210
genes	O	211-216
and	O	217-220
microRNAs	O	221-230
,	O	230-231
such	O	232-236
as	O	237-239
Bmi	O	240-243
-	O	243-244
1	O	244-245
and	O	246-249
miR	B	250-253
-	I	253-254
203	I	254-257
,	O	257-258
have	O	259-263
been	O	264-268
identified	O	269-279
as	O	280-282
cancer	O	283-289
stem	O	290-294
-	O	294-295
like	O	295-299
cell	O	300-304
regulators	O	305-315
using	O	316-321
gene	O	322-326
microarray	O	327-337
or	O	338-340
sequencing	O	341-351
analysis	O	352-360
.	O	360-361

Previously	O	362-372
,	O	372-373
we	O	374-376
used	O	377-381
side	O	382-386
population	O	387-397
(	O	398-399
SP	O	399-401
)	O	401-402
sorting	O	403-410
to	O	411-413
enrich	O	414-420
cancer	O	421-427
stem	O	428-432
-	O	432-433
like	O	433-437
cells	O	438-443
from	O	444-448
esophageal	O	449-459
squamous	O	460-468
cell	O	469-473
carcinoma	O	474-483
(	O	484-485
ESCC	O	485-489
)	O	489-490
cell	O	491-495
line	O	496-500
EC9706	O	501-507
.	O	507-508

Our	O	509-512
results	O	513-520
demonstrated	O	521-533
that	O	534-538
EC9706	O	539-545
SP	O	546-548
cells	O	549-554
shared	O	555-561
common	O	562-568
features	O	569-577
of	O	578-580
cancer	O	581-587
stem	O	588-592
-	O	592-593
like	O	593-597
cells	O	598-603
.	O	603-604

In	O	605-607
this	O	608-612
study	O	613-618
,	O	618-619
we	O	620-622
examined	O	623-631
the	O	632-635
expression	O	636-646
of	O	647-649
Bmi	O	650-653
-	O	653-654
1	O	654-655
and	O	656-659
miR	B	660-663
-	I	663-664
203	I	664-667
in	O	668-670
ESCC	O	671-675
SP	O	676-678
and	O	679-682
non	O	683-686
-	O	686-687
SP	O	687-689
(	O	690-691
NSP	O	691-694
)	O	694-695
cells	O	696-701
.	O	701-702

Our	O	703-706
results	O	707-714
showed	O	715-721
that	O	722-726
,	O	726-727
when	O	728-732
compared	O	733-741
with	O	742-746
NSP	O	747-750
cells	O	751-756
,	O	756-757
Bmi	O	758-761
-	O	761-762
1	O	762-763
was	O	764-767
up	O	768-770
-	O	770-771
regulated	O	771-780
and	O	781-784
miR	B	785-788
-	I	788-789
203	I	789-792
was	O	793-796
down	O	797-801
-	O	801-802
regulated	O	802-811
in	O	812-814
SP	O	815-817
cells	O	818-823
.	O	823-824

During	O	825-831
the	O	832-835
differentiation	O	836-851
from	O	852-856
SP	O	857-859
to	O	860-862
NSP	O	863-866
cells	O	867-872
,	O	872-873
the	O	874-877
expression	O	878-888
levels	O	889-895
of	O	896-898
Bmi	O	899-902
-	O	902-903
1	O	903-904
were	O	905-909
gradually	O	910-919
decreased	O	920-929
.	O	929-930

Overexpression	O	931-945
of	O	946-948
miR	B	949-952
-	I	952-953
203	I	953-956
resulted	O	957-965
in	O	966-968
a	O	969-970
significant	O	971-982
reduction	O	983-992
of	O	993-995
endogenous	O	996-1006
Bmi	O	1007-1010
-	O	1010-1011
1	O	1011-1012
protein	O	1013-1020
level	O	1021-1026
in	O	1027-1029
EC9706	O	1030-1036
cells	O	1037-1042
.	O	1042-1043

SP	O	1044-1046
and	O	1047-1050
NSP	O	1051-1054
analyses	O	1055-1063
revealed	O	1064-1072
that	O	1073-1077
the	O	1078-1081
SP	O	1082-1084
cell	O	1085-1089
fraction	O	1090-1098
was	O	1099-1102
markedly	O	1103-1111
decreased	O	1112-1121
in	O	1122-1124
miR	B	1125-1128
-	I	1128-1129
203	I	1129-1132
overexpressed	O	1133-1146
cells	O	1147-1152
.	O	1152-1153

miR	B	1154-1157
-	I	1157-1158
203	I	1158-1161
overexpressed	O	1162-1175
cells	O	1176-1181
also	O	1182-1186
showed	O	1187-1193
a	O	1194-1195
significant	O	1196-1207
reduction	O	1208-1217
in	O	1218-1220
colony	O	1221-1227
formation	O	1228-1237
,	O	1237-1238
which	O	1239-1244
was	O	1245-1248
resistant	O	1249-1258
to	O	1259-1261
chemotherapeutic	O	1262-1278
drug	O	1279-1283
treatment	O	1284-1293
and	O	1294-1297
tumorigenicity	O	1298-1312
in	O	1313-1315
nude	O	1316-1320
mice	O	1321-1325
.	O	1325-1326

Rescue	O	1327-1333
experiments	O	1334-1345
demonstrated	O	1346-1358
that	O	1359-1363
ectopic	O	1364-1371
expression	O	1372-1382
of	O	1383-1385
Bmi	O	1386-1389
-	O	1389-1390
1	O	1390-1391
in	O	1392-1394
miR	B	1395-1398
-	I	1398-1399
203	I	1399-1402
overexpressed	O	1403-1416
cells	O	1417-1422
increased	O	1423-1432
the	O	1433-1436
SP	O	1437-1439
fraction	O	1440-1448
and	O	1449-1452
restored	O	1453-1461
cell	O	1462-1466
proliferation	O	1467-1480
.	O	1480-1481

Taken	O	1482-1487
together	O	1488-1496
,	O	1496-1497
these	O	1498-1503
results	O	1504-1511
indicated	O	1512-1521
that	O	1522-1526
stem	O	1527-1531
renewal	O	1532-1539
factor	O	1540-1546
Bmi	O	1547-1550
-	O	1550-1551
1	O	1551-1552
was	O	1553-1556
a	O	1557-1558
direct	O	1559-1565
target	O	1566-1572
of	O	1573-1575
miR	B	1576-1579
-	I	1579-1580
203	I	1580-1583
.	O	1583-1584

The	O	1585-1588
regulation	O	1589-1599
of	O	1600-1602
Bmi	O	1603-1606
-	O	1606-1607
1	O	1607-1608
by	O	1609-1611
miR	B	1612-1615
-	I	1615-1616
203	I	1616-1619
may	O	1620-1623
play	O	1624-1628
an	O	1629-1631
important	O	1632-1641
role	O	1642-1646
in	O	1647-1649
controlling	O	1650-1661
cell	O	1662-1666
proliferation	O	1667-1680
and	O	1681-1684
self	O	1685-1689
-	O	1689-1690
renewal	O	1690-1697
of	O	1698-1700
esophageal	O	1701-1711
cancer	O	1712-1718
stem	O	1719-1723
-	O	1723-1724
like	O	1724-1728
cells	O	1729-1734
.	O	1734-1735

It	O	1736-1738
may	O	1739-1742
also	O	1743-1747
promote	O	1748-1755
the	O	1756-1759
development	O	1760-1771
of	O	1772-1774
new	O	1775-1778
therapeutic	O	1779-1790
strategies	O	1791-1801
and	O	1802-1805
efficient	O	1806-1815
drugs	O	1816-1821
that	O	1822-1826
target	O	1827-1833
ESCC	O	1834-1838
stem	O	1839-1843
-	O	1843-1844
like	O	1844-1848
cells	O	1849-1854
.	O	1854-1855

MicroRNA	B	0-8
-	I	8-9
490	I	9-12
-	I	12-13
5p	I	13-15
inhibits	O	16-24
proliferation	O	25-38
of	O	39-41
bladder	O	42-49
cancer	O	50-56
by	O	57-59
targeting	O	60-69
c	O	70-71
-	O	71-72
Fos	O	72-75
.	O	75-76

MicroRNAs	O	77-86
(	O	87-88
miRNAs	O	88-94
)	O	94-95
are	O	96-99
non	O	100-103
-	O	103-104
protein	O	104-111
-	O	111-112
coding	O	112-118
sequences	O	119-128
that	O	129-133
play	O	134-138
a	O	139-140
crucial	O	141-148
role	O	149-153
in	O	154-156
tumorigenesis	O	157-170
by	O	171-173
negatively	O	174-184
regulating	O	185-195
gene	O	196-200
expression	O	201-211
.	O	211-212

Here	O	213-217
,	O	217-218
we	O	219-221
found	O	222-227
that	O	228-232
miR	B	233-236
-	I	236-237
490	I	237-240
-	I	240-241
5p	I	241-243
is	O	244-246
down	O	247-251
-	O	251-252
regulated	O	252-261
in	O	262-264
human	O	265-270
bladder	O	271-278
cancer	O	279-285
tissue	O	286-292
and	O	293-296
cell	O	297-301
lines	O	302-307
compared	O	308-316
to	O	317-319
normal	O	320-326
adjacent	O	327-335
tissue	O	336-342
and	O	343-346
a	O	347-348
non	O	349-352
-	O	352-353
malignant	O	353-362
cell	O	363-367
line	O	368-372
.	O	372-373

To	O	374-376
better	O	377-383
characterize	O	384-396
the	O	397-400
function	O	401-409
of	O	410-412
miR	B	413-416
-	I	416-417
490	I	417-420
-	I	420-421
5p	I	421-423
in	O	424-426
bladder	O	427-434
cancer	O	435-441
,	O	441-442
we	O	443-445
over	O	446-450
-	O	450-451
expressed	O	451-460
miR	B	461-464
-	I	464-465
490	I	465-468
-	I	468-469
5p	I	469-471
in	O	472-474
bladder	O	475-482
cancer	O	483-489
cell	O	490-494
lines	O	495-500
with	O	501-505
chemically	O	506-516
synthesized	O	517-528
mimics	O	529-535
.	O	535-536

Enforced	O	537-545
expression	O	546-556
of	O	557-559
miR	B	560-563
-	I	563-564
490	I	564-567
-	I	567-568
5p	I	568-570
in	O	571-573
bladder	O	574-581
cancer	O	582-588
cells	O	589-594
significantly	O	595-608
inhibited	O	609-618
the	O	619-622
cell	O	623-627
proliferation	O	628-641
via	O	642-645
G1	O	646-648
-	O	648-649
phase	O	649-654
arrest	O	655-661
.	O	661-662

Further	O	663-670
studies	O	671-678
found	O	679-684
the	O	685-688
decreased	O	689-698
c	O	699-700
-	O	700-701
Fos	O	701-704
expression	O	705-715
at	O	716-718
both	O	719-723
mRNA	O	724-728
and	O	729-732
protein	O	733-740
levels	O	741-747
and	O	748-751
Luciferase	O	752-762
reporter	O	763-771
assays	O	772-778
demonstrated	O	779-791
that	O	792-796
c	O	797-798
-	O	798-799
Fos	O	799-802
is	O	803-805
a	O	806-807
direct	O	808-814
target	O	815-821
of	O	822-824
miR	B	825-828
-	I	828-829
490	I	829-832
-	I	832-833
5p	I	833-835
in	O	836-838
bladder	O	839-846
cancer	O	847-853
.	O	853-854

These	O	855-860
findings	O	861-869
indicate	O	870-878
miR	B	879-882
-	I	882-883
490	I	883-886
-	I	886-887
5p	I	887-889
to	O	890-892
be	O	893-895
a	O	896-897
novel	O	898-903
tumor	O	904-909
suppressor	O	910-920
of	O	921-923
bladder	O	924-931
cancer	O	932-938
cell	O	939-943
proliferation	O	944-957
through	O	958-965
targeting	O	966-975
c	O	976-977
-	O	977-978
Fos	O	978-981
.	O	981-982

miR	B	0-3
-	I	3-4
31	I	4-6
promotes	O	7-15
oncogenesis	O	16-27
in	O	28-30
intrahepatic	O	31-43
cholangiocarcinoma	O	44-62
cells	O	63-68
via	O	69-72
the	O	73-76
direct	O	77-83
suppression	O	84-95
of	O	96-98
RASA1	O	99-104
.	O	104-105

MicroRNAs	O	106-115
(	O	116-117
miRNAs	O	117-123
)	O	123-124
are	O	125-128
involved	O	129-137
in	O	138-140
the	O	141-144
pathogenesis	O	145-157
of	O	158-160
intrahepatic	O	161-173
cholangiocarcinoma	O	174-192
(	O	193-194
ICC	O	194-197
)	O	197-198
.	O	198-199

However	O	200-207
,	O	207-208
the	O	209-212
role	O	213-217
of	O	218-220
microRNA	B	221-229
-	I	229-230
31	I	230-232
(	O	233-234
miR	B	234-237
-	I	237-238
31	I	238-240
)	O	240-241
in	O	242-244
ICC	O	245-248
has	O	249-252
yet	O	253-256
to	O	257-259
be	O	260-262
elucidated	O	263-273
.	O	273-274

In	O	275-277
this	O	278-282
study	O	283-288
,	O	288-289
we	O	290-292
demonstrated	O	293-305
that	O	306-310
the	O	311-314
expression	O	315-325
of	O	326-328
miR	B	329-332
-	I	332-333
31	I	333-335
was	O	336-339
significantly	O	340-353
upregulated	O	354-365
in	O	366-368
ICC	O	369-372
tissues	O	373-380
and	O	381-384
the	O	385-388
human	O	389-394
ICC	O	395-398
cell	O	399-403
line	O	404-408
HCCC	O	409-413
-	O	413-414
9810	O	414-418
,	O	418-419
when	O	420-424
compared	O	425-433
with	O	434-438
that	O	439-443
in	O	444-446
normal	O	447-453
adjacent	O	454-462
tissues	O	463-470
.	O	470-471

Bioinformatic	O	472-485
analysis	O	486-494
and	O	495-498
a	O	499-500
dual	O	501-505
-	O	505-506
luciferase	O	506-516
reporter	O	517-525
assay	O	526-531
revealed	O	532-540
RAS	O	541-544
p21	O	545-548
GTPase	O	549-555
activating	O	556-566
protein	O	567-574
1	O	575-576
(	O	577-578
RASA1	O	578-583
)	O	583-584
to	O	585-587
be	O	588-590
a	O	591-592
direct	O	593-599
target	O	600-606
of	O	607-609
miR	B	610-613
-	I	613-614
31	I	614-616
in	O	617-619
HCCC	O	620-624
-	O	624-625
9810	O	625-629
cells	O	630-635
.	O	635-636

Further	O	637-644
investigation	O	645-658
showed	O	659-665
that	O	666-670
the	O	671-674
protein	O	675-682
expression	O	683-693
level	O	694-699
of	O	700-702
RASA1	O	703-708
was	O	709-712
significantly	O	713-726
decreased	O	727-736
in	O	737-739
ICC	O	740-743
tissues	O	744-751
,	O	751-752
suggesting	O	753-763
an	O	764-766
inverse	O	767-774
correlation	O	775-786
between	O	787-794
miR	B	795-798
-	I	798-799
31	I	799-801
and	O	802-805
RASA1	O	806-811
expression	O	812-822
during	O	823-829
the	O	830-833
tumorigenesis	O	834-847
of	O	848-850
ICC	O	851-854
.	O	854-855

Moreover	O	856-864
,	O	864-865
the	O	866-869
forced	O	870-876
downregulation	O	877-891
of	O	892-894
miR	B	895-898
-	I	898-899
31	I	899-901
by	O	902-904
its	O	905-908
inhibitor	O	909-918
in	O	919-921
HCCC	O	922-926
-	O	926-927
9810	O	927-931
cells	O	932-937
significantly	O	938-951
inhibited	O	952-961
cell	O	962-966
proliferation	O	967-980
and	O	981-984
promoted	O	985-993
cell	O	994-998
apoptosis	O	999-1008
.	O	1008-1009

However	O	1010-1017
,	O	1017-1018
when	O	1019-1023
the	O	1024-1027
cells	O	1028-1033
were	O	1034-1038
cotransfected	O	1039-1052
with	O	1053-1057
miR	B	1058-1061
-	I	1061-1062
31	I	1062-1064
inhibitor	O	1065-1074
and	O	1075-1078
RASA1	O	1079-1084
-	O	1084-1085
specific	O	1085-1093
small	O	1094-1099
interfering	O	1100-1111
RNA	O	1112-1115
(	O	1116-1117
siRNA	O	1117-1122
)	O	1122-1123
,	O	1123-1124
these	O	1125-1130
changes	O	1131-1138
were	O	1139-1143
attenuated	O	1144-1154
.	O	1154-1155

Further	O	1156-1163
analysis	O	1164-1172
of	O	1173-1175
the	O	1176-1179
molecular	O	1180-1189
mechanism	O	1190-1199
showed	O	1200-1206
that	O	1207-1211
the	O	1212-1215
activity	O	1216-1224
of	O	1225-1227
the	O	1228-1231
RAS	O	1232-1235
-	O	1235-1236
mitogen	O	1236-1243
-	O	1243-1244
activated	O	1244-1253
protein	O	1254-1261
kinase	O	1262-1268
(	O	1269-1270
MAPK	O	1270-1274
)	O	1274-1275
signaling	O	1276-1285
pathway	O	1286-1293
was	O	1294-1297
significantly	O	1298-1311
decreased	O	1312-1321
in	O	1322-1324
miR	B	1325-1328
-	I	1328-1329
31	I	1329-1331
-	O	1331-1332
downregulated	O	1332-1345
HCCC	O	1346-1350
-	O	1350-1351
8910	O	1351-1355
cells	O	1356-1361
,	O	1361-1362
while	O	1363-1368
cotransfection	O	1369-1383
with	O	1384-1388
miR	B	1389-1392
-	I	1392-1393
31	I	1393-1395
inhibitor	O	1396-1405
and	O	1406-1409
RASA1	O	1410-1415
-	O	1415-1416
specific	O	1416-1424
siRNA	O	1425-1430
attenuated	O	1431-1441
this	O	1442-1446
effect	O	1447-1453
.	O	1453-1454

These	O	1455-1460
results	O	1461-1468
indicate	O	1469-1477
that	O	1478-1482
the	O	1483-1486
downregulation	O	1487-1501
of	O	1502-1504
RASA1	O	1505-1510
by	O	1511-1513
miR	B	1514-1517
-	I	1517-1518
31	I	1518-1520
promoted	O	1521-1529
cellular	O	1530-1538
proliferation	O	1539-1552
and	O	1553-1556
inhibited	O	1557-1566
cellular	O	1567-1575
apoptosis	O	1576-1585
,	O	1585-1586
partially	O	1587-1596
by	O	1597-1599
upregulating	O	1600-1612
the	O	1613-1616
activity	O	1617-1625
of	O	1626-1628
the	O	1629-1632
RAS	O	1633-1636
-	O	1636-1637
MAPK	O	1637-1641
signaling	O	1642-1651
pathway	O	1652-1659
in	O	1660-1662
ICC	O	1663-1666
.	O	1666-1667

In	O	1668-1670
conclusion	O	1671-1681
,	O	1681-1682
the	O	1683-1686
present	O	1687-1694
study	O	1695-1700
revealed	O	1701-1709
important	O	1710-1719
regulatory	O	1720-1730
functions	O	1731-1740
of	O	1741-1743
miR	B	1744-1747
-	I	1747-1748
31	I	1748-1750
and	O	1751-1754
RASA1	O	1755-1760
in	O	1761-1763
ICC	O	1764-1767
,	O	1767-1768
indicating	O	1769-1779
that	O	1780-1784
miR	B	1785-1788
-	I	1788-1789
31	I	1789-1791
and	O	1792-1795
RASA1	O	1796-1801
may	O	1802-1805
become	O	1806-1812
promising	O	1813-1822
diagnostic	O	1823-1833
and	O	1834-1837
/	O	1837-1838
or	O	1838-1840
therapeutic	O	1841-1852
targets	O	1853-1860
for	O	1861-1864
ICC	O	1865-1868
.	O	1868-1869

[	O	0-1
Effect	O	1-7
of	O	8-10
miRNA	B	11-16
-	I	16-17
106a	I	17-21
expression	O	22-32
on	O	33-35
the	O	36-39
prognosis	O	40-49
of	O	50-52
patients	O	53-61
with	O	62-66
esophageal	O	67-77
squamous	O	78-86
cell	O	87-91
carcinoma	O	92-101
]	O	101-102
.	O	102-103

OBJECTIVE	O	104-113
:	O	113-114
To	O	115-117
study	O	118-123
the	O	124-127
expression	O	128-138
of	O	139-141
miRNA	B	142-147
-	I	147-148
106a	I	148-152
gene	O	153-157
in	O	158-160
esophageal	O	161-171
squamous	O	172-180
cell	O	181-185
carcinoma	O	186-195
(	O	196-197
ESCC	O	197-201
)	O	201-202
and	O	203-206
its	O	207-210
association	O	211-222
with	O	223-227
clinicopathological	O	228-247
features	O	248-256
and	O	257-260
prognosis	O	261-270
of	O	271-273
ESCC	O	274-278
patients	O	279-287
.	O	287-288

METHODS	O	289-296
:	O	296-297
Real	O	298-302
-	O	302-303
time	O	303-307
fluorescence	O	308-320
quantitative	O	321-333
polymerase	O	334-344
chain	O	345-350
reaction	O	351-359
(	O	360-361
PCR	O	361-364
)	O	364-365
assay	O	366-371
was	O	372-375
used	O	376-380
to	O	381-383
determine	O	384-393
the	O	394-397
expression	O	398-408
of	O	409-411
miRNA	B	412-417
-	I	417-418
106a	I	418-422
gene	O	423-427
in	O	428-430
esophageal	O	431-441
cancer	O	442-448
tissue	O	449-455
and	O	456-459
corresponding	O	460-473
normal	O	474-480
mucosa	O	481-487
of	O	488-490
81	O	491-493
cases	O	494-499
.	O	499-500

Immunohistochemical	O	501-520
technique	O	521-530
was	O	531-534
applied	O	535-542
to	O	543-545
detect	O	546-552
the	O	553-556
expression	O	557-567
of	O	568-570
p53	O	571-574
,	O	574-575
human	O	576-581
epidermal	O	582-591
growth	O	592-598
factor	O	599-605
receptor	O	606-614
2	O	615-616
(	O	617-618
HER	O	618-621
-	O	621-622
2	O	622-623
)	O	623-624
,	O	624-625
DNA	O	626-629
topoisomerase	O	630-643
II	O	644-646
(	O	647-648
Topo	O	648-652
II	O	653-655
)	O	655-656
and	O	657-660
multidrug	O	661-670
resistance	O	671-681
-	O	681-682
associated	O	682-692
protein	O	693-700
(	O	701-702
MRP	O	702-705
)	O	705-706
.	O	706-707

The	O	708-711
association	O	712-723
of	O	724-726
miRNA	B	727-732
-	I	732-733
106a	I	733-737
expression	O	738-748
with	O	749-753
clinicopathological	O	754-773
features	O	774-782
,	O	782-783
expression	O	784-794
of	O	795-797
related	O	798-805
proteins	O	806-814
,	O	814-815
and	O	816-819
prognosis	O	820-829
of	O	830-832
the	O	833-836
patients	O	837-845
was	O	846-849
analyzed	O	850-858
.	O	858-859

RESULTS	O	860-867
:	O	867-868
Among	O	869-874
the	O	875-878
81	O	879-881
cases	O	882-887
,	O	887-888
under	O	889-894
-	O	894-895
expression	O	895-905
of	O	906-908
miRNA	B	909-914
-	I	914-915
106a	I	915-919
gene	O	920-924
was	O	925-928
found	O	929-934
in	O	935-937
48	O	938-940
cases	O	941-946
(	O	947-948
59	O	948-950
.	O	950-951
3	O	951-952
%	O	952-953
)	O	953-954
,	O	954-955
normal	O	956-962
expression	O	963-973
in	O	974-976
22	O	977-979
cases	O	980-985
(	O	986-987
27	O	987-989
.	O	989-990
2	O	990-991
%	O	991-992
)	O	992-993
,	O	993-994
and	O	995-998
overexpression	O	999-1013
in	O	1014-1016
11	O	1017-1019
cases	O	1020-1025
(	O	1026-1027
13	O	1027-1029
.	O	1029-1030
6	O	1030-1031
%	O	1031-1032
)	O	1032-1033
.	O	1033-1034

The	O	1035-1038
expression	O	1039-1049
of	O	1050-1052
miRNA	B	1053-1058
-	I	1058-1059
106	I	1059-1062
gene	O	1063-1067
was	O	1068-1071
significantly	O	1072-1085
associated	O	1086-1096
with	O	1097-1101
lymph	O	1102-1107
node	O	1108-1112
metastasis	O	1113-1123
,	O	1123-1124
pathological	O	1125-1137
stage	O	1138-1143
,	O	1143-1144
and	O	1145-1148
nerve	O	1149-1154
invasion	O	1155-1163
(	O	1164-1165
all	O	1165-1168
P	O	1169-1170
<	O	1171-1172
0	O	1173-1174
.	O	1174-1175
05	O	1175-1177
)	O	1177-1178
,	O	1178-1179
significantly	O	1180-1193
associated	O	1194-1204
with	O	1205-1209
expression	O	1210-1220
of	O	1221-1223
p53	O	1224-1227
(	O	1228-1229
P	O	1229-1230
=	O	1231-1232
0	O	1233-1234
.	O	1234-1235
006	O	1235-1238
)	O	1238-1239
,	O	1239-1240
and	O	1241-1244
not	O	1245-1248
significantly	O	1249-1262
associated	O	1263-1273
with	O	1274-1278
expressions	O	1279-1290
of	O	1291-1293
HER	O	1294-1297
-	O	1297-1298
2	O	1298-1299
,	O	1299-1300
Topo	O	1301-1305
II	O	1306-1308
and	O	1309-1312
MRP	O	1313-1316
proteins	O	1317-1325
(	O	1326-1327
all	O	1327-1330
P	O	1331-1332
>	O	1333-1334
0	O	1335-1336
.	O	1336-1337
05	O	1337-1339
)	O	1339-1340
.	O	1340-1341

The	O	1342-1345
expression	O	1346-1356
of	O	1357-1359
miRNA	B	1360-1365
-	I	1365-1366
106a	I	1366-1370
gene	O	1371-1375
was	O	1376-1379
also	O	1380-1384
significantly	O	1385-1398
associated	O	1399-1409
with	O	1410-1414
progression	O	1415-1426
-	O	1426-1427
free	O	1427-1431
survival	O	1432-1440
(	O	1441-1442
PFS	O	1442-1445
,	O	1445-1446
P	O	1447-1448
=	O	1449-1450
0	O	1451-1452
.	O	1452-1453
032	O	1453-1456
)	O	1456-1457
,	O	1457-1458
but	O	1459-1462
not	O	1463-1466
significantly	O	1467-1480
with	O	1481-1485
overall	O	1486-1493
survival	O	1494-1502
(	O	1503-1504
OS	O	1504-1506
,	O	1506-1507
P	O	1508-1509
=	O	1510-1511
0	O	1512-1513
.	O	1513-1514
486	O	1514-1517
)	O	1517-1518
.	O	1518-1519

The	O	1520-1523
results	O	1524-1531
of	O	1532-1534
Cox	O	1535-1538
multivariate	O	1539-1551
regression	O	1552-1562
analysis	O	1563-1571
showed	O	1572-1578
that	O	1579-1583
the	O	1584-1587
PFS	O	1588-1591
of	O	1592-1594
ESCC	O	1595-1599
patients	O	1600-1608
was	O	1609-1612
significantly	O	1613-1626
correlated	O	1627-1637
with	O	1638-1642
lymph	O	1643-1648
node	O	1649-1653
metastasis	O	1654-1664
(	O	1665-1666
P	O	1666-1667
=	O	1668-1669
0	O	1670-1671
.	O	1671-1672
029	O	1672-1675
)	O	1675-1676
,	O	1676-1677
but	O	1678-1681
not	O	1682-1685
correlated	O	1686-1696
with	O	1697-1701
the	O	1702-1705
age	O	1706-1709
,	O	1709-1710
gender	O	1711-1717
,	O	1717-1718
tumor	O	1719-1724
length	O	1725-1731
,	O	1731-1732
T	O	1733-1734
stage	O	1735-1740
,	O	1740-1741
degree	O	1742-1748
of	O	1749-1751
differentiation	O	1752-1767
,	O	1767-1768
nerve	O	1769-1774
invasion	O	1775-1783
,	O	1783-1784
and	O	1785-1788
miRNA	B	1789-1794
-	I	1794-1795
106a	I	1795-1799
expression	O	1800-1810
(	O	1811-1812
all	O	1812-1815
P	O	1816-1817
>	O	1818-1819
0	O	1820-1821
.	O	1821-1822
05	O	1822-1824
)	O	1824-1825
.	O	1825-1826

CONCLUSIONS	O	1827-1838
:	O	1838-1839
In	O	1840-1842
esophageal	O	1843-1853
squamous	O	1854-1862
cell	O	1863-1867
carcinomas	O	1868-1878
,	O	1878-1879
the	O	1880-1883
miRNA	B	1884-1889
-	I	1889-1890
106a	I	1890-1894
gene	O	1895-1899
is	O	1900-1902
under	O	1903-1908
-	O	1908-1909
expressed	O	1909-1918
,	O	1918-1919
with	O	1920-1924
tumor	O	1925-1930
suppressor	O	1931-1941
function	O	1942-1950
,	O	1950-1951
and	O	1952-1955
may	O	1956-1959
be	O	1960-1962
regarded	O	1963-1971
as	O	1972-1974
a	O	1975-1976
biological	O	1977-1987
marker	O	1988-1994
to	O	1995-1997
assess	O	1998-2004
the	O	2005-2008
prognosis	O	2009-2018
in	O	2019-2021
patients	O	2022-2030
with	O	2031-2035
esophageal	O	2036-2046
squamous	O	2047-2055
cell	O	2056-2060
carcinoma	O	2061-2070
.	O	2070-2071

The	O	0-3
p53	O	4-7
transcription	O	8-21
factor	O	22-28
modulates	O	29-38
microglia	O	39-48
behavior	O	49-57
through	O	58-65
microRNA	O	66-74
-	O	74-75
dependent	O	75-84
regulation	O	85-95
of	O	96-98
c	O	99-100
-	O	100-101
Maf	O	101-104
.	O	104-105

Neuroinflammation	O	106-123
occurs	O	124-130
in	O	131-133
acute	O	134-139
and	O	140-143
chronic	O	144-151
CNS	O	152-155
injury	O	156-162
,	O	162-163
including	O	164-173
stroke	O	174-180
,	O	180-181
traumatic	O	182-191
brain	O	192-197
injury	O	198-204
,	O	204-205
and	O	206-209
neurodegenerative	O	210-227
diseases	O	228-236
.	O	236-237

Microglia	O	238-247
are	O	248-251
specialized	O	252-263
resident	O	264-272
myeloid	O	273-280
cells	O	281-286
that	O	287-291
mediate	O	292-299
CNS	O	300-303
innate	O	304-310
immune	O	311-317
responses	O	318-327
.	O	327-328

Disease	O	329-336
-	O	336-337
relevant	O	337-345
stimuli	O	346-353
,	O	353-354
such	O	355-359
as	O	360-362
reactive	O	363-371
oxygen	O	372-378
species	O	379-386
(	O	387-388
ROS	O	388-391
)	O	391-392
,	O	392-393
can	O	394-397
influence	O	398-407
microglia	O	408-417
activation	O	418-428
.	O	428-429

Previously	O	430-440
,	O	440-441
we	O	442-444
observed	O	445-453
that	O	454-458
p53	O	459-462
,	O	462-463
a	O	464-465
ROS	O	466-469
-	O	469-470
responsive	O	470-480
transcription	O	481-494
factor	O	495-501
,	O	501-502
modulates	O	503-512
microglia	O	513-522
behaviors	O	523-532
in	O	533-535
vitro	O	536-541
and	O	542-545
in	O	546-548
vivo	O	549-553
,	O	553-554
promoting	O	555-564
proinflammatory	O	565-580
functions	O	581-590
and	O	591-594
suppressing	O	595-606
downregulation	O	607-621
of	O	622-624
the	O	625-628
inflammatory	O	629-641
response	O	642-650
and	O	651-654
tissue	O	655-661
repair	O	662-668
.	O	668-669

In	O	670-672
this	O	673-677
article	O	678-685
we	O	686-688
describe	O	689-697
a	O	698-699
novel	O	700-705
mechanism	O	706-715
by	O	716-718
which	O	719-724
p53	O	725-728
modulates	O	729-738
the	O	739-742
functional	O	743-753
differentiation	O	754-769
of	O	770-772
microglia	O	773-782
both	O	783-787
in	O	788-790
vitro	O	791-796
and	O	797-800
in	O	801-803
vivo	O	804-808
.	O	808-809

Adult	O	810-815
microglia	O	816-825
from	O	826-830
p53	O	831-834
-	O	834-835
deficient	O	835-844
mice	O	845-849
have	O	850-854
increased	O	855-864
expression	O	865-875
of	O	876-878
the	O	879-882
anti	O	883-887
-	O	887-888
inflammatory	O	888-900
transcription	O	901-914
factor	O	915-921
c	O	922-923
-	O	923-924
Maf	O	924-927
.	O	927-928

To	O	929-931
determine	O	932-941
how	O	942-945
p53	O	946-949
negatively	O	950-960
regulates	O	961-970
c	O	971-972
-	O	972-973
Maf	O	973-976
,	O	976-977
we	O	978-980
examined	O	981-989
the	O	990-993
impact	O	994-1000
of	O	1001-1003
p53	O	1004-1007
on	O	1008-1010
known	O	1011-1016
c	O	1017-1018
-	O	1018-1019
Maf	O	1019-1022
regulators	O	1023-1033
.	O	1033-1034

MiR	B	1035-1038
-	I	1038-1039
155	I	1039-1042
is	O	1043-1045
a	O	1046-1047
microRNA	O	1048-1056
that	O	1057-1061
targets	O	1062-1069
c	O	1070-1071
-	O	1071-1072
Maf	O	1072-1075
.	O	1075-1076

We	O	1077-1079
observed	O	1080-1088
that	O	1089-1093
cytokine	O	1094-1102
-	O	1102-1103
induced	O	1103-1110
expression	O	1111-1121
of	O	1122-1124
miR	B	1125-1128
-	I	1128-1129
155	I	1129-1132
was	O	1133-1136
suppressed	O	1137-1147
in	O	1148-1150
p53	O	1151-1154
-	O	1154-1155
deficient	O	1155-1164
microglia	O	1165-1174
.	O	1174-1175

Furthermore	O	1176-1187
,	O	1187-1188
Twist2	O	1189-1195
,	O	1195-1196
a	O	1197-1198
transcriptional	O	1199-1214
activator	O	1215-1224
of	O	1225-1227
c	O	1228-1229
-	O	1229-1230
Maf	O	1230-1233
,	O	1233-1234
is	O	1235-1237
increased	O	1238-1247
in	O	1248-1250
p53	O	1251-1254
-	O	1254-1255
deficient	O	1255-1264
microglia	O	1265-1274
.	O	1274-1275

We	O	1276-1278
identified	O	1279-1289
recognition	O	1290-1301
sites	O	1302-1307
in	O	1308-1310
the	O	1311-1314
3	O	1315-1316
'	O	1316-1317
untranslated	O	1318-1330
region	O	1331-1337
of	O	1338-1340
Twist2	O	1341-1347
mRNA	O	1348-1352
that	O	1353-1357
are	O	1358-1361
predicted	O	1362-1371
to	O	1372-1374
interact	O	1375-1383
with	O	1384-1388
two	O	1389-1392
p53	O	1393-1396
-	O	1396-1397
dependent	O	1397-1406
microRNAs	O	1407-1416
:	O	1416-1417
miR	B	1418-1421
-	I	1421-1422
34a	I	1422-1425
and	O	1426-1429
miR	B	1430-1433
-	I	1433-1434
145	I	1434-1437
.	O	1437-1438

In	O	1439-1441
this	O	1442-1446
article	O	1447-1454
,	O	1454-1455
we	O	1456-1458
demonstrate	O	1459-1470
that	O	1471-1475
miR	B	1476-1479
-	I	1479-1480
34a	I	1480-1483
and	O	1484-1487
-	B	1488-1489
145	I	1489-1492
are	O	1493-1496
regulated	O	1497-1506
by	O	1507-1509
p53	O	1510-1513
and	O	1514-1517
negatively	O	1518-1528
regulate	O	1529-1537
Twist2	O	1538-1544
and	O	1545-1548
c	O	1549-1550
-	O	1550-1551
Maf	O	1551-1554
expression	O	1555-1565
in	O	1566-1568
microglia	O	1569-1578
and	O	1579-1582
the	O	1583-1586
RAW	O	1587-1590
macrophage	O	1591-1601
cell	O	1602-1606
line	O	1607-1611
.	O	1611-1612

Taken	O	1613-1618
together	O	1619-1627
,	O	1627-1628
these	O	1629-1634
findings	O	1635-1643
support	O	1644-1651
the	O	1652-1655
hypothesis	O	1656-1666
that	O	1667-1671
p53	O	1672-1675
activation	O	1676-1686
induced	O	1687-1694
by	O	1695-1697
local	O	1698-1703
ROS	O	1704-1707
or	O	1708-1710
accumulated	O	1711-1722
DNA	O	1723-1726
damage	O	1727-1733
influences	O	1734-1744
microglia	O	1745-1754
functions	O	1755-1764
and	O	1765-1768
that	O	1769-1773
one	O	1774-1777
specific	O	1778-1786
molecular	O	1787-1796
target	O	1797-1803
of	O	1804-1806
p53	O	1807-1810
in	O	1811-1813
microglia	O	1814-1823
is	O	1824-1826
c	O	1827-1828
-	O	1828-1829
Maf	O	1829-1832
.	O	1832-1833

Microrna	B	0-8
-	I	8-9
124	I	9-12
targets	O	13-20
flotillin	O	21-30
-	O	30-31
1	O	31-32
to	O	33-35
regulate	O	36-44
proliferation	O	45-58
and	O	59-62
migration	O	63-72
in	O	73-75
breast	O	76-82
cancer	O	83-89
.	O	89-90

BACKGROUND	O	91-101
:	O	101-102
MicroRNAs	O	103-112
(	O	113-114
miRNAs	O	114-120
)	O	120-121
have	O	122-126
been	O	127-131
documented	O	132-142
as	O	143-145
playing	O	146-153
important	O	154-163
roles	O	164-169
in	O	170-172
cancer	O	173-179
development	O	180-191
.	O	191-192

In	O	193-195
this	O	196-200
study	O	201-206
,	O	206-207
we	O	208-210
investigated	O	211-223
the	O	224-227
role	O	228-232
of	O	233-235
miR	B	236-239
-	I	239-240
124	I	240-243
in	O	244-246
breast	O	247-253
cancer	O	254-260
and	O	261-264
clarified	O	265-274
the	O	275-278
regulation	O	279-289
of	O	290-292
flotillin	O	293-302
-	O	302-303
1	O	303-304
(	O	305-306
FLOT1	O	306-311
)	O	311-312
by	O	313-315
miR	B	316-319
-	I	319-320
124	I	320-323
.	O	323-324

METHODS	O	325-332
:	O	332-333
The	O	334-337
expression	O	338-348
levels	O	349-355
of	O	356-358
miR	B	359-362
-	I	362-363
124	I	363-366
were	O	367-371
examined	O	372-380
in	O	381-383
breast	O	384-390
cancer	O	391-397
cell	O	398-402
lines	O	403-408
and	O	409-412
patient	O	413-420
specimens	O	421-430
using	O	431-436
quantitative	O	437-449
reverse	O	450-457
transcription	O	458-471
-	O	471-472
PCR	O	472-475
.	O	475-476

The	O	477-480
clinicopathological	O	481-500
significance	O	501-513
of	O	514-516
the	O	517-520
resultant	O	521-530
data	O	531-535
was	O	536-539
later	O	540-545
analyzed	O	546-554
.	O	554-555

Next	O	556-560
,	O	560-561
we	O	562-564
explored	O	565-573
the	O	574-577
function	O	578-586
of	O	587-589
miR	B	590-593
-	I	593-594
124	I	594-597
to	O	598-600
determine	O	601-610
its	O	611-614
potential	O	615-624
roles	O	625-630
on	O	631-633
cancer	O	634-640
cell	O	641-645
growth	O	646-652
and	O	653-656
migration	O	657-666
in	O	667-669
vitro	O	670-675
.	O	675-676

A	O	677-678
luciferase	O	679-689
reporter	O	690-698
assay	O	699-704
was	O	705-708
conducted	O	709-718
to	O	719-721
confirm	O	722-729
the	O	730-733
target	O	734-740
gene	O	741-745
of	O	746-748
miR	B	749-752
-	I	752-753
124	I	753-756
,	O	756-757
and	O	758-761
the	O	762-765
results	O	766-773
were	O	774-778
validated	O	779-788
in	O	789-791
cell	O	792-796
lines	O	797-802
and	O	803-806
patient	O	807-814
specimens	O	815-824
.	O	824-825

RESULTS	O	826-833
:	O	833-834
We	O	835-837
found	O	838-843
that	O	844-848
miR	B	849-852
-	I	852-853
124	I	853-856
expression	O	857-867
was	O	868-871
significantly	O	872-885
downregulated	O	886-899
in	O	900-902
breast	O	903-909
cancer	O	910-916
cell	O	917-921
lines	O	922-927
and	O	928-931
patient	O	932-939
specimen	O	940-948
compared	O	949-957
with	O	958-962
normal	O	963-969
cell	O	970-974
lines	O	975-980
and	O	981-984
paired	O	985-991
adjacent	O	992-1000
normal	O	1001-1007
tissues	O	1008-1015
(	O	1016-1017
P	O	1017-1018
<	O	1019-1020
0	O	1021-1022
.	O	1022-1023
0001	O	1023-1027
)	O	1027-1028
,	O	1028-1029
respectively	O	1030-1042
.	O	1042-1043

MiR	B	1044-1047
-	I	1047-1048
124	I	1048-1051
was	O	1052-1055
also	O	1056-1060
associated	O	1061-1071
with	O	1072-1076
tumor	O	1077-1082
node	O	1083-1087
metastasis	O	1088-1098
(	O	1099-1100
TNM	O	1100-1103
)	O	1103-1104
stage	O	1105-1110
(	O	1111-1112
P	O	1112-1113
=	O	1114-1115
0	O	1116-1117
.	O	1117-1118
0007	O	1118-1122
)	O	1122-1123
and	O	1124-1127
lymph	O	1128-1133
node	O	1134-1138
metastasis	O	1139-1149
(	O	1150-1151
P	O	1151-1152
=	O	1153-1154
0	O	1155-1156
.	O	1156-1157
0004	O	1157-1161
)	O	1161-1162
.	O	1162-1163

In	O	1164-1166
breast	O	1167-1173
cancer	O	1174-1180
cell	O	1181-1185
lines	O	1186-1191
,	O	1191-1192
the	O	1193-1196
ectopic	O	1197-1204
expression	O	1205-1215
of	O	1216-1218
miR	B	1219-1222
-	I	1222-1223
124	I	1223-1226
inhibited	O	1227-1236
cell	O	1237-1241
growth	O	1242-1248
and	O	1249-1252
migration	O	1253-1262
in	O	1263-1265
vitro	O	1266-1271
.	O	1271-1272

Moreover	O	1273-1281
,	O	1281-1282
we	O	1283-1285
identified	O	1286-1296
the	O	1297-1300
FLOT1	O	1301-1306
gene	O	1307-1311
as	O	1312-1314
a	O	1315-1316
novel	O	1317-1322
direct	O	1323-1329
target	O	1330-1336
of	O	1337-1339
miR	B	1340-1343
-	I	1343-1344
124	I	1344-1347
,	O	1347-1348
and	O	1349-1352
miR	B	1353-1356
-	I	1356-1357
124	I	1357-1360
ectopic	O	1361-1368
expression	O	1369-1379
significantly	O	1380-1393
inhibited	O	1394-1403
FLOT1	O	1404-1409
.	O	1409-1410

Luciferase	O	1411-1421
assays	O	1422-1428
confirmed	O	1429-1438
that	O	1439-1443
miR	B	1444-1447
-	I	1447-1448
124	I	1448-1451
could	O	1452-1457
directly	O	1458-1466
bind	O	1467-1471
to	O	1472-1474
the	O	1475-1478
3	O	1479-1480
'	O	1480-1481
untranslated	O	1482-1494
region	O	1495-1501
of	O	1502-1504
FLOT1	O	1505-1510
and	O	1511-1514
suppress	O	1515-1523
translation	O	1524-1535
.	O	1535-1536

Moreover	O	1537-1545
,	O	1545-1546
FLOT1	O	1547-1552
was	O	1553-1556
widely	O	1557-1563
upregulated	O	1564-1575
,	O	1575-1576
and	O	1577-1580
inversely	O	1581-1590
correlated	O	1591-1601
with	O	1602-1606
miR	B	1607-1610
-	I	1610-1611
124	I	1611-1614
in	O	1615-1617
breast	O	1618-1624
cancer	O	1625-1631
tissues	O	1632-1639
.	O	1639-1640

Consistent	O	1641-1651
with	O	1652-1656
the	O	1657-1660
effect	O	1661-1667
of	O	1668-1670
miR	B	1671-1674
-	I	1674-1675
124	I	1675-1678
,	O	1678-1679
the	O	1680-1683
knockdown	O	1684-1693
of	O	1694-1696
FLOT1	O	1697-1702
significantly	O	1703-1716
inhibited	O	1717-1726
breast	O	1727-1733
cancer	O	1734-1740
cell	O	1741-1745
growth	O	1746-1752
and	O	1753-1756
migration	O	1757-1766
.	O	1766-1767

We	O	1768-1770
also	O	1771-1775
observed	O	1776-1784
that	O	1785-1789
the	O	1790-1793
rescue	O	1794-1800
expression	O	1801-1811
of	O	1812-1814
FLOT1	O	1815-1820
partially	O	1821-1830
restored	O	1831-1839
the	O	1840-1843
effects	O	1844-1851
of	O	1852-1854
miR	B	1855-1858
-	I	1858-1859
124	I	1859-1862
.	O	1862-1863

CONCLUSIONS	O	1864-1875
:	O	1875-1876
Our	O	1877-1880
study	O	1881-1886
demonstrated	O	1887-1899
that	O	1900-1904
miR	B	1905-1908
-	I	1908-1909
124	I	1909-1912
might	O	1913-1918
be	O	1919-1921
a	O	1922-1923
tumor	O	1924-1929
suppressor	O	1930-1940
in	O	1941-1943
breast	O	1944-1950
cancer	O	1951-1957
via	O	1958-1961
the	O	1962-1965
regulation	O	1966-1976
of	O	1977-1979
FLOT1	O	1980-1985
.	O	1985-1986

This	O	1987-1991
microRNA	O	1992-2000
could	O	2001-2006
serve	O	2007-2012
as	O	2013-2015
a	O	2016-2017
potential	O	2018-2027
diagnostic	O	2028-2038
marker	O	2039-2045
and	O	2046-2049
therapeutic	O	2050-2061
target	O	2062-2068
for	O	2069-2072
breast	O	2073-2079
cancer	O	2080-2086
.	O	2086-2087

Differentially	O	0-14
expressed	O	15-24
wound	O	25-30
healing	O	31-38
-	O	38-39
related	O	39-46
microRNAs	O	47-56
in	O	57-59
the	O	60-63
human	O	64-69
diabetic	O	70-78
cornea	O	79-85
.	O	85-86

MicroRNAs	O	87-96
are	O	97-100
powerful	O	101-109
gene	O	110-114
expression	O	115-125
regulators	O	126-136
,	O	136-137
but	O	138-141
their	O	142-147
corneal	O	148-155
repertoire	O	156-166
and	O	167-170
potential	O	171-180
changes	O	181-188
in	O	189-191
corneal	O	192-199
diseases	O	200-208
remain	O	209-215
unknown	O	216-223
.	O	223-224

Our	O	225-228
purpose	O	229-236
was	O	237-240
to	O	241-243
identify	O	244-252
miRNAs	O	253-259
altered	O	260-267
in	O	268-270
the	O	271-274
human	O	275-280
diabetic	O	281-289
cornea	O	290-296
by	O	297-299
microarray	O	300-310
analysis	O	311-319
,	O	319-320
and	O	321-324
to	O	325-327
examine	O	328-335
their	O	336-341
effects	O	342-349
on	O	350-352
wound	O	353-358
healing	O	359-366
in	O	367-369
cultured	O	370-378
telomerase	O	379-389
-	O	389-390
immortalized	O	390-402
human	O	403-408
corneal	O	409-416
epithelial	O	417-427
cells	O	428-433
(	O	434-435
HCEC	O	435-439
)	O	439-440
in	O	441-443
vitro	O	444-449
.	O	449-450

Total	O	451-456
RNA	O	457-460
was	O	461-464
extracted	O	465-474
from	O	475-479
age	O	480-483
-	O	483-484
matched	O	484-491
human	O	492-497
autopsy	O	498-505
normal	O	506-512
(	O	513-514
n	O	514-515
=	O	515-516
6	O	516-517
)	O	517-518
and	O	519-522
diabetic	O	523-531
(	O	532-533
n	O	533-534
=	O	534-535
6	O	535-536
)	O	536-537
central	O	538-545
corneas	O	546-553
,	O	553-554
Flash	O	555-560
Tag	O	561-564
end	O	565-568
-	O	568-569
labeled	O	569-576
,	O	576-577
and	O	578-581
hybridized	O	582-592
to	O	593-595
Affymetrix	O	596-606
(	O	606-607
R	O	607-608
)	O	608-609
GeneChip	O	610-618
(	O	618-619
R	O	619-620
)	O	620-621
miRNA	O	622-627
Arrays	O	628-634
.	O	634-635

Select	O	636-642
miRNAs	O	643-649
associated	O	650-660
with	O	661-665
diabetic	O	666-674
cornea	O	675-681
were	O	682-686
validated	O	687-696
by	O	697-699
quantitative	O	700-712
RT	O	713-715
-	O	715-716
PCR	O	716-719
(	O	720-721
Q	O	721-722
-	O	722-723
PCR	O	723-726
)	O	726-727
and	O	728-731
by	O	732-734
in	O	735-737
situ	O	738-742
hybridization	O	743-756
(	O	757-758
ISH	O	758-761
)	O	761-762
in	O	763-765
independent	O	766-777
samples	O	778-785
.	O	785-786

HCEC	O	787-791
were	O	792-796
transfected	O	797-808
with	O	809-813
human	O	814-819
pre	O	820-823
-	O	823-824
miRmiRNA	O	824-832
precursors	O	833-843
(	O	844-845
h	O	845-846
-	O	846-847
miR	O	847-850
)	O	850-851
or	O	852-854
their	O	855-860
inhibitors	O	861-871
(	O	872-873
antagomirs	O	873-883
)	O	883-884
using	O	885-890
Lipofectamine	O	891-904
2000	O	905-909
.	O	909-910

Confluent	O	911-920
transfected	O	921-932
cultures	O	933-941
were	O	942-946
scratch	O	947-954
-	O	954-955
wounded	O	955-962
with	O	963-967
P200	O	968-972
pipette	O	973-980
tip	O	981-984
.	O	984-985

Wound	O	986-991
closure	O	992-999
was	O	1000-1003
monitored	O	1004-1013
by	O	1014-1016
digital	O	1017-1024
photography	O	1025-1036
.	O	1036-1037

Expression	O	1038-1048
of	O	1049-1051
signaling	O	1052-1061
proteins	O	1062-1070
was	O	1071-1074
detected	O	1075-1083
by	O	1084-1086
immunostaining	O	1087-1101
and	O	1102-1105
Western	O	1106-1113
blot	O	1114-1118
.	O	1118-1119

Using	O	1120-1125
microarrays	O	1126-1137
,	O	1137-1138
29	O	1139-1141
miRNAs	O	1142-1148
were	O	1149-1153
identified	O	1154-1164
as	O	1165-1167
differentially	O	1168-1182
expressed	O	1183-1192
in	O	1193-1195
diabetic	O	1196-1204
samples	O	1205-1212
.	O	1212-1213

Two	O	1214-1217
miRNA	O	1218-1223
candidates	O	1224-1234
showing	O	1235-1242
the	O	1243-1246
highest	O	1247-1254
fold	O	1255-1259
increased	O	1260-1269
in	O	1270-1272
expression	O	1273-1283
in	O	1284-1286
the	O	1287-1290
diabetic	O	1291-1299
cornea	O	1300-1306
were	O	1307-1311
confirmed	O	1312-1321
by	O	1322-1324
Q	O	1325-1326
-	O	1326-1327
PCR	O	1327-1330
and	O	1331-1334
further	O	1335-1342
characterized	O	1343-1356
.	O	1356-1357

HCEC	O	1358-1362
transfection	O	1363-1375
with	O	1376-1380
h	B	1381-1382
-	I	1382-1383
miR	I	1383-1386
-	I	1386-1387
146a	I	1387-1391
or	O	1392-1394
h	B	1395-1396
-	I	1396-1397
miR	I	1397-1400
-	I	1400-1401
424	I	1401-1404
significantly	O	1405-1418
retarded	O	1419-1427
wound	O	1428-1433
closure	O	1434-1441
,	O	1441-1442
but	O	1443-1446
their	O	1447-1452
respective	O	1453-1463
antagomirs	O	1464-1474
significantly	O	1475-1488
enhanced	O	1489-1497
wound	O	1498-1503
healing	O	1504-1511
vs	O	1512-1514
.	O	1514-1515
controls	O	1516-1524
.	O	1524-1525

Cells	O	1526-1531
treated	O	1532-1539
with	O	1540-1544
h	B	1545-1546
-	I	1546-1547
miR	I	1547-1550
-	I	1550-1551
146a	I	1551-1555
or	O	1556-1558
h	B	1559-1560
-	I	1560-1561
miR	I	1561-1564
-	I	1564-1565
424	I	1565-1568
had	O	1569-1572
decreased	O	1573-1582
p	O	1583-1584
-	O	1584-1585
p38	O	1585-1588
and	O	1589-1592
p	O	1593-1594
-	O	1594-1595
EGFR	O	1595-1599
staining	O	1600-1608
,	O	1608-1609
but	O	1610-1613
these	O	1614-1619
increased	O	1620-1629
over	O	1630-1634
control	O	1635-1642
levels	O	1643-1649
close	O	1650-1655
to	O	1656-1658
the	O	1659-1662
wound	O	1663-1668
edge	O	1669-1673
upon	O	1674-1678
antagomir	O	1679-1688
treatment	O	1689-1698
.	O	1698-1699

In	O	1700-1702
conclusion	O	1703-1713
,	O	1713-1714
several	O	1715-1722
miRNAs	O	1723-1729
with	O	1730-1734
increased	O	1735-1744
expression	O	1745-1755
in	O	1756-1758
human	O	1759-1764
diabetic	O	1765-1773
central	O	1774-1781
corneas	O	1782-1789
were	O	1790-1794
found	O	1795-1800
.	O	1800-1801

Two	O	1802-1805
such	O	1806-1810
miRNAs	O	1811-1817
inhibited	O	1818-1827
cultured	O	1828-1836
corneal	O	1837-1844
epithelial	O	1845-1855
cell	O	1856-1860
wound	O	1861-1866
healing	O	1867-1874
.	O	1874-1875

Dysregulation	O	1876-1889
of	O	1890-1892
miRNA	O	1893-1898
expression	O	1899-1909
in	O	1910-1912
human	O	1913-1918
diabetic	O	1919-1927
cornea	O	1928-1934
may	O	1935-1938
be	O	1939-1941
an	O	1942-1944
important	O	1945-1954
mediator	O	1955-1963
of	O	1964-1966
abnormal	O	1967-1975
wound	O	1976-1981
healing	O	1982-1989
.	O	1989-1990

